PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	APPLEBAUM, EL				APPLEBAUM, EL			PARAGANGLIOMA OF THE MIDDLE-EAR	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											APPLEBAUM, EL (corresponding author), UNIV ILLINOIS,CHICAGO,IL 60612, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 21	1995	333	25					1677	1677		10.1056/NEJM199512213332504	http://dx.doi.org/10.1056/NEJM199512213332504			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL401	7477220				2022-12-28	WOS:A1995TL40100004
J	STEPHENS, DS; HAJJEH, RA; BAUGHMAN, WS; HARVEY, RC; WENGER, JD; FARLEY, MM				STEPHENS, DS; HAJJEH, RA; BAUGHMAN, WS; HARVEY, RC; WENGER, JD; FARLEY, MM			SPORADIC MENINGOCOCCAL DISEASE IN ADULTS - RESULTS OF A 5-YEAR POPULATION-BASED STUDY	ANNALS OF INTERNAL MEDICINE			English	Note							IMMUNODEFICIENCY; MENINGITIS; INFECTION	Objective: To define the incidence, demographics, clinical features, and risk factors for sporadic meningococcal disease in adults (greater than or equal to 18 years) residing in metropolitan Atlanta. Design: Prospective, population-based surveillance, with retrospective review of clinical and laboratory records. Setting: Eight-county metropolitan Atlanta area. Patients: All adult patients in whom Neisseria meningitidis was isolated from normally sterile sites (blood, cerebrospinal fluid) during the period 1 December 1988 to 30 November 1993. Measurements: Incidence, relative risk, clinical and laboratory parameters, and serogroup of meningococcal isolates. Results: For the 5-year period, 44 (33%) of 132 cases of meningococcal disease in Atlanta occurred in adults (annual incidence, 0.50/100 000 adults per year). Twenty-three (52%) of the 44 adults presented without rash or meningitis, the two most obvious signs of meningococcal disease. Pneumonia, sinusitis, or purulent tracheobronchitis, but without rash, were the likely sources of meningococcal bacteremia in 15 (34%) of the 44 adults. Twelve of the 15 patients with meningococcal respiratory infection were older than 50 years of age or were immunocompromised (or both), and three fourths of the 15 patients had disease caused by serogroups B, Y, and W-135. Overall, two thirds of adults older than 24 years of age with meningococcal disease had one or more immunocompromising conditions (for example, low complement 50 level [CH50], corticosteroid use, congestive heart failure, multiple myeloma, human immunodeficiency virus infection). Meningococcemia or meningococcal meningitis, often caused by serogroup C, were the presentations in 14 of 15 adults 18 to 24 years old; only 2 had an identified underlying condition. Conclusions: In this 5-year population-based study, one third of all cases of sporadic meningococcal disease occurred in adults. Over half of the adults presented without rash or meningitis. Pneumonia, sinusitis, and tracheobronchitis are important sources of bacteremic meningococcal disease, especially in immunocompromised patients and elderly persons.	CTR DIS CONTROL & PREVENT, ATLANTA, GA USA	Centers for Disease Control & Prevention - USA	STEPHENS, DS (corresponding author), EMORY UNIV, SCH MED, VET AFFAIRS MED CTR, ATLANTA, GA 30322 USA.		Stephens, David S/A-8788-2012					APICELLA MA, 1995, PRINCIPLES PRACTICE, P1896; BANKS JS, 1948, LANCET, P635; BENOIT FL, 1963, AM J MED, V35, P103, DOI 10.1016/0002-9343(63)90167-0; COHEN MS, 1979, ANN INTERN MED, V91, P7, DOI 10.7326/0003-4819-91-1-7; ELLISON RT, 1983, NEW ENGL J MED, V308, P913, DOI 10.1056/NEJM198304213081601; FARLEY MM, 1992, ANN INTERN MED, V116, P806, DOI 10.7326/0003-4819-116-10-806; FARLEY MM, 1993, NEW ENGL J MED, V328, P1807, DOI 10.1056/NEJM199306243282503; IRWIN RS, 1975, ANN INTERN MED, V82, P493, DOI 10.7326/0003-4819-82-4-493; JACKSON LA, 1995, JAMA-J AM MED ASSOC, V273, P383, DOI 10.1001/jama.273.5.383; Jackson Lisa A., 1993, Morbidity and Mortality Weekly Report, V42, P21; JURADO RL, 1993, CLIN INFECT DIS, V17, P224, DOI 10.1093/clinids/17.2.224; MOORE PS, 1990, JAMA-J AM MED ASSOC, V264, P1271, DOI 10.1001/jama.264.10.1271; NITTA AT, 1993, AIDS, V7, P87, DOI 10.1097/00002030-199301000-00013; PINNER RW, 1992, J INFECT DIS, V166, P359, DOI 10.1093/infdis/166.2.359; SALTZMAN RL, 1987, REV INFECT DIS, V9, P1127; STANWELLSMITH RE, 1994, EPIDEMIOL INFECT, V112, P315, DOI 10.1017/S0950268800057733; WITT D, 1982, AM REV RESPIR DIS, V125, P255; WOLF RE, 1968, AM J MED, V44, P243, DOI 10.1016/0002-9343(68)90156-3; WOODS CR, 1994, J INFECT DIS, V170, P453, DOI 10.1093/infdis/170.2.453; 1995, MMWR-MORBID MORTAL W, V44, P121	20	83	86	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1995	123	12					937	940		10.7326/0003-4819-123-12-199512150-00007	http://dx.doi.org/10.7326/0003-4819-123-12-199512150-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK120	7486489				2022-12-28	WOS:A1995TK12000007
J	MADDOX, J				MADDOX, J			THE PREVALENT DISTRUST OF SCIENCE	NATURE			English	Editorial Material																			0	22	22	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					435	437		10.1038/378435a0	http://dx.doi.org/10.1038/378435a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477396				2022-12-28	WOS:A1995TH05400032
J	GJERTSEN, MK; BAKKA, A; BREIVIK, J; SAETERDAL, I; SOLHEIM, BG; SOREIDE, O; THORSBY, E; GAUDERNACK, G				GJERTSEN, MK; BAKKA, A; BREIVIK, J; SAETERDAL, I; SOLHEIM, BG; SOREIDE, O; THORSBY, E; GAUDERNACK, G			VACCINATION WITH MUTANT RAS PEPTIDES AND INDUCTION OF T-CELL RESPONSIVENESS IN PANCREATIC-CARCINOMA PATIENTS CARRYING THE CORRESPONDING RAS MUTATION	LANCET			English	Note							REJECTION	Mutations in codon 12 of K-RAS are frequently found in pancreatic adenocarcinomas. T-cell responses specific for individual RAS mutations can be elicited in vitro by stimulation of peripheral blood mononuclear cells with synthetic peptides. Mutant ras peptides are therefore a candidate vaccine for specific immunotherapy in pancreatic carcinoma patients. When vaccinated with a synthetic ras peptide representing the K-RAS mutation in their tumours, a transient ras-specific T-cell response was induced in two of five patients treated. The vaccination protocol involved multiple in fusions of large amounts of peptide-pulsed antigen-presenting-cells obtained by leucapheresis. These results indicate that specific T-cell responses against mutations uniquely harboured in tumour cells can be induced in cancer patients by vaccination.	NATL HOSP,INST TRANSPLANTAT IMMUNOL,OSLO,NORWAY; NATL HOSP,DEPT SURG B,OSLO,NORWAY; RED CROSS & NATL HOSP BLOOD CTR,OSLO,NORWAY	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway			Klemp, Marianne/AAQ-5652-2021	Klemp, Marianne/0000-0002-9530-8344				BECKER JC, 1993, INT IMMUNOL, V5, P1501, DOI 10.1093/intimm/5.12.1501; FOSSUM B, 1994, INT J CANCER, V56, P40, DOI 10.1002/ijc.2910560108; FOSSUM B, 1995, CANCER IMMUNOL IMMUN, V40, P165; GEDDEDAHL T, 1992, INT IMMUNOL, V4, P1331, DOI 10.1093/intimm/4.11.1331; GEDDEDAHL T, 1993, EUR J IMMUNOL, V23, P754, DOI 10.1002/eji.1830230328; JUNG S, 1991, J EXP MED, V73, P273; KAHN SM, 1991, ONCOGENE, V6, P1079; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; VAESSEN LMB, 1992, CLIN EXP IMMUNOL, V88, P213	10	164	173	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 25	1995	346	8987					1399	1400		10.1016/S0140-6736(95)92408-6	http://dx.doi.org/10.1016/S0140-6736(95)92408-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG207	7475823	Bronze			2022-12-28	WOS:A1995TG20700011
J	NISHIOKA, T; KONDO, A; SUGA, K				NISHIOKA, T; KONDO, A; SUGA, K			PROGRESSIVE BLURRING OF VISION IN BOTH EYES	LANCET			English	Note									KITANO MED RES INST & HOSP,DEPT OPHTHALMOL,KITA KU,OSAKA 530,JAPAN	Kitano Hospital	NISHIOKA, T (corresponding author), KITANO MED RES INST & HOSP,DEPT NEUROSURG,KITA KU,13-3 KAMIYAMA CHO,OSAKA 530,JAPAN.							Lindenberg R, 1973, NEUROPATHOLOGY VISIO; MILLER NR, 1982, HOYTS CLIN NEUROOPHT, V1, P272; MILLER NR, 1991, WALSH HOYTS CLIN NEU, V4, P1974; RUCKER CW, 1954, AMA ARCH OPHTHALMOL, V51, P161; UNSOLD R, 1989, COMPRESSIVE OPTIC NE	5	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 25	1995	346	8987					1402	1402		10.1016/S0140-6736(95)92410-8	http://dx.doi.org/10.1016/S0140-6736(95)92410-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG207	7475825				2022-12-28	WOS:A1995TG20700013
J	ASOLA, MR				ASOLA, MR			A DIVER UNCONSCIOUS AFTER GASTROENTERITIS	LANCET			English	Note							PERITONEAL-DIALYSIS; AMINO	At the end of 1994, a 23-year-old man went on a diving holiday to Sri Lanka, where he got gastroenteritis. Upon arrival home he became disoriented, dysarthric, and ataxic. When he was admitted to Turku University Central Hospital, on Dec 18, severe metabolic acidosis was found. Examination of cerebrospinal fluid, electroencephalography, and computed tomogram of the brain were normal. Because of the history, decompression sickness was suspected, and the patient was transferred for hyperbaric oxygen treatment. On arrival he was deeply unconscious and his breathing had to be assisted with respirator. Chest radiograph revealed right-side lobar pneumonia. In faecal culture samples, no pathogens mere found and a test for Clostridium difficile toxin was negative.			ASOLA, MR (corresponding author), UNIV TURKU,CENT HOSP,DEPT INTERNAL MED NEPHROL,SF-20520 TURKU,FINLAND.							GORTNER L, 1989, ACTA PAEDIATR SCAND, V78, P706, DOI 10.1111/j.1651-2227.1989.tb11130.x; GOYON JB, 1994, PAEDIATR RES, V35, P357; PEINEMANN F, 1994, J INHERIT METAB DIS, V17, P3, DOI 10.1007/BF00735389; SALLAN SE, 1969, LANCET, V2, P1423; WENDEL U, 1980, EUR J PEDIATR, V134, P57, DOI 10.1007/BF00442404	5	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 18	1995	346	8986					1338	1338		10.1016/S0140-6736(95)92347-0	http://dx.doi.org/10.1016/S0140-6736(95)92347-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE916	7475775				2022-12-28	WOS:A1995TE91600013
J	SMITH, JD; ROSE, ML; POMERANCE, A; BURKE, M; YACOUB, MH				SMITH, JD; ROSE, ML; POMERANCE, A; BURKE, M; YACOUB, MH			REDUCTION OF CELLULAR REJECTION AND INCREASE IN LONGER-TERM SURVIVAL AFTER HEART-TRANSPLANTATION AFTER HLA-DR MATCHING	LANCET			English	Article							CARDIAC ALLOGRAFT RECIPIENTS; RISK-FACTORS; ANTIGENS; HISTOCOMPATIBILITY	HLA matching in cardiac transplants is perceived as being logistically difficult. We studied 1135 consecutive primary cardiac allografts between 1980 and 1994 to assess the effect of HLA mismatching on long-term graft survival acid cellular rejection episodes within 3 months of transplantation. We found a significant association between HLA-DR mismatching and the number of episodes of rejection (no mismatch 0.80 [SE 0.13], one mismatch 1.22 [0.06], two mismatches 1.42 [0.06], p<0.05). We found a similar correlation between the total number of biopsy specimens showing evidence of cellular rejection and HLA-DR mismatch. The time between operation and the first rejection episode shortened with increasing HLA-DR mismatch (no mismatch 85.5 [37.3] days, one mismatch 43.1 [8.1], two mismatches 24.1 [2.9], p<0.05). Furthermore, the proportion of patients with no evidence of rejection correlated with HLA-DR incompatibility. A significant association between improved graft survival and HLA-DR mismatching was found over 1, 5, and 10 years after transplantation (no mismatch 1 year 92%, 5 years 83%, 10 years 76%, one mismatch 1 year 81%, 5 years 73%, 10 years 59%, and two mismatches 78% 1 year, 5 years 70%, and 10 years 52%, p=0.02). Increased efforts to prospectively HLA match patients has resulted in 25% of patients transplanted between January and May 1995 (n=13/52) receiving grafts matched for HLA-DR. HLA matching reduces the frequency and severity of acute cardiac allograft rejection and improves graft survival for up to 10 years. Our preliminary results suggest that it is possible to use HLA matching prospectively for our selection of recipients.	HAREFIELD HOSP,IMPERIAL COLL SCI & TECHNOL,NATL HEART & LUNG INST,DEPT CARDIOTHORAC SURG,HAREFIELD UB9 6JH,MIDDX,ENGLAND; HAREFIELD HOSP,ROYAL BROMPTON & NATL HEART HOSP,CTR HEART SCI,HAREFIELD UB9 6JH,MIDDX,ENGLAND	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital								Billingham M E, 1990, J Heart Transplant, V9, P587; BRAND DL, 1970, HISTOCOMPATIBILITY T, P357; BUYSE I, 1993, TISSUE ANTIGENS, V41, P1, DOI 10.1111/j.1399-0039.1993.tb01970.x; COCHRANE A, 1992, TRANSPLANT P, V24, P169; DISESA VJ, 1990, ANN THORAC SURG, V49, P220, DOI 10.1016/0003-4975(90)90141-R; FESTENSTEIN H, 1989, IMMUNOBIOLOGY HLA II, P526; FRIST WH, 1987, ANN THORAC SURG, V44, P242, DOI 10.1016/S0003-4975(10)62062-0; KERMAN RH, 1994, TRANSPLANTATION, V57, P884, DOI 10.1097/00007890-199403270-00020; KHAGHANI A, 1989, TRANSPLANT P, V21, P799; LAUFER G, 1989, J THORAC CARDIOV SUR, V98, P1113; OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x; OPELZ G, 1994, NEW ENGL J MED, V330, P816, DOI 10.1056/NEJM199403243301203; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PFEFFER PF, 1988, TRANSPLANT P, V20, P367; POLLACK MS, 1990, CLIN TRANSPLANT, V4, P269; RAFFOUX C, 1987, TRANSPLANT P, V19, P3559; ROSE M, 1988, HUM IMMUNOL, V23, P179, DOI 10.1016/0198-8859(88)90056-0; ROSE ML, 1986, TRANSPLANTATION, V41, P776, DOI 10.1097/00007890-198606000-00021; SHEIL AGR, 1993, TRANSPLANT P, V25, P1383; SHELDON S, 1994, TRANSPLANTATION, V6, P719; VALERI M, 1990, TRANSPLANT P, V4, P1906; VANROOD JJ, 1976, NATURE, V262, P795, DOI 10.1038/262795a0; YACOUB M, 1987, TRANSPLANT P, V1, P2487; ZERBE TR, 1991, TRANSPLANTATION, V52, P485, DOI 10.1097/00007890-199109000-00019	24	64	68	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 18	1995	346	8986					1318	1322		10.1016/S0140-6736(95)92341-1	http://dx.doi.org/10.1016/S0140-6736(95)92341-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE916	7475769				2022-12-28	WOS:A1995TE91600007
J	ESSERMAN, L; BELKORA, J; LENERT, L				ESSERMAN, L; BELKORA, J; LENERT, L			POTENTIALLY INEFFECTIVE CARE - A NEW OUTCOME TO ASSESS THE LIMITS OF CRITICAL CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ILL HOSPITALIZED ADULTS; MEDICAL INTENSIVE-CARE; APACHE-II; PREDICTION; MORTALITY; SURVIVAL; TRAUMA; SYSTEM; UNIT; PREFERENCES	Objective.-To examine the limits of the effectiveness of critical care through the study of patients for whom it was ineffective. Design.-We studied the relationship between resource use and long-term outcome (2-year follow-up) in 402 consecutively admitted critical care patients to develop a benchmark for ineffective applications of critical care, We defined an outcome called potentially ineffective care (PIG), developed and evaluated a model with an independent data set to predict PIC from a patient's response to treatment, and estimated the economic effects of limiting care after a prediction of PIC. Setting.-The combined medical and surgical intensive care unit at a 600-bed university teaching hospital. Patients.-Two groups of 402 consecutively admitted critical care patients, one from 1989, the other from 1991. Main Outcome Measures and Results.-Based on observations from a two-dimensional plot of resource use vs benefit for 402 critical care patients, PIC was defined as resource use in the upper 25th percentile and survival for less than 100 days after discharge. Thirteen percent of the patients fell into the PIC category and used 32% of the resources. A product of the APACHE risk estimates on days 1 and 5 of at least 0.35 predicted 37% of PIC outcomes with a specificity of 98%. In a second data set, PIC outcome prediction had a sensitivity of 43% and a specificity of 94%, and a positive predictive value of 80%. For the hospital studied, reduction of intensity of treatment after a prediction of a PIC outcome would result in a reduction of hospital charges in the range of $1.8 million to $5 million per year. Conclusion.-Patients in the PIC category consumed a large portion of the resources devoted to critical care at an academic teaching hospital. We suggest a change in focus from assessment of the quality of critical care and risk-adjusted mortality to an assessment of ineffective care based on outcome and resource use and a patient's response to treatment over time.	STANFORD UNIV,SCH MED,DEPT SURG,STANFORD,CA; STANFORD UNIV,SCH MED,DEPT MED,STANFORD,CA; STANFORD UNIV,DEPT ENGN ECON SYST,STANFORD,CA; STANFORD UNIV,GRAD SCH BUSINESS,STANFORD,CA	Stanford University; Stanford University; Stanford University; Stanford University				Belkora, Jeffrey/0000-0002-0719-4325				ATKINSON S, 1994, CRIT CARE MED, V22, pA41; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; Bierman H.J., 1991, QUANTITATIVE ANAL BU; BORLASE BC, 1990, SURGERY, V109, P687; Breiman L., 1984, CLASSIFICATION REGRE; CHANG RWS, 1988, CRIT CARE MED, V16, P34, DOI 10.1097/00003246-198801000-00007; CHANG RWS, 1989, LANCET, V2, P143; CHARLSON ME, 1987, J CHRON DIS, V40, P705, DOI 10.1016/0021-9681(87)90107-X; CHEADLE WG, 1989, ANN SURG, V209, P541, DOI 10.1097/00000658-198905000-00005; CIVETTA JM, 1990, ANN SURG, V212, P266, DOI 10.1097/00000658-199009000-00005; CIVETTA JM, 1992, SURG GYNECOL OBSTET, V175, P195; CIVETTA JM, 1991, CARE SURGICAL PATIEN, V2, P1; COHEN IL, 1993, JAMA-J AM MED ASSOC, V269, P1025, DOI 10.1001/jama.269.8.1025; CRAWFORD SW, 1992, AM REV RESPIR DIS, V145, P510, DOI 10.1164/ajrccm/145.3.510; DANIS M, 1988, JAMA-J AM MED ASSOC, V260, P797, DOI 10.1001/jama.260.6.797; DAWSON NW, 1990, J CLIN EPIDEMIOL S, V43, P1035; DETSKY AS, 1981, NEW ENGL J MED, V305, P667, DOI 10.1056/NEJM198109173051204; ENDE J, 1989, J GEN INTERN MED, V4, P23, DOI 10.1007/BF02596485; FELLER I, 1980, JAMA-J AM MED ASSOC, V224, P2074; GARBER AM, 1984, NEW ENGL J MED, V310, P1231, DOI 10.1056/NEJM198405103101906; IMBUS SH, 1977, NEW ENGL J MED, V279, P308; KNAUS WA, 1991, SCIENCE, V254, P389, DOI 10.1126/science.1925596; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LANTOS JD, 1989, AM J MED, V87, P81; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEMESHOW S, 1988, CRIT CARE MED, V16, P470, DOI 10.1097/00003246-198805000-00002; Letsch S W, 1991, Health Care Financ Rev, V13, P129; LIDZ CW, 1982, MAKING HLTH CARE DEC, V2, P317; MCANENA OJ, 1992, J TRAUMA, V33, P504, DOI 10.1097/00005373-199210000-00003; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; NORTON R, 1994, FORTUNE, V130, P38; OYE RK, 1991, CHEST, V99, P685, DOI 10.1378/chest.99.3.685; RAFFIN T, 1988, INTENSIVE CARE FACIN; RAUSS A, 1990, MED DECIS MAKING, V10, P155, DOI 10.1177/0272989X9001000302; ROBBINS RA, 1989, AM J MED, V87, P511; ROSENTHAL GE, 1994, JOINT COMM J QUAL IM, V20, P425, DOI 10.1016/S1070-3241(16)30088-8; Rosner B, 1982, FUNDAMENTALS BIOSTAT; RUTLEDGE R, 1993, AM J SURG, V166, P244, DOI 10.1016/S0002-9610(05)80966-3; SCHAPIRA DV, 1993, JAMA-J AM MED ASSOC, V269, P783, DOI 10.1001/jama.269.6.783; WACHTER RM, 1992, JAMA-J AM MED ASSOC, V267, P541, DOI 10.1001/jama.267.4.541; 1989, CRIT CARE MED, V17, P305	43	86	88	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	1995	274	19					1544	1551		10.1001/jama.274.19.1544	http://dx.doi.org/10.1001/jama.274.19.1544			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD571	7474223				2022-12-28	WOS:A1995TD57100031
J	SMYTH, RL; ASHBY, D; OHEA, U; BURROWS, E; LEWIS, P; VANVELZEN, D; DODGE, JA				SMYTH, RL; ASHBY, D; OHEA, U; BURROWS, E; LEWIS, P; VANVELZEN, D; DODGE, JA			FIBROSING COLONOPATHY IN CYSTIC-FIBROSIS - RESULTS OF A CASE-CONTROL STUDY	LANCET			English	Article								Fibrosing colonopathy was first described in cystic fibrosis (CF) children in 1994. We have done a nested case-control study to identify possible associations with this condition. A case ascertainment within the UK CF population to identify any cases that occurred between January, 1984, and April, 1994, found 14 cases, all under 14 years and confirmed by independent histopathological review. All had presented since April, 1993; 12 were boys and six had received some or all of their care in Liverpool. Each case was matched, by date of birth, with four controls from the UK CF Registry. Information was obtained about cases and controls from their case records and by a structured interview with the families. In the 12 months before surgery, there was an association between the occurrence of fibrosing colonopathy and use of high-strength pancreatic enzyme preparations. This association was dose related. Odds ratio per extra 1000 high-strength capsules was 1.45 (95% CI 1.14-1.84), For use of protease, the odds ratio per million extra units per kg was 1.55 (1.19-2.03). For usage of individual high-strength products at any time during the 12 months before surgery some differences were observed; for Creon 25000 the odds ratio was 0.38 (0.10-1.42), for Nutrizym 22 43.4 (2.51-751), and for Pancrease HL 8.4 (1.95-36.1). These last two confidence intervals are extremely wide and compatible with these two products having the same odds ratios. Laxative use was independently predictive (odds ratio 2.42 [1.20-4.94]). We conclude that there is a dose-related association between high-strength pancreatic enzyme preparations and fibrosing colonopathy.	UNIV LIVERPOOL,DEPT STAT & COMPUTAT MATH,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; UNIV WALES COLL CARDIFF,COLL MED,DEPT MED COMP & STAT,CARDIFF,S GLAM,WALES; ROYAL CHILDRENS HOSP,DEPT FETAL & INFANT PATHOL,LIVERPOOL,MERSEYSIDE,ENGLAND; QUEENS UNIV BELFAST,DEPT CHILD HLTH,BELFAST BT7 1NN,ANTRIM,NORTH IRELAND	University of Liverpool; Cardiff University; Queens University Belfast	SMYTH, RL (corresponding author), ROYAL LIVERPOOL CHILDRENS HOSP ALDER HEY,RESP UNIT,LIVERPOOL L12 2AP,MERSEYSIDE,ENGLAND.							BRESLOW N, INT AGENCY RES CANCE, V32; CAMPBELL CA, 1994, LANCET, V343, P109; Dodge J A, 1993, Paediatr Perinat Epidemiol, V7, P157, DOI 10.1111/j.1365-3016.1993.tb00390.x; KNABE N, 1994, LANCET, V343, P1230, DOI 10.1016/S0140-6736(94)92443-0; MACSWEENEY EJ, 1995, LANCET, V345, P752; MAHONY MJ, 1994, LANCET, V343, P599; OADES PJ, 1994, LANCET, V343, P109, DOI 10.1016/S0140-6736(94)90836-2; OHARE MMT, 1995, J PEDIATR GASTR NUTR, V21, P59, DOI 10.1097/00005176-199507000-00010; PETTEI MJ, 1994, J PEDIATR-US, V125, P587, DOI 10.1016/S0022-3476(94)70014-1; ROSENSTEIN BJ, 1983, J PEDIATR GASTR NUTR, V2, P299, DOI 10.1097/00005176-198305000-00014; SMYTH RL, 1994, LANCET, V343, P85, DOI 10.1016/S0140-6736(94)90817-6; WALLER PC, 1992, BRIT MED J, V304, P1470, DOI 10.1136/bmj.304.6840.1470; 1993, GUIDELINES CO SPONSO; ABPI DATA SHEET COMP	14	108	112	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1247	1251		10.1016/S0140-6736(95)91860-4	http://dx.doi.org/10.1016/S0140-6736(95)91860-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475715				2022-12-28	WOS:A1995TE14500008
J	HENGARTNER, MO				HENGARTNER, MO			LIFE AND DEATH DECISIONS - CED-9 AND PROGRAMMED CELL-DEATH IN CAENORHABDITIS-ELEGANS	SCIENCE			English	Editorial Material							NEMATODE; LINEAGES				HENGARTNER, MO (corresponding author), COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA.		Hengartner, Michael O/A-7058-2008; Hengartner, Michael O/E-6235-2011	Hengartner, Michael/0000-0002-7584-596X				DRISCOLL M, 1992, J NEUROBIOL, V23, P1327, DOI 10.1002/neu.480230919; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, PHILOS T R SOC B, V345, P243, DOI 10.1098/rstb.1994.0100; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SCHWARTZ LM, 1994, BIOESSAYS, V16, P387, DOI 10.1002/bies.950160604; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	13	8	16	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 10	1995	270	5238					931	931		10.1126/science.270.5238.931	http://dx.doi.org/10.1126/science.270.5238.931			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD878	7481794				2022-12-28	WOS:A1995TD87800031
J	BANNERMAN, DM; GOOD, MA; BUTCHER, SP; RAMSAY, M; MORRIS, RGM				BANNERMAN, DM; GOOD, MA; BUTCHER, SP; RAMSAY, M; MORRIS, RGM			DISTINCT COMPONENTS OF SPATIAL-LEARNING REVEALED BY PRIOR TRAINING AND NMDA RECEPTOR BLOCKADE	NATURE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL-FORMATION; SELECTIVE IMPAIRMENT; MEMORY; CORTEX; RATS; AP5; ANTAGONIST; ACID; TRANSMISSION	SYNAPTIC plasticity dependent on N-methyl-D-aspartate (NMDA) receptors is thought to underlie certain types of learning and memory(1 3). In support of this, both hippocampal long-term potentiation and spatial learning in a watermaze are impaired by blocking NMDA receptors with a selective antagonist D(-)-2-amino-5-phosphonovaleric acid (AP5)(4) or by a mutation in one of the receptor subunits(5). Here we report, however, that the AP5-induced learning deficit can be almost completely prevented if rats are pretrained in a different watermaze before administration of the drug. This is not because of stimulus generalization, and occurs despite learning of the second task remaining hippocampus dependent. An APS-induced learning deficit is, however, still seen if the animals are pretrained using a non-spatial task. Thus, despite its procedural simplicity, the watermaze may involve multiple cognitive processes with distinct pharmacological properties; although required for some component of spatial learning, NMDA receptors may not be required for encoding the spatial representation of a specific environment.	UNIV EDINBURGH,SCH MED,CTR NEUROSCI,EDINBURGH EH8 9LE,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,SCH MED,DEPT PHARMACOL,EDINBURGH EH8 9LE,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,FUJISAWA INST NEUROSCI,EDINBURGH EH8 9JZ,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh; University of Edinburgh			Morris, Richard G M/C-9982-2013	Bannerman, David/0000-0002-3024-7595				ALFORD S, 1994, NMDA RECEPTOR, P277; BARNES CA, 1994, J NEUROSCI, V14, P5793; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; BUTCHER SP, 1991, EXP BRAIN RES, V83, P521; CARAMANOS Z, 1994, BEHAV NEUROSCI, V108, P30, DOI 10.1037/0735-7044.108.1.30; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DAVIS S, 1992, J NEUROSCI, V12, P21; DIMATTIA BD, 1988, BEHAV NEUROSCI, V102, P471, DOI 10.1037/0735-7044.102.4.471; FOX K, 1990, J NEUROPHYSIOL, V64, P1413, DOI 10.1152/jn.1990.64.5.1413; HEALE V, 1990, PHARMACOL BIOCHEM BE, V36, P145, DOI 10.1016/0091-3057(90)90140-D; JARRARD LE, 1989, J NEUROSCI METH, V29, P251, DOI 10.1016/0165-0270(89)90149-0; Johnson-Laird, 1983, MENTAL MODELS; JOHNSTON D, 1992, ANNU REV PHYSIOL, V54, P489; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MORRIS RGM, 1988, EXCITATORY AMINO ACI, P297; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; SALT TE, 1986, NATURE, V322, P263, DOI 10.1038/322263a0; SILLITO AM, 1990, NEUROSCIENCE, V34, P273, DOI 10.1016/0306-4522(90)90137-S; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SUTHERLAND NS, 1970, MECHANISMS ANIMAL DI; SUTHERLAND RJ, 1988, J NEUROSCI, V8, P1863; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520	27	476	485	1	42	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 9	1995	378	6553					182	186		10.1038/378182a0	http://dx.doi.org/10.1038/378182a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD759	7477320				2022-12-28	WOS:A1995TD75900053
J	PARGE, HE; FOREST, KT; HICKEY, MJ; CHRISTENSEN, DA; GETZOFF, ED; TAINER, JA				PARGE, HE; FOREST, KT; HICKEY, MJ; CHRISTENSEN, DA; GETZOFF, ED; TAINER, JA			STRUCTURE OF THE FIBER-FORMING PROTEIN PILIN AT 2.6-ANGSTROM RESOLUTION	NATURE			English	Article							PSEUDOMONAS-AERUGINOSA; NEISSERIA-GONORRHOEAE; POLAR PILI; DISSOCIATION; EXPRESSION; ANTIBODIES; FIMBRIAE; MUTANT; ACTIN; PAO	The crystallographic structure of Neisseria gonorrhoeae pilin, which assembles into the multifunctional pilus adhesion and virulence factor, reveals an alpha-beta roll fold with a striking 85 Angstrom alpha-helical spine and an O-linked disaccharide. Hey residues stabilize interactions that allow sequence hypervariability, responsible for pilin's celebrated antigenic variation, within disulphide region beta-strands and connections. Pilin surface shape, hydrophobicity and sequence variation constrain pilus assembly to the packing of flat subunit faces against alpha(1) helices. Helical fibre assembly is postulated to form a core of coiled alpha(1) helices banded by beta-sheet, leaving carbohydrate and hypervariable sequence regions exposed to solvent.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute			Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429				BISWAS GD, 1977, J BACTERIOL, V129, P983, DOI 10.1128/JB.129.2.983-992.1977; BORST P, 1995, CELL, V82, P1, DOI 10.1016/0092-8674(95)90044-6; BOSLEGO JW, 1991, VACCINE, V9, P154, DOI 10.1016/0264-410X(91)90147-X; BRADLEY DE, 1980, CAN J MICROBIOL, V26, P146, DOI 10.1139/m80-022; BRADLEY DE, 1974, VIROLOGY, V58, P149, DOI 10.1016/0042-6822(74)90150-0; BRUNGER AT, 1992, X PLOR SYSTEM XRAY C; BUCHANAN TM, 1976, INFECT IMMUN, V13, P1483, DOI 10.1128/IAI.13.5.1483-1489.1976; BULLITT E, 1995, NATURE, V373, P164, DOI 10.1038/373164a0; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DALRYMPLE B, 1987, J MOL EVOL, V25, P261, DOI 10.1007/BF02100020; DUPUY B, 1994, J BACTERIOL, V176, P1323, DOI 10.1128/jb.176.5.1323-1331.1994; ELLEMAN TC, 1987, MOL MICROBIOL, V1, P377, DOI 10.1111/j.1365-2958.1987.tb01945.x; FOLKHARD W, 1981, J MOL BIOL, V149, P79, DOI 10.1016/0022-2836(81)90261-8; FUREY W, 1990, P AM CRYSTALLOGRAPHI, P73; GILSON MK, 1988, PROTEINS, V4, P7, DOI 10.1002/prot.340040104; HAMADEH RM, 1994, 9TH INT PATH NEISS C, P132; JONSSON AB, 1994, MOL MICROBIOL, V13, P403, DOI 10.1111/j.1365-2958.1994.tb00435.x; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MATTICK JS, 1987, J BACTERIOL, V169, P33, DOI 10.1128/jb.169.1.33-41.1987; Mattick JS, 1993, GENETICS MOL BIOL AN, P517; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MIMORI Y, 1995, J MOL BIOL, V249, P69, DOI 10.1006/jmbi.1995.0281; MORGAN DG, 1995, J MOL BIOL, V249, P88, DOI 10.1006/jmbi.1995.0282; NASSIF X, 1994, P NATL ACAD SCI USA, V91, P3769, DOI 10.1073/pnas.91.9.3769; NOGALES E, 1995, NATURE, V375, P424, DOI 10.1038/375424a0; ORENGO CA, 1993, STRUCTURE, V1, P105, DOI 10.1016/0969-2126(93)90026-D; OTTOW JCG, 1975, ANNU REV MICROBIOL, V29, P79, DOI 10.1146/annurev.mi.29.100175.000455; PARGE HE, 1990, J BIOL CHEM, V265, P2278; PASLOSKE BL, 1989, J BACTERIOL, V171, P2142, DOI 10.1128/jb.171.4.2142-2147.1989; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROTHBARD JB, 1985, P NATL ACAD SCI USA, V82, P915, DOI 10.1073/pnas.82.3.915; RUDEL T, 1995, NATURE, V373, P357, DOI 10.1038/373357a0; SCHOOLNIK GK, 1990, NEW GENERATION VACCI, P565; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SEGAL E, 1985, CELL, V40, P293, DOI 10.1016/0092-8674(85)90143-6; Seifert H, 1984, MICROBIOL REV, V52, P327; SEIFERT HS, 1994, J CLIN INVEST, V93, P2744, DOI 10.1172/JCI117290; STEWART DJ, 1982, RES VET SCI, V32, P140, DOI 10.1016/S0034-5288(18)32404-4; STROM MS, 1994, METHOD ENZYMOL, V235, P527; Swanson J., 1989, MOBILE DNA, P743; TANIGUCHI T, 1995, INFECT IMMUN, V63, P724, DOI 10.1128/IAI.63.2.724-728.1995; VIRJI M, 1989, J GEN MICROBIOL, V135, P3239; VIRJI M, 1993, MOL MICROBIOL, V10, P1013, DOI 10.1111/j.1365-2958.1993.tb00972.x; WATTS TH, 1983, BIOCHEMISTRY-US, V22, P3640, DOI 10.1021/bi00284a016; WATTS TH, 1982, CAN J BIOCHEM CELL B, V60, P867, DOI 10.1139/o82-110; WATTS TH, 1982, J BACTERIOL, V151, P1508, DOI 10.1128/JB.151.3.1508-1513.1982; WOODS DE, 1980, INFECT IMMUN, V29, P1146	50	391	404	2	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 2	1995	378	6552					32	38		10.1038/378032a0	http://dx.doi.org/10.1038/378032a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477282				2022-12-28	WOS:A1995TC46900040
J	AUSTIN, MA; BRESLOW, JL; HENNEKENS, CH; BURING, JE; WILLETT, WC; KRAUSS, RM				AUSTIN, MA; BRESLOW, JL; HENNEKENS, CH; BURING, JE; WILLETT, WC; KRAUSS, RM			LOW-DENSITY LIPOPROTEIN SUBCLASS PATTERNS AND RISK OF MYOCARDIAL-INFARCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV CALIF BERKELEY LAWRENCE BERKELEY LAB,DONNER LAB,1 CYCLOTRON RD 1-213,BERKELEY,CA 94720; ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,NEW YORK,NY 10021; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PREVENT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT CLIN EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Rockefeller University; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health			Breslow, Jan L/B-7544-2008		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033577, P01HL018574, R29HL038760] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-33577, HL-38760, HL-18574] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSTIN MA, 1986, LANCET, V2, P592; AUSTIN MA, IN PRESS AM J HUM GE; BRESLOW NE, 1980, PUBLICATION INT A 32, V1; BRUNZELL JD, 1983, J LIPID RES, V24, P147; BRUNZELL JD, 1984, ARTERIOSCLEROSIS, V4, P79, DOI 10.1161/01.ATV.4.2.79; BYARD P J, 1984, Genetic Epidemiology, V1, P43, DOI 10.1002/gepi.1370010107; CASTELLI WP, 1977, CIRCULATION, V55, P767, DOI 10.1161/01.CIR.55.5.767; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CROUSE JR, 1985, J LIPID RES, V26, P566; EISENBERG S, 1984, J CLIN INVEST, V74, P470, DOI 10.1172/JCI111444; ERNST N, 1980, CIRCULATION, V62, P41; FISHER WR, 1983, METABOLISM, V32, P283, DOI 10.1016/0026-0495(83)90194-4; FISHER WR, 1972, BIOCHEMISTRY-US, V11, P519, DOI 10.1021/bi00754a006; Fleiss JL, 1981, STAT METHODS RATES P; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; GRUNDY SM, 1986, NEW ENGL J MED, V314, P745, DOI 10.1056/NEJM198603203141204; HASKELL WL, 1980, CIRCULATION, V62, P53; HEGELE RA, 1986, NEW ENGL J MED, V315, P1509, DOI 10.1056/NEJM198612113152403; HEISS G, 1980, CIRCULATION, V62, P116; HEISS G, 1983, NIH831266 PUBL, P7; HENNEKENS CH, 1987, CIRCULATION, V76, P501; HUANG LS, 1986, P NATL ACAD SCI USA, V83, P644, DOI 10.1073/pnas.83.3.644; HULLEY SB, 1980, NEW ENGL J MED, V302, P1383, DOI 10.1056/NEJM198006193022503; ISELIUS L, 1985, ACTA MED SCAND, V217, P161; KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1; KISSEBAH AH, 1984, ARTERIOSCLEROSIS, V4, P614, DOI 10.1161/01.ATV.4.6.614; KLEINBAUM DJ, 1978, APPLIED REGRESSION A; KRAUSS RM, 1983, CLIN RES, V31, pA503; KRAUSS RM, 1987, AM HEART J, V113, P578, DOI 10.1016/0002-8703(87)90636-3; KRAUSS RM, 1980, CLIN CHIM ACTA, V104, P275, DOI 10.1016/0009-8981(80)90385-X; KRAUSS RM, 1982, J LIPID RES, V23, P97; KRAUSS RM, 1987, LANCET, V2, P62; LALOUEL JM, 1983, AM J HUM GENET, V35, P816; LAW A, 1986, LANCET, V1, P1301; LINDGREN FT, 1972, BLOOD LIPIDS LIPOPRO, P181; LIPPEL K, 1981, ARTERIOSCLEROSIS, V1, P406, DOI 10.1161/01.ATV.1.6.406; MCNAMARA JR, 1987, ARTERIOSCLEROSIS, V7, P483, DOI 10.1161/01.ATV.7.5.483; MICHELI H, 1979, ATHEROSCLEROSIS, V32, P264; MILLER GJ, 1975, LANCET, V1, P16; Morgenstern H, 1982, EPIDEMIOLOGIC RES PR, P403; PEARSON TA, 1979, AM J EPIDEMIOL, V109, P285, DOI 10.1093/oxfordjournals.aje.a112682; PRIESTLEY L, 1985, NUCLEIC ACIDS RES, V13, P6789, DOI 10.1093/nar/13.18.6789; ROHLFING JJ, 1986, WESTERN J MED, V145, P210; ROSS R, 1976, SCIENCE, V193, P1094, DOI 10.1126/science.822515; SCHAEFER EJ, 1987, CIRCULATION, V76, P531; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SHEN MMS, 1981, J LIPID RES, V22, P236; SNIDERMAN A, 1980, P NATL ACAD SCI-BIOL, V77, P604, DOI 10.1073/pnas.77.1.604; TENG B, 1983, P NATL ACAD SCI-BIOL, V80, P6662, DOI 10.1073/pnas.80.21.6662; The Lipid Research Clinics Coronary Primary Prevention Trial results, 1984, JAMA, V251, P351; THIRD JLHC, 1984, METABOLISM, V33, P136, DOI 10.1016/0026-0495(84)90126-4; VERGANI C, 1981, CLIN CHIM ACTA, V114, P45, DOI 10.1016/0009-8981(81)90226-6; WARNICK GR, 1982, CLIN CHEM, V28, P1379; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed; 1985, SAS USERS GUIDE; 1980, NIH801527 PUBL, V1, P28; 1975, DHEW NIH75628 PUBL, V1, P51	57	1391	1423	0	31	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1988	260	13					1917	1921						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q2703	3418853				2022-12-28	WOS:A1988Q270300027
J	ZUGER, A; SCHUSTER, M; SIMBERKOFF, MS; RAHAL, JJ; HOLZMAN, RS				ZUGER, A; SCHUSTER, M; SIMBERKOFF, MS; RAHAL, JJ; HOLZMAN, RS			MAINTENANCE AMPHOTERICIN-B FOR CRYPTOCOCCAL MENINGITIS IN THE ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)	ANNALS OF INTERNAL MEDICINE			English	Note									NYU, SCH MED, DEPT MED, 550 1ST AVE, NEW YORK, NY 10016 USA; BELLEVUE HOSP CTR, MED CTR, NEW YORK, NY 10016 USA; MANHATTAN VET ADM MED CTR, NEW YORK, NY USA; GOLDWATER MEM HOSP, NEW YORK, NY USA	New York University; Bellevue Hospital Center								DISMUKES WE, 1987, NEW ENGL J MED, V317, P334, DOI 10.1056/NEJM198708063170602; KOVACS JA, 1985, ANN INTERN MED, V103, P533, DOI 10.7326/0003-4819-103-4-533; ZUGER A, 1986, ANN INTERN MED, V104, P234, DOI 10.7326/0003-4819-104-2-234	3	50	50	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1988	109	7					592	593		10.7326/0003-4819-109-7-592	http://dx.doi.org/10.7326/0003-4819-109-7-592			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q4157	3421567				2022-12-28	WOS:A1988Q415700013
J	HAI, T; HORIKOSHI, M; ROEDER, RG; GREEN, MR				HAI, T; HORIKOSHI, M; ROEDER, RG; GREEN, MR			ANALYSIS OF THE ROLE OF THE TRANSCRIPTION FACTOR ATF IN THE ASSEMBLY OF A FUNCTIONAL PREINITIATION COMPLEX	CELL			English	Article									ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021	Rockefeller University	HAI, T (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.		Hai, Tsonwin/H-4480-2011; Hai, Tsonwin/E-3185-2011	Hai, Tsonwin/0000-0003-4510-0315; Hai, Tsonwin/0000-0003-4510-0315				BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FIRE A, 1984, J BIOL CHEM, V259, P2509; FRIED MG, 1984, J MOL BIOL, V172, P263, DOI 10.1016/S0022-2836(84)80026-1; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HORIKOSHI M, 1988, CELL, V54; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEE KAW, 1987, EMBO J, V6, P1345, DOI 10.1002/j.1460-2075.1987.tb02374.x; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; NAKAJIMA N, 1988, IN PRESS MOL CELL BI; Ptashne M., 1986, A GENETIC SWITCH; REINBERG D, 1987, J BIOL CHEM, V262, P3310; REINBERG D, 1987, J BIOL CHEM, V262, P3322; Roeder R.G., 1976, RNA POLYMERASE, P285; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SAWADOGO M, 1988, IN PRESS J BIOL CHEM; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SLATTERY E, 1983, J BIOL CHEM, V258, P5955; WEIL PA, 1979, CELL, V18, P469; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; YURA T, 1979, ANNU REV GENET, V13, P59, DOI 10.1146/annurev.ge.13.120179.000423; ZHENG XM, 1987, CELL, V50, P361, DOI 10.1016/0092-8674(87)90490-9	33	154	154	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 23	1988	54	7					1043	1051		10.1016/0092-8674(88)90119-5	http://dx.doi.org/10.1016/0092-8674(88)90119-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	Q3063	3416355				2022-12-28	WOS:A1988Q306300017
J	WOLFFE, AP; BROWN, DD				WOLFFE, AP; BROWN, DD			DEVELOPMENTAL REGULATION OF 2 5S RIBOSOMAL-RNA GENES	SCIENCE			English	Article									CARNEGIE INST WASHINGTON, DEPT EMBRYOL, BALTIMORE, MD 21210 USA	Carnegie Institution for Science					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022395] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22395] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN J, 1981, J CELL BIOL, V90, P279, DOI 10.1083/jcb.90.2.279; ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; ANDREWS MT, 1987, CELL, V51, P445, DOI 10.1016/0092-8674(87)90640-4; BIEKER JJ, 1985, CELL, V40, P119, DOI 10.1016/0092-8674(85)90315-0; BIRKENMEIER EH, 1978, CELL, V15, P1077, DOI 10.1016/0092-8674(78)90291-X; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; BOGENHAGEN DF, 1982, CELL, V28, P413, DOI 10.1016/0092-8674(82)90359-2; BOGENHAGEN DF, 1980, CELL, V19, P27, DOI 10.1016/0092-8674(80)90385-2; BOGENHAGEN DF, 1987, RNA POLYM REGULATION, P219; BOULANGER PA, 1987, J BIOL CHEM, V262, P15098; BROWN DD, 1968, SCIENCE, V160, P272, DOI 10.1126/science.160.3825.272; BROWN DD, 1977, P NATL ACAD SCI USA, V74, P2064, DOI 10.1073/pnas.74.5.2064; BROWN DD, 1985, CELL, V42, P759, DOI 10.1016/0092-8674(85)90272-7; BROWN DD, 1984, CELL, V37, P359, DOI 10.1016/0092-8674(84)90366-0; BROWN DD, 1964, J MOL BIOL, V8, P688, DOI 10.1016/S0022-2836(64)80117-0; BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; CAPLAN A, 1987, J MOL BIOL, V193, P57, DOI 10.1016/0022-2836(87)90626-7; CIZEWSKI V, 1983, NUCLEIC ACIDS RES, V11, P7043, DOI 10.1093/nar/11.20.7043; COZZARELLI NR, 1983, CELL, V34, P829, DOI 10.1016/0092-8674(83)90540-8; CUSICK ME, 1983, BIOCHEMISTRY-US, V22, P3873, DOI 10.1021/bi00285a024; DARBY MK, 1988, P NATL ACAD SCI USA, V85, P5516, DOI 10.1073/pnas.85.15.5516; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; EDGAR BA, 1986, CELL, V44, P871, DOI 10.1016/0092-8674(86)90009-7; EDGAR BA, 1986, CELL, V44, P365, DOI 10.1016/0092-8674(86)90771-3; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; FAIRALL L, 1986, J MOL BIOL, V192, P577, DOI 10.1016/0022-2836(86)90278-0; FEDOROFF NV, 1978, CELL, V13, P701, DOI 10.1016/0092-8674(78)90220-9; FELSENFELD G, 1986, CELL, V44, P375, DOI 10.1016/0092-8674(86)90456-3; FINCH JT, 1976, P NATL ACAD SCI USA, V73, P1897, DOI 10.1073/pnas.73.6.1897; FISHER EA, 1986, BIOCHEMISTRY-US, V25, P8010, DOI 10.1021/bi00372a033; FORD PJ, 1973, NATURE-NEW BIOL, V241, P7, DOI 10.1038/newbio241007a0; GALL JG, 1968, P NATL ACAD SCI USA, V60, P553, DOI 10.1073/pnas.60.2.553; GARGIULO G, 1984, CELL, V38, P511, DOI 10.1016/0092-8674(84)90506-3; GILBERT DM, 1986, P NATL ACAD SCI USA, V83, P2924, DOI 10.1073/pnas.83.9.2924; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; GOLDMAN MA, 1984, SCIENCE, V224, P686, DOI 10.1126/science.6719109; GOTTESFELD J, 1982, CELL, V28, P781, DOI 10.1016/0092-8674(82)90057-5; GRAHAM CF, 1966, DEV BIOL, V14, P439, DOI 10.1016/0012-1606(66)90024-8; GUINTA DR, 1986, MOL CELL BIOL, V6, P2536, DOI 10.1128/MCB.6.7.2536; GUINTA DR, 1986, P NATL ACAD SCI USA, V83, P5150, DOI 10.1073/pnas.83.14.5150; GURDON JB, 1982, NATURE, V299, P652, DOI 10.1038/299652a0; HANAS JS, 1983, J BIOL CHEM, V258, P4120; HANAS JS, 1983, P NATL ACAD SCI-BIOL, V80, P2142, DOI 10.1073/pnas.80.8.2142; HANNON R, 1984, J MOL BIOL, V180, P131, DOI 10.1016/0022-2836(84)90434-0; HANNON R, 1986, EMBO J, V5, P3313, DOI 10.1002/j.1460-2075.1986.tb04645.x; HARPER ME, 1983, NUCLEIC ACIDS RES, V11, P2313, DOI 10.1093/nar/11.8.2313; HENTSCHEL CC, 1978, DEV BIOL, V65, P496, DOI 10.1016/0012-1606(78)90044-1; HIRSCHHORN RR, 1984, P NATL ACAD SCI-BIOL, V81, P6004, DOI 10.1073/pnas.81.19.6004; HONDA BM, 1980, CELL, V22, P119, DOI 10.1016/0092-8674(80)90160-9; JACKSON V, 1985, BIOCHEMISTRY-US, V24, P6921, DOI 10.1021/bi00345a026; KIMELMAN D, 1987, CELL, V48, P399, DOI 10.1016/0092-8674(87)90191-7; KORN LJ, 1981, NATURE, V289, P461, DOI 10.1038/289461a0; LAMARCA MJ, 1975, DEV BIOL, V47, P384, DOI 10.1016/0012-1606(75)90292-4; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LIN SY, 1975, CELL, V4, P107, DOI 10.1016/0092-8674(75)90116-6; LOSA R, 1987, CELL, V50, P801, DOI 10.1016/0092-8674(87)90338-2; MAIRY M, 1971, DEV BIOL, V24, P143, DOI 10.1016/0012-1606(71)90092-3; MATTAJ IW, 1985, NATURE, V316, P163, DOI 10.1038/316163a0; MCCONKEY GA, 1988, GENE DEV, V2, P205, DOI 10.1101/gad.2.2.205; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MILLSTEIN L, 1987, J BIOL CHEM, V262, P17100; NASMYTH K, 1987, EMBO J, V6, P243, DOI 10.1002/j.1460-2075.1987.tb04745.x; OTTONELLO S, 1987, EMBO J, V6, P1921, DOI 10.1002/j.1460-2075.1987.tb02452.x; PARDUE ML, 1973, CHROMOSOMA, V42, P191, DOI 10.1007/BF00320940; PARKER CS, 1977, P NATL ACAD SCI USA, V74, P44, DOI 10.1073/pnas.74.1.44; PECK LJ, 1987, MOL CELL BIOL, V7, P3503, DOI 10.1128/MCB.7.10.3503; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PETERSON RC, 1980, CELL, V20, P131, DOI 10.1016/0092-8674(80)90241-X; PICARD B, 1980, EUR J BIOCHEM, V109, P359, DOI 10.1111/j.1432-1033.1980.tb04802.x; PICARD B, 1979, P NATL ACAD SCI USA, V76, P241, DOI 10.1073/pnas.76.1.241; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; RHODES D, 1986, CELL, V46, P123, DOI 10.1016/0092-8674(86)90866-4; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; RINKE J, 1982, CELL, V29, P149, DOI 10.1016/0092-8674(82)90099-X; SAKONJU S, 1981, CELL, V23, P665, DOI 10.1016/0092-8674(81)90429-3; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SAKONJU S, 1980, CELL, V19, P13, DOI 10.1016/0092-8674(80)90384-0; SAKONJU S, 1982, THESIS J HOPKINS U B; SCHLISSEL MS, 1984, CELL, V37, P903, DOI 10.1016/0092-8674(84)90425-2; SCHUMPERLI D, 1986, CELL, V45, P471, DOI 10.1016/0092-8674(86)90277-1; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SETZER DR, 1985, J BIOL CHEM, V260, P2483; SHASTRY BS, 1982, J BIOL CHEM, V257, P2979; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; Taylor J.H., 1987, Results and Problems in Cell Differentiation, V14, P173; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMAS C, 1969, ARCH INT PHYS BIOCH, V77, P402; THOMAS JO, 1983, EUR J BIOCHEM, V134, P109, DOI 10.1111/j.1432-1033.1983.tb07538.x; URSPRUNG H, 1968, STABILITY DIFFERENTI; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; WAKEFIELD L, 1983, EMBO J, V2, P1613, DOI 10.1002/j.1460-2075.1983.tb01632.x; WANDELT C, 1983, NUCLEIC ACIDS RES, V11, P3795, DOI 10.1093/nar/11.11.3795; WEGNEZ M, 1972, FEBS LETT, V25, P13, DOI 10.1016/0014-5793(72)80443-5; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WILLIAMSON P, 1978, BIOCHEMISTRY-US, V17, P5695, DOI 10.1021/bi00619a015; WOLFFE AP, 1987, CELL, V49, P301, DOI 10.1016/0092-8674(87)90279-0; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; WOLFFE AP, 1986, CELL, V47, P217, DOI 10.1016/0092-8674(86)90444-7; WOLFFE AP, 1988, EMBO J, V7, P1071, DOI 10.1002/j.1460-2075.1988.tb02915.x; WOLFFE AP, 1987, CELL, V51, P732, DOI 10.1016/0092-8674(87)90096-1; WORCEL A, 1978, CELL, V15, P969, DOI 10.1016/0092-8674(78)90280-5; WORMINGTON WM, 1982, COLD SPRING HARB SYM, V47, P879; WORMINGTON WM, 1981, CELL, V24, P809, DOI 10.1016/0092-8674(81)90106-9; WORMINGTON WM, 1983, DEV BIOL, V99, P248, DOI 10.1016/0012-1606(83)90273-7	109	199	200	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 23	1988	241	4873					1626	1632		10.1126/science.3420414	http://dx.doi.org/10.1126/science.3420414			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q1372	3420414				2022-12-28	WOS:A1988Q137200028
J	HOLM, C; KIRCHGESSNER, TG; SVENSON, KL; FREDRIKSON, G; NILSSON, S; MILLER, CG; SHIVELY, JE; HEINZMANN, C; SPARKES, RS; MOHANDAS, T; LUSIS, AJ; BELFRAGE, P; SCHOTZ, MC				HOLM, C; KIRCHGESSNER, TG; SVENSON, KL; FREDRIKSON, G; NILSSON, S; MILLER, CG; SHIVELY, JE; HEINZMANN, C; SPARKES, RS; MOHANDAS, T; LUSIS, AJ; BELFRAGE, P; SCHOTZ, MC			HORMONE-SENSITIVE LIPASE - SEQUENCE, EXPRESSION, AND CHROMOSOMAL LOCALIZATION TO 19 CENT-Q13.3	SCIENCE			English	Article									UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MICROBIOL,LOS ANGELES,CA 90024; CITY HOPE NATL MED CTR,BECKMAN RES INT,DIV IMMUNOL,DUARTE,CA 91010; UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,DEPT PEDIAT,TORRANCE,CA 90509; VET ADM WADSWORTH MED CTR,LOS ANGELES,CA 90073	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; City of Hope; Beckman Research Institute of City of Hope; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	HOLM, C (corresponding author), UNIV LUND,DEPT MED & PHYSIOL CHEM 4,POB 94,S-22100 LUND,SWEDEN.		nilsson, staffan/D-1298-2012					ALBRINK MJ, 1974, DUNCANS DIS METABOLI, P417; Belfrage P., 1984, P365; BENAVRAM CM, 1986, P NATL ACAD SCI USA, V83, P4185, DOI 10.1073/pnas.83.12.4185; BODMER MW, 1987, BIOCHIM BIOPHYS ACTA, V909, P237, DOI 10.1016/0167-4781(87)90083-2; BROOK JD, 1984, HUM GENET, V68, P282, DOI 10.1007/BF00292584; CANNON B, 1985, NEW PERSPECTIVES ADI, P223; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOK KG, 1982, EUR J BIOCHEM, V125, P245, DOI 10.1111/j.1432-1033.1982.tb06675.x; COOK KG, 1983, BIOCHIM BIOPHYS ACTA, V752, P46, DOI 10.1016/0005-2760(83)90231-X; DECARO J, 1981, BIOCHIM BIOPHYS ACTA, V671, P129, DOI 10.1016/0005-2795(81)90126-4; DOCHERTY AJP, 1985, NUCLEIC ACIDS RES, V13, P1891, DOI 10.1093/nar/13.6.1891; ENZI G, 1977, J CLIN INVEST, V60, P1221, DOI 10.1172/JCI108881; FREDRIKSON G, 1987, J IMMUNOL METHODS, V97, P65, DOI 10.1016/0022-1759(87)90106-2; GARTON AJ, 1988, FEBS LETT, V229, P68, DOI 10.1016/0014-5793(88)80799-3; HOLM C, 1987, BIOCHEM BIOPH RES CO, V148, P99, DOI 10.1016/0006-291X(87)91081-3; HOLM C, 1986, J BIOL CHEM, V261, P5659; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KOMAROMY MC, 1987, P NATL ACAD SCI USA, V84, P1526, DOI 10.1073/pnas.84.6.1526; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Krebs E G, 1981, Curr Top Cell Regul, V18, P401; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LUSIS AJ, 1986, P NATL ACAD SCI USA, V83, P3929, DOI 10.1073/pnas.83.11.3929; MCLEAN J, 1986, P NATL ACAD SCI USA, V83, P2335, DOI 10.1073/pnas.83.8.2335; NILSSON S, IN PRESS BIOMED CHRO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIVELY JE, 1987, ANAL BIOCHEM, V163, P517, DOI 10.1016/0003-2697(87)90257-0; SPARKES RS, 1986, HUM GENET, V74, P133, DOI 10.1007/BF00282076; STRALFORS P, 1984, P NATL ACAD SCI-BIOL, V81, P3317, DOI 10.1073/pnas.81.11.3317; STRALFORS P, 1987, ENZYMES B, V18, P147; YANGFENG TL, 1985, SCIENCE, V228, P728, DOI 10.1126/science.3873110	33	297	321	2	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 16	1988	241	4872					1503	1506		10.1126/science.3420405	http://dx.doi.org/10.1126/science.3420405			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q0479	3420405				2022-12-28	WOS:A1988Q047900041
J	MELBY, JC				MELBY, JC			THERAPY OF CUSHING DISEASE - A CONSENSUS FOR PITUITARY MICROSURGERY	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											MELBY, JC (corresponding author), BOSTON UNIV HOSP, MED CTR, BOSTON, MA 02218 USA.							AVGERINOS PC, 1987, J CLIN ENDOCR METAB, V65, P906, DOI 10.1210/jcem-65-5-906; CORRIGAN DF, 1977, NEW ENGL J MED, V296, P861, DOI 10.1056/NEJM197704142961508; Cushing H, 1932, B JOHNS HOPKINS HOSP, V50, P137; EISENHARDT L, 1938, YALE J BIOL MED, V11, P507; Hardy J, 1969, Clin Neurosurg, V16, P185; KJELLBERG RN, 1984, SECRETORY TUMORS PIT, P295; LAWS ER, 1982, J NEUROSURG, V56, P739; MAMPALAM TJ, 1988, ANN INTERN MED, V109, P487, DOI 10.7326/0003-4819-109-6-487; SALASSA RM, 1978, MAYO CLIN PROC, V53, P24; SCHRELL U, 1987, J CLIN ENDOCR METAB, V64, P1150, DOI 10.1210/jcem-64-6-1150; STYNE DM, 1984, NEW ENGL J MED, V310, P889, DOI 10.1056/NEJM198404053101405; TYRRELL JB, 1978, NEW ENGL J MED, V298, P753, DOI 10.1056/NEJM197804062981401; YOUNG WF, 1988, MAYO CLIN PROC, V63, P256, DOI 10.1016/S0025-6196(12)65099-X	13	57	57	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1988	109	6					445	446		10.7326/0003-4819-109-6-445	http://dx.doi.org/10.7326/0003-4819-109-6-445			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q2568	3415103				2022-12-28	WOS:A1988Q256800001
J	DIENSTAG, JL; PERRILLO, RP; SCHIFF, ER; BARTHOLOMEW, M; VICARY, C; RUBIN, M				DIENSTAG, JL; PERRILLO, RP; SCHIFF, ER; BARTHOLOMEW, M; VICARY, C; RUBIN, M			A PRELIMINARY TRIAL OF LAMIVUDINE FOR CHRONIC HEPATITIS-B INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA-INTERFERON; E-ANTIGEN	Background. Better treatments for chronic hepatitis B are needed. Lamivudine, the (-)enantiomer of 3'-thiacytidine, is a potent inhibitor of hepatitis B virus (HBV). Methods. In a double-blind trial, we randomly assigned 32 patients with chronic hepatitis B (including 17 who had no response to earlier treatment with interferon) to receive 25, 100, or 300 mg of oral lamivudine daily for 12 weeks. The patients were then followed for 24 additional weeks. All the patients had hepatitis B e antigen in serum. Results. Levels of HBV DNA became undetectable (less than or equal to 1.5 pg per milliliter) in 70 percent of the patients who received the 25-mg dose of lamivudine and 100 percent of those treated with the 100-mg or 300-mg dose. In most patients, HBV DNA reappeared after therapy was completed; however, six patients (19 percent), including five who had not responded to interferon, had sustained suppression of HBV DNA accompanied by normalization of alanine aminotransferase levels. Hepatitis B e antigen disappeared in four of these six patients (12 percent), three of whom nad had no response to interferon. Levels of HBV DNA fell in all patients, including those who had had high levels at base line or normal alanine aminotransferase levels at base line, but sustained responses were more likely in patients with initially low HBV DNA levels and high alanine aminotransferase levels, During or after therapy, alanine aminotransferase levels at least doubled in five patients (50 percent) given the 25-mg dose and eight patients (36 percent) given the 100-mg or 300-mg dose. Minor adverse events occurred that were not related to the dose, as did transient, asymptomatic elevations of amylase, lipase, and creatine kinase levels. Conclusions. In a preliminary trial, 12 weeks of lamivudine therapy was well tolerated, and daily doses of 100 mg and 300 mg reduced HBV DNA to undetectable levels.	MASSACHUSETTS GEN HOSP,CTR LIVER BILIARY PANCREAS,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; ALTON OCHSNER MED FDN & OCHSNER CLIN,DIV GASTROENTEROL,NEW ORLEANS,LA 70121; UNIV MIAMI,SCH MED,CTR LIVER DIS,MIAMI,FL; VET AFFAIRS MED CTR,MIAMI,FL 33125; GLAXO INC,RES INST,RES TRIANGLE PK,NC 27709	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Ochsner Health System; University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA); GlaxoSmithKline	DIENSTAG, JL (corresponding author), MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,BOSTON,MA 02114, USA.			Dienstag, Jules/0000-0001-7024-0980	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1RR01066] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BENHAMOU Y, 1985, LANCET, V345, P396; COLACINO JM, 1994, ANTIMICROB AGENTS CH, V38, P1997, DOI 10.1128/AAC.38.9.1997; CUI LX, 1995, J CLIN INVEST, V95, P555, DOI 10.1172/JCI117698; DIBISCEGLIE AM, 1993, AM J GASTROENTEROL, V88, P1887; DOONG SL, 1991, P NATL ACAD SCI USA, V88, P8495, DOI 10.1073/pnas.88.19.8495; FRIED MW, 1992, HEPATOLOGY, V16, pA127; HOOFNAGLE JH, 1984, GASTROENTEROLOGY, V86, P150; HOOFNAGLE JH, 1988, GASTROENTEROLOGY, V95, P1318, DOI 10.1016/0016-5085(88)90367-8; HOOFNAGLE JH, 1981, ANN INTERN MED, V94, P744, DOI 10.7326/0003-4819-94-6-744; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; LAU D, 1994, HEPATOLOGY, V20, pA189; LEVINE ES, 1994, HEPATOLOGY, V20, pA189; LEWIS W, 1994, BIOCHEMISTRY-US, V33, P14620, DOI 10.1021/bi00252a030; MCKENZIE R, 1995, NEW ENGL J MED, V333, P1099, DOI 10.1056/NEJM199510263331702; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503; PERRILLO RP, 1990, HEPATOLOGY, V12, P1433, DOI 10.1002/hep.1840120626; RICHARDSON FC, 1994, P NATL ACAD SCI USA, V91, P12003, DOI 10.1073/pnas.91.25.12003; SALLIE R, 1994, HEPATOLOGY, V20, pA209; Tyrrell D. L. J., 1993, Clinical and Investigative Medicine, V16, pB77; TYRRELL DLJ, 1993, HEPATOLOGY, V18, pA112, DOI 10.1016/0270-9139(93)91978-2; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011; ZOULIM F, 1994, J HEPATOL, V21, P142, DOI 10.1016/S0168-8278(05)80386-1	22	752	771	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 21	1995	333	25					1657	1661		10.1056/NEJM199512213332501	http://dx.doi.org/10.1056/NEJM199512213332501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL401	7477217				2022-12-28	WOS:A1995TL40100001
J	MARLER, JR; BROTT, T; BRODERICK, J; KOTHARI, R; ODONOGHUE, M; BARSAN, W; TOMSICK, T; SPILKER, J; MILLER, R; SAUERBECK, L; JARRELL, J; KELLY, J; PERKINS, T; MCDONALD, T; RORICK, M; HICKEY, C; ARMITAGE, J; PERRY, C; THALINGER, K; RHUDE, R; SCHILL, J; BECKER, PS; HEATH, RS; ADAMS, D; REED, R; KLEI, M; HUGHES, S; ANTHONY, J; BAUDENDISTEL, D; ZADICOFF, C; RYMER, M; BETTINGER, I; LAUBINGER, P; SCHMERLER, M; MEIROSE, G; LYDEN, P; RAPP, K; BABCOCK, T; DAUM, P; PERSONA, D; BRODY, M; JACKSON, C; LEWIS, S; LISS, J; MAHDAVI, Z; ROTHROCK, J; TOM, T; ZWEIFLER, R; DUNFORD, J; ZIVIN, J; KOBAYASHI, R; KUNIN, J; LICHT, J; ROWEN, R; STEIN, D; GRISOLIA, J; MARTIN, F; CHAPLIN, E; KAPLITZ, N; NELSON, J; NEUREN, A; SILVER, D; CHIPPENDALE, T; DIAMOND, E; LOBATZ, M; MURPHY, D; ROSENBERG, D; RUEL, T; SADOFF, M; SCHIM, J; SCHLEIMER, J; ATKINSON, R; WENTWORTH, D; CUMMINGS, R; FRINK, R; HEUBLEIN, P; GROTTA, JC; DEGRABA, T; FISHER, M; RAMIREZ, A; HANSON, S; MORGENSTERN, L; SILLS, C; PASTEUR, W; YATSU, F; ANDREWS, K; VILLARCORDOVA, C; PEPE, P; BRATINA, P; GREENBERG, L; ROZEK, S; SIMMONS, K; KWIATKOWSKI, TG; HOROWITZ, SH; LIBMAN, R; KANNER, R; SILVERMAN, R; LAMANTIA, J; MEALIE, C; DUARTE, R; DONNARUMMA, R; OKOLA, M; CULLIN, V; MITCHELL, E; LEVINE, SR; LEWANDOWSKI, CA; TOKARSKI, G; RAMADAN, NM; MITSIAS, P; GORMAN, M; ZAROWITZ, B; KOKKINOS, J; DAYNO, J; VERRO, P; GYMNOPOULOS, C; DAFER, R; DOLHABERRIAGUE, L; SAWAYA, K; DALEY, S; MITCHELL, M; FRANKEL, M; MACKAY, B; BARCH, C; BRAIMAH, J; FAHERTY, B; MACDONALD, J; SAILOR, S; COOK, A; KARP, H; NGUYEN, B; WASHINGTON, J; WEISSMAN, J; WILLIAMS, M; WILLIAMSON, T; KOZINN, M; HELLWICK, L; HALEY, EC; BLECK, TP; CAIL, WS; LINDBECK, GH; GRANNER, MA; WOLF, SS; GWYNN, MW; METTETAL, RW; CHANG, CWJ; SOLENSKI, NJ; BROCK, DG; FORD, GF; KONGABLE, GL; PARKS, KN; WILKINSON, SS; DAVIS, MK; SHEPPARD, GL; ZONTINE, DW; GUSTIN, KH; CROWE, NM; MASSEY, SL; MEYER, M; GAINES, K; PAYNE, A; BALES, C; MALCOLM, J; BARLOW, R; WILSON, M; CAPE, C; BERTORINI, T; MISULIS, K; PAULSEN, W; SHEPARD, D; TILLEY, BC; WELCH, KMA; FAGAN, SC; LU, M; PATEL, S; MASHA, E; VERTER, J; BOURA, J; MAIN, J; GORDON, L; MADDY, N; CHOCIEMSKI, T; WINDHAM, J; ZADEH, HS; ALVES, W; KELLER, MF; WENZEL, JR; RAMAN, N; CANTWELL, L; WARREN, A; SMITH, K; BAILEY, E; WELCH, KMA; TILLEY, BC; FROEHLICH, J; BREED, J; EASTON, JD; HALLENBECK, JF; LAN, G; MARSH, JD; WALKER, MD				MARLER, JR; BROTT, T; BRODERICK, J; KOTHARI, R; ODONOGHUE, M; BARSAN, W; TOMSICK, T; SPILKER, J; MILLER, R; SAUERBECK, L; JARRELL, J; KELLY, J; PERKINS, T; MCDONALD, T; RORICK, M; HICKEY, C; ARMITAGE, J; PERRY, C; THALINGER, K; RHUDE, R; SCHILL, J; BECKER, PS; HEATH, RS; ADAMS, D; REED, R; KLEI, M; HUGHES, S; ANTHONY, J; BAUDENDISTEL, D; ZADICOFF, C; RYMER, M; BETTINGER, I; LAUBINGER, P; SCHMERLER, M; MEIROSE, G; LYDEN, P; RAPP, K; BABCOCK, T; DAUM, P; PERSONA, D; BRODY, M; JACKSON, C; LEWIS, S; LISS, J; MAHDAVI, Z; ROTHROCK, J; TOM, T; ZWEIFLER, R; DUNFORD, J; ZIVIN, J; KOBAYASHI, R; KUNIN, J; LICHT, J; ROWEN, R; STEIN, D; GRISOLIA, J; MARTIN, F; CHAPLIN, E; KAPLITZ, N; NELSON, J; NEUREN, A; SILVER, D; CHIPPENDALE, T; DIAMOND, E; LOBATZ, M; MURPHY, D; ROSENBERG, D; RUEL, T; SADOFF, M; SCHIM, J; SCHLEIMER, J; ATKINSON, R; WENTWORTH, D; CUMMINGS, R; FRINK, R; HEUBLEIN, P; GROTTA, JC; DEGRABA, T; FISHER, M; RAMIREZ, A; HANSON, S; MORGENSTERN, L; SILLS, C; PASTEUR, W; YATSU, F; ANDREWS, K; VILLARCORDOVA, C; PEPE, P; BRATINA, P; GREENBERG, L; ROZEK, S; SIMMONS, K; KWIATKOWSKI, TG; HOROWITZ, SH; LIBMAN, R; KANNER, R; SILVERMAN, R; LAMANTIA, J; MEALIE, C; DUARTE, R; DONNARUMMA, R; OKOLA, M; CULLIN, V; MITCHELL, E; LEVINE, SR; LEWANDOWSKI, CA; TOKARSKI, G; RAMADAN, NM; MITSIAS, P; GORMAN, M; ZAROWITZ, B; KOKKINOS, J; DAYNO, J; VERRO, P; GYMNOPOULOS, C; DAFER, R; DOLHABERRIAGUE, L; SAWAYA, K; DALEY, S; MITCHELL, M; FRANKEL, M; MACKAY, B; BARCH, C; BRAIMAH, J; FAHERTY, B; MACDONALD, J; SAILOR, S; COOK, A; KARP, H; NGUYEN, B; WASHINGTON, J; WEISSMAN, J; WILLIAMS, M; WILLIAMSON, T; KOZINN, M; HELLWICK, L; HALEY, EC; BLECK, TP; CAIL, WS; LINDBECK, GH; GRANNER, MA; WOLF, SS; GWYNN, MW; METTETAL, RW; CHANG, CWJ; SOLENSKI, NJ; BROCK, DG; FORD, GF; KONGABLE, GL; PARKS, KN; WILKINSON, SS; DAVIS, MK; SHEPPARD, GL; ZONTINE, DW; GUSTIN, KH; CROWE, NM; MASSEY, SL; MEYER, M; GAINES, K; PAYNE, A; BALES, C; MALCOLM, J; BARLOW, R; WILSON, M; CAPE, C; BERTORINI, T; MISULIS, K; PAULSEN, W; SHEPARD, D; TILLEY, BC; WELCH, KMA; FAGAN, SC; LU, M; PATEL, S; MASHA, E; VERTER, J; BOURA, J; MAIN, J; GORDON, L; MADDY, N; CHOCIEMSKI, T; WINDHAM, J; ZADEH, HS; ALVES, W; KELLER, MF; WENZEL, JR; RAMAN, N; CANTWELL, L; WARREN, A; SMITH, K; BAILEY, E; WELCH, KMA; TILLEY, BC; FROEHLICH, J; BREED, J; EASTON, JD; HALLENBECK, JF; LAN, G; MARSH, JD; WALKER, MD			TISSUE-PLASMINOGEN ACTIVATOR FOR ACUTE ISCHEMIC STROKE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLINICAL-TRIALS; SEQUENTIAL BOUNDARIES; URGENT THERAPY; OUTCOMES; DISCRETE; MINUTES	Background. Thrombolytic therapy for acute ischemic stroke has been approached cautiously because there were high rates of intracerebral hemorrhage in early clinical trials. We performed a randomized, double-blind trial of intravenous recombinant tissue plasminogen activator (t-PA) for ischemic stroke after recent pilot studies suggested that t-PA was beneficial when treatment was begun within three hours of the onset of stroke. Methods. The trial had two parts, Part 1 (in which 291 patients were enrolled) tested whether t-PA had clinical activity, as indicated by an improvement of 4 points over base-line values in the score of the National Institutes of Health Stroke scale (NIHSS) or the resolution of the neurologic deficit within 24 hours of the onset of stroke. Part 2 (in which 333 patients were enrolled) used a global test statistic to assess clinical outcome at three months, according to scores on the Barthel index, modified Rankin scale, Glasgow outcome scale, and NIHSS. Results. In part 1, there was no significant difference between the group given t-PA and that given placebo in the percentages of patients with neurologic improvement at 24 hours, although a benefit was observed for the t-PA group at three months for all four outcome measures. In part 2, the long-term clinical benefit of t-PA predicted by the results of part 1 was confirmed (global odds ratio for a favorable outcome, 1.7; 95 percent confidence interval, 1.2 to 2.6). As compared with patients given placebo, patients treated with t-PA were at least 30 percent more likely to have minimal or no disability at three months on the assessment scales. Symptomatic intracerebral hemorrhage within 36 hours after the onset of stroke occurred in 6.4 percent of patients given t-PA but only 0.6 percent of patients given placebo (P<0.001). Mortality at three months was 17 percent in the t-PA group and 21 percent in the placebo group (P=0.30). Conclusions. Despite an increased incidence of symptomatic intracerebral hemorrhage, treatment with intravenous t-PA within three hours of the onset of ischemic stroke improved clinical outcome at three months.	UNIV CINCINNATI,CTR CLIN,CINCINNATI,OH; BETHESDA N HOSP,BETHESDA,MD; PROVIDENCE HOSP,PROVIDENCE,RI; ST LUKE HOSP W,FLORENCE,KY; ST ELIZABETH HOSP N,CINCINNATI,OH; BETHESDA OAK HOSP,BETHESDA,MD; ST LUKES HOSP,KANSAS CITY,KS; UNIV CALIF SAN DIEGO,SAN DIEGO,CA 92103; SHARP MEM HOSP & REHABIL CTR,SAN DIEGO,CA 92123; SCRIPPS CLIN & HOSP,LA JOLLA,CA; TRI CITY MED CTR,OCEANSIDE,CA 92056; MERCY GEN HOSP,SACRAMENTO,CA; UNIV TEXAS,SCH MED,HOUSTON,TX; HOUSTON FIRE DEPT,EMERGENCY MED SERV,HOUSTON,TX; HERMANN HOSP,HOUSTON,TX 77030; ST LUKES EPISCOPAL HOSP,HOUSTON,TX 77225; LONG ISL JEWISH MED CTR,NEW HYDE PK,NY 11042; EMORY UNIV,SCH MED,ATLANTA,GA; GRADY MEM HOSP,ATLANTA,GA 30335; EMORY UNIV,CRAWFORD LONG HOSP,ATLANTA,GA 30365; EMORY UNIV HOSP,ATLANTA,GA 30322; UNIV VIRGINIA,HLTH SCI CTR,CHARLOTTESVILLE,VA 22903; WINCHESTER MED CTR,WINCHESTER,VA; UNIV TENNESSEE,KNOXVILLE,TN 37996; BAPTIST MEM HOSP,MEMPHIS,TN 38146; JACKSON MADISON CTY GEN HOSP,JACKSON,TN; UNIV TENNESSEE,MED CTR,KNOXVILLE,TN 37996; UNIV VIRGINIA,MED CTR,CHARLOTTESVILLE,VA 22903; HENRY FORD HOSP,CENT LAB,DETROIT,MI 48202; GENENTECH INC,S SAN FRANCISCO,CA 94080; NINCDS,PROJECT OFF,BETHESDA,MD 20892	University System of Ohio; University of Cincinnati; University of California System; University of California San Diego; Sharp Memorial Hospital Rehabilitation & Physical Therapy; Scripps Research Institute; University of Texas System; Saint Lukes Episcopal Hospital; Northwell Health; Emory University; Emory University; Emory University; University of Virginia; University of Tennessee System; University of Tennessee Knoxville; Baptist Memorial Hospital Memphis; University of Tennessee System; University of Tennessee Health Science Center; University of Virginia; Henry Ford Health System; Henry Ford Hospital; Roche Holding; Genentech; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	MARLER, JR (corresponding author), NINCDS,DIV STROKE & TRAUMA,FED BLDG,RM 800,7550 WISCONSIN AVE,BETHESDA,MD 20892, USA.		Fagan, Susan C/D-3281-2009; Gaines, Kenneth/D-4730-2011; Bleck, Thomas/R-2286-2019; Grotta, James/AAH-7423-2021; Bleck, Thomas/D-3772-2009	Bleck, Thomas/0000-0002-8267-9787; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [N01NS002382, N01NS002377, N01NS002374] Funding Source: NIH RePORTER; NINDS NIH HHS [N01-NS-02374, N01-NS-02382, N01-NS-02377] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBANESE MA, 1994, STROKE, V25, P1746, DOI 10.1161/01.STR.25.9.1746; BROTT TG, 1992, STROKE, V23, P632, DOI 10.1161/01.STR.23.5.632; DELZOPPO GJ, 1992, ANN NEUROL, V32, P78, DOI 10.1002/ana.410320113; DEMETS DL, 1982, BIOMETRIKA, V69, P661; DEMETS DL, 1980, BIOMETRIKA, V67, P651; DONNAN GA, 1995, LANCET, V346, P56, DOI 10.1016/S0140-6736(95)92689-5; Fibrinolytic 'Therapy Trialists' (FTT) Collaborative Group, 1994, LANCET, V343, P311; FIESCHI C, 1989, J NEUROL SCI, V91, P311, DOI 10.1016/0022-510X(89)90060-9; FLETCHER AP, 1976, STROKE, V7, P135, DOI 10.1161/01.STR.7.2.135; Friedman LM, 1985, FUNDAMENTALS CLIN TR; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; HALEY EC, 1992, STROKE, V23, P641, DOI 10.1161/01.STR.23.5.641; HALEY EC, 1993, J NEUROSURG, V78, P537, DOI 10.3171/jns.1993.78.4.0537; HALEY EC, 1993, STROKE, V24, P1000, DOI 10.1161/01.STR.24.7.1000; HOMMEL M, 1995, LANCET, V345, P57, DOI 10.1016/S0140-6736(95)91179-0; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LEFKOPOULOU M, 1989, J AM STAT ASSOC, V84, P810, DOI 10.2307/2289671; LEVY DE, 1994, STROKE, V25, P291, DOI 10.1161/01.STR.25.2.291; LYDEN P, 1994, STROKE, V25, P2220, DOI 10.1161/01.STR.25.11.2220; LYDEN PD, IN PRESS THROMBOLYTI, V3; MAHONEY F I, 1965, Md State Med J, V14, P61; MEYER JOHN S., 1965, P200; MORI E, 1992, NEUROLOGY, V42, P976, DOI 10.1212/WNL.42.5.976; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; POCOCK SJ, 1987, BIOMETRICS, V43, P487, DOI 10.2307/2531989; TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; ZIVIN JA, 1985, SCIENCE, V230, P1289, DOI 10.1126/science.3934754; 1994, CARDIOVASCULAR DISEA; 1992, STROKE, V23, P3; 1992, STROKE, V23, P615; 1994, LANCET, V343, P742	33	7944	8096	9	407	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 14	1995	333	24					1581	1587		10.1056/nejm199512143332401	http://dx.doi.org/10.1056/nejm199512143332401			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK065	7477192	Bronze			2022-12-28	WOS:A1995TK06500001
J	MANABE, YC; VINETZ, JM; MOORE, RD; MERZ, C; CHARACHE, P; BARTLETT, JG				MANABE, YC; VINETZ, JM; MOORE, RD; MERZ, C; CHARACHE, P; BARTLETT, JG			CLOSTRIDIUM DIFICILE COLITIS - AN EFFICIENT CLINICAL APPROACH TO DIAGNOSIS	ANNALS OF INTERNAL MEDICINE			English	Article						CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; DIARRHEA; TOXINS; FECES	DIFFICILE-ASSOCIATED DIARRHEA; RISK-FACTORS; HOSPITALIZED-PATIENTS; TOXIN; INFECTION; COHORT	Objective: To define clinical and laboratory variables that suggest the presence of Clostridium difficile colitis and to establish the number of stool specimens needed to reasonably exclude the diagnosis of C. difficile colitis. Design: Prospective study of consecutive inpatients whose stool specimens were sent to be evaluated for the presence of C. difficile toxin. Setting: University teaching hospital. Patients: 268 hospital inpatients in medical, surgical, and gynecology units. Measurements: Structured history and physical examination; detection of C. difficile toxin by cytotoxin tissue-culture assay with anti-C. difficile antiserum neutralization and by enzyme-linked immunoassay (EIA) for C. difficile toxins A and B; and detection of fecal leukocytes by microscopic examination and by latex agglutination lactoferrin assay. Results: 43 of 268 consecutive inpatients were positive for C. difficile toxin by EIA or tissue-culture assay. Although toxin was detected by EIA alone in 39 of the 43 patients, it was detected in an additional 4 patients (10%) by tissue-culture assay alone. Univariate and multivariate logistic regression analysis showed that the following clinical and laboratory features were associated with C. difficile toxin positivity: the onset of diarrhea 6 or more days after the administration of antibiotics (odds ratio, 1.38 [95% CI, 1.10 to 3.79]); hospital stay longer than 15 days (odds ratio, 1.33 [CI, 1.09 to 3.95]); the presence of fecal leukocytes determined by microscopy (odds ratio, 2.39 [CI, 1.05 to 5.42]) or lactoferrin assay (odds ratio, 3.74 [CI, 1.80 to 7.76]); the presence of semiformed (as opposed to watery) stools (odds ratio, 2.33 [CI, 1.10 to 4.90]); and cephalosporin use (odds ratio, 2.36 [CI, 1.10 to 5.09]). Toxin-positive patients were no more likely than controls to have had fever, abdominal pain or cramps, leukocytosis, green-colored diarrhea, or blood in the stool or to have received clindamycin or penicillin derivatives. Of the 43 patients with C. difficile toxin, 34 (79%) had positive results for the toxin on the first stool specimen, 5 (cumulative, 91%) had positive results on the second specimen, and 4 had positive results on the third specimen. Overall, the negative predictive value of the first stool specimen was 97%. All patients who had two or more clinical or laboratory predictors were diagnosed with C. difficile disease when either the first or the second stool specimen was positive for toxin. Conclusions: Clinicians at the bedside can use readily available clinical and laboratory information to decide which patients are likely to have C. difficile disease and when it is appropriate and useful to order specific diagnostic tests for C. difficile toxin. Such data are also useful in determining the number of stool samples that reasonably excludes the diagnosis of C. difficile colitis.	JOHNS HOPKINS UNIV, SCH MED, DIV INFECT DIS, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DIV INTERNAL MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV HOSP, CLIN MICROBIOL LAB, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, BALTIMORE, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University				Vinetz, Joseph/0000-0001-8344-2004				ANAND A, 1994, AM J GASTROENTEROL, V89, P519; BARTLETT JG, 1990, REV INFECT DIS, V12, pS243, DOI 10.1093/clinids/12.Supplement_2.S243; BARTLETT JG, 1978, NEW ENGL J MED, V298, P531, DOI 10.1056/NEJM197803092981003; BORRIELLO SP, 1992, EUR J CLIN MICROBIOL, V11, P360, DOI 10.1007/BF01962079; BOWMAN RA, 1986, FEMS MICROBIOL LETT, V34, P31, DOI 10.1016/0378-1097(86)90265-X; BROWN E, 1990, INFECT CONT HOSP EP, V11, P283; FEKETY R, 1993, JAMA-J AM MED ASSOC, V269, P71, DOI 10.1001/jama.269.1.71; GERDING DN, 1989, ANN INTERN MED, V110, P255, DOI 10.7326/0003-4819-110-4-255; GERDING DN, 1986, ARCH INTERN MED, V146, P95, DOI 10.1001/archinte.146.1.95; GUERRANT RL, 1992, J CLIN MICROBIOL, V30, P1238, DOI 10.1128/JCM.30.5.1238-1242.1992; MCFARLAND LV, 1991, INFECT IMMUN, V59, P2456, DOI 10.1128/IAI.59.7.2456-2462.1991; MCFARLAND LV, 1990, J INFECT DIS, V162, P678, DOI 10.1093/infdis/162.3.678; MERZ CS, 1994, J CLIN MICROBIOL, V32, P1142, DOI 10.1128/JCM.32.5.1142-1147.1994; MOGG GAG, 1979, BRIT J SURG, V66, P738, DOI 10.1002/bjs.1800661017; TEDESCO FJ, 1974, ANN INTERN MED, V81, P429, DOI 10.7326/0003-4819-81-4-429; THIBAULT A, 1991, INFECT CONT HOSP EP, V12, P345, DOI 10.2307/30145209; VISCIDI R, 1981, GASTROENTEROLOGY, V81, P5; YONG WH, 1994, J CLIN MICROBIOL, V32, P1360, DOI 10.1128/JCM.32.5.1360-1361.1994	18	133	137	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1995	123	11					835	+		10.7326/0003-4819-123-11-199512010-00004	http://dx.doi.org/10.7326/0003-4819-123-11-199512010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG209	7486465				2022-12-28	WOS:A1995TG20900004
J	LUECKE, H; CHANG, BT; MAILLIARD, WS; SCHLAEPFER, DD; HAIGLER, HT				LUECKE, H; CHANG, BT; MAILLIARD, WS; SCHLAEPFER, DD; HAIGLER, HT			CRYSTAL-STRUCTURE OF THE ANNEXIN-XII HEXAMER AND IMPLICATIONS FOR BILAYER INSERTION	NATURE			English	Article							SELF-ASSOCIATION; CALCIUM; SYNEXIN; IDENTIFICATION; RESOLUTION; MEMBRANES; CHANNELS	ANNEXINS are a family of calcium- and phospholipid-binding proteins(1,2) implicated in a number of biological processes including membrane fusion(3) and ion channel formation(4-7). The crystal structure of the annexin XII hexamer, refined at 2.8 Angstrom resolution, forms a concave disk with 3-2 symmetry, about 100 Angstrom in diameter and 70 Angstrom thick with a central hydrophilic pore. Six intermolecular Ca2+ ions are involved in hexamer formation. An additional 18 Ca2+ ions are located on the perimeter of the disk, accessible only from the side of the hexameric disk. On the basis of the hexamer structure we propose here a new mode of protein-phospholipid bilayer interaction that is distinct from the hydrophobic insertion of typical membrane proteins. This speculative model postulates the Ca2+-dependent insertion of the hydrophilic annexin XII hexamer into phospholipid bilayers with local reorientation of the bilayer phospholipids.	UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717	University of California System; University of California Irvine	LUECKE, H (corresponding author), STANFORD SYNCHROTRON RADIAT LAB,MS 69,STANFORD,CA 94305, USA.		Luecke, Hartmut/F-4712-2012; Haigler, Harry/C-3788-2011	Luecke, Hartmut/0000-0002-4938-0775; 				AHN NG, 1988, J BIOL CHEM, V262, P18657; BERENDES R, 1993, SCIENCE, V262, P427, DOI 10.1126/science.7692599; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BURGER A, 1994, J MOL BIOL, V237, P479, DOI 10.1006/jmbi.1994.1249; CONCHA NO, 1992, FEBS LETT, V314, P159, DOI 10.1016/0014-5793(92)80964-I; CREUTZ CE, 1979, J BIOL CHEM, V254, P553; CREUTZ CE, 1978, J BIOL CHEM, V253, P2858; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DEMANGE P, 1994, TRENDS BIOCHEM SCI, V19, P272, DOI 10.1016/0968-0004(94)90002-7; Hille B., 1992, IONIC CHANNELS EXCIT; HOLLAND DR, 1990, J BIOL CHEM, V265, P17649; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; HUBER R, 1990, EMBO J, V99, P3867; JOST M, 1994, BIOCHEM J, V298, P553, DOI 10.1042/bj2980553; LECKBAND DE, 1992, SCIENCE, V255, P1419, DOI 10.1126/science.1542789; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; Moss S. E, 1992, ANNEXINS; MOSSER G, 1991, J MOL BIOL, V217, P241, DOI 10.1016/0022-2836(91)90538-H; NEUMANN JM, 1994, EUR J BIOCHEM, V225, P819, DOI 10.1111/j.1432-1033.1994.0819b.x; POLLARD HB, 1988, P NATL ACAD SCI USA, V85, P2974, DOI 10.1073/pnas.85.9.2974; ROJAS E, 1990, J BIOL CHEM, V265, P21207; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SCHLAEPFER DD, 1992, J BIOL CHEM, V267, P9529; SMART OS, 1994, BIOCHEM SOC T, V22, pS146, DOI 10.1042/bst022146s; SWAIRJO MA, 1994, REV BIOPHYS BIOMOLEC, V23, P193; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; VOGES D, 1994, J MOL BIOL, V238, P199, DOI 10.1006/jmbi.1994.1281; WEAVER JC, 1993, ANN NY ACAD SCI, V720, P141; WENG XW, 1993, PROTEIN SCI, V2, P448; ZAKS WJ, 1991, BIOCHEMISTRY-US, V30, P9607, DOI 10.1021/bi00104a007	30	125	128	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					512	515		10.1038/378512a0	http://dx.doi.org/10.1038/378512a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477411				2022-12-28	WOS:A1995TH05400077
J	XIA, ZG; DICKENS, M; RAINGEAUD, J; DAVIS, RJ; GREENBERG, ME				XIA, ZG; DICKENS, M; RAINGEAUD, J; DAVIS, RJ; GREENBERG, ME			OPPOSING EFFECTS OF ERK AND JNK-P38 MAP KINASES ON APOPTOSIS	SCIENCE			English	Article							NERVE GROWTH-FACTOR; PROGRAMMED CELL-DEATH; MICROTUBULE-ASSOCIATED PROTEIN-2; PC12 CELLS; PHEOCHROMOCYTOMA CELLS; SYMPATHETIC NEURONS; SIGNAL-TRANSDUCTION; FACTOR DEPRIVATION; FACTOR WITHDRAWAL; PROTO-ONCOGENE	Apoptosis plays an important role during neuronal development, and defects in apoptosis may underlie various neurodegenerative disorders, To characterize molecular mechanisms that regulate neuronal apoptosis, the contributions to cell death of mitogen-activated protein (MAP) kinase family members, including ERK (extracellular signal-regulated kinase), JNK (c-JUN NH2-terminal protein kinase), and p38, were examined after withdrawal of nerve growth factor (NGF) from rat PC-12 pheochromocytoma cells. NGF withdrawal led to sustained activation of the JNK and p38 enzymes and inhibition of ERKs, The effects of dominant-interfering or constitutively activated forms of various components of the JNK-p38 and ERK signaling pathways demonstrated that activation of JNK and p38 and concurrent inhibition of ERK are critical for induction of apoptosis in these cells. Therefore, the dynamic balance between growth factor-activated ERK and stress-activated JNK-p38 pathways may be important in determining whether a cell survives or undergoes apoptosis.	CHILDRENS HOSP,DEPT NEUROL,DIV NEUROSCI,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester			Dickens, Martin/B-2001-2012		NCI NIH HHS [CA43855, CA65861] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043855, R01CA065861] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1993, MOL CELL BIOCHEM, V127, P201; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOONSTRA J, 1983, J CELL BIOL, V97, P92, DOI 10.1083/jcb.97.1.92; BORASIO GD, 1989, NEURON, V2, P1087; BORASIO GD, 1993, J CELL BIOL, V121, P665, DOI 10.1083/jcb.121.3.665; BUCKMASTER EA, 1994, EUR J NEUROSCI, V6, P1316, DOI 10.1111/j.1460-9568.1994.tb00322.x; CAMPBELL JS, 1995, RECENT PROG HORM RES, V50, P131; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DINARELLO CA, 1994, EUR CYTOKINE NETW, V5, P517; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FERRARI G, 1993, J NEUROSCI, V13, P1879; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1982, DEV BIOL, V91, P305, DOI 10.1016/0012-1606(82)90037-9; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KOIKE T, 1992, PROG NEUROPSYCHOPHAR, V16, P65; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAINGEAUD J, UNPUB; RAPP UR, 1994, ONCOGENE, V9, P3493; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SIUSS HK, 1994, MOL CELL BIOL, V14, P8376; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TENG KK, 1993, J NEUROSCI, V13, P3124; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TOGARI A, 1983, BIOCHEM BIOPH RES CO, V114, P1189, DOI 10.1016/0006-291X(83)90688-5; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZY, UNPUB; YAN MH, 1994, NATURE, V372, P798; YOUNG SW, 1994, FEBS LETT, V338, P212, DOI 10.1016/0014-5793(94)80367-6	81	4907	5109	7	390	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 24	1995	270	5240					1326	1331		10.1126/science.270.5240.1326	http://dx.doi.org/10.1126/science.270.5240.1326			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF899	7481820				2022-12-28	WOS:A1995TF89900029
J	ROTHMAN, KJ; MOORE, LL; SINGER, MR; NGUYEN, USDT; MANNINO, S; MILUNSKY, A				ROTHMAN, KJ; MOORE, LL; SINGER, MR; NGUYEN, USDT; MANNINO, S; MILUNSKY, A			TERATOGENICITY OF HIGH VITAMIN-A INTAKE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HYPERVITAMINOSIS-A; SUPPLEMENTATION; CONGENERS; DEFECTS	Background. Studies in animals indicate that natural forms of vitamin A are teratogenic. Synthetic retinoids chemically similar to vitamin A cause birth defects in humans; as in animals, the defects appear to affect tissues derived from the cranial neural crest. Methods. Between October 1984 and June 1987, we identified 22,748 pregnant women when they underwent screening either by measurement of maternal serum alpha-fetoprotein or by amniocentesis. Nurse interviewers obtained information on the women's diet, medications, and illnesses during the first trimester of pregnancy, as well as information on their family and medical history and exposure to environmental agents. We obtained information on the outcomes of pregnancy from the obstetricians who delivered the babies or from the women themselves. Of the 22,748 women, 339 had babies with birth defects; 121 of these babies had defects occurring in sites that originated in the cranial neural crest. Results. For defects associated with cranial-neural-crest tissue, the ratio of the prevalence among the babies born to women who consumed more than 15,000 IU of preformed vitamin A per day from food and supplements to the prevalence among the babies whose mothers consumed 5000 IU or less per day was 3.5 (95 percent confidence interval, 1.7 to 7.3). For vitamin A from supplements alone, the ratio of the prevalence among the babies born to women who consumed more than 10,000 IU per day to that among the babies whose mothers consumed 5000 IU or less per day was 4.8 (95 percent confidence interval, 2.2 to 10.5). Using a smoothed regression curve, we found an apparent threshold near 10,000 IU per day of supplemental vitamin A. The increased frequency of defects was concentrated among the babies born to women who had consumed high levels of vitamin A before the seventh week of gestation. Conclusions. High dietary intake of preformed vitamin A appears to be teratogenic. Among the babies born to women who took more than 10,000 IU of preformed vitamin A per day in the form of supplements, we estimate that about 1 infant in 57 had a malformation attributable to the supplement.	BOSTON UNIV,SCH MED,CTR HUMAN GENET,BOSTON,MA 02118; UNIV G DANNUNZIO,INST HUMAN PATHOL & SOCIAL MED,CHAIR HYG,CHIETI,ITALY	Boston University; G d'Annunzio University of Chieti-Pescara	ROTHMAN, KJ (corresponding author), BOSTON UNIV,SCH MED,EVANS DEPT MED,PREVENT MED & EPIDEMIOL SECT,B-612,88 E NEWTON ST,BOSTON,MA 02118, USA.			Nguyen, Uyen-Sa/0000-0003-2715-9073; Singer, Martha/0000-0003-4048-7987; Milunsky, Aubrey/0000-0003-2114-4823; Rothman, Kenneth/0000-0003-2398-1705; Moore, Lynn/0000-0002-1028-919X	NINDS NIH HHS [NS 19561] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019561] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], 1987, Teratology, V35, P269; BENDICH A, 1989, AM J CLIN NUTR, V49, P358, DOI 10.1093/ajcn/49.2.358; BOCKMAN DE, 1984, SCIENCE, V223, P498, DOI 10.1126/science.6606851; COHLAN SQ, 1954, PEDIATRICS, V13, P556; DENCKER L, 1991, J CRAN GENET DEV BIO, V11, P303; ECKHOFF C, 1990, ARCH TOXICOL, V64, P502, DOI 10.1007/BF01977634; EVANS K, 1991, BRIT J OPHTHALMOL, V75, P691, DOI 10.1136/bjo.75.11.691; GEELEN JAG, 1979, CRC CR REV TOXICOL, V6, P351, DOI 10.3109/10408447909043651; GREENLAND S, 1995, EPIDEMIOLOGY, V6, P356, DOI 10.1097/00001648-199507000-00005; HATHCOCK JN, 1990, AM J CLIN NUTR, V52, P183, DOI 10.1093/ajcn/52.2.183; KIRBY ML, 1987, PEDIATR RES, V21, P219, DOI 10.1203/00006450-198703000-00001; KIZER KW, 1990, WESTERN J MED, V152, P78; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; MARSHALL H, 1994, NATURE, V370, P567, DOI 10.1038/370567a0; MARTINEZFRIAS ML, 1990, EUR J EPIDEMIOL, V6, P118, DOI 10.1007/BF00145783; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; PINNOCK CB, 1992, MED J AUSTRALIA, V157, P804; ROSA FW, 1986, TERATOLOGY, V33, P355, DOI 10.1002/tera.1420330315; ROSA FW, 1983, LANCET, V2, P513; Rothman K, 1986, MODERN EPIDEMIOLOGY; STUDER M, 1994, SCIENCE, V265, P1728, DOI 10.1126/science.7916164; WERLER MM, 1990, TERATOLOGY, V42, P497, DOI 10.1002/tera.1420420506; 1985, 0025M CTR DIS CONTR; 1987, MMWR-MORBID MORTAL W, V36, P80; 1989, RECOMMENDED DIETARY, P84	25	461	476	0	22	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 23	1995	333	21					1369	1373		10.1056/NEJM199511233332101	http://dx.doi.org/10.1056/NEJM199511233332101			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF521	7477116				2022-12-28	WOS:A1995TF52100001
J	TRAGER, JDK				TRAGER, JDK			KAWASAKIS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											TRAGER, JDK (corresponding author), CHILDRENS HOSP PITTSBURGH,PITTSBURGH,PA 15213, USA.								0	1	2	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 23	1995	333	21					1391	1391		10.1056/NEJM199511233332105	http://dx.doi.org/10.1056/NEJM199511233332105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF521	7477120				2022-12-28	WOS:A1995TF52100005
J	MOLLOY, JE; BURNS, JE; KENDRICKJONES, J; TREGEAR, RT; WHITE, DCS				MOLLOY, JE; BURNS, JE; KENDRICKJONES, J; TREGEAR, RT; WHITE, DCS			MOVEMENT AND FORCE PRODUCED BY A SINGLE MYOSIN HEAD	NATURE			English	Article							SLIDING MOVEMENT; ACTIN-FILAMENTS; SUBFRAGMENT-1	MUSCLE contraction is driven by the cyclical interaction of myosin with actin, coupled to the breakdown of ATP. Studies of the interaction of filamentous myosin(1) and of a double-headed proteolytic fragment, heavy meromyosin (HMM)(2,3), with actin have demonstrated discrete mechanical events, arising from stochastic interaction of single myosin molecules with actin. Here we show, using an optical-tweezers transducer(2,4), that a single myosin subfragment-1 (S1), which is a single myosin head, can act as an independent generator of force and movement. Our analysis accounts for the broad distribution of displacement amplitudes observed, and indicates that the underlying: movement (working stroke) produced by a single acto-S1 interaction is similar to 4 nm, considerably shorter than previous estimates(1-3,5) but consistent with structural data(6). We measure the average force generated by S1 or HMM to be at least 1.7 pN under isometric conditions.	MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND	MRC Laboratory Molecular Biology	MOLLOY, JE (corresponding author), UNIV YORK, DEPT BIOL, YORK YO1 5DW, N YORKSHIRE, ENGLAND.			Molloy, Justin/0000-0002-8307-2450; Burns, Julie/0000-0003-1238-8826				ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; Einstein A., 1956, THEORY BROWNIAN MOVE; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; HARADA Y, 1987, NATURE, V326, P805, DOI 10.1038/326805a0; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KOJIMA H, 1994, P NATL ACAD SCI USA, V91, P12962, DOI 10.1073/pnas.91.26.12962; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; MIYATA H, 1994, J BIOCHEM, V115, P644, DOI 10.1093/oxfordjournals.jbchem.a124389; MOLLOY JE, 1995, BIOPHYS J, V68, pS298; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0	14	494	515	1	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 9	1995	378	6553					209	212		10.1038/378209a0	http://dx.doi.org/10.1038/378209a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD759	7477328				2022-12-28	WOS:A1995TD75900061
J	BRODINE, SK; MASCOLA, JR; WEISS, PJ; ITO, SI; PORTER, KR; ARTENSTEIN, AW; GARLAND, FC; MCCUTCHAN, FE; BURKE, DS				BRODINE, SK; MASCOLA, JR; WEISS, PJ; ITO, SI; PORTER, KR; ARTENSTEIN, AW; GARLAND, FC; MCCUTCHAN, FE; BURKE, DS			DETECTION OF DIVERSE HIV-1 GENETIC SUBTYPES IN THE USA	LANCET			English	Note								Of the nine genetic subtypes of HIV-1 that exist world wide, subtype B predominates in North America and Europe. Thus, most knowledge about HIV-1 and most vaccine development efforts are based on subtype B viruses. We document here the detection of HIV-1 subtypes A, D, and E in five US servicemen who acquired these non-subtype-B infections during overseas deployments. The dispersal of diverse HIV-1 subtypes into regions of the world with previously restricted genetic diversity may have important implications for the epidemiology of the epidemic and for the design and implementation of vaccine trials.	USN,MED RES INST,DEPT INFECT DIS,BETHESDA,MD; WALTER REED ARMY INST RES,DIV RETROVIROL,ROCKVILLE,MD; USN,MED CTR,DEPT INTERNAL MED,DIV INFECT DIS,SAN DIEGO,CA 92152; HENRY M JACKSON FDN,ROCKVILLE,MD	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); United States Department of Defense; United States Navy; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc	BRODINE, SK (corresponding author), USN,HLTH RES CTR,DIV CLIN EPIDEMIOL,DEPT HLTH SCI & EPIDEMIOL,SAN DIEGO,CA 92186, USA.		Mascola, John/AAI-7193-2021	/0000-0002-5704-8094				ARTENSTEIN AW, 1995, J INFECT DIS, V171, P805, DOI 10.1093/infdis/171.4.805; DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655; GAO F, 1993, AIDS RES HUM RETROV, V10, P625; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; HAWKES S, 1994, AIDS, V8, P247, DOI 10.1097/00002030-199402000-00013; KUNANUSONT C, 1995, LANCET, V345, P1078, DOI 10.1016/S0140-6736(95)90818-8; MASCOLA JR, 1994, J INFECT DIS, V169, P48, DOI 10.1093/infdis/169.1.48; MASTRO TD, 1994, LANCET, V343, P204, DOI 10.1016/S0140-6736(94)90990-3; MYERS G, 1994, HUMAN RETROVIRUSES A; SALMINEN M, 1993, VIROLOGY, V195, P185, DOI 10.1006/viro.1993.1359	10	125	125	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 4	1995	346	8984					1198	1199		10.1016/S0140-6736(95)92901-0	http://dx.doi.org/10.1016/S0140-6736(95)92901-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC976	7475661				2022-12-28	WOS:A1995TC97600011
J	KINGHAM, JGC				KINGHAM, JGC			PEPPERMINT OIL AND COLON SPASM	LANCET			English	Editorial Material							IRRITABLE BOWEL SYNDROME				KINGHAM, JGC (corresponding author), SINGLETON HOSP,SWANSEA SA2 8QA,W GLAM,WALES.							DEW MJ, 1984, BRIT J CLIN PRACT, V38, P394; DUTHIE HL, 1981, BRIT J SURG, V68, P820; FINK AM, 1995, CLIN RADIOL, V50, P160, DOI 10.1016/S0009-9260(05)83047-8; GOEI R, 1995, CLIN RADIOL, V50, P553, DOI 10.1016/S0009-9260(05)83191-5; HAWTHORN M, 1988, Alimentary Pharmacology and Therapeutics, V2, P101; HILLS JM, 1991, GASTROENTEROLOGY, V101, P55, DOI 10.1016/0016-5085(91)90459-X; JARVIS LJ, 1992, CLIN RADIOL, V46, pA435; KLEIN KB, 1988, GASTROENTEROLOGY, V95, P232, DOI 10.1016/0016-5085(88)90319-8; LEICESTER RJ, 1982, LANCET, V2, P989; NASH P, 1986, BRIT J CLIN PRACT, V40, P292; REES WDW, 1979, BMJ-BRIT MED J, V2, P835, DOI 10.1136/bmj.2.6194.835; ROGERS J, 1988, LANCET, V2, P98; SKUCAS J, 1994, AM J ROENTGENOL, V162, P1323, DOI 10.2214/ajr.162.6.8191992; SPARKS MJW, 1995, BRIT J RADIOL, V68, P841, DOI 10.1259/0007-1285-68-812-841; THOENI RF, 1988, RADIOLOGY, V167, P7, DOI 10.1148/radiology.167.1.3347749; 1988, LANCET, V1, P1144	16	14	15	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 14	1995	346	8981					986	986		10.1016/S0140-6736(95)91684-9	http://dx.doi.org/10.1016/S0140-6736(95)91684-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475590				2022-12-28	WOS:A1995RZ59900006
J	VENN, A; WATSON, L; LUMLEY, J; GILES, G; KING, C; HEALY, D				VENN, A; WATSON, L; LUMLEY, J; GILES, G; KING, C; HEALY, D			BREAST AND OVARIAN-CANCER INCIDENCE AFTER INFERTILITY AND IN-VITRO FERTILIZATION	LANCET			English	Article							WOMEN; RISK	Concern has been expressed that exposure to fertility drugs might be associated with a risk of ovarian cancer. We have examined the incidence of breast and ovarian cancer in a cohort of 10 358 women referred for in-vitro fertilisation (IVF) treatment in Victoria, Australia, between 1978 and 1992. The ''exposed'' group (n=5564) had had ovarian stimulation to induce multiple folliculogenesis and the ''unexposed'' group (n=4794) had been referred for IVF but were untreated or had had ''natural cycle'' treatment without ovarian stimulation. Duration of follow-up ranged from 1 to 15 years. Cases of cancer were determined by record linkage with data from population-based cancer registries. 34 cases of invasive breast cancer and 6 of invasive ovarian cancer were observed. A comparison with the expected numbers, derived by applying age-standardised general population rates to the cohort gave standardised incidence ratios (SIR) for breast cancer of 0.89 (95% CI 0.55-1.46) in the exposed group and 0.98 (0.62-1.56) in the unexposed group, and for ovarian cancer SIRs were 1.70 (0.55-5.27) and 1.62 (0.52-5.02), respectively. Rates of all cancers were not significantly different from general population rates. The relative risk (RR) of cancer, adjusted for age and infertility type, was, in the treated group compared with the untreated group, 1.11 (95% CI 0.56-2.20) for breast cancer and 1.45 (0.28-7.55) for ovarian cancer. The risk of body of uterus cancer was increased in the exposed and unexposed groups combined (SIR 2.84 [1.18-6.81]). Women with unexplained infertility, independent of IVF exposure, had significantly increased risks of ovarian cancer (RR=19.19 [2.23-165.0]) and body of uterus cancer (RR=6.34 [1.06-38.0]) compared with women with known causes of infertility. This relatively short-term follow-up suggests that ovarian stimulation with IVF is not associated with an increased risk of breast cancer. Although there was no significantly increased risk of ovarian cancer after ovarian stimulation with IVF the small number of cases limits the conclusions that can be drawn. Longer-term follow-up of large cohorts of women who have been in IVF programmes will be necessary.	NATL PERINATAL EPIDEMIOL UNIT,OXFORD,ENGLAND; ANTICANC COUNCIL VICTORIA,CTR EPIDEMIOL,CARLTON,VIC,AUSTRALIA; MAROONDAH BREASTSCREEN,E RINGWOOD,VIC,AUSTRALIA; MONASH UNIV,MONASH MED CTR,DEPT OBSTET & GYNAECOL,CLAYTON,VIC 3168,AUSTRALIA	University of Oxford; Monash University	VENN, A (corresponding author), LA TROBE UNIV,CTR STUDY MOTHERS & CHILDRENS HLTH,463 CARDIGAN ST,CARLTON,VIC 3053,AUSTRALIA.		Venn, Alison J/J-2803-2013					BRINTON LA, 1989, AM J EPIDEMIOL, V129, P712, DOI 10.1093/oxfordjournals.aje.a115186; COWAN LD, 1981, AM J EPIDEMIOL, V114, P209, DOI 10.1093/oxfordjournals.aje.a113184; Creasy G W, 1992, Obstet Gynecol Surv, V47, P654, DOI 10.1097/00006254-199209000-00026; DEWAARD F, 1982, CANCER EPIDEMIOL, P901; Fischel S., 1989, BRIT MED J, V299, P309; GAMMON MD, 1990, AM J EPIDEMIOL, V132, P708, DOI 10.1093/oxfordjournals.aje.a115712; GILES GG, 1992, CANCER VICTORIA 1982; HEALY DL, 1994, LANCET, V343, P1539, DOI 10.1016/S0140-6736(94)92941-6; MACLACHLAN V, 1989, NEW ENGL J MED, V320, P1233, DOI 10.1056/NEJM198905113201902; PRESTON D. L., 1993, EPICURE USERS GUIDE; RON E, 1987, AM J EPIDEMIOL, V125, P780, DOI 10.1093/oxfordjournals.aje.a114595; ROSSING MA, 1994, NEW ENGL J MED, V331, P771, DOI 10.1056/NEJM199409223311204; TROUNSON AO, 1981, SCIENCE, V212, P616; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; 1995, LONG TERM EFFECTS WO	15	255	261	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 14	1995	346	8981					995	1000		10.1016/S0140-6736(95)91687-3	http://dx.doi.org/10.1016/S0140-6736(95)91687-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475593				2022-12-28	WOS:A1995RZ59900009
J	BURKE, DS; BRUNDAGE, JF; REDFIELD, RR; DAMATO, JJ; SCHABLE, CA; PUTMAN, P; VISINTINE, R; KIM, HI				BURKE, DS; BRUNDAGE, JF; REDFIELD, RR; DAMATO, JJ; SCHABLE, CA; PUTMAN, P; VISINTINE, R; KIM, HI			MEASUREMENT OF THE FALSE POSITIVE RATE IN A SCREENING-PROGRAM FOR HUMAN IMMUNODEFICIENCY VIRUS-INFECTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									WALTER REED ARMY INST RES,DIV PREVENT MED,WASHINGTON,DC 20307; CTR DIS CONTROL,AIDS PROGRAM,ATLANTA,GA 30333; BIOTECH RES LABS,ROCKVILLE,MD; US MIL ENTRANCE PROC COMMAND,N CHICAGO,IL; DAMON LABS,NEWBERRY PK,CA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Centers for Disease Control & Prevention - USA	BURKE, DS (corresponding author), WALTER REED ARMY INST RES,DIV COMMUNICABLE DIS & IMMUNOL,WASHINGTON,DC 20307, USA.		Brundage, John/Q-9244-2019	/0000-0002-5704-8094				BARIN F, 1985, SCIENCE, V228, P1094, DOI 10.1126/science.2986291; BURKE DS, 1987, NEW ENGL J MED, V317, P131, DOI 10.1056/NEJM198707163170302; BURKE DS, 1987, ANN INTERN MED, V106, P671, DOI 10.7326/0003-4819-106-5-671; CLEARY PD, 1987, JAMA-J AM MED ASSOC, V258, P1757, DOI 10.1001/jama.258.13.1757; GOEDERT JJ, 1986, ANN INTERN MED, V105, P609, DOI 10.7326/0003-4819-105-4-609; HERBOLD JR, 1986, MIL MED, V151, P623; MEYER KB, 1987, NEW ENGL J MED, V317, P238, DOI 10.1056/NEJM198707233170410; NEWMARK P, 1987, NATURE, V327, P355, DOI 10.1038/327355a0; NIGHTINGALE SL, 1987, JAMA-J AM MED ASSOC, V257, P3030; THORN RM, 1987, J CLIN MICROBIOL, V25, P1207, DOI 10.1128/JCM.25.7.1207-1212.1987; 1986, IMMUNOLOGY SERIES CT, V15; 1987, MAR CONS C HIV TEST; 1987, MMWR, V36, P509	13	163	165	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	1988	319	15					961	964		10.1056/NEJM198810133191501	http://dx.doi.org/10.1056/NEJM198810133191501			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q4155	3419477				2022-12-28	WOS:A1988Q415500001
J	SMITH, WCS; CROMBIE, IK; TAVENDALE, RT; GULLAND, SK; TUNSTALLPEDOE, HD				SMITH, WCS; CROMBIE, IK; TAVENDALE, RT; GULLAND, SK; TUNSTALLPEDOE, HD			URINARY ELECTROLYTE EXCRETION, ALCOHOL-CONSUMPTION, AND BLOOD-PRESSURE IN THE SCOTTISH HEART HEALTH STUDY	BRITISH MEDICAL JOURNAL			English	Article											SMITH, WCS (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,CARDIOVASC EPIDEMIOL UNIT,DUNDEE DD1 9SY,SCOTLAND.							BEEVERS DG, 1980, BMJ-BRIT MED J, V281, P641, DOI 10.1136/bmj.281.6241.641; BOON NA, 1985, BMJ-BRIT MED J, V290, P949, DOI 10.1136/bmj.290.6473.949; BULPITT CJ, 1986, J CHRON DIS, V39, P211, DOI 10.1016/0021-9681(86)90026-3; GLEIBERMANN L., 1973, Ecology of Food and Nutrition, V2, P143, DOI 10.1080/03670244.1973.9990329; GROBBEE DE, 1986, BRIT MED J, V293, P27, DOI 10.1136/bmj.293.6538.27; JOOSSENS JV, 1983, PREV MED, V12, P53, DOI 10.1016/0091-7435(83)90171-8; LIU K, 1979, AM J EPIDEMIOL, V110, P219, DOI 10.1093/oxfordjournals.aje.a112806; Rose G, 1982, CARDIOVASCULAR SURVE; SALONEN JT, 1983, J EPIDEMIOL COMMUN H, V37, P32, DOI 10.1136/jech.37.1.32; SMITH W C S, 1987, Health Bulletin (Edinburgh), V45, P211; STAESSEN J, 1981, J EPIDEMIOL COMMUN H, V35, P256, DOI 10.1136/jech.35.4.256; WATT GCM, 1982, J EPIDEMIOL COMMUN H, V36, P197, DOI 10.1136/jech.36.3.197	12	115	115	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1988	297	6644					329	330		10.1136/bmj.297.6644.329	http://dx.doi.org/10.1136/bmj.297.6644.329			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P4527	3416163	Bronze, Green Published			2022-12-28	WOS:A1988P452700019
J	WALKER, RE; PARKER, RI; KOVACS, JA; MASUR, H; LANE, HC; CARLETON, S; KIRK, LE; GRALNICK, HR; FAUCI, AS				WALKER, RE; PARKER, RI; KOVACS, JA; MASUR, H; LANE, HC; CARLETON, S; KIRK, LE; GRALNICK, HR; FAUCI, AS			ANEMIA AND ERYTHROPOIESIS IN PATIENTS WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) AND KAPOSI SARCOMA TREATED WITH ZIDOVUDINE	ANNALS OF INTERNAL MEDICINE			English	Article									NIAID, IMMUNOREGULAT LAB,BLDG 10,ROOM 11B-13, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA; NIH, CTR CLIN, DEPT CLIN PATHOL, SERV HEMATOL, BETHESDA, MD 20205 USA; BURROUGHS WELLCOME CO, RES TRIANGLE PK, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Burroughs Wellcome Fund			Kovacs, Joseph/AAU-6105-2021	Kovacs, Joseph/0000-0002-5191-9880				DEVITA VT, 1987, ANN INTERN MED, V106, P568, DOI 10.7326/0003-4819-106-4-568; Erslev A. J., 1983, HEMATOLOGY, P409; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; YARCHOAN R, 1986, LANCET, V1, P575	5	102	104	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR	1988	108	3					372	376		10.7326/0003-4819-108-3-372	http://dx.doi.org/10.7326/0003-4819-108-3-372			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M4641	3422548				2022-12-28	WOS:A1988M464100010
J	AKHURST, RJ; FEE, F; BALMAIN, A				AKHURST, RJ; FEE, F; BALMAIN, A			LOCALIZED PRODUCTION OF TGF-BETA MESSENGER-RNA IN TUMOR PROMOTER-STIMULATED MOUSE EPIDERMIS	NATURE			English	Article									ST MARYS HOSP,SCH MED,DEPT BIOCHEM,LONDON,ENGLAND	Imperial College London	AKHURST, RJ (corresponding author), BEATSON INST CANC RES,SWITCHBACK RD,GLASGOW G61 1BD,SCOTLAND.			AKHURST, ROSEMARY/0000-0002-4474-9668				BAIRD WM, 1971, CANCER RES, V31, P1434; BALMAIN A, 1976, J INVEST DERMATOL, V67, P246, DOI 10.1111/1523-1747.ep12513451; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BALMAIN A, 1982, NUCLEIC ACIDS RES, V10, P4259, DOI 10.1093/nar/10.14.4259; BALMAIN A, 1976, Z KREBSFORSCH KLIN O, V86, P251, DOI 10.1007/BF00286944; BALMAIN A, 1978, CARCINOGENESIS, V2, P153; DERYNCK R, 1986, J BIOL CHEM, V261, P4377; HAWLEYNELSON P, 1982, EXP CELL RES, V137, P155, DOI 10.1016/0014-4827(82)90017-9; HECKER E, 1982, CARCINOGENESIS COMPR, V7; IVERSEN OH, 1969, HOMEOSTATIC REGULATO, P29; JETTEN AM, 1986, EXP CELL RES, V167, P539, DOI 10.1016/0014-4827(86)90193-X; KRIEG L, 1974, CANCER RES, V34, P3135; LASKIN JD, 1981, CELL, V25, P441, DOI 10.1016/0092-8674(81)90062-3; LECHNER JF, 1983, CANCER RES, V43, P5915; Marks F, 1978, CARCINOGENESIS, V2, P97; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; PARKINSON EK, 1982, CARCINOGENESIS, V3, P525, DOI 10.1093/carcin/3.5.525; PARKINSON EK, 1985, BRIT J CANCER, V52, P479, DOI 10.1038/bjc.1985.219; Pinkus H, 1971, SKIN, P1; RAICK AN, 1973, CANCER RES, V33, P269; REINERS JJ, 1983, CELL, V32, P247, DOI 10.1016/0092-8674(83)90515-9; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SPORN MB, 1983, SCIENCE, V219, P1329, DOI 10.1126/science.6572416; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; WEISS P, 1957, J GEN PHYSIOL, V41, P1, DOI 10.1085/jgp.41.1.1; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; YUSPA SH, 1982, CANCER RES, V42, P2344; YUSPA SH, 1981, NATURE, V293, P72, DOI 10.1038/293072a0	29	262	268	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 28	1988	331	6154					363	365		10.1038/331363a0	http://dx.doi.org/10.1038/331363a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	L8032	3422343				2022-12-28	WOS:A1988L803200071
J	DEADWYLER, SA; HAMPSON, RE				DEADWYLER, SA; HAMPSON, RE			ENSEMBLE ACTIVITY AND BEHAVIOR - WHATS THE CODE	SCIENCE			English	Editorial Material							SPATIOTEMPORAL FIRING PATTERNS; INFERIOR TEMPORAL CORTEX; NEURONS; INFORMATION; MEMORY; ASSEMBLIES; NETWORKS; DYNAMICS; TASK				DEADWYLER, SA (corresponding author), WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT PHYSIOL & PHARMACOL, WINSTON SALEM, NC 27157 USA.							ABELES M, 1988, J NEUROPHYSIOL, V60, P909, DOI 10.1152/jn.1988.60.3.909; ABELES M, 1993, J NEUROPHYSIOL, V70, P1629, DOI 10.1152/jn.1993.70.4.1629; ABELES M, 1994, PROG BRAIN RES, V102, P395; BYLANDER E G, 1990, Society for Neuroscience Abstracts, V16, P1224; Churchland P. S., 1992, COMPUTATIONAL BRAIN, DOI 10.7551/mitpress/2010.001.0001; DEADDWYLER SA, IN PRESS J NEUROSCI; EICHENBAUM H, 1989, J NEUROSCI, V9, P2764; EICHENBAUM H, 1993, SCIENCE, V261, P993, DOI 10.1126/science.8351525; ESKANDAR EN, 1992, J NEUROPHYSIOL, V68, P1277, DOI 10.1152/jn.1992.68.4.1277; Fetz Eberhard E., 1993, P165; GAWNE TJ, 1993, J NEUROSCI, V13, P2758; GEORGOPOULOS AP, 1989, SCIENCE, V243, P234, DOI 10.1126/science.2911737; GERSTEIN GL, 1978, BRAIN RES, V140, P43, DOI 10.1016/0006-8993(78)90237-8; GOCHIN PM, 1994, J NEUROPHYSIOL, V71, P2325, DOI 10.1152/jn.1994.71.6.2325; Hampson R. E., 1994, Society for Neuroscience Abstracts, V20, P430; Hampson R. E., 1992, Society for Neuroscience Abstracts, V18, P1065; HAMPSON RE, 1993, BEHAV NEUROSCI, V107, P715, DOI 10.1037/0735-7044.107.5.715; HAMPSON RE, IN PRESS LONG TERM P, V3; HEBB DO, 1949, ORG BEHAVIOR; HOPFIELD JJ, 1995, P NATL ACAD SCI USA, V92, P6655, DOI 10.1073/pnas.92.15.6655; HOPFIELD JJ, 1995, NATURE, V376, P33, DOI 10.1038/376033a0; JEANNEROD M, 1995, TRENDS NEUROSCI, V18, P314, DOI 10.1016/0166-2236(95)93921-J; Kirillov A. B., 1993, Society for Neuroscience Abstracts, V19, P1582; Kohonen T., 1981, PARALLEL MODELS ASS, P105; Laubach M. G., 1994, Society for Neuroscience Abstracts, V20, P781; LISMAN JE, 1995, SCIENCE, V267, P1512, DOI 10.1126/science.7878473; MCNAUGHTON BL, 1987, TRENDS NEUROSCI, V10, P408, DOI 10.1016/0166-2236(87)90011-7; MILLER EK, 1993, J NEUROSCI, V13, P1460; MINAI AA, 1993, BIOL CYBERN, V70, P177, DOI 10.1007/BF00200831; MULLER RU, 1994, J NEUROSCI, V14, P7235; NICOLELIS MAL, 1993, NATURE, V361, P533, DOI 10.1038/361533a0; NICOLELIS MAL, 1995, SCIENCE, V268, P1353, DOI 10.1126/science.7761855; NICOLELIS MAL, 1993, P NATL ACAD SCI USA, V90, P2212, DOI 10.1073/pnas.90.6.2212; NICOLELIS MAL, 1994, J NEUROSCI, V14, P3511; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OPTICAN LM, 1987, J NEUROPHYSIOL, V57, P162, DOI 10.1152/jn.1987.57.1.162; PARIS JM, 1992, SOC NEUR ABSTR, V18, P8485; PELLIZZER G, 1995, SCIENCE, V269, P702, DOI 10.1126/science.7624802; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; ROLLS ET, 1991, COMPUTING NEURON, P125; Sawyer S. F., 1992, Society for Neuroscience Abstracts, V18, P697; SCHOENBAUM G, 1995, J NEUROPHYSIOL, V74, P751, DOI 10.1152/jn.1995.74.2.751; SCHULTZ W, 1993, J NEUROSCI, V13, P900; STEVENS J, 1992, APPLIED MULTIVARIATE, P273; TREVES A, 1992, HIPPOCAMPUS, V2, P189, DOI 10.1002/hipo.450020209; WILSON MA, 1994, SCIENCE, V265, P676, DOI 10.1126/science.8036517; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520; YOUNG BJ, 1994, J NEUROSCI, V14, P6553; YOUNG MP, 1992, SCIENCE, V256, P1327, DOI 10.1126/science.1598577; ZIPSER D, 1993, J NEUROSCI, V13, P3406	50	69	69	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 24	1995	270	5240					1316	1318		10.1126/science.270.5240.1316	http://dx.doi.org/10.1126/science.270.5240.1316			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF899	7481817				2022-12-28	WOS:A1995TF89900026
J	GIBBS, CS; COUTRE, SE; TSIANG, M; LI, WX; JAIN, AK; DUNN, KE; LAW, VS; MAO, CT; MATSUMURA, SY; MEJZA, SJ; PABORSKY, LR; LEUNG, LLK				GIBBS, CS; COUTRE, SE; TSIANG, M; LI, WX; JAIN, AK; DUNN, KE; LAW, VS; MAO, CT; MATSUMURA, SY; MEJZA, SJ; PABORSKY, LR; LEUNG, LLK			CONVERSION OF THROMBIN INTO AN ANTICOAGULANT BY PROTEIN ENGINEERING	NATURE			English	Article							BLOOD-COAGULATION; STRUCTURAL BASIS; HUMAN-FIBRINOGEN; ACTIVATION; COFACTOR; PRIMATES; DOMAINS; INVIVO; CHAIN	AT sites of vascular injury, thrombin interacts with multiple procoagulant substrates(1-6) to mediate both fibrin clotting and platelet aggregation. But upon binding to thrombomodulin on the vascular endothelium, thrombin instead activates protein C, thereby functioning as an anticoagulant and attenuating clot formation(7). Upon infusion in vivo, both the procoagulant and anticoagulant effects of thrombin were observed(8,9). Preliminary studies indicating that thrombin's protein C activating and fibrinogen clotting activities could be dissociated by mutagenesis(10) suggested to us that a thrombin variant that lacked procoagulant activity while retaining anticoagulant function might be an attractive antithrombotic agent. Using protein engineering, we introduced a single substitution, E229A, that substantially shifted thrombin's specificity in favour of the anticoagulant substrate, protein C. In monkeys, this modified thrombin functioned as an endogenous protein C activator demonstrating dose-dependent, reversible anticoagulation without any indication of procoagulant activity. Notably, template bleeding times were not prolonged, suggesting a reduced potential for bleeding complications.	GILEAD SCI,FOSTER CITY,CA 94404	Gilead Sciences				Coutre, Steven/0000-0001-8420-5748				BANFIELD DK, 1992, P NATL ACAD SCI USA, V89, P2779, DOI 10.1073/pnas.89.7.2779; BOROWSKI M, 1985, J BIOL CHEM, V260, P9258; COMP PC, 1982, J CLIN INVEST, V70, P127, DOI 10.1172/JCI110584; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; FENTON JW, 1977, J BIOL CHEM, V252, P3587; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GRAYCAR TP, 1987, J CELL BIOCHEM     S, V11, P234; GRUBER A, 1991, CIRCULATION, V84, P2454, DOI 10.1161/01.CIR.84.6.2454; GRUBER A, 1992, BLOOD, V79, P2340; HANSON SR, 1993, J CLIN INVEST, V92, P2003, DOI 10.1172/JCI116795; HIGGINS DL, 1983, J BIOL CHEM, V258, P9276; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; LORAND L, 1992, THROMBIN STRUCTURE F, P257; Mann K.G.R., 1987, HEMOSTASIS THROMBOSI, P148; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; NI F, 1989, BIOCHEMISTRY-US, V28, P3106, DOI 10.1021/bi00433a054; ORTHNER CL, 1993, THROMB HAEMOSTASIS, V69, P441; OWEN WG, 1981, J BIOL CHEM, V256, P5532; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; TSIANG M, 1995, J BIOL CHEM, V270, P19370, DOI 10.1074/jbc.270.33.19370; TSIANG M, 1992, J BIOL CHEM, V267, P6164; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WU Q, 1991, P NATL ACAD SCI USA, V88, P6675; YE J, 1994, J BIOL CHEM, V269, P17965; 1985, GUIDE CARE USE LABOR, V8523	27	126	133	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 23	1995	378	6555					413	416		10.1038/378413a0	http://dx.doi.org/10.1038/378413a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477382				2022-12-28	WOS:A1995TF89300066
J	JIANG, H; LUO, JQ; URANO, T; FRANKEL, P; LU, ZM; FOSTER, DA; FEIG, LA				JIANG, H; LUO, JQ; URANO, T; FRANKEL, P; LU, ZM; FOSTER, DA; FEIG, LA			INVOLVEMENT OF RAL GTPASE IN V-SRC-INDUCED PHOSPHOLIPASE-D ACTIVATION	NATURE			English	Article							BINDING PROTEIN; KINASE; FAMILY	AN early response to the tyrosine kinase activity of v-Src is an increase in phospholipase D (PLD) activity(1), which leads to the generation of biologically active lipid second messengers, including phosphatidic acid, lysophosphatidic acid and diacylglycerol(2). We have recently demonstrated that v-Src-induced PLD activity is mediated by Ras(3), although Ras involvement was indirect, requiring a cytosolic factor for PLD activation(3). Ras interacts with(4-6) and activates Ral-GDS(13), the exchange factor responsible for the activation of Ral GTPases. Here we report that this newly identified Ras/Ral signalling pathway mediates PLD activation by v-Src. PLD activity could be precipitated from v-Src-transformed cell lysates with immobilized RalA protein and with an anti-Ral antibody. A mutation to the region of RalA analogous to the 'effector domain' of Ras did not reduce the ability of RalA to complex with PLD, although deletion of a Ral-specific amino-terminal region did. Overexpression of RalA potentiated PLD activation by v-Src, and expression of dominant negative RalA mutants inhibited both v-Src- and v-Ras-induced PLD activity. Thus RalA is involved in the tyrosine kinase activation of PLD through its unique N terminus, and that PLD is a downstream target of a Ras/Ral GTPase cascade.	CUNY HUNTER COLL,INST BIOMOLEC STRUCT & FUNCT,NEW YORK,NY 10021; CUNY HUNTER COLL,DEPT SCI BIOL,NEW YORK,NY 10021; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY); Tufts University			Urano, Tomohiko/AFS-9574-2022					BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CAMERO A, 1994, ONCOGENE, V9, P1387; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; EMKEY R, 1991, J BIOL CHEM, V266, P9703; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FOSTER DA, 1993, CELL SIGNAL, V5, P389, DOI 10.1016/0898-6568(93)90078-Z; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; QURESHI SA, 1992, J BIOL CHEM, V267, P17635; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; SONG JG, 1993, BIOCHEM J, V294, P711, DOI 10.1042/bj2940711; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; URANO T, IN PRESS EMBO J; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	25	252	254	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 23	1995	378	6555					409	412		10.1038/378409a0	http://dx.doi.org/10.1038/378409a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477381				2022-12-28	WOS:A1995TF89300065
J	WOOLF, SH				WOOLF, SH			CURRENT CONCEPTS - SCREENING FOR PROSTATE-CANCER WITH PROSTATE-SPECIFIC ANTIGEN - AN EXAMINATION OF THE EVIDENCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DIGITAL RECTAL EXAMINATION; DECISION-ANALYSIS; CARCINOMA; SERUM; MEN; DISEASE; LATENT				WOOLF, SH (corresponding author), VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA, FAIRFAX FAMILY PRACTICE CTR, DEPT FAMILY PRACTICE, FAIRFAX, VA 22033 USA.							ALBERTSEN PC, 1995, JAMA-J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626; ANDREWS GS, 1949, J CLIN PATHOL, V2, P197, DOI 10.1136/jcp.2.3.197; ANDRIOLE GL, 1994, J UROLOGY, V152, P1858, DOI 10.1016/S0022-5347(17)32400-X; [Anonymous], 1994, CANADIAN GUIDE CLIN; AUS G, 1993, BRIT J UROL, V71, P457, DOI 10.1111/j.1464-410X.1993.tb15992.x; AUS G, 1994, SCAND J UROL NEPHROL, P1; Baron E, 1941, ARCH PATHOL, V32, P787; BECK JR, 1994, J UROLOGY, V152, P1894, DOI 10.1016/S0022-5347(17)32409-6; BENSON MC, 1992, J UROLOGY, V147, P815, DOI 10.1016/S0022-5347(17)37393-7; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; CATALONA WJ, 1994, J UROLOGY, V151, P1283, DOI 10.1016/S0022-5347(17)35233-3; CATALONA WJ, 1995, JAMA-J AM MED ASSOC, V273, P1174, DOI 10.1001/jama.273.15.1174; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; COONER WH, 1990, J UROLOGY, V143, P1146, DOI 10.1016/S0022-5347(17)40211-4; DESMOND PM, 1993, J UROLOGY, V150, P1425, DOI 10.1016/S0022-5347(17)35798-1; DHOM G, 1983, J CANCER RES CLIN, V106, P210, DOI 10.1007/BF00402610; EDWARDS CN, 1953, CANCER, V6, P531, DOI 10.1002/1097-0142(195305)6:3<531::AID-CNCR2820060311>3.0.CO;2-9; EPSTEIN JI, 1994, JAMA-J AM MED ASSOC, V271, P368, DOI 10.1001/jama.271.5.368; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; FOWLER FJ, 1993, UROLOGY, V42, P622, DOI 10.1016/0090-4295(93)90524-E; FRANKS LM, 1954, J PATHOL BACTERIOL, V68, P603, DOI 10.1002/path.1700680233; FRIEDMAN GD, 1991, LANCET, V337, P1526, DOI 10.1016/0140-6736(91)93207-P; GERBER GS, 1993, JAMA-J AM MED ASSOC, V269, P591; GERBER GS, 1993, JAMA-J AM MED ASSOC, V269, P61, DOI 10.1001/jama.269.1.61; GOHAGAN JK, 1994, J UROLOGY, V152, P1905, DOI 10.1016/S0022-5347(17)32412-6; GRAVERSEN PH, 1990, UROLOGY, V36, P493, DOI 10.1016/0090-4295(90)80184-O; GUILEYARDO JM, 1980, J NATL CANCER I, V65, P311; HAHN DL, 1993, J FAM PRACTICE, V37, P432; HALPERT B, 1966, CANCER-AM CANCER SOC, V19, P695, DOI 10.1002/1097-0142(196605)19:5<695::AID-CNCR2820190515>3.0.CO;2-W; Hicks R J, 1995, Arch Fam Med, V4, P317, DOI 10.1001/archfami.4.4.317; JOHANSSON JE, 1994, J UROLOGY, V152, P1753, DOI 10.1016/S0022-5347(17)32378-9; KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773; KRAMER BS, 1993, ANN INTERN MED, V119, P914, DOI 10.7326/0003-4819-119-9-199311010-00009; LITTRUP PJ, 1993, CA-CANCER J CLIN, V43, P134, DOI 10.3322/canjclin.43.3.134; MARK DH, 1994, J UROLOGY, V152, P896, DOI 10.1016/S0022-5347(17)32602-2; METTLIN C, 1994, J UROLOGY, V152, P1737, DOI 10.1016/S0022-5347(17)32373-X; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; MOLD JW, 1992, J FAM PRACTICE, V34, P561; OESTERLING JE, 1993, JAMA-J AM MED ASSOC, V270, P860, DOI 10.1001/jama.270.7.860; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; OPTENBERG SA, 1995, J UROLOGY, V153, P1870, DOI 10.1016/S0022-5347(01)67334-8; OPTENBERG SA, 1990, UROL CLIN N AM, V17, P719; POTOSKY AL, 1995, JAMA-J AM MED ASSOC, V273, P548, DOI 10.1001/jama.273.7.548; RIES LAG, 1989, DHHS NIH942789 PUBL; Rosen Mark A., 1995, Journal of Urology, V153, p464A; SAKR WA, 1993, J UROLOGY, V150, P379, DOI 10.1016/S0022-5347(17)35487-3; SCARDINO PT, 1989, UROL CLIN N AM, V16, P635; SCOTT R, 1969, J UROLOGY, V101, P602, DOI 10.1016/S0022-5347(17)62388-7; SERSHON PD, 1994, EUR UROL, V25, P281; Stamey Thomas A., 1995, Journal of Urology, V153, p420A; STENMAN UH, 1991, CANCER RES, V51, P222; WALSH PC, 1993, ANN INTERN MED, V119, P948, DOI 10.7326/0003-4819-119-9-199311010-00015; WALSH PC, 1993, J UROLOGY, V150, P1587, DOI 10.1016/S0022-5347(17)35850-0; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487; WASSON JH, 1993, ARCH FAM MED, V2, P1030; WILT TJ, 1994, J UROLOGY, V152, P1910, DOI 10.1016/S0022-5347(17)32413-8; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; WINGO PA, 1995, CA-CANCER J CLIN, V45, P127; 1993, STATISTICAL ABSTRACT; 1995, GUIDE CLIN PREVENTIV; 1995, OTABPH145 OFF TECHN	63	205	212	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 23	1995	333	21					1401	1405		10.1056/NEJM199511233332107	http://dx.doi.org/10.1056/NEJM199511233332107			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF521	7477122				2022-12-28	WOS:A1995TF52100007
J	WOLRAICH, ML; WILSON, DB; WHITE, JW				WOLRAICH, ML; WILSON, DB; WHITE, JW			THE EFFECT OF SUGAR ON BEHAVIOR OR COGNITION IN CHILDREN - A METAANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PRESCHOOL-CHILDREN; HYPERACTIVE BOYS; SUCROSE; INGESTION; ASPARTAME	Objective.-To examine the effects of sugar on the behavior or cognition of children by using meta-analytic techniques on reported studies. Data Sources.-Studies were identified through a literature search of the MEDLINE and PsychINFO databases and the authors' files using sugar, sucrose, and attention deficit disorder as the search terms. Study Selection.-Studies were required to (1) intervene by having the subjects consume a known quantity of sugar; (2) use a placebo (artificial sweetener) condition; (3) blind the subjects, parents, and research staff to the conditions; and (4) report statistics that could be used to compute the dependent measures effect sizes. Data Extraction.-Variables included publication year, study setting, subject type and number, gender, age, sugar and placebo,type and dose, prior dietary condition, measurement construct, means and SDs for the sugar and placebo conditions, and direction of effect. Data Synthesis.-Sixteen reports met the inclusion criteria for a total of 23 within-subject design studies. The weighted mean effect size and related statistics for each of the 14 measurement constructs revealed that although the range for these means was from -0.14 for direct observations and up to +0.30 for academic tests, the 95% confidence interval for all 14 mean effect sizes included 0. Conclusion.-The meta-analytic synthesis of the studies to date found that sugar does not affect the behavior or cognitive performance of children. The strong belief of parents may be due to expectancy and common association. However, a small effect of sugar or effects on subsets of children cannot be ruled out.	VANDERBILT UNIV,INST PUBL POLICY STUDIES,NASHVILLE,TN; USN HOSP,YOKOSUKA,KANAGAWA,JAPAN	Vanderbilt University	WOLRAICH, ML (corresponding author), VANDERBILT UNIV,CTR CHILD DEV,DEPT PEDIAT,2100 PIERCE AVE,426 MCS,NASHVILLE,TN 37232, USA.							BACHOROWSKI JA, 1990, PEDIATRICS, V86, P244; BEHAR D, 1984, Nutrition and Behavior, V1, P277; BORIS M, 1994, ANN ALLERGY, V72, P462; CONNERS CK, 1983, EFFECTS SUCROSE FRUC; COTT A, 1977, PHYSICIANS HDB ORTHO, P90; DEUTSCH RM, 1977, NEW NUTS BERRIES, V34, P235; DURLAK JA, 1991, AM J COMMUN PSYCHOL, V19, P291; EGGER J, 1985, LANCET, V1, P540; FERGUSON HB, 1986, NUTR REV, V44, P144; GOLDMAN JA, 1986, J ABNORM CHILD PSYCH, V14, P565, DOI 10.1007/BF01260524; GROSS MD, 1984, PEDIATRICS, V74, P876; Hedges L, 1985, STATISTICAL METHODS; Hedges Larry V., 1990, FUTURE META ANAL; HEDGES LV, 1983, PSYCHOL BULL, V93, P388, DOI 10.1037/0033-2909.93.2.388; HOOVER DW, 1994, J ABNORM CHILD PSYCH, V22, P501, DOI 10.1007/BF02168088; JOSEFSBERG Z, 1976, ISRAEL J MED SCI, V12, P189; KAPLAN BJ, 1989, PEDIATRICS, V83, P7; KRUESI MJP, 1987, AM J PSYCHIAT, V144, P1487; LANGSETH L, 1978, FED J COSMET TOXICOL, V16, P120; MAHAN LK, 1988, ANN ALLERGY, V61, P453; MILICH R, 1986, J CONSULT CLIN PSYCH, V54, P714, DOI 10.1037/0022-006X.54.5.714; Orwin RG, 1983, J ED STAT, V8, P157, DOI [DOI 10.2307/1164923, 10.3102/10769986008002157]; OTTO PL, 1982, AM J MENT DEF, V86, P335; PRINZ RJ, 1980, J CONSULT CLIN PSYCH, V48, P760, DOI 10.1037/0022-006X.48.6.760; RANDOLPH TG, 1947, J PEDIATR, V31, P560, DOI 10.1016/S0022-3476(47)80145-3; ROSEN LA, 1988, J CONSULT CLIN PSYCH, V56, P583, DOI 10.1037/0022-006X.56.4.583; ROSENTHAL R, 1979, PSYCHOL BULL, V85, P185; ROSHON MS, 1989, J ABNORM CHILD PSYCH, V17, P349, DOI 10.1007/BF00917404; SARVAIS S, 1990, PEDIATRICS, V86, P75; Shadish W. R., 1994, HDB RES SYNTHESIS; Shannon WR, 1922, AM J DIS CHILD, V24, P89; Speer F., 1954, PEDIATR CLIN N AM, V1, P1029; WENDER EH, 1991, PEDIATRICS, V88, P960; WOLRAICH M, 1985, J PEDIATR-US, V106, P675, DOI 10.1016/S0022-3476(85)80102-5; WOLRAICH ML, 1994, NEW ENGL J MED, V330, P301, DOI 10.1056/NEJM199402033300501; WOLRAICH ML, 1986, J AM DIET ASSOC, V86, P500; WURTMAN JJ, 1988, J CLIN PSYCHIAT, V49, P37	37	133	134	0	56	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	1995	274	20					1617	1621		10.1001/jama.274.20.1617	http://dx.doi.org/10.1001/jama.274.20.1617			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TE738	7474248				2022-12-28	WOS:A1995TE73800028
J	WEINBERG, AD; MINAKER, KL; COBLE, YD; DAVIS, RM; HEAD, CA; HOWE, JP; KARLAN, MS; KENNEDY, WR; NUMANN, PJ; SPILLMAN, MA; SKELTON, WD; STEINHILBER, RM; STRONG, JP; WAGNER, HN; ALLEN, JR; RINALDI, RC				WEINBERG, AD; MINAKER, KL; COBLE, YD; DAVIS, RM; HEAD, CA; HOWE, JP; KARLAN, MS; KENNEDY, WR; NUMANN, PJ; SPILLMAN, MA; SKELTON, WD; STEINHILBER, RM; STRONG, JP; WAGNER, HN; ALLEN, JR; RINALDI, RC			DEHYDRATION - EVALUATION AND MANAGEMENT IN OLDER ADULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEALTHY ELDERLY MEN; WATER; PRESSURE; SYNCOPE; THIRST; FLUIDS; STREAM; BODY; FOOD	Objective.-To review published literature regarding dehydration in older individuals and formulate a consensus on the evaluation and treatment of this unrecognized cause of hospitalizations, morbidity, and mortality. Data Sources and Study Selection.-The literature concerning dehydration in the elderly population from MEDLINE was reviewed from 1976 through 1995. Search terms included dehydration, elderly, evaluation, hospitalization, and treatment, Particular emphasis was placed on articles describing original research leading to the development of new information on the evaluation and treatment of dehydration and review articles relating to the epidemiology, detection, treatment and health outcomes of this syndrome common in the geriatric population, including frail, institutionalized individuals. Data Extraction.-Data contributing to a broad scientific understanding of dehydration were initially grouped according to topic areas of the physiology of normal aging, illness-associated clinical reports of dehydration in the elderly population, and diagnostic and therapeutic interventions, The authors developed a consensus based on the weight of evidence presented and the authors' experience in the field. Conclusions.-Early diagnosis is sometimes difficult because the classical physical signs of dehydration may be absent or misleading in an older patient. Many different etiologies place the elderly at particular risk. In patients identified as being at risk for possible dehydration, an interdisciplinary care plan with regard to prevention of clinically significant dehydration is critical if maximum benefit is to result.	AMER MED ASSOC, COUNCIL SCI AFFAIRS, SCI TECHNOL & PUBL HLTH GRP, CHICAGO, IL 60610 USA; BROCKTON W ROXBURY VET AFFAIRS MED CTR, GERIATR & EXTENDED CARE SERV, BROCKTON, MA USA; HARVARD UNIV, SCH MED, DIV AGING, BOSTON, MA USA	American Medical Association; Harvard University; Harvard University; Harvard Medical School								ABUKHALED M, 1988, AM J CLIN NUTR, V47, P789, DOI 10.1093/ajcn/47.5.789; Adams F, 1988, Geriatr Nurs, V9, P218, DOI 10.1016/S0197-4572(88)80144-7; ATKINS D, 1991, AM J MED, V91, P179, DOI 10.1016/0002-9343(91)90012-M; BERGER EY, 1984, J AM GERIATR SOC, V32, P199, DOI 10.1111/j.1532-5415.1984.tb02002.x; CAMPBELL SM, 1992, SUPPORT LINE, V14, P7; CARTER JE, 1989, MED SCI SPORT EXER, V21, P532; CRANE MG, 1976, J LAB CLIN MED, V87, P947; DALEY J, 1993, MEDICARE DISCHARGE D; EMANUEL EJ, 1988, AM J MED, V84, P291, DOI 10.1016/0002-9343(88)90428-7; FUCHS SM, 1987, ANN EMERG MED, V16, P386, DOI 10.1016/S0196-0644(87)80356-6; Gaspar P M, 1988, Geriatr Nurs, V9, P221, DOI 10.1016/S0197-4572(88)80145-9; GENNARI FJ, 1984, NEW ENGL J MED, V310, P102, DOI 10.1056/NEJM198401123100207; GROSS C R, 1992, Journal of Emergency Medicine, V10, P267, DOI 10.1016/0736-4679(92)90331-M; GUERANT RL, 1992, GERONTOLOGIST, V32, P124; HIMMELSTEIN DU, 1983, J AM GERIATR SOC, V31, P466, DOI 10.1111/j.1532-5415.1983.tb05118.x; HOFFER EC, 1969, J APPL PHYSIOL, V27, P531, DOI 10.1152/jappl.1969.27.4.531; HOFFMAN NB, 1991, GERIATRICS, V46, P35; JOHNSON RH, 1965, LANCET, V1, P731; KIM DE, 1994, JAMA-J AM MED ASSOC, V272, P1447, DOI 10.1001/jama.272.18.1447; KIRKLAND J, 1984, CLIN ENDOCRINOL, V20, P451, DOI 10.1111/j.1365-2265.1984.tb03441.x; KNOPP R, 1980, ANN EMERG MED, V9, P72, DOI 10.1016/S0196-0644(80)80333-7; LAVIZZOMOUREY R, 1988, J AM GERIATR SOC, V36, P213, DOI 10.1111/j.1532-5415.1988.tb01803.x; LIPSITZ LA, 1985, CLIN SCI, V69, P337, DOI 10.1042/cs0690337; LIPSITZ LA, 1986, J CHRON DIS, V39, P619, DOI 10.1016/0021-9681(86)90187-6; LONG CA, 1991, POSTGRAD MED J, V67, P643, DOI 10.1136/pgmj.67.789.643; LUFT FC, 1983, ANN INTERN MED, V98, P758, DOI 10.7326/0003-4819-98-5-758; LUKASKI HC, 1985, AM J CLIN NUTR, V41, P810, DOI 10.1093/ajcn/41.4.810; LYNN J, 1983, HASTINGS CENT REP, V13, P17, DOI 10.2307/3560572; MAHOWALD JM, 1981, J AM GERIATR SOC, V29, P177, DOI 10.1111/j.1532-5415.1981.tb01761.x; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; MCINTYRE KM, 1992, NEW ENGL J MED, V327, P1715, DOI 10.1056/NEJM199212103272404; MEILAENDER G, 1984, HASTINGS CENT REP, V14, P11, DOI 10.2307/3561735; MICETICH KC, 1983, ARCH INTERN MED, V143, P975, DOI 10.1001/archinte.143.5.975; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; Pals J K, 1995, J Gerontol Nurs, V21, P13; PFEIL LA, 1990, GERIATRIC NUTRITION, P193; PHILLIPS PA, 1993, AGE AGEING, V22, pS26, DOI 10.1093/ageing/22.suppl_1.S26; PHILLIPS PA, 1991, AM J PHYSIOL, V261, pR166, DOI 10.1152/ajpregu.1991.261.1.R166; PHILLIPS PA, 1984, NEW ENGL J MED, V311, P753, DOI 10.1056/NEJM198409203111202; ROCKS BF, 1986, ANN CLIN BIOCHEM, V23, P106, DOI 10.1177/000456328602300115; ROWE JW, 1976, J GERONTOL, V31, P155, DOI 10.1093/geronj/31.2.155; ROWE JW, 1982, HLTH DISEASE OLD AGE, P165; SEGAL KR, 1991, AM J CLIN NUTR, V54, P26, DOI 10.1093/ajcn/54.1.26; SIEGLER M, 1985, ARCH INTERN MED, V145, P129, DOI 10.1001/archinte.145.1.129; SILVER AJ, 1992, J AM GERIATR SOC, V40, P556, DOI 10.1111/j.1532-5415.1992.tb02102.x; SILVER AJ, 1990, CLEV CLIN J MED, V57, P341, DOI 10.3949/ccjm.57.4.341; Wandel J C, 1990, J Prof Nurs, V6, P46, DOI 10.1016/S8755-7223(05)80189-9; WEI JY, 1987, CURR PROB CARDIOLOGY, V12, P1; WEIL MH, 1982, AM J CLIN PATHOL, V77, P447, DOI 10.1093/ajcp/77.4.447; Weinberg A D, 1987, Conn Med, V51, P523; Weinberg A D, 1984, Conn Med, V48, P535; WEINBERG AD, 1994, J AM GERIATR SOC, V42, P1070, DOI 10.1111/j.1532-5415.1994.tb06211.x; WEINBERG AD, 1994, J AM GERIATR SOC, V42, P968, DOI 10.1111/j.1532-5415.1994.tb06589.x; WEINBERG AD, 1993, TOP GERIATR MED NURS, V8, P1; 1994, DETAILED DIAGNOSES P; 1991, CODE MED ETHICS REPO, V2, P65; 1989, RECOMMENDED DIETARY; 1988, 03270 OFF RES DEM HL; 1992, CODE MED ETHICS CURR, P14; 1993, HLTH CARE FINANCING, V334	60	156	157	2	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	1995	274	19					1552	1556		10.1001/jama.274.19.1552	http://dx.doi.org/10.1001/jama.274.19.1552			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TD571	7474224				2022-12-28	WOS:A1995TD57100032
J	SACKNERBERNSTEIN, JD; MANCINI, DM				SACKNERBERNSTEIN, JD; MANCINI, DM			RATIONALE FOR TREATMENT OF PATIENTS WITH CHRONIC HEART-FAILURE WITH ADRENERGIC-BLOCKADE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IDIOPATHIC DILATED CARDIOMYOPATHY; LEFT-VENTRICULAR DYSFUNCTION; SYMPATHETIC NERVOUS ACTIVITY; BETA-RECEPTOR DENSITY; CONGESTIVE CARDIOMYOPATHY; DOUBLE-BLIND; HEMODYNAMIC ABNORMALITIES; PLASMA NOREPINEPHRINE; MYOCARDIAL-INFARCTION; BUCINDOLOL	Objective.-Chronic heart failure is the leading cause of hospital admissions in patients older than 65 years. Heart failure due to systolic dysfunction is accompanied by activation of the sympathetic nervous system that contributes to progressive symptoms and an increased risk of death. While several clinical trials have suggested that antagonizing this sympathetic activation with beta-blocking agents may provide clinical benefit, no clear consensus exists regarding use of beta-blockers for congestive heart failure. Therefore, we review the pathophysiology of the sympathetic nervous system as a basis for examining these clinical trials in order to understand the rationale for beta-blockade as a treatment for heart failure. Data Source.-English-language journal articles and reviews from a MEDLINE search and abstracts published at major cardiology meetings that related either to the pathophysiology of the sympathetic nervous system or to therapy of patients with chronic heart failure with beta-blockers. Study Selection.-Uncontrolled trials describing the initial use of this therapy and the subsequent randomized, placebo-controlled trials of beta-blockers were included. Conclusions.-Sympathetic nervous system activation in patients with chronic heart failure is a major contributor to the severity of disease as well as its progression over time. Antagonism of its effects, via beta-blocker therapy, appears overall to improve both quality of life and survival. However, its place as a cornerstone in the therapy of this disease depends on the results of large-scale, randomized, placebo-controlled trials.			SACKNERBERNSTEIN, JD (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, DIV CIRCULATORY PHYSIOL, MILSTEIN 5-435, NEW YORK, NY 10032 USA.							ANDERSON JL, 1985, AM J CARDIOL, V55, P471, DOI 10.1016/0002-9149(85)90396-0; ANDRESEN MC, 1987, CIRC RES, V61, P66; BRISTOW MR, 1984, J CLIN INVEST, V74, P212, DOI 10.1172/JCI111404; BRISTOW MR, 1994, CIRCULATION, V89, P1632, DOI 10.1161/01.CIR.89.4.1632; BRISTOW MR, 1991, CIRCULATION, V84, P1024, DOI 10.1161/01.CIR.84.3.1024; BRISTOW MR, 1986, CIRC RES, V59, P297, DOI 10.1161/01.RES.59.3.297; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; CHADDA K, 1986, CIRCULATION, V73, P503, DOI 10.1161/01.CIR.73.3.503; CHAPLEAU MW, 1990, CIRCULATION, V82, P11; CHIDSEY CA, 1965, AM J MED, V39, P442, DOI 10.1016/0002-9343(65)90211-1; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; CRUICKSHANK JM, 1987, LANCET, V2, P585, DOI 10.1016/s0140-6736(87)92984-9; CURRIE PJ, 1984, J AM COLL CARDIOL, V3, P203, DOI 10.1016/S0735-1097(84)80449-0; DALY PA, 1990, CIRCULATION, V82, P35; DAVIS D, 1987, CIRC RES, V61, P87; DOUGHTY RN, 1994, J AM COLL CARDIOL, V23, P814, DOI 10.1016/0735-1097(94)90773-0; EICHHORN EJ, 1992, AM J MED, V92, P527, DOI 10.1016/0002-9343(92)90750-6; EICHHORN EJ, 1990, CIRCULATION, V82, P473, DOI 10.1161/01.CIR.82.2.473; EICHHORN EJ, 1991, AM J CARDIOL, V67, P67, DOI 10.1016/0002-9149(91)90102-Q; EICHHORN EJ, 1994, J AM COLL CARDIOL, V24, P1310, DOI 10.1016/0735-1097(94)90114-7; ENGELMEIER RS, 1985, CIRCULATION, V72, P536, DOI 10.1161/01.CIR.72.3.536; FISHER ML, 1994, J AM COLL CARDIOL, V23, P943, DOI 10.1016/0735-1097(94)90641-6; FRANCIS GS, 1982, AM HEART J, V104, P725, DOI 10.1016/0002-8703(82)90003-5; FRANCIS GS, 1990, CIRCULATION, V82, P1724, DOI 10.1161/01.CIR.82.5.1724; GAFFNEY TE, 1963, AM J MED, V34, P320, DOI 10.1016/0002-9343(63)90118-9; GILBERT EM, 1990, AM J MED, V88, P223, DOI 10.1016/0002-9343(90)90146-5; GILBERT EM, 1993, AM J CARDIOL, V71, pC23, DOI 10.1016/0002-9149(93)90083-O; GILBERT EM, 1993, CIRCULATION, V88, P472, DOI 10.1161/01.CIR.88.2.472; HASKING GJ, 1986, CIRCULATION, V73, P615, DOI 10.1161/01.CIR.73.4.615; HEILBRUNN SM, 1989, CIRCULATION, V79, P483, DOI 10.1161/01.CIR.79.3.483; HENDERSON EB, 1988, CIRCULATION, V78, P1192, DOI 10.1161/01.CIR.78.5.1192; HORN EM, 1988, CIRCULATION, V78, P1373, DOI 10.1161/01.CIR.78.6.1373; IKRAM H, 1979, BRIT HEART J, V42, P311; IKRAM H, 1981, LANCET, V2, P490; KRUM H, 1995, CIRCULATION, V92, P1499, DOI 10.1161/01.CIR.92.6.1499; LECHAT P, 1994, CIRCULATION, V90, P1765, DOI 10.1161/01.CIR.90.4.1765; LEUENBERGER U, 1992, AM J PHYSIOL, V263, pH56, DOI 10.1152/ajpheart.1992.263.1.H56; LEVINE TB, 1982, AM J CARDIOL, V49, P1659, DOI 10.1016/0002-9149(82)90243-0; LOWN B, 1976, NEW ENGL J MED, V294, P1165; MANN DL, 1992, CIRCULATION, V85, P790, DOI 10.1161/01.CIR.85.2.790; MEREDITH IT, 1993, CIRCULATION, V88, P136, DOI 10.1161/01.CIR.88.1.136; METRA M, 1994, J AM COLL CARDIOL, V24, P1678, DOI 10.1016/0735-1097(94)90174-0; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; OLSEN SL, 1995, J AM COLL CARDIOL, V25, P1225, DOI 10.1016/0735-1097(95)00012-S; PACKER M, 1987, CIRCULATION, V75, P80; PACKER M, 1986, AM J MED, V80, P23, DOI 10.1016/0002-9343(86)90337-2; PACKER M, 1990, CIRCULATION, V82, P77; PACKER M, IN PRESS CIRCULATION; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PODRID PJ, 1990, CIRCULATION, V82, P103; POLLOCK SG, 1990, AM J CARDIOL, V66, P603, DOI 10.1016/0002-9149(90)90488-M; SCHWARTZ B M, 1992, Journal of the American College of Cardiology, V19, p341A; SIMMONS WW, 1994, CIRCULATION, V89, P2843, DOI 10.1161/01.CIR.89.6.2843; SINOWAY LI, 1989, HEART FAILURE    FEB, P199; SOBOTKA PA, 1992, CLIN CARDIOL, V15, P630; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; THOMAS JA, 1978, AM J CARDIOL, V41, P233, DOI 10.1016/0002-9149(78)90162-5; VIQUERAT CE, 1985, AM J MED, V78, P455, DOI 10.1016/0002-9343(85)90338-9; WAAGSTEIN F, 1975, BRIT HEART J, V37, P1022; WAAGSTEIN F, 1989, CIRCULATION, V80, P551, DOI 10.1161/01.CIR.80.3.551; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; WANG W, 1992, HYPERTENSION, V19, P270, DOI 10.1161/01.HYP.19.3.270; White Michel, 1993, Journal of the American College of Cardiology, V21, p115A; WHYTE K, 1987, EUR J CLIN PHARMACOL, V32, P237, DOI 10.1007/BF00607569; WISENBAUGH T, 1993, J AM COLL CARDIOL, V21, P1094, DOI 10.1016/0735-1097(93)90230-X; WIT AL, 1977, CIRC RES, V41, P435, DOI 10.1161/01.RES.41.4.434; WOODLEY SL, 1991, CIRCULATION, V84, P2426, DOI 10.1161/01.CIR.84.6.2426; YUE TL, 1992, J PHARMACOL EXP THER, V263, P92; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; ZELIS R, 1986, HEART FAILURE    FEB, P21	70	56	59	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	1995	274	18					1462	1467		10.1001/jama.274.18.1462	http://dx.doi.org/10.1001/jama.274.18.1462			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC477	7474194				2022-12-28	WOS:A1995TC47700030
J	FRYAUFF, DJ; BAIRD, JK; BASRI, H; SUMAWINATA, I; PURNOMO; RICHIE, TL; OHRT, CK; MOUZIN, E; CHURCH, CJ; RICHARDS, AL; SUBIANTO, B; SANDJAJA, B; WIGNALL, FS; HOFFMAN, SL				FRYAUFF, DJ; BAIRD, JK; BASRI, H; SUMAWINATA, I; PURNOMO; RICHIE, TL; OHRT, CK; MOUZIN, E; CHURCH, CJ; RICHARDS, AL; SUBIANTO, B; SANDJAJA, B; WIGNALL, FS; HOFFMAN, SL			RANDOMIZED PLACEBO-CONTROLLED TRIAL OF PRIMAQUINE FOR PROPHYLAXIS OF FALCIPARUM AND VIVAX MALARIA	LANCET			English	Article							CHLOROQUINE; PREVENTION	Drug resistance has made malaria prevention difficult and the new agents are too expensive for widespread use, Primaquine, an established drug for treatment, is potentially useful for prevention, Malaria prophylaxis with primaquine was evaluated in Irian Jaya during one year in Javanese men who were not deficient in glucose-6-phosphate dehydrogenase (G-6-PD). 126 volunteers were randomised to receive 0 . 5 mg/hg primaquine base or placebo daily (double-blinded), or 300 mg chloroquine base weekly (open). The protective efficacy of primaquine relative to placebo was 94 . 5% (95% confidence interval 57-99) for Plasmodium falciparum and 90 . 4% (95% CI 58-98) for P vivax, Attack rates for either parasite did not differ significantly between the chloroquine and placebo groups. Incidence density of physical complaints not associated with parasitaemia was low (17-18 complaints/person-year) and was about the same in all groups except for cough, which was increased in the primaquine group. Complete blood counts were normal and no evidence of hepatic or renal dysfunction was found with primaquine. However, at 50 weeks the primaquine group had a mean methaemoglobin of 5 . 8% (range 1 . 4-13%), which declined by half within 7 days of ending prophylaxis. When used daily for one year by men with normal G-6-PD activity, primaquine was well tolerated and effective for prevention of malaria.	USN,MED RES UNIT 2,JAKARTA,INDONESIA; TULANE UNIV,MED CTR,DEPT MED,NEW ORLEANS,LA 70112; ARMED FORCES RES INST MED SCI,BANGKOK,THAILAND; PROV HLTH SERV,IRIAN JAYA,INDONESIA; USN,MED RES INST,BETHESDA,MD	University of 19 November Kolaka; Tulane University; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy				Richie, Thomas/0000-0002-2946-5456				ALVING AS, 1959, 6 P INT C TROP MED M, V7, P203; [Anonymous], 1991, MALARIA OBSTACLES OP; ARNOLD J, 1955, J LAB CLIN MED, V46, P391; BAIRD JK, 1991, AM J TROP MED HYG, V44, P547, DOI 10.4269/ajtmh.1991.44.547; BAIRD JK, 1995, AM J TROP MED HYG, V52, P497; BAIRD JK, IN PRESS AM J TROP M; BEUTLER E, 1983, HEMATOLOGY, P1632; BLACK RH, 1981, WHO MONOGR SER, V27; CARSON PE, 1984, HDB EXPT PHARM, V68, P83; CLAYMAN CB, 1952, JAMA-J AM MED ASSOC, V149, P1563, DOI 10.1001/jama.1952.72930340022010b; CLYDE DF, 1981, B WORLD HEALTH ORGAN, V59, P391; FLETCHER KA, 1981, B WORLD HEALTH ORGAN, V59, P407; HOFFMAN SL, 1991, JAMA-J AM MED ASSOC, V265, P398, DOI 10.1001/jama.265.3.398; HOFFMAN SL, 1992, MED CLIN N AM, V76, P1327, DOI 10.1016/S0025-7125(16)30290-5; MURPHY GS, 1993, LANCET, V341, P96, DOI 10.1016/0140-6736(93)92568-E; PETERS W, 1987, CHEMOTHERAPY DRUG RE, V2; SCHMIDT LH, 1982, AM J TROP MED HYG, V31, P666, DOI 10.4269/ajtmh.1982.31.666; SELVIN S, 1991, MONOGR EPIDEMIOL BIO, V17, P241; SHUTE GT, 1988, MALARIA, V1, P781; STRICKLAND GT, 1994, SCI AM, V20, P24; WEISS WR, 1995, J INFECT DIS, V171, P1569, DOI 10.1093/infdis/171.6.1569	21	123	123	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 4	1995	346	8984					1190	1193		10.1016/S0140-6736(95)92898-7	http://dx.doi.org/10.1016/S0140-6736(95)92898-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC976	7475658	Green Submitted, Bronze			2022-12-28	WOS:A1995TC97600008
J	HART, AC; SIMS, S; KAPLAN, JM				HART, AC; SIMS, S; KAPLAN, JM			SYNAPTIC CODE FOR SENSORY MODALITIES REVEALED BY C-ELEGANS GLR-1 GLUTAMATE-RECEPTOR	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; EXPRESSION	How does the nervous system encode environmental stimuli as sensory experiences? Both the type (visual, olfactory, gustatory, mechanical or auditory) and the quality of a stimulus (spatial position, intensity or frequency) are represented as a neural code. Here we undertake a genetic analysis of sensory modality coding in Caenorhabditis elegans. The ASH sensory neurons respond to two distinct sensory stimuli (nose touch and osmotic stimuli). A mutation in the glr-1 (glutamate receptor) gene eliminates the response to nose touch but not to osmotic repellents. The predicted GLR-1 protein is roughly 40% identical to mammalian AMPA-class glutamate receptor (GluR) subunits. Analysis of glr-1 expression and genetic mosaics indicates that GLR-1 receptors act in synaptic targets of the ASH neurons. We propose that discrimination between the ASH sensory modalities arises from differential release of ASH neurotransmitters in response to different stimuli.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School								BARGMANN CI, 1990, COLD SPRING HARB SYM, V55, P529; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; CHALFIE M, 1985, J NEUROSCI, V5, P956; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; DEVRIES SH, 1993, CELL, V72, P139, DOI 10.1016/S0092-8674(05)80033-9; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HODGKIN J, 1983, GENETICS, V103, P43; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; PENG YY, 1993, NEURON, V10, P465, DOI 10.1016/0896-6273(93)90334-N; Riddle DL., 1988, NEMATODE CAENORHABDI, P393; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WAY JC, 1989, GENE DEV, V3, P1823, DOI 10.1101/gad.3.12a.1823; WHIM MD, 1994, J NEUROSCI, V14, P4244; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056	18	309	320	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 2	1995	378	6552					82	85		10.1038/378082a0	http://dx.doi.org/10.1038/378082a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477294				2022-12-28	WOS:A1995TC46900055
J	HENKEMEYER, M; ROSSI, DJ; HOLMYARD, DP; PURI, MC; MBAMALU, G; HARPAL, K; SHIH, TS; JACKS, T; PAWSON, T				HENKEMEYER, M; ROSSI, DJ; HOLMYARD, DP; PURI, MC; MBAMALU, G; HARPAL, K; SHIH, TS; JACKS, T; PAWSON, T			VASCULAR SYSTEM DEFECTS AND NEURONAL APOPTOSIS IN MICE LACKING RAS GTPASE-ACTIVATING PROTEIN	NATURE			English	Article							TYROSINE PHOSPHORYLATION; MOLECULAR-CLONING; GAP; BINDING; RECEPTORS; KINASES; DOMAIN; CELLS; P21	The gene encoding p120-rasGAP, a negative regulator of pas, has been disrupted in mice. This Gap mutation affects the ability of endothelial cells to organize into a highly vascularized network and results in extensive neuronal cell death. Mutations in the Gap and Nf1 genes have a synergistic effect, such that embryos homozygous for mutations in both genes show an exacerbated Gap phenotype. Thus rasGAP and neurofibromin act together to regulate pas activity during embryonic development.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A8,CANADA; MIT,CTR CANC RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	University of Toronto; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	HENKEMEYER, M (corresponding author), MT SINAI HOSP,SAMUEL LUNENFELD RES INST,PROGRAMME MOLEC BIOL & CANC,600 UNIV AVE,TORONTO,ON M5G 1X5,CANADA.		Puri, Mira/C-4412-2014; Pawson, Tony J/E-4578-2013	Henkemeyer, Mark/0000-0002-7525-1061				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; CONLON RA, 1995, DEVELOPMENT, V121, P1533; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FERNANDEZSARABI.MJ, 1993, NATURE, V366, P274; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FOX PL, 1994, ONCOGENE, V9, P3519; GASCA S, 1995, DEV GENET, V17, P141, DOI 10.1002/dvg.1020170206; GOU D, 1995, J BIOL CHEM, V270, P6729; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HSIEH CL, 1989, SOMAT CELL MOLEC GEN, V15, P579, DOI 10.1007/BF01534919; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JIMENEZ B, 1995, ONCOGENE, V10, P811; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIM HA, 1995, ONCOGENE, V11, P325; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MARSHALL CJ, 1991, TRENDS GENET, V7; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1995, CURR OPIN GENET DEV, V5, P51, DOI 10.1016/S0959-437X(95)90053-5; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REY I, 1994, ONCOGENE, V9, P685; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Risau W., 1991, DEV VASCULAR SYSTEM, P58; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SEETHARAM L, 1995, ONCOGENE, V10, P135; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SOSNOWSKI RG, 1993, J CELL BIOL, V121, P113, DOI 10.1083/jcb.121.1.113; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAITENBERGER J, 1994, J BIOL CHEM, V269, P26988; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WURST W, 1993, GENE TARGETING PRACT, P31; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	50	288	291	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 26	1995	377	6551					695	701		10.1038/377695a0	http://dx.doi.org/10.1038/377695a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB469	7477259				2022-12-28	WOS:A1995TB46900045
J	ICHIKI, T; LABOSKY, PA; SHIOTA, C; OKUYAMA, S; IMAGAWA, Y; FOGO, A; NIIMURA, F; ICHIKAWA, I; HOGAN, BLM; INAGAMI, T				ICHIKI, T; LABOSKY, PA; SHIOTA, C; OKUYAMA, S; IMAGAWA, Y; FOGO, A; NIIMURA, F; ICHIKAWA, I; HOGAN, BLM; INAGAMI, T			EFFECTS ON BLOOD-PRESSURE AND EXPLORATORY-BEHAVIOR OF MICE LACKING ANGIOTENSIN-II TYPE-2 RECEPTOR	NATURE			English	Article							RAT-BRAIN; EXPRESSION; SUBTYPES; CLONING; ANTAGONISTS; MECHANISMS; AT1	THERE are two major angiotensin II receptor isoforms, AT(1) and AT(2). AT(1) mediates the well-known presser and mitogenic effects of angiotensin II (refs 1-5), but the signalling mechanism and physiological role of AT(2) (refs 6-11) has not been established. Its abundant expression in fetal tissues(12) and certain brain nuclei(13) suggest possible roles in growth, development and neuronal functions. Here we report the unexpected finding that the targeted disruption of the mouse AT(2) gene resulted in a significant increase in blood pressure and increased sensitivity to the presser action of angiotensin II. Thus AT(2) mediates a depressor effect and antagonizes the AT(1)-mediated presser action of angiotensin II. In addition, disruption of the AT(2) gene attenuated exploratory behaviour and lowered body temperature. Our results show that angiotensin II activates AT(1) and AT(2), which have mutually counteracting haemodynamic effects, and that AT(2) regulates central nervous system functions, including behaviour.	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PEDIAT,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232; TAISHO PHARMACEUT CO LTD,MED RES LABS,LAB 1,OMIYA,SAITAMA 330,JAPAN	Vanderbilt University; Vanderbilt University; Vanderbilt University; Howard Hughes Medical Institute; Vanderbilt University; Taisho Pharmaceutical Holdings Co Ltd				Labosky, Patricia/0000-0001-5880-2194				ASHTON H, 1987, BRAIN SYSTEMS DISORD, P1; BOTTARI SP, 1993, FRONT NEUROENDOCRIN, V14, P123, DOI 10.1006/frne.1993.1005; BUISSON B, 1995, J BIOL CHEM, V270, P1670, DOI 10.1074/jbc.270.4.1670; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; HEIN L, 1995, NATURE, V377, P744, DOI 10.1038/377744a0; ICHIHARA K, 1993, J PHARMACOL EXP THER, V264, P122; ICHIKI T, 1995, CIRC RES, V76, P693, DOI 10.1161/01.RES.76.5.693; Irwin S., 1964, DRUG EVALUATION, P36; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KEISER JA, 1992, J PHARMACOL EXP THER, V262, P1154; KOIKE G, 1994, BIOCHEM BIOPH RES CO, V203, P1842, DOI 10.1006/bbrc.1994.2402; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LO M, 1995, J CLIN INVEST, V95, P1394, DOI 10.1172/JCI117792; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAVERI L, 1994, REGUL PEPTIDES, V52, P21, DOI 10.1016/0167-0115(94)90017-5; PEACH MJ, 1981, BIOCHEM PHARMACOL, V30, P2745, DOI 10.1016/0006-2952(81)90410-X; PHILLIPS MI, 1993, REGUL PEPTIDES, V43, P1; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SCHEUER DA, 1993, AM J PHYSIOL, V264, pR917, DOI 10.1152/ajpregu.1993.264.5.R917; SMITHIES O, 1994, P NATL ACAD SCI USA, V91, P3612, DOI 10.1073/pnas.91.9.3612; SOLISRAMIRES R, 1993, GUIDE TECHNIQUES MOU, P855; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; SUMNERS C, 1991, P NATL ACAD SCI USA, V88, P7567, DOI 10.1073/pnas.88.17.7567; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TOFOVIC SP, 1991, HYPERTENSION, V18, P774, DOI 10.1161/01.HYP.18.6.774; TSUTSUMI K, 1991, AM J PHYSIOL, V261, pR209, DOI 10.1152/ajpregu.1991.261.1.R209; YOSHIDA M, 1994, AM J PHYSIOL, V266, pR802, DOI 10.1152/ajpregu.1994.266.3.R802	29	765	776	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 26	1995	377	6551					748	750		10.1038/377748a0	http://dx.doi.org/10.1038/377748a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB469	7477267				2022-12-28	WOS:A1995TB46900061
J	ERNEST, JT				ERNEST, JT			INTRAOCULAR DEVICE FOR CYTOMEGALOVIRUS-INFECTION	LANCET			English	Editorial Material							SUSTAINED-RELEASE GANCICLOVIR; VIRUS RETINITIS				ERNEST, JT (corresponding author), UNIV CHICAGO,DEPT OPHTHALMOL & VISUAL SCI,CHICAGO,IL 60637, USA.							ANAND R, 1993, ARCH OPHTHALMOL-CHIC, V111, P223, DOI 10.1001/archopht.1993.01090020077027; JABS DA, 1987, OPHTHALMOLOGY, V94, P824; JACOBSON MA, 1989, ANTIMICROB AGENTS CH, V33, P736, DOI 10.1128/AAC.33.5.736; MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023; PEPOSE JS, 1985, OPHTHALMOLOGY, V92, P472; ROWE WP, 1956, P SOC EXP BIOL MED, V92, P418, DOI 10.3181/00379727-92-22497; SANBORN GE, 1992, ARCH OPHTHALMOL-CHIC, V110, P188, DOI 10.1001/archopht.1992.01080140044023; SMITH TJ, 1992, ARCH OPHTHALMOL-CHIC, V110, P255, DOI 10.1001/archopht.1992.01080140111037; 1994, ARCH OPHTHALMOL-CHIC, V112, P19; 1995, INVEST OPHTH VIS SCI, V36, pS180	10	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 14	1995	346	8981					983	984		10.1016/S0140-6736(95)91681-4	http://dx.doi.org/10.1016/S0140-6736(95)91681-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475587				2022-12-28	WOS:A1995RZ59900003
J	ALVAREZBUYLLA, A; NOTTEBOHM, F				ALVAREZBUYLLA, A; NOTTEBOHM, F			MIGRATION OF YOUNG NEURONS IN ADULT AVIAN BRAIN	NATURE			English	Article											ALVAREZBUYLLA, A (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.			Alvarez-Buylla, Arturo/0000-0003-4426-8925				ALVAREZBUYLLA A, 1987, J COMP NEUROL, V264, P159, DOI 10.1002/cne.902640203; ALVAREZBUYLLA A, IN PRESS J NEUROSCI; BAYER SA, 1982, SCIENCE, V216, P890, DOI 10.1126/science.7079742; BURD GD, 1985, J COMP NEUROL, V240, P143, DOI 10.1002/cne.902400204; EDMONDSON JC, 1987, J NEUROSCI, V7, P1928; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; JACOBSON M, 1978, DEV NEUROBIOLOGY, P66; NOTTEBOHM F, 1985, ANN NY ACAD SCI, V457, P143, DOI 10.1111/j.1749-6632.1985.tb20803.x; NOTTEBOHM F, 1987, HDB PHYSL NERVOUS 2, V5; PATON JA, 1984, SCIENCE, V225, P1046, DOI 10.1126/science.6474166; RAKIC P, 1981, TRENDS NEUROSCI, V4, P184, DOI 10.1016/0166-2236(81)90060-6; RAKIC P, 1985, SCIENCE, V227, P1054, DOI 10.1126/science.3975601; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; RAKIC P, 1986, CELL CONTACT ADHESIO; STOKES TM, 1974, J COMP NEUROL, V156, P337, DOI 10.1002/cne.901560305; 1970, ANAT REC, V166, P257	16	286	292	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 22	1988	335	6188					353	354		10.1038/335353a0	http://dx.doi.org/10.1038/335353a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q1373	3419503				2022-12-28	WOS:A1988Q137300059
J	[Anonymous]				[Anonymous]			GENOME MONITORING	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 22	1988	335	6188					284	284						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q1373	3419490				2022-12-28	WOS:A1988Q137300003
J	MARKOWITZ, M; SAAG, M; POWDERLY, WG; HURLEY, AM; HSU, A; VALDES, JM; HENRY, D; SATTLER, F; LAMARCA, A; LEONARD, JM; HO, DD				MARKOWITZ, M; SAAG, M; POWDERLY, WG; HURLEY, AM; HSU, A; VALDES, JM; HENRY, D; SATTLER, F; LAMARCA, A; LEONARD, JM; HO, DD			A PRELIMINARY-STUDY OF RITONAVIR, AN INHIBITOR OF HIV-1 PROTEASE, TO TREAT HIV-1 INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CRYSTAL-STRUCTURE; IMMUNODEFICIENCY; DESIGN	Background. Ritonavir is a potent inhibitor in vitro of human immunodeficiency virus type 1 (HIV-1) protease, which is needed for virions to mature and become infective. We assessed the safety and efficacy of ritonavir in patients with HIV-1 infection. Methods. We administered ritonavir orally to 62 patients in one of four dosages during a 12-week trial containing a 4-week randomized, placebo-controlled, double-blinded phase followed by an 8-week dose-blinded phase, We assessed the response with serial measurements of plasma viremia and serial CD4 cell counts. Results. Fifty-two patients completed the 12-week trial. Diarrhea and nausea were the most common side effects, and reversible elevations in serum triglyceride and gamma-glutamyltransferase levels were the most frequent laboratory abnormalities, Ritonavir had a rapid antiviral effect, with a mean maximal reduction in the number of copies of HIV-1 RNA per milliliter of plasma that ranged from 0.86 to 1.18 log in the four dosage groups. After 12 weeks of treatment, the antiviral effect was partially maintained, with a mean reduction in plasma viremia of 0.5 log, When we used a more sensitive assay for HIV-1 RNA in a subgroup of 20 patients. we found that plasma viremia decreased by a mean of 1.7 log. This antiviral ef feet was partly sustained at week 12, with a mean reduction of approximately 1.1 log. The patients' CD4 cell counts rose during treatment with ritonavir (median increase, 74 and 83 cells per cubic millimeter at weeks 4 and 12, respectively). Conclusions. The protease inhibitor ritonavir is well tolerated and has a potent antiviral effect, as shown by substantial decreases in plasma viremia and significant elevations in CD4 cell counts. Expanded clinical trials of ritonavir are warranted.	NYU,SCH MED,AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016; UNIV ALABAMA,BIRMINGHAM,AL; WASHINGTON UNIV,ST LOUIS,MO; ABBOTT LABS,DIV PHARMACEUT PROD,ABBOTT PK,IL; THERAFIRST MED CTR,FT LAUDERDALE,FL	New York University; University of Alabama System; University of Alabama Birmingham; Washington University (WUSTL); Abbott Laboratories				Powderly, William/0000-0001-7808-3086	NCRR NIH HHS [M01 RR00096, M01 RR00036] Funding Source: Medline; NIAID NIH HHS [AI27742] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000096, M01RR000036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027742] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CAO YZ, 1995, AIDS RES HUM RETROV, V11, P353, DOI 10.1089/aid.1995.11.353; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; Eron J, 1995, 2ND NAT C HUM RETR R, P173; HIRSCH MS, 1993, NEW ENGL J MED, V328, P1686, DOI 10.1056/NEJM199306103282307; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KEMPF DJ, 1991, ANTIMICROB AGENTS CH, V35, P2209, DOI 10.1128/AAC.35.11.2209; KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812; MARKOWITZ M, 1995, J VIROL, V69, P701, DOI 10.1128/JVI.69.2.701-706.1995; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; PACHL C, 1995, J ACQ IMMUN DEF SYND, V8, P446, DOI 10.1097/00042560-199504120-00003; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; YERLY S, 1995, J ACQ IMMUN DEF SYND, V8, P358	17	442	448	2	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 7	1995	333	23					1534	1539		10.1056/NEJM199512073332204	http://dx.doi.org/10.1056/NEJM199512073332204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH157	7477168				2022-12-28	WOS:A1995TH15700004
J	BREGMAN, BS; KUNKELBAGDEN, E; SCHNELL, L; DAI, HN; GAO, D; SCHWAB, ME				BREGMAN, BS; KUNKELBAGDEN, E; SCHNELL, L; DAI, HN; GAO, D; SCHWAB, ME			RECOVERY FROM SPINAL-CORD INJURY MEDIATED BY ANTIBODIES TO NEURITE GROWTH-INHIBITORS	NATURE			English	Article							LOCOMOTOR FUNCTION; ADULT-RATS; NEWBORN; REGENERATION; PLASTICITY; DAMAGE; AXONS; CATS; LESIONS	THERE is little axonal growth after central nervous system (CNS) injury in adult mammals. The administration of antibodies (IN-1) to neutralize the myelin-associated neurite growth inhibitory proteins leads to long-distance regrowth of a proportion of CNS axons after injury(1-5). Our aim was: to determine if spinal cord lesion in adult rats, followed by treatment with antibodies to neurite growth inhibitors, can lead to regeneration and anatomical plasticity of other spinally projecting pathways; to determine if the anatomical projections persist at long survival intervals; and to determine whether this fibre growth is associated with recovery of function. We report here that brain stem-spinal as well as corticospinal axons undergo regeneration and anatomical plasticity after application of IN-1 antibodies. There is a recovery of specific reflex and locomotor functions after spinal cord injury in these adult rats. Removal of the sensorimotor cortex in IN-1-treated rats 2-3 months later abolished the recovered contact-placing responses, suggesting that the recovery was dependent upon the regrowth of these pathways.	UNIV ZURICH,BRAIN RES INST,CH-8029 ZURICH,SWITZERLAND	University of Zurich	BREGMAN, BS (corresponding author), GEORGETOWN UNIV,MED CTR,DEPT CELL BIOL,DIV NEUROBIOL,3900 RESERVOIR RD NW,WASHINGTON,DC 20007, USA.		Schwab, Martin E/B-6818-2016					ALSTERMARK B, 1987, NEUROSCI RES, V5, P66; AMASSIAN VE, 1978, J PHYSIOL-PARIS, V74, P165; BARBEAU H, 1991, BRAIN RES, V546, P250, DOI 10.1016/0006-8993(91)91489-N; BREGMAN BS, 1983, DEV BRAIN RES, V9, P137, DOI 10.1016/0165-3806(83)90047-0; BREGMAN BS, 1989, J COMP NEUROL, V282, P355, DOI 10.1002/cne.902820304; BREGMAN BS, 1993, EXP NEUROL, V123, P3, DOI 10.1006/exnr.1993.1136; BREGMAN BS, 1986, J COMP NEUROL, V244, P86, DOI 10.1002/cne.902440107; BREGMAN BS, 1983, DEV BRAIN RES, V9, P119, DOI 10.1016/0165-3806(83)90046-9; BREGMAN BS, 1982, SCIENCE, V217, P553, DOI 10.1126/science.7089581; BREGMAN BS, 1987, DEV BRAIN RES, V34, P245, DOI 10.1016/0165-3806(87)90213-6; BREGMAN BS, 1987, DEV BRAIN RES, V34, P265, DOI 10.1016/0165-3806(87)90214-8; CADELLI D, 1991, EUR J NEUROSCI, V3, P825, DOI 10.1111/j.1460-9568.1991.tb00093.x; DIETZ V, 1994, LANCET, V344, P1260, DOI 10.1016/S0140-6736(94)90751-X; EIDELBERG E, 1977, EXP NEUROL, V56, P312, DOI 10.1016/0014-4886(77)90350-8; GOLDBERGER ME, 1990, EXP NEUROL, V107, P113, DOI 10.1016/0014-4886(90)90149-M; KUNKELBAGDEN E, 1990, EXP BRAIN RES, V81, P25; KUNKELBAGDEN E, 1992, EXP NEUROL, V116, P40, DOI 10.1016/0014-4886(92)90174-O; KUNKELBAGDEN E, 1993, EXP NEUROL, V119, P153, DOI 10.1006/exnr.1993.1017; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHNELL L, 1993, EUR J NEUROSCI, V5, P1156, DOI 10.1111/j.1460-9568.1993.tb00970.x; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; VILENSKY JA, 1992, J MOTOR BEHAV, V24, P288, DOI 10.1080/00222895.1992.9941624; WEIBEL D, 1994, BRAIN RES, V642, P259, DOI 10.1016/0006-8993(94)90930-X; WERNIG A, 1992, PARAPLEGIA, V30, P229, DOI 10.1038/sc.1992.61; WERNIG A, 1995, EUR J NEUROSCI, V7, P823, DOI 10.1111/j.1460-9568.1995.tb00686.x	25	600	644	1	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					498	501		10.1038/378498a0	http://dx.doi.org/10.1038/378498a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477407				2022-12-28	WOS:A1995TH05400073
J	THOMPSON, JN				THOMPSON, JN			PREVENTING ADHESIONS	LANCET			English	Editorial Material											THOMPSON, JN (corresponding author), HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT SURG, LONDON, ENGLAND.							BECKER JM, 1995, SODIUM HYALURONATE B; DIZEREGA GS, 1994, FERTIL STERIL, V61, P219; SEKIBA K, 1992, OBSTET GYNECOL, V79, P518; THOMPSON JN, 1995, BRIT J SURG, V82, P3, DOI 10.1002/bjs.1800820103; VIPOND MN, 1990, LANCET, V335, P1120, DOI 10.1016/0140-6736(90)91125-T; WHAWELL SA, 1995, EUR J SURG, V161, P315; WISEMAN DM, 1994, POLYM SITE SPECIFIC, P369	7	4	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 25	1995	346	8987					1382	1382		10.1016/S0140-6736(95)92403-5	http://dx.doi.org/10.1016/S0140-6736(95)92403-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG207	7475818				2022-12-28	WOS:A1995TG20700006
J	TRIGGS, WJ; EDGAR, MA; CROS, DP; ADAMS, RD; BARLOW, JS				TRIGGS, WJ; EDGAR, MA; CROS, DP; ADAMS, RD; BARLOW, JS			CASE RECORDS OF THE MASSACHUSETTS GENERAL-HOSPITAL - A 61-YEAR-OLD MAN WITH INCREASING WEAKNESS AND ATROPHY OF ALL EXTREMITIES - PROGRESSIVE MUSCULAR-ATROPHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Discussion							MOTOR-NEURON DISEASE; AMYOTROPHIC-LATERAL-SCLEROSIS; MAGNETIC STIMULATION; BRAIN-STIMULATION; CORTEX; CONDUCTION; CELL; DEGENERATION; NEUROPATHY; LYMPHOMA		UNIV FLORIDA,INST BRAIN,CLIN ELECTROMYOG LAB,GAINESVILLE,FL 32611; UNIV FLORIDA,INST BRAIN,NEUROMUSC CONTROL LAB,GAINESVILLE,FL 32611; UNIV FLORIDA,COLL MED,GAINESVILLE,FL	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	TRIGGS, WJ (corresponding author), UNIV FLORIDA,INST BRAIN,NEUROMUSC CLIN,GAINESVILLE,FL 32611, USA.							ADAMS CR, 1983, JAMA-J AM MED ASSOC, V250, P642; AWISZUS F, 1993, ELECTROEN CLIN NEURO, V89, P408, DOI 10.1016/0168-5597(93)90114-5; BARKER AT, 1985, LANCET, V1, P1106; BROWNELL B, 1970, J NEUROL NEUROSUR PS, V33, P338, DOI 10.1136/jnnp.33.3.338; BUNINA TL, 1962, KORSAKOV J NEUROPATH, V62, P1293; CORNBLATH DR, 1992, MUSCLE NERVE, V15, P1111, DOI 10.1002/mus.880151009; Dyck P J, 1982, Adv Neurol, V36, P105; DYCK PJ, 1968, ARCH NEUROL-CHICAGO, V18, P619, DOI 10.1001/archneur.1968.00470360041003; EISEN A, 1990, MUSCLE NERVE, V13, P146, DOI 10.1002/mus.880130211; EISEN A, 1993, CAN J NEUROL SCI, V20, P11, DOI 10.1017/S031716710004734X; FRIEDMAN AP, 1950, J NERV MENT DIS, V111, P1, DOI 10.1097/00005053-195011110-00001; HAMMER RP, 1979, EXP NEUROL, V63, P336, DOI 10.1016/0014-4886(79)90129-8; HIRANO A, 1991, ADV NEUROL, V56, P91; HIRANO A, 1980, NEUROL MED TOKYO, V13, P148; HUGHES JT, 1982, ADV NEUROL, V36, P611; JOHNSON WG, 1982, ANN NEUROL, V11, P11, DOI 10.1002/ana.410110103; KATO T, 1988, ACTA NEUROPATHOL, V76, P208, DOI 10.1007/BF00688105; KENNEDY WR, 1968, NEUROLOGY, V18, P671, DOI 10.1212/WNL.18.7.671; Lambert EH, 1969, MOTOR NEURON DISEASE, P135; LANGE DJ, 1992, NEUROLOGY, V42, P497, DOI 10.1212/WNL.42.3.497; LATOV N, 1994, PROG BRAIN RES, V101, P295; LAWYER T, 1953, AMA ARCH NEUROL PSY, V69, P171, DOI 10.1001/archneurpsyc.1953.02320260029002; MACKAY RP, 1963, ARCH NEUROL-CHICAGO, V8, P117, DOI 10.1001/archneur.1963.00460020017001; MCMENAMIN J, 1980, J NEUROL NEUROSUR PS, V43, P46, DOI 10.1136/jnnp.43.1.46; MERTON PA, 1980, NATURE, V285, P227, DOI 10.1038/285227a0; MILLS KR, 1987, NEUROSURGERY, V20, P164; MIZUSAWA H, 1989, ACTA NEUROPATHOL, V79, P37, DOI 10.1007/BF00308955; MORTARA P, 1984, J NEUROL SCI, V66, P165, DOI 10.1016/0022-510X(84)90004-2; MULDER DW, 1956, NEUROLOGY, V6, P627, DOI 10.1212/WNL.6.9.627; NORRIS F, 1993, J NEUROL SCI, V118, P48, DOI 10.1016/0022-510X(93)90245-T; OLNEY RK, 1991, NEUROLOGY, V41, P823, DOI 10.1212/WNL.41.6.823; PATTEN BM, 1974, ANN INTERN MED, V80, P182, DOI 10.7326/0003-4819-80-2-182; PESTRONK A, 1994, NEUROLOGY, V44, P2027; PESTRONK A, 1988, ANN NEUROL, V24, P73, DOI 10.1002/ana.410240113; PROUT AJ, 1994, MUSCLE NERVE, V17, P217, DOI 10.1002/mus.880170213; ROTHWELL JC, 1991, EXP PHYSIOL, V76, P159, DOI 10.1113/expphysiol.1991.sp003485; ROWLAND LP, 1992, NEUROLOGY, V42, P1101, DOI 10.1212/WNL.42.5.1101; SASAKI S, 1984, NEUROL MED CHIR TOKY, V20, P39; SCHRIEFER TN, 1989, ELECTROEN CLIN NEURO, V74, P431, DOI 10.1016/0168-5597(89)90032-4; SHAW PJ, 1992, NEUROLOGY, V42, P1477, DOI 10.1212/WNL.42.8.1477; SHY ME, 1986, NEUROLOGY, V36, P1429, DOI 10.1212/WNL.36.11.1429; TRIGGS WJ, 1992, ANN NEUROL, V32, P345, DOI 10.1002/ana.410320307; TRIGGS WJ, 1993, NEUROLOGY, V43, P2615, DOI 10.1212/WNL.43.12.2615; UDAKA F, 1986, ACTA NEUROPATHOL, V70, P289, DOI 10.1007/BF00686086; UOZUMI T, 1991, ELECTROEN CLIN NEURO, V81, P251, DOI 10.1016/0168-5597(91)90010-U; VERMA RK, 1990, NEUROLOGY, V40, P544, DOI 10.1212/WNL.40.3_Part_1.544; Wohlfart G, 1941, ARCH NEURO PSYCHIATR, V46, P0783, DOI 10.1001/archneurpsyc.1941.02280230025003; YOUNGER DS, 1990, NEUROLOGY, V40, P595, DOI 10.1212/WNL.40.4.595; YOUNGER DS, 1991, ANN NEUROL, V29, P78, DOI 10.1002/ana.410290114; 1992, NEW ENGL J MED, V327, P1298	50	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 23	1995	333	21					1406	1412		10.1056/NEJM199511233332108	http://dx.doi.org/10.1056/NEJM199511233332108			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF521	7477123				2022-12-28	WOS:A1995TF52100008
J	SHINGADIA, D; HOWARD, MR; BRINK, NS; GIBB, D; KLEIN, N; TEDDER, R; NOVELLI, V				SHINGADIA, D; HOWARD, MR; BRINK, NS; GIBB, D; KLEIN, N; TEDDER, R; NOVELLI, V			KAPOSIS-SARCOMA AND KSHV	LANCET			English	Letter									GREAT ORMOND ST CHILDRENS HOSP NHS TRUST, DEPT INFECT DIS, LONDON WC1N 3JH, ENGLAND; UNIV LONDON, INST CHILD HLTH, LONDON WC1N 1EH, ENGLAND; UCL, SCH MED, DEPT VIROL, LONDON W1N 8AA, ENGLAND; UCL HOSP NHS TRUST, LONDON, ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London				Tedder, Richard/0000-0002-9672-5721					0	8	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 18	1995	346	8986					1359	1360						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE916	7475783				2022-12-28	WOS:A1995TE91600035
J	PORTEGIES, P				PORTEGIES, P			HIV-1, THE BRAIN, AND COMBINATION THERAPY	LANCET			English	Editorial Material							AIDS DEMENTIA COMPLEX; ZIDOVUDINE TREATMENT; CEREBROSPINAL-FLUID				PORTEGIES, P (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT NEUROL,1105 AZ AMSTERDAM,NETHERLANDS.							BREW BJ, 1992, AIDS, V6, P461, DOI 10.1097/00002030-199205000-00004; BUTLER KM, 1991, NEW ENGL J MED, V324, P137, DOI 10.1056/NEJM199101173240301; CHOO V, 1995, LANCET, V346, P895, DOI 10.1016/S0140-6736(95)92725-5; DEGANS J, 1988, AIDS, V2, P37, DOI 10.1097/00002030-198802000-00006; DISTEFANO M, 1993, LANCET, V342, P865, DOI 10.1016/0140-6736(93)92724-8; GRAY F, 1994, AIDS, V8, P489, DOI 10.1097/00002030-199404000-00011; MAEHLEN J, 1995, AIDS, V9, P1165, DOI 10.1097/00002030-199510000-00008; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; PORTEGIES P, 1989, BRIT MED J, V299, P819, DOI 10.1136/bmj.299.6703.819; PORTEGIES P, 1994, J ACQ IMMUN DEF SYND, V7, pS38; PORTEGIES P, 1993, AIDS, V7, P669, DOI 10.1097/00002030-199305000-00010; PORTEGIES P, 1994, LANCET, V344, P759, DOI 10.1016/S0140-6736(94)92252-7; Price R W, 1995, AIDS, V9 Suppl A, pS221; SIDTIS JJ, 1993, ANN NEUROL, V33, P343, DOI 10.1002/ana.410330403; VAGO L, 1993, J ACQ IMMUN DEF SYND, V6, P42; WILDEMANN B, 1993, NEUROLOGY, V43, P2659, DOI 10.1212/WNL.43.12.2659	16	30	30	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1244	1245		10.1016/S0140-6736(95)91857-4	http://dx.doi.org/10.1016/S0140-6736(95)91857-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475712	Bronze			2022-12-28	WOS:A1995TE14500005
J	WANG, JT; SYED, A; HSIEH, ML; GRALLA, JD				WANG, JT; SYED, A; HSIEH, ML; GRALLA, JD			CONVERTING ESCHERICHIA-COLI RNA-POLYMERASE INTO AN ENHANCER-RESPONSIVE ENZYME - ROLE OF AN NH2-TERMINAL LEUCINE PATCH IN SIGMA(54)	SCIENCE			English	Article							TRANSCRIPTIONAL ENHANCERS; BINDING PROTEINS; PROMOTER; ACTIVATOR; NTRC; INITIATION; SIGMA-54; GLNA	The protein sigma(54) associates with Escherichia coli core RNA polymerase to form a holoenzyme that binds promoters but is inactive in the absence of enhancer activation, Here, mutants of sigma(54) enabled polymerases to transcribe without enhancer protein and adenosine triphosphate. The mutations are in leucines within the NH2-terminal glutamine-rich domain of sigma(54). Multiple leucine substitutions mimicked the effect of enhancer protein, which suggests that the enhancer protein functions to disrupt a leucine patch. The results indicate that sigma(54) acts both as an inhibitor of polymerase activity and as a receptor that interacts with enhancer protein to overcome this inhibition, and that these two activities jointly confer enhancer responsiveness.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NIGMS NIH HHS [GM35754] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035754] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; FENG JL, 1992, J BACTERIOL, V174, P6061, DOI 10.1128/JB.174.19.6061-6070.1992; GRALLA JD, 1991, CELL, V66, P415, DOI 10.1016/0092-8674(81)90001-5; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HSIEH ML, 1994, J MOL BIOL, V239, P15, DOI 10.1006/jmbi.1994.1347; HSIEH ML, 1994, J BIOL CHEM, V269, P373; KUSTU S, 1991, TRENDS BIOCHEM SCI, V16, P397, DOI 10.1016/0968-0004(91)90163-P; MOORE JB, 1993, J BACTERIOL, V175, P2692, DOI 10.1128/JB.175.9.2692-2701.1993; NINFA AJ, 1987, CELL, V50, P1039, DOI 10.1016/0092-8674(87)90170-X; NORTH AK, 1993, J BACTERIOL, V175, P4267, DOI 10.1128/JB.175.14.4267-4273.1993; POPHAM D, 1991, J BIOL CHEM, V266, P19510; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; RAY L, 1990, J BACTERIOL, V172, P818, DOI 10.1128/jb.172.2.818-823.1990; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; SYED A, UNPUB; TINTUT Y, 1994, P NATL ACAD SCI USA, V91, P2120, DOI 10.1073/pnas.91.6.2120; TINTUT Y, 1995, GENE DEV, V9, P2305, DOI 10.1101/gad.9.18.2305; TINTUT Y, 1995, J BIOL CHEM, V270, P24392, DOI 10.1074/jbc.270.41.24392; WANG TW, UNPUB; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; WONG CN, 1994, J MOL BIOL, V236, P81, DOI 10.1006/jmbi.1994.1120	25	82	82	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 10	1995	270	5238					992	994		10.1126/science.270.5238.992	http://dx.doi.org/10.1126/science.270.5238.992			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD878	7481805				2022-12-28	WOS:A1995TD87800050
J	DIRINGER, H				DIRINGER, H			PROPOSED LINK BETWEEN TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES OF MAN AND ANIMALS	LANCET			English	Note							CREUTZFELDT-JAKOB DISEASE; SCRAPIE	A link between scrapie and Creutzfeldt-Jakob disease (CJD) is likely to exist. Based on old observations on scrapie, new experiments on bovine spongiform encephalopathy, and modern reviews on CJD, my proposal fits general rules of virus transmission.			DIRINGER, H (corresponding author), ROBERT KOCH INST,NORDUFER 20,D-13353 BERLIN,GERMANY.							BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; BROWN P, 1979, ANN NEUROL, V6, P438, DOI 10.1002/ana.410060511; BROWN P, 1994, NEURODEGENER DIS, P839; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Cathala F, 1985, Eur J Epidemiol, V1, P90, DOI 10.1007/BF00141798; CHELLE P. L., 1942, Bulletin de l'Academie Veterinaire de France, V15, P294; CLARK WW, 1995, AM J VET RES, V56, P606; CUTLIP RC, 1994, J INFECT DIS, V169, P814, DOI 10.1093/infdis/169.4.814; DIRINGER H, 1994, ANN NY ACAD SCI, V724, P246, DOI 10.1111/j.1749-6632.1994.tb38915.x; GAJDUSEK DC, 1966, NATURE, V209, P794, DOI 10.1038/209794a0; GAJDUSEK DC, 1990, VIROLOGY, P2289; GIBBS CJ, 1968, SCIENCE, V161, P388, DOI 10.1126/science.161.3839.388; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; Pattison I. H., 1965, NINDB MONOGRAPH, V2, P249; PATTISON IH, 1972, VET REC, V90, P465, DOI 10.1136/vr.90.17.465; SARRAET M, 1883, REV MED VET, V7, P310; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; WILESMITH JW, 1991, VET REC, V128, P199, DOI 10.1136/vr.128.9.199; WILLOUGHBY K, 1992, VET REC, V131, P431, DOI 10.1136/vr.131.19.431	20	33	33	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 4	1995	346	8984					1208	1210		10.1016/S0140-6736(95)92905-3	http://dx.doi.org/10.1016/S0140-6736(95)92905-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC976	7475665				2022-12-28	WOS:A1995TC97600015
J	WYATT, J				WYATT, J			NERVOUS ABOUT ARTIFICIAL NEURAL NETWORKS	LANCET			English	Editorial Material											WYATT, J (corresponding author), IMPERIAL CANC RES FUND,BIOMED INFORMAT UNIT,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.		Wyatt, Jeremy/F-8160-2010	Wyatt, Jeremy/0000-0001-7008-1473				BRAHAMS D, 1989, LANCET, V2, P632; CANCATO J, 1993, ANN INTERN MED, V118, P201; Egmont-Petersen M, 1994, Artif Intell Med, V6, P359, DOI 10.1016/0933-3657(94)90002-7; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; KNAUS WA, 1991, SCIENCE, V254, P389, DOI 10.1126/science.1925596; Michie D, 1994, MACHINE LEARNING NEU, P213; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WYATT J, 1991, LANCET, V338, P1431, DOI 10.1016/0140-6736(91)92731-G; WYATT JC, IN PRESS BMJ; YOUNG D, 1990, BR J HEALTHCARE  NOV, P16	10	49	50	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 4	1995	346	8984					1175	1177		10.1016/S0140-6736(95)92893-6	http://dx.doi.org/10.1016/S0140-6736(95)92893-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC976	7475653				2022-12-28	WOS:A1995TC97600003
J	WATAMANIUK, SNJ; MCKEE, SP				WATAMANIUK, SNJ; MCKEE, SP			SEEING MOTION BEHIND OCCLUDERS	NATURE			English	Article								THE visual system has no difficulty maintaining the identity of an object as it disappears and reappears behind stationary occluders, In the natural world, a moving object may differ from occluders by many characteristics (colour, depth, shape and so on), Scene segmentation based on these characteristics is thought to happen early in visual processing, and to influence how objects, including moving objects, are identified(1-5). What happens if the only characteristic distinguishing an object is its direction of motion? Experiments with random dot displays show that one dot moving in a constant trajectory is readily detected among identical dots in brownian motion(6). Detection declines sharply if the trajectory is intermittently broken, but improves if occluders obscure the breaks in the trajectory. It is not sufficient that these occluders be perceived as segmented from the rest of the display (such as by colour or depth). Rather, it is critical that the occluders do not contain motion that is similar in direction to that of the target trajectory. We conclude that detection of the trajectory is due to the integration of information within a network of low-level motion detectors and is not dependent on segmentation processes(7).	SMITH KETTLEWELL EYE RES INST,SAN FRANCISCO,CA 94115	The Smith-Kettlewell Eye Research Institute								BOWNE SF, 1989, J OPT SOC AM A, V6, P1112, DOI 10.1364/JOSAA.6.001112; BRADDICK O, 1988, NATURE, V333, P803, DOI 10.1038/333803a0; Grzywacz N. M., 1989, Proceedings. Workshop on Visual Motion (IEEE Cat. No.89CH2716-9), P148, DOI 10.1109/WVM.1989.47104; GRZYWACZ NM, IN PRESS VISION RES, V325; HE ZJ, 1992, NATURE, V359, P231, DOI 10.1038/359231a0; HE ZJJ, 1994, NATURE, V367, P173, DOI 10.1038/367173a0; NAKAYAMA K, 1990, VISION RES, V30, P1811, DOI 10.1016/0042-6989(90)90161-D; SHIPLEY TF, 1993, SPATIAL VISION, V7, P323, DOI 10.1163/156856893X00478; SHLMOJO S, 1988, NATURE, V333, P265; WATAMANIUK SNJ, 1995, VISION RES, V35, P65, DOI 10.1016/0042-6989(94)E0047-O; YULLE AL, 1988, NATURE, V333, P71	11	45	45	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 26	1995	377	6551					729	730		10.1038/377729a0	http://dx.doi.org/10.1038/377729a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB469	7477261				2022-12-28	WOS:A1995TB46900055
J	GORDON, SM; TIPPLE, M; BLAND, LA; JARVIS, WR				GORDON, SM; TIPPLE, M; BLAND, LA; JARVIS, WR			PYROGENIC REACTIONS ASSOCIATED WITH THE REUSE OF DISPOSABLE HOLLOW-FIBER HEMODIALYZERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											GORDON, SM (corresponding author), CTR DIS CONTROL,CTR INFECT DIS,HOSP INFECT PROGRAM,BLDG 1,ROOM 5044,ATLANTA,GA 30333, USA.							ALTER MJ, 1988, JAMA-J AM MED ASSOC, V260, P2073, DOI 10.1001/jama.260.14.2073; ALTER MJ, 1983, DIALYSIS TRANSPLANT, V12, P860; BERNICK JJ, 1980, CLIN NEPHROL, V14, P13; Bland L, 1985, Trans Am Soc Artif Intern Organs, V31, P556; BOLAN G, 1985, J INFECT DIS, V152, P1013, DOI 10.1093/infdis/152.5.1013; DAUGIRDAS JT, 1988, KIDNEY INT S24, V33, pS37; DUMOULIN GC, 1987, APPL ENVIRON MICROB, V53, P1322, DOI 10.1128/AEM.53.6.1322-1326.1987; Favero MS., 1985, HOSPITAL INFECTIONS, P267; FAVERO MS, 1981, NEPHRON, V27, P307; GAZENFIELDGAZIT E, 1969, ISRAEL J MED SCI, V5, P1032; GREISMAN SE, 1969, P SOC EXP BIOL MED, V131, P1154, DOI 10.3181/00379727-131-34059; HINDMAN SH, 1975, HLTH LAB SCI, V12, P321; KANT KS, 1981, KIDNEY INT, V19, P728, DOI 10.1038/ki.1981.73; KANTOR RJ, 1983, AM J MED, V74, P449, DOI 10.1016/0002-9343(83)90978-6; KOLMOS HJ, 1984, J HOSP INFECT, V5, P70, DOI 10.1016/0195-6701(84)90103-8; LEVIN NW, 1986, GUIDE REPROCESSING H, P75; MOLLER S, 1978, ACTA MED SCAND, V203, P345; PETERSEN NJ, 1981, T AM SOC ART INT ORG, V27, P155; PETERSEN NJ, 1987, DIALYSIS TRANSPLANT, V7, P57; POLLAK VE, 1988, KIDNEY INT S24, V33, pS49; POLLAK VE, 1986, AM J NEPHROL, V6, P101; ROBINSON PJ, 1971, BRIT MED J, V1, P528, DOI 10.1136/bmj.1.5748.528; SOLANO JT, 1975, LANCET, V2, P732; VILLARROEL F, 1985, ARTIF ORGANS, V9, P231, DOI 10.1111/j.1525-1594.1985.tb04384.x; WALLENSTEIN S, 1980, AM J EPIDEMIOL, V111, P367, DOI 10.1093/oxfordjournals.aje.a112908; WESTPHAL O, 1975, INT ARCH ALLER A IMM, V49, P1, DOI 10.1159/000231374; WINEMAN RJ, 1986, GUIDE REPROCESSING H, P173; 1986, REUSE HEMODIALYZERS; 1982, AM NATIONAL STANDARD; 1960, STANDARD METHODS EXA; 1986, MMWR, V35, P417	31	47	47	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1988	260	14					2077	2081		10.1001/jama.260.14.2077	http://dx.doi.org/10.1001/jama.260.14.2077			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q3421	3418872				2022-12-28	WOS:A1988Q342100021
J	BLENDON, RJ; DONELAN, K				BLENDON, RJ; DONELAN, K			DISCRIMINATION AGAINST PEOPLE WITH AIDS - THE PUBLICS PERSPECTIVE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											BLENDON, RJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,HARVARD AIDS INST,BOSTON,MA 02115, USA.		Donelan, Karen/R-6162-2019					[Anonymous], 1988, CONFRONTING AIDS UPD; BRANDT AM, 1988, AM J PUBLIC HEALTH, V78, P367, DOI 10.2105/AJPH.78.4.367; CORBETT M, 1982, POLITICAL TOLERANCE, P65; CURRAN WJ, 1986, PHS860032 PUBL; FACKELMANN KA, 1988, MED HLTH PERSPE 0613, P1; GALLUP G, 1986, GALLUP POLL PUBLIC O; GROSS SJ, 1975, PUBLIC OPIN QUART, V39, P358, DOI 10.1086/268234; HASTINGS EH, 1988, INDEX INT PUBLIC OPI, P192; KUTNER B, 1952, J ABNORM SOC PSYCH, V47, P649, DOI 10.1037/h0053883; MUELLER J, 1988, PUBLIC OPIN QUART, V52, P1, DOI 10.1086/269079; MUSTO DF, 1986, MILBANK Q, V64, P97, DOI 10.2307/3350043; Parmet W E, 1987, Law Med Health Care, V15, P61; QUINLEY H, 1988, PUBLIC OP        MAY, P53; 1985, WASHINGTON POST  SEP; 1988, HLTH CARE ISSUES; 1988, PEOPLE PRESS POLITIC; 1987, WASHINGTON POST 0311; 1987, AIDS SURVEY; 1987, GALLUP POLL     0713; 1988, GALLUP POLL     0720; 1988, ADV DATA VITAL HLTH, V151; 1987, US NEWS WORLD R 0401; 1987, ADV DATA VITAL HLTH, V150; 1987, ADV DATA VITAL HLTH, V147; 1988, ANTIGAY VIOLENCE VIC; 1988, ADV DATA VITAL HLTH, V153; 1985, NY TIMES        0626, P45; 1987, MMWR S6, V36, P1; 1986, GALLUP NEWSWEEK 1124; 1988, GALLUP REPORT    JAN; 1987, GALLUP POLL     1122; 1988, GALLUP REPORT    JUN; 1987, GALLUP POLL     1126; 1987, ADV DATA VITAL HLTH, V146; 1985, HARRIS SURVEY	35	119	119	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	1988	319	15					1022	1026		10.1056/NEJM198810133191522	http://dx.doi.org/10.1056/NEJM198810133191522			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q4155	3419476				2022-12-28	WOS:A1988Q415500033
J	FIG, LM; GROSS, MD; SHAPIRO, B; EHRMANN, DA; FREITAS, JE; SCHTEINGART, DE; GLAZER, GM; FRANCIS, IR				FIG, LM; GROSS, MD; SHAPIRO, B; EHRMANN, DA; FREITAS, JE; SCHTEINGART, DE; GLAZER, GM; FRANCIS, IR			ADRENAL LOCALIZATION IN THE ADRENOCORTICOTROPIC HORMONE-INDEPENDENT CUSHING SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article									VET ADM MED CTR, NUCL MED SERV 115, 2215 FULLER RD, ANN ARBOR, MI 48105 USA; UNIV MICHIGAN, MED CTR, ANN ARBOR, MI 48109 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Michigan System; University of Michigan					NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM021477] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09015] Funding Source: Medline; NCRR NIH HHS [3 M01 RR0042-22-S1CLR] Funding Source: Medline; NIADDK NIH HHS [R01 AM 21477-02RAD] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARON DC, 1982, ENDOCR REV, V3, P229, DOI 10.1210/edrv-3-3-229; Baba H, 1982, Nihon Igaku Hoshasen Gakkai Zasshi, V42, P938; BARBARINO A, 1979, CLIN ENDOCRINOL, V10, P107, DOI 10.1111/j.1365-2265.1979.tb01356.x; BARLIEV GB, 1979, EUR J NUCL MED, V4, P449, DOI 10.1007/BF00300844; BEIERWALTES WH, 1971, J AMER MED ASSOC, V216, P275, DOI 10.1001/jama.216.2.275; CATANIA A, 1986, HORM RES, V23, P9, DOI 10.1159/000180282; CHROUSOS GP, 1985, ANN INTERN MED, V102, P344, DOI 10.7326/0003-4819-102-3-344; DASH RJ, 1975, STEROIDS, V26, P647, DOI 10.1016/0039-128X(75)90057-4; DIGEPETERSEN H, 1975, ACTA ENDOCRINOL-COP, V80, P81, DOI 10.1530/acta.0.0800081; DOPPMAN JL, 1988, RADIOLOGY, V166, P347, DOI 10.1148/radiology.166.2.2827231; DUNNICK NR, 1982, J COMPUT ASSIST TOMO, V6, P978, DOI 10.1097/00004728-198210000-00020; DUNNICK NR, 1982, RADIOLOGY, V142, P429, DOI 10.1148/radiology.142.2.7054832; DUNNICK NR, 1979, AM J ROENTGENOL, V132, P43, DOI 10.2214/ajr.132.1.43; EGHARI M, 1980, J COMPUT ASSIST TOMO, V4, P71; GROSS MD, 1984, ENDOCR REV, V5, P221, DOI 10.1210/edrv-5-2-221; GROSS MD, 1981, J CLIN ENDOCR METAB, V52, P1062, DOI 10.1210/jcem-52-6-1062; GROSS MD, 1984, CLIN NUCL MED, V9, P264, DOI 10.1097/00003072-198405000-00005; GROSS MD, 1983, J CLIN ENDOCR METAB, V57, P477, DOI 10.1210/jcem-57-3-477; GUERIN CK, 1983, AM J MED, V75, P653, DOI 10.1016/0002-9343(83)90452-7; HUEBENER KH, 1984, RADIOLOGY, V150, P195, DOI 10.1148/radiology.150.1.6689760; HUSSAIN S, 1985, AM J ROENTGENOL, V144, P61, DOI 10.2214/ajr.144.1.61; JOFFE SN, 1983, SURGERY, V94, P919; KAPLOWITZ PB, 1986, AM J DIS CHILD, V140, P1072, DOI 10.1001/archpedi.1986.02140240118038; KAZEROONI E, 1988, Journal of Nuclear Medicine, V29, P859; KEHLET H, 1976, BRIT MED J, V2, P665, DOI 10.1136/bmj.2.6037.665; KOROBKIN M, 1979, AM J ROENTGENOL, V132, P231, DOI 10.2214/ajr.132.2.231; LARSEN JL, 1986, AM J MED, V80, P976, DOI 10.1016/0002-9343(86)90648-0; LEGER FA, 1981, NOUV PRESSE MED, V10, P395; LEIBA S, 1986, ACTA ENDOCRINOL-COP, V112, P323, DOI 10.1530/acta.0.1120323; LINDBERG S, 1985, NUCL MED COMMUN, V6, P31, DOI 10.1097/00006231-198501000-00005; MILES JM, 1979, MAYO CLIN PROC, V54, P321; MOSES DC, 1974, SURG GYNECOL OBSTET, V139, P201; ORTEGA D, 1980, CLIN ENDOCRINOL, V13, P145, DOI 10.1111/j.1365-2265.1980.tb01035.x; REYNES CJ, 1979, RADIOL CLIN N AM, V17, P91; RYO UY, 1978, RADIOLOGY, V128, P157, DOI 10.1148/128.1.157; SAMPLE WF, 1978, RADIOLOGY, V128, P377, DOI 10.1148/128.2.377; SARKAR S, 1987, Journal of Nuclear Medicine, V28, P640; SARKAR SD, 1977, J CLIN ENDOCR METAB, V45, P353, DOI 10.1210/jcem-45-2-353; SCHTEINGART DE, 1980, J CLIN ENDOCR METAB, V50, P961, DOI 10.1210/jcem-50-5-961; SCHULTZ CL, 1984, AM J ROENTGENOL, V143, P1235, DOI 10.2214/ajr.143.6.1235; SCOTT HW, 1985, ANN SURG, V201, P586, DOI 10.1097/00000658-198505000-00007; SHAPIRO B, 1981, CLIN ENDOCRINOL, V15, P19, DOI 10.1111/j.1365-2265.1981.tb02743.x; SHAPIRO B, 1982, J NUCL MED, V23, P799; SHENKER Y, 1986, J ENDOCRINOL INVEST, V9, P115, DOI 10.1007/BF03348080; SILBER RH, 1954, J BIOL CHEM, V210, P923; SKALKEAS G, 1982, AM J SURG, V143, P363, DOI 10.1016/0002-9610(82)90107-6; SMALS AGH, 1984, J CLIN ENDOCR METAB, V58, P25, DOI 10.1210/jcem-58-1-25; SUDELL CJ, 1985, NUCL MED COMMUN, V6, P519, DOI 10.1097/00006231-198509000-00005; THRALL JH, 1978, SEMIN NUCL MED, V8, P23, DOI 10.1016/S0001-2998(78)80005-1; TRONCONE L, 1980, EUR J NUCL MED, V5, P345, DOI 10.1007/BF00445622; VAGUE P, 1971, REV EUR ETUD CL BIOL, V16, P485; VALK TW, 1980, J NUCL MED, V21, P1069; VANBERKHOUT FT, 1986, CLIN ENDOCRINOL, V24, P299; WAHNER HW, 1977, CLIN NUCLEAR MEDICIN, V2, P253; WATSON NE, 1985, CLIN NUCL MED, V10, P539, DOI 10.1097/00003072-198508000-00001; WEISS LM, 1984, AM J SURG PATHOL, V8, P163, DOI 10.1097/00000478-198403000-00001	56	47	47	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1988	109	7					547	553		10.7326/0003-4819-109-7-547	http://dx.doi.org/10.7326/0003-4819-109-7-547			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q4157	3421563				2022-12-28	WOS:A1988Q415700007
J	GREATOREX, RA; DIXON, AK; FLOWER, CDR; PULVERTAFT, RW				GREATOREX, RA; DIXON, AK; FLOWER, CDR; PULVERTAFT, RW			LIMITATIONS OF COMPUTED-TOMOGRAPHY IN LEAKING ABDOMINAL AORTIC-ANEURYSMS	BRITISH MEDICAL JOURNAL			English	Article									ADDENBROOKES HOSP,DEPT RADIOL,CAMBRIDGE CB2 2QQ,ENGLAND	Addenbrooke's Hospital; University of Cambridge	GREATOREX, RA (corresponding author), ADDENBROOKES HOSP,DEPT SURG,CAMBRIDGE CB2 2QQ,ENGLAND.							AXELBAUM SP, 1976, AM J ROENTGENOL, V127, P75, DOI 10.2214/ajr.127.1.75; BREWSTER DC, 1975, NEW ENGL J MED, V292, P822, DOI 10.1056/NEJM197504172921602; COHEN JM, 1985, RADIOLOGY, V155, P705, DOI 10.1148/radiology.155.3.4001373; DIXON AK, 1981, BRIT J SURG, V68, P47, DOI 10.1002/bjs.1800680116; GARLIS H, 1980, SURGERY, V87, P300; GOMES MN, 1978, COMPUT TOMOGR, V2, P99, DOI 10.1016/0363-8235(78)90007-8; JOHNSON G, 1980, ARCH SURG-CHICAGO, V115, P51; KADIR S, 1980, ARCH SURG-CHICAGO, V115, P631; LEOPOLD GR, 1972, SURGERY, V72, P939; LINEAWEAVER WC, 1982, ARCH SURG-CHICAGO, V117, P1095; NUSBAUM JW, 1971, ARCH SURG-CHICAGO, V102, P385; PERRETT LV, 1978, AUST NZ J SURG, V48, P275, DOI 10.1111/j.1445-2197.1978.tb05228.x; ROBICSEK F, 1981, SURGERY, V89, P275; SENAPATI A, 1986, J CARDIOVASC SURG, V27, P719; YOUNG AE, 1980, BRIT MED J, V280, P765, DOI 10.1136/bmj.280.6216.765	15	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1988	297	6643					284	285		10.1136/bmj.297.6643.284	http://dx.doi.org/10.1136/bmj.297.6643.284			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P4266	3416149	Bronze, Green Published			2022-12-28	WOS:A1988P426600027
J	KLEMPERER, JD; KLEIN, I; GOMEZ, M; HELM, RE; OJAMAA, K; THOMAS, SJ; ISOM, OW; KRIEGER, K				KLEMPERER, JD; KLEIN, I; GOMEZ, M; HELM, RE; OJAMAA, K; THOMAS, SJ; ISOM, OW; KRIEGER, K			THYROID-HORMONE TREATMENT AFTER CORONARY-ARTERY BYPASS-SURGERY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EUTHYROID SICK SYNDROME; CARDIOPULMONARY BYPASS; TRIIODOTHYRONINE; HYPERTHYROIDISM; ILLNESS; HEART; T3	Background. Thyroid hormone has many effects on the cardiovascular system. During and after cardiopulmonary bypass, serum triiodothyronine concentrations decline transiently, which may contribute to postoperative hemodynamic dysfunction. We investigated whether the perioperative administration of triiodothyronine (liothyronine sodium) enhances cardiovascular performance in high-risk patients undergoing coronary-artery bypass surgery. Methods. We administered triiodothyronine or placebo to 142 patients with coronary artery disease and depressed left ventricular function. The hormone was administered as an intravenous bolus of 0.8 mu g per kilogram of body weight when the aortic cross-clamp was removed after the completion of bypass surgery and then as an infusion of 0.113 mu g per kilogram per hour for six hours, Clinical and hemodynamic responses were serially recorded, as was any need for inotropic or vasodilator drugs. Results. The patients' preoperative serum triiodothyronine concentrations were normal (mean [+/-SD] value, 81+/-22 ng per deciliter [1.2+/-0.3 nmol per liter]), and they decreased by 40 percent (P<0.001) 30 minutes after the onset of cardiopulmonary bypass, The concentrations in patients given intravenous triiodothyronine became supranormal and were significantly higher than those in patients given placebo (P<0.001). However, the concentrations were once again similar in the two groups 24 hours after surgery. The mean postoperative cardiac index was higher in the triiodothyronine group (2.97+/-0.72 vs. 2.67+/-0.61 liters per minute per square meter of body-surface area, P=0.007), and systemic vascular resistance was lower (1073+/-314 vs. 1235+/-387 dyn . sec . cm(-5), P=0.003). The two groups did not differ significantly in the incidence of arrhythmia or the need for therapy with inotropic and vasodilator drugs during the 24 hours after surgery, or in perioperative mortality and morbidity. Conclusions. Raising serum triiodothyronine concentrations in patients undergoing coronary-artery bypass surgery increases cardiac output and lowers systemic vascular resistance but does not change outcome or alter the need for standard postoperative therapy.	CORNELL UNIV,COLL MED,NEW YORK HOSP,DEPT ANESTHESIOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,N SHORE UNIV HOSP,DEPT MED,DIV ENDOCRINOL,MANHASSET,NY	Cornell University; NewYork-Presbyterian Hospital; Cornell University; Northwell Health; North Shore University Hospital	KLEMPERER, JD (corresponding author), CORNELL UNIV,COLL MED,NEW YORK HOSP,DEPT CARDIOTHORAC SURG,525 E 68TH ST,NEW YORK,NY 10021, USA.							BILEZIKIAN JP, 1983, ENDOCR REV, V4, P378, DOI 10.1210/edrv-4-4-378; BRENT GA, 1986, J CLIN ENDOCR METAB, V63, P1; DAVIS PJ, 1993, ANN THORAC SURG, V56, pS16, DOI 10.1016/0003-4975(93)90550-2; DILLMANN WH, 1990, AM J MED, V88, P626, DOI 10.1016/0002-9343(90)90530-Q; DYKE CM, 1991, ANN THORAC SURG, V52, P14, DOI 10.1016/0003-4975(91)91410-W; HOLLAND FW, 1991, ANN THORAC SURG, V52, P46, DOI 10.1016/0003-4975(91)91416-S; JEEVANANDAM V, 1994, J HEART LUNG TRANSPL, V13, P681; KLEIN I, 1994, J CLIN ENDOCR METAB, V78, P1026, DOI 10.1210/jc.78.5.1026; KLEIN I, 1990, AM J MED, V88, P631, DOI 10.1016/0002-9343(90)90531-H; KLEMPERER JD, 1995, J THORAC CARDIOV SUR, V109, P457, DOI 10.1016/S0022-5223(95)70276-8; KLEMPERER JD, PROG CARDIOVASC DIS, V38, P1; KO W, 1991, J THORAC CARDIOV SUR, V102, P532; LEVEY GS, 1990, AM J MED, V88, P642, DOI 10.1016/0002-9343(90)90533-J; Levey GS, 1994, STEINS TXB MED, P1383; NOVITZKY D, 1988, ANN THORAC SURG, V45, P50, DOI 10.1016/S0003-4975(10)62396-X; NOVITZKY D, 1989, J THORAC CARDIOV SUR, V98, P972; Novitzky D, 1989, Eur J Cardiothorac Surg, V3, P140, DOI 10.1016/1010-7940(89)90092-4; OJAMAA K, 1993, ANN THORAC SURG, V56, pS61, DOI 10.1016/0003-4975(93)90556-W; ROBUSCHI G, 1986, HORM RES, V23, P151, DOI 10.1159/000180311; SALTER DR, 1992, J CARDIAC SURG, V7, P363, DOI 10.1111/j.1540-8191.1992.tb01029.x; TOFT AD, 1994, NEW ENGL J MED, V331, P174; UTIGER RD, 1980, AM J MED, V69, P807, DOI 10.1016/S0002-9343(80)80003-9; WALKER JD, 1994, ANN THORAC SURG, V58, P851, DOI 10.1016/0003-4975(94)90766-8; WARTOFSKY L, 1982, ENDOCR REV, V3, P164, DOI 10.1210/edrv-3-2-164	24	327	334	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 7	1995	333	23					1522	1527		10.1056/NEJM199512073332302	http://dx.doi.org/10.1056/NEJM199512073332302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH157	7477166	Bronze			2022-12-28	WOS:A1995TH15700002
J	LOZANO, AM; LANG, AE; GALVEZJIMENEZ, N; MIYASAKI, J; DUFF, J; HUTCHINSON, WD; DOSTROVSKY, JO				LOZANO, AM; LANG, AE; GALVEZJIMENEZ, N; MIYASAKI, J; DUFF, J; HUTCHINSON, WD; DOSTROVSKY, JO			EFFECT OF GPI PALLIDOTOMY ON MOTOR FUNCTION IN PARKINSONS-DISEASE	LANCET			English	Article							LEVODOPA-INDUCED DYSKINESIA; NUCLEUS; STIMULATION; THALAMOTOMY; REVERSAL; MONKEYS	The major motor disturbances in Parkinson's disease are thought to be caused by overactivity of the internal segment of the globus pallidus (GPi), in large part due to excessive drive from the subthalamic nucleus. The excessive inhibitory activity of GPi is thought to ''brake' the motor thalamus and the cortical motor system to produce the slowness, rigidity, and poverty of movement characteristic of parkinsonian states. To test the hypothesis that direct reduction of Gpi activity can improve motor function, we studied the effect of GPi pallidotomy in 14 patients. The location of the GPi nucleus was confirmed by microelectrode recording before lesion creation. Standardised videotape recordings before and after operation were randomised and scored by a ''blinded' evaluator. 6 months after surgery, total motor score in the ''off'' state had improved by 30% and the total akinesia score by 33%. The gait score in the ''off'' state improved by 15% and a composite postural instability and gait score by 23%. After surgery there was almost total elimination of drug-induced involuntary movements (dyskinesias), with a 92% reduction on the side contralateral to the pallidotomy. No patient had visual or corticospinal complications. In these patients GPi pallidotomy enhanced motor performance, reduced akinesia, improved gait, and eliminated the neural elements responsible for levodopa-induced dyskinesias.	TORONTO HOSP,CTR NEUROL,DEPT SURG,DIV NEUROSURG,TORONTO,ON M5T 2S8,CANADA; TORONTO HOSP,CTR NEUROL,MORTON & GLORIA SHULMAN MOVEMENT DISORDERS CTR,DEPT MED,DIV NEUROL,TORONTO,ON M5T 2S8,CANADA; TORONTO HOSP,CTR NEUROL,DEPT PHYSIOL,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto			Lang, Anthony/ABF-8114-2021; Lozano, Andres M/A-5058-2012	Lang, Anthony/0000-0003-1229-3667; Lozano, Andres M./0000-0001-8257-3694; Hutchison, William/0000-0002-3866-4940; Miyasaki, Janis/0000-0002-6372-6007				ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; BENABID AL, 1991, LANCET, V337, P403, DOI 10.1016/0140-6736(91)91175-T; BENAZZOUZ A, 1993, EUR J NEUROSCI, V5, P382, DOI 10.1111/j.1460-9568.1993.tb00505.x; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; CEBALLOSBAUMANN AO, 1994, LANCET, V344, P814, DOI 10.1016/S0140-6736(94)92369-8; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; DOGALI M, 1995, NEUROLOGY, V45, P753, DOI 10.1212/WNL.45.4.753; FILION M, 1991, BRAIN RES, V547, P142; GOETZ CG, 1994, MOVEMENT DISORD, V9, P390, DOI 10.1002/mds.870090403; HUTCHISON WD, 1994, NEUROREPORT, V5, P1533, DOI 10.1097/00001756-199407000-00031; Kawashima Y, 1991, Acta Neurochir Suppl (Wien), V52, P103; LAITINEN LV, 1992, J NEUROSURG, V76, P53, DOI 10.3171/jns.1992.76.1.0053; LANG AE, 1995, MOVEMENT DISORD, V10, P527, DOI 10.1002/mds.870100426; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; LEE MS, 1994, MOVEMENT DISORD, V9, P493, DOI 10.1002/mds.870090502; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4; LOZANO AM, IN PRESS J NEUROSURG; MADRAZO I, 1987, NEW ENGL J MED, V316, P831, DOI 10.1056/NEJM198704023161402; PAGE RD, 1993, NEUROSCIENCE, V55, P147, DOI 10.1016/0306-4522(93)90462-O; PAGE RD, 1992, ACTA NEUROCHIR, V114, P77, DOI 10.1007/BF01400598; PARENT A, 1995, BRAIN RES REV, P91; SCHALTENBRAND G, 1959, EINFURUNG DIE STEREO, V3; SIEGFRIED J, 1994, NEUROSURGERY, V35, P1126, DOI 10.1227/00006123-199412000-00016; SVENNILSON E, 1960, ACTA PSYCH NEUROL, V35, P358, DOI 10.1111/j.1600-0447.1960.tb07606.x	24	548	551	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 25	1995	346	8987					1383	1387		10.1016/S0140-6736(95)92404-3	http://dx.doi.org/10.1016/S0140-6736(95)92404-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG207	7475819				2022-12-28	WOS:A1995TG20700007
J	ECONOMIDES, AN; RAVETCH, JV; YANCOPOULOS, GD; STAHL, N				ECONOMIDES, AN; RAVETCH, JV; YANCOPOULOS, GD; STAHL, N			DESIGNER CYTOKINES - TARGETING ACTIONS TO CELLS OF CHOICE	SCIENCE			English	Article							LEUKEMIA INHIBITORY FACTOR; CILIARY NEUROTROPHIC FACTOR; CNTF RECEPTOR; SIGNAL TRANSDUCER; ALPHA COMPONENT; ONCOSTATIN-M; EXPRESSION; GP-130; GP130	Some growth factors are therapeutically useful partly because restricted expression of their receptors limits their action to particular cell types. However, no unique stimulatory factor is known for many clinically relevant cell types, such as CD34(+) hematopoietic stem cells. Here, soluble alpha receptor (R alpha) components for interleukin-6 (IL-6) and ciliary neurotrophic factor (CNTF) were targeted in an active form to cells expressing surface markers such as CD34 or CD45, thereby rendering those cells responsive to IL-6 or CNTF. The targeting of R alpha components may provide the means to create ''designer'' cytokines that activate a desired cell type expressing a specific cell surface marker.	REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591; SLOAN KETTERING INST,BIOCHEM GENET LAB,NEW YORK,NY 10021	Regeneron; Memorial Sloan Kettering Cancer Center			Ravetch, Jeffrey/Z-1596-2019	Ravetch, Jeffrey/0000-0003-2024-9041; Economides, Aris/0000-0002-6508-8942				ALLEN JM, 1989, SCIENCE, V243, P378, DOI 10.1126/science.2911749; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CORNISH J, 1993, ENDOCRINOLOGY, V132, P1359, DOI 10.1210/en.132.3.1359; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; ECONOMIDES A, UNPUB; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GIMBLE JM, 1994, J CELL BIOCHEM, V54, P122, DOI 10.1002/jcb.240540113; HAAKFRENDSCHO M, 1994, J IMMUNOL, V152, P1347; HILTON DJ, 1991, J CELL BIOCHEM, V46, P21, DOI 10.1002/jcb.240460105; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; METCALF D, 1989, P NATL ACAD SCI USA, V86, P5948, DOI 10.1073/pnas.86.15.5948; METCALF D, 1994, STEM CELLS, V1, P259; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; PANAYOTATOS N, 1994, BIOCHEMISTRY-US, V33, P5813, DOI 10.1021/bi00185a020; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; ROWE JM, 1992, J CLIN PHARMACOL, V32, P486, DOI 10.1177/009127009203200602; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZAULI G, 1994, BLOOD, V83, P167	26	22	35	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 24	1995	270	5240					1351	1353		10.1126/science.270.5240.1351	http://dx.doi.org/10.1126/science.270.5240.1351			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF899	7481821				2022-12-28	WOS:A1995TF89900036
J	PANGANIBAN, G; SEBRING, A; NAGY, L; CARROLL, S				PANGANIBAN, G; SEBRING, A; NAGY, L; CARROLL, S			THE DEVELOPMENT OF CRUSTACEAN LIMBS AND THE EVOLUTION OF ARTHROPODS	SCIENCE			English	Article							DISTAL-LESS; DEVELOPING FOREBRAIN; RESTRICTED EXPRESSION; DROSOPHILA EMBRYO; HOMEOBOX GENES; HOMEODOMAIN	Arthropods exhibit great diversity in the position, number, morphology, and function of their limbs. The evolutionary relations among limb types and among the arthropod groups that bear them (insects, crustaceans, myriapods, and chelicerates) are controversial. Here, the use of molecular probes, including an antibody to proteins encoded by arthropod and vertebrate Distal-less (Dll and Dlx) genes, provided evidence that common genetic mechanisms underlie the development of all arthropod limbs and their branches and that all arthropods derive from a common ancestor. However, differences between crustacean and insect body plans were found to correlate with differences in the deployment of particular homeotic genes and in the ways that these genes regulate limb development.	UNIV WISCONSIN,MOLEC BIOL LAB,MADISON,WI 53706; UNIV WISCONSIN,HOWARD HUGHES MED INST,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison			Boekhoff-Falk, Grace E/B-2240-2008	Boekhoff-Falk, Grace E/0000-0002-9877-8309				AKIMENKO MA, 1994, J NEUROSCI, V14, P3475; Anderson D. T., 1973, EMBRYOLOGY PHYLOGENY; AVEROF M, 1995, NATURE, V376, P420, DOI 10.1038/376420a0; BEAUCHEMIN M, 1992, DEV BIOL, V154, P55, DOI 10.1016/0012-1606(92)90047-K; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BOUDREAUX HB, 1987, ANTHR PHYLOGENY SPEC; BUDD G, COMMUNICATION; BULFONE A, 1993, MECH DEVELOP, V40, P129, DOI 10.1016/0925-4773(93)90071-5; COHEN B, 1993, DEVELOPMENT, V117, P597; Cohen S. M., 1993, DEV DROSOPHILA MELAN, P747; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIRKSEN ML, 1993, MECH DEVELOP, V41, P121, DOI 10.1016/0925-4773(93)90042-V; EKKER M, 1992, NEURON, V9, P27, DOI 10.1016/0896-6273(92)90217-2; EMERSON MJ, 1990, SCIENCE, V250, P667, DOI 10.1126/science.250.4981.667; FRENCH V, 1994, CURR BIOL, V4, P34, DOI 10.1016/S0960-9822(00)00006-3; HELD LI, 1995, BIOESSAYS, V17, P721, DOI 10.1002/bies.950170809; HESSLER R R, 1975, Fossils and Strata, V4, P437; KELSH R, 1994, DEV GENET, V15, P19, DOI 10.1002/dvg.1020150104; KUKALOVAPECK J, 1992, CAN J ZOOL, V70, P236, DOI 10.1139/z92-037; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MANTON SM, 1964, MANDIBULAR MECHANISM, V247; PANGANIBAN G, UNPUB; PANGANIBAN G, 1994, CURR BIOL, V4, P67; PAPALOPULU N, 1993, DEVELOPMENT, V117, P961; PATEL NH, COMMUNICATION; PORTEUS MH, 1991, NEURON, V7, P221, DOI 10.1016/0896-6273(91)90260-7; PRICE M, 1991, NATURE, V351, P748, DOI 10.1038/351748a0; ROBINSON GW, 1991, NEW BIOL, V3, P1183; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schrehardt A, 1987, ARTEMIA RES ITS APPL, V1, P5; SIMCOX AA, 1989, DEVELOPMENT, V107, P715; SIMEONE A, 1994, P NATL ACAD SCI USA, V91, P2250, DOI 10.1073/pnas.91.6.2250; Snodgrass RE, 1935, PRINCIPLES INSECT MO; SNODGRASS RE, 1938, SMITHSONIAN MISCELLA, V97; SNODGRASS RE, 1958, SMITHSONIAN MISCELLA, V138; STRUHL G, 1981, NATURE, V292, P635, DOI 10.1038/292635a0; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; WARREN RW, 1994, NATURE, V372, P458, DOI 10.1038/372458a0; Williams JA, 1995, DNA CLONING, P15; ZRZAVY J, 1994, J EVOLUTION BIOL, V7, P743, DOI 10.1046/j.1420-9101.1994.7060743.x	42	290	300	2	45	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 24	1995	270	5240					1363	1366		10.1126/science.270.5240.1363	http://dx.doi.org/10.1126/science.270.5240.1363			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF899	7481825				2022-12-28	WOS:A1995TF89900040
J	TADDESE, A; NAH, SY; MCCLESKEY, EW				TADDESE, A; NAH, SY; MCCLESKEY, EW			SELECTIVE OPIOID INHIBITION OF SMALL NOCICEPTIVE NEURONS	SCIENCE			English	Article							CONDUCTION-VELOCITY; GANGLION-CELLS; NERVE ACTIVITY; CAT; PAIN; SUBSTANCE; RECEPTORS; MORPHINE; CURRENTS; RELEASE	Opioid analgesia, the selective suppression of pain without effects on other sensations, also distinguishes between different types of pain: severe, persistent pain is potently inhibited by opioids, but they fail to conceal the sensation of a pinprick. The cellular basis for this specificity was analyzed by means of patch-clamp experiments performed on fluorescently labeled nociceptive neurons (nociceptors) that innervate rat tooth pulp. Activation of the mu opioid receptor inhibited calcium channels on almost all small nociceptors but had minimal effect on large nociceptors. Somatostatin had the opposite specificity, preferentially inhibiting calcium channels on the large cells. Because persistent pain is mediated by slow-conducting, small nociceptors, opioids are thus likely to inhibit neurotransmitter release only at those primary synapses specialized for persistent pain.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University								AHLQUIST ML, 1984, PAIN, V19, P353, DOI 10.1016/0304-3959(84)90081-2; AHLQUIST ML, 1985, ADV PAIN RES THER, V9, P352; AKINS PT, 1993, NEUROSCIENCE, V56, P759, DOI 10.1016/0306-4522(93)90372-M; BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; BURGESS PR, 1967, J PHYSIOL-LONDON, V190, P541, DOI 10.1113/jphysiol.1967.sp008227; BYERS MR, 1984, INT REV NEUROBIOL, V25, P39, DOI 10.1016/S0074-7742(08)60677-7; COOPER BY, 1986, PAIN, V24, P93, DOI 10.1016/0304-3959(86)90030-8; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; DONG WK, 1985, BRAIN RES, V334, P389, DOI 10.1016/0006-8993(85)90239-2; EDWALL L, 1977, PAIN, V3, P121, DOI 10.1016/0304-3959(77)90075-6; FORS UGH, 1988, PAIN, V33, P253, DOI 10.1016/0304-3959(88)90097-8; GO VLW, 1987, J PHYSIOL-LONDON, V391, P141, DOI 10.1113/jphysiol.1987.sp016731; GODA Y, 1994, P NATL ACAD SCI USA, V91, P12942, DOI 10.1073/pnas.91.26.12942; GRUDT TJ, 1994, J NEUROSCI, V14, P1646, DOI 10.1523/JNEUROSCI.14-03-01646.1994; HARPER AA, 1985, J PHYSIOL-LONDON, V359, P31, DOI 10.1113/jphysiol.1985.sp015573; HONIG MG, 1986, J CELL BIOL, V103, P171, DOI 10.1083/jcb.103.1.171; JESSELL TM, 1977, NATURE, V268, P549, DOI 10.1038/268549a0; JUMA I, 1978, BRAIN RES, V171, P573; JYVASJARVI E, 1987, J PHYSIOL-LONDON, V391, P193, DOI 10.1113/jphysiol.1987.sp016733; LEE KH, 1986, J COMP NEUROL, V243, P335, DOI 10.1002/cne.902430305; Lewis T, 1937, CLIN SCI, V3, P67; MARFURT CF, 1984, J COMP NEUROL, V223, P353; MOISES HC, 1994, J NEUROSCI, V14, P5903; NARHI M, 1994, ARCH ORAL BIOL, V39, pS23, DOI 10.1016/0003-9969(94)90184-8; RANG HP, 1994, TXB PAIN, pCH1; SANDKUHLER J, 1990, NEUROSCIENCE, V34, P565, DOI 10.1016/0306-4522(90)90165-Z; SCHROEDER JE, 1991, NEURON, V6, P13, DOI 10.1016/0896-6273(91)90117-I; SEWARD E, 1991, P ROY SOC B-BIOL SCI, V244, P129, DOI 10.1098/rspb.1991.0061; SHEFNER SA, 1981, BRAIN RES, V221, P109, DOI 10.1016/0006-8993(81)91066-0; STEPHENSON JL, 1995, EXP NEUROL, V131, P11, DOI 10.1016/0014-4886(95)90003-9; TOREBJORK H, 1972, EXP BRAIN RES, V16, P321; WALL PD, 1994, PAIN, pCH1; WILDING TJ, 1995, J NEUROSCI, V15, P4124; WILLIAMS J, 1981, NEUROSCI LETT, V21, P211, DOI 10.1016/0304-3940(81)90384-0	34	130	133	0	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 24	1995	270	5240					1366	1369		10.1126/science.270.5240.1366	http://dx.doi.org/10.1126/science.270.5240.1366			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF899	7481826				2022-12-28	WOS:A1995TF89900041
J	HUANG, MX; GU, GQ; FERGUSON, EL; CHALFIE, M				HUANG, MX; GU, GQ; FERGUSON, EL; CHALFIE, M			A STOMATIN-LIKE PROTEIN NECESSARY FOR MECHANOSENSATION IN C-ELEGANS	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; MICROTUBULE-ASSOCIATED PROTEINS; NEURONAL MICROTUBULES; SYNTHETIC PEPTIDES; REGULATORY DOMAIN; MEMBRANE-PROTEIN; GENE; EXPRESSION; PRODUCT; TUBULIN	The mec-2 gene is required for the function of a set of six touch receptor neurons in the nematode Caenorhabditis elegans; mec-2 mutants, which are touch-insensitive, have touch cells that appear morphologically normal(1,2). Gene interaction studies suggest that mec-2 positively regulates the activity of the putative mechanosensory transduction channel (ref. 3 and the present paper), comprised in part of proteins encoded by the two degenerin genes mec-4 and mec-10 (refs 3-5). The central region of the mec-2 protein (MEC-2) is very similar to stomatin, an integral membrane protein (band 7.2b) in human red blood cells that is thought to regulate cation conductance(6). MEC-2-LacZ fusions are distributed along the touch receptor axons. This axonal distribution, which is mediated by the mec-2-specific amino terminus, is disrupted by mutations in mec-12, an alpha-tubulin gene needed for touch cell function. Our results indicate that MEC-2 links the mechanosensory channel and the microtubule cytoskeleton of the touch receptor neurons. Such linkage provides the basis for a mechanism of mechanosensation whereby microtubule displacement leads to channel opening.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University				Ferguson, Edwin/0000-0003-4125-4253				BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; CHALFIE M, 1982, J CELL BIOL, V93, P15, DOI 10.1083/jcb.93.1.15; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; CHALFIE M, 1979, J CELL BIOL, V82, P278, DOI 10.1083/jcb.82.1.278; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; GARCIAANOVEROS J, 1995, CURR BIOL, V5, P441, DOI 10.1016/S0960-9822(95)00085-6; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; HUDSPETH AJ, 1994, NEURON, V12, P1, DOI 10.1016/0896-6273(94)90147-3; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; LEWIS JA, 1977, J COMP NEUROL, V172, P489, DOI 10.1002/cne.901720306; MACCIONI RB, 1988, EMBO J, V7, P1957, DOI 10.1002/j.1460-2075.1988.tb03033.x; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MITANI S, 1993, DEVELOPMENT, V119, P773; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RIVAS CI, 1988, P NATL ACAD SCI USA, V85, P6092, DOI 10.1073/pnas.85.16.6092; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SALZER U, 1993, BIOCHIM BIOPHYS ACTA, V1151, P149, DOI 10.1016/0005-2736(93)90098-K; Sambrook J, 1989, MOL CLONING LABORATO; SAVAGE C, 1989, GENE DEV, V3, P870, DOI 10.1101/gad.3.6.870; SAVAGE C, 1994, J CELL SCI, V107, P2165; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; STEWART GW, 1993, BIOCHIM BIOPHYS ACTA, V1225, P15, DOI 10.1016/0925-4439(93)90116-I; STEWART GW, 1992, BLOOD, V79, P1593, DOI 10.1182/blood.V79.6.1593.bloodjournal7961593; WAY JC, 1989, GENE DEV, V3, P1823, DOI 10.1101/gad.3.12a.1823	33	193	209	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 16	1995	378	6554					292	295		10.1038/378292a0	http://dx.doi.org/10.1038/378292a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477350				2022-12-28	WOS:A1995TE85800052
J	DOLAN, RJ; FLETCHER, P; FRITH, CD; FRISTON, KJ; FRACKOWIAK, RSJ; GRASBY, PM				DOLAN, RJ; FLETCHER, P; FRITH, CD; FRISTON, KJ; FRACKOWIAK, RSJ; GRASBY, PM			DOPAMINERGIC MODULATION OF IMPAIRED COGNITIVE ACTIVATION IN THE ANTERIOR CINGULATE CORTEX IN SCHIZOPHRENIA	NATURE			English	Article							MONKEY PREFRONTAL CORTEX; DELAYED-RESPONSE TASK; CEREBRAL BLOOD-FLOW; RECEPTOR-BINDING; APOMORPHINE; TOMOGRAPHY; RELEASE; GABA	DOPAMINERGIC dysregulation remains an empirical cornerstone for theories concerning the causation of schizophrenia. Evidence for a dopamine system dysfunction in schizophrenia includes the psychosis-inducing effects of dopaminergic agonists(1,2) and the antipsychotic potency of dopaminergic antagonists(3'4). Here we use positron emission tomography (PET) to examine the regulatory role of dopamine on cortical function in normal subjects and unmedicated schizophrenic patients. Using a factorial experimental design, we compared the effect of dopaminergic manipulation with apomorphine on a neural response to a cognitive task. In the schizophrenic patients, relative to controls, an impaired cognitive activation of the anterior cingulate cortex was significantly modulated by a manipulation of dopaminergic neurotransmission. Thus, after apomorphine, the schizophrenic subjects displayed a significantly enhanced cognitive activation of the anterior cingulate cortex relative to the controls. These data provide in vivo evidence that an impaired cognitive-task-induced activation of the anterior cingulate cortex in schizophrenic patients can be significantly modulated by a dopaminergic manipulation.	ROYAL FREE HOSP, SCH MED, LONDON NW3, ENGLAND; UCL, DEPT PSYCHOL, LONDON WC1E 6BT, ENGLAND; HAMMERSMITH HOSP, MRC, CYCLOTRON UNIT, LONDON W12 0HS, ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Imperial College London	DOLAN, RJ (corresponding author), INST NEUROL, WELLCOME DEPT COGNIT NEUROL, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.		Friston, Karl/D-9230-2011; Frith, Chris D/A-2171-2009; Frackowiak, Richard/H-4383-2011; Frackowiak, Richard S/I-1809-2013; Fletcher, Paul/F-5380-2011	Friston, Karl/0000-0001-7984-8909; Frith, Chris D/0000-0002-8665-0690; Frackowiak, Richard/0000-0002-3151-822X; Dolan, Ray/0000-0001-9356-761X; Fletcher, Paul/0000-0001-8257-1517	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P943; BENES FM, 1992, J NEUROSCI, V12, P924; BENES FM, 1986, ARCH GEN PSYCHIAT, V43, P31; Bleuler E., 1950, DEMENTIA PRAECOX; CLEGHORN JM, 1991, PSYCHIAT RES-NEUROIM, V40, P135, DOI 10.1016/0925-4927(91)90005-B; CREESE I, 1976, SCIENCE, V192, P481, DOI 10.1126/science.3854; DAVIDSON M, 1987, AM J PSYCHIAT, V144, P934; Fallon JH, 1987, CEREB CORTEX, V6, P41; FLETCHER PC, 1995, BRAIN, V118, P401, DOI 10.1093/brain/118.2.401; Friston K.J., 1994, HUMAN BRAIN MAPPING, V1, P210; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; FRISTON KJ, IN PRESS HUM BRAIN M; FRISTON KJ, 1995, HUM BRAIN MAPP, V2, P198; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; FRITH CD, 1995, BRIT J PSYCHIAT, V167, P343, DOI 10.1192/bjp.167.3.343; GRACE AA, 1991, NEUROSCIENCE, V41, P1, DOI 10.1016/0306-4522(91)90196-U; GRASBY PM, 1993, PSYCHOL MED, V23, P605, DOI 10.1017/S0033291700025381; LIDDLE PF, 1992, BRIT J PSYCHIAT, V160, P179, DOI 10.1192/bjp.160.2.179; LIEBERMAN JA, 1984, AM J PSYCHIAT, V141, P633; MCGHIE A, 1961, BRIT J MED PSYCHOL, V34, P103, DOI 10.1111/j.2044-8341.1961.tb00936.x; MULLERPREUSS P, 1981, BRAIN RES, V215, P61, DOI 10.1016/0006-8993(81)90491-1; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; RETAUX S, 1991, NEUROSCIENCE, V42, P61, DOI 10.1016/0306-4522(91)90150-M; SAWAGUCHI T, 1990, J NEUROPHYSIOL, V63, P1385, DOI 10.1152/jn.1990.63.6.1385; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; SAWAGUCHI T, 1990, J NEUROPHYSIOL, V63, P1401, DOI 10.1152/jn.1990.63.6.1401; SEEMAN P, 1976, NATURE, V261, P717, DOI 10.1038/261717a0; TAMMINGA CA, 1992, ARCH GEN PSYCHIAT, V49, P522; WEINBERGER DR, 1988, TRENDS NEUROSCI, V11, P367, DOI 10.1016/0166-2236(88)90060-4; [No title captured]	30	321	326	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 9	1995	378	6553					180	182		10.1038/378180a0	http://dx.doi.org/10.1038/378180a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TD759	7477319	Green Submitted			2022-12-28	WOS:A1995TD75900052
J	LEVY, D				LEVY, D			HAVE EXPERT PANEL GUIDELINES KEPT PACE WITH NEW CONCEPTS IN HYPERTENSION	LANCET			English	Editorial Material							RISK				LEVY, D (corresponding author), NHLBI, BLDG 10, BETHESDA, MD 20892 USA.							ALDERMAN MH, 1993, ANN INTERN MED, V119, P329, DOI 10.7326/0003-4819-119-4-199308150-00013; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; [Anonymous], 1991, JAMA, V265, P3255; BLACK HR, 1994, HYPERTENSION, V23, P275; BURT VL, 1995, HYPERTENSION, V26, P60, DOI 10.1161/01.HYP.26.1.60; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; Hansson L, 1992, Blood Press, V1, P113, DOI 10.3109/08037059209077502; INSUA JT, 1994, ANN INTERN MED, V121, P355, DOI 10.7326/0003-4819-121-5-199409010-00008; JACKSON R, BRIT MED J, V307, P107; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; OPARIL S, 1993, NEW ENGL J MED, V328, P959, DOI 10.1056/NEJM199304013281311; SAGIE A, 1993, NEW ENGL J MED, V329, P1912, DOI 10.1056/NEJM199312233292602; TOBIAN L, 1994, AM J HYPERTENS, V7, P859, DOI 10.1093/ajh/7.10.859; WOLF PA, 1991, STROKE, V22, P312, DOI 10.1161/01.STR.22.3.312; ZANCHETTI A, 1993, J HYPERTENS, V11, P905	16	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 28	1995	346	8983					1112	1113		10.1016/S0140-6736(95)91792-6	http://dx.doi.org/10.1016/S0140-6736(95)91792-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB549	7475595				2022-12-28	WOS:A1995TB54900002
J	ABRAHAMOV, A; ELSTEIN, D; GROSSTSUR, V; FARBER, B; GLASER, Y; HADASHALPERN, I; RONEN, S; TAFAKJDI, M; HOROWITZ, M; ZIMRAN, A				ABRAHAMOV, A; ELSTEIN, D; GROSSTSUR, V; FARBER, B; GLASER, Y; HADASHALPERN, I; RONEN, S; TAFAKJDI, M; HOROWITZ, M; ZIMRAN, A			GAUCHERS-DISEASE VARIANT CHARACTERIZED BY PROGRESSIVE CALCIFICATION OF HEART-VALVES AND UNIQUE GENOTYPE	LANCET			English	Article							INVOLVEMENT; GLUCOCEREBROSIDASE; DEFICIENCY; MUTATIONS	Gaucher's disease is the most prevalent sphingolipid storage disease, characterised by substantial genetic and phenotypic variability. Cardiac manifestations are rare. We report 12 Arab Gaucher's disease patients, 2-20 years of age, who presented with oculomotor apraxia but only slight classic signs of the disease. All but the youngest had calcifications of the aortic or mitral valves or both. All these patients were homozygous for the rare point mutation D409H (1342C). Valvular calcifications increased with age and showed progression during 2 years of follow-up. Two of the oldest patients underwent aortic valve replacement, and one sibling had died suddenly at age 16, before this study. Corneal opacities were another common feature. The potentially fatal course of this Gaucher's disease variant, and the availability of a reliable PCR-based method for heterozygote detection, mean that population screening and genetic counselling in the geographic area at risk are important. Affected individuals should be closely monitored by echocardiography to gauge the need for valve replacement. The potential of enzyme replacement to prevent these cardiac complications cannot be ascertained at present, because of the high cost of therapy.	SHAARE ZEDEK MED CTR,GAUCHER CLIN,IL-91031 JERUSALEM,ISRAEL; SHAARE ZEDEK MED CTR,DEPT PEDIAT,IL-91031 JERUSALEM,ISRAEL; SHAARE ZEDEK MED CTR,DEPT PEDIAT CARDIOL,IL-91031 JERUSALEM,ISRAEL; SHAARE ZEDEK MED CTR,DEPT PEDIAT NEUROL,IL-91031 JERUSALEM,ISRAEL; SHAARE ZEDEK MED CTR,DEPT OPHTHALMOL,IL-91031 JERUSALEM,ISRAEL; SHAARE ZEDEK MED CTR,DEPT MED,IL-91031 JERUSALEM,ISRAEL; TEL AVIV UNIV,FAC LIFE SCI,DEPT CELLULAR BIOL & IMMUNOL,RAMAT AVIV,ISRAEL; JENIN HLTH DIST OFF,JENIN,JORDAN	Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Tel Aviv University								BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BENBASSA.J, 1968, AM J MED, V44, P647, DOI 10.1016/0002-9343(68)90067-3; Beutler E., 1995, METABOLIC MOL BASES, P2641; BRADY RO, 1994, 4TH INT GAUCH DIS C; CASTA A, 1984, AM J CARDIOL, V54, P1390, DOI 10.1016/S0002-9149(84)80115-0; CHABAS A, 1995, J MED GENET, V32, P740, DOI 10.1136/jmg.32.9.740; EDWARDS WD, 1983, AM J CARDIOL, V52, P654, DOI 10.1016/0002-9149(83)90052-8; GROSSTSUR V, 1989, PEDIATR NEUROL, V5, P128, DOI 10.1016/0887-8994(89)90042-8; HOROWITZ M, 1993, AM J HUM GENET, V53, P921; Lee R. E., 1982, GaAs IC Symposium. IEEE Gallium Arsenide Integrated Circuit Symposium. Technical Digest 1982, P177; PATTERSON MC, 1993, NEUROLOGY, V43, P1993, DOI 10.1212/WNL.43.10.1993; ROBERTS WC, 1967, CIRCULATION, V35, P783, DOI 10.1161/01.CIR.35.4.783; SARACLAR M, 1991, PEDITA CARDIOLOGY, V13, P56; SMITH RRL, 1978, AM J MED, V65, P352, DOI 10.1016/0002-9343(78)90832-X; TAMARI I, 1983, ARCH INTERN MED, V143, P2010, DOI 10.1001/archinte.143.10.2010; THEOPHILUS BDM, 1989, NUCLEIC ACIDS RES, V17, P7707, DOI 10.1093/nar/17.19.7707; TSUTSUMI A, 1982, GANKA RHINSHOIHO, V76, P1730; UYAMA E, 1992, ACTA NEUROL SCAND, V86, P407, DOI 10.1111/j.1600-0404.1992.tb05109.x; WILSON ER, 1985, ARCH PATHOL LAB MED, V109, P82	19	154	160	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 14	1995	346	8981					1000	1003		10.1016/S0140-6736(95)91688-1	http://dx.doi.org/10.1016/S0140-6736(95)91688-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475546				2022-12-28	WOS:A1995RZ59900010
J	TELI, MR; DAY, CP; BURT, AD; BENNETT, MK; JAMES, OFW				TELI, MR; DAY, CP; BURT, AD; BENNETT, MK; JAMES, OFW			DETERMINANTS OF PROGRESSION TO CIRRHOSIS OR FIBROSIS IN PURE ALCOHOLIC FATTY LIVER	LANCET			English	Article							LIPID-PEROXIDATION; DISEASE; INJURY	''Pure'' alcoholic fatty liver has been widely assumed to be ''benign'' with very low risk of progression to cirrhosis. Studies thus far have included either patients with coexisting recognised precursor lesions of cirrhosis or have been restricted to short-term histological follow-up. We have followed 88 patients, first seen between 1978 and 1985, with a histological diagnosis of pure alcoholic fatty liver and no evidence of fibrosis or alcoholic hepatitis, for a median of 10.5 years, to determine any factors predictive of disease progression. Of the 88, at follow-up nine had developed cirrhosis and a further seven fibrosis. Eight of nine patients with cirrhosis had continuing alcohol consumption of more than 40 units per week at follow-up; in the other patients, consumption was unknown. Independent histological predictors of progression on index biopsy were: presence of mixed macro/microvesicular fat, and presence of giant mitochondria. We can no longer regard alcoholic fatty liver as benign. in the presence of continuing high alcohol consumption the above histological features identified those at high risk (47-61%) of disease progression. Therefore, patients with these features should be counselled intensively regarding their alcohol consumption.	MED SCH NEWCASTLE UPON TYNE, DEPT MED, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND; MED SCH NEWCASTLE UPON TYNE, DEPT PATHOL, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND	Newcastle University - UK; Newcastle University - UK			Burt, Alastair D/D-3634-2013; Day, Christopher/Z-3305-2019	Burt, Alastair D/0000-0002-3011-7774; 				CEDERBAUM AI, 1989, FREE RADICAL BIO MED, V7, P537, DOI 10.1016/0891-5849(89)90029-4; CHEDID A, 1986, GASTROENTEROLOGY, V90, P1858, DOI 10.1016/0016-5085(86)90253-2; CHRISTOFFERSEN P, 1972, ACTA PATH MICRO IM A, VA 80, P557; EDMONDSON HA, 1967, MEDICINE, V46, P119, DOI 10.1097/00005792-196703000-00006; FROMENTY B, 1995, GASTROENTEROLOGY, V108, P193, DOI 10.1016/0016-5085(95)90024-1; ITOH S, 1987, AM J GASTROENTEROL, V82, P650; LEEVY CM, 1962, MEDICINE, V41, P249, DOI 10.1097/00005792-196209000-00003; LEEVY CM, 1968, MED CLIN N AM, V52, P1445, DOI 10.1016/S0025-7125(16)32838-3; LETTERON P, 1993, GUT, V34, P409, DOI 10.1136/gut.34.3.409; LIEBER CS, 1976, FED PROC, V35, P1232; LIEBER CS, 1965, J CLIN INVEST, V44, P1009, DOI 10.1172/JCI105200; MORGAN MY, 1977, BRIT MED J, V1, P939, DOI 10.1136/bmj.1.6066.939; MORGAN MY, 1991, OXFORD TXB CLIN HEPA, P816; PAROLA M, 1993, BIOCHEM BIOPH RES CO, V194, P1044, DOI 10.1006/bbrc.1993.1927; PORTA EA, 1965, AM J PATHOL, V46, P657; SHERLOCK S, 1995, LANCET, V345, P227; SORENSEN TIA, 1984, LANCET, V2, P241, DOI 10.1016/S0140-6736(84)90295-2; TELI MR, IN PRESS HEPATOLOGY; WORNER TM, 1985, JAMA-J AM MED ASSOC, V254, P627, DOI 10.1001/jama.254.5.627; ZAKIM D, 1990, HEPATOLOGY TXB LIVER, P848	20	344	351	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 14	1995	346	8981					987	990		10.1016/S0140-6736(95)91685-7	http://dx.doi.org/10.1016/S0140-6736(95)91685-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475591				2022-12-28	WOS:A1995RZ59900007
J	DUBOIS, RW; BROOK, RH				DUBOIS, RW; BROOK, RH			PREVENTABLE DEATHS - WHO, HOW OFTEN, AND WHY	ANNALS OF INTERNAL MEDICINE			English	Article									RAND CORP, SANTA MONICA, CA 90406 USA; UNIV CALIF LOS ANGELES, CTR HLTH SCI, LOS ANGELES, CA 90024 USA	RAND Corporation; University of California System; University of California Los Angeles								BRINKLEY J, 1986, NY TIMES         MAR, V12, P1; DUBOIS RW, 1987, AM J PUBLIC HEALTH, V77, P1162, DOI 10.2105/AJPH.77.9.1162; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; DUCKETT SJ, 1978, MED CARE, V16, P400, DOI 10.1097/00005650-197805000-00004; HARRELL FE, 1983, SUGI SUPPLEMENTAL LI; KORAN LM, 1975, NEW ENGL J MED, V293, P642, DOI 10.1056/NEJM197509252931307; Roemer M I, 1968, Health Serv Res, V3, P96	7	198	199	2	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1988	109	7					582	589		10.7326/0003-4819-109-7-582	http://dx.doi.org/10.7326/0003-4819-109-7-582			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q4157	3421565				2022-12-28	WOS:A1988Q415700011
J	ERON, JJ; BENOIT, SL; JEMSEK, J; MACARTHUR, RD; SANTANA, J; QUINN, JB; KURITZKES, DR; FALLON, MA; RUBIN, M				ERON, JJ; BENOIT, SL; JEMSEK, J; MACARTHUR, RD; SANTANA, J; QUINN, JB; KURITZKES, DR; FALLON, MA; RUBIN, M			TREATMENT WITH LAMIVUDINE, ZIDOVUDINE, OR BOTH IN HIV-POSITIVE PATIENTS WITH 200 TO 500 CD4+ CELLS PER CUBIC MILLIMETER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 REVERSE-TRANSCRIPTASE; CONTROLLED TRIAL; IN-VITRO; INFECTION; INHIBITOR; LYMPHOCYTES; THERAPY; AZIDOTHYMIDINE; SENSITIVITY	Background. The reverse-transcriptase inhibitor lamivudine has in vitro synergy with zidovudine against the human immunodeficiency virus (HIV). We studied the activity and safety of lamivudine plus zidovudine as compared with either drug alone as treatment for patients with HIV infection, most of whom had not previously received zidovudine. Methods. Three hundred sixty-six patients with 200 to 500 CD4+ cells per cubic millimeter who had received zidovudine for four weeks or less were randomly assigned to treatment with one of four regimens: 300 mg of lamivudine every 12 hours; 200 mg of zidovudine every 8 hours; 150 mg of lamivudine every 12 hours plus zidovudine; or 300 mg of lamivudine every 12 hours plus zidovudine. The study was double-blind and lasted 24 weeks, with an extension phase for another 28 weeks. Results. Over the 24-week period, the low-dose and high-dose regimens combining lamivudine and zidovudine were associated with greater increases in the CD4+ cell count (P=0.002 and P=0.015, respectively) and the percentage of CD4+ cells (P<0.001 for both) and with greater decreases in plasma levels of HIV type 1 (HIV-1) RNA (P<0.001 for both) than was treatment with zidovudine alone, Combination therapy was also more effective than lamivudine alone in lowering plasma HIV-1 RNA levels and increasing the percentage of CD4+ cells (P<0.001 for all comparisons), and these advantages persisted through 52 weeks. Adverse events were no more frequent with combination therapy than with zidovudine alone. Conclusions. In HIV-infected patients with little or no prior antiretroviral therapy, treatment with a combination of lamivudine and zidovudine is well tolerated over a one-year period and produces more improvement in immunologic and virologic measures than does treatment with either agent alone.	GLAXO WELLCOME,RES TRIANGLE PK,NC; NALLE CLIN,CHARLOTTE,NC; MED COLL OHIO,TOLEDO,OH 43699; SAN JUAN AIDS INST,SANTURCE,PR; UNIV COLORADO,HLTH SCI CTR,DENVER,CO; VET AFFAIRS MED CTR,DENVER,CO	GlaxoSmithKline; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)	ERON, JJ (corresponding author), UNIV N CAROLINA,SCH MED,CB 7030,BURNETT WOMACK,CHAPEL HILL,NC 27599, USA.							BOUCHER CAB, 1993, ANTIMICROB AGENTS CH, V37, P2231, DOI 10.1128/AAC.37.10.2231; BOYER PL, 1992, J VIROL, V66, P1031, DOI 10.1128/JVI.66.2.1031-1039.1992; CALIENDO AM, 1994, CLIN INFECT DIS, V18, P516, DOI 10.1093/clinids/18.4.516; CALIENDO AM, 1994, CLIN INFECT DIS, V19, P379; COATES JAV, 1992, ANTIMICROB AGENTS CH, V36, P733, DOI 10.1128/AAC.36.4.733; COATES JAV, 1992, ANTIMICROB AGENTS CH, V36, P2025; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; COLLIER AC, 1993, ANN INTERN MED, V119, P786, DOI 10.7326/0003-4819-119-8-199310150-00003; DOLIN R, 1995, ARCH INTERN MED, V155, P961, DOI 10.1001/archinte.155.9.961; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FISCHL MA, 1995, ANN INTERN MED, V122, P24, DOI 10.7326/0003-4819-122-1-199501010-00004; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCUS SA, 1995, J INFECT DIS, V171, P305, DOI 10.1093/infdis/171.2.305; GAO WY, 1993, J CLIN INVEST, V91, P2326, DOI 10.1172/JCI116463; HENRARD DR, 1995, JAMA-J AM MED ASSOC, V274, P554, DOI 10.1001/jama.274.7.554; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOOPER C, 1994, 3RD INT WORKSH HIV D, P67; IOANNIDIS JPA, 1995, ANN INTERN MED, V122, P856, DOI 10.7326/0003-4819-122-11-199506010-00009; KATLAMA C, 1995, 2 NAT C HUM RETR REL, P173; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; MATHEZ D, 1993, ANTIMICROB AGENTS CH, V37, P2206, DOI 10.1128/AAC.37.10.2206; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; OBRIEN WA, IN PRESS N ENGL J ME; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PAVIA AT, 1995, 35 INT C ANT AG CHEM, P235; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; SANDE MA, 1993, JAMA-J AM MED ASSOC, V270, P2583, DOI 10.1001/jama.270.21.2583; SCHINAZI RF, 1992, ANTIMICROB AGENTS CH, V36, P672, DOI 10.1128/AAC.36.3.672; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; VANLEEUWEN R, 1992, AIDS, V6, P1471, DOI 10.1097/00002030-199212000-00008; VANLEEUWEN R, 1995, J INFECT DIS, V171, P1166, DOI 10.1093/infdis/171.5.1166; VINER KC, 1993, 9 INT C AIDS JUN 6 1, P236; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WEI LJ, 1985, BIOMETRIKA, V72, P359; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WELIES SL, 1995, 2ND NAT C HUM RETR W, P96; YARCHOAN R, 1994, J INFECT DIS, V170, P260; YARCHOAN R, 1994, J INFECT DIS, V169, P9, DOI 10.1093/infdis/169.1.9; 1994, LANCET, V343, P871; [No title captured]	47	453	457	1	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 21	1995	333	25					1662	1669		10.1056/NEJM199512213332502	http://dx.doi.org/10.1056/NEJM199512213332502			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL401	7477218	Green Submitted			2022-12-28	WOS:A1995TL40100002
J	PION, IA				PION, IA			TOXIC EPIDERMAL NECROLYSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											PION, IA (corresponding author), NYU,MED CTR,NEW YORK,NY 10016, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 14	1995	333	24					1609	1609		10.1056/NEJM199512143332406	http://dx.doi.org/10.1056/NEJM199512143332406			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK065	7477197				2022-12-28	WOS:A1995TK06500006
J	KOKKINOS, PF; NARAYAN, P; COLLERAN, JA; PITTARAS, A; NOTARGIACOMO, A; REDA, D; PAPADEMETRIOU, V				KOKKINOS, PF; NARAYAN, P; COLLERAN, JA; PITTARAS, A; NOTARGIACOMO, A; REDA, D; PAPADEMETRIOU, V			EFFECTS OF REGULAR EXERCISE ON BLOOD-PRESSURE AND LEFT-VENTRICULAR HYPERTROPHY IN AFRICAN-AMERICAN MEN WITH SEVERE HYPERTENSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; INSULIN RESISTANCE; RECOMMENDATIONS; ECHOCARDIOGRAPHY; MASS; REVERSAL; STROKE; VOLUME; DEATH	Background. The prevalence of hypertension and its cardiovascular complications is higher in African Americans than in whites. Interventions to control blood pressure in this population are particularly important. Regular exercise lowers blood pressure in patients with mild-to-moderate hypertension, but its effects in patients with severe hypertension have not been studied. We examined the effects of moderately intense exercise on blood pressure and left ventricular hypertrophy in African-American men with severe hypertension. Methods. We randomly assigned 46 men 35 to 76 years of age to exercise plus antihypertensive medication (23 men) or antihypertensive medication alone (23 men). A total of 18 men in the exercise group completed 16 weeks of exercise, and 14 completed 32 weeks of exercise, which was performed three times per week at 60 to 80 percent of the maximal heart rate. Results. After 16 weeks, mean (+/-SD) diastolic blood pressure had decreased from 88+/-7 to 83i8 mm Hg in the patients who exercised, whereas it had increased slightly, from 88+/-6 to 90+/-7 mm Hg, in those who did not exercise (P=0.002). Diastolic blood pressure remained significantly lower after 32 weeks of exercise, even with Substantial reductions in the dose of antihypertensive medication. In addition, the thickness of the interventricular septum (P=0.03), the left ventricular mass (P=0.02), and the left-ventricular mass index (P=0.04) had decreased significantly after 16 weeks in the patients who exercised, whereas there was no significant change in the nonexercisers. Conclusions. Regular exercise reduced blood pressure and left ventricular hypertrophy in African-American men with severe hypertension.	VET AFFAIRS MED CTR,DIV CARDIOL,WASHINGTON,DC 20422; GEORGETOWN UNIV,MED CTR,DIV CARDIOL,WASHINGTON,DC 20007; VET AFFAIRS HOSP,COOPERAT STUDIES PROGRAM,HINES,IL	US Department of Veterans Affairs; Veterans Health Administration (VHA); Georgetown University				Papademetriou, Vasilios/0000-0002-2882-2757; , Domenic/0000-0003-1831-4270				AMES RP, 1983, AM J CARDIOL, V51, P632, DOI 10.1016/S0002-9149(83)80200-8; BAGLIVO HP, 1990, HYPERTENSION S1, V15, P153; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; DEVEREUX RB, 1987, HYPERTENSION, V9, P97; DEVEREUX RB, 1990, HYPERTENSION PATHOPH, V1, P359; DUNCAN JJ, 1985, JAMA-J AM MED ASSOC, V254, P2609, DOI 10.1001/jama.254.18.2609; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FLETCHER GF, 1992, CIRCULATION, V86, P340, DOI 10.1161/01.CIR.86.1.340; FRIEDEWALD VE, 1990, AM J CARDIOL, V66, P183, DOI 10.1016/0002-9149(90)90585-O; FROHLICH ED, 1988, CIRCULATION, V77, pA502; GRANGER CB, 1985, J AM COLL CARDIOL, V5, P862, DOI 10.1016/S0735-1097(85)80424-1; HAGBERG JM, 1990, EXERCISE, FITNESS, AND HEALTH, P455; HAGBERG JM, 1989, AM J CARDIOL, V64, P348, DOI 10.1016/0002-9149(89)90533-X; KOKKINOS PF, 1994, CARDIOL ELDER, V2, P443; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LIEBSON PR, 1990, AM J HYPERTENS, V3, P512, DOI 10.1093/ajh/3.6.512; LIEBSON PR, 1990, AM J HYPERTENS, V9; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MARON BJ, 1986, J AM COLL CARDIOL, V7, P190, DOI 10.1016/S0735-1097(86)80282-0; MARTIN WH, 1986, J AM COLL CARDIOL, V7, P982, DOI 10.1016/S0735-1097(86)80215-7; MCLENACHAN JM, 1987, NEW ENGL J MED, V317, P787, DOI 10.1056/NEJM198709243171302; NEATON JD, 1992, ARCH INTERN MED, V152, P56, DOI 10.1001/archinte.152.1.56; PELLICCIA A, 1991, NEW ENGL J MED, V324, P295, DOI 10.1056/NEJM199101313240504; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; POWELL KE, 1986, PHYSICIAN SPORTSMED, V14, P100, DOI 10.1080/00913847.1986.11709103; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SCHULMAN SP, 1990, NEW ENGL J MED, V322, P1350, DOI 10.1056/NEJM199005103221904; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; URATA H, 1987, HYPERTENSION, V9, P245, DOI 10.1161/01.HYP.9.3.245; [No title captured]; 1993, ARCH INTERN MED, V153, P154; 1982, JAMA-J AM MED ASSOC, V248, P1465; 1991, J HYPERTENS, V9, P283; 1970, JAMA-J AM MED ASSOC, V213, P1143; 1978, JAMA-J AM MED ASSOC, V242, P2562; [No title captured]; 1985, HYPERTENSION, V7, P457	39	224	233	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 30	1995	333	22					1462	1467		10.1056/NEJM199511303332204	http://dx.doi.org/10.1056/NEJM199511303332204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG445	7477146	Bronze			2022-12-28	WOS:A1995TG44500004
J	HENDERSON, AS; EASTEAL, S; JORM, AF; MACKINNON, AJ; KORTEN, AE; CHRISTENSEN, H; CROFT, L; JACOMB, PA				HENDERSON, AS; EASTEAL, S; JORM, AF; MACKINNON, AJ; KORTEN, AE; CHRISTENSEN, H; CROFT, L; JACOMB, PA			APOLIPOPROTEIN-E ALLELE EPSILON-4, DEMENTIA, AND COGNITIVE DECLINE IN A POPULATION-SAMPLE	LANCET			English	Article							ALZHEIMERS-DISEASE; TYPE-4 ALLELE	From clinically based series it has been proposed that, in homozygotes for the apolipoprotein E epsilon 4 (apoE epsilon 4) allele, Alzheimer's disease is almost inevitable by the age of 80. A population sample of persons aged 70 years and over was interviewed in 1990-91 to ascertain the presence of dementia or cognitive impairment. The sample was re-interviewed in 1994, when the apoE genotype was also determined. Prevalence data for the 638 persons who completed the second examination revealed a linear association between having an apoE epsilon 4 allele and both dementia and cognitive impairment (for heterozygotes, odds ratio for dementia 1.89, 95% confidence interval 1.04-3.44 and for homozygotes OR 3.58, 95% CI 1.82-11.82; both adjusted for age). However, even in subjects homozygous for epsilon 4 the estimated prevalence of dementia by age 90 was only about 50%. Persons with one or two epsilon 4 alleles were more likely to have a family history of dementia than those with none. This study confirms in a population sample that the epsilon 4 allele is a risk factor for dementia, but refutes the suggestion that homozygosity for the epsilon 4 allele is sufficient for the development of Alzheimer's disease: persons with either one or two epsilon 4 alleles may reach late old age without cognitive impairment.	AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,HUMAN GENET GRP,CANBERRA,ACT 2601,AUSTRALIA; MENTAL HLTH RES INST,BIOSTAT & PSYCHOMETR UNIT,PARKVILLE,VIC,AUSTRALIA	Australian National University; John Curtin School of Medical Research; Florey Institute of Neuroscience & Mental Health	HENDERSON, AS (corresponding author), AUSTRALIAN NATL UNIV,NATL HLTH & MED RES COUNCIL,SOCIAL PSYCHIAT RES UNIT,GPO BOX 4,CANBERRA,ACT 0200,AUSTRALIA.		Christensen, Helen/F-5053-2012; Jorm, Anthony F/B-5555-2009	Christensen, Helen/0000-0003-0435-2065; Jorm, Anthony F/0000-0002-1424-4116; Mackinnon, Andrew/0000-0003-0831-9801; Easteal, Simon/0000-0002-0462-502X				[Anonymous], 1993, ICD 10 CLASSIFICATIO; BENJAMIN R, 1994, LANCET, V343, P1564; BROUSSEAU T, 1994, NEUROLOGY, V44, P342, DOI 10.1212/WNL.44.2.342; CHRISTENSEN H, 1994, AGE AGEING, V23, P204, DOI 10.1093/ageing/23.3.204; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; FESKENS EJM, 1994, BRIT MED J, V309, P1202, DOI 10.1136/bmj.309.6963.1202; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HENDERSON AS, 1994, PSYCHOL MED, V24, P473, DOI 10.1017/S0033291700027446; HENDRIE HC, 1995, ANN NEUROL, V37, P118, DOI 10.1002/ana.410370123; HIXSON JE, 1990, J LIPID RES, V31, P545; Jorm AF, 1992, MEMORY FUNCTIONING D, P267, DOI DOI 10.1016/S0166-4115(08)60939-5; JORM AF, 1993, PROBLEM DEMENTIA AUS; KERVINEN K, 1994, ATHEROSCLEROSIS, V105, P89, DOI 10.1016/0021-9150(94)90011-6; KUUSISTO J, 1995, BRIT MED J, V309, P636; MACKINNON A, 1993, ACTA PSYCHIAT SCAND, V87, P146, DOI 10.1111/j.1600-0447.1993.tb03346.x; MAESTRE G, 1995, ANN NEUROL, V37, P254, DOI 10.1002/ana.410370217; Nelson H.E., 1982, NATIONAL ADULT READI; PEACOCK ML, 1994, NEUROLOGY, V44, P339, DOI 10.1212/WNL.44.2.339; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; RICHARDS B, 1992, HUM MOL GENET, V2, P159; RIGGS JE, 1994, ARCH NEUROL-CHICAGO, V51, P750, DOI 10.1001/archneur.1994.00540200024011; ROSES AD, 1994, LANCET, V343, P1564, DOI 10.1016/S0140-6736(94)92960-2; ROYCHOUDHURY AK, 1958, HUMAN POLYMORPHIC GE; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCOTT J, 1993, LANCET, V342, P696, DOI 10.1016/0140-6736(93)91704-P; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74; 1992, ACTA PSYCHIAT SCAND, V85, P105; 1987, DIAGNOSTIC STATISTIC	30	250	254	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 25	1995	346	8987					1387	1390		10.1016/S0140-6736(95)92405-1	http://dx.doi.org/10.1016/S0140-6736(95)92405-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG207	7475820				2022-12-28	WOS:A1995TG20700008
J	TASDEMIR, M; MARAL, I; TASDEMIR, S; TASDEMIR, I				TASDEMIR, M; MARAL, I; TASDEMIR, S; TASDEMIR, I			VAGINAL LISURIDE FOR HYPERPROLACTINEMIA	LANCET			English	Letter									SSK EGE MATERN & WOMENS HOSP,IZMIR,TURKEY; KAMIL WOMENS & PEDIAT HOSP,ISTANBUL,TURKEY; SEVGI HOSP,IVF LAB,ANKARA,TURKEY	Istanbul Zeynep Kamil Maternity & Children's Diseases Training & Research Hospital; Sevgi Hospital	TASDEMIR, M (corresponding author), SEVGI HOSP,DEPT REPROD ENDOCRINOL & INFERTIL,ANKARA,TURKEY.							BOHNET HG, 1979, ACTA ENDOCRINOL-COP, V92, P8, DOI 10.1530/acta.0.0920008; DOROW R, 1983, LISURIDE OTHER DOPAM, P161; VERDE G, 1980, J ENDOCRINOL INVEST, V4, P405	3	3	3	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 18	1995	346	8986					1362	1362		10.1016/S0140-6736(95)92373-X	http://dx.doi.org/10.1016/S0140-6736(95)92373-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE916	7475789				2022-12-28	WOS:A1995TE91600042
J	SCHYVE, PM; LOEB, JM; SIMMONS, BP				SCHYVE, PM; LOEB, JM; SIMMONS, BP			A COLLABORATIVE PROJECT TO STUDY HOSPITAL PERFORMANCE-MEASURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											SCHYVE, PM (corresponding author), JOINT COMMISS ACCREDITAT HLTHCARE ORG,DEPT RES & EVALUAT,1 RENAISSANCE BLVD,OAKBROOK TERRACE,IL 60181, USA.							1995, JAMA-J AM MED ASSOC, V273, P1405; 1995, INT J QUAL HEALTH CA, V7, P81; 1995, JAMA-J AM MED ASSOC, V273, P691; 1995, JAMA-J AM MED ASSOC, V274, P317	4	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	1995	274	19					1497	1497						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD571	7474201				2022-12-28	WOS:A1995TD57100004
J	SHAHID, NS; STEINHOFF, MC; HOQUE, SS; BEGUM, T; THOMPSON, C; SIBER, GR				SHAHID, NS; STEINHOFF, MC; HOQUE, SS; BEGUM, T; THOMPSON, C; SIBER, GR			SERUM, BREAST-MILK, AND INFANT ANTIBODY AFTER MATERNAL IMMUNIZATION WITH PNEUMOCOCCAL VACCINE	LANCET			English	Article							INFLUENZAE TYPE-B; HEMOPHILUS-INFLUENZAE; STREPTOCOCCUS-PNEUMONIAE; POLYSACCHARIDE VACCINE; PREGNANT-WOMEN; IMMUNIZATION; CHILDREN; NEWBORN	Pneumococci are a leading cause of severe bacterial disease in infants and children world wide, A possible means of protecting infants in the first few months of life is immunisation of the mother during prospectively assessed pneumococcal pregnant women to determine the amount pneumococcal antibody transmitted to the infants in serum and milk and the half-life of the passively acquired antibody. Healthy pregnant women in Dhaka, Bangladesh, were randomised to receive pneumococcal or meningococcal vaccine with routine prenatal tetanus immunisation at 30-34 weeks of gestation. Serum and breast milk specimens from the mothers and sera from infants were collected up to 22 weeks of age and assayed for specific serum IgG, IgG1, and IgG2 and for milk IgA antibodies to pneumococcal serotypes 6B and 19F. 55 mothers and 56 infants were followed from birth to five months, Women who received pneumococcal vaccine had geometric mean antibody increases of 2.6 and 3.4 to types 6B and 19F, respectively, The mean infant/maternal antibody ratios were 0.56 and 0.59 (range 0.11-1.46) for these serotypes. Infant cord antibody titres correlated with maternal titres, Infant/maternal IgG ratios correlated with the interval between immunisation and birth and were higher for specific IgG1 than for IgG2. infants of pneumococcal vaccine recipients had geometric mean antibody concentrations of 6.8 and 7.5 mu g/mL to serotypes 6B and 19F in cord blood; in cord blood and in all subsequent serum specimens the concentrations were 2-3 fold higher than in control infants, The median half-life of passive antibody was about 35 days; at five months of age 63-71% of infants of pneumococcal Vaccine recipients had antibody concentrations greater than 0.15 mu g/mL. Breast milk IgA antibodies for pneumococcal serotype 19F, but. not for type 6B, were significantly higher in vaccine recipients up to five months after delivery. If maternal pneumococcal polysaccharide antibodies do not interfere with active immunisation of the infant with new glycoprotein conjugate pneumococcal vaccines, passive-active immunisation of infants can be a feasible strategy for developing regions.	INT CTR DIARRHOEAL DIS RES,DHAKA 1000,BANGLADESH; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV INFECT DIS,BOSTON,MA 02111	International Centre for Diarrhoeal Disease Research (ICDDR); Johns Hopkins University; Johns Hopkins University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School								AMSTEY MS, 1985, AM J OBSTET GYNECOL, V153, P607, DOI 10.1016/S0002-9378(85)80243-X; ANDERSON P, 1992, PEDIATR INFECT DIS J, V11, P677; BAKER CJ, 1988, NEW ENGL J MED, V319, P1180, DOI 10.1056/NEJM198811033191802; BALLARD JL, 1979, J PEDIATR-US, V95, P769, DOI 10.1016/S0022-3476(79)80734-9; BARDARDOTTIR E, 1990, J INFECT DIS, V162, P482, DOI 10.1093/infdis/162.2.482; CHUDWIN DS, 1985, AM J DIS CHILD, V139, P378, DOI 10.1001/archpedi.1985.02140060060029; CLAESSON BA, 1989, J PEDIATR-US, V114, P97, DOI 10.1016/S0022-3476(89)80611-0; ENGLUND JA, 1995, PEDIATRICS, V96, P580; ENGLUND JA, 1995, J INFECT DIS, V171, P91; GEELEN SPM, 1990, J PERINAT MED, V18, P125, DOI 10.1515/jpme.1990.18.2.125; GHAFOOR A, 1990, REV INFECT DIS, V12, pS907; GLEZEN WP, 1992, J INFECT DIS S1, V156, pS134; GRANT JP, 1995, STATE WORLDS CHILDRE, P84; GRUNEBAUM AN, 1986, OBSTET GYNECOL, V68, P483; HALSEY NA, 1990, PEDIATR INFECT DIS J, V9, P574, DOI 10.1097/00006454-199008000-00010; Insel R A, 1994, Int J Technol Assess Health Care, V10, P143; KOSKELA M, 1986, PEDIATR INFECT DIS J, V5, P45, DOI 10.1097/00006454-198601000-00009; LETSON GW, 1988, PEDIATR INFECT DIS J, V7, P747, DOI 10.1097/00006454-198811000-00001; MCCORMICK JB, 1980, J CLIN INVEST, V65, P1141, DOI 10.1172/JCI109768; RAHMAN M, 1982, B WORLD HEALTH ORGAN, V60, P264; RAHMAN M, 1990, REV INFECT DIS    S8, V12, P899; REILLY CM, 1961, NEW ENGL J MED, V265, P165, DOI 10.1056/NEJM196107272650403; RILEY ID, 1981, REV INFECT DIS, V3, P233; RILEY ID, 1991, REV INFECT DIS, V13, pS535; SARVAS H, 1992, J INFECT DIS, V165, P977, DOI 10.1093/infdis/165.5.977; SHURIN PA, 1993, J PEDIATR-US, V123, P801, DOI 10.1016/S0022-3476(05)80865-0; SIBER GR, 1992, J INFECT DIS, V16, pS129; STEINHOFF MC, 1994, PEDIATR INFECT DIS J, V13, P368, DOI 10.1097/00006454-199405000-00007; VINCENTBALLEREA.F, 1985, PATHOL BIOL, V33, P764; WESTH H, 1990, REV INFECT DIS, V12, P416; ZOLLINGER WD, 1981, J IMMUNOL METHODS, V46, P129, DOI 10.1016/0022-1759(81)90130-7; 1986, DISEASE IMPORTANCE D, V2, P357	32	147	149	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1252	1257		10.1016/S0140-6736(95)91861-2	http://dx.doi.org/10.1016/S0140-6736(95)91861-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475716	hybrid			2022-12-28	WOS:A1995TE14500009
J	KIM, E; NIETHAMMER, M; ROTHSCHILD, A; JAN, YN; SHENG, M				KIM, E; NIETHAMMER, M; ROTHSCHILD, A; JAN, YN; SHENG, M			CLUSTERING OF SHAKER-TYPE K+ CHANNELS BY INTERACTION WITH A FAMILY OF MEMBRANE-ASSOCIATED GUANYLATE KINASES	NATURE			English	Article							TUMOR-SUPPRESSOR PROTEIN; SEPTATE JUNCTIONS; POTASSIUM CHANNEL; NMDA RECEPTOR; NEURONS; DIVERSITY; HOMOLOG; BRAIN; GENE	ANCHORING Of ion channels at specific subcellular sites is critical for neuronal signalling, but the mechanisms underlying channel localization and clustering are largely unknown (reviewed in ref. 1). Voltage-gated K+ channels are concentrated in various neuronal domains, including presynaptic terminals, nodes of Ranvier and dendrites, where they regulate local membrane excitability. Here we present functional and biochemical evidence that cell-surface clustering of Shaker-subfamily K+ channels is mediated by the PSD-95 family of membrane-associated putative guanylate kinases, as a result of direct binding of the carboxy-terminal cytoplasmic tails of the K+ channel subunits to two PDZ (also known as GLGF or DHR) domains in the PSD-95 protein(2). The ability of PDZ domains to function as independent modules for protein-protein interaction, and their presence in other junction-associated molecules (such as ZO-1 (ref. 3) and syntrophin(4)), suggest that PDZ-domain-containing polypeptides may be widely involved in the organization of proteins at sites of membrane specialization.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROBIOL,BOSTON,MA 02114; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	Harvard University; Harvard Medical School; Massachusetts General Hospital; Howard Hughes Medical Institute; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Kim, Eunjoon/C-1566-2011	Sheng, Morgan/0000-0002-8703-5366				ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F; Bartel PL, 1993, USING 2 HYBRID SYSTE, P153; CHANDY KG, 1995, HDB RECEPTORS CHANNE, P1; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISHII T, 1993, J BIOL CHEM, V268, P2836; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; SHENG M, 1994, J NEUROSCI, V14, P2408; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; WANG H, 1994, J NEUROSCI, V14, P4588; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	29	881	912	0	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 2	1995	378	6552					85	88		10.1038/378085a0	http://dx.doi.org/10.1038/378085a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477295				2022-12-28	WOS:A1995TC46900056
J	BLOCH, S; KISSANE, DW				BLOCH, S; KISSANE, DW			PSYCHOSOCIAL CARE AND BREAST-CANCER	LANCET			English	Editorial Material							TRIAL		MONASH UNIV,DEPT PSYCHOL MED,CLAYTON,VIC 3168,AUSTRALIA	Monash University	BLOCH, S (corresponding author), UNIV MELBOURNE,DEPT PSYCHIAT,MELBOURNE,VIC,AUSTRALIA.			Kissane, David/0000-0002-5930-4573				ANDERSEN BL, 1992, J CONSULT CLIN PSYCH, V60, P552, DOI 10.1037/0022-006X.60.4.552; FALLOWFIELD LJ, 1990, BRIT MED J, V301, P575, DOI 10.1136/bmj.301.6752.575; FAWZY FI, 1993, ARCH GEN PSYCHIAT, V50, P681; GREER S, 1990, LANCET, V335, P49, DOI 10.1016/0140-6736(90)90173-3; GREER S, 1992, BRIT MED J, V304, P675, DOI 10.1136/bmj.304.6828.675; Moorey S., 1989, PSYCHOL THERAPY PATI; MULDER CL, 1992, PSYCHO-ONCOLOGY, V1, P155; PRESBERG BA, 1993, PSYCHO-ONCOLOGY, V2, P215; SPIEGEL D, 1989, LANCET, V1, P888; TRIJSBURG RW, 1992, PSYCHOSOM MED, V54, P489, DOI 10.1097/00006842-199207000-00011; 1995, CLIN PRACTICE GUIDEL; 1994, MED J AUST S, V161	12	17	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 28	1995	346	8983					1114	1115		10.1016/S0140-6736(95)91794-2	http://dx.doi.org/10.1016/S0140-6736(95)91794-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TB549	7475597				2022-12-28	WOS:A1995TB54900004
J	CANDINAS, D; GUNSON, BK; NIGHTINGALE, P; HUBSCHER, S; MCMASTER, P; NEUBERGER, JM				CANDINAS, D; GUNSON, BK; NIGHTINGALE, P; HUBSCHER, S; MCMASTER, P; NEUBERGER, JM			SEX MISMATCH AS A RISK FACTOR FOR CHRONIC REJECTION OF LIVER ALLOGRAFTS	LANCET			English	Article							MINOR HISTOCOMPATIBILITY ANTIGENS; VANISHING-BILEDUCT SYNDROME; DUCT SYNDROME; TRANSPLANTATION; GRAFT; IMMUNOSUPPRESSION; INFECTION	Chronic irreversible rejection is a major cause of graft loss and retransplantation after orthotopic liver allotransplantation. To identify risk factors we retrospectively analysed 423 adult consecutive primary liver allograft recipients. The endpoint of the study was graft failure due to chronic rejection leading either to retransplantation or death. Chronic rejection developed in 22 (5.2%) patients. Pretransplant diagnosis of primary biliary cirrhosis or autoimmune hepatitis, recipient age less than 30 years, 1 or more episodes of acute cellular rejection, and transplantation of an organ from cytomegalovirus (CMV). IgG positive donor to an IgG negative recipient were identified as risk factors for chronic rejection. Transplantation of a liver from a male donor into a female recipient was also associated with an increased probability of chronic rejection. By logistic regression analysis, the probability of chronic rejection was predicted by: sex and cytomegalovirus match of donor and recipient, the presence of acute rejection, recipient age, transplantation for autoimmune hepatitis or primary biliary cirrhosis, and recipients receiving no azathioprine during the third month after transplantation. Sensitisation to antigens expressed by bile-duct epithelium as in primary biliary cirrhosis or exposure to donor bile-duct minor histocompatibility antigens, such as the male sex related H-Y antigen, may provide an explanation, More selective allocation of donor organs may allow a reduction in the incidence of ductopaenic rejection and graft loss.	QUEEN ELIZABETH HOSP,LIVER & HEPATOBILIARY UNIT,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT MED,WOLFSON COMP LABS,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,SCH MED,DEPT PATHOL,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham; University of Birmingham			Neuberger, James/ABG-3010-2020	Gunson, Bridget/0000-0001-6149-9915				ADAMS DH, 1990, J HEPATOL, V10, P113, DOI 10.1016/0168-8278(90)90081-2; BACKMAN L, 1993, TRANSPLANTATION, V55, P1078; BASADONNA GP, 1995, TRANSPLANTATION, V55, P993; BISMUTH A, 1991, REV FR TRANSFUS HEM, V34, P449, DOI 10.1016/S1140-4639(05)80139-X; BLATTS KP, 1988, TRANSPLANTATION, V45, P376; DEMETRIS AJ, 1988, HEPATOLOGY, V8, P939, DOI 10.1002/hep.1840080439; DEVLIN JJ, 1993, TRANSPLANTATION, V56, P1381, DOI 10.1097/00007890-199312000-00020; DONALDSON P, 1993, HEPATOLOGY, V17, P1008, DOI 10.1002/hep.1840170611; DONALDSON PT, 1987, LANCET, V1, P945; DOUSSET B, 1993, TRANSPLANTATION, V55, P529, DOI 10.1097/00007890-199303000-00014; GNANT MFX, 1991, TRANSPLANT P, V23, P1434; GOULMY E, 1991, BONE MARROW TRANSPL, V7, P49; GRIEM P, 1991, CELL, V65, P633, DOI 10.1016/0092-8674(91)90095-G; GUBERNATIS G, 1988, TRANSPLANT INT, V1, P155, DOI 10.1111/j.1432-2277.1988.tb01805.x; HUBSCHER S, 1993, IMMUNOLOGY LIVER TRA, P216; LESOURD BM, 1994, IMMUNOL LETT, V40, P235, DOI 10.1016/0165-2478(94)00062-X; MANEZ R, 1993, TRANSPLANTATION, V55, P1067, DOI 10.1097/00007890-199305000-00024; MCMASTER P, 1994, TRANSPL INT S1, V7, P32; OGRADY JG, 1988, LANCET, V2, P302; PADBURY RTA, 1993, TRANSPLANTATION, V55, P789, DOI 10.1097/00007890-199304000-00020; PAYA CV, 1992, HEPATOLOGY, V16, P66, DOI 10.1002/hep.1840160113; SIMPSON E, 1991, IMMUNOL LETT, V29, P9, DOI 10.1016/0165-2478(91)90192-D; SOIN AS, 1995, TRANSPLANT P, V27, P1129; VANHOEK B, 1991, TRANSPLANT P, V23, P1403; VOOGT PJ, 1990, LANCET, V335, P131, DOI 10.1016/0140-6736(90)90003-N; WIESNER RH, 1991, HEPATOLOGY, V14, P721, DOI 10.1002/hep.1840140424	26	111	111	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 28	1995	346	8983					1117	1121		10.1016/S0140-6736(95)91797-7	http://dx.doi.org/10.1016/S0140-6736(95)91797-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB549	7475600				2022-12-28	WOS:A1995TB54900007
J	DEGRAAF, RM; VISSCHER, J; SCHWARTZ, AW				DEGRAAF, RM; VISSCHER, J; SCHWARTZ, AW			A PLAUSIBLY PREBIOTIC SYNTHESIS OF PHOSPHONIC-ACIDS	NATURE			English	Article							AQUEOUS FORMALDEHYDE; ELEMENT	THE insolubility of calcium phosphate in water is a significant stumbling block in the chemistry required for the origin of life(1). The discovery of alkyl phosphonic acids in the Murchison meteorite(2) suggests the possibility of delivery of these water-soluble, phosphorus-containing molecules by meteorites or comets to the early Earth. This could have provided a supply of organic phosphorus for the earliest stages of chemical evolution; although probably not components of early genetic systems, phosphonic acids may have been precursors to the first nucleic acids(3). Here we report the synthesis of several phosphonic acids, including the most abundant found in the Murchison meteorite, by ultraviolet irradiation of orthophosphorous acid in the presence of formaldehyde, primary alcohols, or acetone, We argue that similar reactions might explain the presence of phosphonic acids in Murchison, and could also have occurred on the prebiotic Earth.	CATHOLIC UNIV NIJMEGEN,FAC SCI,EVOLUT BIOL RES GRP,6525 ED NIJMEGEN,NETHERLANDS	Radboud University Nijmegen			de Graaf, Rob/E-7665-2012	de Graaf, Rob/0000-0001-9143-8961				BUNCH TE, 1980, GEOCHIM COSMOCHIM AC, V44, P1543, DOI 10.1016/0016-7037(80)90118-0; Calvert J. G., 1966, PHOTOCHEMISTRY; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; COOPER GW, 1992, GEOCHIM COSMOCHIM AC, V56, P4109, DOI 10.1016/0016-7037(92)90023-C; ENGEL R, 1977, CHEM REV, V77, P349, DOI 10.1021/cr60307a003; FEGLEY B, 1980, ICARUS, V41, P439, DOI 10.1016/0019-1035(80)90228-6; FREEDMAN LD, 1957, CHEM REV, V57, P479, DOI 10.1021/cr50015a003; GULICK A, 1955, AM SCI, V43, P479; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; MATSUURA N, 1971, B CHEM SOC JPN, V44, P1027, DOI 10.1246/bcsj.44.1027; MILLER SL, 1959, SCIENCE, V130, P245, DOI 10.1126/science.130.3370.245; PARK HR, 1988, J PHOTOCH PHOTOBIO A, V43, P155, DOI 10.1016/1010-6030(88)80015-7; SCHWARTZ AW, 1993, J MOL EVOL, V36, P101, DOI 10.1007/BF00166245; SCHWARTZ AW, 1973, INORG NUCL CHEM LETT, V9, P39, DOI 10.1016/0020-1650(73)80083-2; SCHWARTZ AW, 1993, TETRAHEDRON LETT, V34, P2201, DOI 10.1016/S0040-4039(00)60382-9; SEIFERT KG, 1973, ANGEW CHEM INT EDIT, V12, P763, DOI 10.1002/anie.197307631; VANDERLINDE HJ, 1971, PHOTOCHEM PHOTOBIOL, V13, P147; Walker J. F., 1964, FORMALDEHYDE	18	63	64	1	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					474	477		10.1038/378474a0	http://dx.doi.org/10.1038/378474a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477402				2022-12-28	WOS:A1995TH05400065
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PROPOSAL FOR EMERGENCY USE RESEARCH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1995, FED REGISTER, V60, P49086	1	6	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	1995	274	20					1578	1578		10.1001/jama.274.20.1578	http://dx.doi.org/10.1001/jama.274.20.1578			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE738	7474231				2022-12-28	WOS:A1995TE73800004
J	OPTENBERG, SA; THOMPSON, IM; FRIEDRICHS, P; WOJCIK, B; STEIN, CR; KRAMER, B				OPTENBERG, SA; THOMPSON, IM; FRIEDRICHS, P; WOJCIK, B; STEIN, CR; KRAMER, B			RACE, TREATMENT, AND LONG-TERM SURVIVAL FROM PROSTATE-CANCER IN AN EQUAL-ACCESS MEDICAL-CARE DELIVERY SYSTEM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RACIAL-DIFFERENCES; UNITED-STATES; BLACK; ADENOCARCINOMA; MORTALITY; STAGE; POPULATIONS; CARCINOMA; DIAGNOSIS; PATTERNS	Objective.-To evaluate long-term survival of black and white prostate cancer patients in an equal-access medical care system to help distinguish biological from medical and social explanations of mortality differences. Design and Setting.-Retrospective study of US Department of Defense tumor registry patients with prostate cancer. Ethnicity, age, diagnosis, staging, risk factors, treatment, and survival end points were extracted. Patients.-Prostate cancer patients (N=1606; 7.5% black, 92.5% white) who were active-duty personnel, dependents, or retirees eligible for care in the military medical system. Main Outcome Measuress-Racial differences in tumor stage and grade, risk factors, recurrence, and treatment wait time (time between initial diagnosis and initial treatment); influence of stage, grade, treatment, wait time, age, and race on survival. Results.-No differences were found in behavioral risk factors or tumor grade or size, but blacks entered active treatment (P<.001) and exhibited a higher relative risk of cancer (P=.01) in younger age groups, presented with higher stage (P<.001), and demonstrated increased progression in distant metastatic disease (P=.01). No significant differences were detected in overall wait time. When adjusted for stage, no difference was found in type of treatment. Overall, stage, grade, and age were found to affect survival (P=.04 to P<.001), but race did not, When analyzed by stage, blacks demonstrated a clear trend of longer survival for distant metastatic disease (P=.04 to P=.06). This trend was confirmed using Kaplan-Meier estimates (P=.04, likelihood ratio), Conclusions.-This analysis suggests that in an equal-access medical care system there are no stage-specific differences in treatment between black and white prostate cancer patients, Survival among blacks is similar to that among whites and may surpass it for high-stage disease.	USA,MED DEPT CTR & SCH,CTR HLTHCARE EDUC & STUDIES,SAN ANTONIO,TX; BROOKE ARMY MED CTR,UROL SERV,SAN ANTONIO,TX; NCI,DIV CANC PREVENT & CONTROL,BETHESDA,MD	San Antonio Military Medical Center; United States Department of Defense; United States Army; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								APRIKIAN AG, 1994, CANCER, V74, P1768, DOI 10.1002/1097-0142(19940915)74:6<1768::AID-CNCR2820740620>3.0.CO;2-9; AUSTIN JP, 1990, AM J CLIN ONCOL-CANC, V13, P465, DOI 10.1097/00000421-199012000-00002; AUSTIN JP, 1993, AM J CLIN ONCOL-CANC, V16, P140, DOI 10.1097/00000421-199304000-00012; AZIZ H, 1988, AM J CLIN ONCOL-CANC, V11, P166, DOI 10.1097/00000421-198804000-00015; BALLWEG JA, 1989, PUBLIC HEALTH REP, V104, P498; BANG KM, 1988, CANCER, V61, P1255, DOI 10.1002/1097-0142(19880315)61:6<1255::AID-CNCR2820610634>3.0.CO;2-7; BEAHRS OH, 1992, MANUAL STAGING CANCE; BLAIR A, 1978, J NATL CANCER I, V61, P1379; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; BRAWN PN, 1994, CANCER, V74, P1607, DOI 10.1002/1097-0142(19940901)74:5<1607::AID-CNCR2820740518>3.0.CO;2-F; DAYAL HH, 1982, J CHRON DIS, V35, P553, DOI 10.1016/0021-9681(82)90074-1; DEMARKWAHNEFRIED W, 1993, UROLOGY, V42, P269, DOI 10.1016/0090-4295(93)90615-H; DEMERS RY, 1994, ARCH INTERN MED, V154, P1211, DOI 10.1001/archinte.154.11.1211; ELEY JW, 1994, JAMA-J AM MED ASSOC, V242, P947; FLEISS JL, 1981, STATISTICAL METHODS, V23, P26; HARLAN L, 1995, J CLIN ONCOL, V13, P93, DOI 10.1200/JCO.1995.13.1.93; HUSSAIN F, 1992, INT J RADIAT ONCOL, V24, P451, DOI 10.1016/0360-3016(92)91059-V; JEPSON C, 1991, AM J PUBLIC HEALTH, V81, P501, DOI 10.2105/AJPH.81.4.501; LAWTON CA, 1994, RADIOLOGY, V92, P37; LEE JY, 1990, SOUTHERN MED J, V83, P185, DOI 10.1097/00007611-199002000-00012; LEVINE RL, 1979, J UROLOGY, V121, P761, DOI 10.1016/S0022-5347(17)56981-5; LIFF JM, 1991, CANCER, V67, P1454, DOI 10.1002/1097-0142(19910301)67:5<1454::AID-CNCR2820670533>3.0.CO;2-K; MEBANE C, 1990, J NATL MED ASSOC, V82, P782; METTLIN C, 1987, CANCER, V60, P474, DOI 10.1002/1097-0142(19870801)60:3+<474::AID-CNCR2820601508>3.0.CO;2-5; METTLIN CJ, 1994, CANCER, V74, P1640, DOI 10.1002/1097-0142(19940901)74:5<1640::AID-CNCR2820740525>3.0.CO;2-3; MYERS RE, 1994, UROLOGY, V43, P480, DOI 10.1016/0090-4295(94)90235-6; NATARAJAN N, 1989, J SURG ONCOL, V40, P232, DOI 10.1002/jso.2930400406; PAMIES RJ, 1992, PRIMARY CARE, V19, P443; POLEDNAK AP, 1990, CANCER-AM CANCER SOC, V66, P1654, DOI 10.1002/1097-0142(19901001)66:7<1654::AID-CNCR2820660734>3.0.CO;2-I; POLEDNAK AP, 1992, CANCER, V70, P2152, DOI 10.1002/1097-0142(19921015)70:8<2152::AID-CNCR2820700824>3.0.CO;2-#; RIES LAG, 1994, SEER CANCER STATISTI; ROACH M, 1992, INT J RADIAT ONCOL, V24, P441, DOI 10.1016/0360-3016(92)91058-U; RUFFER J E, 1991, International Journal of Radiation Oncology, Biology, Physics, V21, P212, DOI 10.1016/0360-3016(91)90609-8; TANARI N, 1993, CANCER, V71, P1289; TARGONSKI PV, 1991, J NATL MED ASSOC, V83, P1094; WHITMORE WF, 1984, UROL CLIN N AM, V11, P205; 1994, PHS951101 US DHEW PU, V2; 1992, SAS P229 SAS I INC R, P433; 1993, DEFENSE ENROLLMENT E; 1989, SAS STATOR USERS GUI; 1974, US DHEW HRA751101 PH, V2; 1994, DEFENSE MED INFORMAT; 1985, PHS851101 US DHEW PU, V2	43	198	201	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	1995	274	20					1599	1605		10.1001/jama.274.20.1599	http://dx.doi.org/10.1001/jama.274.20.1599			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE738	7474244				2022-12-28	WOS:A1995TE73800024
J	LIP, GYH				LIP, GYH			DOES ATRIAL-FIBRILLATION CONFER A HYPERCOAGULABLE STATE	LANCET			English	Editorial Material							SPONTANEOUS ECHO CONTRAST; RISK				LIP, GYH (corresponding author), UNIV BIRMINGHAM,CITY HOSP,DEPT MED,BIRMINGHAM,W MIDLANDS,ENGLAND.							[Anonymous], 1994, ARCH INTERN MED, V154, P1449; ASAKURA H, 1992, BLOOD COAGUL FIBRIN, V3, P469, DOI 10.1097/00001721-199203040-00015; BLACK IW, 1993, J AM COLL CARDIOL, V21, P451, DOI 10.1016/0735-1097(93)90688-W; FATKIN D, 1994, AM J CARDIOL, V73, P672, DOI 10.1016/0002-9149(94)90932-6; FOWKES FGR, 1993, LANCET, V342, P84, DOI 10.1016/0140-6736(93)91288-W; GUSTAFSSON C, 1990, STROKE, V21, P47, DOI 10.1161/01.STR.21.1.47; Heppell R. M., 1995, European Heart Journal, V16, P5; KUMAGAI K, 1990, J AM COLL CARDIOL, V16, P377, DOI 10.1016/0735-1097(90)90589-H; LIP GYH, 1995, INT J CARDIOL, V51, P245, DOI 10.1016/0167-5273(95)02434-X; LIP GYH, 1995, BRIT HEART J, V73, P527; LIP GYH, IN PRESS AM HEART J; LOWE GDO, 1995, BLOOD COAGUL FIBRIN, V6, P156; RIDKER PM, 1994, CIRCULATION, V90, P2263; ROWBOTHAM BJ, 1992, BLOOD COAGUL FIBRIN, V3, P25, DOI 10.1097/00001721-199202000-00005; TSAI LM, 1992, AM J CARDIOL, V70, P327; 1992, ANN INTERN MED, V116, P6	16	195	209	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 18	1995	346	8986					1313	1314		10.1016/S0140-6736(95)92339-X	http://dx.doi.org/10.1016/S0140-6736(95)92339-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE916	7475767				2022-12-28	WOS:A1995TE91600005
J	DAN, BB				DAN, BB			INFORMATION LIVES - MEDICAL TELEVISION DIES	LANCET			English	Editorial Material											DAN, BB (corresponding author), NATL AIDS FUND, 1400 I ST NW, SUITE 1220, WASHINGTON, DC 20005 USA.							KASSIRER JP, 1995, NEW ENGL J MED, V332, P52, DOI 10.1056/NEJM199501053320110; KASSIRER JP, 1995, NEW ENGL J MED, V332, P1709, DOI 10.1056/NEJM199506223322509; LUNDBERG GD, 1995, JAMA-J AM MED ASSOC, V273, P891; McLuhan M., 1994, UNDERSTANDING MEDIA; Negroponte N, 1995, BEING DIGITAL; Rheingold H, 1995, VIRTUAL COMMUNITY HO	6	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 11	1995	346	8985					1280	1281		10.1016/S0140-6736(95)91869-8	http://dx.doi.org/10.1016/S0140-6736(95)91869-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475724				2022-12-28	WOS:A1995TE14500017
J	DEACON, NJ; TSYKIN, A; SOLOMON, A; SMITH, K; LUDFORDMENTING, M; HOOKER, DJ; MCPHEE, DA; GREENWAY, AL; ELLETT, A; CHATFIELD, C; LAWSON, VA; CROWE, S; MAERZ, A; SONZA, S; LEARMONT, J; SULLIVAN, JS; CUNNINGHAM, A; DWYER, D; DOWTON, D; MILLS, J				DEACON, NJ; TSYKIN, A; SOLOMON, A; SMITH, K; LUDFORDMENTING, M; HOOKER, DJ; MCPHEE, DA; GREENWAY, AL; ELLETT, A; CHATFIELD, C; LAWSON, VA; CROWE, S; MAERZ, A; SONZA, S; LEARMONT, J; SULLIVAN, JS; CUNNINGHAM, A; DWYER, D; DOWTON, D; MILLS, J			GENOMIC STRUCTURE OF AN ATTENUATED QUASI-SPECIES OF HIV-1 FROM A BLOOD-TRANSFUSION DONOR AND RECIPIENTS	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEF GENE; FOLLOW-UP; AIDS; INFECTION; PROGRESSION; DISEASE; CELLS; MEN; DNA	A blood donor infected with human immunodeficiency virus-type 1 (HIV-1) and a cohort of six blood or blood product recipients infected from this donor remain free of HIV-1-related disease with stable and normal CD4 lymphocyte counts 10 to 14 years after infection. HIV-1 sequences from either virus isolates or patient peripheral blood mononuclear cells had similar deletions in the nef gene and in the region of overlap of nef and the U3 region of the long terminal repeat (LTR). Full-length sequencing of one isolate genome and amplification of selected HIV-1 genome regions from other cohort members revealed no other abnormalities of obvious functional significance. These data show that survival after HIV infection can be determined by the HIV genome and support the importance of nef or the U3 region of the LTR in determining the pathogenicity of HIV-1.	MACFARLANE BURNET CTR MED RES,NATL CTR HIV VIROL RES,AIDS CELLULAR BIOL UNIT,FAIRFIELD,VIC 3078,AUSTRALIA; MACFARLANE BURNET CTR MED RES,NATL CTR HIV VIROL RES,AIDS PATHOGENESIS UNIT,FAIRFIELD,VIC 3078,AUSTRALIA; NEW S WALES RED CROSS,BLOOD TRANSFUS SERV,SYDNEY 2000,NSW,AUSTRALIA; WESTMEAD HOSP,DEPT VIROL,WESTMEAD,NSW 2145,AUSTRALIA; WESTMEAD HOSP,NATL CTR HIV VIROL RES,INST CLIN PATHOL & MED RES,WESTMEAD,NSW 2145,AUSTRALIA	Australian Red Cross Blood Service; University of Sydney; University of Sydney	DEACON, NJ (corresponding author), MACFARLANE BURNET CTR MED RES,NATL CTR HIV VIROL RES,AIDS MOLEC BIOL UNIT,YARRA BEND RD,FAIRFIELD,VIC 3078,AUSTRALIA.		Lawson, Victoria/AAJ-7392-2021; McPhee, Dale A/D-1825-2011	Tsykin, Anna/0000-0001-5965-6803; Cunningham, Anthony/0000-0002-6744-5667; Greenway, Alison/0000-0001-8908-2708; Lawson, Victoria/0000-0002-7362-7176				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ARCHER G, 1988, 4TH INT C AIDS STOCK; AUGER I, 1988, NATURE, V336, P575, DOI 10.1038/336575a0; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; FERRE F, 1993, AIDS, V7, pS21, DOI 10.1097/00002030-199311002-00006; FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992; GOODALL J, 1994, THESIS U MELBOURNE; GOU LH, 1982, NUCLEIC ACIDS RES, V10, P2065; GREENOUGH TC, 1994, AIDS RES HUM RETROV, V10, P395, DOI 10.1089/aid.1994.10.395; GREENWAY AL, UNPUB; GROENINK M, 1993, SCIENCE, V260, P1513, DOI 10.1126/science.8502996; HUANG YX, 1995, J VIROL, V69, P93, DOI 10.1128/JVI.69.1.93-100.1995; KAPLAN JE, 1992, J ACQ IMMUN DEF SYND, V5, P565; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1994, J VIROL, V68, P2031, DOI 10.1128/JVI.68.3.2031-2037.1994; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; LEAMONT J, 1995, AIDS RES HUM RETROV, V11, P1; LEAMONT J, 1992, LANCET, V340, P863; LEARMONT J, 1994, 10TH INT C AIDS YOK; LEARMONT J, UNPUB; LEE TH, 1991, AIDS, V5, P683, DOI 10.1097/00002030-199106000-00007; MCPHEE DJ, UNPUB; MEYERS G, 1994, HUMAN RETROVIRUSES A; NEATE EV, 1987, AUST NZ J MED, V17, P461, DOI 10.1111/j.1445-5994.1987.tb00096.x; NOWAK M, 1993, AIDS, V7, pS3, DOI 10.1097/00002030-199301001-00002; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SANGER F, 1977, P NATL ACAD SCI USA, V84, P5463; SCHRAGER LK, 1994, AIDS, V8, P895; SELWYN PA, 1992, NEW ENGL J MED, V327, P1697, DOI 10.1056/NEJM199212103272401; SEMPLE MG, 1993, J VIROL METHODS, V41, P176; SHUGARS DC, 1993, J VIROL, V67, P4639, DOI 10.1128/JVI.67.8.4639-4650.1993; SMITH J, 1992, J GEN VIROL, V73, P1825, DOI 10.1099/0022-1317-73-7-1825; SOLOMON AI, UNPUB; TYSKIN A, UNPUB; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; 1992, MMWR-MORBID MORTAL W, V41, P961	40	1006	1021	0	16	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 10	1995	270	5238					988	991		10.1126/science.270.5238.988	http://dx.doi.org/10.1126/science.270.5238.988			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD878	7481804				2022-12-28	WOS:A1995TD87800049
J	BENEDETTI, F; AMANZIO, M; MAGGI, G				BENEDETTI, F; AMANZIO, M; MAGGI, G			POTENTIATION OF PLACEBO ANALGESIA BY PROGLUMIDE	LANCET			English	Letter									UNIV TURIN,CIND,CTR NEUROPHYSIOL PAIN,I-10125 TURIN,ITALY; UNIV TURIN,DEPT THORAC SURG,TURIN,ITALY	University of Turin; University of Turin	BENEDETTI, F (corresponding author), UNIV TURIN,DEPT HUMAN ANAT & PHYSIOL,CORSO RAFFAELLO 30,I-10125 TURIN,ITALY.		Amanzio, Martina/A-9085-2010	Amanzio, Martina/0000-0002-2504-032X				BABER NS, 1989, PAIN, V39, P307, DOI 10.1016/0304-3959(89)90045-6; BENEDETTI F, IN PRESS PAIN; GREVERT P, 1983, PAIN, V16, P129, DOI 10.1016/0304-3959(83)90203-8; LEVINE JD, 1984, NATURE, V312, P755, DOI 10.1038/312755a0; LEVINE JD, 1978, LANCET, V2, P654, DOI 10.1016/S0140-6736(78)92762-9	5	151	158	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 4	1995	346	8984					1231	1231		10.1016/S0140-6736(95)92938-X	http://dx.doi.org/10.1016/S0140-6736(95)92938-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC976	7475687	Bronze			2022-12-28	WOS:A1995TC97600049
J	COBB, SR; BUHL, EH; HALASY, K; PAULSEN, O; SOMOGYI, P				COBB, SR; BUHL, EH; HALASY, K; PAULSEN, O; SOMOGYI, P			SYNCHRONIZATION OF NEURONAL-ACTIVITY IN HIPPOCAMPUS BY INDIVIDUAL GABAERGIC INTERNEURONS	NATURE			English	Article							MEMBRANE-POTENTIAL OSCILLATIONS; INHIBITORY INTERNEURONS; PYRAMIDAL NEURONS; RAT HIPPOCAMPUS; THETA-RHYTHM; CELLS; CA1	SYNCHRONIZATION Of neuronal activity is fundamental in the operation of cortical networks(1). With respect to an ongoing synchronized oscillation, the precise timing of action potentials is an attractive candidate mechanism for information coding(2-5) Networks of inhibitory interneurons have been proposed to have a role in entraining cortical, synchronized 40-Hz activity(6,7). Here we demonstrate that individual GABAergic interneurons(8) can effectively phase spontaneous firing and subthreshold oscillations in hippocampal pyramidal cells at theta frequencies (4-7 Hz). The efficiency of this entrainment is due to interaction of GABA(A)-receptor-mediated hyperpolarizing synaptic events with intrinsic oscillatory mechanisms tuned to this frequency range in pyramidal cells. Moreover, this GABAergic mechanism is sufficient to synchronize the firing of pyramidal cells. Thus, owing to the divergence of each GABAergic interneuron(9,10), more than a thousand pyramidal cells may share a common temporal reference established by an individual interneuron.	ATTILA JOZSEF UNIV, DEPT ZOOL & CELL BIOL, H-6722 SZEGED, HUNGARY	Szeged University	COBB, SR (corresponding author), UNIV OXFORD, DEPT PHARMACOL, MRC, ANAT NEUROPHARMACOL UNIT, MANSFIELD RD, OXFORD OX1 3TH, ENGLAND.		Paulsen, Ole/ABB-4843-2020	Paulsen, Ole/0000-0002-2258-5455	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALONSO A, 1989, NATURE, V342, P175, DOI 10.1038/342175a0; ANDERSEN P, 1962, NATURE, V196, P645, DOI 10.1038/196645a0; ANDERSEN P, 1963, NATURE, V198, P540, DOI 10.1038/198540a0; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; FOX SE, 1989, EXP BRAIN RES, V77, P283, DOI 10.1007/BF00274985; FREUND TF, 1988, NATURE, V336, P170, DOI 10.1038/336170a0; GINSBORG BL, 1973, BIOCHIM BIOPHYS ACTA, V300, P289, DOI 10.1016/0304-4157(73)90007-5; GULYAS AI, 1993, NATURE, V366, P683, DOI 10.1038/366683a0; HOPFIELD JJ, 1995, NATURE, V376, P33, DOI 10.1038/376033a0; KANDEL ER, 1961, J NEUROPHYSIOL, V24, P243, DOI 10.1152/jn.1961.24.3.243; LEUNG LWS, 1991, BRAIN RES, V553, P261, DOI 10.1016/0006-8993(91)90834-I; LI XG, 1992, EXP BRAIN RES, V90, P519; LISMAN JE, 1995, SCIENCE, V267, P1512, DOI 10.1126/science.7878473; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; NIEDERMEYER Ernst, 1982, ELECTROEN CLIN NEURO; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; SIK A, IN PRESS J NEUROSCI; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; SOLTESZ I, 1993, J NEUROPHYSIOL, V70, P97, DOI 10.1152/jn.1993.70.1.97; SOMOGYI P, 1989, P RET RES F, V2, P35; STERIADE M, 1993, J NEUROSCI, V13, P3252, DOI 10.1523/jneurosci.13-08-03252.1993; VANDERWOLF CH, 1969, ELECTROEN CLIN NEURO, V26, P407, DOI 10.1016/0013-4694(69)90092-3; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0; YLINEN A, 1995, J NEUROSCI, V15, P30; YLINEN A, 1995, HIPPOCAMPUS, V5, P79	28	1146	1159	3	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 2	1995	378	6552					75	78		10.1038/378075a0	http://dx.doi.org/10.1038/378075a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477292				2022-12-28	WOS:A1995TC46900053
J	DEWEERD, P; GATTASS, R; DESIMONE, R; UNGERLEIDER, LG				DEWEERD, P; GATTASS, R; DESIMONE, R; UNGERLEIDER, LG			RESPONSES OF CELLS IN MONKEY VISUAL-CORTEX DURING PERCEPTUAL FILLING-IN OF AN ARTIFICIAL SCOTOMA	NATURE			English	Article							RECEPTIVE-FIELDS; MACAQUE MONKEY; STRIATE CORTEX; CONNECTIONS	WHEN we view a scene through one eye, we typically do not see the scotomas created by the optic disc and the blood vessels overlying the retinal surface. Similarly, when a texture field containing a hole is steadily viewed in peripheral vision (artificial scotoma), the hole appears to fill in with the surrounding texture in a matter of seconds, demonstrating that the visual system fills in information across regions where no information is available(1-5). Here we show that, in monkeys viewing a similar texture field with a hole, the responses of extrastriate visual neurons with receptive fields covering the hole increase gradually to a level comparable to that elicited by the same texture without a hole. The time course of these dynamic changes in activity parallels the time course of perceived filling-in of the hole by human observers, suggesting that this process mediates perceptual filling-in.	NIMH,PSYCHOL & PSYCHOPATHOL LAB,BETHESDA,MD 20892; NIMH,NEUROPSYCHOL LAB,BETHESDA,MD 20892; UNIV FED RIO DE JANEIRO,BIOPHYS INST CARLOS CHAGAS,DEPT NEUROBIOL,BR-21941 RIO JANEIRO,BRAZIL	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Universidade Federal do Rio de Janeiro			Desimone, Robert/G-1121-2018	Desimone, Robert/0000-0002-5938-4227				BENDER MB, 1946, ARCH NEURO PSYCHIATR, V55, P627, DOI 10.1001/archneurpsyc.1946.02300170075008; DAS A, 1995, NATURE, V375, P780, DOI 10.1038/375780a0; DISTLER C, 1993, J COMP NEUROL, V334, P125, DOI 10.1002/cne.903340111; FIORANI M, 1992, P NATL ACAD SCI USA, V89, P8547, DOI 10.1073/pnas.89.18.8547; GATTASS R, 1988, J NEUROSCI, V8, P1831; GATTASS R, 1981, J COMP NEUROL, V201, P519, DOI 10.1002/cne.902010405; GROSSBERG S, 1994, PERCEPT PSYCHOPHYS, V55, P48, DOI 10.3758/BF03206880; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; KOMATSU H, 1994, VISUAL NEUROSCI, V11, P1103, DOI 10.1017/S0952523800006921; LEVITT JB, 1994, J COMP NEUROL, V342, P551, DOI 10.1002/cne.903420405; MAFFEI L, 1976, VISION RES, V16, P1131, DOI 10.1016/0042-6989(76)90253-4; MCGUIRE BA, 1991, J COMP NEUROL, V305, P370, DOI 10.1002/cne.903050303; MILLER EK, 1993, J NEUROSCI, V13, P1460; NELSON JI, 1985, EXP BRAIN RES, V61, P54; NELSON JI, 1978, BRAIN RES, V139, P359, DOI 10.1016/0006-8993(78)90937-X; OHZAWA I, 1985, J NEUROPHYSIOL, V42, P833; PETTET MW, 1992, P NATL ACAD SCI USA, V89, P8366, DOI 10.1073/pnas.89.17.8366; RAMACHANDRAN VS, 1991, NATURE, V350, P699, DOI 10.1038/350699a0; RAMACHANDRAN VS, 1993, VISION RES, V33, P717, DOI 10.1016/0042-6989(93)90191-X; SPILLMANN L, 1992, VISION RES, V32, P1941, DOI 10.1016/0042-6989(92)90053-L; YOSHIOKA T, 1992, J NEUROSCI, V12, P2785; Zipser K., 1994, Society for Neuroscience Abstracts, V20, P1477	22	176	176	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 26	1995	377	6551					731	734						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB469	7477262				2022-12-28	WOS:A1995TB46900056
J	VANDOREN, K; HIRSH, D				VANDOREN, K; HIRSH, D			TRANS-SPLICED LEADER RNA EXISTS AS SMALL NUCLEAR RIBONUCLEOPROTEIN-PARTICLES IN CAENORHABDITIS-ELEGANS	NATURE			English	Article											VANDOREN, K (corresponding author), SYNERGEN INC,1885 33RD ST,BOULDER,CO 80301, USA.							BEKTESH S, 1988, GENE DEV, V2, P1277, DOI 10.1101/gad.2.10.1277; BEKTESH SL, 1988, NUCLEIC ACIDS RES, V16, P5692, DOI 10.1093/nar/16.12.5692; BILLINGS PB, 1984, J BIOL CHEM, V259, P2850; BRINGMANN P, 1986, EMBO J, V5, P3509, DOI 10.1002/j.1460-2075.1986.tb04676.x; BRODY E, 1985, SCIENCE, V228, P963, DOI 10.1126/science.3890181; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CAMPBELL DA, 1984, NATURE, V311, P350, DOI 10.1038/311350a0; EPSTEIN P, 1980, J BIOL CHEM, V255, P8901; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; GRABOWSKI PJ, 1985, CELL, V42, P345, DOI 10.1016/S0092-8674(85)80130-6; GREEN MR, 1983, CELL, V32, P681, DOI 10.1016/0092-8674(83)90054-5; HAMM J, 1987, EMBO J, V6, P3479, DOI 10.1002/j.1460-2075.1987.tb02672.x; HINTERBERGER M, 1983, J BIOL CHEM, V258, P2604; KINLAW CS, 1983, J BIOL CHEM, V258, P7181; KOOTER JM, 1984, EMBO J, V3, P2387, DOI 10.1002/j.1460-2075.1984.tb02144.x; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; LUHRMANN R, 1982, NUCLEIC ACIDS RES, V10, P7103, DOI 10.1093/nar/10.22.7103; MATTAJ IW, 1985, CELL, V40, P111, DOI 10.1016/0092-8674(85)90314-9; MILHAUSEN M, 1984, CELL, V38, P721, DOI 10.1016/0092-8674(84)90267-8; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; NELSON DW, 1985, GENE, V38, P245, DOI 10.1016/0378-1119(85)90224-0; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; REDDY R, 1974, J BIOL CHEM, V249, P6486; RIEDEL N, 1987, SCIENCE, V235, P328, DOI 10.1126/science.2948278; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; THOMAS JD, 1988, CELL, V54, P533, DOI 10.1016/0092-8674(88)90075-X; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	28	87	87	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1988	335	6190					556	559						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q3412	3419533				2022-12-28	WOS:A1988Q341200058
J	KEATES, RAB; HALLETT, FR				KEATES, RAB; HALLETT, FR			DYNAMIC INSTABILITY OF SHEARED MICROTUBULES OBSERVED BY QUASI-ELASTIC LIGHT-SCATTERING	SCIENCE			English	Article									UNIV GUELPH,DEPT PHYS,BIOPHYS INTERDEPT GRP,GUELPH N1G 2W1,ONTARIO,CANADA	University of Guelph	KEATES, RAB (corresponding author), UNIV GUELPH,DEPT CHEM & BIOCHEM,BIOPHYS INTERDEPT GRP,GUELPH N1G 2W1,ONTARIO,CANADA.							CAPLOW M, 1986, J BIOL CHEM, V261, P6233; CARLIER MF, 1984, P NATL ACAD SCI-BIOL, V81, P771, DOI 10.1073/pnas.81.3.771; CHEN YD, 1985, P NATL ACAD SCI USA, V82, P1131, DOI 10.1073/pnas.82.4.1131; HALLETT FR, 1985, BIOPOLYMERS, V24, P947, DOI 10.1002/bip.360240604; HALLETT FR, 1985, BIOPOLYMERS, V24, P2403, DOI 10.1002/bip.360241216; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; KEATES RAB, 1984, CAN J BIOCHEM CELL B, V62, P803, DOI 10.1139/o84-102; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KRISTOFFERSON D, 1986, J CELL BIOL, V102, P1007, DOI 10.1083/jcb.102.3.1007; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MORRISON ID, 1985, LANGMUIR, V1, P496, DOI 10.1021/la00064a016; ROTHWELL SW, 1987, J CELL BIOL, V105, P863, DOI 10.1083/jcb.105.2.863; SAMMAK PJ, 1987, J CELL BIOL, V104, P395, DOI 10.1083/jcb.104.3.395; SCHULZE E, 1987, J CELL BIOL, V104, P277, DOI 10.1083/jcb.104.2.277; WALKER R A, 1987, Journal of Cell Biology, V105, p29A	16	21	21	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 23	1988	241	4873					1642	1645		10.1126/science.3420415	http://dx.doi.org/10.1126/science.3420415			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q1372	3420415				2022-12-28	WOS:A1988Q137200031
J	BALABAN, E; TEILLET, MA; LEDOUARIN, N				BALABAN, E; TEILLET, MA; LEDOUARIN, N			APPLICATION OF THE QUAIL-CHICK CHIMERA SYSTEM TO THE STUDY OF BRAIN-DEVELOPMENT AND BEHAVIOR	SCIENCE			English	Article									COLL FRANCE,INST EMBRYOL CELLULAIRE & MOLEC,F-94736 NOGENT SUR MARNE,FRANCE; ROCKEFELLER UNIV,FIELD RES CTR,MILLBROOK,NY 12545	UDICE-French Research Universities; PSL Research University Paris; College de France; Rockefeller University	BALABAN, E (corresponding author), CNRS,INST EMBRYOL CELLULAIRE & MOLEC,49BIS AVE BELLE GABRIELLE,F-94736 NOGENT SUR MARNE,FRANCE.		Balaban, Evan/AAV-2353-2020	Balaban, Evan/0000-0002-0391-3433	NIMH NIH HHS [5T32 MH15125-10] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH015125] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Andrew R. J., 1969, P97; BALABAN E, UNPUB; BROWN JL, 1971, BEHAVIOUR, V39, P91, DOI 10.1163/156853971X00203; CARIOU M-L, 1969, Bulletin Biologique de la France et de la Belgique, V103, P323; CARIOU ML, 1971, THESIS U RENNES; COULY GF, 1985, DEV BIOL, V110, P422, DOI 10.1016/0012-1606(85)90101-0; COULY GF, 1987, DEV BIOL, V120, P198, DOI 10.1016/0012-1606(87)90118-7; GUYOMARCH JC, 1965, B SOC SCI BRETAGNE, V60, P81; Hamilton JB, 1938, ENDOCRINOLOGY, V23, P53, DOI 10.1210/endo-23-1-53; KINUTANI M, 1985, DEV BIOL, V111, P243, DOI 10.1016/0012-1606(85)90449-X; KINUTANI M, 1986, CELL, V45, P307, DOI 10.1016/0092-8674(86)90395-8; Konishi M., 1963, Z TIERPSYCHOL, V20, P349, DOI DOI 10.1111/J.1439-0310.1963.TB01156.X; Le Douarin N., 1984, CHIMERAS DEV BIOL; Le Douarin N.M., 1982, NEURAL CREST; LEDOUARIN NM, 1986, TRENDS NEUROSCI, V9, P175, DOI 10.1016/0166-2236(86)90055-X; MARLER P.M. KREITH, 1962, ANIMAL BEHAVIOUR, V10, P48, DOI 10.1016/0003-3472(62)90130-6; NOTTEBOHM F, 1976, J COMP NEUROL, V165, P457, DOI 10.1002/cne.901650405; OHKI H, 1987, SCIENCE, V237, P1032, DOI 10.1126/science.3616623; Phillips R.E., 1975, P243; RAKIC P, 1977, J COMP NEUROL, V176, P23, DOI 10.1002/cne.901760103; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAKIC P, 1984, J COMP NEUROL, V223, P1; SCHEICH H, 1983, ADV VERTEBRATE NEURO, P731; Seller T.J., 1983, P93; SELLER TJ, 1981, TRENDS NEUROSCI, V4, P301, DOI 10.1016/0166-2236(81)90094-1; SELLER TJ, 1983, BEHAV BRAIN RES, V9, P305, DOI 10.1016/0166-4328(83)90135-3; SIEGEL P. B., 1965, BEHAVIOUR, V24, P229, DOI 10.1163/156853965X00039	27	106	107	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 9	1988	241	4871					1339	1342		10.1126/science.3413496	http://dx.doi.org/10.1126/science.3413496			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	P9812	3413496				2022-12-28	WOS:A1988P981200027
J	GODFREY, C; MAYNARD, A				GODFREY, C; MAYNARD, A			ECONOMIC-ASPECTS OF TOBACCO USE AND TAXATION POLICY	BRITISH MEDICAL JOURNAL			English	Article									UNIV YORK,ADDICT RES CTR,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK								[Anonymous], 1962, SMOKING HLTH; Atkinson A. B., 1973, Manchester School of Economic and Social Studies, P265, DOI 10.1111/j.1467-9957.1973.tb00081.x; DOLL R, 1964, BRIT MED J, V1, P1399, DOI 10.1136/bmj.1.5395.1399; GODFREY C, 1985, Q J SOC AFF, V1, P329; LEU RE, 1984, J HEALTH ECON, V3, P101, DOI 10.1016/0167-6296(84)90001-8; LEWIT EM, 1981, J LAW ECON, V24, P545, DOI 10.1086/466999; MACKAY DI, 1982, UK TOBACCO IND ITS E; MCGUINNESS T, 1975, EUR ECON REV, V6, P311, DOI 10.1016/0014-2921(75)90015-X; PETO J, 1974, BRIT J PREV SOC MED, V28, P241; RADFAR M, 1985, EUROPEAN EC REV, V85, P225; RUSSELL MAH, 1973, BRIT J PREV SOC MED, V27, P1; SUMNER M. T., 1971, Manchr Sch. Econ. Social Stud., Manchester, V1, P23, DOI 10.1111/j.1467-9957.1971.tb00365.x; TOWNSEND JL, 1987, APPL ECON, V19, P355, DOI 10.1080/00036848700000007; WITT SF, 1981, SCOT J POLIT ECON, V28, P86, DOI 10.1111/j.1467-9485.1981.tb00076.x; WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P329, DOI 10.1001/jama.1950.02910390001001; 1983, HLTH SMOKING; 1987, EC TRENDS, V405, P101; 1979, RELATIONSHIP TOTAL C; [No title captured]; 1980, EC TRENDS        MAR, P97	20	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1988	297	6644					339	343		10.1136/bmj.297.6644.339	http://dx.doi.org/10.1136/bmj.297.6644.339			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	P4527	3416168	Green Published, Bronze			2022-12-28	WOS:A1988P452700027
J	HILL, D; WHITE, V; JOLLEY, D; MAPPERSON, K				HILL, D; WHITE, V; JOLLEY, D; MAPPERSON, K			SELF EXAMINATION OF THE BREAST - IS IT BENEFICIAL - META-ANALYSIS OF STUDIES INVESTIGATING BREAST SELF EXAMINATION AND EXTENT OF DISEASE IN PATIENTS WITH BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article											HILL, D (corresponding author), ANTICANC COUNCIL VICTORIA,CTR BEHAV RES CANC,CARLTON,VIC 3053,AUSTRALIA.			White, Victoria/0000-0001-6619-8484				BRADLEY GW, 1978, J PERS SOC PSYCHOL, V36, P56, DOI 10.1037/0022-3514.36.1.56; BREMOND A, 1982, SEMAINE HOSPITAUX PA, V58, P1317; Bullough B, 1980, Nurse Pract, V5, P31; DOWLE CS, 1987, BRIT J SURG, V74, P217, DOI 10.1002/bjs.1800740323; FELDMAN JG, 1981, CANCER, V47, P2740, DOI 10.1002/1097-0142(19810601)47:11<2740::AID-CNCR2820471133>3.0.CO;2-4; Fleiss JL, 1981, STAT METHODS RATES P; FOSTER RS, 1984, CANCER, V53, P999, DOI 10.1002/1097-0142(19840215)53:4<999::AID-CNCR2820530429>3.0.CO;2-N; FOSTER RS, 1978, NEW ENGL J MED, V299, P265, DOI 10.1056/NEJM197808102990601; GOULDMARTIN K, 1982, PREV MED, V11, P429, DOI 10.1016/0091-7435(82)90046-9; GREENWALD P, 1978, NEW ENGL J MED, V299, P271, DOI 10.1056/NEJM197808102990602; HARRIS JR, 1985, CANCER PRINCIPLES PR, V2, P1119; HISLOP TG, 1984, CAN MED ASSOC J, V131, P1349; HOLLEB AI, 1981, ISRAEL J MED SCI, V17, P839; HOWE HL, 1983, CANCER DETECT PREV, V6, P473; HUGULEY CM, 1981, CANCER, V47, P989, DOI 10.1002/1097-0142(19810301)47:5<989::AID-CNCR2820470530>3.0.CO;2-V; LOUIS TA, 1985, ANNU REV PUBL HEALTH, V6, P1; MOORE FD, 1978, NEW ENGL J MED, V299, P304, DOI 10.1056/NEJM197808102990610; OMALLEY MS, 1987, JAMA-J AM MED ASSOC, V257, P2197; OWEN WL, 1985, SOUTHERN MED J, V78, P1170, DOI 10.1097/00007611-198510000-00007; PAYNE CD, 1985, GLIM SYSTEM MANUAL R; PHILIP J, 1984, BRIT J CANCER, V50, P7, DOI 10.1038/bjc.1984.133; PHILIP J, 1986, CANCER, V58, P973, DOI 10.1002/1097-0142(19860815)58:4<973::AID-CNCR2820580429>3.0.CO;2-5; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; SCHWARTZ M, 1978, CANCER, V41, P1550; SEMIGLAZOV VF, 1987, B WORLD HEALTH ORGAN, V65, P391; SENIE RT, 1981, AM J PUBLIC HEALTH, V71, P583, DOI 10.2105/AJPH.71.6.583; SMITH EM, 1980, PREV MED, V9, P409, DOI 10.1016/0091-7435(80)90235-2; SMITH EM, 1985, CANCER, V55, P432, DOI 10.1002/1097-0142(19850115)55:2<432::AID-CNCR2820550223>3.0.CO;2-9; STRAX P, 1979, CANCER B, V31, P142; TAMBURINI M, 1981, TUMORI J, V67, P219; TURNER J, 1984, LANCET, V2, P337; WEISS NS, 1983, AM J EPIDEMIOL, V118, P457	32	97	98	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1988	297	6643					271	275		10.1136/bmj.297.6643.271	http://dx.doi.org/10.1136/bmj.297.6643.271			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P4266	3416148	Green Published			2022-12-28	WOS:A1988P426600023
J	RAO, JK; WEINBERGER, M; ODDONE, EZ; ALLEN, NB; LANDSMAN, P; FEUSSNER, JR				RAO, JK; WEINBERGER, M; ODDONE, EZ; ALLEN, NB; LANDSMAN, P; FEUSSNER, JR			THE ROLE OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (C-ANCA) TESTING IN THE DIAGNOSIS OF WEGENER GRANULOMATOSIS - A LITERATURE-REVIEW AND METAANALYSIS	ANNALS OF INTERNAL MEDICINE			English	Review						WEGENERS GRANULOMATOSIS; AUTOANTIBODIES; BIOLOGICAL MARKERS; VASCULITIS; GLOMERULONEPHRITIS	NECROTIZING-CRESCENTIC GLOMERULONEPHRITIS; AUTOANTIBODY-ASSOCIATED DISEASES; SYSTEMIC VASCULITIS; ANTICYTOPLASMIC AUTOANTIBODIES; CLASSIFICATION; NEUTROPHILS; ANTIGEN; MYELOPEROXIDASE; POLYARTERITIS; PERSPECTIVE	Purpose: To summarize the literature on the clinical utility of antineutrophil cytoplasmic antibody (c-ANCA) as a diagnostic marker for Wegener granulomatosis. Data Sources: A structured literature search was done using MEDLINE; this search, combined with a manual search, yielded 747 articles for potential inclusion. These articles passed through a 4-stage review. Studies were included if they had a specified reference standard and a systematic method of patient selection and if a 2 x 2 contingency table could be constructed from their results. Fifteen articles met these criteria. Data Extraction: 3 physicians reviewed all selected articles. Detailed data abstraction was done, and the quality of the study methods was assessed. Items abstracted included the method of patient selection, the study design, the reference standard, the c-ANCA testing technique, disease activity, and the test results. Disagreements among reviewers were resolved by consensus. Contingency tables were used to calculate the operating characteristics for Wegener granulomatosis overall and for active and inactive Wegener granulomatosis. Results: The sensitivities of c-ANCA testing for overall Wegener granulomatosis ranged from 34% to 92%, and the specificities ranged from 88% to 100%. The pooled sensitivity was 66% (95% CI, 57% to 74%), and the pooled specificity was 98% (CI, 96% to 99.5%). Four articles provided data on disease activity. For active disease, the pooled sensitivity was 91% (CI, 87% to 95%), and the pooled specificity was 99% (CI, 97% to 99.9%). For inactive disease, the pooled sensitivity and specificity were 63% and 99.5%, respectively. Conclusions: Although c-ANCA test results may serve clinicians as adjunct evidence for the diagnosis of Wegener granulomatosis, these results must be viewed in the context of the patient's clinical picture and disease activity and the prevalence of Wegener granulomatosis in the clinical setting in which the patient is seen.	VET AFFAIRS MED CTR, HLTH SERV RES & DEV 152, DURHAM, NC 27705 USA; DUKE UNIV, MED CTR, DIV RHEUMATOL, DURHAM, NC 27710 USA; INDIANA UNIV, MED CTR, INDIANAPOLIS, IN USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; Indiana University System; Indiana University-Purdue University Indianapolis	RAO, JK (corresponding author), RICHARD L ROUDEBUSH VET AFFAIRS MED CTR, HLTH SERV RES & DEV 11H, 1481 W 10TH ST, INDIANAPOLIS, IN 46202 USA.							Alon U, 1990, Pediatr Nephrol, V4, P299; ANDRASSY K, 1989, CLIN NEPHROL, V32, P159; ANTONOVYCH TT, 1989, MODERN PATHOL, V2, P349; BINDI P, 1993, Q J MED, V86, P55; BLEIL L, 1991, J RHEUMATOL, V18, P1199; BOSCH X, 1992, AM J KIDNEY DIS, V20, P231, DOI 10.1016/S0272-6386(12)80695-0; CHRISTENSON VD, 1991, J RHEUMATOL, V18, P575; DAVENPORT A, 1992, CLIN NEPHROL, V37, P124; DAVIES DJ, 1982, BMJ-BRIT MED J, V285, P606, DOI 10.1136/bmj.285.6342.606; DECLERCK LS, 1989, CLIN RHEUMATOL, V8, P512, DOI 10.1007/BF02032106; DEREMEE RA, 1976, MAYO CLIN PROC, V51, P777; DEVANEY KO, 1990, AM J SURG PATHOL, V14, P555, DOI 10.1097/00000478-199006000-00006; Eddy DM., 1992, META ANAL CONFIDENCE; ESNAULT VLM, 1990, J CLIN LAB IMMUNOL, V32, P153; FALK RJ, 1988, NEW ENGL J MED, V318, P1651, DOI 10.1056/NEJM198806233182504; FAUCI AS, 1973, MEDICINE, V52, P535, DOI 10.1097/00005792-197311000-00002; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; FEIGENBAUM PA, 1982, J RHEUMATOL, V9, P408; GROSS WL, 1991, AM J KIDNEY DIS, V18, P175, DOI 10.1016/S0272-6386(12)80876-6; GROSS WL, 1995, APMIS, V103, P81, DOI 10.1111/j.1699-0463.1995.tb01083.x; HASSELBLAD V, 1995, PSYCHOL BULL, V117, P167, DOI 10.1037/0033-2909.117.1.167; HAYNES BF, 1986, MED CLIN N AM, V70, P355, DOI 10.1016/S0025-7125(16)30958-0; IRWIG L, 1994, ANN INTERN MED, V120, P667, DOI 10.7326/0003-4819-120-8-199404150-00008; JENNETTE J C, 1992, Current Opinion in Rheumatology, V4, P9; JENNETTE JC, 1991, AM J KIDNEY DIS, V18, P184, DOI 10.1016/S0272-6386(12)80878-X; JENNETTE JC, 1991, AM J KIDNEY DIS, V18, P164, DOI 10.1016/S0272-6386(12)80874-2; KERR GS, 1993, ARTHRITIS RHEUM, V36, P365, DOI 10.1002/art.1780360312; KODERISCH J, 1990, LANCET, V335, P1227, DOI 10.1016/0140-6736(90)92755-7; LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101, DOI 10.1002/art.1780330807; LUDEMANN G, 1987, CLIN EXP IMMUNOL, V69, P350; MACISAAC AI, 1990, CLIN NEPHROL, V34, P5; MAINS B, 1989, J LARYNGOL OTOL, V103, P524, DOI 10.1017/S0022215100156774; MANDELL BF, 1994, RHEUM DIS CLIN N AM, V20, P409; MUSTONEN J, 1990, AM J NEPHROL, V10, P482, DOI 10.1159/000168173; NILES JL, 1989, BLOOD, V74, P1888; NOLLE B, 1989, ANN INTERN MED, V111, P28, DOI 10.7326/0003-4819-111-1-28; PINCUS T, 1993, PRIMARY CARE, V20, P795; SACKETT DL, 1989, CHEST, V95, pS2, DOI 10.1378/chest.95.2.2S; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P51; Savage C O, 1987, Trans Assoc Am Physicians, V100, P276; SAVAGE COS, 1987, LANCET, V1, P1389; SAXENA R, 1991, NEPHROL DIAL TRANSPL, V6, P389, DOI 10.1093/ndt/6.6.389; SPECKS U, 1989, MAYO CLIN PROC, V64, P28, DOI 10.1016/S0025-6196(12)65300-2; TERVAERT JWC, 1989, ARCH INTERN MED, V149, P2461, DOI 10.1001/archinte.149.11.2461; TERVAERT JWC, 1990, KIDNEY INT, V37, P799, DOI 10.1038/ki.1990.48; ULMER M, 1992, CLIN NEPHROL, V37, P161; VANDERWOUDE FJ, 1985, LANCET, V1, P425; VANDERWOUDE FJ, 1985, LANCET, V2, P48; VELOSA JA, 1993, MAYO CLIN PROC, V68, P561, DOI 10.1016/S0025-6196(12)60370-X; VENNING MC, 1987, LANCET, V2, P850; VENNING MC, 1990, Q J MED, V77, P1287, DOI 10.1093/qjmed/77.3.1287; WIESLANDER J, 1991, AM J KIDNEY DIS, V18, P154, DOI 10.1016/S0272-6386(12)80872-9; 1989, APMIS S1, V6, P1	53	283	301	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1995	123	12					925	+		10.7326/0003-4819-123-12-199512150-00005	http://dx.doi.org/10.7326/0003-4819-123-12-199512150-00005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK120	7486487				2022-12-28	WOS:A1995TK12000005
J	VANPEENEN, HJ				VANPEENEN, HJ			MARRYING MEDICINE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	DEC 15	1995	123	12					957	959		10.7326/0003-4819-123-12-199512150-00013	http://dx.doi.org/10.7326/0003-4819-123-12-199512150-00013			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK120	7486495				2022-12-28	WOS:A1995TK12000013
J	KERRIDGE, I; LOWE, M; MITCHELL, K				KERRIDGE, I; LOWE, M; MITCHELL, K			COMPETENT PATIENTS, INCOMPETENT DECISIONS	ANNALS OF INTERNAL MEDICINE			English	Note							STAGE RENAL-DISEASE; CARDIOPULMONARY RESUSCITATION; DIALYSIS PATIENTS; HEMODIALYSIS; FUTILITY	We describe the epidemiologic aspects of dialysis withdrawal, the role of patient autonomy and of medical beneficence in the decision to discontinue dialysis, and the conditions under which limits may be placed on patient autonomy. A case is presented that provides insight into the issues involved in making such decisions and that should provoke further discussion on the role of ''medical guidelines'' for dialysis refusal and withdrawal.	UNIV NEWCASTLE, NEWCASTLE, NSW, AUSTRALIA; JOHN HUNTER HOSP, NEWCASTLE, NSW, AUSTRALIA	University of Newcastle; John Hunter Hospital			Kerridge, Ian H/A-8355-2011	Kerridge, Ian/0000-0001-7445-4660				Beauchamp TL, 2009, PRINCIPLES BIOMEDICA; CASSELL EJ, 1985, HEALERS ART, P38; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; HOLLEY JL, 1989, AM J NEPHROL, V9, P245, DOI 10.1159/000167974; Katz J., 1984, SILENT WORLD DOCTOR; KILNER JF, 1988, AM J PUBLIC HEALTH, V78, P144, DOI 10.2105/AJPH.78.2.144; KILNER JF, 1990, AM J KIDNEY DIS, V15, P218, DOI 10.1016/S0272-6386(12)80766-9; LANTOS JD, 1989, AM J MED, V87, P81; LEVINSKY NG, 1991, NEW ENGL J MED, V324, P1143, DOI 10.1056/NEJM199104183241628; LOWANCE DC, 1993, AM J KIDNEY DIS, V21, P679, DOI 10.1016/S0272-6386(12)80045-X; LOWANCE DC, 1988, KIDNEY INT, V34, P124, DOI 10.1038/ki.1988.155; LUNDIN AP, 1980, JAMA-J AM MED ASSOC, V244, P38, DOI 10.1001/jama.244.1.38; MAILLOUX LU, 1991, AM J KIDNEY DIS, V18, P326, DOI 10.1016/S0272-6386(12)80091-6; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; PORT FK, 1989, AM J KIDNEY DIS, V14, P119, DOI 10.1016/S0272-6386(89)80187-8; PORT FK, 1989, AM J NEPHROL, V9, P145, DOI 10.1159/000167954; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; 1982, MAKING HLTH CARE DEC, P57	20	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1995	123	11					878	881		10.7326/0003-4819-123-11-199512010-00011	http://dx.doi.org/10.7326/0003-4819-123-11-199512010-00011			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG209	7486472				2022-12-28	WOS:A1995TG20900011
J	SAMAD, AH; CAI, WW; HU, XH; IRVIN, B; JING, JP; REED, J; MENG, X; HUANG, J; HUFF, E; PORTER, B; SHENKAR, A; ANANTHARAMAN, T; MISHRA, B; CLARKE, V; DIMALANTA, E; EDINGTON, J; HIORT, C; RABBAH, R; SKIADA, J; SCHWARTZ, DC				SAMAD, AH; CAI, WW; HU, XH; IRVIN, B; JING, JP; REED, J; MENG, X; HUANG, J; HUFF, E; PORTER, B; SHENKAR, A; ANANTHARAMAN, T; MISHRA, B; CLARKE, V; DIMALANTA, E; EDINGTON, J; HIORT, C; RABBAH, R; SKIADA, J; SCHWARTZ, DC			MAPPING THE GENOME ONE MOLECULE AT A TIME - OPTICAL MAPPING	NATURE			English	Article							PHYSICAL MAP		NYU,DEPT CHEM,NEW YORK,NY 10003	New York University	SAMAD, AH (corresponding author), CORNELL UNIV,COLL MED,DEPT PATHOL,NEW YORK,NY 10021, USA.							CAI WW, 1995, P NATL ACAD SCI USA, V92, P5164, DOI 10.1073/pnas.92.11.5164; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7826; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; MENG X, 1995, NAT GENET, V9, P432, DOI 10.1038/ng0495-432; OLSON M, 1986, P NATL ACAD SCI USA, V83, P7821; SCHWARTZ DC, 1993, SCIENCE, V262, P110, DOI 10.1126/science.8211116; WANG YK, 1995, P NATL ACAD SCI USA, V92, P165, DOI 10.1073/pnas.92.1.165	8	22	26	2	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					516	517		10.1038/378516a0	http://dx.doi.org/10.1038/378516a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477412				2022-12-28	WOS:A1995TH05400078
J	ONATE, SA; TSAI, SY; TSAI, MJ; OMALLEY, BW				ONATE, SA; TSAI, SY; TSAI, MJ; OMALLEY, BW			SEQUENCE AND CHARACTERIZATION OF A COACTIVATOR FOR THE STEROID-HORMONE RECEPTOR SUPERFAMILY	SCIENCE			English	Article							HUMAN PROGESTERONE-RECEPTOR; THYROID-HORMONE; RETINOIC ACID; RETINOBLASTOMA PROTEIN; RESPONSE ELEMENTS; ESTROGEN-RECEPTOR; ACTIVATION; TRANSCRIPTION; TRANSACTIVATION; ANTIHORMONE	A yeast two-hybrid system was used to identify a protein that interacts with and enhances the human progesterone receptor (hPR) transcriptional activity without altering the basal activity of the promoter. Because the protein stimulated transactivation of all the steroid receptors tested, it has been termed steroid receptor coactivator-1 (SRC-1). Coexpression of SRC-1 reversed the ability of the estrogen receptor to squelch activation by hPR. Also, the amino terminal truncated form of SRC-1 acted as a dominant-negative repressor. Together, these results indicate that SRC-1 encodes a coactivator that is required for full transcriptional activity of the steroid receptor superfamily.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Baylor College of Medicine					NICHD NIH HHS [HD08188] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLAN GF, 1992, J BIOL CHEM, V267, P19513; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Conneely OM, 1989, GENE REGULATION STER, V4, P220; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELASHRY D, 1989, MOL ENDOCRINOL, V3, P1545, DOI 10.1210/mend-3-10-1545; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LENG XH, 1994, J BIOL CHEM, V269, P31436; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; ONATE SA, UNPUB; PEREIRA F, 1991, BIOCHEM BIOPH RES CO, V175, P831, DOI 10.1016/0006-291X(91)91640-X; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P6120, DOI 10.1073/pnas.90.13.6120; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4	30	1943	1992	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 24	1995	270	5240					1354	1357						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF899	7481822				2022-12-28	WOS:A1995TF89900037
J	EDEKI, TI; HE, HB; WOOD, AJJ				EDEKI, TI; HE, HB; WOOD, AJJ			PHARMACOGENETIC EXPLANATION FOR EXCESSIVE BETA-BLOCKADE FOLLOWING TIMOLOL EYE DROPS - POTENTIAL FOR ORAL-OPHTHALMIC DRUG-INTERACTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPARTEINE OXIDATION; HEALTHY-VOLUNTEERS; OCULAR TIMOLOL; QUINIDINE; DEBRISOQUINE; POOR; METABOLIZERS; BLOCKERS; EXERCISE; 2-HYDROXYLATION	Objective.-To determine whether the effects of topically administered timolol in an individual would be dependent on the presence or absence in that individual of the P-450 enzyme CYP2D6 and whether the effects of topically administered timolol would be increased and its metabolism decreased by the oral administration of quinidine, a known inhibitor of CYP2D6. Design,-Single-blind randomized crossover comparison of topical timolol, placebo, and the effects of inhibition of timolol metabolism by oral quinidine. Setting.-Clinical research center of an academic medical center. Participants.-Eight male extensive metabolizers (EMs) and five male poor metabolizers (PMs) of debrisoquin. Intervention.-Two drops of 0.5% timolol or artificial tears were administered into each nostril in random order, and placebo or 50 mg of quinidine was administered orally to the EMs in random order, followed 30 minutes later by either the timolol or placebo drops. Main Outcome Measurement.-Plasma timolol concentrations were measured by high-pressure liquid chromatography, while the extent of P-blockade was determined by the suppression of exercise-induced rise in heart rate. Results.-The exercise heart rate was reduced following timolol eye drops compared with placebo in both EMs (P<.001) and PMs (P<.001) with significantly greater heart rate reduction (P=.01) and higher plasma timolol concentration in PMs compared with EMs (P=.03). Administration of quinidine with timolol eye drops to EMs resulted in a further significant reduction in heart rate (P=.02) and increase in plasma timolol concentration (P=.04). Conclusions.-An individual's debrisoquin phenotype is an important determinant of beta-blockade following timolol eye drops, and metabolism of timolol is inhibited and beta-blockade increased by coadministration of oral quinidine. Clinicians should be aware of the potential for drug interactions that occur when orally administered drugs inhibit the metabolism of a topically administered drug.	VANDERBILT UNIV,SCH MED,DIV CLIN PHARMACOL,NASHVILLE,TN 37232; MEHARRY MED COLL,DEPT PHARMACOL,CLIN PHARMACOL PROGRAM,NASHVILLE,TN	Vanderbilt University; Meharry Medical College					NIGMS NIH HHS [GM 31304, GM 46622] Funding Source: Medline; FDA HHS [FDT 000888] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046622, P01GM031304] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FDA HHS; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFFRIME MB, 1980, CLIN PHARMACOL THER, V27, P471, DOI 10.1038/clpt.1980.66; ALSEREITI MR, 1990, INT J CLIN PHARM RES, V10, P339; ALVAN G, 1980, CLIN PHARMACOKINET, V5, P95, DOI 10.2165/00003088-198005010-00004; ATKINS JM, 1985, AM J OPHTHALMOL, V99, P173, DOI 10.1016/0002-9394(85)90227-2; BACON PJ, 1989, BRIT J CLIN PHARMACO, V27, P1; BAUER K, 1991, CLIN PHARMACOL THER, V49, P658, DOI 10.1038/clpt.1991.83; BROSEN K, 1990, BRIT J CLIN PHARMACO, V29, P248, DOI 10.1111/j.1365-2125.1990.tb03628.x; BROSEN K, 1989, EUR J CLIN PHARMACOL, V37, P155, DOI 10.1007/BF00558224; BURGGRAF GW, 1980, CAN J OPHTHALMOL, V15, P159; Collignon P, 1989, Surv Ophthalmol, V33 Suppl, P455, DOI 10.1016/0039-6257(89)90087-8; DINAI Y, 1985, ANN INTERN MED, V103, P890, DOI 10.7326/0003-4819-103-6-890; DOYLE WJ, 1984, ARCH OPHTHALMOL-CHIC, V102, P1517; EICHELBAUM M, 1990, PHARMACOL THERAPEUT, V46, P377, DOI 10.1016/0163-7258(90)90025-W; FRAUNFELDER FT, 1986, ARCH INTERN MED, V146, P1073, DOI 10.1001/archinte.146.6.1073; FRAUNFELDER FT, 1987, J OCUL PHARMACOL, V3, P177, DOI 10.1089/jop.1987.3.177; FUNCKBRENTANO C, 1989, BRIT J CLIN PHARMACO, V27, P435, DOI 10.1111/j.1365-2125.1989.tb05391.x; HE HB, 1994, J CHROMATOGR B, V661, P351, DOI 10.1016/0378-4347(94)00357-2; He N., 1995, Journal of Investigative Medicine, V43, p296A; HUUPPONEN R, 1991, J OCUL PHARMACOL, V7, P183, DOI 10.1089/jop.1991.7.183; LEWIS RV, 1985, BRIT J CLIN PHARMACO, V19, P329, DOI 10.1111/j.1365-2125.1985.tb02651.x; NIELSEN MD, 1990, BRIT J CLIN PHARMACO, V29, P299, DOI 10.1111/j.1365-2125.1990.tb03639.x; PLAZONNET B, 1987, OPHTHALMIC DRUG DELI, V11, P118; RELLING MV, 1991, CLIN PHARMACOL THER, V50, P308, DOI 10.1038/clpt.1991.141; SPEIRS CJ, 1986, BRIT J CLIN PHARMACO, V22, P739, DOI 10.1111/j.1365-2125.1986.tb02969.x; STEINER E, 1988, CLIN PHARMACOL THER, V43, P577, DOI 10.1038/clpt.1988.76; STEINER E, 1985, CLIN PHARMACOL THER, V38, P394, DOI 10.1038/clpt.1985.193; ZHOU HH, 1990, CLIN PHARMACOL THER, V47, P686, DOI 10.1038/clpt.1990.94	27	61	62	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	1995	274	20					1611	1613		10.1001/jama.274.20.1611	http://dx.doi.org/10.1001/jama.274.20.1611			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE738	7474246				2022-12-28	WOS:A1995TE73800026
J	GOOD, MF				GOOD, MF			WHAT CAN A WORM TEACH US ABOUT AUTOIMMUNITY	LANCET			English	Editorial Material							T-CELLS; TOLERANCE; EPITOPES				GOOD, MF (corresponding author), QUEENSLAND INST MED RES,BRISBANE,QLD 4006,AUSTRALIA.							BRAUN G, 1991, J EXP MED, V174, P169, DOI 10.1084/jem.174.1.169; BRONZE MS, 1988, J EXP MED, V167, P1849, DOI 10.1084/jem.167.6.1849; GALLIN MY, 1995, J EXP MED, V182, P41, DOI 10.1084/jem.182.1.41; GROSS WL, 1993, CLIN EXP IMMUNOL, V91, P1; LANZAVECCHIA A, 1995, J EXP MED, V181, P1945, DOI 10.1084/jem.181.6.1945; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; POMBO D, 1988, J IMMUNOL, V140, P3594; PRUKSAKORN S, 1994, INT IMMUNOL, V6, P1235, DOI 10.1093/intimm/6.8.1235; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; TAYLORROBINSON AW, 1994, EUR J IMMUNOL, V24, P980, DOI 10.1002/eji.1830240430	12	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 18	1995	346	8986					1311	1312		10.1016/S0140-6736(95)92337-3	http://dx.doi.org/10.1016/S0140-6736(95)92337-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE916	7475765				2022-12-28	WOS:A1995TE91600003
J	DYBOWSKI, R; GANT, V				DYBOWSKI, R; GANT, V			ARTIFICIAL NEURAL NETWORKS IN PATHOLOGY AND MEDICAL LABORATORIES	LANCET			English	Article							CLASSIFICATION; DIAGNOSIS; CARCINOMA; SMEARS		UNITED MED & DENT SCH,DEPT MICROBIOL,INFECT & IMMUNIT LAB,LONDON SE1 7EH,ENGLAND	University of London; King's College London								ASTION ML, 1992, CLIN CHEM, V38, P34; BECKER RL, 1994, CANCER LETT, V77, P111, DOI 10.1016/0304-3835(94)90093-0; BLEICH HL, 1985, NEW ENGL J MED, V312, P756, DOI 10.1056/NEJM198503213121205; Boddy Lynne, 1993, Binary Computing in Microbiology, V5, P17; BOON ME, 1993, DIAGN CYTOPATHOL, V9, P411, DOI 10.1002/dc.2840090408; BOON ME, 1995, CELL VISION, V2, P23; BOSCH MMC, 1992, ACTA CYTOL, V36, P711; Breiman L, 1984, CLASSIFICATION REGIS; CHUN J, 1993, FEMS MICROBIOL LETT, V114, P115, DOI 10.1016/0378-1097(93)90151-Q; DAWSON AE, 1991, AM J CLIN PATHOL, V95, pS29; DOWNS J, 1995, 5TH P C ART INT MED, P239; ERLER BS, 1994, LAB INVEST, V71, P446; FENG C., 1994, MACHINE LEARNING NEU, P50; FREEMAN R, 1994, J MED MICROBIOL, V40, P170, DOI 10.1099/00222615-40-3-170; FURLONG JW, 1991, AM J CLIN PATHOL, V96, P134, DOI 10.1093/ajcp/96.1.134; GOODACRE R, 1994, J APPL BACTERIOL, V76, P124, DOI 10.1111/j.1365-2672.1994.tb01607.x; GOODACRE R, IN PRESS INT J MED M; HAWKES N, 1994, TIMES           0825; Jackson P., 1990, INTRO EXPERT SYSTEMS; KOSS LG, 1989, JAMA-J AM MED ASSOC, V261, P737, DOI 10.1001/jama.261.5.737; MANGO LJ, 1994, CANCER LETT, V77, P155, DOI 10.1016/0304-3835(94)90098-1; MEHDI B, 1994, ANAL CELL PATHOL, V7, P171; OLEARY TJ, 1992, MODERN PATHOL, V5, P402; REIBNEGGER G, 1993, EUR J CLIN CHEM CLIN, V31, P311; REIBNEGGER G, 1991, P NATL ACAD SCI USA, V88, P11426, DOI 10.1073/pnas.88.24.11426; Rosenthal Dorothy L., 1993, American Journal of Clinical Pathology, V100, P331; ROSZAK DB, 1987, MICROBIOL REV, V51, P363; SCHEWEIGER CR, 1993, CLIN CHEM, V39, P1966; SCHINDLER J, 1994, BINARY-COMPUT MICROB, V6, P191; Smith JW, 1990, MED INFORMATICS COMP, P273; WIED GL, 1970, AUTOMATED CYTOLOGY, P43; WILKINS MF, 1994, BINARY-COMPUT MICROB, V6, P64; WOLBERG WH, 1990, ANAL QUANT CYTOL, V12, P314	33	99	104	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 4	1995	346	8984					1203	1207		10.1016/S0140-6736(95)92904-5	http://dx.doi.org/10.1016/S0140-6736(95)92904-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC976	7475664	Bronze			2022-12-28	WOS:A1995TC97600014
J	KIECOLTGLASER, JK; MARUCHA, PT; MALARKEY, WB; MERCADO, AM; GLASER, R				KIECOLTGLASER, JK; MARUCHA, PT; MALARKEY, WB; MERCADO, AM; GLASER, R			SLOWING OF WOUND-HEALING BY PSYCHOLOGICAL STRESS	LANCET			English	Article							EXPRESSION; HEALTH	There is evidence that psychological stress adversely affects the immune system. We have investigated the effects of such stress, caused by caring for a relative with Alzheimer's disease, on wound healing. We studied 13 women caring for demented relatives (mean age 62 . 3 [SE 2 . 3] years) and 13 controls matched for age (60 . 4 [2 . 8] years) and family income. All subjects underwent a 3 . 5 mm punch biopsy wound. Healing was assessed by photography of the wound and the response to hydrogen peroxide (healing was defined as no foaming). Wound healing took significantly longer in caregivers than in controls (48 . 7 [2 . 9] vs 39 . 3 [3 . 0] days, p<0 . 05). Peripheral-blood leucocytes from caregivers produced significantly less interleukin-1 beta mRNA in response to lipopolysaccharide stimulation than did controls' cells. Stress-related defects in wound repair could have important clinical implications, for instance for recovery from surgery.	OHIO STATE UNIV,COLL DENT,DEPT PSYCHIAT,PERIODONTOL SECT,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL MED,DEPT MED,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL MED,DEPT MED MICROBIOL & IMMUNOL,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			Mercado, Ana/ABB-5559-2021; Kiecolt-Glaser, Janice K/A-3236-2009; Glaser, Ronald/E-3124-2011	Kiecolt-Glaser, Janice K/0000-0003-4900-9578; 	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH042096, R01MH050538] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR0034] Funding Source: Medline; NIMH NIH HHS [R37 MH42096, R01 MH50538] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADER R, 1995, LANCET, V345, P99, DOI 10.1016/S0140-6736(95)90066-7; BARBUL A, 1990, CLIN PLAST SURG, V17, P433; BURNS EA, 1990, GERIATRIC MED, P312; Cohen S., 1988, SOCIAL PSYCHOL HLTH; ESTERLING BA, 1994, HEALTH PSYCHOL, V13, P291, DOI 10.1037/0278-6133.13.4.291; GIASER R, 1994, HDB HUMAN STRESS IMM; GROVE GL, 1982, ARCH DERMATOL RES, V272, P381, DOI 10.1007/BF00509069; GRUBER RP, 1975, PLAST RECONSTR SURG, V55, P472, DOI 10.1097/00006534-197555040-00013; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1037/0003-066X.59.8.676; KIECOLTGLASER JK, 1991, PSYCHOSOM MED, V53, P345, DOI 10.1097/00006842-199107000-00001; LIGHT E, 1994, STRESS EFFECTS FAMIL; LOWRY SF, 1993, ARCH SURG-CHICAGO, V28, P1235; MARUCHA PT, 1990, J IMMUNOL, V145, P2932; MCCANN JJ, 1991, THESIS RUSH U COLLEG; NEMETH AJ, 1991, ARCH DERMATOL, V127, P1679, DOI 10.1001/archderm.127.11.1679; SHERIDAN JF, 1991, J NEUROIMMUNOL, V31, P245, DOI 10.1016/0165-5728(91)90046-A; STRIETER RM, 1990, J LEUKOCYTE BIOL, V47, P366, DOI 10.1002/jlb.47.4.366; THOMPSON R, 1990, PHYS WORLD, V3, P18, DOI 10.1088/2058-7058/3/12/16	18	655	666	0	58	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 4	1995	346	8984					1194	1196		10.1016/S0140-6736(95)92899-5	http://dx.doi.org/10.1016/S0140-6736(95)92899-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TC976	7475659	Bronze			2022-12-28	WOS:A1995TC97600009
J	MCCARTHY, K				MCCARTHY, K			MICROSATELLITES - HEROES AND VILLAINS	LANCET			English	Editorial Material							MUTATOR				MCCARTHY, K (corresponding author), ROYAL MARSDEN NHS TRUST,DEPT HISTOPATHOL,LONDON,ENGLAND.							BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; LAKHANI SR, 1995, J CLIN PATHOL, V48, P611, DOI 10.1136/jcp.48.7.611; LOEB LA, 1991, CANCER RES, V51, P3075; LOEB LA, 1994, CANCER RES, V54, P5059; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211; WESISSENBACH J, 1992, NATURE, V395, P794; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152	12	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 4	1995	346	8984					1177	1177		10.1016/S0140-6736(95)92894-4	http://dx.doi.org/10.1016/S0140-6736(95)92894-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC976	7475654	Bronze			2022-12-28	WOS:A1995TC97600004
J	UNGERLEIDER, LG				UNGERLEIDER, LG			FUNCTIONAL BRAIN IMAGING STUDIES OF CORTICAL MECHANISMS FOR MEMORY	SCIENCE			English	Review							INFERIOR TEMPORAL CORTEX; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CEREBRAL-LESIONS; HUMAN VISUAL-CORTEX; WORKING-MEMORY; MOTOR CORTEX; HIPPOCAMPAL-FORMATION; SENSORY STIMULATION; MACAQUE MONKEY; FRONTAL-CORTEX	Recent functional brain imaging studies in humans indicate that learning and memory involve many of the same regions of the cortex that process sensory information and control motor output. The forms of perceptual and motor learning that can occur without conscious recollection are mediated in part by contractions and expansions of representations in the sensory and motor cortex. The same regions are also engaged during the conscious storage and retrieval of facts and events, but these types of memory also bring into play structures involved in the active maintenance of memories ''on line'' and in the establishment of associative links between the information stored in different sensory areas. Although the picture of memory that is emerging from functional imaging studies is consistent with current physiological accounts, there are puzzles and surprises that will be solved only through a combination of human and animal studies.			UNGERLEIDER, LG (corresponding author), NIMH, PSYCHOL & PSYCHOPATHOL LAB, BETHESDA, MD 20892 USA.							ALLISON T, 1994, J NEUROPHYSIOL, V71, P821, DOI 10.1152/jn.1994.71.2.821; ANDERSEN RA, 1990, J NEUROSCI, V10, P1176; [Anonymous], COMMUNICATION; Baddeley A.D., 1986, WORKING MEMORY THOUG; BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; BAYLIS GC, 1987, EXP BRAIN RES, V65, P614; Bertini G., 1995, Society for Neuroscience Abstracts, V21, P276; BOUSSAOUD D, 1991, J COMP NEUROL, V306, P554, DOI 10.1002/cne.903060403; Brodmann K, 1909, VERGLEICHENDE LOKALI; BUCKNER RL, 1995, J NEUROSCI, V15, P12; BUCKNER RL, 1995, HDB NEUROPSYCHOLOGY, V10, P439; Chelazzi L., 1993, Society for Neuroscience Abstracts, V19, P975; Clark V. P., 1994, Society for Neuroscience Abstracts, V20, P839; CLARK VP, 1995, HUMAN BRAIN MAPPING, V1, P32; CORBETTA M, 1991, J NEUROSCI, V11, P2383; CORBETTA M, 1993, J NEUROSCI, V13, P1202; COURTNEY S, IN PRESS; COURTNEY SM, 1995, HUM BRAIN MAPP S, V1, P332; DAMASIO AR, 1990, COLD SH Q B, V55, P1039; DAMASIO AR, 1983, NEUROLOGY, V33, P1573, DOI 10.1212/WNL.33.12.1573; DAMASIO AR, 1982, NEUROLOGY, V32, P331, DOI 10.1212/WNL.32.4.331; DAMASIO AR, 1990, ANNU REV NEUROSCI, V13, P89, DOI 10.1146/annurev.ne.13.030190.000513; Darley, 1967, BRAIN MECH UNDERLY, P122; DAS A, 1995, NATURE, V375, P780, DOI 10.1038/375780a0; DESIMONE R, 1986, J COMP NEUROL, V248, P164, DOI 10.1002/cne.902480203; Desimone R., 1989, HDB NEUROPSYCHOLOGY, P267; DEYOE EA, 1994, J NEUROSCI METH, V54, P171, DOI 10.1016/0165-0270(94)90191-0; DISTLER C, 1993, J COMP NEUROL, V334, P125, DOI 10.1002/cne.903340111; DONOGHUE JP, 1992, EXP BRAIN RES, V89, P1; DOYON J, IN PRESS EUR J NEURO; DUFFY CJ, 1991, J NEUROPHYSIOL, V65, P1329, DOI 10.1152/jn.1991.65.6.1329; FARAH MJ, 1990, VISUAL AGNOSIA; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FLETCHER PC, 1995, NEUROIMAGE, V2, P195, DOI 10.1006/nimg.1995.1025; FLETCHER PC, 1995, BRAIN, V118, P401, DOI 10.1093/brain/118.2.401; FOX PT, 1985, J NEUROPHYSIOL, V54, P348, DOI 10.1152/jn.1985.54.2.348; FOX PT, 1986, P NATL ACAD SCI USA, V83, P1140, DOI 10.1073/pnas.83.4.1140; FRACKOWIAK RSJ, 1994, TRENDS NEUROSCI, V17, P109, DOI 10.1016/0166-2236(94)90119-8; Friston K. J., 1993, Human Brain Mapping, V1, P69, DOI 10.1002/hbm.460010108; Friston KJ, 1995, HUM BRAIN MAPP, V3, P56, DOI 10.1002/hbm.460030106; FRISTON KJ, 1992, P ROY SOC B-BIOL SCI, V248, P223, DOI 10.1098/rspb.1992.0065; Friston KJ, 1995, HUM BRAIN MAPP, V3, P302, DOI 10.1002/hbm.460030405; Fuster JM, 1995, MEMORY CEREBRAL CORT; GILBERT CD, 1992, NATURE, V356, P150, DOI 10.1038/356150a0; Goldman-Rakic P. S., 1994, Society for Neuroscience Abstracts, V20, P808; GOLDMANRAKIC PS, 1990, PROG BRAIN RES, V85, P325; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; GOULD HJ, 1986, J COMP NEUROL, V247, P297, DOI 10.1002/cne.902470303; GRAFTON ST, 1992, J NEUROSCI, V12, P2542; GRAFTON ST, 1995, HUM BRAIN MAPP S, V1, P411; GRASBY PM, 1993, NEUROSCI LETT, V163, P185, DOI 10.1016/0304-3940(93)90378-X; GRASBY PM, 1994, BRAIN, V117, P1271, DOI 10.1093/brain/117.6.1271; GRASBY PM, 1993, BRAIN, V116, P1, DOI 10.1093/brain/116.1.1; GULYAS B, 1991, NEUROREPORT, V2, P585, DOI 10.1097/00001756-199110000-00008; HAXBY JV, 1991, P NATL ACAD SCI USA, V88, P1621, DOI 10.1073/pnas.88.5.1621; HAXBY JV, 1994, J NEUROSCI, V14, P6336; HAXBY JV, 1993, WENN GR INT, P329; HAXBY JV, IN PRESS HUM BRAIN M; HAXBY JV, IN PRESS P NATL ACAD; Horwitz Barry, 1994, Human Brain Mapping, V2, P112, DOI 10.1002/hbm.460020111; JEANNEROD M, 1993, BAILLIERE CLIN NEUR, V2, P439; JENKINS IH, 1994, J NEUROSCI, V14, P3775; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; KAAS JH, 1983, ANNU REV NEUROSCI, V6, P325, DOI 10.1146/annurev.ne.06.030183.001545; KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637; KAPUR N, 1995, CORTEX, V31, P99, DOI 10.1016/S0010-9452(13)80108-6; KAPUR S, 1994, P NATL ACAD SCI USA, V91, P2008, DOI 10.1073/pnas.91.6.2008; KAPUR S, IN PRESS NEUROREPORT; Karni A., 1995, Society for Neuroscience Abstracts, V21, P276; KARNI A, 1995, NATURE, V377, P155; KAWASHIMA R, 1994, J NEUROSCI, V14, P3462; KOHLER S, 1995, NEUROREPORT, V6, P1865, DOI 10.1097/00001756-199510020-00011; KOSSLYN SM, 1993, J COGNITIVE NEUROSCI, V5, P263, DOI 10.1162/jocn.1993.5.3.263; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LI L, 1993, J NEUROPHYSIOL, V69, P1918, DOI 10.1152/jn.1993.69.6.1918; LOGOTHETIS NK, 1995, CURR BIOL, V5, P552, DOI 10.1016/S0960-9822(95)00108-4; MARTIN A, 1995, SCIENCE, V270, P102, DOI 10.1126/science.270.5233.102; Martin A., 1995, Society for Neuroscience Abstracts, V21, P1497; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1127, DOI 10.1152/jn.1983.49.5.1127; MAZZIOTTA JC, 1981, BRAIN WORK MENTAL AC, P280; MCCARTHY G, 1994, P NATL ACAD SCI USA, V91, P8690, DOI 10.1073/pnas.91.18.8690; McCarthy G., 1994, HUM BRAIN MAPP, V2, P234, DOI [10.1002/hbm.460020405, DOI 10.1002/HBM.460020405]; McIntosh A. R., 1994, Human Brain Mapping, V2, P2; MCINTOSH AR, 1994, J NEUROSCI, V14, P655; MILLER EK, 1993, J NEUROSCI, V13, P1460; Milliken G. W., 1992, Society for Neuroscience Abstracts, V18, P506; MISHKIN M, 1994, CURR OPIN NEUROBIOL, V4, P200, DOI 10.1016/0959-4388(94)90073-6; MOSCOVITCH M, 1995, P NATL ACAD SCI USA, V92, P3721, DOI 10.1073/pnas.92.9.3721; NEWCOMBE F, 1987, NEUROPSYCHOLOGIA, V25, P149, DOI 10.1016/0028-3932(87)90127-8; NEWCOMBE F, 1969, J NEUROL NEUROSUR PS, V32, P73, DOI 10.1136/jnnp.32.2.73; NOBRE AC, 1994, NATURE, V372, P260, DOI 10.1038/372260a0; NUDO RJ, 1992, J NEUROSCI, V12, P2918, DOI 10.1523/JNEUROSCI.12-08-02918.1992; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; ONO T, 1993, J NEUROPHYSIOL, V70, P1516, DOI 10.1152/jn.1993.70.4.1516; PASCUALLEONE A, 1994, SCIENCE, V263, P1287, DOI 10.1126/science.8122113; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; PAULESU E, 1995, FUNCT NEUROIMAGING, V5, P207; PETERSEN SE, 1990, SCIENCE, V249, P1041, DOI 10.1126/science.2396097; PETIT L, 1993, J NEUROPHYSIOL, V69, P1009, DOI 10.1152/jn.1993.69.4.1009; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P873, DOI 10.1073/pnas.90.3.873; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; Posner M. I., 1994, IMAGES MIND; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; RAO SL, 1995, HUM BRAIN MAPP S, V1, P412; RATCLIFF G, 1972, BRAIN, V95, P49, DOI 10.1093/brain/95.1.49; RATCLIFF G, 1973, J NEUROL NEUROSUR PS, V36, P448, DOI 10.1136/jnnp.36.3.448; RAUCH SL, 1995, HUM BRAIN MAPP S, V1, P409; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1031, DOI 10.1152/jn.1992.67.5.1031; RICHES IP, 1991, J NEUROSCI, V11, P1763; ROLAND PE, 1995, CEREB CORTEX, V5, P79, DOI 10.1093/cercor/5.1.79; ROLLS ET, 1989, J NEUROSCI, V9, P1835; SANES JN, 1992, CEREB CORTEX, V2, P141, DOI 10.1093/cercor/2.2.141; SANES JN, 1995, SCIENCE, V268, P1775, DOI 10.1126/science.7792606; SCHACTER DL, 1987, J EXP PSYCHOL LEARN, V13, P501, DOI 10.1037/0278-7393.13.3.501; SCHACTER DL, 1995, NATURE, V376, P587, DOI 10.1038/376587a0; SCHACTER DL, IN PRESS P NATL ACAD; SCHIEBER MH, 1993, SCIENCE, V261, P489, DOI 10.1126/science.8332915; SCHLAUG G, 1994, EXP BRAIN RES, V98, P523; SCHNEIDER W, 1993, NATURE, V365, P150, DOI 10.1038/365150a0; Seitz R J, 1990, Neuroreport, V1, P57, DOI 10.1097/00001756-199009000-00016; SELTZER B, 1978, BRAIN RES, V149, P1, DOI 10.1016/0006-8993(78)90584-X; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; SHALLICE T, 1994, NATURE, V368, P633, DOI 10.1038/368633a0; SHIPP S, 1995, NEUROIMAGE, V2, P125, DOI 10.1006/nimg.1995.1015; SMITH EE, 1995, J COGNITIVE NEUROSCI, V7, P337, DOI 10.1162/jocn.1995.7.3.337; Squire L. R., 1987, MEMORY BRAIN; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; Stern C. E., 1994, Society for Neuroscience Abstracts, V20, P1290; SUZUKI WA, 1994, J COMP NEUROL, V350, P497, DOI 10.1002/cne.903500402; TANAKA K, 1989, J NEUROPHYSIOL, V62, P626, DOI 10.1152/jn.1989.62.3.626; TOOTELL RBH, 1995, J NEUROSCI, V15, P3215; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2016, DOI 10.1073/pnas.91.6.2016; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2012, DOI 10.1073/pnas.91.6.2012; TULVING E, 1994, NEUROREPORT, V5, P2525, DOI 10.1097/00001756-199412000-00030; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549; Ungerleider Leslie G., 1994, Current Opinion in Neurobiology, V4, P157, DOI 10.1016/0959-4388(94)90066-3; von Bonin G., 1947, NEOCORTEX MACACA MUL; WARRINGTON EK, 1968, NATURE, V217, P972, DOI 10.1038/217972a0; WATSON JDG, 1993, CEREB CORTEX, V3, P79, DOI 10.1093/cercor/3.2.79; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520; ZEKI S, 1991, J NEUROSCI, V11, P641; ZEKI SM, 1974, J PHYSIOL-LONDON, V236, P549, DOI 10.1113/jphysiol.1974.sp010452	147	374	380	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 3	1995	270	5237					769	775		10.1126/science.270.5237.769	http://dx.doi.org/10.1126/science.270.5237.769			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC712	7481764				2022-12-28	WOS:A1995TC71200031
J	POMBO, CM; KEHRL, JH; SANCHEZ, I; KATZ, P; AVRUCH, J; ZON, LI; WOODGETT, JR; FORCE, T; KYRIAKIS, JM				POMBO, CM; KEHRL, JH; SANCHEZ, I; KATZ, P; AVRUCH, J; ZON, LI; WOODGETT, JR; FORCE, T; KYRIAKIS, JM			ACTIVATION OF THE SAPK PATHWAY BY THE HUMAN STE20 HOMOLOG GERMINAL CENTER KINASE	NATURE			English	Article								EUKARYOTIC cells respond to different extracellular stimuli by recruiting homologous signalling pathways that use members of the MEKK, MEK and ERK families of protein kinases. The MEKK-->MEK-->ERK core pathways of Saccharomyces cerevisiae may themselves be regulated by members of the STE20 family of protein kinases(1,2). Here we report specific activation of the mammalian stress-activated protein kinase (SAPK) pathway by germinal centre kinase (GCK; ref. 3), a human STE20 homologue(3,4). SAPKs, members of the ERK family, are activated in situ by inflammatory stimuli, including tumour-necrosis factor (TNF) and interleukin-1, and phosphorylate and probably stimulate the transactivation function of c-Jun(5-7). Although GCK is found in many tissues, its expression in lymphoid follicles is restricted to the cells of the germinal centre, where it may participate in B-cell differentiation(3). Activation of the SAPK pathway by GCK illustrates further the striking, conservation of eukaryotic signalling mechanisms and defines the first physiological function of a mammalian Ste20.	MASSACHUSETTS GEN HOSP E, DIABET RES LAB, BOSTON, MA 02129 USA; MASSACHUSETTS GEN HOSP E, CARDIOL UNIT, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02129 USA; NIAID, IMMUNOREGULAT LAB, BETHESDA, MD 20892 USA; GEORGETOWN UNIV, MED CTR, DEPT MED, WASHINGTON, DC 20007 USA; CHILDRENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; CHILDRENS HOSP, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; PRINCESS MARGARET HOSP, ONTARIO CANC INST, TORONTO, ON M4X 1K9, CANADA	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Georgetown University; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre			Kehrl, John/AAE-6292-2019; Woodgett, Jim/F-1087-2010; Pombo, Celia M/L-4479-2014	Woodgett, Jim/0000-0003-3731-5797; Force, Thomas/0000-0002-0450-8659; Pombo, Celia M/0000-0003-2541-9468; Kehrl, John/0000-0002-6526-159X				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHOI KY, 1994, CELL, V78, P499; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HATZ P, 1994, J BIOL CHEM, V269, P16802; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; YAN MH, 1994, NATURE, V372, P798	23	207	215	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 26	1995	377	6551					750	754		10.1038/377750a0	http://dx.doi.org/10.1038/377750a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB469	7477268				2022-12-28	WOS:A1995TB46900062
J	MISHKIN, B				MISHKIN, B			RESPONDING TO SCIENTIFIC MISCONDUCT DUE PROCESS AND PREVENTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											MISHKIN, B (corresponding author), HOGAN & HARTSON,555 13TH ST NW,WASHINGTON,DC 20004, USA.							Broad W., 1982, BETRAYERS TRUTH; BROAD WJ, 1980, SCIENCE, V210, P38, DOI 10.1126/science.210.4465.38; CULLITON BJ, 1983, SCIENCE, V220, P31, DOI 10.1126/science.6828878; Knox R, 1983, JAMA, V249, P1797, DOI 10.1001/jama.249.14.1797; OAKES AN, 1982, WHISTLEBLOWING BIOME, P111; WOOLF P, 1988, PROJECT SCI FRAUD MI, P37; 1988, GUIDELINES INVESTIGA; 1986, GUIDE GRANTS CONTRAC, P1; 1984, MAINTAINING INTEGRIT; 1988, ANN INTERN MED, V108, P304; 1987, FED REG         0701, V52, P24466; 1985, LANCET, V2, P595; 1988, ANN INTERN MED, V108, P258; 1981, PROTECTING HUMAN SUB, P181; 1982, REPORT AD HOC ADVISO; 1983, YALE U POLICY STATEM, P161; 1982, MAINTENANCE HIGH ETH; 1984, REPORT NATIONAL HEAR, P19; 1982, REPORT HARVARD MED S	19	23	24	1	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1988	260	13					1932	1936						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q2703	3418855				2022-12-28	WOS:A1988Q270300030
J	JACKSON, TR; BLAIR, LAC; MARSHALL, J; GOEDERT, M; HANLEY, MR				JACKSON, TR; BLAIR, LAC; MARSHALL, J; GOEDERT, M; HANLEY, MR			THE MAS ONCOGENE ENCODES AN ANGIOTENSIN RECEPTOR	NATURE			English	Article									MRC,MOLEC NEUROBIOL UNIT,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND; MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology								BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BURT DR, 1980, NEUROTRANSMITTER B 1, V9, P152; CONNELL JMC, 1986, TRENDS PHARMACOL SCI, V7, P412, DOI 10.1016/0165-6147(86)90404-9; CORPS AN, 1985, BIOCHEM J, V231, P781, DOI 10.1042/bj2310781; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; FARGIN A, 1988, NATURE, V335, P358, DOI 10.1038/335358a0; FERRARIO CM, 1983, HYPERTENSION, V5, pV73, DOI 10.1161/01.HYP.5.6_Pt_3.V73; GILLO B, 1987, J PHYSIOL-LONDON, V392, P349, DOI 10.1113/jphysiol.1987.sp016784; GOEDERT M, 1987, EMBO J, V6, P3627, DOI 10.1002/j.1460-2075.1987.tb02694.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANLEY MR, 1987, NATURE, V329, P766, DOI 10.1038/329766a0; HANLEY MR, 1985, NATURE, V315, P14, DOI 10.1038/315014a0; HANLEY MR, 1988, NEURON, V1, P175, DOI 10.1016/0896-6273(88)90137-7; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; JACKSON TR, 1987, EMBO J, V6, P49, DOI 10.1002/j.1460-2075.1987.tb04717.x; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KOBILKA BK, 1987, NATURE, V329, P75, DOI 10.1038/329075a0; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NATHANS J, 1987, A REV NEUROSCI, V10, P161; RABIN M, 1988, ONCOGENE RES, V1, P169; REGOLI D, 1979, CAN J PHYSIOL PHARM, V57, P129, DOI 10.1139/y79-020; WHITE MM, 1985, P NATL ACAD SCI USA, V82, P4852, DOI 10.1073/pnas.82.14.4852; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; YOUNG D, 1988, P NATL ACAD SCI USA, V85, P5339, DOI 10.1073/pnas.85.14.5339; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0	29	373	376	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 29	1988	335	6189					437	440		10.1038/335437a0	http://dx.doi.org/10.1038/335437a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q2364	3419518				2022-12-28	WOS:A1988Q236400050
J	BARTLETT, JG; MUNDY, LM				BARTLETT, JG; MUNDY, LM			COMMUNITY-ACQUIRED PNEUMONIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MICROBIAL ETIOLOGY; HOSPITALIZATION; BRONCHOSCOPY; INFECTIONS; MANAGEMENT; FEATURES; DISEASE; ADULTS		JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD USA	Johns Hopkins University								ANDREWS BE, 1987, Q J MED, V62, P195; AUSTRIAN R, 1956, AM J MED SCI, V232, P624, DOI 10.1097/00000441-195612000-00003; AUSTRIAN R, 1994, ANN INTERN MED, V121, P807, DOI 10.7326/0003-4819-121-10-199411150-00013; BARRETTC.E, 1971, AM REV RESPIR DIS, V103, P845; BARTLETT JG, 1979, AM REV RESPIR DIS, V119, P19; BATES JH, 1992, CHEST, V101, P1005, DOI 10.1378/chest.101.4.1005; BISNO AL, 1971, AM J MED SCI, V261, P251, DOI 10.1097/00000441-197105000-00004; BOHTE R, 1995, EUR J CLIN MICROBIOL, V14, P182, DOI 10.1007/BF02310353; Bullowa JGM, 1935, J AMER MED ASSOC, V105, P1512; DANS PE, 1984, ARCH INTERN MED, V144, P1392, DOI 10.1001/archinte.144.7.1392; DORFF GJ, 1973, AM J MED SCI, V266, P349, DOI 10.1097/00000441-197311000-00002; EDELSTEIN PH, 1993, CLIN INFECT DIS, V16, P741, DOI 10.1093/clind/16.6.741; FANG GD, 1990, MEDICINE, V69, P307, DOI 10.1097/00005792-199009000-00004; FARR BM, 1991, ANN INTERN MED, V115, P428, DOI 10.7326/0003-4819-115-6-428; FARR BM, 1989, THORAX, V44, P1031, DOI 10.1136/thx.44.12.1031; FEINSILVER SH, 1990, CHEST, V98, P1322, DOI 10.1378/chest.98.6.1322; FEKETY RF, 1971, AM REV RESPIR DIS, V104, P499; FICK RB, 1983, AM J MED, V74, P1, DOI 10.1016/0002-9343(83)91110-5; FINCH R, 1993, BRIT J HOSP MED, V49, P346; FINE MJ, 1990, AM J MED, V89, P713, DOI 10.1016/0002-9343(90)90211-U; FINE MJ, 1993, AM J MED, V94, P153, DOI 10.1016/0002-9343(93)90177-Q; GARIBALDI RA, 1985, AM J MED, V78, P32, DOI 10.1016/0002-9343(85)90361-4; GOLDSTEIN RA, 1990, AM REV RESPIR DIS, V142, P481; HEFFNER JE, 1995, AM J RESP CRIT CARE, V151, P1700, DOI 10.1164/ajrccm.151.6.7767510; HEFFRON R, 1979, PNEUMONIA SPECIAL RE, P302; Hoeprich P D, 1970, Calif Med, V112, P1; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; HYMAN CL, 1995, CLIN INFECT DIS, V20, P1174, DOI 10.1093/clinids/20.5.1174; JANSSEN RS, 1992, NEW ENGL J MED, V327, P445, DOI 10.1056/NEJM199208133270701; JAY SJ, 1975, NEW ENGL J MED, V293, P798, DOI 10.1056/NEJM197510162931604; KALINSKE RW, 1967, NEW ENGL J MED, V276, P604, DOI 10.1056/NEJM196703162761103; KINASEWITZ G, 1991, EUR J CLIN MICROBIOL, V10, P872, DOI 10.1007/BF01975846; Larsen R A, 1984, Compr Ther, V10, P20; LIM I, 1989, MED J AUSTRALIA, V151, P87, DOI 10.5694/j.1326-5377.1989.tb101168.x; MARRIE TJ, 1994, CLIN INFECT DIS, V18, P501, DOI 10.1093/clinids/18.4.501; MARRIE TJ, 1989, REV INFECT DIS, V11, P586; MARSTON BJ, 1993, LEGIONELLA, P36; MUFSON MA, 1967, AM J EPIDEMIOL, V86, P526, DOI 10.1093/oxfordjournals.aje.a120763; MUNDY LM, 1995, AM J RESP CRIT CARE, V152, P1309, DOI 10.1164/ajrccm.152.4.7551387; MUNDY LM, 1995, 95TH ANN M AM SOC MI, P297; NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418; OPRAVIL M, 1994, J ACQ IMMUN DEF SYND, V7, P39; PALLARES R, 1995, NEW ENGL J MED, V333, P474, DOI 10.1056/NEJM199508243330802; POLLOCK HM, 1983, J CLIN MICROBIOL, V17, P255, DOI 10.1128/JCM.17.2.255-259.1983; REIN MF, 1978, JAMA-J AM MED ASSOC, V239, P2671, DOI 10.1001/jama.239.25.2671; RIES K, 1974, ARCH INTERN MED, V133, P453, DOI 10.1001/archinte.133.3.453; SAHN SA, 1993, AM REV RESPIR DIS, V148, P813, DOI 10.1164/ajrccm/148.3.813; SULLIVAN RJ, 1972, ARCH INTERN MED, V129, P935, DOI 10.1001/archinte.129.6.935	48	572	608	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 14	1995	333	24					1618	1624		10.1056/NEJM199512143332408	http://dx.doi.org/10.1056/NEJM199512143332408			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK065	7477199				2022-12-28	WOS:A1995TK06500008
J	COLLURA, RV; STEWART, CB				COLLURA, RV; STEWART, CB			INSERTIONS AND DUPLICATIONS OF MTDNA IN THE NUCLEAR GENOMES OF OLD-WORLD MONKEYS AND HOMINOIDS	NATURE			English	Article							MITOCHONDRIAL-DNA; EVOLUTION; SEQUENCES; AMPLIFICATION; PRIMATES	USING oligonucleotide primers designed to match conserved regions of mammalian mitochondrial DNA (mtDNA)(1), we have amplified and sequenced two divergent cytochrome b nuclear pseudogenes from orangutan cellular DNA. Evolutionary analysis suggests that a nuclear transfer occurred about 30 million years ago on the lineage leading to the catarrhines (Old World monkeys and hominoids), and involved a long (at least 3 kilobases), probably damaged, piece of mtDNA. After this transfer, the pseudogene duplicated, giving rise to the two copies that are probably present in all hominoids, including humans. More recent transfers involving the entire cytochrome b gene have also occurred in the Old World monkeys. Such nuclear copies of mtDNA can confound phylogenetic and population genetic studies(2-4), and be an insidious source of DNA contamination of 'ancient'(3,5) and forensic DNA. Indeed, contamination with these anciently transferred human pseudogenes(5) is almost certainly the source of the cytochrome b sequences recently reported from 'dinosaur bone DNA'(6).	SUNY ALBANY,DEPT BIOL SCI,ALBANY,NY 12222	State University of New York (SUNY) System; State University of New York (SUNY) Albany								ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Ausubel FM, 1988, MOL REPROD DEV; BROWN WM, 1982, J MOL EVOL, V18, P225, DOI 10.1007/BF01734101; COHEN J, 1995, SCIENCE, V268, P22, DOI 10.1126/science.7701333; FELSENSTEIN J, 1994, PHYLIP PHYLOGENY INF; FUKUDA M, 1985, J MOL BIOL, V186, P257, DOI 10.1016/0022-2836(85)90102-0; GINGERICH PD, 1986, MOL BIOL EVOL, V3, P205; GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298; HANDT O, 1994, EXPERIENTIA, V50, P524, DOI 10.1007/BF01921720; HEDGES SB, 1995, SCIENCE, V268, P1191, DOI 10.1126/science.7761839; HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532; HU GX, 1994, GENE, V147, P197, DOI 10.1016/0378-1119(94)90065-5; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; LI WH, IN PRESS MOL PHYLOGE; LOPEZ JV, 1994, J MOL EVOL, V39, P174; MADDISON WP, 1994, ANAL PHYLOGENY CHARA; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; Quinn TW, 1992, MOL ECOL, V1, P105, DOI 10.1111/j.1365-294X.1992.tb00162.x; SAITOU N, 1994, MOL BIOL EVOL, V11, P504; SHAY JW, 1992, MUTAT RES, V275, P227, DOI 10.1016/0921-8734(92)90026-L; SMITH MF, 1992, MOL BIOL EVOL, V9, P204; SWOFFORD DL, 1993, PAUP PHYLOGENETIC AN; VANDERKUYL AC, 1995, J MOL EVOL, V40, P652, DOI 10.1007/BF00160513; VANDERKUYL AC, 1995, J MOL EVOL, V40, P173, DOI 10.1007/BF00167111; WOODWARD SR, 1995, SCIENCE, V268, P1194, DOI 10.1126/science.268.5214.1194; WOODWARD SR, 1994, SCIENCE, V266, P1229; WRISCHNIK LA, 1987, NUCLEIC ACIDS RES, V15, P529, DOI 10.1093/nar/15.2.529; ZISCHLER H, 1995, SCIENCE, V268, P1192, DOI 10.1126/science.7605504; ZULLO S, 1991, J MOL BIOL, V221, P1223	29	168	176	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					485	489		10.1038/378485a0	http://dx.doi.org/10.1038/378485a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477403				2022-12-28	WOS:A1995TH05400069
J	JOHNSTON, CI				JOHNSTON, CI			ANGIOTENSIN RECEPTOR ANTAGONISTS - FOCUS ON LOSARTAN	LANCET			English	Article							II ANTAGONIST; VOLUNTEERS; INHIBITION; HEART				JOHNSTON, CI (corresponding author), UNIV MELBOURNE,AUSTIN REPATRIAT MED CTR,DEPT MED,HEIDELBERG,VIC 3084,AUSTRALIA.							Arcuri K., 1994, American Journal of Hypertension, V7, p110A; ASHINO K, 1994, BLOOD PRESSURE S5, V3, P122; BRUNNER HR, 1994, EUR HEART J, V15, P123, DOI 10.1093/eurheartj/15.suppl_D.123; BRUNNER HR, 1994, J HYPERTENS, V12, pS29; BURNIER M, 1993, HYPERTENSION, V22, P339, DOI 10.1161/01.HYP.22.3.339; CHRISTEN Y, 1991, CIRCULATION, V83, P1333, DOI 10.1161/01.CIR.83.4.1333; COCKCROFT JR, 1993, J CARDIOVASC PHARM, V22, P579, DOI 10.1097/00005344-199310000-00011; CROZIER I, 1995, CIRCULATION, V91, P691, DOI 10.1161/01.CIR.91.3.691; DELZCRETAZ E, 1995, HYPERTENSION, V25, P14; DOIG JK, 1993, J CARDIOVASC PHARM, V21, P732, DOI 10.1097/00005344-199305000-00007; Faison E. P., 1994, American Journal of Hypertension, V7, p34A; GANSEVOORT RT, 1994, KIDNEY INT, V45, P861, DOI 10.1038/ki.1994.113; GOLDBERG AI, 1995, AM J CARDIOL, V75, P793, DOI 10.1016/S0002-9149(99)80413-5; GOLDBERG MR, 1993, HYPERTENSION, V21, P704, DOI 10.1161/01.HYP.21.5.704; GOLDBERG MR, 1995, HYPERTENSION, V25, P37, DOI 10.1161/01.HYP.25.1.37; GOTTLIEB SS, 1993, CIRCULATION, V88, P1602, DOI 10.1161/01.CIR.88.4.1602; GROSSMAN E, 1994, AM J HYPERTENS, V7, P1041, DOI 10.1093/ajh/7.12.1041; JOHNSTON CI, 1995, J HUM HYPERTENS, V9, P375; JOHNSTON CI, 1993, RENIN ANGIOTENSIN SY; Kawabata M, 1994, Blood Press Suppl, V5, P117; LACOURCIERE Y, 1994, J HYPERTENS, V12, P1387; Moan A, 1994, Blood Press, V3, P185, DOI 10.3109/08037059409102250; Mueller P., 1994, European Journal of Clinical Pharmacology, V47, P231; MUNAFO A, 1992, CLIN PHARMACOL THER, V51, P513, DOI 10.1038/clpt.1992.56; NAGANO M, 1994, BLOOD PRESS S5, V3, P130; NELSON E, 1992, AM J HYPERTENS, V5, pA19; OGIHARA T, 1994, J HYPERTENS, V12, pS35; OHTAWA M, 1993, BRIT J CLIN PHARMACO, V35, P290, DOI 10.1111/j.1365-2125.1993.tb05696.x; SISSMANN J, 1994, J HYPERTENS       S3, V12, P508; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TSUNODA K, 1993, AM J HYPERTENS, V6, P28, DOI 10.1093/ajh/6.1.28; URATA H, 1993, J CLIN INVEST, V91, P1269, DOI 10.1172/JCI116325; VANDENMEIRACKER AH, 1995, HYPERTENSION, V25, P22, DOI 10.1161/01.HYP.25.1.22; Waeber Bernard, 1995, P2861; WEBER MA, 1992, AM J HYPERTENS, V5, pS247, DOI 10.1093/ajh/5.12.247S; WEBER MA, 1995, ARCH INTERN MED, V155, P405, DOI 10.1001/archinte.155.4.405	36	201	207	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 25	1995	346	8987					1403	1407		10.1016/S0140-6736(95)92411-6	http://dx.doi.org/10.1016/S0140-6736(95)92411-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG207	7475826				2022-12-28	WOS:A1995TG20700014
J	WOODWARD, B				WOODWARD, B			THE COMPUTER-EASED PATIENT RECORD AND CONFIDENTIALITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARE				WOODWARD, B (corresponding author), BRANDEIS UNIV,WALTHAM,MA 02254, USA.							ANNAS GJ, 1989, RIGHTS PATIENTS BASI, P178; BARTLETT E, 1993, HOSP RISK MANAGE, V15, P132; Dick R.S., 1991, COMPUTER BASED PATIE; DONALDSON MS, 1994, HLTH DATA INFORMATIO, P45; EKSTRAND LE, 1993, GAOTGGD9341 PUBL; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V270, P2487; GOSTIN LO, 1995, CORNELL LAW REV, V80, P515; HERSHEY RD, 1994, NY TIMES        0719, pD1; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; KASSIRER JP, 1995, NEW ENGL J MED, V332, P52, DOI 10.1056/NEJM199501053320110; KOLATA G, 1994, NY TIMES        0809, pA21; NOBLE HB, 1995, NY TIMES        0703, pA1; SCHWARTZ PM, 1995, VANDERBILT LAW REV, V48, P301; SZOLOVITS P, 1994, J AM MED INFORM ASSN, V1, P316, DOI 10.1136/jamia.1994.95236164; VALENTINE PW, 1995, WASHINGTON POST 0614, pB1; 1994, POSITION PAPER ACCES, P2	16	53	58	1	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 23	1995	333	21					1419	1422		10.1056/NEJM199511233332112	http://dx.doi.org/10.1056/NEJM199511233332112			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF521	7477127				2022-12-28	WOS:A1995TF52100012
J	PATEL, P; KHULUSI, S; MENDALL, MA; LLOYD, R; JAZRAWI, R; MAXWELL, JD; NORTHFIELD, TC				PATEL, P; KHULUSI, S; MENDALL, MA; LLOYD, R; JAZRAWI, R; MAXWELL, JD; NORTHFIELD, TC			PROSPECTIVE SCREENING OF DYSPEPTIC PATIENTS BY HELICOBACTER-PYLORI SEROLOGY	LANCET			English	Article							ACCESS ENDOSCOPY SERVICE	Helicobacter pylori infection is associated with 95% of duodenal ulcers and more than 80% of gastric ulcers. Several reports have indicated that screening for H pylori may avoid subsequent endoscopic examination. We screened 183 dyspeptic patients, aged under 45, by taking a history of sinister symptoms and regular use of non-steroidal anti-inflammatory drugs (NSAIDs), together with serological testing for H pylori. Endoscopy was performed on 113 patients, of whom 90 (49%) were seropositive, 14 (8%) had sinister symptoms, and 9 (5%) had used NSAIDs regularly. In 34 (19%) patients we detected peptic ulceration. The remaining 70 (38%) patients who were H pylori seronegative, had no sinister symptoms, and had not taken NSAIDs (screen-negative), did not undergo endoscopy but were returned to their primary care physician for treatment of symptoms, At subsequent reassessment (of the non-endoscoped group), symptom severity (p=0.002), interference with life events (p=0.01), and medication (p=0.0002) were all significantly lower in the 6 months after screening than in the 6 month period before screening. Only three screen-negative patients were re-referred after screening endoscopic findings were normal. Thus, endoscopies were avoided. When the non-endoscoped screen-negative patients were compared with a cohort of endoscoped screen-negative patients, the groups did not differ in terms of symptom severity (odds ratio 1.12, 95% CI 0.53-2.35, p=0.77) or interference with life events (0.82, 0.38-1.76, p=0.61). However, medication use was significantly less (0.37, 0.17-0.80, p=0.01) in those who did not have an endoscopy. Our study indicates that colonisation screening based on H pylori serology, a history of sinister symptoms, or a history of NSAID use was worthwhile in dyspeptic patients. We avoided 37% of endoscopies and reduced drug usage without disadvantaging those not endoscoped.	ST GEORGE HOSP,SCH MED,DEPT MED,LONDON SW17 0RE,ENGLAND	St Georges University London								AXON ATR, 1987, GUT, V28, P1527, DOI 10.1136/gut.28.11.1527; COLINJONES DG, 1988, LANCET, V1, P576; GEAR MWL, 1989, BRIT J HOSP MED, V41, P438; HANSEN JM, 1991, DAN MED BULL, V38, P288; HOLDSTOCK G, 1979, BRIT MED J, V1, P457, DOI 10.1136/bmj.1.6161.457; JONES R, 1988, PRACTITIONER, V232, P75; KNILLJONES RP, 1991, SCAND J GASTROENTERO, V26, P17, DOI 10.3109/00365529109109532; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P439, DOI 10.5694/j.1326-5377.1985.tb113444.x; MENDALL MA, 1995, GUT, V36, P330, DOI 10.1136/gut.36.3.330; MENDALL MA, 1992, EUR J GASTROEN HEPAT, V4, P713; PATCHETT S, 1991, BMJ-BRIT MED J, V303, P1238, DOI 10.1136/bmj.303.6812.1238; PATEL P, 1994, LANCET, V344, P511, DOI 10.1016/S0140-6736(94)91899-6; QUINE MA, 1994, GUT, V35, P1209, DOI 10.1136/gut.35.9.1209; SOBALA GM, 1991, LANCET, V338, P94, DOI 10.1016/0140-6736(91)90085-4; SOBALA GM, 1992, HELICOBACTER PYLORI, P150; TALLEY NJ, 1994, GASTROENTEROLOGY, V106, P1174, DOI 10.1016/0016-5085(94)90007-8; WILLIAMS B, 1988, LANCET, V2, P1349; 1990, PROVISION GASTROINTE	18	183	183	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 18	1995	346	8986					1315	1318		10.1016/S0140-6736(95)92340-3	http://dx.doi.org/10.1016/S0140-6736(95)92340-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE916	7475768				2022-12-28	WOS:A1995TE91600006
J	CHENG, AM; ROWLEY, B; PAO, W; HAYDAY, A; BOLEN, JB; PAWSON, T				CHENG, AM; ROWLEY, B; PAO, W; HAYDAY, A; BOLEN, JB; PAWSON, T			SYK TYROSINE KINASE REQUIRED FOR MOUSE VIABILITY AND B-CELL DEVELOPMENT	NATURE			English	Article							BONE-MARROW; PROTEIN; CHAIN; REARRANGEMENT; SELECTION; RECEPTOR; GENES	The Syk cytoplasmic protein-tyrosine kinase has two amino-terminal SH2 domains and a carboxy-terminal catalytic domain(1). Syk, and its close relative ZAP-70 (ref. 2), are apparently pivotal in coupling antigen- and Fc-receptors to downstream signalling events(3,4). Syk associates with activated Fc receptors(5), the T cell receptor complex(6) and the B-cell antigen-receptor complex (BCR) in immature and mature B lymphocytes(7). On receptor activation, the tandem SH2 domains of Syk bind dual phosphotyrosine sites in the conserved ITAM motifs of receptor signalling chains, such as the immunoglobulin alpha and beta-chains of the BCR, leading to Syk activation(3,4,8). Here we have investigated Syk function in vivo by generating a mouse strain with a targeted mutation in the syk gene. Homozygous syk mutants suffered severe haemorrhaging as embryos and died perinatally, indicating that Syk has a critical role in maintaining vascular integrity or in wound healing during embryogenesis. Analysis of syk(-/-) lymphoid cells showed that the syk mutation impaired the differentiation of B-lineage cells, apparently by disrupting signalling from the pre-BCR complex and thereby preventing the clonal expansion, and further maturation, of pre-B cells.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A8,CANADA; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,PROGRAMME MOLEC BIOL & CANC,TORONTO,ON M5G 1X5,CANADA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT ONCOL,PRINCETON,NJ 08453; YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Bristol-Myers Squibb; Yale University			Pawson, Tony J/E-4578-2013					ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; CARLSSON L, 1992, EUR J IMMUNOL, V22, P71, DOI 10.1002/eji.1830220112; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1994, J IMMUNOL, V152, P4758; CHUKWUOCHA RU, 1994, J IMMUNOGENET, V40, P76; CLARK EA, 1994, J BIOL CHEM, V269, P28859; DECKER DJ, 1991, J IMMUNOL, V146, P350; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; DURDEN DL, 1994, BLOOD, V84, P2102; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; HAASNER D, 1994, INT IMMUNOL, V6, P21, DOI 10.1093/intimm/6.1.21; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HAYAKAWA K, 1985, J EXP MED, V161, P1554, DOI 10.1084/jem.161.6.1554; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; Joyner AL, 1993, GENE TARGETING PRACT; KARASUYAMA H, 1992, J EXP MED, V172, P969; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; MALLICK CA, 1993, CELL, V73, P513, DOI 10.1016/0092-8674(93)90138-G; MISENER V, 1991, INT IMMUNOL, V3, P1129, DOI 10.1093/intimm/3.11.1129; PAPAVASILIOU F, 1995, SCIENCE, V268, P408, DOI 10.1126/science.7716544; REZAUL K, 1995, FIBROSIS HEMOSTAS, V72, P937; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043	31	544	574	1	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 16	1995	378	6554					303	306		10.1038/378303a0	http://dx.doi.org/10.1038/378303a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477353				2022-12-28	WOS:A1995TE85800055
J	PIEPER, R; LUO, GL; CANE, DE; KHOSLA, C				PIEPER, R; LUO, GL; CANE, DE; KHOSLA, C			CELL-FREE SYNTHESIS OF POLYKETIDES BY RECOMBINANT ERYTHROMYCIN POLYKETIDE SYNTHASES	NATURE			English	Article							MACROLIDE BIOSYNTHESIS; CHAIN-ELONGATION; SACCHAROPOLYSPORA-ERYTHRAEA; STREPTOMYCES-ERYTHREUS; COENZYME-A; ACID; IDENTIFICATION; ORGANIZATION; INTERMEDIATE	Modular polyketide synthases (PKSs) are complex multi-enzyme proteins that catalyse the bacterial biosynthesis of many pharmaceutically useful polyketides. The PKSs are organized into a series of modules, each containing the active catalytic sites required for one step in the synthesis process(1,4). Here we report a method for cell-free enzymatic synthesis of 6-deoxyerythronolide B (6-dEB), the parent molecule of the antibiotic erythromycin A, using recombinant 6-deoxyerythronolide B synthase (DEBS), a modular PKS with at least 28 distinct active sites. We have also synthesized in vitro a triketide lactone by using a truncated mutant of DEBS. The availability of such cell-free synthetic routes will allow direct investigation of the structural and mechanistic basis for the unusual combination of high substrate specificity(5-10) and tolerance to genetic reprogramming(2,11-15) found in this enzyme family.	STANFORD UNIV,DEPT CHEM ENGN,STANFORD,CA 94305; BROWN UNIV,DEPT CHEM,PROVIDENCE,RI 02912	Stanford University; Brown University				Khosla, Chaitan/0000-0001-6529-495X				BROWN MJB, 1995, J CHEM SOC CHEM COMM, P1517, DOI 10.1039/c39950001517; CAFFREY P, 1992, FEBS LETT, V304, P225, DOI 10.1016/0014-5793(92)80624-P; CANE DE, 1995, J ANTIBIOT, V48, P647, DOI 10.7164/antibiotics.48.647; CANE DE, 1987, J AM CHEM SOC, V109, P1255, DOI 10.1021/ja00238a051; CANE DE, 1991, TETRAHEDRON LETT, V32, P5457, DOI 10.1016/0040-4039(91)80057-D; CANE DE, 1993, J AM CHEM SOC, V115, P522, DOI 10.1021/ja00055a023; CANE DE, 1995, J AM CHEM SOC, V117, P6633, DOI 10.1021/ja00129a044; CORCORAN JW, 1981, ANTIBIOTICS, V4, P146; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; CORTES J, 1995, SCIENCE, V288, P1487; DAGNOLO G, 1973, BIOCHIM BIOPHYS ACTA, V326, P155, DOI 10.1016/0005-2760(73)90241-5; DIMROTH P, 1970, EUR J BIOCHEM, V13, P98, DOI 10.1111/j.1432-1033.1970.tb00904.x; DONADIO S, 1993, P NATL ACAD SCI USA, V90, P7119, DOI 10.1073/pnas.90.15.7119; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; DULTON CJ, 1994, TETRAHEDRON LETT, V35, P327; HUNAITI AA, 1984, ANTIMICROB AGENTS CH, V25, P173, DOI 10.1128/AAC.25.2.173; KAO CM, 1994, SCIENCE, V265, P509, DOI 10.1126/science.8036492; KAO CM, 1995, J AM CHEM SOC, V117, P9105, DOI 10.1021/ja00140a043; KAO CM, 1994, J AM CHEM SOC, V116, P11612, DOI 10.1021/ja00104a069; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; LANZ T, 1991, J BIOL CHEM, V266, P9971; LEADLAY PF, 1993, BIOCHEM SOC T, V21, P218, DOI 10.1042/bst0210218; MACNEIL DJ, 1992, GENE, V115, P119, DOI 10.1016/0378-1119(92)90549-5; MARSDEN AFA, 1994, SCIENCE, V263, P378, DOI 10.1126/science.8278811; OFFENZELLER M, 1993, J BIOL CHEM, V268, P26127; OHagan D., 1991, POLYKETIDE METABOLIT; PIEPER R, IN PRESS J AM CHEM S; PLATE CA, 1970, J BIOL CHEM, V245, P2868; ROBERTS G, 1984, BIOCHEM SOC T, V12, P642, DOI 10.1042/bst0120642; SCHWECKE T, 1995, P NATL ACAD SCI USA, V92, P7839, DOI 10.1073/pnas.92.17.7839; SHEN B, 1993, SCIENCE, V262, P1535, DOI 10.1126/science.8248801; WALDT SJ, 1989, BIOCHEMISTRY-US, V28, P4523; WAWSZKIEWICZ EJ, 1964, BIOCHEM Z, V340, P213; WIESMANN KEH, 1995, CHEM BIOL, V2, P583, DOI 10.1016/1074-5521(95)90122-1; YUE S, 1987, J AM CHEM SOC, V109, P1253, DOI 10.1021/ja00238a050	35	95	105	2	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 16	1995	378	6554					263	266		10.1038/378263a0	http://dx.doi.org/10.1038/378263a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477343				2022-12-28	WOS:A1995TE85800043
J	REID, RC; ALONSO, JM				REID, RC; ALONSO, JM			SPECIFICITY OF MONOSYNAPTIC CONNECTIONS FROM THALAMUS TO VISUAL-CORTEX	NATURE			English	Article							SIMPLE RECEPTIVE-FIELDS; CAT STRIATE CORTEX; SPATIAL STRUCTURE; INPUTS; CELLS	In cortical area 17 of the cat, simple receptive fields are arranged in elongated subregions that respond best to bright (on) or dark (off) oriented contours, whereas the receptive fields of their thalamic inputs have a concentric on and off organization(1). This dramatic transformation suggests that there are specific rules governing the connections made between thalamic and cortical neurons(1-3) (see ref. 4). Here we report a study of these rules in which we recorded from thalamic (lateral geniculate nucleus; LGN) and cortical neurons simultaneously and related their receptive fields to their connectivity, as measured by cross-correlation analysis(5,6). The probability of finding a monosynaptic connection was high when a geniculate receptive field was superimposed anywhere over an elongated simple-cell subregion of the same signature (on or off). However, 'inappropriate' connections from geniculate cells of the opposite receptive field signature were extremely rare. Together, these findings imply that the outline of the elongated, simple receptive field, and thus of cortical orientation selectivity, is laid down at the level of the first synapse from the thalamic afferents.			REID, RC (corresponding author), ROCKEFELLER UNIV, NEUROBIOL LAB, NEW YORK, NY 10021 USA.							Alonso Jose-Manuel, 1993, Society for Neuroscience Abstracts, V19, P425; CHAPMAN B, 1991, J NEUROSCI, V11, P1347; FERSTER D, 1987, J NEUROSCI, V7, P1780; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JONES JP, 1987, J NEUROPHYSIOL, V58, P1187, DOI 10.1152/jn.1987.58.6.1187; JONES JP, 1987, J NEUROPHYSIOL, V58, P1233, DOI 10.1152/jn.1987.58.6.1233; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; REID RC, 1992, NATURE, V356, P716, DOI 10.1038/356716a0; REID RC, 1994, SOC NEUR ABSTR, V20, P425; RODLECK RW, 1965, VISION RES, V5, P583; SILLITO AM, 1975, J PHYSIOL-LONDON, V250, P305, DOI 10.1113/jphysiol.1975.sp011056; Sutter E.E., 1987, ADV METHODS PHYSIOLO, V1, P303; TANAKA K, 1983, J NEUROPHYSIOL, V49, P1303, DOI 10.1152/jn.1983.49.6.1303; TANAKA K, 1985, VISION RES, V25, P357, DOI 10.1016/0042-6989(85)90060-4; Usrey W. Martin, 1995, Society for Neuroscience Abstracts, V21, P21	15	541	546	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 16	1995	378	6554					281	284						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477347				2022-12-28	WOS:A1995TE85800049
J	PETCHEY, R				PETCHEY, R			GENERAL-PRACTITIONER FUNDHOLDING - WEIGHING THE EVIDENCE	LANCET			English	Review								A new development in the British National Health Service is fundholding, whereby certain general practitioners are given budgets from which they purchase services for patients. Our knowledge about fundholding is rudimentary. Many important questions remain unanswered. These include: the impact of fundholding on the efficiency of overall resource utilisation; its effect on Strategic planning; its effect on equity; its impact on the role of the doctor and the doctor-patient relationship; and its consequences for practice organisation and the culture of primary care. Even the scant results we do have must be interpreted cautiously. Fundholding was introduced during a period of great turbulence for general practice. Its strategic function was uncertain and its impact has been confounded by the effects of a series of earlier and concurrent policy changes. Few reliable conclusions about fundholding, either positive or negative, can be drawn from existing research.			PETCHEY, R (corresponding author), QUEENS MED CTR,DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND.							ANDREWS J, 1995, DOCTOR           FEB, P1; BAILEY JJ, 1994, BRIT MED J, V308, P1083, DOI 10.1136/bmj.308.6936.1083; BAIN J, 1994, BRIT MED J, V309, P396, DOI 10.1136/bmj.309.6951.396; BLACK DG, 1994, BRIT MED J, V309, P930, DOI 10.1136/bmj.309.6959.930; BOSANQUET N, 1989, FAMILY DOCTORS EC IN; BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; BURR AJ, 1992, PHARM J         1024, pR8; CORNEY R, 1994, BRIT J GEN PRACT, V44, P34; COULTER A, 1995, BRIT J GEN PRACT, V45, P119; COULTER A, 1993, BRIT MED J, V306, P433, DOI 10.1136/bmj.306.6875.433; DIXON J, 1994, BRIT MED J, V309, P30, DOI 10.1136/bmj.309.6946.30; DOWELL JS, 1995, BRIT MED J, V310, P505, DOI 10.1136/bmj.310.6978.505; EVE R, 1992, BMJ; GILLAM SJ, 1995, FAM PRACT, V12, P262; GLENNERSTER H, 1994, IMPLEMENTING GP FUND; GRAFFY JP, 1994, BRIT MED J, V308, P391, DOI 10.1136/bmj.308.6925.391; GRIFFIN JP, 1993, J ROY COLL PHYS LOND, V27, P121; HAM C, 1995, BRIT MED J, V310, P1150, DOI 10.1136/bmj.310.6988.1150; HARRIS A, 1994, BRIT MED J, V308, P1053, DOI 10.1136/bmj.308.6936.1053; Heaney DJ, 1994, HLTH B, V52, P285; Howie J G, 1993, Health Bull (Edinb), V51, P94; HOWIE JGR, 1995, BRIT J GEN PRACT, V45, P121; HOWIE JGR, 1995, GENERAL PRACTICE FUN; HUGHES D, 1991, J SOC WELFARE LAW, V13, P296; LEESE B, 1995, BRIT MED J, V310, P705, DOI 10.1136/bmj.310.6981.705; MARINKER M, 1984, NEW NHS ACT 1996; MAXWELL M, 1993, BRIT MED J, V307, P1990; MAYNARD A, 1986, HLTH ED GENERAL PRAC; NEWTON J, 1993, BRIT MED J, V306, P375, DOI 10.1136/bmj.306.6874.375; ORTON P, 1994, LANCET, V344, P1413; PENNINGTON S, 1995, GP              0421, P21; PRINGLE M, 1995, 68 ROYAL COLL GEN PR; WHYNES DK, IN PRESS J PUBLIC HL; 1995, GP              0421, P13; 1989, NHS COMMUNITY CARE B; 1995, ACCOUNTABILITY FRAME; 1995, BRIEFING GP FUNDHOLD; 1994, EL9479 NHSE NAT HLTH; 1994, SOCIAL TRENDS	39	27	27	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 28	1995	346	8983					1139	1142		10.1016/S0140-6736(95)91805-1	http://dx.doi.org/10.1016/S0140-6736(95)91805-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB549	7475608				2022-12-28	WOS:A1995TB54900015
J	DIEPOLDER, HM; ZACHOVAL, R; HOFFMANN, RM; WIERENGA, EA; SANTANTONIO, T; JUNG, MC; EICHENLAUB, D; PAPE, GR				DIEPOLDER, HM; ZACHOVAL, R; HOFFMANN, RM; WIERENGA, EA; SANTANTONIO, T; JUNG, MC; EICHENLAUB, D; PAPE, GR			POSSIBLE MECHANISM INVOLVING T-LYMPHOCYTE RESPONSE TO NONSTRUCTURAL PROTEIN-3 IN VIRAL CLEARANCE IN ACUTE HEPATITIS-C VIRUS-INFECTION	LANCET			English	Note								In acute hepatitis C virus (HCV) infection only 20-50% of patients spontaneously clear the virus. To characterise the immune reaction during that phase we studied the response of peripheral blood mononuclear cells (PBMC) to the recombinant HCV proteins core, non-structural protein 3 (NS3), NS4, and NS5 in 14 patients with acute hepatitis C. All eight patients with self-limited disease compared with two of six with evolving chronic infection showed an NS3- specific PBMC response (p=0.015). Of 65 patients with established chronic hepatitis C, five showed a PBMC response to NS3. NS3-specific CD4 T-cell clones from patients with self-limited infection predominantly produced interferon-gamma and may thus support cytotoxic effector mechanisms important for viral clearance.	UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT MED 2,D-81377 MUNICH,GERMANY; UNIV AMSTERDAM,CELL BIOL & HISTOL LAB,1105 AZ AMSTERDAM,NETHERLANDS; UNIV BARI,MALATTIE INFETT CLIN,BARI,ITALY; HOSP SCHWABING,DEPT INTERNAL MED 4,MUNICH,GERMANY	University of Munich; University of Amsterdam; Universita degli Studi di Bari Aldo Moro	DIEPOLDER, HM (corresponding author), UNIV MUNICH,KLINIKUM GROSSHADERN,INST IMMUNOL,D-81377 MUNICH,GERMANY.		Yang, Chen/G-1379-2010					ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; BOTARELLI P, 1993, GASTROENTEROLOGY, V104, P580, DOI 10.1016/0016-5085(93)90430-K; CERNY A, 1995, J CLIN INVEST, V95, P521, DOI 10.1172/JCI117694; FARCI P, 1991, SCIENCE, V258, P135; FERRARI C, 1994, HEPATOLOGY, V19, P286; HOFFMANN RM, 1995, HEPATOLOGY, V21, P632, DOI 10.1002/hep.1840210305; JUNG MC, 1995, J VIROL, V69, P3358, DOI 10.1128/JVI.69.6.3358-3368.1995; KOZIEL MJ, 1993, J VIROL, V67, P7522, DOI 10.1128/JVI.67.12.7522-7532.1993; LAI ME, 1994, LANCET, V343, P388, DOI 10.1016/S0140-6736(94)91224-6; MINUTELLO MA, 1993, J EXP MED, V178, P17, DOI 10.1084/jem.178.1.17	10	624	654	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 14	1995	346	8981					1006	1007		10.1016/S0140-6736(95)91691-1	http://dx.doi.org/10.1016/S0140-6736(95)91691-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475549				2022-12-28	WOS:A1995RZ59900013
J	KUMAR, L; GULATI, SC				KUMAR, L; GULATI, SC			ALPHA-INTERFERON IN CHRONIC MYELOGENOUS LEUKEMIA	LANCET			English	Editorial Material							MARROW TRANSPLANTATION; LEUKEMIA		CORNELL UNIV, MED CTR, NEW YORK HOSP, NEW YORK, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital	KUMAR, L (corresponding author), ALL INDIA INST MED SCI, INST ROTARY CANC HOSP, NEW DELHI, INDIA.							ALLAN NC, 1995, LANCET, V345, P1392, DOI 10.1016/S0140-6736(95)92596-1; GUILHOT F, 1993, LEUKEMIA LYMPHOMA, V11, P181, DOI 10.3109/10428199309047883; HEHLMANN R, 1994, BLOOD, V84, P4064, DOI 10.1182/blood.V84.12.4064.bloodjournal84124064; KANTARJIAN HM, 1995, ANN INTERN MED, V122, P254, DOI 10.7326/0003-4819-122-4-199502150-00003; KANTARJIAN HM, 1992, J CLIN ONCOL, V10, P772, DOI 10.1200/JCO.1992.10.5.772; KANTARJIAN HM, 1993, BLOOD, V82, P691; KUMAR L, 1994, J CLIN ONCOL, V12, P1710, DOI 10.1200/JCO.1994.12.8.1710; LION T, 1993, LANCET, V341, P275, DOI 10.1016/0140-6736(93)92619-5; OZER H, 1993, BLOOD, V82, P2975; SCHOFIELD JR, 1994, ANN INTERN MED, V121, P736, DOI 10.7326/0003-4819-121-10-199411150-00002; THOMAS ED, 1989, BLOOD, V73, P861; TURA S, 1994, NEW ENGL J MED, V330, P820	12	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 14	1995	346	8981					984	986		10.1016/S0140-6736(95)91683-0	http://dx.doi.org/10.1016/S0140-6736(95)91683-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475589				2022-12-28	WOS:A1995RZ59900004
J	PURUGGANAN, MD; KUMAR, CV; TURRO, NJ; BARTON, JK				PURUGGANAN, MD; KUMAR, CV; TURRO, NJ; BARTON, JK			ACCELERATED ELECTRON-TRANSFER BETWEEN METAL-COMPLEXES MEDIATED BY DNA	SCIENCE			English	Article									COLUMBIA UNIV,DEPT CHEM,NEW YORK,NY 10027	Columbia University				Kumar, Challa/0000-0002-8399-1334				Adam G., 1968, STRUCTURAL CHEM MOL, P198; BARTON JK, 1986, J AM CHEM SOC, V108, P6391, DOI 10.1021/ja00280a047; BARTON JK, 1986, J AM CHEM SOC, V108, P2081, DOI 10.1021/ja00268a057; BARTON JK, 1986, SCIENCE, V233, P727, DOI 10.1126/science.3016894; BARTON JK, 1984, J AM CHEM SOC, V106, P2172, DOI 10.1021/ja00319a043; BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; BRUNSCHWIG B, 1978, J AM CHEM SOC, V100, P7568, DOI 10.1021/ja00492a023; CHEN SF, 1981, J AM CHEM SOC, V103, P369; CLEMENTI E, 1982, INT J QUANTUM CHEM Q, V9, P213; CLOSS GL, 1986, J PHYS CHEM-US, V90, P3673, DOI 10.1021/j100407a039; DEVAULT D, 1980, Q REV BIOPHYS, V13, P387, DOI 10.1017/S003358350000175X; FROMHERZ P, 1986, J AM CHEM SOC, V108, P5361, DOI 10.1021/ja00277a060; FUJITA I, 1973, INORG CHEM, V12, P2758, DOI 10.1021/ic50130a004; GUARR T, 1983, J AM CHEM SOC, V105, P616, DOI 10.1021/ja00341a049; HEITELE H, 1985, J AM CHEM SOC, V107, P8286, DOI 10.1021/ja00312a093; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P3640, DOI 10.1073/pnas.71.9.3640; INOKUTI M, 1965, J CHEM PHYS, V43, P1978, DOI 10.1063/1.1697063; ISIED SS, 1984, PROG INORG CHEM, V32, P443, DOI 10.1002/9780470166338.ch5; IVANOV VI, 1973, BIOPOLYMERS, V12, P89, DOI 10.1002/bip.1973.360120109; JORAN A, 1986, NATURE, V327, P508; JORAN AD, 1984, J AM CHEM SOC, V106, P6090, DOI 10.1021/ja00332a062; KUMAR CV, 1985, J AM CHEM SOC, V107, P5518, DOI 10.1021/ja00305a032; LIANG N, 1986, J AM CHEM SOC, V108, P4665, DOI 10.1021/ja00275a076; MACGREGOR RB, 1987, BIOCHEMISTRY-US, V26, P4008, DOI 10.1021/bi00387a040; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MARCUS RA, 1964, ANNU REV PHYS CHEM, V15, P155, DOI 10.1146/annurev.pc.15.100164.001103; MARCUS RA, 1968, J PHYS CHEM-US, V72, P891, DOI 10.1021/j100849a019; MAYO SL, 1986, SCIENCE, V233, P948, DOI 10.1126/science.3016897; MCGOURTY JL, 1983, J AM CHEM SOC, V105, P4472; MCLENDON G, 1985, J AM CHEM SOC, V107, P7811, DOI 10.1021/ja00312a002; OTTO P, 1983, J CHEM PHYS, V78, P454; PAGLIA E, 1957, GAZZ CHIM ITAL, V87, P1125; REDI M, 1980, J CHEM PHYS, V72, P6651, DOI 10.1063/1.439124; REHMANN J, 1988, THESIS COLUMBIA U NE; RICHTER PH, 1974, BIOPHYS CHEM, V2, P255, DOI 10.1016/0301-4622(74)80050-5; SIMOLO KP, 1984, J AM CHEM SOC, V106, P5012, DOI 10.1021/ja00329a067; TERRY BJ, 1985, J BIOL CHEM, V260, P3130; Tonks L, 1936, PHYS REV, V50, P955, DOI 10.1103/PhysRev.50.955; Turro N. J., 1978, MODERN MOL PHOTOCHEM, P246	39	149	176	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 23	1988	241	4873					1645	1649		10.1126/science.3420416	http://dx.doi.org/10.1126/science.3420416			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q1372	3420416				2022-12-28	WOS:A1988Q137200032
J	KAY, R; WONG, KS; YU, YL; CHAN, YW; TSOI, TH; AHUJA, AT; CHAN, FL; FONG, KY; LAW, CB; WONG, A; WOO, J				KAY, R; WONG, KS; YU, YL; CHAN, YW; TSOI, TH; AHUJA, AT; CHAN, FL; FONG, KY; LAW, CB; WONG, A; WOO, J			LOW-MOLECULAR-WEIGHT HEPARIN FOR THE TREATMENT OF ACUTE ISCHEMIC STROKE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBROVASCULAR-DISEASE; ANTITHROMBOTIC THERAPY; CEREBRAL INFARCTION; STANDARD HEPARIN; VEIN THROMBOSIS; NATURAL-HISTORY; BRAIN ISCHEMIA; ANTICOAGULATION; CLASSIFICATION; RELIABILITY	Background. Despite doubts about their efficacy and concern about their safety, antithrombotic agents are often used to treat acute ischemic stroke. Recent experience in patients with other thromboembolic disorders suggests that low-molecular-weight heparin, which requires only subcutaneous administration once or twice daily, may be more effective and safer than standard (unfractionated) heparin. Methods. We conducted a randomized, double-blind, placebo-controlled trial comparing two dosages of low-molecular-weight heparin with placebo in the treatment of ischemic stroke. Patients were randomly assigned within 48 hours of the onset of symptoms to receive high-dose nadroparin (4100 anti-factor Xa IU twice daily), low-dose nadroparin (4100 IU once daily), or placebo subcutaneously for 10 days. The primary measure of outcome was death or dependency regarding activities of daily living six months after randomization. Secondary outcomes were death, hemorrhagic transformation of the infarction, and other complications at 10 days, and death of dependency at 3 months. Results. A total of 2750 patients were screened for the study. Among 312 patients randomized, 306 had outcomes that were analyzed at six months. Forty-five patients (45 percent) in the high-dose group, 53 patients (52 percent) in the low-dose group, and 68 patients (65 percent) in the placebo group died or became dependent. There was a significant dose-dependent effect among the three study groups in favor of low-molecular-weight heparin (P=0.005 by the chi-square test for trend). No significant differences among the groups in the occurrence of secondary outcomes were observed at 10 days. Conclusions. For patients with ischemic stroke treated within 48 hours of the onset of symptoms, low-molecular-weight heparin was effective in improving outcomes at six months.	PRINCE WALES HOSP,DEPT DIAGNOST RADIOL & ORGAN IMAGING,SHA TIN,HONG KONG; QUEEN MARY HOSP,DEPT MED,HONG KONG,HONG KONG; QUEEN MARY HOSP,DEPT DIAGNOST RADIOL,HONG KONG,HONG KONG; KWONG WAH HOSP,DEPT MED & GERIATR,HONG KONG,HONG KONG; PAMELA YOUDE NETHERSOLE EASTERN HOSP,DEPT MED,HONG KONG,HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital; University of Hong Kong; University of Hong Kong; Kwong Wah Hospital; Pamela Youde Nethersole Eastern Hospital	KAY, R (corresponding author), PRINCE WALES HOSP,DEPT MED,SHA TIN,HONG KONG.		Woo, Jean/K-2625-2014; Ahuja, Anil T/H-4031-2017; Wong, Ka Sing Lawrence/N-3434-2015	Woo, Jean/0000-0001-7593-3081; Ahuja, Anil T/0000-0002-0726-5402; Wong, Ka Sing Lawrence/0000-0002-2031-9866				ADAMS HP, 1994, STROKE, V25, P1901, DOI 10.1161/01.STR.25.9.1901; ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; ANDERSON CS, 1994, J NEUROL NEUROSUR PS, V57, P1173, DOI 10.1136/jnnp.57.10.1173; Armitage P., 1994, STAT METHODS MED RES, P403; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BARNETT HJM, 1995, NEW ENGL J MED, V332, P238, DOI 10.1056/NEJM199501263320408; BILLER J, 1991, SEMIN NEUROL, V11, P353, DOI 10.1055/s-2008-1041240; CANDELISE L, 1994, CEREBROVASC DIS, V4, P341, DOI 10.1159/000108505; CAPLAN LR, 1989, STROKE, V20, P968, DOI 10.1161/str.20.7.968a; GRANGER CV, 1979, ARCH PHYS MED REHAB, V60, P14; HEISS WD, 1992, J CEREBR BLOOD F MET, V12, P193, DOI 10.1038/jcbfm.1992.29; HIRSH J, 1992, BLOOD, V79, P1; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; KAKKAR VV, 1993, LANCET, V341, P259, DOI 10.1016/0140-6736(93)92614-Y; KAY R, 1994, STROKE, V25, P684, DOI 10.1161/01.STR.25.3.684; KAY R, 1992, NEUROLOGY, V42, P985, DOI 10.1212/WNL.42.5.985; LEIZOROVICZ A, 1994, BMJ-BRIT MED J, V309, P299, DOI 10.1136/bmj.309.6950.299; LINDLEY RI, 1993, STROKE, V24, P1801, DOI 10.1161/01.STR.24.12.1801; LINDLEY RI, 1994, CEREBROVASC DIS, V4, P314, DOI 10.1159/000108501; MARSH EE, 1989, NEUROLOGY, V39, P1631, DOI 10.1212/WNL.39.12.1631; MARSHAL RS, 1993, J NEUROL NEUROSUR PS, V56, P6, DOI 10.1136/jnnp.56.1.6; MILLER VT, 1988, STROKE, V19, P403, DOI 10.1161/01.STR.19.3.403; PHILLIPS SJ, 1989, STROKE, V20, P295, DOI 10.1161/01.STR.20.2.295; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; ROTHROCK JF, 1991, ANN INTERN MED, V115, P885, DOI 10.7326/0003-4819-115-11-885; Sackett D., 1985, CLIN EPIDEMIOLOGY BA, P59; SANDERCOCK PAG, 1993, J NEUROL NEUROSUR PS, V56, P17, DOI 10.1136/jnnp.56.1.17; SCHEINBERG P, 1989, STROKE, V20, P173, DOI 10.1161/01.STR.20.2.173; SHINAR D, 1987, ARCH PHYS MED REHAB, V68, P723; WADE DT, 1987, J NEUROL NEUROSUR PS, V50, P177, DOI 10.1136/jnnp.50.2.177; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003	31	391	425	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 14	1995	333	24					1588	1593		10.1056/NEJM199512143332402	http://dx.doi.org/10.1056/NEJM199512143332402			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK065	7477193				2022-12-28	WOS:A1995TK06500002
J	GLOTH, FM; GUNDBERG, CM; HOLLIS, BW; HADDAD, JG; TOBIN, JD				GLOTH, FM; GUNDBERG, CM; HOLLIS, BW; HADDAD, JG; TOBIN, JD			VITAMIN-D DEFICIENCY IN HOMEBOUND ELDERLY PERSONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTMENOPAUSAL WOMEN; POPULATION; SERUM; OSTEOCALCIN; CALCIUM	Objective.-To assess the vitamin D status in homebound, community-dwelling elderly persons; sunlight-deprived elderly nursing home residents; and healthy, ambulatory elderly persons. Design.-A cohort analytic study. Participants.-Of 244 subjects at least 65 years old, 116 subjects (85 women and 31 men) had been confined indoors for at least 6 months, either in private dwellings in the community (the Hopkins Elder Housecall Program) or in a teaching nursing home (The Johns Hopkins Geriatrics Center). The 128 control subjects, a healthy ambulatory group, came from the Baltimore Longitudinal Study on Aging. All subjects were free of diseases or medications that might interfere with their vitamin D status. Main Outcome measures.-Serum levels of 25-hydroxyvitamin D (25-OHD) and 1,25-dihydroxyvitamin D (1,25-[OH]D-2) were measured in all subjects. In a subgroup of 80 subjects, serum levels of intact parathyroid hormone (PTH), ionized calcium, and osteocalcin and intake of vitamin D (through 3-day food records) were assessed. A randomly selected cohort of sunlight-deprived subjects also had serum levels of vitamin D binding protein measured. Results.-In sunlight-deprived subjects overall, the mean 25-OHD level was 30 nmol/L (12 ng/mL) (range, <10 to 77 nmol/L [<4 to 31 ng/mL]) and the mean 1,25(OH)(2)D level was 52 pmol/L (20 pg/mL) (range, 18 to 122 pmol/L [7 to 47 pg/mL]). In the sunlight-deprived subjects, 54% of community dwellers and 38% of nursing home residents had serum levels of 25-OHD below 25 nmol/L (10 ng/mL) (normal range, 25 to 137 nmol/L [10 to 55 ng/mL]). A significant inverse relationship existed between 25-OHD (ie, Log [25-OHD]) and PTH when they were analyzed together (r=-0.42; R(2)=0.18; P<.001) and for each cohort separately. All other parameters measured, except ionized calcium, differed significantly from the Baltimore Longitudinal Study Group means. The mean (SD) daily intakes of vitamin D (121 [132] IU) and calcium (583 [322] mg) were below the recommended dietary allowance only in the community-dwelling homebound population. The mean vitamin D binding protein level in the sunlight-deprived subgroup was in the normal range. Conclusions.-Despite a relatively high degree of vitamin supplementation in the United States, homebound elderly persons are likely to suffer from vitamin D deficiency.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV GERIATR MED & GERONTOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS BAYVIEW MED CTR, BALTIMORE, MD USA; YALE UNIV, SCH MED, DEPT ORTHOPED, NEW HAVEN, CT USA; MED UNIV S CAROLINA, CHILDRENS HOSP, DEPT PEDIAT, CHARLESTON, SC 29425 USA; UNIV PENN, DIV ENDOCRINOL, PHILADELPHIA, PA 19104 USA; NIA, GERONTOL RES CTR, BALTIMORE, MD 21224 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Yale University; Medical University of South Carolina; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	GLOTH, FM (corresponding author), UNION MEM HOSP, DEPT MED, DIV GERIATR, 201 E UNIV PKWY, BALTIMORE, MD 21218 USA.				NCRR NIH HHS [MO1 RR02719] Funding Source: Medline; NIAMS NIH HHS [AR 38460] Funding Source: Medline; NIA NIH HHS [5 T32 AG00120-03] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002719] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000120] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOUILLON R, 1977, J CLIN ENDOCR METAB, V45, P225, DOI 10.1210/jcem-45-2-225; Chalmers J, 1967, J Bone Joint Surg Br, V49, P403; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; GLOTH FM, 1991, J AM GERIATR SOC, V39, P137, DOI 10.1111/j.1532-5415.1991.tb01615.x; GLOTH FM, 1995, J AM GERIATR SOC, V43, P822, DOI 10.1111/j.1532-5415.1995.tb07059.x; GLOTH FM, 1995, AM J PHYS MED REHAB, V74, P45, DOI 10.1097/00002060-199501000-00008; GLOTH FM, 1991, ARCH INTERN MED, V151, P1662, DOI 10.1001/archinte.151.8.1662; GLOTH FM, 1995, J AM GERIATR SOC, V43, P1269, DOI 10.1111/j.1532-5415.1995.tb07404.x; GLOTH FM, 1993, J BONE MINER RES, V8, pS216; GLOTH FM, 1990, J BONE MINER RES S2, V5, pS268; GLOTH FM, IN PRESS J AM DIET A; GUILLEMANT S, 1989, J STEROID BIOCHEM, V33, P1155, DOI 10.1016/0022-4731(89)90424-X; GUNDBERG CM, 1984, METHOD ENZYMOL, V107, P516; HOLLIS BW, 1986, CLIN CHEM, V32, P2060; HOLLIS BW, 1993, CLIN CHEM, V39, P529; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; OMDAHL JL, 1982, AM J CLIN NUTR, V36, P1225, DOI 10.1093/ajcn/36.6.1225; OOMS ME, 1995, J BONE MINER RES, V10, P1177; PARFITT AM, 1982, AM J CLIN NUTR, V36, P1014, DOI 10.1093/ajcn/36.5.1014; SHERMAN SS, 1990, J CLIN ENDOCR METAB, V71, P405, DOI 10.1210/jcem-71-2-405; SKARIA J, 1975, ACTA NEUROL SCAND, V51, P37; VILLAREAL DT, 1991, J CLIN ENDOCR METAB, V72, P628, DOI 10.1210/jcem-72-3-628; WEBB AR, 1990, AM J CLIN NUTR, V51, P1075, DOI 10.1093/ajcn/51.6.1075; YASUMURA S, 1987, J CLIN ENDOCR METAB, V64, P681, DOI 10.1210/jcem-64-4-681; [No title captured]; 1989, NATIONAL ACADEMY SCI	26	359	375	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	1995	274	21					1683	1686		10.1001/jama.274.21.1683	http://dx.doi.org/10.1001/jama.274.21.1683			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH151	7474272				2022-12-28	WOS:A1995TH15100024
J	FISHER, B; ANDERSON, S; REDMOND, CK; WOLMARK, N; WICKERHAM, DL; CRONIN, WM				FISHER, B; ANDERSON, S; REDMOND, CK; WOLMARK, N; WICKERHAM, DL; CRONIN, WM			REANALYSIS AND RESULTS AFTER 12 YEARS OF FOLLOW-UP IN A RANDOMIZED CLINICAL-TRIAL COMPARING TOTAL MASTECTOMY WITH LUMPECTOMY WITH OR WITHOUT IRRADIATION IN THE TREATMENT OF BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. Previous findings from a clinical trial (Protocol B-06) conducted by the National Surgical Adjuvant Breast and Bower Project (NSABP) indicated the worth of lumpectomy and breast irradiation for treating breast cancer. After the discovery by NSABP staff members of falsified information on patients enrolled in the study by St. Luc Hospital in Montreal, separate audits were conducted at St, Luc Hospital and other participating institutions. We report the results of both audits and update the study findings through an average of 12 years of follow-up. Methods. Patients with either negative or positive axillary nodes and tumors 4 cm or less in diameter were randomly assigned to one of three treatments: total mastectomy, lumpectomy followed by breast irradiation, or lumpectomy without irradiation. Three cohorts of patients were analyzed. The first cohort included all 2105 randomized patients, who were analyzed according to the intention-to-treat principle. The second cohort consisted of 1851 eligible patients in the first cohort with known nodal status who agreed to be followed and who accepted their assigned therapy (among those excluded were 6 patients from St. Luc Hospital who were declared ineligible because of falsified biopsy dates). The third cohort consisted of the patients in the second cohort minus the 322 eligible patients from St. Luc Hospital (total, 1529 patients). Results. Regardless of the cohort, no significant differences were found in overall survival, disease-free survival, or survival free of disease at distant sites between the patients who underwent total mastectomy and those treated by lumpectomy alone or by lumpectomy plus breast irradiation. After 12 years of follow-up, the cumulative incidence of a recurrence of tumor in the ipsilateral breast was 35 percent in the group treated with lumpectomy alone and 10 percent in the group treated with lumpectomy and breast irradiation (P<0.001). Conclusions. Our findings continue to indicate that lumpectomy followed by breast irradiation is appropriate therapy for women with either negative or positive axillary nodes and breast tumors 4 cm or less in diameter.	NATL SURG ADJUVANT BREAST & BOWEL PROJECT, PITTSBURGH, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project				Anderson, Stewart/0000-0001-8948-0650	NATIONAL CANCER INSTITUTE [U10CA012027] Funding Source: NIH RePORTER; NCI NIH HHS [U10-CA-12027] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHRISTIAN MC, 1995, NEW ENGL J MED, V333, P1469, DOI 10.1056/NEJM199511303332206; COLLINS R, 1996, OXFORD TXB MED; CUTLER SJ, 1958, J CHRON DIS, V8, P699; DIGNAM JJ, 1995, STAT MED, V14, P1985, DOI 10.1002/sim.4780141805; FISHER B, 1991, LANCET, V338, P327, DOI 10.1016/0140-6736(91)90475-5; FISHER B, 1994, WORLD J SURG, V18, P63, DOI 10.1007/BF00348193; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; FISHER B, 1994, NEW ENGL J MED, V330, P1458; GAIL MH, 1985, CANCER TREAT REP, V69, P1107; HANKEY BF, 1971, J CHRON DIS, V24, P523, DOI 10.1016/0021-9681(71)90041-5; KORN EL, 1992, STAT MED, V11, P813, DOI 10.1002/sim.4780110611; LEWIS JA, 1993, BRIT J CANCER, V68, P647, DOI 10.1038/bjc.1993.402; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; NEATON JD, 1991, CONTROL CLIN TRIALS, V12, P731, DOI 10.1016/0197-2456(91)90036-L; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; 1990, 1990 NIH CONS DEV C, V8, P1; 1993, DHHS ORI9108 OFF RES	17	1092	1136	1	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 30	1995	333	22					1456	1461		10.1056/NEJM199511303332203	http://dx.doi.org/10.1056/NEJM199511303332203			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG445	7477145				2022-12-28	WOS:A1995TG44500003
J	MEIER, UC; KLENERMAN, P; GRIFFIN, P; JAMES, W; KOPPE, B; LARDER, B; MCMICHAEL, A; PHILLIPS, R				MEIER, UC; KLENERMAN, P; GRIFFIN, P; JAMES, W; KOPPE, B; LARDER, B; MCMICHAEL, A; PHILLIPS, R			CYTOTOXIC T-LYMPHOCYTE LYSIS INHIBITED BY VIABLE HIV MUTANTS	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; GENETIC-VARIATION; RECOGNITION; RETROVIRUS; CELLS	Immune evasion by the human immunodeficiency virus (HIV) is unexplained but may involve the mutation of viral antigens. When cytotoxic T lymphocytes engaged CD4-positive cells that were acutely infected with HIV bearing natural variant epitopes in reverse transcriptase, substantial inhibition of specific antiviral lysis was observed. Mutant viruses capable of these transactive effects could facilitate the persistence of a broad range of HIV variants in the face of an active and specific immune response.	JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,OXFORD OX1 3RE,ENGLAND; WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND	University of Oxford; University of Oxford; University of Oxford; GlaxoSmithKline; Wellcome Research Laboratories			james, william/H-4289-2013; Meier, Ute Christiane/N-6891-2018; Larder, Brendan/AAB-3106-2020	james, william/0000-0002-2506-1198; Meier, Ute Christiane/0000-0002-8838-5464; klenerman, paul/0000-0003-4307-9161	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; BEVAN MJ, 1975, J EXP MED, V142, P1349, DOI 10.1084/jem.142.6.1349; BOSWORTH N, 1989, NATURE, V341, P167, DOI 10.1038/341167a0; COFFIN JM, 1995, NATURE, V375, P534, DOI 10.1038/375534a0; COLLIN M, 1994, J GEN VIROL, V75, P1597, DOI 10.1099/0022-1317-75-7-1597; COUILLIN I, 1994, J EXP MED, V180, P1129, DOI 10.1084/jem.180.3.1129; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DELVAL M, 1991, CELL, V66, P1145, DOI 10.1016/0092-8674(91)90037-Y; EBERLE J, 1992, J VIROL METHODS, V40, P347, DOI 10.1016/0166-0934(92)90092-R; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; KLENERMAN P, 1995, EUR J IMMUNOL, V25, P1927, DOI 10.1002/eji.1830250720; KLENERMAN P, UNPUB; KLENERMAN P, 1994, NATURE, V269, P403; KOUP RA, 1995, J EXP MED, V180, P779; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1993, NATURE, V365, P451, DOI 10.1038/365451a0; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; MCADAM S, 1995, J IMMUNOL, V155, P2729; MDRENAS J, 1995, SCIENCE, V267, P515; MEIER UE, UNPUB; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; NOWAK MA, 1995, NATURE, V375, P606, DOI 10.1038/375606a0; PAUL WE, 1995, CELL, V82, P177, DOI 10.1016/0092-8674(95)90304-6; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; REID S, UNPUB; SHIMOTOHNO K, 1982, J VIROL, V41, P163, DOI 10.1128/JVI.41.1.163-171.1982; SIMON JHM, 1993, J EXP MED, V177, P949, DOI 10.1084/jem.177.4.949; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; TEMIN HM, 1993, P NATL ACAD SCI USA, V90, P6900, DOI 10.1073/pnas.90.15.6900; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; WALKER BD, 1989, P NATL ACAD SCI USA, V86, P9514, DOI 10.1073/pnas.86.23.9514; ZHANG LQ, 1991, AIDS, V5, P675, DOI 10.1097/00002030-199106000-00006	33	93	94	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 24	1995	270	5240					1360	1362		10.1126/science.270.5240.1360	http://dx.doi.org/10.1126/science.270.5240.1360			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF899	7481824				2022-12-28	WOS:A1995TF89900039
J	MCCULLOCH, P; CHOY, A; MARTIN, L				MCCULLOCH, P; CHOY, A; MARTIN, L			ASSOCIATION BETWEEN TUMOR ANGIOGENESIS AND TUMOR-CELL SHEDDING INTO EFFLUENT VENOUS-BLOOD DURING BREAST-CANCER SURGERY	LANCET			English	Note							CARCINOMA; INDICATOR	Tumour angiogenesis is a powerful prognostic indicator in breast cancer. Shedding of tumour cells into the bloodstream is essential for haematogenous metastasis. The relation between cell shedding and angiogenesis in human cancer is not known. We studied vascular density and cell shedding in 16 women undergoing breast cancer surgery. Circulating cells were found in one patient before, in six during, acid none after operation. Vascular density was related to detection of circulating tumour cells during surgery (correlation coefficient for first intraoperative sampling=0.56, p=0.024, 95% CI 0.08 to 0.83). Tumour cell shedding during surgery is related to vascular density; the relevance of this relation to the prognostic significance of vascular density in breast cancer merits further study.			MCCULLOCH, P (corresponding author), ROYAL LIVERPOOL UNIV HOSP,DEPT SURG,LIVERPOOL L7 8XP,MERSEYSIDE,ENGLAND.			McCulloch, Peter/0000-0002-3210-8273				FOLKMAN J, 1994, J CLIN ONCOL, V12, P441, DOI 10.1200/JCO.1994.12.3.441; HORAK ER, 1992, LANCET, V340, P1120, DOI 10.1016/0140-6736(92)93150-L; LIOTTA LA, 1976, CANCER RES, V36, P889; MCCULLOCH P, 1994, LANCET, V344, P402; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101	6	90	91	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 18	1995	346	8986					1334	1335		10.1016/S0140-6736(95)92345-4	http://dx.doi.org/10.1016/S0140-6736(95)92345-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE916	7475773				2022-12-28	WOS:A1995TE91600011
J	VAUGHAN, J; DONALDSON, C; BITTENCOURT, J; PERRIN, MH; LEWIS, K; SUTTON, S; CHAN, R; TURNBULL, AV; LOVEJOY, D; RIVIER, C; RIVIER, J; SAWCHENKO, PE; VALE, W				VAUGHAN, J; DONALDSON, C; BITTENCOURT, J; PERRIN, MH; LEWIS, K; SUTTON, S; CHAN, R; TURNBULL, AV; LOVEJOY, D; RIVIER, C; RIVIER, J; SAWCHENKO, PE; VALE, W			UROCORTIN, A MAMMALIAN NEUROPEPTIDE RELATED TO FISH UROTENSIN-I AND TO CORTICOTROPIN-RELEASING FACTOR	NATURE			English	Article							EDINGER-WESTPHAL NUCLEUS; RAT; EXPRESSION; CLONING; CRF; SEQUENCE; RECEPTOR; SYSTEM; GENE	Corticotropin-releasing factor (CRF), a peptide first isolated from mammalian brain(1), is critical in the regulation of the pituitary-adrenal axis, and in complementary stress-related endocrine, autonomic and behavioural responses(2). Fish urotensin I and amphibian sauvagine were considered to be homologues(3) of CRF until peptides even more closely related to CRF were identified in these same vertebrate classes(4,5). We have characterized another mammalian member of the CRF family and have localized its urotensin-like immunoreactivity to, and cloned related complementary DNAs from, a discrete rat midbrain region. The deduced protein encodes a peptide that we name urocortin, which is related to urotensin (63% sequence identity) and CRF (45% sequence identity). Synthetic urocortin evokes secretion of adrenocorticotropic hormone (ACTH) both in vitro and in vivo and binds and activates transfected type-1 CRF receptors(6,9), the subtype expressed by pituitary corticotropes. The coincidence of urotensin-like immunoreactivity with type-2 CRF receptors(10-13) in brain, and our observation that urocortin is more potent than CRF at binding and activating type-2 CRF receptors, as well as at inducing c-Fos (an index of cellular activation) in regions enriched in type-2 CRF receptors, indicate that this new peptide could be an endogenous ligand for type-2 CRF receptors.	SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,LA JOLLA,CA 92037; SALK INST BIOL STUDIES,NEURONAL STRUCT & FUNCT LAB,LA JOLLA,CA 92037	Salk Institute; Salk Institute			Bittencourt, Jackson/B-4696-2011; Bittencourt, Jackson/I-9187-2014; Bittencourt, Jackson Cioni/AAF-6896-2021	Bittencourt, Jackson/0000-0002-8908-6474; Bittencourt, Jackson/0000-0002-8908-6474; Bittencourt, Jackson Cioni/0000-0002-8908-6474	NIDDK NIH HHS [DK-26741] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK026741] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHAN RKW, 1993, J NEUROSCI, V13, P5125; CHANG CP, 1993, NEURON, V11, P1187, DOI 10.1016/0896-6273(93)90230-O; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; CHUNG RY, 1987, NEUROSCI LETT, V83, P13, DOI 10.1016/0304-3940(87)90208-4; IMAKI J, 1991, BRAIN RES, V547, P28; ISHIDA I, 1986, P NATL ACAD SCI USA, V83, P803; KISHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P1108, DOI 10.1073/pnas.92.4.1108; Lederis K., 1985, Recent Progress in Hormone Research, V41, P553; Lederis K., 1994, P67; LOEWY AD, 1978, BRAIN RES, V141, P153, DOI 10.1016/0006-8993(78)90624-8; LOVENBERG TW, 1995, P NATL ACAD SCI USA, V92, P836, DOI 10.1073/pnas.92.3.836; LOVENBERG TW, 1995, ENDOCRINOLOGY, V136, P3351; McDougal D. H., 2014, COMPR PHYSIOL, DOI [10.1002/cphy.c140014, DOI 10.1002/CPHY.C140014]; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MUGLIA L, 1995, NATURE, V373, P427, DOI 10.1038/373427a0; OKAWARA Y, 1988, P NATL ACAD SCI USA, V85, P8439, DOI 10.1073/pnas.85.22.8439; PERRIN M, 1995, P NATL ACAD SCI USA, V92, P2969, DOI 10.1073/pnas.92.7.2969; PERRIN MH, 1993, ENDOCRINOLOGY, V133, P3058, DOI 10.1210/en.133.6.3058; POTTER E, 1992, P NATL ACAD SCI USA, V89, P4192, DOI 10.1073/pnas.89.9.4192; POTTER E, 1994, P NATL ACAD SCI USA, V91, P8777, DOI 10.1073/pnas.91.19.8777; SAPER CB, 1979, J COMP NEUROL, V183, P689, DOI 10.1002/cne.901830402; STENZEL P, 1995, MOL ENDOCRINOL, V9, P637, DOI 10.1210/me.9.5.637; STENZELPOORE MP, 1992, MOL ENDOCRINOL, V6, P1716, DOI 10.1210/me.6.10.1716; SUTTON SW, 1995, ENDOCRINOLOGY, V136, P1097, DOI 10.1210/en.136.3.1097; THOMPSON RC, 1987, MOL ENDOCRINOL, V1, P363, DOI 10.1210/mend-1-5-363; VALE W, 1983, METHOD ENZYMOL, V103, P565; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VALE W, 1983, RECENT PROG HORM RES, V39, P245; VITA N, 1993, FEBS LETT, V335, P1, DOI 10.1016/0014-5793(93)80427-V; Webster William R., 1995, P797	30	1334	1368	0	40	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 16	1995	378	6554					287	292		10.1038/378287a0	http://dx.doi.org/10.1038/378287a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477349				2022-12-28	WOS:A1995TE85800051
J	NYGARD, O; VOLLSET, SE; REFSUM, H; STENSVOLD, I; TVERDAL, A; NORDREHAUG, JE; UELAND, PM; KVALE, G				NYGARD, O; VOLLSET, SE; REFSUM, H; STENSVOLD, I; TVERDAL, A; NORDREHAUG, JE; UELAND, PM; KVALE, G			TOTAL PLASMA HOMOCYSTEINE AND CARDIOVASCULAR RISK PROFILE - THE HORDALAND HOMOCYSTEINE STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; CORONARY-ARTERY DISEASE; VASCULAR-DISEASE; METHIONINE METABOLISM; LIPOPROTEIN LEVELS; CIGARETTE-SMOKING; PHYSICAL-ACTIVITY; UNITED-STATES; HEART-DISEASE; FOLATE LEVELS	Objective.-To estimate the relations between established cardiovascular risk factors and total homocysteine (tHcy) in plasma. Design.-Health examination survey by the Norwegian Health Screening Service in 1992 and 1993. Setting.-General community, Hordaland County of Western Norway. Participants.-A total of 7591 men and 8585 women, 40 to 67 years of age, with no history of hypertension, diabetes, coronary heart disease, or cerebrovascular disease were included. Main Outcome Measure.-Plasma tHcy level. Results.-The level of plasma tHcy was higher in men than in women and increased with age. In subjects 40 to 42 years old, geometric means were 10.8 mu mol/L for 5918 men and 9.1 mu mol/L for 6348 women. At age 65 to 67 years, the corresponding tHcy values were 12.3 mu mol/L (1386 men) and 11.0 mu mol/L (1932 women). Plasma tHcy level increased markedly with the daily number of cigarettes smoked in all age groups. Its relation to smoking was particularly strong in women. The combined effect of age, sex, and smoking was striking. Heavy-smoking men aged 65 to 67 years had a mean tHcy level 4.8 mu mol/L higher than never-smoking women aged 40 to 42 years. Plasma tHcy level also was positively related to total cholesterol level, blood pressure, and heart rate and inversely related to physical activity. The relations were not substantially changed by multivariate adjustment, including intake of vitamin supplements, fruits, and vegetables. Conclusions.-Elevated plasma tHcy level was associated with major components of the cardiovascular risk profile, ie, male sex, old age, smoking, high blood pressure, elevated cholesterol level, and lack of exercise. These findings should influence future studies on the etiology and pathogenesis of cardiovascular disease.	UNIV BERGEN, DEPT BIOL CLIN, DIV PHARMACOL, BERGEN, NORWAY; UNIV BERGEN, CTR INT HLTH, BERGEN, NORWAY; HAUKELAND UNIV HOSP, DEPT HEART DIS, BERGEN, NORWAY; NATL HLTH SCREENING SERV, OSLO, NORWAY	University of Bergen; University of Bergen; University of Bergen; Haukeland University Hospital			Ueland, Per M/C-7340-2013; Refsum, Helga/A-4073-2010	Tverdal, Aage/0000-0002-2909-5678; Ueland, Per Magne/0000-0002-1903-0571				ANDERSSON A, 1992, EUR J CLIN CHEM CLIN, V30, P377; ANDERSSON A, 1992, EUR J CLIN INVEST, V22, P79, DOI 10.1111/j.1365-2362.1992.tb01940.x; ANKER G, 1995, INT J CANCER, V60, P365; ARAKI A, 1993, ATHEROSCLEROSIS, V103, P149, DOI 10.1016/0021-9150(93)90258-V; ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; ARAKI A, 1989, ATHEROSCLEROSIS, V79, P139, DOI 10.1016/0021-9150(89)90118-4; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BERG K, 1992, CLIN GENET, V41, P315; BERGMARK C, 1993, EUR J VASCULAR SURG, V7, P391, DOI 10.1016/S0950-821X(05)80255-5; BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; Bjartveit K, 1979, Acta Med Scand Suppl, V634, P1; BOERS GH, 1983, J CLIN INVEST, V72, P1971, DOI 10.1172/JCI111161; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BRATTSTROM L, 1992, SCAND J CLIN LAB INV, V52, P283, DOI 10.3109/00365519209088360; BRATTSTROM L, 1994, J INTERN MED, V236, P633, DOI 10.1111/j.1365-2796.1994.tb00856.x; BRATTSTROM LE, 1985, METABOLISM, V34, P1073, DOI 10.1016/0026-0495(85)90082-4; CHEN ATL, 1989, ENVIRON MOL MUTAGEN, V13, P319, DOI 10.1002/em.2850130407; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; D'Avanzo B, 1993, Ann Epidemiol, V3, P645; DASTUR DK, 1972, BMJ-BRIT MED J, V3, P260, DOI 10.1136/bmj.3.5821.260; DECESARIS R, 1992, CARDIOLOGY, V81, P233, DOI 10.1159/000175809; DIXON WJ, 1992, BMDP STATISTICAL SOF, V1; FISKERSTRAND T, 1993, CLIN CHEM, V39, P263; GOLDBERG L, 1985, MED CLIN N AM, V69, P41; JACOBSEN DW, 1994, CLIN CHEM, V40, P873; JOOSTEN E, 1993, AM J CLIN NUTR, V58, P468, DOI 10.1093/ajcn/58.4.468; KANG SS, 1986, J CLIN INVEST, V77, P1482, DOI 10.1172/JCI112461; KANG SS, 1986, METABOLISM, V35, P889, DOI 10.1016/0026-0495(86)90049-1; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; LAKKA TA, 1994, NEW ENGL J MED, V330, P1549, DOI 10.1056/NEJM199406023302201; LINNELL JC, 1968, BRIT MED J, V2, P215, DOI 10.1136/bmj.2.5599.215; MALINOW MR, 1989, CIRCULATION, V79, P1180, DOI 10.1161/01.CIR.79.6.1180; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; MALINOW MR, 1994, J INTERN MED, V236, P603, DOI 10.1111/j.1365-2796.1994.tb00854.x; MALINOW MR, 1994, CLIN CHEM, V40, P857; MANSOOR MA, 1995, ARTERIOSCL THROM VAS, V15, P232, DOI 10.1161/01.ATV.15.2.232; MCCULLY KS, 1975, ATHEROSCLEROSIS, V22, P215, DOI 10.1016/0021-9150(75)90004-0; MCPHILLIPS JB, 1994, J AM DIET ASSOC, V94, P287, DOI 10.1016/0002-8223(94)90370-0; MOLGAARD J, 1992, J INTERN MED, V231, P273; MORRIS JN, 1980, LANCET, V2, P1207; Mudd Sh, 1989, METABOLIC BASIS INHE, V1, P693; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PIYATHILAKE CJ, 1994, AM J CLIN NUTR, V60, P559, DOI 10.1093/ajcn/60.4.559; PRYOR WA, 1993, ANN NY ACAD SCI, V686, P12, DOI 10.1111/j.1749-6632.1993.tb39148.x; REFSUM H, 1989, CLIN CHEM, V35, P1921; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; SUBAR AF, 1990, AM J PUBLIC HEALTH, V80, P1323, DOI 10.2105/AJPH.80.11.1323; UBBINK JB, 1993, AM J CLIN NUTR, V57, P47, DOI 10.1093/ajcn/57.1.47; UELAND PM, 1995, CLIN CHEM, V41, P340; UELAND PM, 1993, CLIN CHEM, V39, P1764; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; VANDERMOOREN MJ, 1994, EUR J CLIN INVEST, V24, P733; VERMAAK WJH, 1990, AM J CLIN NUTR, V51, P1058, DOI 10.1093/ajcn/51.6.1058; VESTER B, 1991, EUR J CLIN CHEM CLIN, V29, P549; WEINTRAUB MS, 1989, CIRCULATION, V79, P1007, DOI 10.1161/01.CIR.79.5.1007; WILCKEN DEL, 1976, J CLIN INVEST, V57, P1079, DOI 10.1172/JCI108350; WILLIAMS RR, 1990, CORONARY ARTERY DIS, V1, P681, DOI 10.1097/00019501-199011000-00008; WONG PWK, 1988, AM J MED, V84, P1093, DOI 10.1016/0002-9343(88)90328-2; WU LL, 1994, CLIN CHEM, V40, P552; 1991, S PLUS USERS MANUAL, V1	62	896	932	0	33	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	1995	274	19					1526	1533		10.1001/jama.274.19.1526	http://dx.doi.org/10.1001/jama.274.19.1526			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD571	7474221				2022-12-28	WOS:A1995TD57100029
J	CORBETTA, M; SHULMAN, GL; MIEZIN, FM; PETERSEN, SE				CORBETTA, M; SHULMAN, GL; MIEZIN, FM; PETERSEN, SE			SUPERIOR PARIETAL CORTEX ACTIVATION DURING SPATIAL ATTENTION SHIFTS AND VISUAL FEATURE CONJUNCTION	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; BRAIN; RESPONSES; SEARCH; PET	Positron emission tomography was used to measure changes in the regional cerebral blood flow of normal people while they searched visual displays for targets defined by color, by motion, or by a conjunction of color and motion. A region in the superior parietal cortex was activated only during the conjunction task, at a location that had previously been shown to be engaged by successive shifts of spatial attention. Correspondingly, the time needed to detect a conjunction target increased with the number of items in the display, which is consistent with the use of a mechanism that successively analyzes each item in the visual field.	WASHINGTON UNIV,SCH MED,MCDONNELL CTR STUDY HIGHER BRAIN FUNCT,ST LOUIS,MO 63110	Washington University (WUSTL)	CORBETTA, M (corresponding author), WASHINGTON UNIV,SCH MED,DEPT NEUROL & NEUROL SURG,ST LOUIS,MO 63110, USA.		Corbetta, Maurizio/AAZ-5219-2020; Petersen, Steve/ABF-1368-2020	CORBETTA, MAURIZIO/0000-0001-8295-3304	NEI NIH HHS [EY08775] Funding Source: Medline; NINDS NIH HHS [NS2533, NS06833] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008775] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS006833, P50NS006833] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BUCKNER RL, 1995, J NEUROSCI, V15, P12; BUNDESEN C, 1990, PSYCHOL REV, V97, P523, DOI 10.1037/0033-295X.97.4.523; BUSHNELL MC, 1981, J NEUROPHYSIOL, V46, P755, DOI 10.1152/jn.1981.46.4.755; CORBETTA M, 1993, J NEUROSCI, V13, P1202; CORBETTA M, 1991, J NEUROSCI, V8, P2383; De Renzi E., 1982, DISORDERS SPACE EXPL; DUNCAN J, 1989, PSYCHOL REV, V96, P433, DOI 10.1037/0033-295X.96.3.433; FOX PT, 1985, J COMPUT ASSIST TOMO, V9, P141, DOI 10.1097/00004728-198501000-00025; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; HEINZE HJ, 1995, NATURE, V372, P543; HERSCOVITCH P, 1983, J NUCL MED, V24, P782; HUNTON DE, UNPUB; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; MINTUN MA, 1989, J CEREBR BLOOD F MET, V9, P96, DOI 10.1038/jcbfm.1989.13; POSNER MI, 1984, J NEUROSCI, V4, P1863; Talairach J., 1988, COPLANAR STEREOTAXIC; TOWNSEND JT, 1972, BRIT J MATH STAT PSY, V25, P168, DOI 10.1111/j.2044-8317.1972.tb00490.x; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; WOLFE JM, 1989, J EXP PSYCHOL HUMAN, V15, P419, DOI 10.1037/0096-1523.15.3.419; YAMAMOTO M, 1982, IEEE T NUCL SCI, V29, P529, DOI 10.1109/TNS.1982.4335901	20	565	576	0	29	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 3	1995	270	5237					802	805		10.1126/science.270.5237.802	http://dx.doi.org/10.1126/science.270.5237.802			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TC712	7481770				2022-12-28	WOS:A1995TC71200042
J	DEAVER, DR				DEAVER, DR			A NEW NONISOTOPIC DETECTION SYSTEM FOR IMMUNOASSAYS	NATURE			English	Article								A new technology for conducting immunoassays that uses an electrochemiluminescence detection system, eliminates the use of radioisotopes and offers improved assay performance.	PENN STATE UNIV, CTR CELL RES, UNIVERSITY PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	DEAVER, DR (corresponding author), PENN STATE UNIV, DEPT DAIRY & ANIM SCI, UNIVERSITY PK, PA 16802 USA.							BLACKBURN GF, 1991, CLIN CHEM, V37, P1534; LELAND JK, 1990, J ELECTROCHEM SOC, V137, P3127, DOI 10.1149/1.2086171; MATTERI RL, 1987, DOMEST ANIM ENDOCRIN, V4, P157, DOI 10.1016/0739-7240(87)90011-7; YANG HJ, 1994, BIO-TECHNOL, V12, P193, DOI 10.1038/nbt0294-193	4	143	162	3	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 26	1995	377	6551					758	760		10.1038/377758a0	http://dx.doi.org/10.1038/377758a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB469	7477271				2022-12-28	WOS:A1995TB46900065
J	CHRISTY, NP				CHRISTY, NP			CORTICOSTEROID-THERAPY AND UNINTENTIONAL CAMOUFLAGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											CHRISTY, NP (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032, USA.							CHRISTY NP, 1962, J CLIN ENDOCR METAB, V22, P155, DOI 10.1210/jcem-22-2-155; CHRISTY NP, 1960, CLIN ENDOCRINOL, V1, P53; CHRISTY NP, 1988, CURRENT THERAPY ENDO, P104; CHRISTY NP, 1988, CURRENT THERAPY ENDO, P112; CHRISTY NP, 1971, HUMAN ADRENAL CORTEX, P395; COPE CL, 1972, ADRENAL STEROIDS DIS, P519; DRUCKER WD, 1965, AM J MED, V38, P522, DOI 10.1016/0002-9343(65)90130-0; GAMBERTOGLIO JG, 1980, J PHARMACOKINET BIOP, V8, P1, DOI 10.1007/BF01059447; JACOBS TP, 1988, JAMA-J AM MED ASSOC, V260, P2082, DOI 10.1001/jama.260.14.2082; JENKINS JS, 1967, BRIT MED J, V2, P205, DOI 10.1136/bmj.2.5546.205; Kepler EJ, 1941, ARCH INTERN MED, V68, P1010, DOI 10.1001/archinte.1941.00200110162009; KNOWLTON AI, 1971, HUMAN ADRENAL CORTEX, P329; MULLER AF, 1958, INT S ALDOSTERONE, P111; Peterson RR, 1971, HUMAN ADRENAL CORTEX; PICKUP ME, 1979, CLIN PHARMACOKINET, V4, P111, DOI 10.2165/00003088-197904020-00004; POWELL LW, 1972, GUT, V13, P690, DOI 10.1136/gut.13.9.690; SALASSA RM, 1953, JAMA-J AM MED ASSOC, V152, P1509, DOI 10.1001/jama.1953.03690160009004; SHEEHAN HL, 1949, Q J MED, V42, P319; TYRRELL JB, 1987, ENDOCRINOL METAB, P788; WYNN V, 1955, BR MED J, V4912, P505	20	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1988	260	14					2107	2109						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q3421	3418878				2022-12-28	WOS:A1988Q342100032
J	LI, HH; GYLLENSTEN, UB; CUI, XF; SAIKI, RK; ERLICH, HA; ARNHEIM, N				LI, HH; GYLLENSTEN, UB; CUI, XF; SAIKI, RK; ERLICH, HA; ARNHEIM, N			AMPLIFICATION AND ANALYSIS OF DNA-SEQUENCES IN SINGLE HUMAN-SPERM AND DIPLOID-CELLS	NATURE			English	Article									UNIV SO CALIF,DEPT BIOL SCI,MOLEC BIOL SECT,LOS ANGELES,CA 90089; CETUS CORP,DEPT HUMAN GENET,EMERYVILLE,CA 94608	University of Southern California				Arnheim, Norman/0000-0003-1247-1347				BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; CHAKRAVARTI A, 1986, P NATL ACAD SCI USA, V83, P1045, DOI 10.1073/pnas.83.4.1045; CHAKRAVARTI A, 1984, AM J HUM GENET, V36, P1239; CONNER BJ, 1983, P NATL ACAD SCI-BIOL, V80, P278, DOI 10.1073/pnas.80.1.278; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; GILL P, 1985, BIOTECHNOLOGY, V3, P1008; HOBBS HH, 1987, NUCLEIC ACIDS RES, V15, P379, DOI 10.1093/nar/15.1.379; LINDGREN V, 1985, P NATL ACAD SCI USA, V82, P8567, DOI 10.1073/pnas.82.24.8567; MIGONE N, 1985, AM J HUM GENET, V37, P1146; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PUWARAVUTIPANIC.T, 1975, EXP CELL RES, V90, P153, DOI 10.1016/0014-4827(75)90368-7; RENWICK JH, 1969, BRIT MED BULL, V25, P65, DOI 10.1093/oxfordjournals.bmb.a070673; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561	16	543	600	0	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 29	1988	335	6189					414	417		10.1038/335414a0	http://dx.doi.org/10.1038/335414a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q2364	3419517				2022-12-28	WOS:A1988Q236400040
J	SYKES, PA; KERR, R				SYKES, PA; KERR, R			TREATMENT OF INGROWING TOENAILS BY SURGEONS AND CHIROPODISTS	BRITISH MEDICAL JOURNAL			English	Article									TRAFFORD HOSP,DEPT SURG,MANCHESTER,ENGLAND; TRAFFORD HOSP,DEPT CHIROPODY,MANCHESTER,ENGLAND									MILLER SS, 1985, BRIT MED J, V291, P91, DOI 10.1136/bmj.291.6488.91-a; MURRAY WR, 1975, BRIT J SURG, V62, P409, DOI 10.1002/bjs.1800620522; SYKES P A, 1986, Journal of the Royal College of Surgeons of Edinburgh, V31, P300; WALLACE A, 1986, PULSE           0712, P25	4	18	18	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1988	297	6644					335	336		10.1136/bmj.297.6644.335	http://dx.doi.org/10.1136/bmj.297.6644.335			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P4527	3416165	Bronze, Green Published			2022-12-28	WOS:A1988P452700024
J	CHEN, YT; COLEMAN, RA; SCHEINMAN, JI; KOLBECK, PC; SIDBURY, JB				CHEN, YT; COLEMAN, RA; SCHEINMAN, JI; KOLBECK, PC; SIDBURY, JB			RENAL-DISEASE IN TYPE-I GLYCOGEN-STORAGE DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; NICHHD,HUMAN GENET BRANCH,BETHESDA,MD 20205	Duke University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	CHEN, YT (corresponding author), DUKE UNIV,MED CTR,DEPT PEDIAT,BOX 3028,DURHAM,NC 27710, USA.				NCRR NIH HHS [RR-30] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104; CHEN YT, 1984, NEW ENGL J MED, V310, P171, DOI 10.1056/NEJM198401193100306; DIAMOND JR, 1987, KIDNEY INT, V32, P671, DOI 10.1038/ki.1987.259; DITZEL J, 1967, DIABETES, V16, P264, DOI 10.2337/diab.16.4.264; EMMETT M, 1978, JAMA-J AM MED ASSOC, V239, P1642, DOI 10.1001/jama.239.16.1642; GOLDSZER RC, 1984, ANNU REV MED, V35, P429, DOI 10.1146/annurev.me.35.020184.002241; GREENE HL, 1976, NEW ENGL J MED, V294, P423, DOI 10.1056/NEJM197602192940805; GROSSMAN H, 1981, RADIOLOGY, V141, P753, DOI 10.1148/radiology.141.3.6272355; HOLLING HE, 1963, ANN INTERN MED, V58, P654, DOI 10.7326/0003-4819-58-4-654; HOWELL RR, 1976, JAMA-J AM MED ASSOC, V236, P1481, DOI 10.1001/jama.236.13.1481; JOHANNESEN J, 1977, AM J PHYSIOL, V233, pF61, DOI 10.1152/ajprenal.1977.233.1.F61; JONAS AJ, IN PRESS AM J KIDNEY; KOLB OF, 1955, METAB CLIN EXP, V4, P310; LAMPERT F, 1967, AMINO ACID METABOLIS, P353; MATSUO N, 1986, ACTA PAEDIATR SCAND, V75, P332, DOI 10.1111/j.1651-2227.1986.tb10210.x; MOGENSEN CE, 1976, DIABETES, V25, P872; MOORHEAD JF, 1982, LANCET, V2, P1309; NISHIO S, 1981, ACTA PATHOL JAPON, V31, P873; SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259; SONOBE H, 1976, ACTA PATHOL JAPON, V26, P727; STEIM H, 1967, KLIN WOCHENSCHR, V45, P295, DOI 10.1007/BF01747099; SUNDER TR, 1981, ARCH NEUROL-CHICAGO, V38, P251, DOI 10.1001/archneur.1981.00510040077014	22	127	129	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 7	1988	318	1					7	11		10.1056/NEJM198801073180102	http://dx.doi.org/10.1056/NEJM198801073180102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	L5234	3422104				2022-12-28	WOS:A1988L523400002
J	ROSENBERG, PS				ROSENBERG, PS			SCOPE OF THE AIDS EPIDEMIC IN THE UNITED-STATES	SCIENCE			English	Article							INCUBATION PERIOD; HOMOSEXUAL MEN; HIV-INFECTION; SAN-FRANCISCO; COHORT; PREVALENCE; THERAPY; AGE	Two-dimensional deconvolution techniques are used here to reconstruct age-specific human immunodeficiency virus(HIV) infection rates in the United States from surveillance data on acquired immunodeficiency syndrome (AIDS). This approach suggests that 630,000 to 897,000 adults and adolescents in the United States were living with HIV infection as of January 1993, including 107,000 to 150,000 women. The estimated incidence of HIV infection declined markedly over time among white males, especially those older than 30 years. In contrast, HIV incidence appears to have remained relatively constant among women and minorities. As of January 1993, prevalence was highest among young adults in their late twenties and thirties and among minorities. An estimated 3 percent of black men and 1 percent of black women in their thirties were living with HIV infection as of that date. If infection rates remain at these levels, HIV must be considered as endemic in the United States.			ROSENBERG, PS (corresponding author), NCI,ROCKVILLE,MD 20852, USA.			Rosenberg, Philip/0000-0001-6349-9126				BECKER NG, 1993, BIOMETRIKA, V80, P165, DOI 10.1093/biomet/80.1.165; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; EYSTER ME, 1987, ANN INTERN MED, V107, P1, DOI 10.7326/0003-4819-107-1-1; GAIL MH, 1990, J ACQ IMMUN DEF SYND, V3, P296; GRAHAM NMH, 1991, J ACQ IMMUN DEF SYND, V4, P267; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HENDRIKS JCM, 1993, AIDS, V7, P231, DOI 10.1097/00002030-199302000-00012; KARON JM, COMMUNICATION; LANG W, 1993, J ACQ IMMUN DEF SYND, V6, P191; MARIOTTO AB, 1992, AM J EPIDEMIOL, V135, P428, DOI 10.1093/oxfordjournals.aje.a116303; MCQUILLAN GM, 1994, J ACQ IMMUN DEF SYND, V7, P1195; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; ROSENBERG PS, 1994, AIDS, V8, P803, DOI 10.1097/00002030-199406000-00013; ROSENBERG PS, 1991, J ACQ IMMUN DEF SYND, V4, P392; ROSENBERG PS, 1992, STAT MED, V11, P1633, DOI 10.1002/sim.4780111302; ROSENBERG PS, 1994, STAT MED, V13, P1975, DOI 10.1002/sim.4780131909; VERDECCHIA A, 1994, INT J EPIDEMIOL, V23, P1027, DOI 10.1093/ije/23.5.1027; 1994, LANCET, V343, P871; 1987, MORB MORTAL WKLY S1, V36; 1992, MORB MORTAL WKLY REP, V41; 1990, MMWR-MORBID MORTAL W, V39, P110; 1994, MMWR-MORBID MORTAL W, V43, P826	24	150	152	1	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 24	1995	270	5240					1372	1375		10.1126/science.270.5240.1372	http://dx.doi.org/10.1126/science.270.5240.1372			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF899	7481828				2022-12-28	WOS:A1995TF89900043
J	GASSMANN, M; CASAGRANDA, F; ORIOLI, D; SIMON, H; LAI, C; KLEIN, R; LEMKE, G				GASSMANN, M; CASAGRANDA, F; ORIOLI, D; SIMON, H; LAI, C; KLEIN, R; LEMKE, G			ABERRANT NEURAL AND CARDIAC DEVELOPMENT IN MICE LACKING THE ERBB4 NEUREGULIN RECEPTOR	NATURE			English	Article							GLIAL GROWTH-FACTOR; NERVOUS-SYSTEM; PROTEIN; FAMILY; HINDBRAIN; MEMBER; HER4/P180(ERBB4); IDENTIFICATION; PURIFICATION; DISRUPTION	VARIOUS in vitro studies have suggested that ErbB4 (HER4) is a receptor for the neuregulins, a family of closely related proteins implicated as regulators of neural and muscle development, and of the differentiation and oncogenic transformation of mammary epithelia(1-3). Here we demonstrate that ErbB4 is an essential in vivo regulator of both cardiac muscle differentiation and axon guidance in the central nervous system (CNS). Mice lacking ErbB4 die during mid-embryogenesis from the aborted development of myocardial trabeculae in the heart ventricle. They also display striking alterations in innervation of the hindbrain in the CNS that are consistent with the restricted expression of the ErbB4 gene in rhombomeres 3 and 5. Similarities in the cardiac phenotype of ErbB4 and neuregulin gene mutants suggest that ErbB4 functions as a neuregulin receptor in the heart; however, differences in the hindbrain phenotypes of these mutants are consistent with the action of a new ErbB4 ligand in the CNS.	EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAMME, D-69012 HEIDELBERG, GERMANY; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	European Molecular Biology Laboratory (EMBL); Scripps Research Institute	GASSMANN, M (corresponding author), SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA.		Klein, Ruediger/C-6147-2008	Klein, Ruediger/0000-0002-3109-0163; Gassmann, Martin/0000-0001-6201-3032; ORIOLI, DONATA/0000-0002-3830-3408				CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; CHALLICE CE, 1974, TISSUE CELL, V6, P447, DOI 10.1016/0040-8166(74)90037-8; Chang H., 1994, Society for Neuroscience Abstracts, V20, P1694; CORFAS G, 1995, NEURON, V14, P103, DOI 10.1016/0896-6273(95)90244-9; COVELL DA, 1989, J COMP NEUROL, V286, P488, DOI 10.1002/cne.902860407; DENT JA, 1989, DEVELOPMENT, V105, P61; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GOODEARL ADJ, 1993, J BIOL CHEM, V268, P18095; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LEMKE GE, 1984, J NEUROSCI, V4, P75; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MOODY SA, 1989, J COMP NEUROL, V279, P567, DOI 10.1002/cne.902790406; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NIETO MA, 1991, DEVELOPMENT, P59; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SIMON H, 1993, NEURON, V11, P209, DOI 10.1016/0896-6273(93)90179-U; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SWLATEK PJ, 1993, GENE DEV, V7, P2071; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361	32	893	920	4	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 23	1995	378	6555					390	394		10.1038/378390a0	http://dx.doi.org/10.1038/378390a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477376				2022-12-28	WOS:A1995TF89300060
J	WHITFIELD, LS; SULSTON, JE; GOODFELLOW, PN				WHITFIELD, LS; SULSTON, JE; GOODFELLOW, PN			SEQUENCE VARIATION OF THE HUMAN Y-CHROMOSOME	NATURE			English	Article							DNA POLYMORPHISM	WE have generated over 100 kilobases of sequence from the nonrecombining portion of the Y chromosomes from five humans and one common chimpanzee. The human subjects were chosen to match the earliest branches of the human mitochondrial tree. The survey of 18.3 kilobases from each human detected only three sites at which substitutions were present, whereas the human and chimpanzee sequences showed 1.3% divergence. The coalescence time estimated from our Y chromosome sample is more recent than that of the mitochondrial genome. A recent coalescence time for the Y chromosome could have been caused by the selected sweep of an advantageous Y chromosome or extensive migration of human males.	SANGER CTR, HINXTON CB10 1RQ, CAMBS, ENGLAND	Wellcome Trust Sanger Institute	WHITFIELD, LS (corresponding author), UNIV CAMBRIDGE, DEPT GENET, CAMBRIDGE CB2 3EH, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEGUN DJ, 1992, NATURE, V356, P519, DOI 10.1038/356519a0; CLARK AG, 1987, GENETICS, V115, P569; DORIT RL, 1995, SCIENCE, V268, P1183, DOI 10.1126/science.7761836; ELLIS N, 1990, NATURE, V344, P663, DOI 10.1038/344663a0; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; JAKUBICZKA S, 1989, HUM GENET, V84, P86, DOI 10.1007/BF00210680; Kumar S., 1993, MEGA MOL EVOLUTIONAR; MALASPINA P, 1990, ANN HUM GENET, V54, P297, DOI 10.1111/j.1469-1809.1990.tb00385.x; Maynard-Smith J, 1974, GENET RES, V23, P23, DOI [10.1017/S0016672308009579, 10.1017/S0016672300014634]; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; WHITFIELD LS, 1995, GENOMICS, V27, P306, DOI 10.1006/geno.1995.1047; YANG Z, 1995, SYST BIOL, V44, P384, DOI 10.2307/2413599; Yang Z., 1995, PAML PHYLOGENETIC AN; YANG ZB, 1994, J MOL EVOL, V39, P105; YANG ZH, 1995, J MOL EVOL, V40, P689, DOI 10.1007/BF00160518	16	210	212	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 23	1995	378	6555					379	380		10.1038/378379a0	http://dx.doi.org/10.1038/378379a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477372				2022-12-28	WOS:A1995TF89300056
J	BIGNALL, J; HORTON, R				BIGNALL, J; HORTON, R			LEARNING FROM STORIES - THE LANCETS CASE-REPORTS	LANCET			English	Editorial Material																			0	30	33	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1246	1246		10.1016/S0140-6736(95)91859-0	http://dx.doi.org/10.1016/S0140-6736(95)91859-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475714				2022-12-28	WOS:A1995TE14500007
J	EPSTEIN, PR; PENA, OC; RACEDO, JB				EPSTEIN, PR; PENA, OC; RACEDO, JB			CLIMATE AND DISEASE IN COLOMBIA	LANCET			English	Editorial Material									UNIV MAGDALENA,SANTA MARTA,COLOMBIA; UNIV JORGE TADEO LOZANO,BOGOTA,COLOMBIA	Universidad del Magdalena; Universidad de Bogota Jorge Tadeo Lozano	EPSTEIN, PR (corresponding author), HARVARD UNIV,CAMBRIDGE HOSP,SCH PUBL HLTH,NEW DIS GRP,CAMBRIDGE,MA, USA.							DOBSON A, 1993, LANCET, V342, P1096, DOI 10.1016/0140-6736(93)92069-6; EPSTEIN PR, 1993, LANCET, V341, P1404, DOI 10.1016/0140-6736(93)90962-G; Mancera P. Jose Ernesto, 1994, Anales del Instituto de Investigaciones Marinas de Punta de Betin, V23, P103; Valiela I., 1984, MARINE ECOLOGICAL PR, DOI 10.1007/978-1-4757-4125-4; 1995, MMWR-MORBID MORTAL W, V44, P775; 1995, MMWR-MORBID MORTAL W, V44, P721	6	24	30	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1243	1244		10.1016/S0140-6736(95)91856-6	http://dx.doi.org/10.1016/S0140-6736(95)91856-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475711				2022-12-28	WOS:A1995TE14500004
J	FAURISSON, F; CONTREPOIS, A; GROSSKOPF, C				FAURISSON, F; CONTREPOIS, A; GROSSKOPF, C			AEROSOL INHALATION BEFORE READING AGE	LANCET			English	Letter									ROCHE PROD LTD,NEUILLY SUR SEINE,FRANCE	Roche Holding	FAURISSON, F (corresponding author), INSERM,U13,F-75877 PARIS,FRANCE.								0	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1298	1298		10.1016/S0140-6736(95)91898-1	http://dx.doi.org/10.1016/S0140-6736(95)91898-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475739				2022-12-28	WOS:A1995TE14500048
J	HAYWARD, A				HAYWARD, A			WHOS TO BLAME FOR ASTHMA	LANCET			English	Editorial Material							CHROMOSOME-11Q; LINKAGE; ATOPY				HAYWARD, A (corresponding author), UNIV COLORADO,SCH MED,DEPT PEDIAT,DENVER,CO 80262, USA.							AMELUNG PJ, 1992, CLIN EXP ALLERGY, V22, P1077, DOI 10.1111/j.1365-2222.1992.tb00133.x; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; COOKSON WOCM, 1989, LANCET, V1, P1292; HAY JG, 1995, AM J PHYSIOL-LUNG C, V268, pL565, DOI 10.1152/ajplung.1995.268.4.L565; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; MEYERS DA, 1994, AM J RESP CRIT CARE, V150, pS91, DOI 10.1164/ajrccm/150.5_Pt_2.S91; NIEMINEN MM, 1991, CHEST, V100, P70, DOI 10.1378/chest.100.1.70; PHELAN PD, 1994, BRIT MED J, V308, P1584, DOI 10.1136/bmj.308.6944.1584; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5	10	14	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1243	1243		10.1016/S0140-6736(95)91855-8	http://dx.doi.org/10.1016/S0140-6736(95)91855-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475710				2022-12-28	WOS:A1995TE14500003
J	LANGFORD, LA; PIATYSZEK, MA; XU, RS; SCHOLD, SC; SHAY, JW				LANGFORD, LA; PIATYSZEK, MA; XU, RS; SCHOLD, SC; SHAY, JW			TELOMERASE ACTIVITY IN HUMAN BRAIN-TUMORS	LANCET			English	Note								Malignant gliomas are invasive into surrounding brain and are refractory to therapy. Telomerase stabilises telomere length and may immortalise cells to allow unlimited proliferation. Our analysis of telomerase activity in 90 human gliomas showed that 19 of 19 oligodendrogliomas and 38 of 51 glioblastoma multiformes have detectable telomerase activity. The absence of telomerase activity in anaplastic astrocytomas (2/20 positive)and in one-quarter (13/51) of the glioblastomas suggests that these tumours follow different pathways of neoplastic progression. Thus we have found that a distinct subgroup of brain tumour consists of transformed yet pre-immortal cells.	UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT NEUROL,DALLAS,TX 75235; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL NEUROPATHOL,HOUSTON,TX	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center			Piatyszek, Mieczyslaw A./F-9365-2015; Shay, Jerry W/F-7878-2011	Piatyszek, Mieczyslaw A./0000-0003-0502-3239; 				COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; GREIDER CW, 1994, CURR OPIN GENET DEV, V4, P203, DOI 10.1016/S0959-437X(05)80046-2; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; NURNBERG P, 1993, HUM GENET, V91, P190; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; Shay Jerry W., 1994, Molecular and Cellular Differentiation, V2, P1; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; WRIGHT WE, IN PRESS DEV GENET	10	215	224	1	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1267	1268		10.1016/S0140-6736(95)91865-5	http://dx.doi.org/10.1016/S0140-6736(95)91865-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475720				2022-12-28	WOS:A1995TE14500013
J	WAXMAN, J; SHEER, D				WAXMAN, J; SHEER, D			IS PROSTATE-CANCER WORTH DIAGNOSING	LANCET			English	Editorial Material							POPULATION		IMPERIAL CANC RES FUND, HYMAN CYTOGENET LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK	WAXMAN, J (corresponding author), HAMMERSMITH HOSP, DEPT ONCOL, LONDON, ENGLAND.		Sheer, Denise/C-6705-2011	Sheer, Denise/0000-0001-9067-1796	Cancer Research UK [A3585] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		BANDYK MG, 1994, GENE CHROMOSOME CANC, V9, P19, DOI 10.1002/gcc.2870090105; BOOKSTEIN R, 1994, J CELL BIOCHEM, P217; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; GADDIPATI JP, 1994, CANCER RES, V54, P2861; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; HANKS GE, 1987, INT J RADIAT ONCOL, V13, P499, DOI 10.1016/0360-3016(87)90063-0; JOHANSSON JE, 1989, LANCET, V1, P799; NAROD SA, 1995, NAT MED, V1, P99, DOI 10.1038/nm0295-99; PEDERSEN KV, 1990, BRIT MED J, V300, P1041, DOI 10.1136/bmj.300.6731.1041; SMITH DS, 1995, UROLOGY, V45, P70, DOI 10.1016/S0090-4295(95)96812-1; TAKAHASHI S, 1994, CANCER RES, V54, P3574; UMBAS R, 1994, CANCER RES, V54, P3929; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; ZINCKE H, 1994, J CLIN ONCOL, V12, P2254, DOI 10.1200/JCO.1994.12.11.2254	15	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 4	1995	346	8984					1177	1178		10.1016/S0140-6736(95)92895-2	http://dx.doi.org/10.1016/S0140-6736(95)92895-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC976	7475655				2022-12-28	WOS:A1995TC97600005
J	SINGER, W				SINGER, W			DEVELOPMENT AND PLASTICITY OF CORTICAL PROCESSING ARCHITECTURES	SCIENCE			English	Review							CAT VISUAL-CORTEX; LONG-TERM POTENTIATION; CROSS-CORRELATION ANALYSIS; CLUSTERED HORIZONTAL CONNECTIONS; OSCILLATORY NEURONAL RESPONSES; BINOCULAR IMPULSE BLOCKADE; KITTEN STRIATE CORTEX; NERVE GROWTH-FACTOR; NMDA-RECEPTORS; ORIENTATION SELECTIVITY	One of the basic functions of the cerebral cortex is the analysis and representation of relations among the components of sensory and motor patterns. It is proposed that the cortex applies two complementary strategies to cope with the combinatorial problem posed by the astronomical number of possible relations: (i) the analysis and representation of frequently occurring, behaviorally relevant relations by groups of cells with fixed but broadly tuned response properties; and (ii) the dynamic association of these cells into functionally coherent assemblies. Feedforward connections and reciprocal associative connections, respectively, are thought to underlie these two operations. The architectures of both types of connections are susceptible to experience-dependent modifications during development, but they become fixed in the adult. As development proceeds, feedforward connections also appear to lose much of their functional plasticity, whereas the synapses of the associative connections retain a high susceptibility to use-dependent modifications. The reduced plasticity of feedforward connections is probably responsible for the invariance of cognitive categories acquired early in development. The persistent adaptivity of reciprocal connections is a likely substrate for the ability to generate representations for new perceptual objects and motor patterns throughout life.			SINGER, W (corresponding author), MAX PLANCK INST HIRNFORSCH,DEUTSCHORDENSTR 46,D-60528 FRANKFURT,GERMANY.		Singer, Wolf/D-6874-2012					ABELES M, 1993, J NEUROPHYSIOL, V70, P1629, DOI 10.1152/jn.1993.70.4.1629; Abeles M., 1991, CORTICONICS; AHISSAR E, 1992, SCIENCE, V257, P1412, DOI 10.1126/science.1529342; AIPLE F, 1988, EXP BRAIN RES, V72, P141, DOI 10.1007/BF00248509; ANTONINI A, 1993, J NEUROSCI, V13, P3549; ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; ARTOLA A, 1990, NATURE, V347, P69, DOI 10.1038/347069a0; ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; BEAR MF, 1987, SCIENCE, V237, P42, DOI 10.1126/science.3037696; BEAR MF, 1990, J NEUROSCI, V10, P909; BEAR MF, 1986, NATURE, V320, P172, DOI 10.1038/320172a0; BERARDI N, 1994, P NATL ACAD SCI USA, V91, P684, DOI 10.1073/pnas.91.2.684; BLAKEMORE C, 1970, NATURE, V228, P477, DOI 10.1038/228477a0; Blakemore C, 1976, Cold Spring Harb Symp Quant Biol, V40, P601; BLAKEMORE C, 1972, EXP BRAIN RES, V15, P439; BODEGREUEL KM, 1989, DEV BRAIN RES, V46, P197, DOI 10.1016/0165-3806(89)90283-6; BRAITENBERG V, 1978, LECTURE NOTES BIOMAT, V21, P171; BRESSLER SL, 1993, NATURE, V366, P153, DOI 10.1038/366153a0; BROCHER S, 1992, BRAIN RES, V573, P27, DOI 10.1016/0006-8993(92)90110-U; BULLIER J, 1992, SOC NEUR ABSTR, V18; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; CALLAWAY EM, 1991, P NATL ACAD SCI USA, V88, P745, DOI 10.1073/pnas.88.3.745; CALLAWAY EM, 1990, J NEUROSCI, V10, P1134; CARMIGNOTO G, 1993, J PHYSIOL-LONDON, V464, P343, DOI 10.1113/jphysiol.1993.sp019638; CHAPMAN B, 1991, J NEUROSCI, V11, P1347; CHINO YM, 1995, SCIENCE, V15, P2417; CRAIR MC, 1995, NATURE, V375, P325, DOI 10.1038/375325a0; DARIANSMITH C, 1995, J NEUROSCI, V15, P1631, DOI 10.1523/JNEUROSCI.15-03-01631.1995; DAS A, 1995, NATURE, V375, P780, DOI 10.1038/375780a0; DOMENICI L, 1994, NEUROREPORT, V5, P2041, DOI 10.1097/00001756-199410270-00013; Douglas RJ, 1989, NEURAL COMPUT, V1, P480, DOI 10.1162/neco.1989.1.4.480; ECKHORN R, 1993, NEUROREPORT, V4, P243, DOI 10.1097/00001756-199303000-00004; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; Eckhorn R., 1992, INDUCED RHYTHMS BRAI, P47; Edelman G. M, 1989, REMEMBERED PRESENT; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P6048, DOI 10.1073/pnas.88.14.6048; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; ENGEL AK, 1990, EUR J NEUROSCI, V2, P588, DOI 10.1111/j.1460-9568.1990.tb00449.x; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P9136, DOI 10.1073/pnas.88.20.9136; FOX K, 1992, J NEUROSCI, V12, P2672; FOX K, 1993, TRENDS NEUROSCI, V16, P116, DOI 10.1016/0166-2236(93)90136-A; FOX K, 1989, J NEUROSCI, V9, P2443; FREGNAC Y, 1988, NATURE, V333, P367, DOI 10.1038/333367a0; FREGNAC Y, 1984, PHYSIOL REV, V64, P325, DOI 10.1152/physrev.1984.64.1.325; FRIEDLANDER MJ, 1991, J NEUROSCI, V11, P3268; GALLI L, 1988, SCIENCE, V242, P90, DOI 10.1126/science.3175637; GALUSKE RAW, 1994, SOC NEUR ABSTR, V20; GALUSKE RAW, IN PRESS CEREB CORTE; GAWNE TJ, 1993, J NEUROSCI, V13, P2758; GERSTEIN GL, 1992, INFORMATION PROCESSI, P139; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1992, NATURE, V356, P150, DOI 10.1038/356150a0; GOCHIN PM, 1991, EXP BRAIN RES, V84, P505; GOODMAN CS, 1993, NEURON S, V10, P77; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; GRAY CM, 1993, SOC NEUR ABSTR, V19; GREUEL JM, 1988, SCIENCE, V242, P74, DOI 10.1126/science.2902687; GROSSBERG S, 1980, PSYCHOL REV, V87, P1, DOI 10.1037/0033-295X.87.1.1; GU Q, 1993, EUR J NEUROSCI, V5, P475, DOI 10.1111/j.1460-9568.1993.tb00514.x; GU Q, 1995, EUR J NEUROSCI, V7, P1146, DOI 10.1111/j.1460-9568.1995.tb01104.x; GU Q, 1989, DEV BRAIN RES, V47, P281, DOI 10.1016/0165-3806(89)90183-1; HANSEL C, 1994, EUR J NEUROSCI S, V7; HATA Y, 1991, J PHYSIOL-LONDON, V441, P593, DOI 10.1113/jphysiol.1991.sp018769; HATA Y, 1988, NATURE, V335, P815, DOI 10.1038/335815a0; HEBB DO, 1949, ORG BEHAVIOR; HESTRIN S, 1992, NATURE, V357, P686, DOI 10.1038/357686a0; HIRSCH HVB, 1970, SCIENCE, V168, P869, DOI 10.1126/science.168.3933.869; HIRSCH JA, 1993, J PHYSIOL-LONDON, V461, P247, DOI 10.1113/jphysiol.1993.sp019512; HUBEL DH, 1963, J NEUROPHYSIOL, V26, P994, DOI 10.1152/jn.1963.26.6.994; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; HUGEL DH, 1975, SENSORY PHYSL BEHAVI, P21; INNOCENTI GM, 1979, NATURE, V280, P231, DOI 10.1038/280231a0; JAGADEESH B, 1993, SCIENCE, V262, P1901, DOI 10.1126/science.8266083; Kaas Jon H., 1995, P51; KASAMATSU T, 1979, J COMP NEUROL, V185, P139, DOI 10.1002/cne.901850109; KATO N, 1991, DEV BRAIN RES, V60, P43, DOI 10.1016/0165-3806(91)90153-A; KATO N, 1991, EXP BRAIN RES SER, V20, P81; KIRKWOOD A, 1994, J NEUROSCI, V14, P3404; KIRKWOOD A, 1994, J NEUROSCI, V14, P1634, DOI 10.1523/JNEUROSCI.14-03-01634.1994; KIRKWOOD A, 1995, NATURE, V375, P328, DOI 10.1038/375328a0; KIRKWOOD A, 1993, SCIENCE, V260, P1518, DOI 10.1126/science.8502997; KLEINSCHMIDT A, 1987, SCIENCE, V238, P355, DOI 10.1126/science.2443978; KONIG P, 1993, EUR J NEUROSCI, V5, P501, DOI 10.1111/j.1460-9568.1993.tb00516.x; KOSSEL A, 1995, J NEUROSCI, V15, P3913; LAMME VAF, 1993, NATURE, V363, P541, DOI 10.1038/363541a0; LAMME VAF, 1995, J NEUROSCI, V15, P1605; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; LIVINGSTONE S, 1991, SOC NEUR ABSTR, V17; LOWEL S, 1992, SCIENCE, V255, P209, DOI 10.1126/science.1372754; LUBKE J, 1992, EUR J NEUROSCI, V4, P189, DOI 10.1111/j.1460-9568.1992.tb00866.x; LUHMANN HJ, 1990, EUR J NEUROSCI, V2, P344, DOI 10.1111/j.1460-9568.1990.tb00426.x; MAFFEI L, 1992, J NEUROSCI, V12, P4651; MALACH R, 1993, P NATL ACAD SCI USA, V90, P10469, DOI 10.1073/pnas.90.22.10469; MAUNSELL JHR, 1995, SCIENCE, V270, P764, DOI 10.1126/science.270.5237.764; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; Merzenich M M, 1993, Curr Opin Neurobiol, V3, P187, DOI 10.1016/0959-4388(93)90209-H; MERZENICH MM, IN PRESS MIND BRAIN; MICHALSKI A, 1983, EXP BRAIN RES, V51, P97; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; MIYASHITA Y, 1988, NATURE, V335, P817, DOI 10.1038/335817a0; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MORRONE C, 1992, P R SOC LONDON B, V216, P335; MURTHY VN, 1992, P NATL ACAD SCI USA, V89, P5670, DOI 10.1073/pnas.89.12.5670; NELSON JI, 1992, SOC NEUR ABSTR, V18; NELSON JI, 1985, MODELS VISUAL CORTEX, P108; NOWAK LG, 1994, OSCILLATORY EVENT RE, P85; Palm G, 1990, CONC NEUROSCI, V1, P133; PETTET MW, 1992, P NATL ACAD SCI USA, V89, P8366, DOI 10.1073/pnas.89.17.8366; PRICE DJ, 1985, NATURE, V316, P721, DOI 10.1038/316721a0; RAUSCHECKER JP, 1979, NATURE, V280, P58, DOI 10.1038/280058a0; RAUSCHECKER JP, 1991, PHYSIOL REV, V71, P587, DOI 10.1152/physrev.1991.71.2.587; RAUSCHECKER JP, 1981, J PHYSIOL-LONDON, V310, P215, DOI 10.1113/jphysiol.1981.sp013545; RECANZONE GH, 1993, J NEUROSCI, V13, P87; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; RODMAN HR, 1993, J NEUROPHYSIOL, V70, P1115, DOI 10.1152/jn.1993.70.3.1115; ROE AW, 1992, SOC NEUR ABSTR, V18; ROELFSEMA PR, 1994, EUR J NEUROSCI, V6, P1645, DOI 10.1111/j.1460-9568.1994.tb00556.x; ROELFSEMA PR, 1994, EUR J NEUROSCI S, V7; SAKAI K, 1991, NATURE, V354, P152, DOI 10.1038/354152a0; SCHMID LM, 1995, NEUROREPORT, V6, P1349, DOI 10.1097/00001756-199506090-00030; SCHMIDT KE, 1993, SOC NEUR ABSTR, V19; SCHMIDT KE, 1994, 22ND P NEUR C GOTT, V2, P502; SCHWARZ C, 1991, J NEUROSCI, V11, P2995; SHAW C, 1984, PROG NEURO-PSYCHOPH, V8, P627, DOI 10.1016/0278-5846(84)90025-3; SILLITO AM, 1994, NATURE, V369, P479, DOI 10.1038/369479a0; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; SINGER W, 1976, EXP BRAIN RES, V26, P171; SINGER W, 1990, J EXP BIOL, V153, P177; SINGER W, 1985, MODELS VISUAL CORTEX, P123; Singer W., 1994, LARGE SCALE NEURONAL, P201; SINGER W, IN PRESS EXCITATORY; STRYKER MP, 1986, J NEUROSCI, V6, P2117; STRYKER MP, 1991, DEV VISUAL SYSTEM, P267; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; SzentuYgothai J., 1979, NEUROSCIENCES 4TH ST, P399; TOYAMA K, 1981, J NEUROPHYSIOL, V46, P202, DOI 10.1152/jn.1981.46.2.202; TOYAMA K, 1981, J NEUROPHYSIOL, V46, P191, DOI 10.1152/jn.1981.46.2.191; TRETTER F, 1975, BRAIN RES, V84, P143, DOI 10.1016/0006-8993(75)90808-2; TSO DY, 1986, J NEUROSCI, V6, P1160; TSUMOTO T, 1987, NATURE, V327, P513, DOI 10.1038/327513a0; TSUMOTO T, 1993, NEUROSCI RES, V16, P263, DOI 10.1016/0168-0102(93)90036-P; TSUMOTO T, 1992, PROG NEUROBIOL, V39, P209, DOI 10.1016/0301-0082(92)90011-3; VAADIA E, 1995, NATURE, V373, P515, DOI 10.1038/373515a0; VONDERMALSBURG C, 1985, BER BUNSEN PHYS CHEM, V89, P703, DOI 10.1002/bbpc.19850890625; Weinberger N M, 1993, Curr Opin Neurobiol, V3, P570, DOI 10.1016/0959-4388(93)90058-7; WIESEL TN, 1974, J COMP NEUROL, V158, P307, DOI 10.1002/cne.901580306; WURTZ RH, 1980, PROGR PSYCHOBIOLOGY, V9, P43; YOUNG MP, 1992, SCIENCE, V256, P1327, DOI 10.1126/science.1598577; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0; [No title captured]	152	465	473	0	23	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 3	1995	270	5237					758	764		10.1126/science.270.5237.758	http://dx.doi.org/10.1126/science.270.5237.758			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC712	7481762				2022-12-28	WOS:A1995TC71200029
J	WHATLEY, SD; ROBERTS, AG; ELDER, GH				WHATLEY, SD; ROBERTS, AG; ELDER, GH			DE-NOVO MUTATION AND SPORADIC PRESENTATION OF ACUTE INTERMITTENT PORPHYRIA	LANCET			English	Note							PORPHOBILINOGEN DEAMINASE GENE	Acute intermittent porphyria (AIP) is a low-penetrant autosomal dominant disorder characterised by life-threatening neurovisceral attacks, often precipitated by drugs. Prognosis is improved by presymptomatic diagnosis and counselling. We found that 29 of 103 (28%) unrelated patients presented as sporadic cases. One patient had a de-novo mutation. The same mutation has arisen de novo at least three times in 12% of British AIP families. About 3% (95% CI 1-8%) of all AIP index cases may have de-novo mutations. These findings emphasise the high frequency of sporadic presentation of AIP and indicate the limitations of presymptomatic diagnosis as an aid to management.	UNIV WALES HOSP,COLL MED,DEPT BIOCHEM MED,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University				Anderson, Karl/0000-0002-6499-8573	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BONKOVSKY HL, 1993, GASTROENTEROLOGY, V105, P590, DOI 10.1016/0016-5085(93)90739-Y; BROWNLIE PD, 1994, PROTEIN SCI, V3, P1644, DOI 10.1002/pro.5560031004; CHEN CH, 1994, J CLIN INVEST, V94, P1927, DOI 10.1172/JCI117543; Cooper D. N., 1993, HUMAN GENE MUTATION; KAPPAS A, 1989, METABOLIC BASIS INHE, P1305; KAUPPINEN R, 1995, HUM MOL GENET, V4, P215, DOI 10.1093/hmg/4.2.215; LLEWELLYN DH, 1987, LANCET, V2, P706; ONG PML, 1995, J MED GENET, V32, pA141; SCOBIE GA, 1990, HUM GENET, V85, P157	9	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 14	1995	346	8981					1007	1008		10.1016/S0140-6736(95)91692-X	http://dx.doi.org/10.1016/S0140-6736(95)91692-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475550				2022-12-28	WOS:A1995RZ59900014
J	MAXWELL, AP; NELSON, WE; HILL, CM				MAXWELL, AP; NELSON, WE; HILL, CM			REVERSAL OF RENAL-FAILURE IN NEPHRITIS ASSOCIATED WITH ANTIBODY TO GLOMERULAR BASEMENT-MEMBRANE	BRITISH MEDICAL JOURNAL			English	Article									BELFAST CITY HOSP,RENAL UNIT,BELFAST BT9 7AB,NORTH IRELAND; QUEENS UNIV BELFAST,INST PATHOL,BELFAST BT12 6BA,NORTH IRELAND	Belfast City Hospital; Queens University Belfast				Maxwell, Alexander P./0000-0002-6110-7253				FLORES JC, 1986, LANCET, V1, P5; FORT J, 1984, CLIN NEPHROL, V22, P211; PUSEY CD, 1983, INT J ARTIF ORGANS, V6, P15; SAVAGE COS, 1986, BRIT MED J, V292, P301, DOI 10.1136/bmj.292.6516.301; SAVAGE COS, 1987, LANCET, V1, P1389	5	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1988	297	6644					333	334		10.1136/bmj.297.6644.333	http://dx.doi.org/10.1136/bmj.297.6644.333			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P4527	3416164	Bronze, Green Published			2022-12-28	WOS:A1988P452700022
J	KLEIN, RS; PHELAN, JA; FREEMAN, K; SCHABLE, C; FRIEDLAND, GH; TRIEGER, N; STEIGBIGEL, NH				KLEIN, RS; PHELAN, JA; FREEMAN, K; SCHABLE, C; FRIEDLAND, GH; TRIEGER, N; STEIGBIGEL, NH			LOW OCCUPATIONAL RISK OF HUMAN IMMUNODEFICIENCY VIRUS-INFECTION AMONG DENTAL PROFESSIONALS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									MONTEFIORE MED CTR,DEPT DENT,BRONX,NY 10467; MONTEFIORE MED CTR,DEPT BIOSTAT,BRONX,NY 10467; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DENT,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT ORAL & MAXILLOFACIAL SURG,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10461; CTR DIS CONTROL,AIDS PROGRAM,ATLANTA,GA 30333	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Centers for Disease Control & Prevention - USA	KLEIN, RS (corresponding author), MONTEFIORE MED CTR,DEPT MED,DIV INFECT DIS,111 E 210TH ST,BRONX,NY 10467, USA.			Steigbigel, Neal/0000-0002-9378-5403				[Anonymous], 1982, MMWR-MORBID MORTAL W; AUERBACH DM, 1984, AM J MED, V76, P487, DOI 10.1016/0002-9343(84)90668-5; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BRODER S, 1984, NEW ENGL J MED, V311, P1292, DOI 10.1056/NEJM198411153112006; BRODERSEN M, 1974, LANCET, V1, P675; CURRAN JW, 1984, NEW ENGL J MED, V310, P69, DOI 10.1056/NEJM198401123100201; ECHAVEZ MI, 1987, J PUBLIC HEALTH DENT, V47, P182, DOI 10.1111/j.1752-7325.1987.tb02002.x; EVATT BL, 1984, ANN INTERN MED, V100, P499, DOI 10.7326/0003-4819-100-4-499; FELDMAN RE, 1975, JAMA-J AM MED ASSOC, V232, P1228, DOI 10.1001/jama.232.12.1228; FLYNN NM, 1987, WESTERN J MED, V146, P439; FRIEDLAND GH, 1985, ARCH INTERN MED, V145, P1413, DOI 10.1001/archinte.145.8.1413; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GERBERDING JL, 1987, J INFECT DIS, V156, P1, DOI 10.1093/infdis/156.1.1; GERBERDING JL, 1986, 26TH INT C ANT AG CH, P283; GERBERT B, 1987, J AM DENT ASSOC, V114, P311, DOI 10.14219/jada.archive.1987.0078; GOCKE DJ, 1969, LANCET, V2, P248; GRINT P, 1985, COMMUNICAB DIS REP, V42, P4; GROOPMAN JE, 1984, SCIENCE, V226, P447, DOI 10.1126/science.6093247; HARRIS C, 1983, NEW ENGL J MED, V308, P1181, DOI 10.1056/NEJM198305193082001; HEATHCOT.J, 1974, LANCET, V1, P71; HENDERSON DK, 1986, ANN INTERN MED, V104, P644, DOI 10.7326/0003-4819-104-5-644; HIRSCH MS, 1985, NEW ENGL J MED, V312, P1, DOI 10.1056/NEJM198501033120101; HO DD, 1985, NEW ENGL J MED, V313, P1606; JAFFE HW, 1983, ANN INTERN MED, V99, P145, DOI 10.7326/0003-4819-99-2-145; KUNIN CM, 1959, AM J MED SCI, V237, P293, DOI 10.1097/00000441-195903000-00003; LANDESMAN SH, 1983, ARCH INTERN MED, V143, P2307, DOI 10.1001/archinte.143.12.2307; LOURIA DB, 1967, ANN INTERN MED, V67, P1, DOI 10.7326/0003-4819-67-1-1; LUBICK HA, 1986, J AM DENT ASSOC, V113, P10, DOI 10.14219/jada.archive.1986.0139; MARMOR M, 1982, LANCET, V1, P1083; MCCRAY E, 1986, NEW ENGL J MED, V314, P1127, DOI 10.1056/NEJM198604243141729; MCDONALD MI, 1983, LANCET, V2, P882; MOSLEY JW, 1975, J AM DENT ASSOC, V90, P992, DOI 10.14219/jada.archive.1975.0239; MOSLEY JW, 1975, NEW ENGL J MED, V293, P729, DOI 10.1056/NEJM197510092931501; NEISSONVERNANT C, 1986, LANCET, V2, P814; OKSENHENDLER E, 1986, NEW ENGL J MED, V315, P582; OLESKE J, 1983, JAMA-J AM MED ASSOC, V249, P2345, DOI 10.1001/jama.249.17.2345; PRINCE AM, 1968, P NATL ACAD SCI USA, V60, P814, DOI 10.1073/pnas.60.3.814; RAVENHOLT RT, 1983, LANCET, V2, P885; REDEKER AG, 1975, NEW ENGL J MED, V293, P1055; RUBINSTEIN A, 1983, JAMA-J AM MED ASSOC, V249, P2350, DOI 10.1001/jama.249.17.2350; SCHIFF ER, 1986, J AM DENT ASSOC, V113, P390, DOI 10.14219/jada.archive.1986.0210; SCHREEDER MT, 1982, J INFECT DIS, V146, P7, DOI 10.1093/infdis/146.1.7; SHIMIZU Y, 1963, GASTROENTEROLOGY, V44, P740; SMITH JL, 1976, J INFECT DIS, V133, P705, DOI 10.1093/infdis/133.6.705; SNYDMAN DR, 1975, ANN INTERN MED, V83, P838, DOI 10.7326/0003-4819-83-6-838; STRICOF RL, 1986, NEW ENGL J MED, V314, P1115; SZMUNESS W, 1975, ANN INTERN MED, V83, P489, DOI 10.7326/0003-4819-83-4-489; THOMAS PA, 1984, JAMA-J AM MED ASSOC, V252, P639, DOI 10.1001/jama.252.5.639; TSANG VCW, 1983, METHOD ENZYMOL, V92, P377; VILLAREJOS VM, 1974, NEW ENGL J MED, V291, P1375, DOI 10.1056/NEJM197412262912602; Weil R B, 1977, N Y State Dent J, V43, P587; WEISS SH, 1985, JAMA-J AM MED ASSOC, V254, P2089, DOI 10.1001/jama.254.15.2089; ZAGURY D, 1984, SCIENCE, V226, P449, DOI 10.1126/science.6208607; 1984, LANCET, V2, P1376; 1986, MMWR, V35, P237; [No title captured]; 1986, MMWR, V35, P76; 1987, MMWR, V36, P285; 1985, MMWR, V34, P313; 1983, MMWR, V32, P613; 1984, MMWR, V33, P377; [No title captured]; 1985, MMWR, V34, P329	63	172	174	1	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1988	318	2					86	90		10.1056/NEJM198801143180205	http://dx.doi.org/10.1056/NEJM198801143180205			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	L6001	3422106				2022-12-28	WOS:A1988L600100005
J	HSU, SL; MARKS, J; SHAW, JP; TAM, M; HIGGS, DR; SHEN, CC; SHEN, CKJ				HSU, SL; MARKS, J; SHAW, JP; TAM, M; HIGGS, DR; SHEN, CC; SHEN, CKJ			STRUCTURE AND EXPRESSION OF THE HUMAN THETA-1-GLOBIN GENE	NATURE			English	Article									UNIV CALIF DAVIS, DEPT GENET, DAVIS, CA 95616 USA; ACAD SINICA, INST MOL BIOL, TAIPEI 115, TAIWAN; UNIV OXFORD, JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,MRC, MOLEC HAEMATOL UNIT, OXFORD OX3 9DU, ENGLAND	University of California System; University of California Davis; Academia Sinica - Taiwan; University of Oxford			shen, Che-Kun James/L-1343-2015					CHARNAY P, 1983, SCIENCE, V220, P1281, DOI 10.1126/science.6574602; CHENG JF, 1986, J BIOL CHEM, V261, P839; DEAN A, 1981, SCIENCE, V212, P459, DOI 10.1126/science.6163216; DEAN A, 1983, P NATL ACAD SCI-BIOL, V80, P5515, DOI 10.1073/pnas.80.18.5515; FEI, IN PRESS BR J HAEMAT; FISCHELGHODSIAM N, IN PRESS NATURE; HESS J, 1985, J MOL BIOL, V184, P7, DOI 10.1016/0022-2836(85)90039-7; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KARLSSON S, 1985, ANNU REV BIOCHEM, V54, P1071; LAUER J, 1980, CELL, V20, P119, DOI 10.1016/0092-8674(80)90240-8; LEUNG S, 1987, NATURE, V329, P551, DOI 10.1038/329551a0; LIEBHABER SA, 1981, NATURE, V290, P26, DOI 10.1038/290026a0; LOZZIO BB, 1979, LEUKEMIA RES, V3, P363, DOI 10.1016/0145-2126(79)90033-X; MARKS J, 1986, COLD SPRING HARB SYM, V51, P499, DOI 10.1101/SQB.1986.051.01.061; MARKS J, 1986, NATURE, V321, P785, DOI 10.1038/321785a0; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; NICHOLLS RD, 1987, CELL, V49, P369, DOI 10.1016/0092-8674(87)90289-3; NORTH G, 1987, NATURE, V326, P641, DOI 10.1038/326641a0; PERLER F, 1980, CELL, V20, P555, DOI 10.1016/0092-8674(80)90641-8; RUTHERFORD T, 1981, P NATL ACAD SCI-BIOL, V78, P348, DOI 10.1073/pnas.78.1.348; RUTHERFORD TR, 1979, NATURE, V280, P164, DOI 10.1038/280164a0; SAWADA I, 1986, J MOL BIOL, V192, P693, DOI 10.1016/0022-2836(86)90022-7; SHAW JP, 1987, NATURE, V326, P717, DOI 10.1038/326717a0; SHAW JP, IN PRESS HAEMOGLOBUL, V5; SLIGHTOM JL, 1980, CELL, V21, P627, DOI 10.1016/0092-8674(80)90426-2; TREISMAN R, 1982, CELL, V29, P903, DOI 10.1016/0092-8674(82)90452-4	26	51	52	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 7	1988	331	6151					94	96		10.1038/331094a0	http://dx.doi.org/10.1038/331094a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	L5505	3422341				2022-12-28	WOS:A1988L550500065
J	MULLER, AD; SONNENBERG, A				MULLER, AD; SONNENBERG, A			PREVENTION OF COLORECTAL-CANCER BY FLEXIBLE ENDOSCOPY AND POLYPECTOMY - A CASE-CONTROL STUDY OF 32702 VETERANS	ANNALS OF INTERNAL MEDICINE			English	Article						COLORECTAL NEOPLASMS; ENDOSCOPY, GASTROINTESTINAL; SIGMOIDOSCOPY; COLONOSCOPY; COLONIC POLYPS	RISK; POLYPS; CARCINOMA; ADENOMAS; RECTUM; COLON	Objective: To determine whether patients with colorectal cancer are less likely than unaffected controls to have had one or more endoscopic procedures (flexible sigmoidoscopy, colonoscopy, or polypectomy) before being diagnosed with cancer. Design: Case-control study. Setting: Hospitals of the Department of Veterans Affairs. Patients: 8722 and 7629 case-patients with colon and rectal cancer, respectively, and age-, sex-, race-matched controls who were discharged at the same time as the corresponding case-patients. Measurements: Number and type of endoscopic procedures of the large bowel done from 1981 until the development of colorectal cancer in each case-patient. The influence of endoscopic procedures on the development of colorectal cancer was tested by conditional multiple logistic regression analysis. Results: Compared with controls, patients with colorectal cancer were less likely to have had an endoscopic procedure of the large bowel before being diagnosed with cancer (odds ratio for colon cancer, 0.51 [95% CI, 0.44 to 0.58]; odds ratio for rectal cancer, 0.55 [CI, 0.47 to 0.64]). In patients who had flexible sigmoidoscopy, colonoscopy, and polypectomy, the odds ratios were even smaller. When analyzed by separate 1-year intervals, patients with cancer had significantly fewer procedures during periods of up to 6 years before the onset of their cancer. Similarly, fewer inpatient and outpatient procedures were done in patients than in controls. Conclusions: Endoscopic procedures of the large bowel reduce the risk for developing colon and rectal cancer by 50%, their protective influence lasting 6 years.	VET AFFAIRS MED CTR, GASTROENTEROL SECT, ALBUQUERQUE, NM 87108 USA; MED COLL WISCONSIN, DEPT FAMILY MED, MILWAUKEE, WI 53226 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Medical College of Wisconsin								AHLQUIST DA, 1993, NEW ENGL J MED, V329, P1351; ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; Breslow N, 1980, STAT METHODS CANC RE, P248; EKBOM A, 1990, LANCET, V336, P357, DOI 10.1016/0140-6736(90)91889-I; EKBOM A, 1990, NEW ENGL J MED, V323, P1228, DOI 10.1056/NEJM199011013231802; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GILBERTSEN VA, 1978, CANCER, V41, P1137, DOI 10.1002/1097-0142(197803)41:3<1137::AID-CNCR2820410350>3.0.CO;2-G; GREENBERG ER, 1993, JNCI-J NATL CANCER I, V85, P912, DOI 10.1093/jnci/85.11.912; KEEFFE EB, 1993, GASTROINTEST ENDOSC, V39, P840, DOI 10.1016/S0016-5107(93)70284-9; KIRSCHNER CG, 1994, PHYSICIANS CURRENT P; LOTFI AM, 1986, MAYO CLIN PROC, V61, P337, DOI 10.1016/S0025-6196(12)61950-8; MACRAE FA, 1983, GUT, V24, P376, DOI 10.1136/gut.24.5.376; MADARA JL, 1983, AM J PATHOL, V110, P230; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; SANDLER RS, 1995, GASTROENTEROLOGY, V109, P302; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SIMONS BD, 1992, J NATL CANCER I, V84, P962, DOI 10.1093/jnci/84.12.962; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; TURNER D, 1993, CAN MED ASSOC J, V149, P595; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; 1989, DHHS PHS891260; 1992, SAS STAT SOFTWARE CH, P435	23	484	490	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1995	123	12					904	+		10.7326/0003-4819-123-12-199512150-00002	http://dx.doi.org/10.7326/0003-4819-123-12-199512150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK120	7486484				2022-12-28	WOS:A1995TK12000002
J	WILLIAMS, MV; PARKER, RM; BAKER, DW; PARIKH, NS; PITKIN, K; COATES, WC; NURSS, JR				WILLIAMS, MV; PARKER, RM; BAKER, DW; PARIKH, NS; PITKIN, K; COATES, WC; NURSS, JR			INADEQUATE FUNCTIONAL HEALTH LITERACY AMONG PATIENTS AT 2 PUBLIC HOSPITALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EDUCATION MATERIALS; READING-ABILITY; CONSENT FORMS; READABILITY; COMPREHENSION; EMERGENCY	Objective.-To determine the ability of patients to complete successfully basic reading and numeracy tasks required to function adequately in the health care setting, Design.-Cross-sectional survey. Setting.-Two urban, public hospitals. Patients.-A total of 2659 predominantly indigent and minority patients, 1892 English-speaking and 767 Spanish-speaking, presenting for acute care. Main Outcome Measure.-Functional health literacy as measured by the Test of Functional Health Literacy in Adults (TOFHLA), an instrument that measures ability to read and understand medical instructions and health care information presented in prose passages and passages containing numerical information leg, prescription bottle labels and appointment slips). Results.-A high proportion of patients were unable to read and understand written basic medical instructions. Of 2659 patients, 1106 (41.6%) were unable to comprehend directions for taking medication on an empty stomach, 691 (26%) were unable to understand information regarding when a next appointment is scheduled, and 1582 (59.5%) could not understand a standard informed consent document. A total of 665 (35.1%) of 1892 English-speaking patients and 473 (61.7%) of 767 Spanish-speaking patients had inadequate or marginal functional health literacy. The prevalence of inadequate or marginal functional health literacy among the elderly (age greater than or equal to 60 years) was 81.3% (187/230) for English-speaking patients and 82.6% (57/69) for Spanish-speaking patients, and was significantly higher (P<.001) than in younger patients. Conclusions.-Many patients at our institutions cannot perform the basic reading tasks required to function in the health care environment. Inadequate health literacy may be an important barrier to patients' understanding of their diagnoses and treatments, and to receiving high-quality care.	UNIV CALIF LOS ANGELES, HARBOR MED CTR, DEPT MED, TORRANCE, CA 90509 USA; UNIV CALIF LOS ANGELES, HARBOR MED CTR, DEPT EMERGENCY MED, TORRANCE, CA USA; GEORGIA STATE UNIV, CTR STUDY ADULT LITERACY, ATLANTA, GA 30303 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University System of Georgia; Georgia State University	WILLIAMS, MV (corresponding author), EMORY UNIV, SCH MED, DEPT MED, DIV GEN MED, 69 BUTLER ST SE, ATLANTA, GA 30303 USA.		Coates, Wendy/M-1165-2019; Parker, Ruth M/S-4583-2017	Coates, Wendy/0000-0002-3305-8802; Parker, Ruth M/0000-0001-9685-6396; Williams, Mark V/0000-0001-6107-0457; Parikh, Nina/0000-0002-6159-7758				Beder H., 1991, ADULT BASIC ED, V1, P67; Boyd M, 1983, J CARDIAC REHABIL, V3, P513; DAVIS T, IN PRESS PEDIATRICS; Davis T C, 1993, Fam Med, V25, P391; Davis T C, 1991, Fam Med, V23, P433; DAVIS TC, 1990, J FAM PRACTICE, V31, P533; DAVIS TC, 1993, INT J ADDICT, V28, P571, DOI 10.3109/10826089309039648; DAVIS TC, 1994, PEDIATRICS, V93, P460; Dean AG, 1990, EPI INFO WORD PROCES; DOAK LG, 1980, PATIENT COUNS HEALTH, V2, P101, DOI 10.1016/S0738-3991(80)80049-8; FRANKEL DH, 1987, LANCET, V2, P1515; GLAZERWALDMAN H, 1985, NURS RES, V34, P184; GRUNDNER TM, 1980, NEW ENGL J MED, V302, P900, DOI 10.1056/NEJM198004173021606; HOLCOMB CA, 1981, J READING, V25, P130; JACKSON RH, 1991, SOUTHERN MED J, V84, P1172, DOI 10.1097/00007611-199110000-00004; JACKSON RH, 1994, AM J MED SCI, V308, P79, DOI 10.1097/00000441-199408000-00002; Jastak S., 1984, WIDE RANGE ACHIEVEME; JAYCOX S, 1989, AM J PUBLIC HEALTH, V79, P1058, DOI 10.2105/AJPH.79.8.1058; JOLLY BT, 1993, ANN EMERG MED, V22, P573, DOI 10.1016/S0196-0644(05)81944-4; KIRSCH IS, 1993, ADULT LITERACY AM 1S; LAUBACH R, 1977, USING READABILITY FO; LEICHTER SB, 1981, DIABETES CARE, V4, P627, DOI 10.2337/diacare.4.6.627; MARINER JD, 1985, LAW MED HLTH, V13, P68; MCCABE BJ, 1989, J AM DIET ASSOC, V89, P1290; MCNEAL B, 1984, DIABETES CARE, V7, P232, DOI 10.2337/diacare.7.3.232; Meade C D, 1992, Oncol Nurs Forum, V19, P1523; MEADE CD, 1989, AM J PUBLIC HEALTH, V79, P204, DOI 10.2105/AJPH.79.2.204; MEADE CD, 1991, PATIENT EDUC COUNS, V17, P153, DOI 10.1016/0738-3991(91)90017-Y; MEADE CD, 1994, AM J PUBLIC HEALTH, V84, P119, DOI 10.2105/AJPH.84.1.119; Michielutte R, 1992, J Cancer Educ, V7, P251; MORROW GR, 1980, JAMA-J AM MED ASSOC, V244, P56, DOI 10.1001/jama.244.1.56; NURSS JR, 1995, J READING, V38, P632; OLMSTEAD WT, 1995, HLTH FACILITIES MANA, V8, P35; PARIKH NS, IN PRESS PATIENT ED; PARKER RM, 1995, J GEN INTERN MED, V10, P537, DOI 10.1007/BF02640361; PLIMPTON S, 1994, PUBLIC HEALTH REP, V109, P86; POWERS RD, 1988, ANN EMERG MED, V17, P124, DOI 10.1016/S0196-0644(88)80295-6; ROSSOF AH, 1988, LANCET, V1, P362; SAID MB, 1994, J AM MED INFORM AS S, P10; SHUPTRINE S, 1993, IMPROVING ACCESS MED; SPANDORFER JM, 1995, ANN EMERG MED, V25, P71, DOI 10.1016/S0196-0644(95)70358-6; Sweeney M A, 1988, J Biocommun, V15, P6; TAUB HA, 1986, J AM GERIATR SOC, V34, P601, DOI 10.1111/j.1532-5415.1986.tb05766.x; Taylor WL, 1953, JOURNALISM QUART, V30, P415, DOI 10.1177/107769905303000401; 1982, MAKING HLTH CARE DEC, V3, P193; 1993, 1994 ACCREDITATION M; 1994, PATIENT ED NEWSLETT, V1, P3	48	667	673	0	104	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	1995	274	21					1677	1682						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TH151	7474271				2022-12-28	WOS:A1995TH15100023
J	COLEMAN, MJ; MEYRAND, P; NUSBAUM, MP				COLEMAN, MJ; MEYRAND, P; NUSBAUM, MP			A SWITCH BETWEEN 2 MODES OF SYNAPTIC TRANSMISSION MEDIATED BY PRESYNAPTIC INHIBITION	NATURE			English	Article							SENSORY AFFERENTS; MODULATION; MECHANISM; TERMINALS; GANGLION; NEURONS; SYSTEM; CRAB	PRESYNAPTIC inhibition reduces chemical synaptic transmission in the central nervous system between pairs of neurons(1-4), but its role(s) in shaping the multisynaptic interactions underlying neural network activity are not well studied. We therefore used the crustacean stomatogastric nervous system to study how presynaptic inhibition of the identified projection neuron, modulatory commissural neuron 1 (MCN1), influences the MCN1 synaptic effects on the gastric mill neural network. Tonic MCN1 discharge excites gastric mill network neurons and activates the gastric mill rhythm(5,6). One network neuron, the lateral gastric (LG) neuron, presynaptically inhibits MCN1 and is electrically coupled to its terminals(5,6). We show here that this presynaptic inhibition selectively reduces or eliminates transmitter-mediated excitation from MCN1 without reducing its electrically mediated excitatory effects, thereby switching the network neurons excited by MCN1. By switching the type of synaptic output from MCN1 and, hence, the activated network neurons, this presynaptic inhibition is pivotal to motor pattern generation.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294; UNIV ALABAMA,NEUROBIOL RES CTR,BIRMINGHAM,AL 35294; UNIV PENN,SCH MED,DEPT NEUROSCI,PHILADELPHIA,PA 19104; UNIV BORDEAUX 1,NEUROBIOL & PHYSIOL COMPAREES LAB,F-33120 ARCACHON,FRANCE; CNRS,F-33120 ARCACHON,FRANCE	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Pennsylvania; UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS)			Nusbaum, Michael/GWC-1917-2022	Nusbaum, Michael/0000-0001-5935-0046				ALFORD S, 1991, EUR J NEUROSCI, V3, P107, DOI 10.1111/j.1460-9568.1991.tb00071.x; Bennett M V, 1992, Semin Cell Biol, V3, P29; CATTAERT D, 1992, J NEUROPHYSIOL, V67, P610, DOI 10.1152/jn.1992.67.3.610; Clarac F, 1992, Curr Opin Neurobiol, V2, P764, DOI 10.1016/0959-4388(92)90131-4; COLEMAN MJ, 1992, J COMP NEUROL, V325, P581, DOI 10.1002/cne.903250410; COLEMAN MJ, 1994, J NEUROSCI, V14, P6544; COLEMAN MJ, 1995, THESIS U ALABAMA BIR; DIXON DB, 1993, NEURON, V11, P267, DOI 10.1016/0896-6273(93)90183-R; GRILLNER S, 1995, TRENDS NEUROSCI, V18, P270, DOI 10.1016/0166-2236(95)93914-J; Harris -Warrick R.M., 1992, DYNAMIC BIOL NETWORK; Harris-Warrick Ronald M., 1992, P87; HARRISWARRICK RM, 1991, ANNU REV NEUROSCI, V14, P39, DOI 10.1146/annurev.ne.14.030191.000351; HAYDON PG, 1991, J NEUROSCI, V11, P3851; KATZ PS, 1995, J NEUROSCI, V15, P6035; MAGEE JC, 1995, SCIENCE, V268, P301, DOI 10.1126/science.7716525; NORRIS BJ, 1994, J NEUROPHYSIOL, V72, P1451, DOI 10.1152/jn.1994.72.4.1451; Nusbaum Michael P., 1994, Current Opinion in Neurobiology, V4, P909, DOI 10.1016/0959-4388(94)90141-4; NUSBAUM MP, 1992, J NEUROSCI, V12, P2706; Rossignol Serge, 1994, Current Opinion in Neurobiology, V4, P894, DOI 10.1016/0959-4388(94)90139-2; Rudomin P, 1993, Curr Opin Neurobiol, V3, P997, DOI 10.1016/0959-4388(93)90173-V; SEGEV I, 1990, J NEUROPHYSIOL, V63, P987, DOI 10.1152/jn.1990.63.5.987; Selverston A.I., 1987, CRUSTACEAN STOMATOGA; SILLAR KT, 1994, J NEUROSCI, V14, P2636; SMALL SA, 1992, J NEUROSCI, V12, P1616; SPRUSTON N, 1995, SCIENCE, V268, P297, DOI 10.1126/science.7716524; TOTH PT, 1993, NATURE, V364, P635, DOI 10.1038/364635a0; WATSON AHD, 1992, COMP BIOCHEM PHYS A, V103, P227, DOI 10.1016/0300-9629(92)90573-9; WEIMANN JM, 1991, J NEUROPHYSIOL, V65, P111, DOI 10.1152/jn.1991.65.1.111; WEIMANN JM, 1994, CURR BIOL, V4, P896, DOI 10.1016/S0960-9822(00)00199-8; [No title captured]	30	126	126	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					502	505		10.1038/378502a0	http://dx.doi.org/10.1038/378502a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477408				2022-12-28	WOS:A1995TH05400074
J	MEYER, D; BIRCHMEIER, C				MEYER, D; BIRCHMEIER, C			MULTIPLE ESSENTIAL FUNCTIONS OF NEUREGULIN IN DEVELOPMENT	NATURE			English	Article							SEGMENT-SPECIFIC EXPRESSION; ZINC-FINGER GENE; NERVOUS-SYSTEM; MOUSE; HINDBRAIN; CELLS	NEUREGULIN (also called NDF, heregulin, GGF and ARIA) is a member of the EGF family which induces growth and differentiation of epithelial, glial and muscle cells in culture(1-4). The biological effects of the factor are mediated by tyrosine kinase receptors. Neuregulin can bind directly to erbB3 and erbB4 and receptor heterodimerization allows neuregulin-dependent activation of erbB2 (refs 1, 2, 5), A targeted mutation in mice reveals multiple essential roles of neuregulin in development, Here we show that neuregulin -/- embryos die during embryogenesis and display heart malformations. In addition, Schwann cell precursors and cranial ganglia fail to develop normally. The phenotype demonstrates that in vivo neuregulin acts locally and frequently in a paracrine manner. All cell types affected by the mutation express either erbB3 or erbB4, indicating that either of these tyrosine kinase receptors can be a component in recognition and transmission of essential neuregulin signals.						Meyer, Dirk/0000-0002-4020-4484				Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRONNERFRASER M, 1995, EXP CELL RES, V118, P405; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CORFAS G, 1995, NEURON, V14, P103, DOI 10.1016/0896-6273(95)90244-9; DAMICOMARTEL A, 1983, AM J ANAT, V166, P445, DOI 10.1002/aja.1001660406; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GOSSLER A, 1993, GENE TARGETING PRACT, P207; HAMBURGER V, 1961, J EXP ZOOL, V148, P91, DOI 10.1002/jez.1401480202; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; ICARDO JM, 1987, ACTA ANAT, V130, P264; JIN JJ, 1993, CELL GROWTH DIFFER, V4, P227; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEDOUARIN NM, 1986, TRENDS NEUROSCI, V9, P175, DOI 10.1016/0166-2236(86)90055-X; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO	30	984	1016	1	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 23	1995	378	6555					386	390		10.1038/378386a0	http://dx.doi.org/10.1038/378386a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477375				2022-12-28	WOS:A1995TF89300059
J	SILVERS, SM; HAMPSON, NB				SILVERS, SM; HAMPSON, NB			CARBON-MONOXIDE POISONING AMONG RECREATIONAL BOATERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To describe the case characteristics of a series of patients poisoned with carbon monoxide (CO) while boating for recreation. Design.-Cases of patients referred for treatment of CO poisoning with hyperbaric oxygen were reviewed. Those cases that occurred during recreational boating were selected for analysis. Setting.-A private, urban, tertiary care center studied from July 1984 to June 1994. Patients.-Thirty-nine patients ranging in age from 6 months to 69 years who were poisoned in 27 separate incidents. Main Outcome Measures.-Characteristics of the poisoning incidents were assessed at initial patient presentation, immediately following treatment, and with follow-up telephone interviews. Results.-Of 512 patients treated for acute unintentional CO poisoning, 39 cases (8%) occurred in 27 incidents related to recreational boating activities. Individuals typically lost consciousness as a result of the poisoning. Most cases occurred aboard a boat that was older than 10 years, had an enclosable cabin, was longer than 22 feet, was powered by a gasoline engine, and was without a CO detector on board. Conclusions.-Carbon monoxide poisoning is a serious hazard associated with recreational boating. The installation of CO detectors aboard boat types typically associated with this syndrome st-could be strongly encouraged.	VIRGINIA MASON CLIN,DEPT MED,SEATTLE,WA 98111; VIRGINIA MASON MED CTR,DEPT HYPERBAR,SEATTLE,WA; UNIV ROCHESTER,SCH MED & DENT,ROCHESTER,NY 14627	Virginia Mason Medical Center; Virginia Mason Medical Center; University of Rochester			Silvers, Scott/AAM-1234-2021		NIEHS NIH HHS [ESO-0220] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		COBB N, 1991, JAMA-J AM MED ASSOC, V226, P659; GOMEZ GA, 1991, SURG CLIN N AM, V71, P419; GRACE TW, 1981, JAMA-J AM MED ASSOC, V246, P1698; HAMPSON NB, 1992, JAMA-J AM MED ASSOC, V267, P538, DOI 10.1001/jama.267.4.538; HAMPSON NB, 1994, JAMA-J AM MED ASSOC, V271, P52, DOI 10.1001/jama.271.1.52; KOREN G, 1991, REPROD TOXICOL, V5, P397, DOI 10.1016/0890-6238(91)90002-W; PIANTADOSI CA, 1990, UPDATE INTENSIVE CAR, V10, P460; RADFORD EP, 1982, PHS821250 PUBL; Tan E S, 1993, Ned Tijdschr Geneeskd, V137, P2266; 1994, BOATING 1994; 1994, BOATING STATISTICS 1; 1982, MMWR-MORBID MORTAL W, V31, P529	12	26	26	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	1995	274	20					1614	1616						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE738	7474247				2022-12-28	WOS:A1995TE73800027
J	WILSON, MC; HAYWARD, RSA; TUNIS, SR; BASS, EB; GUYATT, G				WILSON, MC; HAYWARD, RSA; TUNIS, SR; BASS, EB; GUYATT, G			USERS GUIDES TO THE MEDICAL LITERATURE .8. HOW TO USE CLINICAL-PRACTICE GUIDELINES .B. WHAT ARE THE RECOMMENDATIONS AND WILL THEY HELP YOU IN CARING FOR YOUR PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									MCMASTER UNIV, HLTH SCI CTR, DEPT MED, HAMILTON, ON L8N 3Z5, CANADA; MCMASTER UNIV, HLTH SCI CTR, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON, ON L8N 3Z5, CANADA; JOHNS HOPKINS UNIV, SCH MED, DIV INTERNAL MED, BALTIMORE, MD USA; US CONGRESS, OFF TECHNOL ASSESSMENT, HLTH PROGRAM, WASHINGTON, DC USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT MED, WINSTON SALEM, NC USA	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; Johns Hopkins University; Wake Forest University; Wake Forest Baptist Medical Center				Bass, Eric/0000-0001-9106-527X; Wilson, Mark/0000-0003-1271-9664				[Anonymous], COMMON SCREENING TES; [Anonymous], 1992, ACUTE PAIN MANAGEMEN; BATTISTA R N, 1988, American Journal of Preventive Medicine, V4, P53; COOK DJ, 1992, CHEST, V102, pS305; GRADY D, 1992, ANN INTERN MED, V117, P1038; GUYATT GH, IN PRESS JAMA; Hayward R S, 1993, Ann Intern Med, V118, P731; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; KOTTKE TE, 1990, J CLIN EPIDEMIOL, V43, P1023, DOI 10.1016/0895-4356(90)90147-H; LAUPACIS A, 1992, ACP J CLUB       MAY, pA12; LAUPACIS A, ANN INTERN MED S3, V116; LOGAN AG, 1993, CAN MED ASSOC J, V148, P521; RICHARDSON WS, 1995, JAMA-J AM MED ASSOC, V273, P1610, DOI 10.1001/jama.273.20.1610; RUSH AJ, 1993, AM FAM PHYSICIAN, V47, P1776; SACKETT DL, 1986, CHEST, V89, pS2, DOI 10.1378/chest.89.2_Supplement.2S; SCHLANT RC, 1986, J AM COLL CARDIOL, V8, P725; SOX HC, 1989, ANN INTERN MED, V110, P456, DOI 10.7326/0003-4819-110-6-456; SOX HC, 1989, ANN INTERN MED, V111, P489, DOI 10.7326/0003-4819-111-6-489; WEINGARTEN SR, 1994, ANN INTERN MED, V120, P257, DOI 10.7326/0003-4819-120-4-199402150-00001; WHELTON P K, 1990, Journal of General Internal Medicine, V5, pS17, DOI 10.1007/BF02600834; WOOLF SH, 1990, J CLIN EPIDEMIOL, V43, P891, DOI 10.1016/0895-4356(90)90073-X; 1979, CAN MED ASS J, V121, P1193	23	195	200	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	1995	274	20					1630	1632		10.1001/jama.274.20.1630	http://dx.doi.org/10.1001/jama.274.20.1630			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE738	7474251				2022-12-28	WOS:A1995TE73800031
J	MALIN, AS; GWANZURA, LKZ; KLEIN, S; ROBERTSON, VJ; MUSVAIRE, P; MASON, PR				MALIN, AS; GWANZURA, LKZ; KLEIN, S; ROBERTSON, VJ; MUSVAIRE, P; MASON, PR			PNEUMOCYSTIS-CARINII PNEUMONIA IN ZIMBABWE	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED PATIENTS; CENTRAL-AFRICA; LUSAKA; ZAMBIA; AIDS	Pneumocystis carinii pneumonia (PCP) is said to be rare in Africa, with reported rates of 0-22% in human-immunodeficiency-virus (HIV) infected individuals with respiratory symptoms. Over one year in a central hospital in southern Africa, 64 HIV-infected patients with acute diffuse pneumonia unresponsive to penicillin and sputum smear-negative for acid-fast bacilli underwent fibreoptic bronchoscopy. Bronchoalveolar lavage fluid was assessed for bacteria, fungi, Pneumocystis carinii, and mycobacteria. 21 patients (33%) had PCP and 24 (39%) had tuberculosis; 6 of these had both infections. 5 patients had Kaposi's sarcoma (KS) associated with PCP, tuberculosis, or another infection, in 1 patient KS was the only finding, and in 21 no pathogen was identified. A logistic regression model was used to assess clinical, radiographic, and arterial blood gas predictors of PCP and tuberculosis, Fine reticulonodular shadowing on the chest radiograph (nodular component <1 mm) was the strongest independent predictor of PCP (odds ratio 8.5 [95% CI 6.1-10.9]). A respiratory rate of more than 40/min was the best clinical predictor of PCP (odds ratio 11.2 [95% CI 8.8-13.6]). Median CD4(+) T cell count for all cases of PCP was 134/mu L (range 5-355) and for tuberculosis without PCP 206/mu L (range 61-787). In resource-limited countries, a regionally appropriate management algorithm is required.	UNIV ZIMBABWE,DEPT CLIN PHARMACOL,HARARE,ZIMBABWE; UNIV ZIMBABWE,DEPT MED MICROBIOL,HARARE,ZIMBABWE; UNIV ZIMBABWE,DEPT PATHOL,HARARE,ZIMBABWE	University of Zimbabwe; University of Zimbabwe; University of Zimbabwe								ABOUYA YL, 1992, AM REV RESPIR DIS, V145, P617, DOI 10.1164/ajrccm/145.3.617; AFOLABI OA, 1993, 9 P INT C AIDS BERL; ALTMAN DG, 1991, PRACTICAL STAT MED R, P457; ATZORI C, 1993, T ROY SOC TROP MED H, V87, P55, DOI 10.1016/0035-9203(93)90418-P; BATUNGWANAYO J, 1994, AM J RESP CRIT CARE, V149, P1591, DOI 10.1164/ajrccm.149.6.8004318; CARME B, 1991, T ROY SOC TROP MED H, V85, P80, DOI 10.1016/0035-9203(91)90167-W; ELVIN KM, 1989, T ROY SOC TROP MED H, V83, P553, DOI 10.1016/0035-9203(89)90290-3; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; KAMANFU G, 1993, AM REV RESPIR DIS, V147, P658, DOI 10.1164/ajrccm/147.3.658; Lucas S., 1988, AIDS and associated cancers in Africa., P124; LUCAS SB, 1991, AIDS, V5, pS143; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; MACHIELS G, 1992, T ROY SOC TROP MED H, V86, P399, DOI 10.1016/0035-9203(92)90237-7; MCLEOD DT, 1989, T ROY SOC TROP MED H, V83, P694, DOI 10.1016/0035-9203(89)90400-8; MILLAR AB, 1990, THORAX, V45, P57, DOI 10.1136/thx.45.1.57; MILLER RF, 1992, LANCET, V339, P747, DOI 10.1016/0140-6736(92)90650-R; MILLER RF, 1989, THORAX, V44, P559, DOI 10.1136/thx.44.7.559; MUFSON MA, 1994, CURR OPIN INFECT DIS, V7, P178, DOI 10.1097/00001432-199404000-00006; PIOT P, 1992, AIDS AFRICA MANUAL P; SERWADDA D, 1989, AIDS, V3, P47; WAKEFIELD AE, 1990, T ROY SOC TROP MED H, V84, P800, DOI 10.1016/0035-9203(90)90087-U; WAKEFIELD AE, 1994, J CLIN MICROBIOL, V32, P2959, DOI 10.1128/JCM.32.12.2959-2961.1994; 1991, RRESPIRATORY CONDITI; 1986, WEEKLY EPIDEMIOL REC, V10, P72; 1994, ESSENTIAL DRUGS LIST, P95	25	89	91	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1258	1261		10.1016/S0140-6736(95)91862-0	http://dx.doi.org/10.1016/S0140-6736(95)91862-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475717				2022-12-28	WOS:A1995TE14500010
J	KIRZ, J				KIRZ, J			REMEMBERING X-RAYS	SCIENCE			English	Editorial Material											KIRZ, J (corresponding author), SUNY STONY BROOK,DEPT PHYS,STONY BROOK,NY 11794, USA.		Kirz, Janos/AHE-9085-2022					glasser otto, 1934, WC RONTGEN EARLY HIS; Mould RF, 1993, CENTURY XRAYS RADIOA, V1st; Rontgen W C, 1896, Science, V3, P227, DOI 10.1126/science.3.59.227; Rontgen WC, 1896, NATURE, V53, P274	4	2	2	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 10	1995	270	5238					934	934		10.1126/science.270.5238.934	http://dx.doi.org/10.1126/science.270.5238.934			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD878	7481797				2022-12-28	WOS:A1995TD87800034
J	COHENCORY, S; FRASER, SE				COHENCORY, S; FRASER, SE			EFFECTS OF BRAIN-DERIVED NEUROTROPHIC FACTOR ON OPTIC AXON BRANCHING AND REMODELING IN-VIVO	NATURE			English	Article							NERVE GROWTH-FACTOR; RETINAL GANGLION-CELLS; RECEPTOR; TRKB; RAT; EXPRESSION; SURVIVAL; BDNF; NGF	NEUROTROPHINS are thought to be important for the survival and differentiation of vertebrate neurons(1). Roles have been suggested for target-derived neurotrophins, based both on their expression in target tissues at the time of neuron innervation(2,3), and on their effects on axonal sprouting(4-6). However, direct in vivo evidence of their involvement in axon arborization has remained elusive. We have used in vivo microscopy to follow individual optic axons over time, and have examined the role of the neurotrophin brain-derived neurotrophic factor (BDNF) in their development. Here we show that injection of BDNF into the optic tectum of live Xenopus laevis tadpoles increased the branching and complexity of optic axon terminal arbors. In contrast, injection of specific neutralizing antibodies to BDNF reduced axon arborization and complexity. The onset of these effects was rapid (within 2 hours) and persisted throughout the 24-hour observation period. Other neurotrophins had little or no significant effects. These results demonstrate the involvement of neurotrophins in the dynamic elaboration of axon terminals, and suggest a direct role for target-derived BDNF during synaptic patterning in the developing central nervous system.			COHENCORY, S (corresponding author), CALTECH, CTR BIOL IMAGING, DIV BIOL 139-74, PASADENA, CA 91125 USA.		Fraser, Scott/Y-3406-2019	Fraser, Scott/0000-0002-5377-0223				BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; CLINE HT, 1989, NEURON, V3, P413, DOI 10.1016/0896-6273(89)90201-8; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; COHENCORY S, 1994, NEURON, V12, P747, DOI 10.1016/0896-6273(94)90328-X; COHENCORY S, 1993, EXP NEUROL, V119, P165, DOI 10.1006/exnr.1993.1018; DAVIES AM, 1994, J NEUROBIOL, V25, P1334, DOI 10.1002/neu.480251103; DIAMOND J, 1992, J NEUROSCI, V12, P1454; DUGICHDJORDJEVIC MM, 1992, NEURON, V8, P1127, DOI 10.1016/0896-6273(92)90133-X; EMFORS P, 1992, EUR J NEUROSCI, V4, P1140; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HARRIS WA, 1987, DEVELOPMENT, V101, P123; JOHNSON JE, 1986, J NEUROSCI, V6, P3031; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KORSCHING S, 1988, DEV BIOL, V126, P40, DOI 10.1016/0012-1606(88)90236-9; KORSCHING S, 1993, J NEUROSCI, V13, P2739; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LINDHOLM D, 1994, J NEUROBIOL, V25, P1362, DOI 10.1002/neu.480251105; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; NAKAMURA H, 1989, J NEUROSCI, V9, P3776; NAWA H, 1994, J NEUROSCI, V14, P3751; OROURKE NA, 1990, NEURON, V5, P159, DOI 10.1016/0896-6273(90)90306-Z; OROURKE NA, 1994, NEURON, V12, P921, DOI 10.1016/0896-6273(94)90343-3; RODRIGUEZTEBAR A, 1989, DEV BIOL, V136, P296, DOI 10.1016/0012-1606(89)90256-X; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; SIMON DK, 1994, DEV BIOL, V162, P384, DOI 10.1006/dbio.1994.1095; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F	30	506	514	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 9	1995	378	6553					192	196		10.1038/378192a0	http://dx.doi.org/10.1038/378192a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD759	7477323				2022-12-28	WOS:A1995TD75900056
J	BAUTISTA, JL; BUDHRAJA, MD; BARCIA, TD; SHANKEL, SW				BAUTISTA, JL; BUDHRAJA, MD; BARCIA, TD; SHANKEL, SW			PNEUMOBILIA ASSOCIATED WITH SMALL BOWEL OBSTRUCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note									UNIV NEVADA,SCH MED SCI,DEPT INTERNAL MED,RENO,NV 89557; VET ADM HOSP,DEPT RADIOL,RENO,NV; LOMA LINDA UNIV,DEPT MED,LOMA LINDA,CA 92350	Nevada System of Higher Education (NSHE); University of Nevada Reno; Loma Linda University	BAUTISTA, JL (corresponding author), LOGAN HTS FAMILY HLTH CTR,SAN DIEGO,CA, USA.							COVONI AF, 1976, RADIOLOGY, V118, P526; GOSINK BB, 1981, AM J ROENTGENOL, V137, P763, DOI 10.2214/ajr.137.4.763; GRANT EG, 1980, J COMPUT ASSIST TOMO, V4, P630, DOI 10.1097/00004728-198010000-00011; HARLEY WD, 1978, AM J ROENTGENOL, V131, P661, DOI 10.2214/ajr.131.4.661; LEBLANC KA, 1983, SOUTHERN MED J, V76, P1249, DOI 10.1097/00007611-198310000-00013; LEWANDOWSKI BJ, 1984, RADIOLOGY, V153, P329, DOI 10.1148/radiology.153.2.6385105; MCSHERRY CK, 1969, SURG GYNECOL OBSTETR, V128, P49; Ndiyob J, 1976, J Natl Med Assoc, V68, P177; SEDLACK RE, 1961, GASTROENTEROLOGY, V41, P551; SUSSMAN N, 1960, AM J ROENTGENOL RADI, V83, P847; WIOT JF, 1961, AMER J ROENTGENOL RA, V86, P920	11	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1988	260	13					1930	1931						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q2703	3418854				2022-12-28	WOS:A1988Q270300029
J	HOSSACK, KF; LEDDY, CL; JOHNSON, AM; SCHRIER, RW; GABOW, PA				HOSSACK, KF; LEDDY, CL; JOHNSON, AM; SCHRIER, RW; GABOW, PA			ECHOCARDIOGRAPHIC FINDINGS IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									UNIV COLORADO,SCH MED,DEPT MED,DENVER,CO 80202	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	HOSSACK, KF (corresponding author), DENVER GEN HOSP,DIV CARDIOL,777 BANNOCK ST A009,DENVER,CO 80204, USA.			Johnson, Anne/0000-0003-1330-7100				ABBASI AS, 1980, CIRCULATION, V61, P143, DOI 10.1161/01.CIR.61.1.143; AKASAKA T, 1987, CIRCULATION, V76, P262, DOI 10.1161/01.CIR.76.2.262; BARLOW JB, 1963, AM HEART J, V66, P443, DOI 10.1016/0002-8703(63)90375-2; BIGELOW NH, 1953, AM J MED SCI, V225, P485, DOI 10.1097/00000441-195305000-00004; BUTKOWSKI RJ, 1985, KIDNEY INT, V28, P744, DOI 10.1038/ki.1985.193; CIOBANU M, 1982, AM J CARDIOL, V49, P339, DOI 10.1016/0002-9149(82)90510-0; DALGAARD OZ, 1957, ACTA MED SCAND, V328, P10; DEVEREUX RB, 1982, ANN INTERN MED, V97, P826, DOI 10.7326/0003-4819-97-6-826; DUREN DR, 1988, J AM COLL CARDIOL, V11, P42; FEIGENBAUM H, 1981, ECHOCARDIOGR-J CARD, P551; GABOW PA, 1984, ANN INTERN MED, V101, P238, DOI 10.7326/0003-4819-101-2-238; GOOCH AS, 1972, AM J CARDIOL, V29, P611, DOI 10.1016/0002-9149(72)90161-0; GRANOT Y, 1988, CLIN RES, V36, pA135; GRANTHAM JJ, 1988, DISEASES KIDNEY, P583; HAMMER D, 1979, AM J MED, V67, P863, DOI 10.1016/0002-9343(79)90746-0; KISSANE JM, 1979, NEPHROLOGY, P887; KOLIBASH AJ, 1986, AM J CARDIOL, V58, P762, DOI 10.1016/0002-9149(86)90352-8; LEIER CV, 1984, ANN INTERN MED, V100, P683, DOI 10.7326/0003-4819-100-5-683; LEIER CV, 1980, ANN INTERN MED, V92, P171, DOI 10.7326/0003-4819-92-2-171; LEVINE RA, 1987, CIRCULATION, V75, P756, DOI 10.1161/01.CIR.75.4.756; LOBSTEIN HP, 1973, NEW ENGL J MED, V289, P127, DOI 10.1056/NEJM197307192890304; MARDELLI TJ, 1981, CHEST, V79, P201, DOI 10.1378/chest.79.2.201; MILUTINOVIC J, 1980, AM J MED, V68, P741, DOI 10.1016/0002-9343(80)90266-1; MONTOLIU J, 1980, LANCET, V1, P1133; MORGANROTH J, 1981, CHEST, V79, P23, DOI 10.1378/chest.79.1.23; NAGGAR CZ, 1986, AM J CARDIOL, V58, P1209, DOI 10.1016/0002-9149(86)90383-8; NUNEZ L, 1986, CHEST, V90, P299, DOI 10.1378/chest.90.2.299; OGAWA S, 1982, CIRCULATION, V65, P174, DOI 10.1161/01.CIR.65.1.174; PERLOFF JK, 1986, AM J CARDIOL, V57, P1124, DOI 10.1016/0002-9149(86)90686-7; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SAVAGE DD, 1983, AM HEART J, V106, P571, DOI 10.1016/0002-8703(83)90704-4; SAVAGE DD, 1983, AM HEART J, V106, P577, DOI 10.1016/0002-8703(83)90705-6; SAVAGE DD, 1983, AM HEART J, V106, P582, DOI 10.1016/0002-8703(83)90706-8; SCHEFF RT, 1980, ANN INTERN MED, V92, P202, DOI 10.7326/0003-4819-92-2-202; THOMPSON JS, 1986, GENETICS MED, V4, P44; WANN LS, 1983, BRIT HEART J, V49, P334; WEISS AN, 1975, CIRCULATION, V52, P1091, DOI 10.1161/01.CIR.52.6.1091; WILSON PD, 1986, KIDNEY INT, V30, P371, DOI 10.1038/ki.1986.194	38	177	180	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 6	1988	319	14					907	912		10.1056/NEJM198810063191404	http://dx.doi.org/10.1056/NEJM198810063191404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q2854	3419455				2022-12-28	WOS:A1988Q285400004
J	RUMSEY, WL; VANDERKOOI, JM; WILSON, DF				RUMSEY, WL; VANDERKOOI, JM; WILSON, DF			IMAGING OF PHOSPHORESCENCE - A NOVEL METHOD FOR MEASURING OXYGEN DISTRIBUTION IN PERFUSED TISSUE	SCIENCE			English	Article											RUMSEY, WL (corresponding author), UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104, USA.			Wilson, David F/0000-0002-2626-5838	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036393, R01GM021524] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21524, GM 36393] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAMPRA JC, 1982, LIVER BIOL PATHOBIOL, P632; KEKONEN EM, 1987, J CELL PHYSIOL, V133, P119, DOI 10.1002/jcp.1041330115; MATSUMURA T, 1986, AM J PHYSIOL, V250, pG800, DOI 10.1152/ajpgi.1986.250.6.G800; VANDERKOOI JM, 1987, J BIOL CHEM, V262, P5476; VANDERKOOI JM, 1987, ADV EXP MED BIOL, V200, P189; Wilson D F, 1987, Adv Exp Med Biol, V215, P71; WILSON DF, 1988, J BIOL CHEM, V263, P2712; WILSON DF, 1988, ADV EXP MED BIOL, V220, P121	8	439	442	2	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 23	1988	241	4873					1649	1651		10.1126/science.3420417	http://dx.doi.org/10.1126/science.3420417			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q1372	3420417				2022-12-28	WOS:A1988Q137200033
J	BORZAK, S; RIDKER, PM				BORZAK, S; RIDKER, PM			DISCORDANCE BETWEEN METAANALYSES AND LARGE-SCALE RANDOMIZED, CONTROLLED TRIALS - EXAMPLES FROM THE MANAGEMENT OF ACUTE MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Note							INTRAVENOUS-MAGNESIUM; CLINICAL-TRIALS; INTERVENTION; MORTALITY; HEART	Clinicians making treatment decisions are faced with ever-growing numbers of therapies, each supported by different types of clinical data. By bringing together large amounts of data, meta-analysis has emerged as a useful tool for generating hypotheses with which to plan definitive trials, and it has also been recommended as a basis for decision making in the absence of definitive trials. In several instances, early meta-analyses have provided evidence of efficacy that was subsequently confirmed. However, in other instances, the results of initial meta-analyses have disagreed with the results of subsequent large-scale trials. Nitrate and magnesium therapy for acute myocardial infarction are two contemporary examples of treatments about which hypothesis-generating meta-analyses and subsequent large trials have disagreed. We review the issues surrounding the interpretation of meta-analyses in these cases, and we suggest that the appropriate use of meta-analyses in clinical decision making be carefully placed in the context of a review of pathophysiologic principles and the results of basic laboratory research and individual trials.	BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	BORZAK, S (corresponding author), HENRY FORD HOSP, DIV CARDIOVASC, 2799 W GRAND BLVD, DETROIT, MI 48202 USA.							ANELLO C, 1995, J CLIN EPIDEMIOL, V48, P109, DOI 10.1016/0895-4356(94)00084-4; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1986, LANCET, V2, P57; ANTMAN EM, 1995, AM J CARDIOL, V75, P391, DOI 10.1016/S0002-9149(99)80561-X; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; ANTMAN EM, 1994, CIRCULATION, V90, P325; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; COLLINS R, 1995, LANCET, V345, P669; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DEVITA C, 1994, LANCET, V343, P1115; DOMANSKI MJ, 1994, AM J CARDIOL, V74, P395, DOI 10.1016/0002-9149(94)90411-1; DUTOIT EF, 1992, CIRC RES, V70, P960, DOI 10.1161/01.RES.70.5.960; GHEORGHIADE M, 1996, IN PRESS AM HEART J; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; Laird N M, 1990, Int J Technol Assess Health Care, V6, P5; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; MANTEL N, 1959, J NATL CANCER I, V22, P719; Oakes M, 1993, Stat Methods Med Res, V2, P147; PETO R, 1995, J CLIN EPIDEMIOL, V48, P23, DOI 10.1016/0895-4356(94)00150-O; RIDKER PM, 1992, HEART DISEASE TXB CA, V3, P54; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; TEO KK, 1991, BMJ-BRIT MED J, V303, P1499, DOI 10.1136/bmj.303.6816.1499; THACKER SB, 1988, JAMA-J AM MED ASSOC, V259, P1685, DOI 10.1001/jama.259.11.1685; VILLAR J, 1995, LANCET, V345, P772, DOI 10.1016/S0140-6736(95)90646-0; WOODS KL, 1995, LANCET, V346, P611, DOI 10.1016/S0140-6736(95)91440-4; WOODS KL, 1994, LANCET, V343, P816, DOI 10.1016/S0140-6736(94)92024-9; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1993, CIRCULATION, V87, P2043, DOI 10.1161/01.CIR.87.6.2043; YUSUF S, 1988, LANCET, V1, P1088; 1991, AM J CARDIOL, V68, pD87	33	112	113	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1995	123	11					873	877		10.7326/0003-4819-123-11-199512010-00010	http://dx.doi.org/10.7326/0003-4819-123-11-199512010-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG209	7486471				2022-12-28	WOS:A1995TG20900010
J	ABE, O; ABE, R; ASAISHI, K; ENOMOTO, K; HATTORI, T; IINO, Y; KIKUCHI, K; KOYAMA, H; SAWA, K; UCHINO, J; YOSHIDA, M; VANDEVELDE, AO; VERMORKEN, JB; FOROGLOU, P; GIOKAS, G; LISSAIOS, B; HARVEY, VJ; HOLDAWAY, TM; KAY, RG; MASON, BH; FORBES, JF; FOCAN, C; LOBELLE, JP; PEEK, U; OATES, GD; POWELL, J; BASTERT, G; RAUSCHECKER, H; SAUER, R; SAUERBREI, W; SCHAUER, A; SCHUMACHER, M; GELMAN, RS; HENDERSON, IC; SHAPIRO, CL; HANCOCK, AK; JACKSON, S; RAGAZ, J; DELOZIER, T; MACELESECH, J; HAYBITTLE, JL; CIRRINCIONE, C; KORZUN, A; WEISS, RB; WOOD, WC; BAUM, M; HOUGHTON, J; RILEY, D; DENT, DM; GUDGEON, CA; HACKING, A; HORGAN, K; HUGHES, L; STEWART, HJ; GORDON, NH; DAVIS, HL; OWEN, JR; MEIER, P; HOWELL, A; RIBEIRO, GC; SWINDELL, R; ALBANO, J; DEOLIVEIRA, CF; GERVASIO, H; GORDILHO, J; CARSTENSEN, B; PALSHOF, T; JOHANSEN, H; KORZENIOWSKI, S; SKOLYSZEWSKI, J; ANDERSEN, KW; AXELSSON, CK; BLICHERTTOFT, M; MOURIDSEN, HT; OVERGAARD, M; ROSE, C; CORCORAN, N; TRAMPISCH, HJ; ABELOFF, MD; CARBONE, PC; GLICK, J; GRAY, R; TORMEY, DC; BARTELINK, H; FENTIMAN, IS; PARIDAENS, R; VANDRIEL, OJR; SYLVESTER, RJ; VANDEVELDE, CJH; VANDERSCHUEREN, E; VANDONGEN, JA; WELVAART, K; SCANLON, EF; SCHURMAN, S; DESCHRYVER, A; YOSEF, HMA; MCARDLE, CS; SMITH, DC; LARA, PC; BOCCARDO, F; IZUO, M; MORISHITA, Y; BENTLEY, A; DORAN, Z; HAYWARD, JL; RUBENS, RD; KAUFMANN, M; JONAT, W; SCHEURLEN, H; VONFOURNIER, D; KAUFMANN, M; KLEFSTROM, P; CUZICK, J; MARGREITER, R; CAVALLI, F; COLLINS, J; GELBER, RD; GOLDHIRSCH, A; ISLEY, MR; LINDTNER, J; PRICE, KN; RUDENSTAM, CM; BLISS, JM; CHILVERS, CED; COOMBES, RC; MARTY, M; BRUFMAN, G; HAYAT, H; BOROVIK, R; ROBINSON, E; PANNUTI, F; TAKASHIMA, S; YASUTOMI, T; SONOO, H; YAMASHITA, J; OGAWA, M; NOMURA, Y; BONTE, J; TENGRUP, I; TENNVALLNITTBY, L; MARTIN, P; ROMAIN, S; AHMANN, D; SCHAID, DJ; BUZDAR, AU; SMITH, T; HAKES, T; NORTON, L; WITTES, R; DELAHUERTA, R; SAINZ, MG; BONADONNA, G; DELVECCHIO, M; VALAGUSSA, P; VERONESI, U; DUBOIS, JB; BIANCO, AR; LIPPMAN, ME; PIERCE, LJ; SIMON, R; STEINBERG, SM; BROWN, A; FISHER, B; REDMOND, C; WOLMARK, N; JACKSON, IM; PALMER, MK; INGLE, JN; BENGTSSON, NO; LARSSON, LG; LYTHGOE, JP; KISSIN, M; HANNISDAL, E; VARHAUG, JE; BLAMEY, RW; MITCHELL, AK; ROBERTSON, JFR; NAKAMURA, Y; MATHE, G; MISSET, JL; CLARKE, EA; MCLAUGHLIN, JR; CLARK, RM; LEVINE, M; MORIMOTO, K; GUNDERSEN, S; HAUERJENSEN, M; HOST, H; CROSSLEY, E; DURRANT, K; HARRIS, A; BEIGHTON, A; CHADBON, D; CLARKE, M; COLLINS, R; DAVIES, C; EVANS, V; GODWIN, J; GREAVES, E; HARWOOD, C; JAMES, S; MEAD, G; MULDAHL, A; PETO, R; TOOTH, A; WHEATLEY, K; RAMBERT, P; ASSELAIN, B; SALMON, RJ; VILCOQ, JR; ARRIAGADA, R; HILL, C; LAPLANCHE, A; LE, MG; SPIELMANN, M; COCCONI, G; DIBLASIO, B; CATALANO, R; CREECH, RH; BROCKSCHMIDT, J; COOPER, MR; ANDRYSEK, O; BARKMANOVA, J; TREURNIETDONKER, AD; VANPUTTEN, WLJ; EASTON, D; POWLES, TJ; GAZET, JC; SEMIGLAZOV, V; DESHPANDE, N; DIMARTINO, L; DOUGLAS, P; LINDTNER, A; NOTTER, G; NISSENMEYER, R; FORREST, APM; JACK, W; MCDONALD, C; MOLLER, TR; RYDEN, S; CARSTENSEN, J; HATSCHEK, T; SODERBERG, M; CARPENTER, JT; ALBAIN, K; CROWLEY, J; GREEN, S; OSBORNE, CK; RUTQUIST, LE; WALLGREN, A; HOLM, LE; CASTIGLIONE, M; FLUCKIGER, H; THURLIMANN, B; BRENNER, H; HERCBERGS, A; YOSHIMOTO, M; DEBOER, G; PATERSON, AHG; PRITCHARD, KI; MEAKIN, JW; PANZARELLA, T; NAJA, A; BAHI, J; REID, M; SPITTLER, M; SENANAYAKE, F; HOLMBERG, L; SEVELDA, P; ZIELINSKY, CC; JAKESZ, R; BUCHANAN, RB; CROSS, M; DUNN, JA; GILLESPIE, WM; KELLY, K; MORRISON, JM; LITTON, A; CHLEBOWSKI, RT; BEZWODA, WR; CAFFIER, H				ABE, O; ABE, R; ASAISHI, K; ENOMOTO, K; HATTORI, T; IINO, Y; KIKUCHI, K; KOYAMA, H; SAWA, K; UCHINO, J; YOSHIDA, M; VANDEVELDE, AO; VERMORKEN, JB; FOROGLOU, P; GIOKAS, G; LISSAIOS, B; HARVEY, VJ; HOLDAWAY, TM; KAY, RG; MASON, BH; FORBES, JF; FOCAN, C; LOBELLE, JP; PEEK, U; OATES, GD; POWELL, J; BASTERT, G; RAUSCHECKER, H; SAUER, R; SAUERBREI, W; SCHAUER, A; SCHUMACHER, M; GELMAN, RS; HENDERSON, IC; SHAPIRO, CL; HANCOCK, AK; JACKSON, S; RAGAZ, J; DELOZIER, T; MACELESECH, J; HAYBITTLE, JL; CIRRINCIONE, C; KORZUN, A; WEISS, RB; WOOD, WC; BAUM, M; HOUGHTON, J; RILEY, D; DENT, DM; GUDGEON, CA; HACKING, A; HORGAN, K; HUGHES, L; STEWART, HJ; GORDON, NH; DAVIS, HL; OWEN, JR; MEIER, P; HOWELL, A; RIBEIRO, GC; SWINDELL, R; ALBANO, J; DEOLIVEIRA, CF; GERVASIO, H; GORDILHO, J; CARSTENSEN, B; PALSHOF, T; JOHANSEN, H; KORZENIOWSKI, S; SKOLYSZEWSKI, J; ANDERSEN, KW; AXELSSON, CK; BLICHERTTOFT, M; MOURIDSEN, HT; OVERGAARD, M; ROSE, C; CORCORAN, N; TRAMPISCH, HJ; ABELOFF, MD; CARBONE, PC; GLICK, J; GRAY, R; TORMEY, DC; BARTELINK, H; FENTIMAN, IS; PARIDAENS, R; VANDRIEL, OJR; SYLVESTER, RJ; VANDEVELDE, CJH; VANDERSCHUEREN, E; VANDONGEN, JA; WELVAART, K; SCANLON, EF; SCHURMAN, S; DESCHRYVER, A; YOSEF, HMA; MCARDLE, CS; SMITH, DC; LARA, PC; BOCCARDO, F; IZUO, M; MORISHITA, Y; BENTLEY, A; DORAN, Z; HAYWARD, JL; RUBENS, RD; KAUFMANN, M; JONAT, W; SCHEURLEN, H; VONFOURNIER, D; KAUFMANN, M; KLEFSTROM, P; CUZICK, J; MARGREITER, R; CAVALLI, F; COLLINS, J; GELBER, RD; GOLDHIRSCH, A; ISLEY, MR; LINDTNER, J; PRICE, KN; RUDENSTAM, CM; BLISS, JM; CHILVERS, CED; COOMBES, RC; MARTY, M; BRUFMAN, G; HAYAT, H; BOROVIK, R; ROBINSON, E; PANNUTI, F; TAKASHIMA, S; YASUTOMI, T; SONOO, H; YAMASHITA, J; OGAWA, M; NOMURA, Y; BONTE, J; TENGRUP, I; TENNVALLNITTBY, L; MARTIN, P; ROMAIN, S; AHMANN, D; SCHAID, DJ; BUZDAR, AU; SMITH, T; HAKES, T; NORTON, L; WITTES, R; DELAHUERTA, R; SAINZ, MG; BONADONNA, G; DELVECCHIO, M; VALAGUSSA, P; VERONESI, U; DUBOIS, JB; BIANCO, AR; LIPPMAN, ME; PIERCE, LJ; SIMON, R; STEINBERG, SM; BROWN, A; FISHER, B; REDMOND, C; WOLMARK, N; JACKSON, IM; PALMER, MK; INGLE, JN; BENGTSSON, NO; LARSSON, LG; LYTHGOE, JP; KISSIN, M; HANNISDAL, E; VARHAUG, JE; BLAMEY, RW; MITCHELL, AK; ROBERTSON, JFR; NAKAMURA, Y; MATHE, G; MISSET, JL; CLARKE, EA; MCLAUGHLIN, JR; CLARK, RM; LEVINE, M; MORIMOTO, K; GUNDERSEN, S; HAUERJENSEN, M; HOST, H; CROSSLEY, E; DURRANT, K; HARRIS, A; BEIGHTON, A; CHADBON, D; CLARKE, M; COLLINS, R; DAVIES, C; EVANS, V; GODWIN, J; GREAVES, E; HARWOOD, C; JAMES, S; MEAD, G; MULDAHL, A; PETO, R; TOOTH, A; WHEATLEY, K; RAMBERT, P; ASSELAIN, B; SALMON, RJ; VILCOQ, JR; ARRIAGADA, R; HILL, C; LAPLANCHE, A; LE, MG; SPIELMANN, M; COCCONI, G; DIBLASIO, B; CATALANO, R; CREECH, RH; BROCKSCHMIDT, J; COOPER, MR; ANDRYSEK, O; BARKMANOVA, J; TREURNIETDONKER, AD; VANPUTTEN, WLJ; EASTON, D; POWLES, TJ; GAZET, JC; SEMIGLAZOV, V; DESHPANDE, N; DIMARTINO, L; DOUGLAS, P; LINDTNER, A; NOTTER, G; NISSENMEYER, R; FORREST, APM; JACK, W; MCDONALD, C; MOLLER, TR; RYDEN, S; CARSTENSEN, J; HATSCHEK, T; SODERBERG, M; CARPENTER, JT; ALBAIN, K; CROWLEY, J; GREEN, S; OSBORNE, CK; RUTQUIST, LE; WALLGREN, A; HOLM, LE; CASTIGLIONE, M; FLUCKIGER, H; THURLIMANN, B; BRENNER, H; HERCBERGS, A; YOSHIMOTO, M; DEBOER, G; PATERSON, AHG; PRITCHARD, KI; MEAKIN, JW; PANZARELLA, T; NAJA, A; BAHI, J; REID, M; SPITTLER, M; SENANAYAKE, F; HOLMBERG, L; SEVELDA, P; ZIELINSKY, CC; JAKESZ, R; BUCHANAN, RB; CROSS, M; DUNN, JA; GILLESPIE, WM; KELLY, K; MORRISON, JM; LITTON, A; CHLEBOWSKI, RT; BEZWODA, WR; CAFFIER, H			EFFECTS OF RADIOTHERAPY AND SURGERY IN EARLY BREAST-CANCER - AN OVERVIEW OF THE RANDOMIZED TRIALS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REQUIRING PROLONGED OBSERVATION; POSTOPERATIVE RADIOTHERAPY; MORTALITY; PATIENT; DESIGN	Background. Randomized trials of radiotherapy and surgery for early breast cancer may have been too small to detect differences in long-term survival and recurrence reliably. We therefore performed a systematic overview (meta-analysis) of the results of such trials. Methods. Information was sought on each subject from investigators who conducted trials that began before 1985 and that compared local therapies for early breast cancer. Data on mortality were available from 36 trials comparing radiotherapy plus surgery with the same type of surgery alone, 10 comparing more-extensive surgery with less-extensive surgery, and 18 comparing more-extensive surgery with less-extensive surgery plus radiotherapy. Information on mortality was available for 28,405 women (97.4 percent of the 29,175 women in the trials). Results. The addition of radiotherapy to surgery resulted in a rate of local recurrence that was three times lower than the rate with surgery alone, but there was no significant difference in 10-year survival; among a total of 17,273 women enrolled in such trials, mortality was 40.3 percent with radiotherapy and 41.4 percent without radiotherapy (P=0.3). Radiotherapy was associated with a reduced risk of death due to breast cancer (odds ratio, 0.94; 95 percent confidence interval, 0.88 to 1.00; P=0.03), which indicates that, after 10 years, there would be about 0 to 5 fewer deaths due to breast cancer per 100 women. However, there was an increased risk of death from other causes (odds ratio, 1.24; 95 percent confidence interval, 1.09 to 1.42; P=0.002). This, together with the age-specific death rates, implies, after 10 years, a few extra deaths not due to breast cancer per 100 older women or per 1000 younger women, During the first decade or two after diagnosis, the excess in the rate of such deaths that was associated with radiotherapy was much greater among women who were over 60 years of age at randomization (15.3 percent vs. 11.1 percent [339 vs. 249 deaths]) than among those under 50 (2.5 percent vs. 2.0 percent [62 vs. 49 deaths]). Breast-conserving surgery involved some risk of recurrence in the remaining tissue, but no significant differences in overall survival at 10 years were found in the studies of mastectomy versus breast-conserving surgery plus radiotherapy (4891 women), more-extensive surgery versus less-extensive surgery (4818 women), or axillary clearance versus radiotherapy as adjuncts to mastectomy (4370 women). Conclusions. Some of the local therapies for breast cancer had substantially different effects on the rates of local recurrence - such as the reduced recurrence with the addition of radiotherapy to surgery - but there were no definite differences in overall survival at 10 years.	INTEGRAAL KANKERCENTRUM ZUID, EINDHOVEN, NETHERLANDS; METAXAS MEM HOSP, PIRAEUS, GREECE; AUCKLAND BREAST CANC STUDY GRP, AUCKLAND, NEW ZEALAND; AKAD WISSENSCH BERLIN, BERLIN, GERMANY; BIRMINGHAM GEN HOSP, BIRMINGHAM, W MIDLANDS, ENGLAND; BUNDESMINIST FORSCH & TECHNOL, BONN, GERMANY; FDN BERGONIE, BORDEAUX, FRANCE; DANA FARBER CANC INST, BOSTON, MA 02115 USA; BRADFORD ROYAL INFIRM, BRADFORD, W YORKSHIRE, ENGLAND; BRITISH COLUMBIA CANC AGCY, VANCOUVER, BC, CANADA; ADDENBROOKES HOSP, CAMBRIDGE, ENGLAND; CANC RES CAMPAIGN, LONDON, ENGLAND; GROOTE SCHUUR HOSP, CAPE TOWN, SOUTH AFRICA; CARDIFF SURG TRIALISTS, CARDIFF, S GLAM, WALES; CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA; CHELTENHAM GEN HOSP, CHELTENHAM, PA USA; UNIV CHICAGO, CHICAGO, IL 60637 USA; CHRISTIE HOSP & HOLT RADIUM INST, MANCHESTER, LANCS, ENGLAND; COIMBRA INST ONCOL, COIMBRA, PORTUGAL; DANISH CANC REGISTRY, COPENHAGEN, DENMARK; COPENHAGEN RADIUM CTR, COPENHAGEN, DENMARK; CRACOW INST ONCOL, KRAKOW, POLAND; DUBLIN ST LUKES HOSP, DUBLIN, IRELAND; UNIV DUSSELDORF, DUSSELDORF, GERMANY; EASTERN COOPERAT ONCOL GRP, BOSTON, MA USA; EUROPEAN ORG RES TREATMENT CANC, AMSTERDAM, NETHERLANDS; EVANSTON HOSP CORP, EVANSTON, IL USA; GLASGOW BEATSON ONCOL CTR, GLASGOW, LANARK, SCOTLAND; GLASGOW VICTORIA INFIRM, GLASGOW, LANARK, SCOTLAND; GRANADA UNIV HOSP, GRANADA, SPAIN; GUNMA UNIV, MAEBASHI, GUMMA, JAPAN; GUYS HOSP, LONDON, ENGLAND; UNIV HEIDELBERG, W-6900 HEIDELBERG, GERMANY; DEACONESS MED CTR, HELSINKI, FINLAND; IMPERIAL CANC RES FUND, LONDON, ENGLAND; UNIV INNSBRUCK, INNSBRUCK, AUSTRIA; INT BREAST CANC STUDY GRP, BERN, SWITZERLAND; CHARING CROSS HOSP, INT COLLABORAT CANC GRP, LONDON, ENGLAND; TECHNION ISRAEL INST TECHNOL, RAMBAM MED CTR, IL-32000 HAIFA, ISRAEL; Kawasaki Med Sch, KAWASAKI, KANAGAWA, JAPAN; KUMAMOTO UNIV GRP, KUMAMOTO, JAPAN; ACAD ZIEKENHUIS ST RAFAEL, LOUVAIN, BELGIUM; LUND UNIV, S-22100 LUND, SWEDEN; APM, CANCEROL BIOL LAB, MARSEILLE, FRANCE; MAYO CLIN, ROCHESTER, MN 55905 USA; MD ANDERSON CANC CTR, HOUSTON, TX 77030 USA; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA; NATL MED CTR, MEXICO CITY, DF, MEXICO; IST NAZL STUDIO & CURA TUMORI, I-20133 MILAN, ITALY; MONTPELLIER CTR PAUL LAMARQUE, MONTPELLIER, FRANCE; UNIV NAPLES, I-80138 NAPLES, ITALY; NCI, BETHESDA, MD 20892 USA; NATL SURG ADJUVANT BREAST & BOWEL PROJECT, PITTSBURGH, PA USA; NORTHWICK PK HOSP & CLIN RES CTR, HARROW, MIDDX, ENGLAND; CITY HOSP NOTTINGHAM, NOTTINGHAM, ENGLAND; OITA PREFECTURAL HOSP, OITA, JAPAN; ONTARIO CANC TREATMENT & RES FDN, TORONTO, ON, CANADA; ONTARIO CLIN ONCOL GRP, HAMILTON, ON, CANADA; OSAKA CITY MED SCH, OSAKA, JAPAN; OSLO RADIUM HOSP, OSLO, NORWAY; OXFORD CHURCHILL HOSP, OXFORD, ENGLAND; IMPERIAL CANC RES FUND, MRC,CLIN TRIAL SERV UNIT, LONDON, ENGLAND; CTR RENE HUGUENIN, ST CLOUD, FRANCE; INST CURIE, F-75231 PARIS, FRANCE; INST GUSTAVE ROUSSY, F-94805 VILLEJUIF, FRANCE; PARMA HOSP, PARMA, ITALY; FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA; PIEDMONT ONCOL ASSOC, WINSTON SALEM, NC USA; CHARLES UNIV, PRAGUE, CZECH REPUBLIC; ROTTERDAM RADIO THERAPEUT INST, ROTTERDAM, NETHERLANDS; ROYAL MARSDEN HOSP, INST CANC RES, LONDON, ENGLAND; ST GEORGE HOSP, LONDON, ENGLAND; ONCOL HOSP A BUSINICO, SARDINIA, ITALY; SASKATCHEWAN CANC FDN, SASKATOON, SK, CANADA; SCOTTISH CANC TRIALS OFF, EDINBURGH, MIDLOTHIAN, SCOTLAND; SW ONCOL GRP, SEATTLE, WA USA; STOCKHOLM BREAST CANC STUDY GRP, STOCKHOLM, SWEDEN; KAROLINSKA HOSP, STOCKHOLM, SWEDEN; TEL AVIV UNIV, IL-69978 TEL AVIV, ISRAEL; CANC INST HOSP, TOKYO, JAPAN; TORONTO EDMONTON BREAST CANC STUDY GRP, TORONTO, ON, CANADA; TOULOUSE CTR CLAUDIUS REGAUD, TOULOUSE, FRANCE; INST SALAH AZAIZ, TUNIS, TUNISIA; UPPSALA OREBRO CANC STUDY GRP, UPPSALA, SWEDEN; UNIV HOSP VIENNA, VIENNA, AUSTRIA; UNIV WITWATERSRAND, JOHANNESBURG 2050, SOUTH AFRICA	University of Birmingham; UNICANCER; Institut Bergonie; Harvard University; Dana-Farber Cancer Institute; Bradford Royal Infirmary; British Columbia Cancer Agency; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cape Town; Case Western Reserve University; Gloucestershire Hospitals NHS Foundation Trust; Cheltenham General Hospital; University of Chicago; Christie NHS Foundation Trust; Christie Hospital; Maria Sklodowska-Curie National Research Institute of Oncology; Heinrich Heine University Dusseldorf; NorthShore University Health System; Beatson Oncology Centre; Gunma University; Guy's & St Thomas' NHS Foundation Trust; Ruprecht Karls University Heidelberg; Cancer Research UK; University of Innsbruck; International Breast Cancer Study Group; Imperial College London; Rambam Health Care Campus; Technion Israel Institute of Technology; Kawasaki Medical School; Kumamoto University; KU Leuven; Lund University; Mayo Clinic; University of Texas System; UTMD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Naples Federico II; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project; Imperial College London; Nottingham University Hospital NHS Trust; Nottingham City Hospital; Cancer Research UK; Rene Huguenin Hospital; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UNICANCER; Gustave Roussy; University of Parma; University Hospital of Parma; Fox Chase Cancer Center; Charles University Prague; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; St Georges University London; University of Saskatchewan; Southwest Oncology Group; Karolinska Institutet; Karolinska University Hospital; Tel Aviv University; Japanese Foundation for Cancer Research; UNICANCER; Institut Claudius Regaud; Universite de Tunis-El-Manar; Institut Salah Azaiez; University Hospital Vienna; University of Witwatersrand			Brenner, Hermann/B-4627-2017; Pritchard, Kathleen I/I-2184-2014; Boccardo, Francesco Mario/AAF-2654-2019; Schurman, Shepherd/ABF-8125-2021; Gkiokas, Georgios/AAE-6312-2020; Fentiman, Ian S/I-7644-2019; Barkmanova, Jaroslava/A-1411-2017; Fentiman, Ian/AAB-9886-2020; Jonat, Walter/E-3024-2010; Brenner, Hermann/ABE-6383-2020	Brenner, Hermann/0000-0002-6129-1572; Pritchard, Kathleen I/0000-0003-0758-9666; Boccardo, Francesco Mario/0000-0002-5392-4077; Barkmanova, Jaroslava/0000-0003-1406-7292; Brenner, Hermann/0000-0002-6129-1572; Schurman, Shepherd/0000-0002-9133-7906; Bliss, Judith/0000-0001-7957-7424; Coombes, Raoul Charles/0000-0002-4811-1100				[Anonymous], 1988, NEW ENGL J MED, V319, P1681; CLARKE MJ, 1994, BRIT MED J, V309, P1007, DOI 10.1136/bmj.309.6960.1007; CUZICK J, 1987, CANCER TREAT REP, V71, P15; CUZICK J, 1994, J CLIN ONCOL, V12, P447, DOI 10.1200/JCO.1994.12.3.447; Early Breast Cancer Trialists' Collaborative Group, 1990, TREATMENT EARLY BREA, V1; FISHER B, 1991, LANCET, V338, P327, DOI 10.1016/0140-6736(91)90475-5; FISHER B, 1995, NEW ENGL J MED, V333, P1456, DOI 10.1056/NEJM199511303332203; GELMAN R, 1990, J CLIN ONCOL, V8, P548, DOI 10.1200/JCO.1990.8.3.548; HAYBITTLE JL, 1989, BRIT MED J, V298, P1611, DOI 10.1136/bmj.298.6688.1611; HAYWARD J, 1987, ARCH SURG-CHICAGO, V122, P1244; HOST H, 1986, INT J RADIAT ONCOL, V12, P727, DOI 10.1016/0360-3016(86)90029-5; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; 1992, LANCEDT, V339, P71	14	864	877	1	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 30	1995	333	22					1444	1455						12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG445	7477144				2022-12-28	WOS:A1995TG44500002
J	DASGUPTA, B; BOWLES, J				DASGUPTA, B; BOWLES, J			SCINTIGRAPHIC LOCALIZATION OF STEROID INJECTION SITE IN PLANTAR FASCIITIS	LANCET			English	Note								Plantar fasciitis is a common cause of heel pain. We evaluated scintigraphic localisation of the inflammatory focus in 15 patients with this condition. Technetium-labelled bone scans precisely localised abnormal discrete areas of tracer uptake in 12 (80%) of patients in the medial and posterior aspect below the inferior surface of the calcaneum. Steroid injection at the inflammatory site abolished local tenderness and reduced pain in all 12. Our findings support an injection approach through the medial heel border posterior to the point of heel tenderness. Technetium scintigraphy may be a useful investigation to localise the steroid injection site in resistant cases of plantar fasciitis.			DASGUPTA, B (corresponding author), SOUTHEND HLTH CARE TRUST,WESTCLIFF ON SEA SS0 0RY,ESSEX,ENGLAND.		Bowles, Josephine/AAG-4903-2020	Bowles, Josephine/0000-0003-2867-7438				BEIKOWITZ JF, 1991, RADIOLOGY, V179, P665; INTENZO CM, 1991, CLIN NUCL MED, V16, P325, DOI 10.1097/00003072-199105000-00006; MAPP PI, 1993, OXFORD TXB RHEUMATOL; SCHEPSIS AA, 1991, CLIN ORTHOPAEDICS, V266, P185; SELMAN JR, 1994, FOOT ANKLE INT, V15, P376; Wall J R, 1993, Foot Ankle, V14, P465	6	29	29	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 25	1995	346	8987					1400	1401		10.1016/S0140-6736(95)92409-4	http://dx.doi.org/10.1016/S0140-6736(95)92409-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG207	7475824				2022-12-28	WOS:A1995TG20700012
J	WINSTON, DJ				WINSTON, DJ			PREVENTION OF CYTOMEGALOVIRUS DISEASE IN TRANSPLANT RECIPIENTS	LANCET			English	Editorial Material							BONE-MARROW TRANSPLANTATION; IMMUNE GLOBULIN; GANCICLOVIR PROPHYLAXIS; VIRUS INFECTION; DOUBLE-BLIND; TRIAL				WINSTON, DJ (corresponding author), UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024, USA.							BOECKH M, 1994, 34TH INT C ANT AG CH, V7; BOWDEN RA, 1986, NEW ENGL J MED, V314, P1006, DOI 10.1056/NEJM198604173141602; GOODRICH JM, 1993, ANN INTERN MED, V118, P173, DOI 10.7326/0003-4819-118-3-199302010-00003; GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303; HIBBERD PL, 1995, ANN INTERN MED, V123, P18, DOI 10.7326/0003-4819-123-1-199507010-00002; MARTIN M, 1994, TRANSPLANTATION, V58, P225; PRENTICE HG, 1994, LANCET, V343, P749, DOI 10.1016/S0140-6736(94)91835-X; SINGH N, 1994, ANN INTERN MED, V120, P375, DOI 10.7326/0003-4819-120-5-199403010-00004; SNYDMAN DR, 1993, ANN INTERN MED, V119, P984, DOI 10.7326/0003-4819-119-10-199311150-00004; WINSTON DJ, 1993, ANN INTERN MED, V118, P179, DOI 10.7326/0003-4819-118-3-199302010-00004; WINSTON DJ, 1987, ANN INTERN MED, V106, P12, DOI 10.7326/0003-4819-106-1-12; WINSTON DJ, 1995, LANCET, V346, P69, DOI 10.1016/S0140-6736(95)92110-9; WINSTON DJ, IN PRESS TRANSPLANTA	13	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 25	1995	346	8987					1380	1381		10.1016/S0140-6736(95)92401-9	http://dx.doi.org/10.1016/S0140-6736(95)92401-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG207	7475816	Bronze			2022-12-28	WOS:A1995TG20700004
J	BALDINI, N; SCOTLANDI, K; BARBANTIBRODANO, G; MANARA, MC; MAURICI, D; BACCI, G; BERTONI, F; PICCI, P; SOTTILI, S; CAMPANACCI, M; SERRA, M				BALDINI, N; SCOTLANDI, K; BARBANTIBRODANO, G; MANARA, MC; MAURICI, D; BACCI, G; BERTONI, F; PICCI, P; SOTTILI, S; CAMPANACCI, M; SERRA, M			EXPRESSION OF P-GLYCOPROTEIN IN HIGH-GRADE OSTEOSARCOMAS IN RELATION TO CLINICAL OUTCOME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MULTIDRUG-RESISTANCE GENE; MONOCLONAL-ANTIBODIES; DRUG-RESISTANCE; OSTEO-SARCOMA; IMMUNOHISTOCHEMICAL DETECTION; MULTIPLE-MYELOMA; HUMAN CANCERS; CELL-LINES; CHEMOTHERAPY; VERAPAMIL	Background. Increased levels of P-glycoprotein occur in some osteosarcomas. In this study we determined the relation between P-glycoprotein status and outcome in patients with high-grade osteosarcoma. Methods. P-glycoprotein status was determined immunohistochemically in specimens of osteosarcoma of the extremities (stage II) from 92 patients who were treated with surgery and chemotherapy. The P-glycoprotein status was analyzed in relation to the length of event-free survival. Results. The presence of increased levels of P-glycoprotein in the osteosarcoma was significantly associated with a decreased probability of remaining event-free after diagnosis (P=0.002). In a multivariate analysis, P-glycoprotein status (P=0.001) and the extent of tumor necrosis after preoperative chemotherapy (P=0.04) were independent predictors of clinical outcome. The risk of adverse events was increased substantially (rate ratio, 3.37; 95 percent confidence interval, 1.60 to 7.10) among patients with increased levels of P-glycoprotein in tumor cells, as compared with patients who did not have increased levels of P-glycoprotein in tumor cells. Conclusions. In patients with high-grade osteosarcoma treated with surgery and chemotherapy, the presence of increased levels of P-glycoprotein in tumor cells is associated with a significantly increased risk of adverse events and is independent of the extent of necrosis after preoperative chemotherapy.			BALDINI, N (corresponding author), IST ORTOPED RIZZOLI,DIPARTIMENTO ONCOL,RIC ONCOL LAB,VIA BARBIANO 1-10,I-40136 BOLOGNA,ITALY.		Baldini, Nicola/J-4806-2016; Scotlandi, Katia/J-9009-2016; Serra, Massimo/J-4878-2016; Manara, Maria Cristina/K-3366-2018; Picci, Piero/J-5979-2016	Baldini, Nicola/0000-0003-2228-3833; Scotlandi, Katia/0000-0001-6114-9499; Serra, Massimo/0000-0003-0742-1177; Manara, Maria Cristina/0000-0001-5686-720X; Picci, Piero/0000-0002-8519-4101; Barbanti Brodano, Giovanni/0000-0002-7075-7020				BACCI G, 1993, CANCER, V72, P3227, DOI 10.1002/1097-0142(19931201)72:11<3227::AID-CNCR2820721116>3.0.CO;2-C; BALDINI N, IN PRESS EUR J CELL; Blaney S M, 1993, Cancer Treat Res, V62, P55; BOIOCCHI M, 1992, EUR J CANCER, V28A, P1099, DOI 10.1016/0959-8049(92)90465-E; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; BRADLEY G, 1988, BIOCHIM BIOPHYS ACTA, V948, P87, DOI 10.1016/0304-419X(88)90006-6; CAMPANACCI M, 1981, CANCER, V48, P1569, DOI 10.1002/1097-0142(19811001)48:7<1569::AID-CNCR2820480717>3.0.CO;2-X; CHAN HSL, 1990, J CLIN ONCOL, V8, P689, DOI 10.1200/JCO.1990.8.4.689; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; COX DR, 1972, J R STAT SOC B, V34, P187; DAHLIN DC, 1977, AM J SURG PATHOL, V1, P61, DOI 10.1097/00000478-197701010-00007; DALTON WS, 1989, J CLIN ONCOL, V7, P415, DOI 10.1200/JCO.1989.7.4.415; DAVIS AM, 1994, J CLIN ONCOL, V12, P423, DOI 10.1200/JCO.1994.12.2.423; EILBER F, 1987, J CLIN ONCOL, V5, P21, DOI 10.1200/JCO.1987.5.1.21; ENNEKING WF, 1980, CLIN ORTHOP RELAT R, V153, P106; FIENBERG SE, 1977, ANAL CROSS CLASSIFIE, P8; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; GERLACH JH, 1987, J CLIN ONCOL, V5, P1452, DOI 10.1200/JCO.1987.5.9.1452; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROGAN T, 1990, LAB INVEST, V63, P815; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; LINK MP, 1991, CLIN ORTHOP RELAT R, V270, P8; MILLER RG, 1981, SURVIVAL ANAL, P44; OMEARA A, 1992, ONCOLOGY, V49, P203; PICCI P, 1985, CANCER, V56, P1515, DOI 10.1002/1097-0142(19851001)56:7<1515::AID-CNCR2820560707>3.0.CO;2-6; SALMON SE, 1991, BLOOD, V78, P44; SAMUELS BL, 1991, CANCER RES, V51, P521; SCHEPER RJ, 1988, INT J CANCER, V42, P389, DOI 10.1002/ijc.2910420314; SCHLAIFER D, 1991, BRIT J CANCER, V63, P164; SCHLAIFER D, 1990, BRIT J CANCER, V62, P177, DOI 10.1038/bjc.1990.256; SERRA M, 1993, ANTICANCER RES, V13, P323; SERRA M, IN PRESS EUR J CANCE; SIKIC BI, 1993, J CLIN ONCOL, V11, P1629, DOI 10.1200/JCO.1993.11.9.1629; SONNEVELD P, 1992, LANCET, V340, P255, DOI 10.1016/0140-6736(92)92353-H; SONNEVELD P, 1994, J CLIN ONCOL, V12, P1584, DOI 10.1200/JCO.1994.12.8.1584; STEIN U, 1993, EUR J CANCER, V29A, P1979, DOI 10.1016/0959-8049(93)90457-Q; TAWA A, 1990, CANCER, V66, P1980, DOI 10.1002/1097-0142(19901101)66:9<1980::AID-CNCR2820660922>3.0.CO;2-E; TOFFOLI G, 1992, ANN ONCOL, V3, P63, DOI 10.1093/oxfordjournals.annonc.a058073; TWENTYMAN PR, 1992, BIOCHEM PHARMACOL, V43, P109, DOI 10.1016/0006-2952(92)90668-9; VANDERVALK P, 1990, ANN ONCOL, V1, P56; VERGIER B, 1993, BRIT J CANCER, V68, P1221, DOI 10.1038/bjc.1993.508; WUNDER JS, 1993, J ORTHOPAED RES, V11, P396, DOI 10.1002/jor.1100110311; YUEN AR, 1994, J CLIN ONCOL, V12, P2453, DOI 10.1200/JCO.1994.12.11.2453; YUSA K, 1989, CANCER RES, V49, P5002; Zelterman D., 1992, MED USES STAT, P293	49	346	358	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 23	1995	333	21					1380	1385		10.1056/NEJM199511233332103	http://dx.doi.org/10.1056/NEJM199511233332103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF521	7477118				2022-12-28	WOS:A1995TF52100003
J	LEE, KF; SIMON, H; CHEN, H; BATES, B; HUNG, MC; HAUSER, C				LEE, KF; SIMON, H; CHEN, H; BATES, B; HUNG, MC; HAUSER, C			REQUIREMENT FOR NEUREGULIN RECEPTOR ERBB2 IN NEURAL AND CARDIAC DEVELOPMENT	NATURE			English	Article							NERVOUS-SYSTEM; TRIGEMINAL MOTONEURONS; CHICK-EMBRYOS; CREST CELLS; EXPRESSION; MIGRATION; GANGLIA; DIFFERENTIATION; HINDBRAIN; PROTEIN	THE receptor erbB2/neu is a member of the epidermal growth factor receptor (EGFR or erbB) family that also includes erbB3 and erbB4(1). Amplification of the erbB2/neu gene is found in many cancer types and its overexpression is correlated with a poor prognosis for breast and ovarian cancer patients(2). Investigation of the biology of erbB2 led to the identification of a family of ligands termed neuregulins which included the neu-differentiation factors(3,4), the heregulins(5), a ligand with acctylcholine-receptor-inducing activity(6) and glial growth factor(7). Several lines of evidence suggest that heterodimerization of erbB2 with other erbB receptors is required for neuregulin signalling(1). Here we investigate the developmental role of erbB2 in mammalian development in mice carrying an erbB2 null allele. We find that mutant embryos die before E11, probably as a result of dysfunctions associated with a lack of cardiac trabeculae. Development of cranial neural-crest-derived sensory ganglia was markedly affected, DiI retrograde tracing revealed that the development of motor nerves was also compromised. Our results demonstrate the importance of erbB2 in neural and cardiac development.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; WHITEHEAD INST,CAMBRIDGE,MA 02142	University of Texas System; UTMD Anderson Cancer Center; Massachusetts Institute of Technology (MIT); Whitehead Institute	LEE, KF (corresponding author), SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740				CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P1; CORFAS G, 1995, NEURON, V14, P103, DOI 10.1016/0896-6273(95)90244-9; DAMICOMARTEL A, 1983, AM J ANAT, V166, P445, DOI 10.1002/aja.1001660406; DENT JA, 1989, DEVELOPMENT, V105, P61; DONG Z, 1995, NEURON, V15, P589; EASTER SS, 1993, J NEUROSCI, V13, P285; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; LEDOUARIN NM, 1988, ANNU REV CELL BIOL, V4, P375, DOI 10.1146/annurev.cellbio.4.1.375; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEYER D, 1995, NATURE, V378, P394; MEYER D, 1994, P NATL ACAD SCI USA, V94, P1064; MOODY SA, 1983, J COMP NEUROL, V213, P344, DOI 10.1002/cne.902130309; MOODY SA, 1983, J COMP NEUROL, V213, P327, DOI 10.1002/cne.902130308; NICHOLS DH, 1981, J EMBRYOL EXP MORPH, V64, P105; ORRURTREGER A, 1993, P NATL ACAD SCI USA, V90, P1867, DOI 10.1073/pnas.90.5.1867; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; PRESS MF, 1990, ONCOGENE, V5, P953; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SIMON H, 1993, NEURON, V11, P209, DOI 10.1016/0896-6273(93)90179-U; VARTANIAN T, 1994, P NATL ACAD SCI USA, V91, P11626, DOI 10.1073/pnas.91.24.11626; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WESTON JA, 1966, DEV BIOL, V14, P246, DOI 10.1016/0012-1606(66)90015-7; WHITE MRA, 1992, ONCOGENE, V7, P677	32	1001	1037	2	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 23	1995	378	6555					394	398		10.1038/378394a0	http://dx.doi.org/10.1038/378394a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477377				2022-12-28	WOS:A1995TF89300061
J	KLEIN, DF				KLEIN, DF			RESPIRATION DISORDERS IN PANIC ATTACKS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											KLEIN, DF (corresponding author), NEW YORK STATE PSYCHIAT INST & HOSP,NEW YORK,NY 10032, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	1995	274	19					1504	1504						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD571	7474207				2022-12-28	WOS:A1995TD57100011
J	MIXON, MB; LEE, E; COLEMAN, DE; BERGHUIS, AM; GILMAN, AG; SPRANG, SR				MIXON, MB; LEE, E; COLEMAN, DE; BERGHUIS, AM; GILMAN, AG; SPRANG, SR			TERTIARY AND QUATERNARY STRUCTURAL-CHANGES IN G(I-ALPHA-1) INDUCED BY GTP HYDROLYSIS	SCIENCE			English	Article							GAMMA-SUBUNIT COMPLEX; BETA-GAMMA; G-PROTEIN; ALPHA-SUBUNIT; SIGNAL-TRANSDUCTION; GUANINE-NUCLEOTIDES; ADENYLYL-CYCLASE; PHOSPHOLIPASE-C; BINDING; DISAGGREGATION	Crystallographic analysis of 2.2 angstrom resolution shows that guanosine triphosphate (GTP) hydrolysis triggers conformational changes in the heterotrimeric G-protein alpha subunit, G(i alpha 1). The switch II and switch III segments become disordered, and linker II connecting the Ras and alpha helical domains moves, thus altering the structures of potential effector and beta gamma binding regions. Contacts between the alpha-helical and Ras domains are weakened, possibly facilitating the release of guanosine diphosphate (GDP). The amino and carboxyl termini, which contain receptor and beta gamma binding determinants, are disordered in the complex with GTP, but are organized into a compact microdomain on GDP hydrolysis. The amino terminus also forms extensive quaternary contacts with neighboring alpha subunits in the lattice, suggesting that multimers of alpha subunits or heterotrimers may play a role in signal transduction.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Berghuis, Albert M/A-6495-2008	Berghuis, Albert/0000-0002-2663-025X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 46371] Funding Source: Medline; NIGMS NIH HHS [GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; BARFORD D, 1989, NATURE, V340, P609, DOI 10.1038/340609a0; BERGHUIS A, UNPUB; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHAKRABARTI P, 1993, J MOL BIOL, V234, P463, DOI 10.1006/jmbi.1993.1599; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CODINA J, 1994, J BIOL CHEM, V269, P29339; COLEMAN DC, UNPUB; COLEMAN DE, 1994, J MOL BIOL, V238, P630, DOI 10.1006/jmbi.1994.1320; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; COPLEY RR, 1994, J MOL BIOL, V242, P321; COULTER S, 1992, P NATL ACAD SCI USA, V89, P5842, DOI 10.1073/pnas.89.13.5842; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAF R, 1992, J BIOL CHEM, V267, P24307; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HINGORANI VN, 1988, J BIOL CHEM, V263, P6916; JAHANGEER S, 1993, P NATL ACAD SCI USA, V90, P8782, DOI 10.1073/pnas.90.19.8782; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1990, UNPUB O VERSION 5 6; KLEUSS C, UNPUB; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE E, 1992, J BIOL CHEM, V267, P1212; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NAKAMURA S, 1990, P NATL ACAD SCI USA, V87, P6413, DOI 10.1073/pnas.87.16.6413; NAKAMURA SI, 1991, P NATL ACAD SCI USA, V88, P7150, DOI 10.1073/pnas.88.16.7150; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NICHOLLS A, 1992, GRASP GRAPHIC REPRES; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RODBELL M, 1992, CURR TOP CELL REGUL, V32, P1; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; VAILLANCOURT RR, 1990, P NATL ACAD SCI USA, V87, P3645, DOI 10.1073/pnas.87.10.3645; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0	58	260	261	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 10	1995	270	5238					954	960		10.1126/science.270.5238.954	http://dx.doi.org/10.1126/science.270.5238.954			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD878	7481799				2022-12-28	WOS:A1995TD87800038
J	WATERHOUSE, P; PENNINGER, JM; TIMMS, E; WAKEHAM, A; SHAHINIAN, A; LEE, KP; THOMPSON, CB; GRIESSER, H; MAK, TW				WATERHOUSE, P; PENNINGER, JM; TIMMS, E; WAKEHAM, A; SHAHINIAN, A; LEE, KP; THOMPSON, CB; GRIESSER, H; MAK, TW			LYMPHOPROLIFERATIVE DISORDERS WITH EARLY LETHALITY IN MICE DEFICIENT IN CTLA-4	SCIENCE			English	Article							T-CELL PROLIFERATION; COUNTER-RECEPTOR; LYMPHOCYTES-T; FAS ANTIGEN; CD28; MOUSE; ACTIVATION; IDENTIFICATION; LIGAND	The role of the cell-surface molecule CTLA-4 in the regulation of T cell activation has been controversial. Here, lymph nodes and spleens of CTLA-4-deficient mice accumulated T cell blasts with up-regulated activation markers. These blast cells also infiltrated liver, heart, lung, and pancreas tissue, and amounts of serum immunoglobulin were elevated. The mice invariably became moribund by 3 to 4 weeks of age. Although CTLA-4-deficient T cells proliferated spontaneously and strongly when stimulated through the T cell receptor, they were sensitive to cell death induced by cross-linking of the Fas receptor and by gamma irradiation. Thus, CTLA-4 acts as a negative regulator of T cell activation and is vital for the control of lymphocyte homeostasis.	UNIV TORONTO,ONTARIO CANC INST,DEPT IMMUNOL,TORONTO,ON M5G 2C1,CANADA; UNIV TORONTO,ONTARIO CANC INST,DEPT MED BIOPHYS,TORONTO,ON M5G 2C1,CANADA; UNIV CHICAGO,GWEN KNAPP CTR,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV TORONTO,DEPT PATHOL,TORONTO,ON M5G 2C1,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Howard Hughes Medical Institute; University of Chicago; University of Toronto			Penninger, Josef M/I-6860-2013	Penninger, Josef M/0000-0002-8194-3777; Waterhouse, Paul/0000-0001-8745-5224				ALLISON JP, 1994, CURR OPIN IMMUNOL, V6, P414, DOI 10.1016/0952-7915(94)90120-1; AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; DAMLE NK, 1994, J IMMUNOL, V152, P2686; DEGERMANN S, 1994, J IMMUNOL, V152, P3254; FREEMAN GJ, 1993, SCIENCE, V262, P907, DOI 10.1126/science.7694362; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; GREEN JM, 1994, IMMUNITY, V1, P501, DOI 10.1016/1074-7613(94)90092-2; GRIBBEN JG, 1995, P NATL ACAD SCI USA, V92, P811, DOI 10.1073/pnas.92.3.811; GROSS JA, 1992, J IMMUNOL, V149, P380; HARPER K, 1991, J IMMUNOL, V147, P1037; HATHCOCK KS, 1993, SCIENCE, V262, P905, DOI 10.1126/science.7694361; HOWARD TA, 1991, IMMUNOGENETICS, V33, P74, DOI 10.1007/BF00211698; JENKINS MK, 1994, IMMUNITY, V1, P443, DOI 10.1016/1074-7613(94)90086-8; JONES LA, 1993, INT IMMUNOL, V5, P503, DOI 10.1093/intimm/5.5.503; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KEARNEY ER, 1995, J IMMUNOL, V155, P1032; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, J EXP MED, V176, P1595, DOI 10.1084/jem.176.6.1595; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; PAGE DM, 1993, J IMMUNOL, V151, P1868; PUNT JA, 1994, J EXP MED, V179, P709, DOI 10.1084/jem.179.2.709; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0	33	2202	2314	2	92	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 10	1995	270	5238					985	988		10.1126/science.270.5238.985	http://dx.doi.org/10.1126/science.270.5238.985			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD878	7481803				2022-12-28	WOS:A1995TD87800048
J	TALBOT, WS; TREVARROW, B; HALPERN, ME; MELBY, AE; FARR, G; POSTLETHWAIT, JH; JOWETT, T; KIMMEL, CB; KIMELMAN, D				TALBOT, WS; TREVARROW, B; HALPERN, ME; MELBY, AE; FARR, G; POSTLETHWAIT, JH; JOWETT, T; KIMMEL, CB; KIMELMAN, D			A HEMEOBOX GENE ESSENTIAL FOR ZEBRAFISH NOTOCHORD DEVELOPMENT	NATURE			English	Article							HOMEO-BOX GENE; MOUSE T-GENE; FLOOR PLATE; MESODERM FORMATION; EMPTY SPIRACLES; XENOPUS-LAEVIS; NEURAL-TUBE; EMBRYO; EXPRESSION; INDUCTION	The notochord is a midline mesodermal structure with an essential patterning function in all vertebrate embryos. Zebrafish floating head (flh) mutants lack a notochord, but develop with prechordal plate and other mesodermal derivatives, indicating that flh functions specifically in notochord development. We show that floating head Is the zebrafish homologue of Xnot, a homeobox gene expressed In the amphibian organizer and notochord. We propose that flh regulates notochord precursor cell fate.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV OREGON,INST NEUROSCI,EUGENE,OR 97403; UNIV NEWCASTLE UPON TYNE,DEPT BIOCHEM & GENET,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	University of Washington; University of Washington Seattle; University of Oregon; Newcastle University - UK					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTABA ARI, 1992, DEVELOPMENT, V116, P81; ALTABA ARI, 1992, DEVELOPMENT, V115, P67; ANG SL, 1993, DEVELOPMENT, V119, P1301; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; Chesley P, 1935, J EXP ZOOL, V70, P429, DOI 10.1002/jez.1400700306; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EISEN JS, 1989, NEURON, V2, P1097, DOI 10.1016/0896-6273(89)90234-1; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; GONT LK, 1993, DEVELOPMENT, V119, P991; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; Halpern ME, 1995, DEVELOPMENT, V121, P4257; HATTA K, 1992, NEURON, V9, P629, DOI 10.1016/0896-6273(92)90027-B; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HELDE KA, 1993, DEV BIOL, V159, P418, DOI 10.1006/dbio.1993.1252; HENION PD, IN PRESS DEV GENET; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; Ho R.K., 1992, Seminars in Developmental Biology, V3, P53; KELLER RE, 1976, DEV BIOL, V51, P118, DOI 10.1016/0012-1606(76)90127-5; KESSAIN S, 1993, ADV DEV BIOL, V2, P1; KIMMEL CB, 1990, DEVELOPMENT, V108, P581; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; MICHELMORE RW, 1991, P NATL ACAD SCI USA, V88, P9828, DOI 10.1073/pnas.88.21.9828; MULLINS MC, 1994, CURR BIOL, V4, P189, DOI 10.1016/S0960-9822(00)00048-8; OPPENHEIMER JM, 1959, J EXP ZOOL, V140, P247, DOI 10.1002/jez.1401400205; PIKE SH, 1992, DEVELOPMENT, V144, P825; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; POSTLETHWAIT JH, 1994, SCIENCE, V264, P699, DOI 10.1126/science.8171321; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SASAKI H, 1993, DEVELOPMENT, V118, P47; SCHULTEMERKER S, 1992, DEVELOPMENT, V116, P1021; SCHULTEMERKER S, 1994, DEVELOPMENT, V120, P1009; SIMEONE A, 1992, EMBO J, V11, P2541, DOI 10.1002/j.1460-2075.1992.tb05319.x; SMITH JC, 1985, DIFFERENTIATION, V29, P109, DOI 10.1111/j.1432-0436.1985.tb00302.x; SOLNICAKREZEL L, 1994, GENETICS, V136, P1401; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STACHEL SE, 1993, DEVELOPMENT, V117, P1261; STEIN S, 1995, MECH DEVELOP, V49, P37, DOI 10.1016/0925-4773(94)00300-C; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; THISSE C, 1993, DEVELOPMENT, V119, P1203; TREVARROW B, 1990, NEURON, V4, P669, DOI 10.1016/0896-6273(90)90194-K; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILLIAMS JGK, 1990, NUCLEIC ACIDS RES, V18, P6531, DOI 10.1093/nar/18.22.6531; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; YAN YL, 1995, DEV DYNAM, V203, P363, DOI 10.1002/aja.1002030308	51	404	408	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 9	1995	378	6553					150	157		10.1038/378150a0	http://dx.doi.org/10.1038/378150a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD759	7477317				2022-12-28	WOS:A1995TD75900043
J	CHEN, YM; CHEN, CF; RILEY, DJ; ALLRED, DC; CHEN, PL; VONHOFF, D; OSBORNE, CK; LEE, WH				CHEN, YM; CHEN, CF; RILEY, DJ; ALLRED, DC; CHEN, PL; VONHOFF, D; OSBORNE, CK; LEE, WH			ABERRANT SUBCELLULAR-LOCALIZATION OF BRCA1 IN BREAST-CANCER	SCIENCE			English	Article							GLUCOCORTICOID RECEPTOR; NUCLEAR-LOCALIZATION; CELL-CYCLE; HORMONE; PROTEIN; PHOSPHORYLATION; EXPRESSION; CLONING; GENE	The BRCA1 gene product was identified as a 220-kilodalton nuclear phosphoprotein in normal cells, including breast ductal epithelial cells, and in 18 of 20 tumor cell lines derived from tissues other than breast and ovary. In 16 of 17 breast and ovarian cancer lines and 17 of 17 samples of cells obtained from malignant effusions, however, BRCA1 localized mainly in cytoplasm. Absence of BRCA1 or aberrant subcellular location was also observed to a variable extent in histological sections of many breast cancer biopsies. These findings suggest that BRCA1 abnormalities may be involved in the pathogenesis of many breast cancers, sporadic as well as familial.	UNIV TEXAS, HLTH SCI CTR, CTR MOLEC MED, INST BIOTECHNOL, SAN ANTONIO, TX 78245 USA; UNIV TEXAS, HLTH SCI CTR, DEPT PATHOL, SAN ANTONIO, TX 78284 USA; UNIV TEXAS, HLTH SCI CTR, DEPT MED, DIV MED ONCOL, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio				Chen, Chi-Fen/0000-0002-6391-821X	NCI NIH HHS [CA58318, P50CA58183] Funding Source: Medline; NEI NIH HHS [EY05758] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058183] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS HD, 1982, CELL, V29, P427, DOI 10.1016/0092-8674(82)90159-3; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; BOYD J, 1995, NAT GENET, V9, P335, DOI 10.1038/ng0495-335; CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen Y, UNPUB; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; CLAUS EB, 1991, AM J HUM GENET, V48, P232; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; EASTON DF, 1993, AM J HUM GENET, V52, P678; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Jensen E V, 1991, Curr Top Pathol, V83, P365; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; LAUDET V, 1991, NUCLEIC ACIDS RES, V19, P1105, DOI 10.1093/nar/19.5.1105; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; SCHNEIDER J, 1988, CELL, V54, P117, DOI 10.1016/0092-8674(88)90185-7; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; VOGELSTEIN B, 1994, CELL, V79, P1, DOI 10.1016/0092-8674(94)90393-X	29	286	304	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 3	1995	270	5237					789	791		10.1126/science.270.5237.789	http://dx.doi.org/10.1126/science.270.5237.789			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC712	7481765				2022-12-28	WOS:A1995TC71200037
J	OKAMURA, H; TSUTSUI, H; KOMATSU, T; YUTSUDO, M; HAKURA, A; TANIMOTO, T; TORIGOE, K; OKURA, T; NUKADA, Y; HATTORI, K; AKITA, K; NAMBA, M; TANABE, F; KONISHI, K; FUKUDA, S; KURIMOTO, M				OKAMURA, H; TSUTSUI, H; KOMATSU, T; YUTSUDO, M; HAKURA, A; TANIMOTO, T; TORIGOE, K; OKURA, T; NUKADA, Y; HATTORI, K; AKITA, K; NAMBA, M; TANABE, F; KONISHI, K; FUKUDA, S; KURIMOTO, M			CLONING OF A NEW CYTOKINE THAT INDUCES IFN-GAMMA PRODUCTION BY T-CELLS	NATURE			English	Article								THE mechanism underlying the differentiation of CD4(+) T cells into functionally distinct subsets (Th1 and Th2) is incompletely understood(1-3), and hitherto unidentified cytokines may be required for the functional maturation of these cells(4). Here we report the cloning of a recently identified IFN-gamma-inducing factor (IGIF) that augments natural killer (NK) activity in spleen cells(5,6). The gene encodes a precursor protein of 192 amino acids and a mature protein of 157 amino acids, which have no obvious similarities to any peptide in the databases. Messenger RNAs for IGIF and interleukin-12 (IL-12) are readily detected in Kupffer cells and activated macrophages. Recombinant IGIF induces IFN-gamma more potently than does IL-12, apparently through a separate pathway. Administration of anti-IGIF antibodies prevents liver damage in mice inoculated with Propionibacterium acnes and challenged with lipopolysaccharide, which induces toxic shock. IGIF may he involved in the development of Th1 cells and also in mechanisms of tissue injury in inflammatory reactions.	HYOGO MED UNIV,DEPT IMMUNOL & MED ZOOL,NISHINOMIYA,HYOGO,JAPAN; OSAKA CITY UNIV,TONEYAMA INST TB,TOYONAKA,OSAKA,JAPAN; INST MICROBIAL DIS,SUITA,OSAKA,JAPAN; HAYASHIBARA CO INC,FUJISAKI INST,HAYASHIBARA BIOCHEM LABS,OKAYAMA,JAPAN	Hyogo College of Medicine; University of Hyogo; Osaka Metropolitan University; Hayashibara Biochemical Laboratories, Inc.	OKAMURA, H (corresponding author), HYOGO MED UNIV,DEPT BACTERIOL,1-1 MUKOGAWA CHO,NISHINOMIYA,HYOGO,JAPAN.			Tsutsui, Hiroko/0000-0001-7928-4875				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EYHORN S, 1988, J HEPATOL, V6, P23, DOI 10.1016/S0168-8278(88)80459-8; FERLUGA J, 1978, LANCET, P661; KARASUYAMA H, 1989, J EXP MED, V196, P13; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LOCKSLEY RM, 1993, P NATL ACAD SCI USA, V90, P5879, DOI 10.1073/pnas.90.13.5879; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; NAKAMURA K, 1993, INFECT IMMUN, V61, P64, DOI 10.1128/IAI.61.1.64-70.1993; OKAMURA H, IN PRESS INFECT IMMU; SCOTT P, 1993, SCIENCE, V260, P496, DOI 10.1126/science.8097337; TSUTSUI H, 1992, HEPATO-GASTROENTEROL, V39, P553; WYNN TA, 1994, J EXP MED, V179, P1551, DOI 10.1084/jem.179.5.1551; WYSOCKA M, 1995, EUR J IMMUNOL, V25, P672, DOI 10.1002/eji.1830250307	13	2253	2526	4	63	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 2	1995	378	6552					88	91		10.1038/378088a0	http://dx.doi.org/10.1038/378088a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477296				2022-12-28	WOS:A1995TC46900057
J	MCMANUS, IC				MCMANUS, IC			HUMANITY AND THE MEDICAL HUMANITIES	LANCET			English	Article							SOCIAL-SCIENCES; EDUCATION; PHYSICIAN; STUDENTS				MCMANUS, IC (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,NORFOLK PL,LONDON W2 1PG,ENGLAND.			McManus, Ian/0000-0003-3510-4814				ALMY TP, 1992, ANN INTERN MED, V116, P569, DOI 10.7326/0003-4819-116-7-569; ARNOLD RM, 1987, ANN INTERN MED, V106, P313, DOI 10.7326/0003-4819-106-2-313; ASHIKAWA H, 1991, ACAD MED, V66, P458, DOI 10.1097/00001888-199108000-00009; BANKS SA, 1973, J MED EDUC, V48, P248; BARNARD D, 1994, ACAD MED, V69, P628, DOI 10.1097/00001888-199408000-00004; Bassett K, 1995, CAM U CAMBRIDGE ALUM, P7; BENSON JA, 1983, ANN INTERN MED, V99, P720, DOI 10.7326/0003-4819-99-5-720; Berger J., 1968, FORTUNATE MAN STORY; BERTMAN SL, 1985, MED EDUC, V19, P374, DOI 10.1111/j.1365-2923.1985.tb01340.x; CLOUSER KD, 1971, BR J MED ED, V5, P266; CONSTABLE T, 1975, HOSP UPDATE, V1, P635; COSSART YE, 1993, DOCTOR LOOK YOU, P3; DOBLIN B, 1992, ACAD MED, V67, P539, DOI 10.1097/00001888-199208000-00013; Eliot T. S., 1948, NOTES DEFINITION CUL; FRASER DW, 1989, ACAD MED, V64, P532, DOI 10.1097/00001888-198909000-00011; HUMPHREY NK, 1983, CONSCIOUSNESS REGAIN, P116; Keynes Geoffrey, 1981, GATES MEMORY; KOPELMAN LM, 1989, ACAD MED, V64, P730, DOI 10.1097/00001888-198912000-00008; LEAKE CD, 1973, J MED EDUC, V48, P878; MAHEUX B, 1992, ACAD MED, V67, pS25, DOI 10.1097/00001888-199210000-00028; MANDELL H, 1992, YALE J BIOL MED, V65, P183; MCMANUS IC, 1985, THESIS U LONDON MD; Mengel M B, 1992, Fam Med, V24, P234; MENKEN M, 1992, MED EDUC, V26, P429, DOI 10.1111/j.1365-2923.1992.tb00201.x; MOORE AR, 1976, NEW ENGL J MED, V295, P1479, DOI 10.1056/NEJM197612232952610; MOORE FD, 1985, ANN SURG, V201, P231, DOI 10.1097/00000658-198502000-00016; NEAME RLB, 1992, MED EDUC, V26, P433, DOI 10.1111/j.1365-2923.1992.tb00202.x; NIEMI RG, 1980, J MED EDUC, V55, P194; NORMAN AW, 1992, ACAD MED, V67, P785, DOI 10.1097/00001888-199211000-00018; PELLEGRINO ED, 1974, JAMA-J AM MED ASSOC, V227, P1288, DOI 10.1001/jama.227.11.1288; PELLEGRINO ED, 1974, NEW ENGL J MED, V290, P1083, DOI 10.1056/NEJM197405092901914; PELLEGRINO ED, 1979, HUMANISM PHYSICIAN; PENCE GE, 1983, J MED ETHICS, V9, P189, DOI 10.1136/jme.9.4.189; REYNOLDS RC, 1976, J MED EDUC, V51, P142; Sinclair D.C., 1972, BASIC MED ED; Steiner George, 1971, BLUEBEARDS CASTLE; TROUTMAN J, 1982, MOBIUS, V2, P23; WARREN KS, 1984, ANN INTERN MED, V101, P697, DOI 10.7326/0003-4819-101-5-697; WASSERSUG JD, 1987, POSTGRAD MED, V82, P317, DOI 10.1080/00325481.1987.11700018; WEATHERALL DJ, 1994, BRIT MED J, V309, P1671, DOI 10.1136/bmj.309.6970.1671; Williams R., 1976, KEYWORDS	41	33	36	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 28	1995	346	8983					1143	1145		10.1016/S0140-6736(95)91806-X	http://dx.doi.org/10.1016/S0140-6736(95)91806-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TB549	7475609				2022-12-28	WOS:A1995TB54900016
J	WARD, JB; PETERSEN, OH; JENKINS, SA; SUTTON, R				WARD, JB; PETERSEN, OH; JENKINS, SA; SUTTON, R			IS AN ELEVATED CONCENTRATION OF ACINAR CYTOSOLIC-FREE IONIZED CALCIUM THE TRIGGER FOR ACUTE-PANCREATITIS	LANCET			English	Note							INTRACELLULAR CALCIUM; CELLS; CERULEIN; RAT; CHOLECYSTOKININ; HOMEOSTASIS; INHIBITION; SECRETION; TOXICITY; MICE	The pathogenesis of acute pancreatitis is poorly understood, despite well-recognised precipitating factors. Current evidence suggests that the earliest abnormalities of acute pancreatitis arise within acinar cells, but the key intracellular trigger has yet to be identified. Within the pancreas, physiological concentrations of secretagogues bind to G-protein-linked cell-surface receptors on acinar cells, evoking short, oscillatory spikes of acinar cytosolic-free ionised calcium ([Ca2+](i)), an ubiquitous intracellular messenger. Specific effects within acinar cells include initiation of enzyme release through the phosphorylation cascades of stimulus-secretion coupling. Low resting levels of [Ca2+](i) are restored by Ca2+-ATPase, which pumps calcium into the endoplasmic reticulum and out of the cell. If high concentrations of [Ca2+](i) persist, toxicity results, intracellular signalling is disrupted, and cell damage occurs. Sustained elevations in acinar [Ca2+](i) result from exposure to high concentrations of secretagogues, high doses of which also induce acute pancreatitis. Similarly, sustained elevations of [Ca2+](i) may result from ductal hypertension, alcohol, hypoxia, hypercalcaemia, hyperlipidaemia, viral infection, and various drugs-all factors known to precipitate acute pancreatitis. We suggest that these factors precipitate acute pancreatitis by causing either excessive release of acinar [Ca2+](i), or damage to the integrity of mechanisms that restore low resting levels of [Ca2+](i), and that the consequent calcium toxicity is the key trigger in the pathogenesis of acute pancreatitis.	UNIV LIVERPOOL,DEPT SURG,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,PHYSIOL LAB,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool; University of Liverpool			Sutton, Robert/I-3587-2016; Petersen, Ole H/E-8708-2010	Sutton, Robert/0000-0001-6600-562X; Petersen, Ole/0000-0002-6998-0380				ARNOULD T, 1992, J CELL PHYSIOL, V152, P215, DOI 10.1002/jcp.1041520127; Banks Peter A., 1993, P593; BARTHOLOMEW C, 1970, BMJ-BRIT MED J, V1, P666, DOI 10.1136/bmj.1.5697.666; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; BLONDEL O, 1995, TRENDS NEUROSCI, V18, P157, DOI 10.1016/0166-2236(95)93894-4; BOCHKOV V, 1992, BIOCHEM BIOPH RES CO, V188, P1295, DOI 10.1016/0006-291X(92)91372-W; BOOBIS AR, 1990, BIOCHEM PHARMACOL, V39, P1277, DOI 10.1016/0006-2952(90)90003-4; BOZKORT T, 1992, DIGESTION, V52, pA72; BURGOYNE RD, 1995, TRENDS NEUROSCI, V18, P191, DOI 10.1016/0166-2236(95)93900-I; CANGA L, 1988, P NATL ACAD SCI USA, V85, P905, DOI 10.1073/pnas.85.3.905; CAULEY JA, 1993, ANN INTERN MED, V118, P666, DOI 10.7326/0003-4819-118-9-199305010-00002; CHEVALIER P, 1994, J CARDIOVASC PHARM, V23, P944, DOI 10.1097/00005344-199406000-00013; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DAVIDSON M, 1990, BIOCHEM PHARMACOL, V39, P1283, DOI 10.1016/0006-2952(90)90004-5; DRENCKHAHN D, 1983, EUR J CELL BIOL, V30, P167; FAN ST, 1993, NEW ENGL J MED, V328, P228, DOI 10.1056/NEJM199301283280402; FERNANDEZDELCAS.C, 1991, NEW ENGL J MED, V325, P832; FRICK TW, 1993, DIGEST DIS, V11, P113, DOI 10.1159/000171405; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; GOMEZ G, 1990, J CLIN INVEST, V86, P323, DOI 10.1172/JCI114703; GRONROOS JM, 1994, EXP TOXICOL PATHOL, V45, P503; JAAKKOLA M, 1993, GUT, V34, P1255, DOI 10.1136/gut.34.9.1255; JENKINS SA, 1992, BRIT J SURG, V79, P112; LAINECESSAC P, 1993, RES COMMUN CHEM PATH, V79, P185; LEACH SD, 1991, J CLIN INVEST, V87, P362, DOI 10.1172/JCI114995; LEAHY A, 1992, BRIT J SURG, V79, P1241; MANN DV, 1994, BRIT J SURG, V81, P890, DOI 10.1002/bjs.1800810632; MARUYAMA Y, 1994, CELL CALCIUM, V16, P419, DOI 10.1016/0143-4160(94)90035-3; MICHELANGELI F, 1991, VIROLOGY, V181, P520, DOI 10.1016/0042-6822(91)90884-E; MORLEY P, 1992, ENDOCRINOLOGY, V131, P1305, DOI 10.1210/en.131.3.1305; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; NIEDERAU C, 1986, J CLIN INVEST, V78, P1056, DOI 10.1172/JCI112661; NIEDERAU C, 1990, GASTROENTEROLOGY, V99, P1120, DOI 10.1016/0016-5085(90)90633-C; NORBACK ICH, 1991, ANN SURG, V214, P671; OKONSKI MS, 1990, J CLIN INVEST, V86, P1649, DOI 10.1172/JCI114887; PAUWELS PJ, 1989, MOL PHARMACOL, V36, P525; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; REBER HA, 1991, NEW ENGL J MED, V325, P423, DOI 10.1056/NEJM199108083250609; SANFEY H, 1985, AM J SURG, V150, P297, DOI 10.1016/0002-9610(85)90064-9; Steer Michael L., 1993, P489; THOM P, 1993, CELL, V74, P661; WISNER J, 1988, GUT, V29, P1516, DOI 10.1136/gut.29.11.1516; ZHOU WG, 1993, AM J PATHOL, V142, P1504	43	132	140	2	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 14	1995	346	8981					1016	1019		10.1016/S0140-6736(95)91695-4	http://dx.doi.org/10.1016/S0140-6736(95)91695-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475553				2022-12-28	WOS:A1995RZ59900017
J	KEMPER, K; FORSYTH, B				KEMPER, K; FORSYTH, B			MEDICALLY UNNECESSARY HOSPITAL USE IN CHILDREN SEROPOSITIVE FOR HUMAN IMMUNODEFICIENCY VIRUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									YALE UNIV,SCH MED,DEPT PEDIAT,DIV GEN PEDIAT,NEW HAVEN,CT 06510	Yale University								BAUMSLAG N, 1987, LANCET, V2, P400; BERTHIER A, 1986, LANCET, V2, P598; BLANCHE S, 1986, J PEDIATR-US, V109, P965, DOI 10.1016/S0022-3476(86)80277-3; DOWDLE WR, 1987, SURGEON GENERALS WOR, P20; DUFF RS, 1972, PEDIATRICS, V49, P169; FELDBLUM PJ, 1988, AM J PUBLIC HEALTH, V78, P52, DOI 10.2105/AJPH.78.1.52; FISCHL MA, 1987, JAMA-J AM MED ASSOC, V257, P640, DOI 10.1001/jama.257.5.640; Fleiss JL, 1981, STAT METHODS RATES P; FRANCIS DP, 1987, JAMA-J AM MED ASSOC, V257, P1357, DOI 10.1001/jama.257.10.1357; FRIEDLAND GH, 1987, NEW ENGL J MED, V317, P1125, DOI 10.1056/NEJM198710293171806; FUJIKAWA LS, 1985, LANCET, V2, P529; GERTMAN PM, 1981, MED CARE, V19, P855, DOI 10.1097/00005650-198108000-00005; GLASS RM, 1988, JAMA-J AM MED ASSOC, V259, P1369, DOI 10.1001/jama.259.9.1369; HO DD, 1985, NEW ENGL J MED, V313, P1606; HOFF R, 1988, NEW ENGL J MED, V318, P525, DOI 10.1056/NEJM198803033180901; KAPLAN JE, 1985, PEDIATR INFECT DIS J, V4, P468, DOI 10.1097/00006454-198509000-00004; KAPLAN LD, 1987, JAMA-J AM MED ASSOC, V257, P1367; KEMPER KJ, 1988, NEW ENGL J MED, V318, P1033, DOI 10.1056/NEJM198804213181605; KUSHNIK H, 1987, SURGEON GENERALS WOR, P48; LEPAGE P, 1987, LANCET, V2, P400; LIFSON AR, 1988, JAMA-J AM MED ASSOC, V259, P1353, DOI 10.1001/jama.259.9.1353; LOVEJOY FH, 1971, J PEDIATR-US, V79, P868, DOI 10.1016/S0022-3476(71)80408-0; MARZUK PM, 1988, JAMA-J AM MED ASSOC, V259, P1333, DOI 10.1001/jama.259.9.1333; MATTHEWS GW, 1987, JAMA-J AM MED ASSOC, V257, P344, DOI 10.1001/jama.257.3.344; MEYER KB, 1987, NEW ENGL J MED, V317, P238, DOI 10.1056/NEJM198707233170410; MOK JQ, 1987, LANCET, V1, P1164; OLESKE J, 1988, 56TH ANN M AM AC PED; OLESKE J, 1987, AAP NEWS         NOV, P2; OPPENHEIMER GM, 1986, HASTINGS CENT REP, V16, P18, DOI 10.2307/3562690; PAHWA S, 1986, JAMA-J AM MED ASSOC, V255, P2299, DOI 10.1001/jama.255.17.2299; QUINN TC, 1987, SURGEON GENERAL WORK, P7; ROGERS MF, 1987, PEDIATRICS, V79, P1008; RUBENSTEIN A, 1987, SURGEON GENERALS WOR, P29; RUBINSTEIN A, 1986, CURR PROBL PEDIATR, V16, P365; SCHECHTER MT, 1985, LANCET, V1, P379; SCOTT GB, 1985, JAMA-J AM MED ASSOC, V253, P363, DOI 10.1001/jama.253.3.363; SCOTT GB, 1984, NEW ENGL J MED, V310, P76, DOI 10.1056/NEJM198401123100202; SIU AL, 1988, JAMA-J AM MED ASSOC, V259, P1343, DOI 10.1001/jama.259.9.1343; TERVO T, 1986, LANCET, V1, P379; WAHN V, 1986, LANCET, V2, P694; WEINBERG DS, 1987, NEW ENGL J MED, V317, P1469, DOI 10.1056/NEJM198712033172309; 1987, MMWR, V36, P728; 1988, MMWR, V27, P1; 1986, MMWR, V35, P595; 1987, SURVEILLANCE REPORT; 1988, MMWR, V36, P833; 1987, FDA DRUG B, V17, P14; 1988, PEDIATR NEWS     JAN, P30; 1988, AJDC, V142, P267; 1988, AIDS WEEKLY SURVEILL	50	22	22	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1988	260	13					1906	1909		10.1001/jama.260.13.1906	http://dx.doi.org/10.1001/jama.260.13.1906			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q2703	3418852				2022-12-28	WOS:A1988Q270300025
J	HODES, RM; KLOOS, H				HODES, RM; KLOOS, H			HEALTH AND MEDICAL-CARE IN ETHIOPIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									UNIV ADDIS ABABA,DEPT MED,ADDIS ABABA,ETHIOPIA; UNIV ADDIS ABABA,DEPT GEOG,ADDIS ABABA,ETHIOPIA	Addis Ababa University; Addis Ababa University								ABEBE M, 1988, ECOLOGY HLTH DISEASE, P158; ABRAHAM G, 1982, ETHIOPIAN MED J, V20, P63; AYALEW S, 1985, SOC SCI MED, V21, P865, DOI 10.1016/0277-9536(85)90142-X; AYELE T, 1984, AM J TROP MED HYG, V33, P548, DOI 10.4269/ajtmh.1984.33.548; AYELE T, 1982, P S HUMAN SCHISTOSOM, P1; BISHAW T, 1986, 9TH P PUBLIC HLTH RE, P20; Chang WP, 1969, ETHIOPIA OBSERVER, V12, P230; DESOLE G, 1988, ECOLOGY HLTH DISEASE, P281; ENGDASEW A, 1986, 9TH P PUBL HLTH RES, P35; GEBREEGZIABHER E, 1986, 9TH P PUBL HLTH RES, P1; GEDEBOU M, 1986, ETHIOP MED J, V24, P201; GISH O, 1983, SOC SCI MED, V17, P1961, DOI 10.1016/0277-9536(83)90136-3; GRANT JP, 1987, STATE WORLDS CHILDRE, P90; Habte-Gabr E, 1984, ETHIOP J HEALTH DEV, V1, P47; HODES R, 1988, ECOLOGY HLTH DISEASE, P177; HODES RM, 1987, 23RD ETH DOCT ASS AN, P45; Howarth F, 1965, Isr J Med Sci, V1, P1038; KLOOS H, 1987, ETHIOPIAN MED J, V25, P157; KLOOS H, 1986, SOC SCI MED, V22, P653, DOI 10.1016/0277-9536(86)90038-9; KLOOS H, 1987, SOC SCI MED, V25, P1003, DOI 10.1016/0277-9536(87)90005-0; KLOOS H, 1988, SOC SCI MED, V26, P803, DOI 10.1016/0277-9536(88)90174-8; KLOOS H, IN PRESS GEOGR J; Korn D., 1986, ETHIOPIA US SOVIET U; LESTER FT, 1988, ECOLOGY HLTH DISEASE, P295; LESTER FT, 1988, ECOLOGY HLTH DISEASE, P306; MECHE H, 1984, ETHIOP J HEALTH DEV, V1, P31; MEKONNEN M, 1988, ECOLOGY HLTH DISEASE, P151; MENGISTU G, 1987, ETHIOPIAN MED J, V25, P203; PELLY M, 1986, LANCET, V1, P1144; Price E. W., 1984, Tropical Diseases Bulletin, V81, pR1; SIDELEL F, 1978, P SEMINAR POPULATION, P45; TEDLA T, 1984, ETHIOP J HLTH DEV, V1, P57; TEKA T, 1984, RURAL POVERTY ALLEVI; TEKLEHAIMANOT A, 1986, LANCET, V2, P127; Tesfa-Yohannes TM, 1988, ECOLOGY HLTH DIS ETH, P214; TURSHEN M, 1985, NE AFR STUD, V1, P49; WOLDEAB M, 1988, ECOLOGY HLTH DISEASE, P43; ZEIN ZA, 1986, TROP GEOGR MED, V38, P33; 1986, 3 YEAR DEV PLAN 1986; 1986, 1983 84 STATISTICAL, P329; 1987, POPULATION HOUSIN S1, V1, P188; 1986, NEGARIT GAZETA, V46, P34; 1985, ARE WE PRIMARY HLT 1, P23; 1981, 1980 FOOD PRODUCTION, V34, P243; 1986, 1985 FOOD PRODUCTION, V39, P87; 1987, COUNTRY REPORTS HUMA, P102; 1980, HLTH MANPOWER STUDY; 1973, NEGARIT GAZETA, V32, P116; 1986, NEGARIT GAZETA, V46, P37; 1984, RESULT DIARRHEAL DIS; 1986, NEGARIT GAZETA, V46, P50; 1985, PRIMARY HLTH CARE RE; 1986, STATISTICS CHILDREN; 1987, SPANPSMISC872 ETH MI; 1984, POPULATION HOUSING C, V1, P14; 1984, WORLD HLTH STAT Q, V37, P421; 1980, 33 UN FUND POP ACT R, P53; 1987, RETAIL PRICE SURVEY, P2; 1986, WORLD HLTH STATISTIC, P22; 1986, COMPREHENSIVE HLTH S	60	34	34	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 6	1988	319	14					918	924		10.1056/NEJM198810063191406	http://dx.doi.org/10.1056/NEJM198810063191406			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q2854	3419456				2022-12-28	WOS:A1988Q285400006
J	HORIKOSHI, M; HAI, T; LIN, YS; GREEN, MR; ROEDER, RG				HORIKOSHI, M; HAI, T; LIN, YS; GREEN, MR; ROEDER, RG			TRANSCRIPTION FACTOR ATF INTERACTS WITH THE TATA FACTOR TO FACILITATE ESTABLISHMENT OF A PREINITIATION COMPLEX	CELL			English	Article									HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Harvard University	HORIKOSHI, M (corresponding author), ROCKEFELLER UNIV, BIOCHEM & MOLEC BIOL LAB, NEW YORK, NY 10021 USA.		Hai, Tsonwin/H-4480-2011; Hai, Tsonwin/E-3185-2011	Hai, Tsonwin/0000-0003-4510-0315; Hai, Tsonwin/0000-0003-4510-0315				ABMAYR SM, 1988, GENE DEV, V2, P542, DOI 10.1101/gad.2.5.542; BITTER GA, 1983, ANAL BIOCHEM, V128, P294, DOI 10.1016/0003-2697(83)90378-0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN DD, 1984, CELL, V37, P359, DOI 10.1016/0092-8674(84)90366-0; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FIRE A, 1984, J BIOL CHEM, V259, P2509; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FRIED MG, 1984, J MOL BIOL, V172, P263, DOI 10.1016/S0022-2836(84)80026-1; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HEINTZ N, 1984, P NATL ACAD SCI-BIOL, V81, P2713, DOI 10.1073/pnas.81.9.2713; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LEE KAW, 1987, EMBO J, V6, P1345, DOI 10.1002/j.1460-2075.1987.tb02374.x; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MIZUSHIMASUGANO J, 1986, P NATL ACAD SCI USA, V83, P8511, DOI 10.1073/pnas.83.22.8511; MONCOLLIN V, 1986, EMBO J, V5, P2577, DOI 10.1002/j.1460-2075.1986.tb04537.x; NAKAJIMA N, 1988, IN PRESS MOL CELL BI; Ptashne M., 1986, A GENETIC SWITCH; REINBERG D, 1987, J BIOL CHEM, V262, P3310; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; SUZUKI Y, 1986, P NATL ACAD SCI USA, V83, P9522, DOI 10.1073/pnas.83.24.9522; TOPOL J, 1985, CELL, V42, P527, DOI 10.1016/0092-8674(85)90110-2; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WIEDERRECHT G, 1987, CELL, V48, P507, DOI 10.1016/0092-8674(87)90201-7; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; ZHENG XM, 1987, CELL, V50, P361, DOI 10.1016/0092-8674(87)90490-9	51	409	411	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 23	1988	54	7					1033	1042		10.1016/0092-8674(88)90118-3	http://dx.doi.org/10.1016/0092-8674(88)90118-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	Q3063	3416354				2022-12-28	WOS:A1988Q306300016
J	SAVINO, JS; WEISS, SJ				SAVINO, JS; WEISS, SJ			RIGHT ATRIAL TUMOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											SAVINO, JS (corresponding author), UNIV PENN,SCH MED,PHILADELPHIA,PA 19104, USA.								0	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 14	1995	333	24					1608	1608		10.1056/NEJM199512143332405	http://dx.doi.org/10.1056/NEJM199512143332405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK065	7477196				2022-12-28	WOS:A1995TK06500005
J	MANNING, WJ; WEINTRAUB, RM; WAKSMONSKI, CA; HAERING, JM; ROONEY, PS; MASLOW, AD; JOHNSON, RG; DOUGLAS, PS				MANNING, WJ; WEINTRAUB, RM; WAKSMONSKI, CA; HAERING, JM; ROONEY, PS; MASLOW, AD; JOHNSON, RG; DOUGLAS, PS			ACCURACY OF TRANSESOPHAGEAL ECHOCARDIOGRAPHY FOR IDENTIFYING LEFT ATRIAL THROMBI - A PROSPECTIVE, INTRAOPERATIVE STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; HEART ATRIUM; THROMBOSIS, CORONARY; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS	RHEUMATIC HEART-DISEASE; MITRAL-VALVE; DIMENSIONAL ECHOCARDIOGRAPHY; FIBRILLATION; CARDIOVERSION; DIAGNOSIS; CONTRAST	Objective: To determine the ability of transesophageal echocardiography to accurately identify or exclude left atrial thrombi. Design: Prospective cohort study. Setting: University hospital. Patients: 231 consecutive patients having transesophageal echocardiography before elective repair or replacement of the mitral valve or excision of a left atrial tumor. Fifty-six percent of patients had a history of atrial fibrillation, and 17% had a history of thromboembolism. Measurement: Identification of left atrial thrombi during transesophageal echocardiographic examination and comparison with direct near-simultaneous visualization during cardiac surgery. Results: Transesophageal echocardiography identified 14 left atrial thrombi in 14 patients (6%). Thrombus size ranged from 3 to 80 mm. Surgery confirmed 12 of 14 thrombi (86%), including 9 thrombi confined to the left appendage. No additional thrombi were found on direct inspection of the atria (sensitivity, 100% [95% CI, 74% to 100%]; specificity, 99% [CI, 97% to 99.9%]; positive predictive value, 86% [12/14]; negative predictive value, 100% [217/217]; for a population that had a 5.2% prevalence of thrombi). All 12 surgically confirmed thrombi were identified by two independent observers. Neither thrombus seen by only a single observer on transesophageal echocardiography was confirmed during direct inspection of the atria at surgery. Conclusion: Transesophageal echocardiography is highly accurate for identifying left atrial thrombi and can be used clinically to exclude left atrial thrombi.	HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Harvard Medical School	MANNING, WJ (corresponding author), BETH ISRAEL HOSP, DIV CARDIOVASC, CHARLES A DANA & HARVARD THORNDIKE LAB, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.			Douglas, Pamela/0000-0001-9876-4049				ABERG H, 1969, ACTA MED SCAND, V185, P373; ASCHENBERG W, 1986, J AM COLL CARDIOL, V7, P163, DOI 10.1016/S0735-1097(86)80275-3; BLACK IW, 1991, J AM COLL CARDIOL, V18, P398, DOI 10.1016/0735-1097(91)90592-W; BLACKSHEAR JL, 1993, AM J CARDIOL, V72, P840, DOI 10.1016/0002-9149(93)91079-W; CASTELLO R, 1990, AM J CARDIOL, V65, P1149, DOI 10.1016/0002-9149(90)90330-4; DEPACE NL, 1981, AM J CARDIOL, V48, P954, DOI 10.1016/0002-9149(81)90364-7; GUIRAUDON GM, 1991, ANN THORAC SURG, V52, P1058, DOI 10.1016/0003-4975(91)91281-Y; HERZOG CA, 1984, J AM COLL CARDIOL, V3, P1340, DOI 10.1016/S0735-1097(84)80195-3; HWANG JJ, 1993, AM J CARDIOL, V72, P677; KRONZON I, 1990, J AM COLL CARDIOL, V16, P1320, DOI 10.1016/0735-1097(90)90572-7; MANNING WJ, 1993, NEW ENGL J MED, V328, P750, DOI 10.1056/NEJM199303183281102; MANNING WJ, 1992, BRIT HEART J, V67, P170; MUGGE A, 1990, American Journal of Cardiac Imaging, V4, P173; Olson J D, 1992, J Am Soc Echocardiogr, V5, P52; ORSINELLI DA, 1993, AM J CARDIOL, V72, P1337, DOI 10.1016/0002-9149(93)90315-4; Pearlman A S, 1992, J Am Soc Echocardiogr, V5, P187; PEARSON AC, 1991, J AM COLL CARDIOL, V17, P66, DOI 10.1016/0735-1097(91)90705-E; POP G, 1990, STROKE, V21, P560, DOI 10.1161/01.STR.21.4.560; SCHWEIZER P, 1981, BRIT HEART J, V45, P148; Seward J B, 1992, J Am Soc Echocardiogr, V5, P288; SHRESTHA NK, 1983, CIRCULATION, V67, P341, DOI 10.1161/01.CIR.67.2.341; STARLING MR, 1983, AM HEART J, V106, P1143, DOI 10.1016/0002-8703(83)90664-6; TARDIF JC, 1994, AM HEART J, V128, P156, DOI 10.1016/0002-8703(94)90022-1; VISSER CA, 1983, CHEST, V83, P228, DOI 10.1378/chest.83.2.228	24	301	312	1	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1995	123	11					817	+		10.7326/0003-4819-123-11-199512010-00001	http://dx.doi.org/10.7326/0003-4819-123-11-199512010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG209	7486462				2022-12-28	WOS:A1995TG20900001
J	STEWART, T; STEWART, N				STEWART, T; STEWART, N			BREAST-CANCER IN FEMALE FLIGHT ATTENDANTS	LANCET			English	Editorial Material									UNIV OTTAWA,OTTAWA,ON,CANADA	University of Ottawa	STEWART, T (corresponding author), OTTAWA GEN HOSP,OTTAWA,ON K1H 8L6,CANADA.			Stewart, Nicolas/0000-0002-8969-4242				COHEN BL, 1994, INT ARCH OCC ENV HEA, V66, P71, DOI 10.1007/BF00383360; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; LEVY JA, 1995, LANCET, V346, P786, DOI 10.1016/S0140-6736(95)91611-3; LIU SZ, 1985, CHINESE J RADIOL MED, V5, P124; LIU SZ, 1987, HLTH PHYS, V52, P579; Luckey TD, 1991, RAD HORMESIS; PUKKALA E, 1995, BRIT MED J, V311, P649, DOI 10.1136/bmj.311.7006.649; STEWART T, 1995, LANCET, V346, P796, DOI 10.1016/S0140-6736(95)91618-0; TUSCHL H, 1980, RADIAT RES, V81, P1, DOI 10.2307/3575358	9	5	5	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 25	1995	346	8987					1379	1379		10.1016/S0140-6736(95)92400-0	http://dx.doi.org/10.1016/S0140-6736(95)92400-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG207	7475815				2022-12-28	WOS:A1995TG20700003
J	TROTTIER, Y; LUTZ, Y; STEVANIN, G; IMBERT, G; DEVYS, D; CANCEL, G; SAUDOU, F; WEBER, C; DAVID, G; TORA, L; AGID, Y; BRICE, A; MANDEL, JL				TROTTIER, Y; LUTZ, Y; STEVANIN, G; IMBERT, G; DEVYS, D; CANCEL, G; SAUDOU, F; WEBER, C; DAVID, G; TORA, L; AGID, Y; BRICE, A; MANDEL, JL			POLYGLUTAMINE EXPANSION AS A PATHOLOGICAL EPITOPE IN HUNTINGTONS-DISEASE AND 4 DOMINANT CEREBELLAR ATAXIAS	NATURE			English	Article							LOCUS	A POLYGLUTAMINE expansion (encoded by a CAG repeat) in specific proteins causes neurodegeneration in Huntington's disease (HD) and four other disorders(1-6), by an unknown mechanism thought to involve gain of function or toxicity of the mutated protein(7,8). The pathological threshold is 37-40 glutamines in three of these diseases, whereas the corresponding normal proteins contain polymorphic repeats of up to about 35 glutamines(1-3). The age of onset of clinical manifestations is inversely correlated to the length of the polyglutamine expansion. Here we report the characterization of a monoclonal antibody that selectively recognizes polyglutamine expansion in the proteins implicated in HD and in spinocerebellar ataxia (SCA) 1 and 3. The intensity of signal depends on the length of the polyglutamine expansion, and the antibody also detects specific pathological proteins expected to contain such expansion, in SCA2 and in autosomal dominant cerebellar ataxia with retinal degeneration, whose genes have not yet been identified(9-13).	ULP,CNRS,INSERM,INST GENET & BIOL MOLEC CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE; HOP LA PITIE SALPETRIERE,INSERM,U289,F-75651 PARIS 13,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite			Stevanin, Giovanni/E-5038-2016; brice, alexis/AAE-8275-2019; Trottier, Yvon/H-8852-2016; Tora, Laszlo/E-9999-2018; Brice, Alexis/A-2170-2009; SAUDOU, Frédéric/L-3454-2014	Stevanin, Giovanni/0000-0001-9368-8657; brice, alexis/0000-0002-0941-3990; Tora, Laszlo/0000-0001-7398-2250; SAUDOU, Frédéric/0000-0001-6107-1046; Trottier, Yvon/0000-0001-7230-4810; Devys, Didier/0000-0001-9655-3512; Cancel-Tassin, Geraldine/0000-0002-9583-6382				ALBIN RL, 1995, TRENDS NEUROSCI, V18, P11, DOI 10.1016/0166-2236(95)93943-R; BELAL S, 1994, NEUROLOGY, V44, P1423, DOI 10.1212/WNL.44.8.1423; BENOMAR A, 1995, NAT GENET, V10, P84, DOI 10.1038/ng0595-84; DURR A, IN PRESS BRAIN; GARDNER K, 1994, NEUROLOGY, V44, pA361; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GISPERT S, 1993, NAT GENET, V4, P295, DOI 10.1038/ng0793-295; GISPERT S, 1995, AM J HUM GENET, V56, P183; GOSTOUT B, 1995, AM J HUM GENET, V52, P1182; GOUW LG, 1995, NAT GENET, V10, P89, DOI 10.1038/ng0595-89; HAZAN J, 1993, NAT GENET, V5, P163, DOI 10.1038/ng1093-163; HAZAN J, 1994, HUM MOL GENET, V3, P1569, DOI 10.1093/hmg/3.9.1569; HOUSMAN D, 1995, NAT GENET, V10, P3, DOI 10.1038/ng0595-3; IMBERT G, 1994, GENOMICS, V21, P667, DOI 10.1006/geno.1994.1335; KAWAGUCHI Y, 1995, NAT GENET, V8, P221; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; LEZIN A, IN PRESS HUM GENET; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; PULST SM, 1993, NAT GENET, V5, P8, DOI 10.1038/ng0993-8c; RANUM LPW, 1994, NAT GENET, V8, P280, DOI 10.1038/ng1194-280; ROSS CA, 1993, TRENDS NEUROSCI, V16, P254, DOI 10.1016/0166-2236(93)90175-L; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; SITTLER A, IN PRESS HUM MOL GEN; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; TROTTIER Y, 1994, J MED GENET, V31, P377, DOI 10.1136/jmg.31.5.377; 1993, CELL, V72, P971	31	567	589	1	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 23	1995	378	6555					403	406		10.1038/378403a0	http://dx.doi.org/10.1038/378403a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477379				2022-12-28	WOS:A1995TF89300063
J	FAIRLEY, CK; SMOLENIEC, JS; CAUL, OE; MILLER, E				FAIRLEY, CK; SMOLENIEC, JS; CAUL, OE; MILLER, E			OBSERVATIONAL STUDY OF EFFECT OF INTRAUTERINE TRANSFUSIONS ON OUTCOME OF FETAL HYDROPS AFTER PARVOVIRUS B19 INFECTION	LANCET			English	Note							DIAGNOSIS	The role of intrauterine transfusion for fetal hydrops arising from maternal paravirus B19 infection is unclear. 66 cases of fetal hydrops arising from B19 infection were reported in England and Wales between June, 1992, and September, 1994. In 29 cases the fetus was dead at the time of the first abnormal ultrasound or a therapeutic abortion as performed; 12 of the 38 alive at the first abnormal scan received intrauterine transfusions and 3 of the 12 died, 26 did not receive intrauterine transfusions and 13 died. After adjustment for the severity of the hydrops as assessed by the ultrasound and for gestational age, the odds of death among those who received an intrauterine transfusion was significantly less than among those who did not (odds ratio 0.14, 95% CI 0.02-0.96). These findings suggest that intrauterine transfusion will benefit some fetuses with hydrops arising from parvovirus B19 infection.	PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5EQ,ENGLAND; ST MICHAELS HOSP,BRISTOL,AVON,ENGLAND; BRISTOL PUBL HLTH LAB,REG VIRUS LAB,BRISTOL,AVON,ENGLAND	Public Health England				Christopher, Fairley/0000-0001-9081-1664				CHITKARA U, 1988, OBSTET GYNECOL, V71, P393; GLONING KP, 1990, BEHRING I MITT, V85, P79; Hall S. M., 1990, Reviews in Medical Microbiology, V1, P160; KILBY MD, 1995, OBSTET GYNAECOL REV, V7, P5; NAIDES SJ, 1989, PRENATAL DIAG, V9, P105, DOI 10.1002/pd.1970090205; PETERS MT, 1990, OBSTET GYNECOL, V75, P501; ROSENFELD SJ, 1993, VIRAL INFECTIONS DIA, P147; SMOLENIEC JS, 1994, BRIT J OBSTET GYNAEC, V101, P1079, DOI 10.1111/j.1471-0528.1994.tb13586.x; SMOLENIEC JS, 1995, OBSTET GYNECOL, V14, P142; TOROK TJ, 1992, CLIN INFECT DIS, V14, P149, DOI 10.1093/clinids/14.1.149	10	104	108	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 18	1995	346	8986					1335	1337		10.1016/S0140-6736(95)92346-2	http://dx.doi.org/10.1016/S0140-6736(95)92346-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE916	7475774				2022-12-28	WOS:A1995TE91600012
J	SCHIPPER, H; DICK, J				SCHIPPER, H; DICK, J			HERODOTUS AND THE MULTIDISCIPLINARY CLINIC	LANCET			English	Editorial Material											SCHIPPER, H (corresponding author), UNIV MANITOBA,WINNIPEG,MB,CANADA.							DURANT JR, 1990, SURG CLIN N AM, V70, P977; HUTCHINS RM, 1952, GREAT BOOKS W WORLD, V6, P65	2	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 18	1995	346	8986					1312	1313		10.1016/S0140-6736(95)92338-1	http://dx.doi.org/10.1016/S0140-6736(95)92338-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE916	7475766				2022-12-28	WOS:A1995TE91600004
J	BEHAN, DP; HEINRICHS, SC; TRONCOSO, JC; LIU, XJ; KAWAS, CH; LING, N; DESOUZA, EB				BEHAN, DP; HEINRICHS, SC; TRONCOSO, JC; LIU, XJ; KAWAS, CH; LING, N; DESOUZA, EB			DISPLACEMENT OF CORTICOTROPIN-RELEASING FACTOR FROM ITS BINDING-PROTEIN AS A POSSIBLE TREATMENT FOR ALZHEIMERS-DISEASE	NATURE			English	Article							FACTOR-LIKE IMMUNOREACTIVITY; CENTRAL NERVOUS-SYSTEM; FACTOR RECEPTORS; HUMAN-PLASMA; RAT; CRF; DIAGNOSIS; DISORDERS; DEMENTIA; BEHAVIOR	In Alzheimer's disease (AD) there are dramatic reductions in the content of corticotropin releasing factor (CRF)(1-4), reciprocal increases in CRF receptors(1,2), and morphological abnormalities in CRF neurons(5) in affected brain areas. Cognitive impairment in AD patients is associated with a lower cerebrospinal fluid concentration of CRF(6), which is known to induce increases in learning and memory in rodents(7-9). This suggests that CRF deficits contribute to cognitive impairment. The identification in post-mortem brain of CRF-binding protein (CRF-BP)(10,11), a high-affinity binding protein that inactivates CRF, and the differential distribution of CRF-BP12 and CRF receptors(13), provides the potential for improving learning and memory without stress effects of CRF receptor agonists(14). Here we show that ligands that dissociate CRF from CRF-BP increase brain levels of 'free CRF' in AD to control levels and show cognition-enhancing properties in models of learning and memory in animals without the characteristic stress effects of CRF receptor agonists.	JOHNS HOPKINS UNIV, SCH MED, NEUROPATHOL LAB, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	BEHAN, DP (corresponding author), NEUROCRINE BIOSCI INC, 3050 SCI PK RD, SAN DIEGO, CA 92121 USA.			Kawas, Claudia/0000-0001-9577-230X; Heinrichs, Stephen/0000-0002-8395-6096				BEHAN DP, 1993, ANN NY ACAD SCI, V697, P1, DOI 10.1111/j.1749-6632.1993.tb49918.x; BISSETTE G, 1985, JAMA-J AM MED ASSOC, V254, P3067, DOI 10.1001/jama.254.21.3067; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244; DESOUZA EB, 1987, J NEUROSCI, V7, P88; DESOUZA EB, 1988, HOSP PRACT, V23, P59; DESOUZA EB, 1985, J NEUROSCI, V5, P3189; DESOUZA EB, 1986, NATURE, V319, P591; DESOUZA EB, 1990, ANNU REP MED CHEM, V25, P215; DIAMANT M, 1993, NEUROENDOCRINOLOGY, V57, P1071, DOI 10.1159/000126473; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; KOOB GF, 1985, FED PROC, V44, P259; KOOB GF, 1993, CIBA F SYMP, V172, P277; LIANG KC, 1988, PSYCHOPHARMACOLOGY, V96, P232; LINTON EA, 1988, CLIN ENDOCRINOL, V28, P315, DOI 10.1111/j.1365-2265.1988.tb01218.x; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; ORTH DN, 1987, BIOCHEM BIOPH RES CO, V143, P411, DOI 10.1016/0006-291X(87)91369-6; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; POMARA N, 1989, BIOL PSYCHIAT, V26, P500, DOI 10.1016/0006-3223(89)90071-1; POTTER E, 1991, NATURE, V349, P423, DOI 10.1038/349423a0; POTTER E, 1992, P NATL ACAD SCI USA, V89, P4192, DOI 10.1073/pnas.89.9.4192; POWERS RE, 1987, SYNAPSE, V1, P405, DOI 10.1002/syn.890010504; STEWART CA, 1993, BEHAV NEUROSCIENCE P, P107; SUDA T, 1988, J CLIN ENDOCR METAB, V67, P1278, DOI 10.1210/jcem-67-6-1278; SUTTON SW, 1995, ENDOCRINOLOGY, V136, P1097, DOI 10.1210/en.136.3.1097; WHITEHOUSE PJ, 1987, NEUROLOGY, V37, P905, DOI 10.1212/WNL.37.6.905	26	203	215	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 16	1995	378	6554					284	287		10.1038/378284a0	http://dx.doi.org/10.1038/378284a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477348	Green Published			2022-12-28	WOS:A1995TE85800050
J	YAO, B; ZHANG, YH; DELIKAT, S; MATHIAS, S; BASU, S; KOLESNICK, R				YAO, B; ZHANG, YH; DELIKAT, S; MATHIAS, S; BASU, S; KOLESNICK, R			PHOSPHORYLATION OF RAF BY CERAMIDE-ACTIVATED PROTEIN-KINASE	NATURE			English	Article							TYROSINE PHOSPHORYLATION; RECEPTOR; SERINE; C-RAF-1; INSULIN; CELLS	The sphingomyelin pathway, initiated by hydrolysis of sphingomyelin to ceramide and stimulation of a Ser/Thr ceramide-activated protein (CAP) kinase, mediates tumour necrosis factor-alpha (TNF-alpha) and interleukin-1 beta action(1-4). CAP kinase is membrane-bound and proline-directed, recognizing the minimal substrate motif Thr-Leu-Pro (ref. 5). TNF may use the sphingomyelin pathway to signal Raf1 to activate the MAP kinase cascade(6-8). Evidence shows that cytoplasmic Raf1 binds to GTP-ras upon cellular stimulation, is recruited to the plasma membrane, and activated(9,11). How membrane-bound Raf1 is activated is uncertain, but regulation of its kinase activity may involve its phosphorylation(12,19). Specific Raf kinases, however, have not hitherto been identified. Here we report that CAP kinase phosphorylates Raf1 on Thr 269, increasing its activity towards MEK (MAP kinase or ERK kinase). Moreover, in intact HL-60 cells, CAP kinase complexes with Raf1 and, in response to TNF and ceramide analogues, phosphorylates and activates Raf1, implicating CAP kinase as a link between the TNF receptor and Raf1.	MEM SLOAN KETTERING CANC CTR,SIGNAL TRANSDUCT LAB,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center								APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GUILBINS E, 1995, IMMUNITY, V2, P341; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; IZUMI T, 1991, J BIOL CHEM, V266, P7933; JOSEPH CK, 1993, J BIOL CHEM, V268, P2002; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIU J, 1994, J BIOL CHEM, V269, P3047; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MOORE DJ, 1994, METHOD ENZYMOL, V226, P448; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; PANTAZIS P, 1991, P NATL ACAD SCI USA, V88, P2481, DOI 10.1073/pnas.88.6.2481; RAINES MA, 1993, J BIOL CHEM, V268, P14572; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VIETOR I, 1993, J BIOL CHEM, V268, P18994; WANG HG, 1994, ONCOGENE, V9, P2751; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	30	306	315	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 16	1995	378	6554					307	310		10.1038/378307a0	http://dx.doi.org/10.1038/378307a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477354				2022-12-28	WOS:A1995TE85800056
J	WALD, NJ; MURPHY, P; MAJOR, P; PARKES, C; TOWNSEND, J; FROST, C				WALD, NJ; MURPHY, P; MAJOR, P; PARKES, C; TOWNSEND, J; FROST, C			UKCCCR MULTICENTER RANDOMIZED CONTROLLED TRIAL OF ONE AND 2 VIEW MAMMOGRAPHY IN BREAST-CANCER SCREENING	BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare one view (oblique) and two view (oblique and craniocaudal) mammography in breast cancer screening. Design-Randomised controlled trial. Setting-Nine breast screening centres in England. Subjects-40 163 women aged 50-64 attending their first breast screening examination. Interventions-Women were randomised to have one view mammography, two view mammography, or two view mammography in which one view was read by one reader and both views were read by another. Main outcome measures-Prevalence of cancer detected, recall rates, cost per cancer detected, and marginal cost per extra cancer detected. Results-Two view mammography detected 24% more women with breast cancer (95% confidence interval 16% to 31%) than one view mammography. Prevalence of detected cancer was 6.84 with two view mammography and 5.52 per 1000 women with one view. The proportion of women recalled for assessment was 15% lower (95% confidence interval 6% to 23%) with two view (6.97%) than with one view (8.16%) mammography. The cost of two view screening was higher (pound 26.46 compared with pound 22.00 per examination) but the average cost per cancer detected was similar (pound 5330 compared with pound 5310) and the marginal cost per extra cancer detected with two views was similar to the average cost (pound 5400). Conclusion-Two view mammography is medically more effective than one view; it detects more cancers and reduces recall rates; it is also similarly cost effective financially.	ST BARTHOLOMEWS HOSP,COLL MED,WOLFSON INST PREVENT MED,MRC,EPIDEMIOL & MED CARE UNIT,LONDON EC1M 6BQ,ENGLAND	University of London; Queen Mary University London	WALD, NJ (corresponding author), ST BARTHOLOMEWS HOSP,COLL MED,WOLFSON INST PREVENT MED,CANC RES CAMPAIGN,CANC SCREENING RES GRP,LONDON EC1M 6BQ,ENGLAND.		Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					ANDERSSON I, 1981, ACTA RADIOL DIAGN, V22, P407, DOI 10.1177/028418518102200404; ANDERSSON I, 1978, AM J ROENTGENOL, V130, P349, DOI 10.2214/ajr.130.2.349; CLARKE PR, 1991, EC ANAL SCREENING BR; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; FEIG SA, 1984, AM J ROENTGENOL, V143, P469, DOI 10.2214/ajr.143.3.469; FORREST P, 1986, BREAST CANCER SCREEN; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; LUNDGREN B, 1977, BRIT J RADIOL, V50, P626, DOI 10.1259/0007-1285-50-597-626; SICKLES EA, 1986, AM J ROENTGENOL, V147, P1149, DOI 10.2214/ajr.147.6.1149; TABAR L, 1987, BRIT J CANCER, V55, P547, DOI 10.1038/bjc.1987.112; Wald NJ, 1993, BREAST, V2, P209; 1994, NHS BREAST SCREENING	12	122	123	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 4	1995	311	7014					1189	1193		10.1136/bmj.311.7014.1189	http://dx.doi.org/10.1136/bmj.311.7014.1189			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD768	7488893	Green Published			2022-12-28	WOS:A1995TD76800016
J	WHITE, HD				WHITE, HD			ANGIOPLASTY VERSUS BYPASS-SURGERY	LANCET			English	Editorial Material							CORONARY				WHITE, HD (corresponding author), GREEN LANE HOSP, DEPT CARDIOL, AUCKLAND 3, NEW ZEALAND.							BLAUTH CI, 1988, J THORAC CARDIOV SUR, V95, P668; BOURASSA MG, 1984, AM J CARDIOL, V53, pC102, DOI 10.1016/0002-9149(84)90759-8; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; COWLEY MJ, 1993, J AM COLL CARDIOL, V22, P1289, DOI 10.1016/0735-1097(93)90532-6; GARDNER TJ, 1985, ANN THORAC SURG, V40, P574, DOI 10.1016/S0003-4975(10)60352-9; HAMPTON JR, 1993, LANCET, V341, P573; HOLMES DR, 1984, AM J CARDIOL, V53, pC77, DOI 10.1016/0002-9149(84)90752-5; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; MARK DB, 1994, CIRCULATION, V89, P2015, DOI 10.1161/01.CIR.89.5.2015; PEDERSEN TR, 1994, LANCET, V344, P1383; RODEWALD G, 1988, THORAC CARDIOV SURG, V36, P254, DOI 10.1055/s-2007-1020091; SCULPHER MJ, 1994, LANCET, V344, P927, DOI 10.1016/S0140-6736(94)92274-8; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	15	19	20	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 4	1995	346	8984					1174	1175		10.1016/S0140-6736(95)92892-8	http://dx.doi.org/10.1016/S0140-6736(95)92892-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC976	7475652				2022-12-28	WOS:A1995TC97600002
J	GEKAKIS, N; SAEZ, L; DELAHAYEBROWN, AM; MYERS, MP; SEHGAL, A; YOUNG, MW; WEITZ, CJ				GEKAKIS, N; SAEZ, L; DELAHAYEBROWN, AM; MYERS, MP; SEHGAL, A; YOUNG, MW; WEITZ, CJ			ISOLATION OF TIMELESS BY PER PROTEIN-INTERACTION - DEFECTIVE INTERACTION BETWEEN TIMELESS PROTEIN AND LONG-PERIOD MUTANT PER(L)	SCIENCE			English	Article							CIRCADIAN BEHAVIORAL RHYTHMS; DROSOPHILA CLOCK; GENE-PRODUCT; MOSAIC ANALYSIS; TRANSFORMATION; MELANOGASTER; EXPRESSION; SYSTEM; DNA; ELEMENT	The period (per) gene likely encodes a component of the Drosophila circadian clock. Circadian oscillations in the abundance of per messenger RNA and per protein (PER) are thought to arise from negative feedback control of per gene transcription by PER. A recently identified second clock locus, timeless (tim), apparently regulates entry of PER into the nucleus. Reported here are the cloning of complementary DNAs derived from the tim gene in a two-hybrid screen for PER-interacting proteins and the demonstration of a physical interaction between the tim protein (TIM) and PER in vitro. A restricted segment of TIM binds directly to a part of the PER dimerization domain PAS. PER(L), a mutation that causes a temperature-sensitive lengthening of circadian period and a temperature-sensitive delay in PER nuclear entry, exhibits a temperature-sensitive defect in binding to TIM. These results suggest that the interaction between TIM and PER determines the timing of PER nuclear entry and therefore the duration of part of the circadian cycle.	HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; ROCKEFELLER UNIV,CTR BIOL TIMING,HOWARD HUGHES MED INST,NATL SCI FDN SCI & TECHNOL,NEW YORK,NY 10021; ROCKEFELLER UNIV,GENET LAB,NEW YORK,NY 10021; UNIV PENN,MED CTR,DEPT NEUROSCI,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,CTR SLEEP & RESP NEUROBIOL,PHILADELPHIA,PA 19104	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Rockefeller University; Rockefeller University; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine			, 机智的马小跳和机智的羊不愁/ABC-5169-2020					ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BARGIELLO TA, 1984, NATURE, V312, P752, DOI 10.1038/312752a0; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BAYLIES MK, 1987, NATURE, V326, P390, DOI 10.1038/326390a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BRUCE VG, 1972, GENETICS, V70, P537; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; CHUA KL, UNPUB; COLOT HV, 1988, EMBO J, V7, P3929, DOI 10.1002/j.1460-2075.1988.tb03279.x; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; Edmunds LN, 1988, CELLULAR MOL BASES B; EWER J, 1992, J NEUROSCI, V12, P3321; FELDMAN J F, 1973, Genetics, V75, P605; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRIESEN WO, 1993, ANNU REV PHYSIOL, V55, P661, DOI 10.1146/annurev.ph.55.030193.003305; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; GEKAKIS N, UUNPUB; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HILL J, 1991, NUCLEIC ACIDS RES, V19, P57911; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOFFMANN K, 1976, P DAHLEM WORKSHOP, V20, P63; HUANG ZJ, 1995, SCIENCE, V267, P1169, DOI 10.1126/science.7855598; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; KONDO T, 1993, P NATL ACAD SCI USA, V90, P5672, DOI 10.1073/pnas.90.12.5672; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; KONOPKA R, 1983, MOL GEN GENET, V190, P284, DOI 10.1007/BF00330652; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KONOPKA RJ, 1989, J NEUROGENET, V6, P1, DOI 10.3109/01677068909107096; LIU X, 1991, NEURON, V6, P753, DOI 10.1016/0896-6273(91)90172-V; MCCLUNG CR, 1989, NATURE, V339, P558, DOI 10.1038/339558a0; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; Moore-Ede MC., 1982, CLOCKS TIME US; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; ROTHENFLUHHILFI.A, UNPUB; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VOSSHALL LB, 1995, NEURON, V15, P345, DOI 10.1016/0896-6273(95)90039-X; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; ZEHRING WA, 1984, CELL, V39, P369, DOI 10.1016/0092-8674(84)90015-1; ZENG H, 1994, EMBO J, V3, P3590; ZWEIBEL LJ, 1991, P NATL ACAD SCI USA, V88, P3882	49	299	313	2	30	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 3	1995	270	5237					811	815		10.1126/science.270.5237.811	http://dx.doi.org/10.1126/science.270.5237.811			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC712	7481773				2022-12-28	WOS:A1995TC71200045
J	LOPEZ, MJ; WONG, SKF; KISHIMOTO, I; DUBOIS, S; MACH, V; FRIESEN, J; GARBERS, DL; BEUVE, A				LOPEZ, MJ; WONG, SKF; KISHIMOTO, I; DUBOIS, S; MACH, V; FRIESEN, J; GARBERS, DL; BEUVE, A			SALT-RESISTANT HYPERTENSION IN MICE LACKING THE GUANYLYL CYCLASE-A RECEPTOR FOR ATRIAL-NATRIURETIC-PEPTIDE	NATURE			English	Article							BLOOD-PRESSURE; SODIUM SENSITIVITY; CLEARANCE RECEPTOR; BRAIN; GENES	AROUND half of all humans with essential hypertension are resistant to salt (blood pressure does not change by more than 5 mm Hg when salt intake is high)(1-5), and although various inbred strains of rats display salt-insensitive elevated blood pressure(6), a gene defect to account for the phenotype has not been described. Atrial natriuretic peptide (ANP) is released from the heart in response to atrial stretch and is thought to mediate its natriuretic and vasorelaxant effects through the guanylyl cyclase-A receptor (GC-A)(7). Here we report that disruption of the GC-A gene results in chronic elevations of blood pressure in mice on a normal salt diet. Unexpectedly, the blood pressure remains elevated and unchanged in response to either minimal or high salt diets. Aldosterone and ANP concentrations are not affected by the genotype. Therefore, mutations in the GC-A gene could explain some salt-resistant forms of essential hypertension and, coupled with previous works further suggest that the GC-A signalling pathway dominates at the level of peripheral resistance, where it can operate independently of ANP.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT PEDIAT, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	LOPEZ, MJ (corresponding author), UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA.							ANANDSRIVASTAVA MB, 1993, PHARMACOL REV, V45, P455; ATLAS SA, 1990, HYPERTENSION PATHOPH, P861; BALLERMANN BJ, 1991, KIDNEY, P510; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; DIETZ JR, 1994, CLIN EXP PHARMACOL P, V21, P599, DOI 10.1111/j.1440-1681.1994.tb02560.x; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; FUJITA T, 1980, AM J MED, V69, P334, DOI 10.1016/0002-9343(80)90002-9; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; FULLER F, 1988, J BIOL CHEM, V263, P9395; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JOHN SWM, 1995, SCIENCE, V267, P679, DOI 10.1126/science.7839143; KAWASAKI T, 1978, AM J MED, V64, P193, DOI 10.1016/0002-9343(78)90045-1; Kimura G, 1994, Curr Opin Nephrol Hypertens, V3, P1; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; LEVIN ER, 1993, AM J PHYSIOL, V264, pE483, DOI 10.1152/ajpendo.1993.264.4.E483; NUSSENZVEIG DR, 1990, J BIOL CHEM, V265, P20952; OGAWA Y, 1994, J CLIN INVEST, V93, P1911, DOI 10.1172/JCI117182; OPARIL S, 1988, J CARDIOVASC PHARM, V12, pS56; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEINHELPER ME, 1990, HYPERTENSION, V16, P301, DOI 10.1161/01.HYP.16.3.301; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; SULLIVAN JM, 1988, HYPERTENSION, V11, P717, DOI 10.1161/01.HYP.11.6.717; WEINBERGER MH, 1986, HYPERTENSION, V8, P127, DOI 10.1161/01.HYP.8.6_Pt_2.II127; WEINBERGER MH, 1990, HYPERTENSION PATHOPH, P1999; YAMAGUCHI M, 1990, J BIOL CHEM, V265, P20414	28	387	400	0	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 2	1995	378	6552					65	68		10.1038/378065a0	http://dx.doi.org/10.1038/378065a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477288				2022-12-28	WOS:A1995TC46900050
J	VANDENBERG, C; WILLEMSEN, V; HAGE, W; WEISBEEK, P; SCHERES, B				VANDENBERG, C; WILLEMSEN, V; HAGE, W; WEISBEEK, P; SCHERES, B			CELL FATE IN THE ARABIDOPSIS ROOT-MERISTEM DETERMINED BY DIRECTIONAL SIGNALING	NATURE			English	Article							LINEAGE PATTERNS; CAENORHABDITIS-ELEGANS; SHOOT MERISTEM; ZEA-MAYS; REGENERATION; EMBRYO; PLANTS	POSTEMBRYONIC development in plants is achieved by apical meristems. Surgical studies and clonal analysis have revealed indirectly that cells in shoot meristems have no predictable destiny(1-3) and that position is likely to play a role in the acquisition of cell identity(4-7). In contrast to animal systems(8-10) there has been no direct evidence for inductive signalling in plants until now. Here we present evidence for such signalling using laser ablation of cells in the root meristem of Arabidopsis thaliana. Although these cells show rigid clonal relationships, we now demonstrate that it is positional control that is most important in the determination of cell fate. Positional signals can be perpetuated from more mature to initial cells to guide the pattern of meristem cell differentiation. This offers an alternative to the general opinion that meristems are the source of patterning information(12).	NETHERLANDS INST DEV BIOL,3584 CT UTRECHT,NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	VANDENBERG, C (corresponding author), UNIV UTRECHT,DEPT MOLEC CELL BIOL,PADUALAAN 8,3584 CH UTRECHT,NETHERLANDS.			Scheres, Ben/0000-0001-5400-9578				ALBERTS B, 1994, MOL BIOL CELL, P1108; BARLOW P, 1974, NEW PHYTOL, V73, P937, DOI 10.1111/j.1469-8137.1974.tb01323.x; BENFEY PN, 1993, DEVELOPMENT, V119, P57; BENFEY PN, 1990, EMBO J, V9, P1685, DOI 10.1002/j.1460-2075.1990.tb08292.x; BERGER F, 1994, SCIENCE, V263, P1421, DOI 10.1126/science.263.5152.1421; DAWE RK, 1991, PLANT J, V1, P3, DOI 10.1111/j.1365-313X.1991.00003.x; DOLAN L, 1993, DEVELOPMENT, V119, P71; DUCKETT CM, 1994, DEVELOPMENT, V120, P3247; FELDMAN LJ, 1976, AM J BOT, V63, P345, DOI 10.2307/2441580; GODDIJN OJM, 1993, PLANT J, V4, P863, DOI 10.1046/j.1365-313X.1993.04050863.x; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HAESMAN J, 1984, CELL, V37, P185; JEGLA DE, 1989, DEV BIOL, V131, P215, DOI 10.1016/S0012-1606(89)80053-3; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; MCDANIEL CN, 1988, PLANTA, V175, P13, DOI 10.1007/BF00402877; Pilkington M, 1929, NEW PHYTOL, V28, P37; POETHIG RS, 1987, AM J BOT, V74, P581, DOI 10.2307/2443838; SCHERES B, 1995, DEVELOPMENT, V121, P53; SCHERES B, 1994, DEVELOPMENT, V120, P2475; SCHIAVONE FM, 1991, DEVELOPMENT, V113, P1305; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STEEVES TA, 1989, PATTERNS PLANT DEV, P86; STEWART RN, 1975, AM J BOT, V57, P816; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; SUSSEX IM, 1989, CELL, V56, P225, DOI 10.1016/0092-8674(89)90895-7; WARDLAW CW, 1950, PHILOS T ROY SOC B, V234, P583, DOI 10.1098/rstb.1950.0012	27	401	415	0	54	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 2	1995	378	6552					62	65		10.1038/378062a0	http://dx.doi.org/10.1038/378062a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477287	Green Submitted			2022-12-28	WOS:A1995TC46900049
J	SHARP, NC; CRONIN, N; FELDBERG, I; EVANS, M; HODGSON, D; ELLIS, S				SHARP, NC; CRONIN, N; FELDBERG, I; EVANS, M; HODGSON, D; ELLIS, S			MICROWAVES FOR MENORRHAGIA - A NEW FAST TECHNIQUE FOR ENDOMETRIAL ABLATION	LANCET			English	Note								Current ablative techniques for treating menorrhagia are unsatisfactory. We tried microwave energy, delivered by an 8 mm diameter probe in the uterine cavity, to treat 23 patients with functional menorrhagia. The mean treatment time was 2 min 12 s (range 50-310 s). 6 months after treatment the success rate is 83%, 13 patients (57%) are amenorrhoeic, and six (26%) are experiencing light menstruation. Three initial failures have been successfully retreated. The technique is safe, and is easier and quicker to perform than current alternatives.	UNIV BATH,SCH PHYS,BATH BA2 7AY,AVON,ENGLAND; ROYAL UNITED HOSP,DEPT MED PHYS,BATH,AVON,ENGLAND	University of Bath	SHARP, NC (corresponding author), ROYAL UNITED HOSP,DEPT OBSTET & GYNAECOL,PRINCESS ANNE WING,BATH BA1 3NG,AVON,ENGLAND.							ARIEFF AI, 1993, JAMA-J AM MED ASSOC, V270, P1230, DOI 10.1001/jama.270.10.1230; BAUMANN R, 1990, BRIT MED J, V300, P304, DOI 10.1136/bmj.300.6720.304; PHIPPS JH, 1990, LANCET, V335, P374, DOI 10.1016/0140-6736(90)90207-L; 1994, MISTLETOE SURGERY UP	4	85	94	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 14	1995	346	8981					1003	1004		10.1016/S0140-6736(95)91689-X	http://dx.doi.org/10.1016/S0140-6736(95)91689-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475547				2022-12-28	WOS:A1995RZ59900011
J	LOWRY, PW; JARVIS, WR; OBERLE, AD; BLAND, LA; SILBERMAN, R; BOCCHINI, JA; DEAN, HD; SWENSON, JM; WALLACE, RJ				LOWRY, PW; JARVIS, WR; OBERLE, AD; BLAND, LA; SILBERMAN, R; BOCCHINI, JA; DEAN, HD; SWENSON, JM; WALLACE, RJ			MYCOBACTERIUM-CHELONAE CAUSING OTITIS-MEDIA IN AN EAR-NOSE-AND-THROAT PRACTICE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									CTR DIS CONTROL,CTR INFECT DIS,HOSP INFECT PROGRAM,RM 5044,MAILSTOP C-10,1600 CLIFTON RD NE,ATLANTA,GA 30333; LOUISIANA DEPT HLTH & HOSP,OFF PUBL HLTH,NEW ORLEANS,LA; UNIV TEXAS,CTR HLTH,TYLER,TX; LOUISIANA STATE UNIV,MED CTR,DEPT PATHOL,SHREVEPORT,LA 71105; LOUISIANA STATE UNIV,MED CTR,DEPT PEDIAT,SHREVEPORT,LA 71105	Centers for Disease Control & Prevention - USA; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT); Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport								AUSTIN WK, 1976, ARCH OTOLARYNGOL, V102, P558; Bland L, 1985, Trans Am Soc Artif Intern Organs, V31, P556; BLAND LA, 1985, 1985 P AM ASS ADV ME, P11; BOLAN G, 1985, J INFECT DIS, V152, P1013, DOI 10.1093/infdis/152.5.1013; CARSON LA, 1978, APPL ENVIRON MICROB, V36, P839, DOI 10.1128/AEM.36.6.839-846.1978; CARSON LA, 1988, APPL ENVIRON MICROB, V54, P1756, DOI 10.1128/AEM.54.7.1756-1760.1988; CARSON LA, 1985, 1985 ANN M AM SOC MI, P105; COLLINS CH, 1984, J APPL BACTERIOL, V57, P193, DOI 10.1111/j.1365-2672.1984.tb01384.x; COLLINS FM, 1986, J APPL BACTERIOL, V61, P247, DOI 10.1111/j.1365-2672.1986.tb04283.x; GOSLEE S, 1976, AM REV RESPIR DIS, V113, P287; HOEKELMAN RA, 1977, PEDIATRICS, V59, P119; KINSELLA JP, 1986, PEDIATR INFECT DIS J, V5, P704, DOI 10.1097/00006454-198611000-00023; LABIDI A, 1984, CURR MICROBIOL, V11, P235, DOI 10.1007/BF01567167; MCINERNY TK, 1978, PEDIATRICS, V61, P389, DOI 10.1542/peds.61.3.389; NEITCH SM, 1982, ARCH OTOLARYNGOL, V108, P11; PLESTER D, 1980, J LARYNGOL OTOL, V94, P1415, DOI 10.1017/S0022215100090265; RHAME FS, 1986, HOSPITAL INFECTIONS, P223; SAMUEL J, 1986, ANN OTO RHINOL LARYN, V95, P264, DOI 10.1177/000348948609500310; SILCOX VA, 1981, J CLIN MICROBIOL, V14, P686, DOI 10.1128/JCM.14.6.686-691.1981; SWENSON JM, 1985, ANTIMICROB AGENTS CH, V28, P807, DOI 10.1128/AAC.28.6.807; Turner A, 1915, J LARYNGOL RHINOL OT, V30, P209; WALLACE RJ, 1983, REV INFECT DIS, V5, P657; WARDROP PA, 1984, ARCH OTOLARYNGOL, V110, P686; WOLINSKY E, 1979, AM REV RESPIR DIS, V119, P107; WOODS GL, 1987, REV INFECT DIS, V9, P275; 1987, N ENGL J MED, V316, P1589	26	127	130	2	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	1988	319	15					978	982		10.1056/NEJM198810133191504	http://dx.doi.org/10.1056/NEJM198810133191504			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q4155	3419478				2022-12-28	WOS:A1988Q415500004
J	PENCE, GE				PENCE, GE			ON THE ROAD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material													Papadimitratos, Panagiotis/J-4928-2012	Papadimitratos, Panagiotis/0000-0002-3267-5374					0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1988	260	13					1946	1946						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q2703	3418860				2022-12-28	WOS:A1988Q270300035
J	VANDYKE, MW; ROEDER, RG; SAWADOGO, M				VANDYKE, MW; ROEDER, RG; SAWADOGO, M			PHYSICAL ANALYSIS OF TRANSCRIPTION PREINITIATION COMPLEX ASSEMBLY ON A CLASS-II GENE PROMOTER	SCIENCE			English	Article											VANDYKE, MW (corresponding author), ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021, USA.		Van Dyke, Michael W./AAY-6751-2020	Van Dyke, Michael W./0000-0003-0306-4002	NCI NIH HHS [CA 42567] Funding Source: Medline; NIGMS NIH HHS [GM 38212] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038212] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATEMAN E, 1986, CELL, V47, P445, DOI 10.1016/0092-8674(86)90601-X; BATEMAN E, 1985, P NATL ACAD SCI USA, V82, P8004, DOI 10.1073/pnas.82.23.8004; BITTER GA, 1983, ANAL BIOCHEM, V128, P294, DOI 10.1016/0003-2697(83)90378-0; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; CAI H, 1987, J BIOL CHEM, V262, P298; CAI H, 1987, MOL CELL BIOL, V7, P3371, DOI 10.1128/MCB.7.10.3371; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CONCINO M, 1983, J BIOL CHEM, V258, P8493; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FIRE A, 1984, J BIOL CHEM, V259, P2509; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HEN R, 1982, P NATL ACAD SCI-BIOL, V79, P7132, DOI 10.1073/pnas.79.23.7132; HERTZBERG RP, 1982, J AM CHEM SOC, V104, P313, DOI 10.1021/ja00365a069; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HU SL, 1981, P NATL ACAD SCI-BIOL, V78, P820, DOI 10.1073/pnas.78.2.820; IVERSON BL, 1987, NUCLEIC ACIDS RES, V15, P7823, DOI 10.1093/nar/15.19.7823; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MATSUI T, 1980, J BIOL CHEM, V255, P1992; Maxam A M, 1980, Methods Enzymol, V65, P499; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MONCOLLIN V, 1986, EMBO J, V5, P2577, DOI 10.1002/j.1460-2075.1986.tb04537.x; NAKAJIMA N, IN PRESS MOL CELL BI; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; VANDYKE M, UNPUB; VANDYKE MW, 1987, MOL CELL BIOL, V7, P1021, DOI 10.1128/MCB.7.3.1021; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; YU YT, 1984, NUCLEIC ACIDS RES, V12, P9309, DOI 10.1093/nar/12.24.9309	36	289	289	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 9	1988	241	4871					1335	1338		10.1126/science.3413495	http://dx.doi.org/10.1126/science.3413495			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	P9812	3413495				2022-12-28	WOS:A1988P981200026
J	BLAU, HM; SPRINGER, ML				BLAU, HM; SPRINGER, ML			MUSCLE-MEDIATED GENE-THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SYSTEMIC DELIVERY; MYOBLASTS				BLAU, HM (corresponding author), STANFORD UNIV,SCH MED,DEPT MOLEC PHARMACOL,STANFORD,CA 94305, USA.							BARR E, 1991, SCIENCE, V254, P1507, DOI 10.1126/science.1962212; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; DHAWAN J, 1995, SOMAT CELL MOLEC GEN, V21, P233, DOI 10.1007/BF02255778; GUSSONI E, 1992, NATURE, V356, P435, DOI 10.1038/356435a0; MENDELL JR, 1995, NEW ENGL J MED, V333, P832, DOI 10.1056/NEJM199509283331303; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; SOONPAA MH, 1994, SCIENCE, V264, P98, DOI 10.1126/science.8140423	8	87	95	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 7	1995	333	23					1554	1556		10.1056/NEJM199512073332308	http://dx.doi.org/10.1056/NEJM199512073332308			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH157	7477172				2022-12-28	WOS:A1995TH15700008
J	MOLRINE, DC; GEORGE, S; TARBELL, N; MAUCH, P; DILLER, L; NEUBERG, D; SHAMBERGER, RC; ANDERSON, EL; PHILLIPS, NR; KINSELLA, K; AMBROSINO, DM				MOLRINE, DC; GEORGE, S; TARBELL, N; MAUCH, P; DILLER, L; NEUBERG, D; SHAMBERGER, RC; ANDERSON, EL; PHILLIPS, NR; KINSELLA, K; AMBROSINO, DM			ANTIBODY-RESPONSES TO POLYSACCHARIDE AND POLYSACCHARIDE-CONJUGATE VACCINES AFTER TREATMENT OF HODGKIN DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						HODGKIN DISEASE; HAEMOPHILUS VACCINE; VACCINES, CONJUGATE; POLYSACCHARIDES, BACTERIAL; PNEUMOCOCCAL INFECTIONS	INFLUENZAE TYPE-B; PNEUMOCOCCAL VACCINE; CAPSULAR POLYSACCHARIDE; IMMUNIZATION; INFECTIONS; CHILDREN; EFFICACY; PROTEIN; SEPSIS; RISK	Objective: To compare the immunogenicity of polysaccharide-conjugate vaccines with that of polysaccharide vaccines in patients previously treated for Hodgkin disease, Design: All patients were immunized with Haemophilus influenzae type b (HIB)-conjugate and 4-valent meningococcal polysaccharide vaccines. Subgroups of patients were randomly assigned to receive either 23-valent pneumococcal polysaccharide vaccine or a 7-valent pneumococcal-conjugate vaccine that links seven pneumococcal serotypes to the outer membrane protein complex of Neisseria meningitidis. Patients: 144 patients who had completed treatment for Hodgkin disease, which had been diagnosed at least 2 years before the study. Measurements: Antigen-specific antibody concentrations before and 3 to 6 weeks after immunization; number of persons who achieved anti-HIB antibody concentrations considered to be in the protective range. Results: The geometric mean anti-HIB antibody concentration increased from 1.79 mu g/mL before immunization to 54.1 mu g/mL after; the percentage of persons with antibody concentrations in the protective range increased from 62% before immunization to 99% after. Patients immunized with 23-valent pneumococcal vaccine had a geometric mean pneumococcal antibody concentration after immunization (9.15 mu g/mL) that was similar to that of healthy controls (10.0 mu g/ml) for the seven serotypes measured, In contrast, patients who received 7-valent pneumococcal-conjugate vaccine had a significantly lower mean response compared with patients who received 23-valent vaccine; their geometric mean antibody concentration after immunization was 4.95 mu g/mL (P = 0.005). Conclusion: A single dose of HIB-conjugate vaccine was immunogenic in patients who had completed treatment for Hodgkin disease diagnosed at least 2 years before immunization. In addition, responses to the 23-valent pneumococcal and 4-valent meningococcal vaccines were equivalent to those seen in healthy controls. Finally, patients had a significantly lower response to a single dose of 7-valent pneumococcal-conjugate vaccine than to 23-valent vaccine.	CHILDRENS HOSP, BOSTON, MA 02115 USA; ST LOUIS UNIV, HLTH SCI CTR, DIV INFECT DIS & IMMUNOL, ST LOUIS, MO 63110 USA	Harvard University; Boston Children's Hospital; Saint Louis University	MOLRINE, DC (corresponding author), JOINT CTR RADIAT THERAPY, DANA FARBER CANC INST, INFECT DIS LAB, JFB ROOM 410, 44 BINNEY ST, BOSTON, MA 02115 USA.				NCI NIH HHS [CA01730] Funding Source: Medline; PHS HHS [A129623] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K12CA001730] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMBROSINO DM, 1986, J INFECT DIS, V154, P893, DOI 10.1093/infdis/154.5.893; [Anonymous], 1993, MMWR Recomm Rep, V42, P1; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P92, DOI 10.1097/00006454-199102000-00003; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; CARLONE GM, 1992, J CLIN MICROBIOL, V30, P154, DOI 10.1128/JCM.30.1.154-159.1992; CHILCOTE RR, 1976, NEW ENGL J MED, V295, P798, DOI 10.1056/NEJM197610072951502; DONALDSON SS, 1981, REV INFECT DIS, V3, pS133; DONALDSON SS, 1978, CANCER-AM CANCER SOC, V41, P1949, DOI 10.1002/1097-0142(197805)41:5<1949::AID-CNCR2820410539>3.0.CO;2-K; FELDMAN S, 1990, J INFECT DIS, V161, P926, DOI 10.1093/infdis/161.5.926; FREDERIKSEN B, 1989, EUR J HAEMATOL, V43, P45; GRANOFF DM, 1994, JAMA-J AM MED ASSOC, V272, P1116, DOI 10.1001/jama.272.14.1116; HAYS DM, 1986, J PEDIATR SURG, V21, P628, DOI 10.1016/S0022-3468(86)80419-5; JAKACKI R, 1990, ANN INTERN MED, V112, P143, DOI 10.7326/0003-4819-112-2-143; KAYHTY H, 1983, J INFECT DIS, V147, P1100; LANDESMAN SH, 1981, REV INFECT DIS, V3, pS184; MENDELMAN PM, 1994, AM PEDIATRIC SOC SOC; NOTTER DT, 1980, REV INFECT DIS, V2, P761; QUATAERT SA, 1993, PEDIATR RES, V33, pA179; REID MM, 1994, LANCET, V344, P970; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; SIBER GR, 1978, NEW ENGL J MED, V299, P442, DOI 10.1056/NEJM197808312990903; SIBER GR, 1981, REV INFECT DIS, V3, pS144; SIBER GR, 1980, AM J DIS CHILD, V134, P668, DOI 10.1001/archpedi.1980.02130190036009; SIBER GR, 1986, ANN INTERN MED, V104, P467, DOI 10.7326/0003-4819-104-4-467; WEITZMAN S, 1977, AM J MED, V62, P47, DOI 10.1016/0002-9343(77)90348-5; WEITZMAN SA, 1977, NEW ENGL J MED, V297, P245, DOI 10.1056/NEJM197708042970504	27	51	61	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1995	123	11					828	+		10.7326/0003-4819-123-11-199512010-00003	http://dx.doi.org/10.7326/0003-4819-123-11-199512010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG209	7486464				2022-12-28	WOS:A1995TG20900003
J	CAUVIN, JM; GOLDFAIN, D; LERHUN, M; ROBASZKIEWICZ, M; CADIOT, G; CARPENTIER, S; ROTENBERG, A; MIGNON, M; BOYER, J; GALMICHE, JP				CAUVIN, JM; GOLDFAIN, D; LERHUN, M; ROBASZKIEWICZ, M; CADIOT, G; CARPENTIER, S; ROTENBERG, A; MIGNON, M; BOYER, J; GALMICHE, JP			MULTICENTER PROSPECTIVE CONTROLLED-STUDY OF BARRETTS-ESOPHAGUS AND COLORECTAL ADENOMAS	LANCET			English	Article							COLON CANCER; ESOPHAGUS; PREVALENCE; NEOPLASMS; RISK; POLYPS; AGE	Previous studies have suggested that patients with Barrett's oesophagus may be at increased risk of colorectal neoplasia, though the association is disputed. In a multicentre prospective study we compared the prevalence of colorectal adenomas in patients with Barrett's oesophagus and controls. Barrett's oesophagus patients (n=104) had histological confirmation of columnar epithelium extending more than 3 cm above the gastro-esophageal junction. The 537 controls were patients with symptoms suggesting irritable bowel syndrome. No participant had a personal history of colonic neoplasm. Each patient underwent colonoscopy. Histologically proven adenomas were found in 26 Barrett's patients (25%) and 75 controls (14%). Three colorectal cancers were discovered in each group. The prevalence of adenomas was greater in the Barrett's oesophagus group than in the control group (p<0.01) but the relation became non-significant after adjustment for age and sex and control for other known risk factors by a logistic regression model (odds ratio 1.4 [0.7-2.7]). The relative risk of adenoma was significantly higher in patients older than 59 than in younger patients(2.2 [1.3-3.5]) and in men than in women (3.4 [2.0-5.7]). Other factors contributing significantly to the risk of adenoma were a family history of colorectal cancer (2.3 [1.1-4.8]), rectal bleeding (2.1 [1.1-3.9]), previous colonic investigation (0.3 [0.1-0.7]), and complete as opposed to partial colonoscopy (6.4 [0.8-48.3]). We conclude that Barrett's oesophagus is not an independent risk factor for colorectal neoplasia and, therefore, is not, in itself an indication for colorectal screening.	UNIV HOSP BREST,DEPT GASTROENTEROL,BREST,FRANCE; UNIV HOSP DREUX,DEPT GASTROENTEROL,DREUX,FRANCE; UNIV HOSP NANTES,DEPT GASTROENTEROL,NANTES,FRANCE; UNIV HOSP PARIS,DEPT GASTROENTEROL,F-75252 PARIS,FRANCE; UNIV HOSP ANGERS,DEPT GASTROENTEROL,ANGERS,FRANCE; GEN HOSP,DEPT GASTROENTEROL,BREST,FRANCE; GEN HOSP,DEPT GASTROENTEROL,DREUX,FRANCE; GEN HOSP,DEPT GASTROENTEROL,NANTES,FRANCE; GEN HOSP,DEPT GASTROENTEROL,PARIS,FRANCE; GEN HOSP,DEPT GASTROENTEROL,PARIS,FRANCE; GEN HOSP,DEPT GASTROENTEROL,ANGERS,FRANCE	CHU Brest; Universite de Bretagne Occidentale; Nantes Universite; CHU de Nantes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Hopital Universitaire Pitie-Salpetriere - APHP; Universite d'Angers; Centre Hospitalier Universitaire d'Angers								CAMERON AJ, 1992, GASTROENTEROLOGY, V103, P1241, DOI 10.1016/0016-5085(92)91510-B; CAMERON AJ, 1990, GASTROENTEROLOGY, V99, P918, DOI 10.1016/0016-5085(90)90607-3; CAMERON AJ, 1994, GASTROEN CLIN BIOL, V18, pD3; CLARK JC, 1985, INT J CANCER, V36, P179, DOI 10.1002/ijc.2910360209; COOPER BT, 1987, LANCET, V2, P1084; DISARIO JA, 1991, AM J GASTROENTEROL, V86, P941; HAMEETEMAN W, 1989, GASTROENTEROLOGY, V96, P1249, DOI 10.1016/S0016-5085(89)80011-3; HEADING RC, 1987, BRIT MED J, V294, P461, DOI 10.1136/bmj.294.6570.461; ISOLAURI J, 1994, GASTROENTEROLOGY, V106, pA397; JENSEN J, 1993, SCAND J GASTROENTERO, V28, P911, DOI 10.3109/00365529309103134; JOHNSON DA, 1990, AM J GASTROENTEROL, V85, P969; KLEINBAUM DG, 1982, COMMUN STAT A-THEOR, V11, P485, DOI 10.1080/03610928208828251; LIMBURG PJ, 1994, GASTROENTEROLOGY, V106, pA409; LYONS MF, 1993, GASTROENTEROLOGY, V104, pA139; OLSEN HW, 1988, DIS COLON RECTUM, V31, P216, DOI 10.1007/BF02552550; POORMAN JC, 1994, GASTROENTEROLOGY, V106, pA429; POST AB, 1993, AM J GASTROENTEROL, V88, P877; RAMAGE JK, 1987, LANCET, V2, P851; REX DK, 1991, GASTROENTEROLOGY, V10, P64; RINER MA, 1987, LANCET, V2, P1084; ROBERTSON DAF, 1989, BRIT MED J, V298, P650, DOI 10.1136/bmj.298.6674.650; ROTHSTEIN R I, 1991, Gastroenterology, V100, pA150; SONTAG SJ, 1985, LANCET, V1, P946; SPECHLER SJ, 1994, LANCET, V344, P1533, DOI 10.1016/S0140-6736(94)90349-2; TRIPP MR, 1986, AM J GASTROENTEROL, V81, P1063; WINAWER SJ, 1990, B WORLD HEALTH ORGAN, V68, P505; 1991, INT J CANCER, V48, P364; 1981, GASTROENTEROL CLIN B, V5, P58	28	23	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 25	1995	346	8987					1391	1394						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG207	7475821				2022-12-28	WOS:A1995TG20700009
J	NICHOLLS, MG; RICHARDS, AM; LEWIS, LK; YANDLE, TG				NICHOLLS, MG; RICHARDS, AM; LEWIS, LK; YANDLE, TG			OUABAIN - A NEW STEROID-HORMONE	LANCET			English	Editorial Material							DIGITALIS-LIKE-FACTOR; HUMAN PLASMA		CHRISTCHURCH HOSP,DEPT ENDOCRINOL,CHRISTCHURCH,NEW ZEALAND	Christchurch Hospital New Zealand	NICHOLLS, MG (corresponding author), CHRISTCHURCH HOSP,DEPT MED,CHRISTCHURCH,NEW ZEALAND.							BOULANGER BR, 1993, AM J PHYSIOL, V264, pE413, DOI 10.1152/ajpendo.1993.264.3.E413; CAPPUCCIO FP, 1986, POSTGRAD MED J, V62, P265, DOI 10.1136/pgmj.62.726.265; DORIS PA, 1994, HYPERTENSION, V23, P632, DOI 10.1161/01.HYP.23.5.632; GOMEZSANCHEZ EP, 1994, AM J HYPERTENS, V7, P647, DOI 10.1093/ajh/7.7.647; HAMLYN JM, 1992, J HYPERTENS S7, V10, P99; HINSON JP, 1995, J ENDOCRINOL, V146, P369, DOI 10.1677/joe.0.1460369; LAREDO J, 1994, ENDOCRINOLOGY, V135, P794, DOI 10.1210/en.135.2.794; LEWIS LK, 1994, HYPERTENSION, V24, P549, DOI 10.1161/01.HYP.24.5.549; LUDENS JH, 1992, HYPERTENSION, V19, P721, DOI 10.1161/01.HYP.19.6.721; LUDENS JH, 1991, HYPERTENSION, V17, P923, DOI 10.1161/01.HYP.17.6.923; MATHEWS WR, 1991, HYPERTENSION, V17, P930, DOI 10.1161/01.HYP.17.6.930; NARUSE K, 1994, HYPERTENSION S1, V23, P102; ROSSI GP, 1995, 7TH EUR M HYP MIL; TYMIAK AA, 1993, P NATL ACAD SCI USA, V90, P8189, DOI 10.1073/pnas.90.17.8189; WOOLFSON RG, 1994, KIDNEY INT, V46, P297, DOI 10.1038/ki.1994.275	15	16	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 25	1995	346	8987					1381	1382		10.1016/S0140-6736(95)92402-7	http://dx.doi.org/10.1016/S0140-6736(95)92402-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG207	7475817				2022-12-28	WOS:A1995TG20700005
J	MORGAN, MJ; CASTET, E				MORGAN, MJ; CASTET, E			STEREOSCOPIC DEPTH-PERCEPTION AT HIGH VELOCITIES	NATURE			English	Article							MOTION; SENSITIVITY; SELECTIVITY; STEREOPSIS; ACUITY; DELAY	THE view of the world from different perspectives provided by the two eyes is used by the human visual system to compute the relative distances and solid shapes of objects(1). However, the traditional theory of binocular disparity takes little account of the fact that a moving target will stimulate many different sets of disparate points in the two eyes with a range of temporal delays. Here we show that stereoacuity for periodic gratings is not degraded by velocities of up to 640 degrees s(-1) provided that they do not move at a greater rate than 30 cycles s(-1). The minimum detectable spatial phase difference between the eyes was equivalent to a spatial phase difference of about 5 degrees and an interocular temporal delay as small as 450 mu s. We suggest that stereopsis for moving targets is accomplished by neurons having a spatial-temporal phase shift in their receptive fields between the eyes.	UNIV STRASBOURG 1,PSYCHOPHYS LAB,STRASBOURG,FRANCE	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	MORGAN, MJ (corresponding author), INST OPHTHALMOL,DEPT VISUAL SCI,BATH ST,LONDON EC1V 9EL,ENGLAND.							ANDERSON SJ, 1985, VISION RES, V25, P1147, DOI 10.1016/0042-6989(85)90104-X; BARLOW HB, 1967, J PHYSIOL-LONDON, V193, P327, DOI 10.1113/jphysiol.1967.sp008360; BURR DC, 1986, PROC R SOC SER B-BIO, V227, P249, DOI 10.1098/rspb.1986.0022; BURR DC, 1978, VISION RES, V18, P523; DEANGELIS GC, 1991, NATURE, V352, P152; DERRINGTON AM, 1984, J PHYSIOL-LONDON, V357, P219, DOI 10.1113/jphysiol.1984.sp015498; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; MCLEAN J, 1994, VISUAL NEUROSCI, V11, P271, DOI 10.1017/S0952523800001632; MORGAN MJ, 1975, PERCEPTION, V4, P3, DOI 10.1068/p040003; MORGAN MJ, 1982, VISION RES, V22, P863, DOI 10.1016/0042-6989(82)90021-9; MORGAN MJ, 1980, PERCEPTION, V9, P161, DOI 10.1068/p090161; MORGAN MJ, 1983, VISION RES, V23, P541, DOI 10.1016/0042-6989(83)90129-3; MORGAN MJ, IN PRESS P R SOC B; PALMER AR, 1990, HEARING RES, V50, P71, DOI 10.1016/0378-5955(90)90034-M; Pulfrich C, 1922, NATURWISSENSCHAFTEN, V10, P553, DOI 10.1007/BF01571319; REGAN D, 1973, VISION RES, V13, P2369, DOI 10.1016/0042-6989(73)90236-8; REID RC, 1991, J NEUROPHYSIOL, V66, P505, DOI 10.1152/jn.1991.66.2.505; ROSS J, 1974, NATURE, V248, P363, DOI 10.1038/248363a0; ROSS J, 1983, VISION BRAIN COOPERA; SCHOR CM, 1984, VISION RES, V24, P573, DOI 10.1016/0042-6989(84)90111-1; Watt R. J., 1981, CURR PSYCHOL REV, V1, P205, DOI [DOI 10.1007/BF02979265, 10. 1007/BF02979265]; WESTHEIMER G, 1978, J OPT SOC AM, V68, P450, DOI 10.1364/JOSA.68.000450; WHEATSTONE C, 1838, PHILOS T R SOC LON B, V2, P371	23	44	44	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 23	1995	378	6555					380	383		10.1038/378380a0	http://dx.doi.org/10.1038/378380a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477373				2022-12-28	WOS:A1995TF89300057
J	DOUHAL, A; KIM, SK; ZEWAIL, AH				DOUHAL, A; KIM, SK; ZEWAIL, AH			FEMTOSECOND MOLECULAR-DYNAMICS OF TAUTOMERIZATION IN MODEL BASE-PAIRS	NATURE			English	Article							DOUBLE-PROTON-TRANSFER; TEMPERATURE	Hydrogen bonds commonly lend robustness and directionality to molecular recognition processes and supramolecular structures(1,2). In particular, the two or three hydrogen bonds in Watson-Crick base pairs bind the double-stranded DNA helix and determine the complementarity of the pairing. Watson and Crick pointed out(3), however, that the possible tautomers of base pairs, in which hydrogen atoms become attached to the donor atom of the hydrogen bond, might disturb the genetic code, as the tautomer is capable of pairing with different partners. But the dynamics of hydrogen bonds in general, and of this tautomerization process in particular, are not well understood. Here we report observations of the femtosecond dynamics of tautomerization in model base pairs (7-azaindole dimers) containing two hydrogen bonds. Because of the femtosecond resolution of proton motions, we are able to examine the cooperativity of formation of the tautomer (in which the protons on each base are shifted sequentially to the other base), and to determine the characteristic timescales of the motions in a solvent-free environment. We find that the first step occurs on a timescale of a few hundred femtoseconds, whereas the second step, to form the full tautomer, is much slower, taking place within several picoseconds; the timescales are changed significantly by replacing hydrogen with deuterium. These results establish the molecular basis of the dynamics and the role of quantum tunnelling.			DOUHAL, A (corresponding author), CALTECH, ARTHUR AMOS NOYES LAB CHEM PHYS, PASADENA, CA 91125 USA.		Kim, Sang Kyu/C-1613-2011; Douhal, Abderrazzak/L-4940-2014	Douhal, Abderrazzak/0000-0003-2247-7566				Ball P., 1994, DESIGNING MOL WORLD; BENDERSKII VA, 1992, INT REV PHYS CHEM, V11, P1, DOI 10.1080/01442359209353265; CAIRNS J, 1963, J MOL BIOL, V6, P208, DOI 10.1016/S0022-2836(63)80070-4; FUKE K, 1989, J PHYS CHEM-US, V93, P614, DOI 10.1021/j100339a023; HEREK JL, 1992, J CHEM PHYS, V97, P9046, DOI 10.1063/1.463331; HETHERINGTON WM, 1979, CHEM PHYS LETT, V66, P230, DOI 10.1016/0009-2614(79)85004-6; INGHAM KC, 1974, J AM CHEM SOC, V96, P1674, DOI 10.1021/ja00813a006; KIM SK, 1995, J PHYS CHEM-US, V99, P7421, DOI 10.1021/j100019a027; LOWDIN PO, 1965, ADV QUANTUM CHEM, V2, P213, DOI DOI 10.1016/S0065-3276(08)60076-3; REIN R, 1965, J CHEM PHYS, V42, P2177, DOI 10.1063/1.1696263; SHARE P, 1991, J LUMIN, V48-9, P204, DOI 10.1016/0022-2313(91)90105-5; Stryer L., 1988, BIOCHEMISTRY-US; TAYLOR CA, 1969, P NATL ACAD SCI USA, V63, P253, DOI 10.1073/pnas.63.2.253; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; YU HT, 1992, J AM CHEM SOC, V114, P8449, DOI 10.1021/ja00048a015; Zewail A., 1992, CHEM BOND STRUCTURE; Zewail A. H., 1994, FEMTOCHEMISTRY ULTRA	17	425	427	2	98	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 16	1995	378	6554					260	263		10.1038/378260a0	http://dx.doi.org/10.1038/378260a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477342				2022-12-28	WOS:A1995TE85800042
J	TURNER, M; MEE, PJ; COSTELLO, PS; WILLIAMS, O; PRICE, AA; DUDDY, LP; FURLONG, MT; GEAHLEN, RL; TYBULEWICZ, VLJ				TURNER, M; MEE, PJ; COSTELLO, PS; WILLIAMS, O; PRICE, AA; DUDDY, LP; FURLONG, MT; GEAHLEN, RL; TYBULEWICZ, VLJ			PERINATAL LETHALITY AND BLOCKED B-CELL DEVELOPMENT IN MICE LACKING THE TYROSINE KINASE SYK	NATURE			English	Article							PRECURSORS; DISRUPTION; CULTURE; PROTEIN	The tyrosine kinase Syk (relative molecular mass 72,000), which is widely expressed in haematopoietic cells, becomes associated with and activated by engagement of the B-cell antigen receptor(1,2). Furthermore, it has been implicated in signalling through the receptors for interleukin-2 (IL-2)(3), granulocyte colony-stimulating factor (G-CSF)(4) and Fc(5), the T cell receptor, as well as through receptors for several platelet agonists(7). A homologous kinase, ZAP-70, is crucial in signalling through the T-cell receptor and in T-cell development(8,9). Using homologous recombination in embryonic stem cells, we created mice null for the syk gene which showed petechiae in utero and died shortly after birth. Irradiated mice reconstituted with Syk-deficient fetal liver showed a block in B-cell development at the pro-B to pre-B cell transition, consistent with a key role for Syk in pre-B-cell receptor signalling. Despite the production of small numbers of immature B cells, Syk-deficient radiation chimaeras failed to accumulate mature B cells, indicating a possible role for this protein in the production or maintenance of mature B cells. In addition, whereas the development of alpha beta T cells proceeded normally, Syk-deficient mice showed impaired development of thymocytes using the V gamma 3 variable region gene (V gamma 3(+) thymocytes). Finally, we show that Syk is not required for signalling through the IL-2 and G-CSF receptors.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND; PURDUE UNIV,DEPT MED CHEM & PHARMACOGNOSY,W LAFAYETTE,IN 47907	MRC National Institute for Medical Research; Purdue University System; Purdue University; Purdue University West Lafayette Campus			Williams, Owen/B-5003-2013; Turner, Martin/N-9976-2014	Williams, Owen/0000-0002-1760-6880; Turner, Martin/0000-0002-3801-9896; Tybulewicz, Victor/0000-0003-2439-0798; Geahlen, Robert/0000-0001-8400-2924				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; CHEN JZ, 1994, INT IMMUNOL, V6, P1265, DOI 10.1093/intimm/6.8.1265; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; GUIDOS CJ, 1995, J EXP MED, V181, P1187, DOI 10.1084/jem.181.3.1187; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARDY RR, 1991, P NATL ACAD SCI USA, V88, P11550, DOI 10.1073/pnas.88.24.11550; HAVRAN WL, 1990, NATURE, V344, P68, DOI 10.1038/344068a0; HERBERTSON B M, 1964, J Med Genet, V1, P10, DOI 10.1136/jmg.1.1.10; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KONG GH, 1995, IMMUNITY, V2, P485, DOI 10.1016/1074-7613(95)90029-2; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; MELCHERS F, 1995, CURR OPIN IMMUNOL, V7, P214, DOI 10.1016/0952-7915(95)80006-9; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; OGAWA M, 1988, EMBO J, V7, P1337, DOI 10.1002/j.1460-2075.1988.tb02949.x; PAIGE CJ, 1984, EUR J IMMUNOL, V14, P979, DOI 10.1002/eji.1830141104; RAMSDEN DA, 1994, J IMMUNOL, V153, P1150; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; ROLINK A, 1994, INT IMMUNOL, V6, P1257, DOI 10.1093/intimm/6.8.1257; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VONFREEDENJEFFR.U, 1995, J EXP MED, V181, P1518	30	629	656	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 16	1995	378	6554					298	302		10.1038/378298a0	http://dx.doi.org/10.1038/378298a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477352				2022-12-28	WOS:A1995TE85800054
J	CROFT, NM; MARSHALL, TG; FERGUSON, A				CROFT, NM; MARSHALL, TG; FERGUSON, A			GUT INFLAMMATION IN CHILDREN WITH CYSTIC-FIBROSIS ON HIGH-DOSE ENZYME SUPPLEMENTS	LANCET			English	Note							LAVAGE FLUID; DISEASE	We used a whole-gut perfusion technique to study subclinical gut inflammation in children with cystic fibrosis (18 elective tests, three lavages to treat distal intestinal obstruction syndrome); and in 12 control children with constipation or pre-colonoscopy. We assayed for haemoglobin, IgG, albumin, alpha-1-antitrypsin, granulocyte elastase, interleukin-1 beta (IL-1 beta) and IL-8 concentrations in whole-gut ravage fluid. Results for two children with distal intestinal obstruction syndrome, the only children in the series taking Nutrizym 22, were strikingly abnormal. This new test has revealed subclinical gut mucosal inflammation in a minority of CF children, for which distal intestinal obstruction syndrome, Nutrizym 22 treatment, or both, may be risk factors.	ROYAL HOSP SICK CHILDREN,EDINBURGH EH9 1LF,MIDLOTHIAN,SCOTLAND		CROFT, NM (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT MED,GASTROINTESTINAL UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BRYDON WG, 1993, EUR J GASTROEN HEPAT, V5, P269, DOI 10.1097/00042737-199304000-00013; BRYDON WG, 1992, LANCET, V340, P1381, DOI 10.1016/0140-6736(92)92562-T; FERGUSON A, 1994, SCAND J GASTROENTERO, V29, P15, DOI 10.3109/00365529409091390; FERGUSON A, IN PRESS ADV DRUG DE; HODGES M, 1994, J PEDIATR GASTR NUTR, V19, P65, DOI 10.1097/00005176-199407000-00010; OMAHONY S, 1991, GUT, V32, P29, DOI 10.1136/gut.32.1.29; SMYTH RL, 1995, LANCET, V346, P1247, DOI 10.1016/S0140-6736(95)91860-4; SMYTH RL, 1994, LANCET, V343, P85, DOI 10.1016/S0140-6736(94)90817-6	8	25	25	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1265	1267						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475719				2022-12-28	WOS:A1995TE14500012
J	MACCONNELL, TJ; FERRO, A				MACCONNELL, TJ; FERRO, A			A SORE EYE AND MENINGITIS	LANCET			English	Note							DISEASE; ADULTS		BRISTOL ROYAL INFIRM & GEN HOSP,DEPT CARDIOL,BRISTOL BS2 8HW,AVON,ENGLAND	Bristol Royal Infirmary								FARLEY MM, 1993, NEW ENGL J MED, V328, P1807, DOI 10.1056/NEJM199306243282503; Fry RM, 1938, LANCET, V1, P199; LESAR TS, 1985, DRUG INTEL CLIN PHAR, V19, P642, DOI 10.1177/106002808501900905; SCHWARTZ B, 1991, JAMA-J AM MED ASSOC, V266, P1112, DOI 10.1001/jama.266.8.1112; 1992, MMWR-MORBID MORTAL W, V41, P25	5	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1269	1269		10.1016/S0140-6736(95)91866-3	http://dx.doi.org/10.1016/S0140-6736(95)91866-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475721				2022-12-28	WOS:A1995TE14500014
J	HALL, TMT; PORTER, JA; BEACHY, PA; LEAHY, DJ				HALL, TMT; PORTER, JA; BEACHY, PA; LEAHY, DJ			A POTENTIAL CATALYTIC SITE REVEALED BY THE 1.7-ANGSTROM CRYSTAL-STRUCTURE OF THE AMINO-TERMINAL SIGNALING DOMAIN OF SONIC HEDGEHOG	NATURE			English	Article							ANOMALOUS DIFFRACTION; RESOLUTION	WITHIN the past few years, members of the hedgehog (hh) family of secreted signalling proteins have emerged as the primary signals generated by certain embryonic patterning centres. In vertebrate embryos, for example, sonic hedgehog expression in the notochord appears to be responsible for the local and long-range induction of ventral cell types within the neural tube and somites (reviewed in refs 1, 2). Protein products encoded by hh family members are synthesized as precursors that undergo autoprocessing to generate an amino-terminal domain that appears to be responsible for both local and long-range signalling activities, and a carboxy-terminal domain that contains the autoprocessing activity(3'4). As part of an effort to understand how hit family members participate in cell-to-cell signalling, we have determined and report here the crystal structure at 1.7 Angstrom of the amino-terminal domain of murine Sonic hedgehog (Shh-N)(5-9). The structure revealed a tetrahedrally coordinated zinc ion that appears to be structurally analogous to the zinc coordination sites of zinc hydrolases, such as thermolysin and carboxypeptidase A. This previously unsuspected catalytic site represents a distinct activity from the autoprocessing activity that resides in the carboxy-terminal domain.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University			Hall, Traci/F-5849-2019	Hall, Traci/0000-0001-6166-3009				Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHANG DT, 1994, DEVELOPMENT, V120, P3339; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; CONCORDET JP, 1995, NATURE, V375, P279, DOI 10.1038/375279a0; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EKKER SC, 1995, DEVELOPMENT, V121, P2337; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLMES MA, 1982, J MOL BIOL, V160, P623, DOI 10.1016/0022-2836(82)90319-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P1; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LEAHY DJ, 1994, PROTEINS, V19, P48, DOI 10.1002/prot.340190107; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; ORENGO CA, 1993, STRUCTURE, V1, P105, DOI 10.1016/0969-2126(93)90026-D; OTINOWSKI Z, 1993, P CCP4 STUDY WEEKEND, P56; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; ZECCA M, 1995, DEVELOPMENT, V121, P2265; 1979, SERC4 DAR LAB COLL C	30	163	174	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 9	1995	378	6553					212	216		10.1038/378212a0	http://dx.doi.org/10.1038/378212a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD759	7477329				2022-12-28	WOS:A1995TD75900062
J	RIDDLE, DR; LO, DC; KATZ, LC				RIDDLE, DR; LO, DC; KATZ, LC			NT-4-MEDIATED RESCUE OF LATERAL GENICULATE NEURONS FROM EFFECTS OF MONOCULAR DEPRIVATION	NATURE			English	Article							NERVE GROWTH-FACTOR; RAT VISUAL-CORTEX; FACTOR NGF; GENE-EXPRESSION; STRIATE CORTEX; MESSENGER-RNA; NUCLEUS; ORGANIZATION; MICROSPHERES; PLASTICITY	ALTERING the balance of activity between the two eyes during the critical period for visual-system development profoundly affects competitive interactions among neurons in the lateral geniculate nucleus and primary visual cortex(1-6). Neurons in the lateral geniculate nucleus that are deprived of activity by closing or silencing one eye atrophy as a result of competition with non-deprived neurons for some critical factor(s) presumed to be present in the cortex. Based on their actions in the developing visual system(7-12) neurotrophins are attractive candidates for such factors. We tested whether neurotrophins mediate intracortical competition of afferents from the lateral geniculate nucleus by using monocular deprivation and a new method for highly localized, in vivo delivery of neurotrophins. This method allowed unambiguous identification of neurons that were exposed to neurotrophin. Here we report that only one neurotrophin, the TrkB ligand NT-4, rescued neurons in the lateral geniculate nucleus from the dystrophic effects of monocular deprivation.			RIDDLE, DR (corresponding author), DUKE UNIV,MED CTR,DEPT NEUROBIOL,DURHAM,NC 27710, USA.							ANTONINI A, 1993, SCIENCE, V260, P1819, DOI 10.1126/science.8511592; BERARDI N, 1993, P ROY SOC B-BIOL SCI, V251, P17, DOI 10.1098/rspb.1993.0003; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; CALLAWAY EM, 1990, J NEUROSCI, V10, P1134; CARMIGNOTO G, 1993, J PHYSIOL-LONDON, V464, P343, DOI 10.1113/jphysiol.1993.sp019638; CONOVER JC, 1995, NATURE, V375, P235, DOI 10.1038/375235a0; DOMENICI L, 1994, VISUAL NEUROSCI, V11, P1093, DOI 10.1017/S095252380000691X; DOMENICI L, 1991, P NATL ACAD SCI USA, V88, P8811, DOI 10.1073/pnas.88.19.8811; DOMENICI L, 1993, P ROY SOC B-BIOL SCI, V251, P25, DOI 10.1098/rspb.1993.0004; GUILLERY RW, 1970, J COMP NEUROL, V139, P413, DOI 10.1002/cne.901390403; GUILLERY RW, 1973, J COMP NEUROL, V144, P117; HAYASHI M, 1990, NEUROSCIENCE, V36, P683, DOI 10.1016/0306-4522(90)90011-R; HOLTZMAN DM, 1995, J NEUROSCI, V15, P1567; HOLTZMAN DM, 1992, NEURON, V9, P465, DOI 10.1016/0896-6273(92)90184-F; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; KATZ LC, 1990, NEUROSCIENCE, V34, P511, DOI 10.1016/0306-4522(90)90159-2; KATZ LC, 1984, NATURE, V310, P498, DOI 10.1038/310498a0; LARGE TH, 1986, SCIENCE, V234, P352, DOI 10.1126/science.3764415; LAW MI, 1988, J COMP NEUROL, V278, P157, DOI 10.1002/cne.902780202; LIN CS, 1978, J COMP NEUROL, V181, P809, DOI 10.1002/cne.901810408; LIU X, 1995, NATURE, V375, P238, DOI 10.1038/375238a0; Lo D. C., 1995, Society for Neuroscience Abstracts, V21, P537; MAFFEI L, 1992, J NEUROSCI, V12, P4651; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; SHERMAN SM, 1982, PHYSIOL REV, V62, P738, DOI 10.1152/physrev.1982.62.2.738; TIMMUSK T, 1993, EUR J NEUROSCI, V5, P605, DOI 10.1111/j.1460-9568.1993.tb00526.x; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P978, DOI 10.1152/jn.1963.26.6.978; WIESEL TN, 1982, NATURE, V299, P583, DOI 10.1038/299583a0	29	191	193	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 9	1995	378	6553					189	191		10.1038/378189a0	http://dx.doi.org/10.1038/378189a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD759	7477322				2022-12-28	WOS:A1995TD75900055
J	SAKAI, H; MEDRANO, LJ; MEYEROWITZ, EM				SAKAI, H; MEDRANO, LJ; MEYEROWITZ, EM			ROLE OF SUPERMAN IN MAINTAINING ARABIDOPSIS FLORAL WHORL BOUNDARIES	NATURE			English	Article							TRANSCRIPTION FACTOR-IIIA; HOMEOTIC GENES; PROTEIN; THALIANA; PRODUCT; DOMAIN; PLANTS; PETALS	THE Arabidopsis gene SUPERMAN (SUP) is necessary for the proper spatial development of reproductive floral tissues(1-3) Recessive mutations cause extra stamens to form interior to the normal third whorl stamens, at the expense of fourth whorl carpel development(1-3). The mutant phenotype is associated with the ectopic expression of the B function genes, AP3 and PI, in the altered floral region, closer to the centre of the flower than in the wild type(3), and ap3 sup and pi sup double mutants exhibit a phenotype similar to ap3 and pi single mutants. These findings led to SUP being interpreted as an upstream negative regulator of the B function organ-identity genes, acting in the fourth whorl(2,3), to establish a boundary between stamen and carpel whorls. Here we show, using molecular cloning and analysis, that it is expressed in the third whorl and acts to maintain this boundary in developing flowers. The putative SUPERMAN protein contains one zinc-finger and a region resembling a basic leucine zipper motif, suggesting a function in transcriptional regulation.			SAKAI, H (corresponding author), CALTECH, DIV BIOL, 156-29, PASADENA, CA 91125 USA.		Meyerowitz, Elliot M/A-7118-2009					BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1992, DEVELOPMENT, V114, P599; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; GAISER JC, 1995, PLANT CELL, V7, P333, DOI 10.1105/tpc.7.3.333; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GOTO K, 1994, GENE DEV, V8, P1548, DOI 10.1101/gad.8.13.1548; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HO CY, 1994, EMBO J, V13, P1403, DOI 10.1002/j.1460-2075.1994.tb06394.x; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; JACK T, 1994, CELL, V76, P703, DOI 10.1016/0092-8674(94)90509-6; KRIZEK BA, IN PRESS DEVELOPMENT; MEYEROWITZ EM, 1991, DEVELOPMENT S1, V112, P157; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; RAIKHEL N, 1992, PLANT PHYSIOL, V100, P1627, DOI 10.1104/pp.100.4.1627; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; SCHULTZ EA, 1991, PLANT CELL, V3, P1221, DOI 10.1105/tpc.3.11.1221; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; TAGUE BW, 1995, PLANT MOL BIOL, V28, P267, DOI 10.1007/BF00020246; TAKATSUJI H, 1992, EMBO J, V11, P241, DOI 10.1002/j.1460-2075.1992.tb05047.x; TAKATSUJI H, 1994, PLANT CELL, V6, P947, DOI 10.1105/tpc.6.7.947; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WILSON AK, 1990, MOL GEN GENET, V222, P377, DOI 10.1007/BF00633843; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	29	335	376	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 9	1995	378	6553					199	203		10.1038/378199a0	http://dx.doi.org/10.1038/378199a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD759	7477325				2022-12-28	WOS:A1995TD75900058
J	THOMAS, PS; BELLAMY, M; GEDDES, D				THOMAS, PS; BELLAMY, M; GEDDES, D			MALABSORPTION OF VITAMIN-E IN CYSTIC-FIBROSIS IMPROVED AFTER URSODEOXYCHOLIC ACID	LANCET			English	Letter							E-DEFICIENCY		ROYAL BROMPTON HOSP, DEPT RESP MED, LONDON SW3 6LY, ENGLAND	Royal Brompton Hospital	THOMAS, PS (corresponding author), WOLLONGONG HOSP, INTENS CARE UNIT, WOLLONGONG, NSW 2500, AUSTRALIA.							KAYDEN HJ, 1993, J LIPID RES, V34, P343; SITRIN MD, 1987, ANN INTERN MED, V107, P51, DOI 10.7326/0003-4819-107-1-51; SOKOL RJ, 1983, GASTROENTEROLOGY, V85, P1172	3	16	16	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 4	1995	346	8984					1230	1231		10.1016/S0140-6736(95)92937-1	http://dx.doi.org/10.1016/S0140-6736(95)92937-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC976	7475686	Bronze			2022-12-28	WOS:A1995TC97600048
J	MAUNSELL, JHR				MAUNSELL, JHR			THE BRAINS VISUAL WORLD - REPRESENTATION OF VISUAL TARGETS IN CEREBRAL-CORTEX	SCIENCE			English	Article							PARIETAL ASSOCIATION CORTEX; INFERIOR TEMPORAL CORTEX; LATERAL INTRAPARIETAL AREA; SACCADE-RELATED ACTIVITY; SHORT-TERM-MEMORY; STATE DEPENDENT ACTIVITY; LIGHT-SENSITIVE NEURONS; MACAQUE MONKEY; BEHAVIORAL ENHANCEMENT; INFEROTEMPORAL CORTEX	Microelectrode recordings from behaving monkeys have shown that neuronal responses in the visual cerebral cortex can depend greatly on which aspect of the scene is the target of the animal's attention. Accumulating evidence suggests that while the early stages of the visual pathway provide a faithful representation of the retinal image, later stages of processing in the visual cortex hold representations that emphasize the viewer's current interest. By filtering out irrelevant signals and adding information about objects whose presence is remembered or inferred, the cortex creates an edited representation of the visual world that is dynamically modified to suit the immediate goals of the viewer.			MAUNSELL, JHR (corresponding author), BAYLOR COLL MED,DIV NEUROSCI,1 BAYLOR PLAZA S-603,HOUSTON,TX 77030, USA.		Maunsell, John/G-5702-2010	Maunsell, John/0000-0003-0018-4439	NEI NIH HHS [R01 EY005911, EY05911] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALLPORT A, 1993, ATTENTION PERFORM, V14, P183; ANDERSEN RA, 1987, EXP BRAIN RES, V67, P316; ANDERSEN RA, 1990, J NEUROSCI, V10, P1176; ANDERSEN RA, 1983, J NEUROSCI, V3, P532; ANDERSEN RA, 1987, HDB PHYSL 1, P483; ASSAD JA, 1995, NATURE, V373, P518, DOI 10.1038/373518a0; BARASH S, 1991, J NEUROPHYSIOL, V66, P1109, DOI 10.1152/jn.1991.66.3.1109; BARASH S, 1991, J NEUROPHYSIOL, V66, P1095, DOI 10.1152/jn.1991.66.3.1095; BAYLIS GC, 1987, EXP BRAIN RES, V65, P614; BROTCHIE PR, 1995, NATURE, V375, P232, DOI 10.1038/375232a0; BUSHNELL MC, 1981, J NEUROPHYSIOL, V46, P755, DOI 10.1152/jn.1981.46.4.755; CHELAZZI L, 1993, NATURE, V363, P345, DOI 10.1038/363345a0; COLBY CL, 1993, PROG BRAIN RES, V95, P307, DOI 10.1016/S0079-6123(08)60378-7; COLBY CL, 1991, J CHILD NEUROL, V6, pS90, DOI 10.1177/0883073891006001S11; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; DESIMONE R, 1991, J COGNITIVE NEUROSCI, V3, P1, DOI 10.1162/jocn.1991.3.1.1; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FUSTER JM, 1982, J NEUROSCI, V2, P361; FUSTER JM, 1981, SCIENCE, V212, P952, DOI 10.1126/science.7233192; FUSTER JM, 1990, J NEUROPHYSIOL, V64, P681, DOI 10.1152/jn.1990.64.3.681; GALLANT JL, 1995, INVEST OPHTH VIS SCI, V36, pS1052; Gibson J. R., 1994, Society for Neuroscience Abstracts, V20, P316; GNADT JW, 1988, EXP BRAIN RES, V70, P2160; GOODALE MA, 1994, CURR BIOL, V4, P604, DOI 10.1016/S0960-9822(00)00132-9; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; GROADBENT DE, 1958, PERCEPTION COMMUNICA; HAENNY PE, 1988, EXP BRAIN RES, V69, P225, DOI 10.1007/BF00247569; HAENNY PE, 1988, EXP BRAIN RES, V69, P245, DOI 10.1007/BF00247570; KAWANO K, 1984, J NEUROPHYSIOL, V51, P340, DOI 10.1152/jn.1984.51.2.340; KAWANO K, 1980, NEUROSCI LETT, V17, P55, DOI 10.1016/0304-3940(80)90061-0; KINCHLA RA, 1992, ANNU REV PSYCHOL, V43, P711, DOI 10.1146/annurev.ps.43.020192.003431; KOBATAKE E, 1994, J NEUROPHYSIOL, V71, P856, DOI 10.1152/jn.1994.71.3.856; LYNCH JC, 1977, J NEUROPHYSIOL, V40, P362, DOI 10.1152/jn.1977.40.2.362; MAUNSELL JHR, 1991, VISUAL NEUROSCI, V7, P561, DOI 10.1017/S095252380001035X; MAUNSELL JHR, 1983, J NEUROSCI, V3, P2563; MCADAMS CJ, UNPUB; MERIGAN WH, 1993, ANNU REV NEUROSCI, V16, P369, DOI 10.1146/annurev.ne.16.030193.002101; MIKAMI A, 1980, BRAIN RES, V182, P65, DOI 10.1016/0006-8993(80)90830-6; MILLER EK, 1993, J NEUROSCI, V13, P1460; MILLER EK, 1991, SCIENCE, V254, P1377, DOI 10.1126/science.1962197; MIYASHITA Y, 1988, NATURE, V331, P68, DOI 10.1038/331068a0; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MOTTER BC, 1994, J NEUROSCI, V14, P2178; MOTTER BC, 1994, J NEUROSCI, V14, P2190; MOUNTCASTLE VB, 1981, J NEUROSCI, V1, P1218; MOUNTCASTLE VB, 1987, J NEUROSCI, V7, P2239; MOUNTCASTLE VB, 1975, J NEUROPHYSIOL, V38, P871, DOI 10.1152/jn.1975.38.4.871; OCRAVEN KM, 1994, TRENDS NEUROSCI, V17, P281; OPTICAN LM, 1987, J NEUROPHYSIOL, V57, P162, DOI 10.1152/jn.1987.57.1.162; QUINTANA J, 1992, NEUROREPORT, V3, P721, DOI 10.1097/00001756-199208000-00018; RICHMOND BJ, 1987, J NEUROPHYSIOL, V58, P1292, DOI 10.1152/jn.1987.58.6.1292; ROBINSON DL, 1978, J NEUROPHYSIOL, V41, P910, DOI 10.1152/jn.1978.41.4.910; ROBINSON DL, 1980, INVEST OPHTH VIS SCI, V19, P1120; ROCKLAND KS, 1981, BRAIN RES, V212, P249, DOI 10.1016/0006-8993(81)90461-3; SAKATA H, 1980, J NEUROPHYSIOL, V43, P1654, DOI 10.1152/jn.1980.43.6.1654; SAKATA H, 1985, VISION RES, V25, P453, DOI 10.1016/0042-6989(85)90070-7; SCHILLER PH, 1990, TRENDS NEUROSCI, V13, P392, DOI 10.1016/0166-2236(90)90117-S; SERENO AB, 1995, INVEST OPHTH VISUAL, V36, P692; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; SPITZER H, 1988, SCIENCE, V240, P338, DOI 10.1126/science.3353728; SPITZER H, 1991, EXP BRAIN RES, V83, P340; TANAKA K, 1991, J NEUROPHYSIOL, V66, P170, DOI 10.1152/jn.1991.66.1.170; TREUE S, 1995, INVEST OPHTH VIS SCI, V36, pS1052; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549; Ungerleider Leslie G., 1994, Current Opinion in Neurobiology, V4, P157, DOI 10.1016/0959-4388(94)90066-3; VANESSEN DC, 1994, NEURON, V13, P1, DOI 10.1016/0896-6273(94)90455-3; VERGHESE P, 1992, VISION RES, V32, P983, DOI 10.1016/0042-6989(92)90040-P; WURTZ RH, 1969, J NEUROPHYSIOL, V32, P727, DOI 10.1152/jn.1969.32.5.727; WURTZ RH, 1976, J NEUROPHYSIOL, V39, P766, DOI 10.1152/jn.1976.39.4.766; WURTZ RH, 1982, DYNAMICAL ASPECTS NE, P195	71	223	225	1	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 3	1995	270	5237					764	769		10.1126/science.270.5237.764	http://dx.doi.org/10.1126/science.270.5237.764			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC712	7481763				2022-12-28	WOS:A1995TC71200030
J	HE, GP; MUISE, A; LI, AW; RO, HS				HE, GP; MUISE, A; LI, AW; RO, HS			A EUKARYOTIC TRANSCRIPTIONAL REPRESSOR WITH CARBOXYPEPTIDASE ACTIVITY	NATURE			English	Article							ENHANCER BINDING-PROTEIN; GENE-EXPRESSION; MOLECULAR-CLONING; FACTOR-VIII; ADIPOCYTE DIFFERENTIATION; GLUCOCORTICOID RECEPTOR; MESSENGER-RNA; CDNA CLONING; C-JUN; DNA	ADIPOCYTE differentiation involves the transcriptional activation of several genes in triglyceride metabolism, including the adipose P2 (aP2 or 422) gene that encodes the adipocyte lipid-binding protein ALBP(1-3). Within the mouse aP2 promoter region, the AE1 sequence functions as either a positive or a negative element in the regulation of aP2 gene expression(4-8). The AE-1 sequence is the binding site for the positive murine (3T3) adipocyte factor C/EBP-alpha(5,6), several human preadipocyte factors(7), and a 3T3 preadipocyte factor(s) that has been implicated as a repressor of aP2 gene expression(4,5,7,8). Here we report the cloning of new complementary DNAs that encode the 3T3 preadipocyte factor (termed AEBP1), and demonstrate that AEBP1 expression is abolished during adipocyte differentiation. Furthermore, we show that an activity of a carboxypeptidase associated with AEBP1 is important in the transcriptional repression function of AEBP1. Thus AEBP1 might represent a new type of transcription factor that regulates transcription by cleavage of factors involved in transcription.	DALHOUSIE UNIV,FAC MED,DEPT BIOCHEM,HALIFAX,NS B3H 4H7,CANADA	Dalhousie University				Ro, Hyo-Sung/0000-0003-4411-0386				AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; CHAPMAN AB, 1984, J BIOL CHEM, V259, P5548; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FOLK JE, 1960, J BIOL CHEM, V235, P2272; GEBHARD W, 1989, EUR J BIOCHEM, V178, P603, DOI 10.1111/j.1432-1033.1989.tb14488.x; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MANSER E, 1990, BIOCHEM J, V267, P517, DOI 10.1042/bj2670517; POOLE S, 1981, J MOL BIOL, V153, P273, DOI 10.1016/0022-2836(81)90278-3; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; RO HS, 1991, MOL CELL BIOL, V11, P2303, DOI 10.1128/MCB.11.4.2303; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TAN FL, 1989, J BIOL CHEM, V264, P13165; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; XU L, 1994, NUCLEIC ACIDS RES, V22, P646, DOI 10.1093/nar/22.4.646; YANG VW, 1989, P NATL ACAD SCI USA, V86, P3629, DOI 10.1073/pnas.86.10.3629; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	29	130	141	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 2	1995	378	6552					92	96		10.1038/378092a0	http://dx.doi.org/10.1038/378092a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477299				2022-12-28	WOS:A1995TC46900058
J	ROOT, RA				ROOT, RA			PRIMARY HEALTH-CARE AT THE VILLAGE LEVEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1988	260	13					1963	1964						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q2703	3418861				2022-12-28	WOS:A1988Q270300041
J	PRIMAKOFF, P; LATHROP, W; WOOLMAN, L; COWAN, A; MYLES, D				PRIMAKOFF, P; LATHROP, W; WOOLMAN, L; COWAN, A; MYLES, D			FULLY EFFECTIVE CONTRACEPTION IN MALE AND FEMALE GUINEA-PIGS IMMUNIZED WITH THE SPERM PROTEIN PH-20	NATURE			English	Article											PRIMAKOFF, P (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT PHYSIOL,FARMINGTON,CT 06032, USA.							ADA GL, 1985, NATURE, V317, P288, DOI 10.1038/317288b0; ANDERSON DJ, 1983, FERTIL STERIL, V40, P557; BRONSON R, 1984, FERTIL STERIL, V42, P171; CHEN C, 1986, ARCH ANDROLOGY, V16, P183, DOI 10.3109/01485018608986940; COWAN AE, 1986, J CELL BIOL, V103, P1289, DOI 10.1083/jcb.103.4.1289; CROSS NL, 1988, BIOL REPROD, V38, P235, DOI 10.1095/biolreprod38.1.235; GOLDBERG E, 1973, SCIENCE, V181, P458, DOI 10.1126/science.181.4098.458; GOLDBERG E, 1981, FERTIL STERIL, V35, P214; Goldberg E, 1983, Res Front Fertil Regul, V2, P1; HAAS GG, 1986, FERTIL STERIL, V46, P753; HALENDA RM, 1987, BIOL REPROD, V36, P491, DOI 10.1095/biolreprod36.2.491; JONES WR, 1982, IMMUNOLOGICAL FERTIL; KUMMERFELD HL, 1976, BIOL REPROD, V14, P300, DOI 10.1095/biolreprod14.3.300; LERUM JE, 1974, BIOL REPROD, V11, P108, DOI 10.1095/biolreprod11.1.108; MENGE AC, 1979, BIOL REPROD, V20, P931, DOI 10.1095/biolreprod20.4.931; MORALES P, 1988, J ANDROL, V9, P24; MORTON DB, 1979, J REPROD IMMUNOL, V1, P61, DOI 10.1016/0165-0378(79)90030-5; MUNOZ MG, 1978, BIOL REPROD, V18, P669, DOI 10.1095/biolreprod18.4.669; MYLES DG, 1984, J CELL BIOL, V99, P1634, DOI 10.1083/jcb.99.5.1634; MYLES DG, 1987, DEV BIOL, V121, P559, DOI 10.1016/0012-1606(87)90191-6; PRIMAKOFF P, 1985, J CELL BIOL, V101, P2239, DOI 10.1083/jcb.101.6.2239; PRIMAKOFF P, 1988, BIOL REPROD, V38, P921, DOI 10.1095/biolreprod38.4.921; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; SINGER SL, 1985, GAMETE RES, V12, P29, DOI 10.1002/mrd.1120120104; SYNER FN, 1979, FERTIL STERIL, V32, P468; TUNG KSK, 1979, J REPROD IMMUNOL, V1, P145, DOI 10.1016/0165-0378(79)90015-9; TUNG KSK, 1986, REPRODUCTIVE IMMUNOL, P143	27	244	259	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1988	335	6190					543	546		10.1038/335543a0	http://dx.doi.org/10.1038/335543a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q3412	3419530				2022-12-28	WOS:A1988Q341200054
J	TOWNSEND, RR; HARDY, M; OLECHNO, JD; CARTER, SR				TOWNSEND, RR; HARDY, M; OLECHNO, JD; CARTER, SR			CHROMATOGRAPHY OF CARBOHYDRATES	NATURE			English	Review									JOHNS HOPKINS UNIV,MCCOLLUM PRATT INST,BALTIMORE,MD 21218; DIONEX CORP,501 MERCURY DR,SUNNYVALE,CA 94088	Johns Hopkins University; Thermo Fisher Scientific; Dionex Corporation	TOWNSEND, RR (corresponding author), JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218, USA.							BLANKEN WM, 1985, ANAL BIOCHEM, V145, P322, DOI 10.1016/0003-2697(85)90369-0; HARDY MR, 1988, P NATL ACAD SCI USA, V85, P3289, DOI 10.1073/pnas.85.10.3289; HUGHES S, 1981, ANAL CHIM ACTA, V132, P11, DOI 10.1016/S0003-2670(01)93872-3; NEUBERGER A, 1971, CARBOHYD RES, V17, P89, DOI 10.1016/S0008-6215(00)81545-1; RENDLEMAN JA, 1971, ADV CHEM SER, V117, P51; TAKASAKI S, 1982, METHOD ENZYMOL, V83, P263; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1; TOWNSEND RR, UNPUB; TOWNSEND RR, IN PRESS ANAL BIOCH; WANG WT, 1984, ANAL BIOCHEM, V141, P366, DOI 10.1016/0003-2697(84)90057-5	10	24	24	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 22	1988	335	6188					379	380		10.1038/335379a0	http://dx.doi.org/10.1038/335379a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q1373	3419506				2022-12-28	WOS:A1988Q137300068
J	CHAMEIDES, WL; LINDSAY, RW; RICHARDSON, J; KIANG, CS				CHAMEIDES, WL; LINDSAY, RW; RICHARDSON, J; KIANG, CS			THE ROLE OF BIOGENIC HYDROCARBONS IN URBAN PHOTOCHEMICAL SMOG - ATLANTA AS A CASE-STUDY	SCIENCE			English	Article											CHAMEIDES, WL (corresponding author), GEORGIA INST TECHNOL,SCH GEOPHYS SCI,ATLANTA,GA 30332, USA.							ALTSHULLER AP, 1983, ATMOS ENVIRON, V17, P2131, DOI 10.1016/0004-6981(83)90211-1; ARNTS RR, 1981, ATMOSPHERIC BIOGENIC, V2, P117; COLLUM R, COMMUNICATION; FRIEDMAN RM, 1988, URBAN OZONE CLEAN AI, P1; HAAGENSMIT AJ, 1952, IND ENG CHEM, V44, P1362; LAMB B, 1987, ATMOS ENVIRON, V21, P1695, DOI 10.1016/0004-6981(87)90108-9; LINDSAY RM, UNPUB; LURMANN FW, 1984, ATMOS ENVIRON, V18, P1133, DOI 10.1016/0004-6981(84)90145-8; LURMANN FW, 1986, J GEOPHYS RES-ATMOS, V91, P905, DOI 10.1029/JD091iD10p10905; RASMUSSEN RA, 1972, JAPCA J AIR WASTE MA, V22, P537, DOI 10.1080/00022470.1972.10469676; RICHARDSON JL, 1988, THESIS GEORGIA I TEC; SCHERE KL, 1988, ENVIRON SCI TECHNOL, V22, P488, DOI 10.1021/es00170a002; SEINFELD JH, 1988, JAPCA J AIR WASTE MA, V38, P616, DOI 10.1080/08940630.1988.10466404; TRAINER M, 1987, NATURE, V329, P705, DOI 10.1038/329705a0; WALKER HM, 1985, JAPCA J AIR WASTE MA, V35, P903, DOI 10.1080/00022470.1985.10465969; WENT FW, 1960, P NATL ACAD SCI USA, V46, P212, DOI 10.1073/pnas.46.2.212; WESTBERG H, 1985, EPA600S385013 REP, P1; WHITTEN GZ, 1980, ENVIRON SCI TECHNOL, V14, P690, DOI 10.1021/es60166a008; Zimmerman P. R, 1979, EPA450479004, P1; ZIMMERMAN PR, 1980, P SPECIALTY C OZONE, P299; 1987, GUIDELINE USE CITY S, P1	21	784	804	6	236	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 16	1988	241	4872					1473	1475		10.1126/science.3420404	http://dx.doi.org/10.1126/science.3420404			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q0479	3420404				2022-12-28	WOS:A1988Q047900031
J	SCHELLENBERG, GD; BIRD, TD; WIJSMAN, EM; MOORE, DK; BOEHNKE, M; BRYANT, EM; LAMPE, TH; NOCHLIN, D; SUMI, SM; DEEB, SS; BEYREUTHER, K; MARTIN, GM				SCHELLENBERG, GD; BIRD, TD; WIJSMAN, EM; MOORE, DK; BOEHNKE, M; BRYANT, EM; LAMPE, TH; NOCHLIN, D; SUMI, SM; DEEB, SS; BEYREUTHER, K; MARTIN, GM			ABSENCE OF LINKAGE OF CHROMOSOME 21Q21 MARKERS TO FAMILIAL ALZHEIMERS-DISEASE	SCIENCE			English	Article									VET ADM MED CTR,DIV NEUROL,SEATTLE,WA 98108; UNIV WASHINGTON,CTR INHERITED DIS,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195; UNIV MICHIGAN,DEPT BIOSTAT,ANN ARBOR,MI 48109; AMER LAKE VET ADM MED CTR,CTR GERIATR RES EDUC & CLIN,TACOMA,WA 98493; UNIV HEIDELBERG,CTR MOLEC BIOL,D-6900 HEIDELBERG,FED REP GER	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Michigan System; University of Michigan; Geriatric Research Education & Clinical Center; Ruprecht Karls University Heidelberg	SCHELLENBERG, GD (corresponding author), UNIV WASHINGTON,DIV NEUROL RG-27,SEATTLE,WA 98195, USA.				NIA NIH HHS [AG 00057, AG 05136] Funding Source: Medline; NIGMS NIH HHS [GM 15253] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015253] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005136] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BIRD TD, 1988, ANN NEUROL, V23, P25, DOI 10.1002/ana.410230106; BIRD TD, IN PRESS ANN NEUROL; BREITNER JCS, 1986, J PSYCHIAT RES, V20, P31, DOI 10.1016/0022-3956(86)90021-X; BREITNER JCS, 1986, J PSYCHIAT RES, V20, P45, DOI 10.1016/0022-3956(86)90022-1; CAVALLISFORZA LL, 1986, AM J HUM GENET, V38, P599; COOK RH, 1981, ARCH NEUROL-CHICAGO, V38, P300, DOI 10.1001/archneur.1981.00510050066011; COOK RH, 1979, NEUROLOGY, V29, P1402, DOI 10.1212/WNL.29.10.1402; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GOODFELLOW PJ, 1986, NUCLEIC ACIDS RES, V14, P4375, DOI 10.1093/nar/14.10.4375; HESTON LL, 1981, ARCH GEN PSYCHIAT, V38, P1085; HESTON LL, 1966, ARCH NEUROL-CHICAGO, V15, P225, DOI 10.1001/archneur.1966.00470150003001; HEYMAN A, 1983, ANN NEUROL, V14, P507, DOI 10.1002/ana.410140503; HEYMAN A, 1988, Neurology, V38, P231; Hodge SE, 1979, AM J HUM GENET, V31, P761; HUNTER R, 1972, J NEUROL NEUROSUR PS, V35, P707, DOI 10.1136/jnnp.35.5.707; KALLMAN FJ, 1956, MENTAL DISORDERS LAT; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; KITTUR SD, 1985, EMBO J, V4, P2257, DOI 10.1002/j.1460-2075.1985.tb03923.x; KORENBERG J R, 1988, Neurology, V38, P265; LARRSON T, 1963, ACTA PSYCHIATR  S167, V39, P1; Maniatis T., 1982, MOL CLONING; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MOHS RC, 1987, ARCH GEN PSYCHIAT, V44, P405; MORTON NE, 1956, AM J HUM GENET, V8, P80; NOCHLIN D, 1988, Neurology, V38, P266; OLIVER C, 1986, PSYCHOL MED, V16, P307, DOI 10.1017/S0033291700009120; OTT J, 1974, AM J HUM GENET, V26, P588; OTT J, 1985, ANAL HUMAN GENETIC L, P109; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; ROBAKIS NK, 1987, LANCET, V1, P384; ROSES A D, 1988, Neurology, V38, P173; RUDD NL, 1988, HUM GENET, V78, P175, DOI 10.1007/BF00278191; SCHELLENBERG GD, 1987, J NEUROGENET, V4, P97, DOI 10.3109/01677068709102337; SHARMAN MG, 1979, PSYCHOL MED, V9, P771, DOI 10.1017/S0033291700034103; STEWART GD, 1985, NUCLEIC ACIDS RES, V13, P4125, DOI 10.1093/nar/13.11.4125; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; SULKAVA R, 1983, J NEUROL NEUROSUR PS, V46, P9, DOI 10.1136/jnnp.46.1.9; TANZI R, 1985, CYTOGENET CELL GENET, V40, P760; TANZI RE, 1987, NATURE, V329, P156, DOI 10.1038/329156a0; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; VAN BROECKHOVEN C, 1987, NATURE, V329, P153; WATKINS PC, 1985, NUCLEIC ACIDS RES, V13, P6075, DOI 10.1093/nar/13.17.6075; WHALLEY LJ, 1982, BRIT J PSYCHIAT, V140, P249, DOI 10.1192/bjp.140.3.249; WIJSMAN EM, 1987, AM J HUM GENET, V41, P356; WILLARD HF, 1985, CYTOGENET CELL GENET, V40, P360, DOI 10.1159/000132180	49	226	239	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 16	1988	241	4872					1507	1510		10.1126/science.3420406	http://dx.doi.org/10.1126/science.3420406			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q0479	3420406				2022-12-28	WOS:A1988Q047900042
J	MAYS, N; CHALLAH, S; PATEL, S; PALFREY, E; CREESER, R; VADERA, P; BURNEY, P				MAYS, N; CHALLAH, S; PATEL, S; PALFREY, E; CREESER, R; VADERA, P; BURNEY, P			CLINICAL COMPARISON OF EXTRACORPOREAL SHOCK-WAVE LITHOTRIPSY AND PERCUTANEOUS NEPHROLITHOTOMY IN TREATING RENAL CALCULI	BRITISH MEDICAL JOURNAL			English	Article									ST THOMAS HOSP,DEPT UROL,LONDON SE1 7EH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust	MAYS, N (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT COMMUNITY MED,ST THOMAS CAMPUS,LONDON SE1 7EH,ENGLAND.			Burney, Peter/0000-0001-8635-5678				BAUMGARTNER BR, 1987, RADIOLOGY, V163, P531, DOI 10.1148/radiology.163.2.3562837; Blume E, 1983, JAMA, V249, P2434; CHALLAH S, 1986, BRIT MED J, V292, P877, DOI 10.1136/bmj.292.6524.877; CHARIG CR, 1986, BRIT MED J, V292, P879, DOI 10.1136/bmj.292.6524.879; CHAUSSY C, 1984, UROLOGY, V23, P59, DOI 10.1016/0090-4295(84)90243-7; CHAUSSY C, 1984, UROL RADIOL, V6, P80, DOI 10.1007/BF02923707; CHAUSSY C, 1983, UROL CLIN N AM, V10, P743; DAS G, 1987, BRIT MED J, V295, P891, DOI 10.1136/bmj.295.6603.891; FUCHS G, 1984, KLINISCHE EXPT UROLO, V8, P153; KAUDE JV, 1985, AM J ROENTGENOL, V145, P305, DOI 10.2214/ajr.145.2.305; LEE WJ, 1986, UROL RADIOL, V8, P61, DOI 10.1007/BF02924078; LINGEMAN JE, 1986, J UROLOGY, V135, P1134, DOI 10.1016/S0022-5347(17)46016-2; MILLER K, 1984, EUR UROL, V10, P217; Newman R C, 1986, Semin Urol, V4, P170; PALFREY ELH, 1986, BRIT J UROL, V58, P573, DOI 10.1111/j.1464-410X.1986.tb05887.x; RIEHLE RA, 1986, JAMA-J AM MED ASSOC, V255, P2043, DOI 10.1001/jama.255.15.2043; SLEIGHT MW, 1977, BRIT J UROL, V49, P601, DOI 10.1111/j.1464-410X.1977.tb04538.x; WICKHAM J, 1985, BRIT MED J, V290, P188; 1987, HLTH B EDINB, V45, P2	19	36	36	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1988	297	6643					253	258		10.1136/bmj.297.6643.253	http://dx.doi.org/10.1136/bmj.297.6643.253			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P4266	3416143	Green Published, Bronze			2022-12-28	WOS:A1988P426600017
J	GOLD, MR; HURLEY, R; LAKE, T; ENSOR, T; BERENSON, R				GOLD, MR; HURLEY, R; LAKE, T; ENSOR, T; BERENSON, R			A NATIONAL SURVEY OF THE ARRANGEMENTS MANAGED-CARE PLANS MAKE WITH PHYSICIANS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INCENTIVES	Background. Despite the growth of managed care in the United States, there is little information about the arrangements managed-care plans make with physicians. Methods. In 1994 we surveyed by telephone 138 managed-care plans that were selected from 20 metropolitan areas nationwide, Of the 108 plans that responded, 29 were group-model or staff-model health maintenance organizations (HMOs), 50 were network or independent-practice-association (IPA) HMOs, and 29 were preferred-provider organizations (PPOs). Results. Respondents from all three types of plan said they emphasized careful selection of physicians, although the group or staff HMOs tended to have more demanding requirements, such as board certification or eligibility. Sixty-one percent of the plans responded that physicians' previous patterns of costs or utilization of resources had little influence on their selection; 26 percent said these factors had a moderate influence; and 13 percent said they had a large influence. Some risk sharing with physicians was typical in the HMOs but rare in the PPOs. Fifty-six percent of the network or IPA HMOs used capitation as the predominant method of paying primary care physicians, as compared with 34 percent of the group or staff HMOs and 7 percent of the PPOs. More than half the HMOs reported adjusting payments according to utilization or cost patterns, patient complaints, and measures of the quality of care. Ninety-two percent of the network or IPA HMOs and 61 percent of the group or staff HMOs required their patients to select a primary care physician, who was responsible for most referrals to specialists. About three quarters of the HMOs and 31 percent of the PPOs reported using studies of the outcomes of medical care as part of their quality-improvement programs. Conclusions. Managed-care plans, particularly HMOs, have complex systems for selecting, paying, and monitoring their physicians, Hybrid forms are common, and the differences between group or staff HMOs and network or IPA HMOs are less extensive than is commonly assumed.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT HLTH ADM,RICHMOND,VA 23298; GEORGETOWN UNIV,ROBERT WOOD JOHNSON FDN IMPACS PROGRAM CHPS,WASHINGTON,DC; NATL CAPITAL PREFERRED PROVIDER ORG,WASHINGTON,DC	Virginia Commonwealth University; Georgetown University; Robert Wood Johnson Foundation (RWJF)	GOLD, MR (corresponding author), MATH POLICY RES,SUITE 550,600 MARYLAND AVE SW,WASHINGTON,DC 20024, USA.		Ensor, Tim/ABD-5899-2020	Ensor, Tim/0000-0003-0279-9576				BERENSON RA, 1991, HEALTH AFFAIR, V10, P106, DOI 10.1377/hlthaff.10.4.106; BLALOCK HM, 1979, SOCIAL STATISTICS; Freeborn DK, 1994, PROMISE PERFORMANCE; GABEL J, 1994, HEALTH AFFAIR, V13, P327, DOI 10.1377/hlthaff.13.1.327; GOLD M, 1995, SELECTED EXTERNAL RE, V3; GOLD ML, 1995, MED CARE RES REV S, V2, P307; HILLMAN AL, 1987, NEW ENGL J MED, V317, P1743, DOI 10.1056/NEJM198712313172725; HILLMAN AL, 1991, HEALTH AFFAIR, V10, P138, DOI 10.1377/hlthaff.10.4.138; LUFT HS, 1981, HLTH MAINTENANCE ORG; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; WEINER JP, 1993, J HEALTH POLIT POLIC, V18, P75, DOI 10.1215/03616878-18-1-75; 1994, NATIONAL DIRECTORY H; 1994, EFFECTS MANAGED CARE; 1995, EFFECTS MANAGED CARE; 1995, REPORT CARD PILOT PR; 1993, STANDARDS ACCREDITAT; 1995, ANN REPORT C	17	267	269	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 21	1995	333	25					1678	1683		10.1056/NEJM199512213332505	http://dx.doi.org/10.1056/NEJM199512213332505			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TL401	7477221	Green Published			2022-12-28	WOS:A1995TL40100005
J	WEN, SW; HERNANDEZ, R; NAYLOR, CD				WEN, SW; HERNANDEZ, R; NAYLOR, CD			PITFALLS IN NONRANDOMIZED OUTCOMES STUDIES - THE CASE OF INCIDENTAL APPENDECTOMY WITH OPEN CHOLECYSTECTOMY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORTALITY; PROSTATECTOMY; COMORBIDITY; DATABASES; RESECTION; MORBIDITY	Objectives.-To assess the short-term outcomes of incidental appendectomy through analysis of hospital administrative data and determine the consistency and plausibility of the observed results. Design.-Population-based historical cohort study. Setting.-All general hospitals in Ontario between 1981 and 1990. Patients.-Patients undergoing open primary cholecystectomy with (7846 exposed) and without (191 599 unexposed) incidental appendectomy. Main Outcome Measures.-In-hospital fatality rates, complication rates, and lengths of hospital stay. Results.-Crude comparisons showed a striking and paradoxical reduction in mortality after cholecystectomy when incidental appendectomy was performed (odds ratio [OR], 0.37; 95% confidence interval [CI], 0.23 to 0.57; P<.001); mean length of stay was also lower by -0.46 day (P<.001). After adjustment for confounding differences, such as comorbidity and nonelective surgery, mortality and lengths of stay were similar for exposed and unexposed patients; but exposed patients showed a significant increase in nonfatal complications (OR, 1.53; 95% CI, 1.39 to 1.68; P<.001). Adverse effects from incidental appendectomy emerged consistently for all three outcomes only after restricting the analysis to subgroups of patients at low surgical risk. The increased mortality for exposed patients was largest among low-risk groups; for example, among those younger than 70 years undergoing elective surgery, the OR was 2.65 (95% CI, 1.25 to 5.64; P<.001). Conclusion.-These findings suggest that incidental appendectomy is associated with a small but definite increase in adverse postoperative outcomes. However, plausible and consistent findings were only obtained after restricting the analysis to low-risk subgroups in which unmeasured differences in patients' baseline characteristics were less likely to confound adjusted outcome comparisons. This exercise highlights the potential pitfalls in nonrandomized outcomes comparisons using data sources with limited clinical detail, such as hospital discharge abstracts,	SUNNYBROOK HLTH SCI CTR,CLIN EPIDEMIOL UNIT,N YORK,ON M4N 3M5,CANADA; INST CLIN EVALUAT SCI,TORONTO,ON,CANADA; UNIV TORONTO,DEPT PREVENT MED & BIOSTAT,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,DEPT MED & SURG,TORONTO,ON M5S 1A1,CANADA	University of Toronto; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto								ADDISS DG, 1990, AM J EPIDEMIOL, V132, P910, DOI 10.1093/oxfordjournals.aje.a115734; ANDERSEN TF, 1990, MED CARE, V28, P870, DOI 10.1097/00005650-199010000-00002; BOGART J N, 1969, American Surgeon, V35, P650; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CONCATO J, 1992, JAMA-J AM MED ASSOC, V267, P1077, DOI 10.1001/jama.267.8.1077; DALEY J, 1994, RISK ADJUSTMENT MEAS, P199; DANS PE, 1993, ANN INTERN MED, V119, P855, DOI 10.7326/0003-4819-119-8-199310150-00014; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; DONALDSON DR, 1989, BRIT J CLIN PRACT, V43, P15; ELSEFI TAM, 1989, INT SURG, V74, P32; GREEN J, 1993, MED CARE, V31, P719, DOI 10.1097/00005650-199308000-00005; GREENFIELD S, 1989, NEW ENGL J MED, V320, P1142, DOI 10.1056/NEJM198904273201710; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; LOWERY CH, 1962, ARCH SURG-CHICAGO, V85, P476; MALENKA DJ, 1990, J UROLOGY, V144, P224, DOI 10.1016/S0022-5347(17)39416-8; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; PASS HI, 1988, HARDYS TXB SURG, P574; POLLOCK AV, 1977, BRIT MED J, V1, P20, DOI 10.1136/bmj.1.6052.20; RILEY G, 1993, MED CARE, V31, P921, DOI 10.1097/00005650-199310000-00005; ROOS NP, 1989, NEW ENGL J MED, V320, P1120, DOI 10.1056/NEJM198904273201705; ROOS NP, 1992, JAMA-J AM MED ASSOC, V268, P1269, DOI 10.1001/jama.1992.03490100063027; SHUMAKE L B, 1971, American Surgeon, V37, P310; STROM PR, 1983, AM J SURG, V145, P819, DOI 10.1016/0002-9610(83)90150-2; SUGIMOTO T, 1987, AM J PUBLIC HEALTH, V77, P471, DOI 10.2105/AJPH.77.4.471; TUNGPHAISAL S, 1989, Journal of the Medical Association of Thailand, V72, P633; WATERS EG, 1977, OBSTET GYNECOL, V50, P511; WEN SW, 1994, PATTERNS HLTH CARE O, V95, P98; WENNBERG JE, 1994, SCIENCE, V264, P758, DOI 10.1126/science.7513442; WILSON EA, 1973, AM J OBSTET GYNECOL, V116, P76, DOI 10.1016/0002-9378(73)90887-9; 1990, INT CLASSIFICATION D, V1; 1991, CANADIAN HOSPITAL DI; 1986, CANADIAN CLASSIFICAT	32	51	52	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	1995	274	21					1687	1691		10.1001/jama.274.21.1687	http://dx.doi.org/10.1001/jama.274.21.1687			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH151	7474273				2022-12-28	WOS:A1995TH15100025
J	FREDMAN, CS; BIERMANN, KM; PATEL, V; UPPSTROM, EL; AUER, AI				FREDMAN, CS; BIERMANN, KM; PATEL, V; UPPSTROM, EL; AUER, AI			TRANSCRANIAL DOPPLER ULTRASONOGRAPHY DURING HEAD-UPRIGHT TILT-TABLE TESTING	ANNALS OF INTERNAL MEDICINE			English	Note							UNEXPLAINED SYNCOPE; UNKNOWN ORIGIN; VELOCITY		ST JOHNS MERCY HEART CTR, PACEMAKER SERV, ST LOUIS, MO 63141 USA; CHRISTIAN NE HOSP, ST LOUIS, MO 63136 USA	Saint Johns Mercy Medical Center	FREDMAN, CS (corresponding author), ST JOHNS MERCY HEART CTR, ELECTROPHYSIOL LAB, 621 S NEW BALLAS RD, 3005-B, ST LOUIS, MO 63141 USA.							AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; ABISAMRA F, 1988, PACE, V11, P1202, DOI 10.1111/j.1540-8159.1988.tb03973.x; ALMQUIST A, 1989, NEW ENGL J MED, V320, P346, DOI 10.1056/NEJM198902093200603; FOUAD FM, 1986, ANN INTERN MED, V104, P298, DOI 10.7326/0003-4819-104-3-298; GRUBB BP, 1991, AM J MED, V90, P6, DOI 10.1016/0002-9343(91)90499-N; GRUBB BP, 1991, CIRCULATION, V84, P1157, DOI 10.1161/01.CIR.84.3.1157; KONTOS HA, 1989, STROKE, V20, P1; PETTY GW, 1990, MAYO CLIN PROC, V65, P1350, DOI 10.1016/S0025-6196(12)62146-6; SRA JS, 1991, ANN INTERN MED, V114, P1013, DOI 10.7326/0003-4819-114-12-1013	9	34	35	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1995	123	11					848	849		10.7326/0003-4819-123-11-199512010-00007	http://dx.doi.org/10.7326/0003-4819-123-11-199512010-00007			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG209	7486468				2022-12-28	WOS:A1995TG20900007
J	TRIEMSTRA, M; ROSENDAAL, FR; SMIT, C; VANDERPLOEG, HM; BRIET, E				TRIEMSTRA, M; ROSENDAAL, FR; SMIT, C; VANDERPLOEG, HM; BRIET, E			MORTALITY IN PATIENTS WITH HEMOPHILIA - CHANGES IN A DUTCH POPULATION FROM 1986 TO 1992 AND 1973 TO 1986	ANNALS OF INTERNAL MEDICINE			English	Article						HEMOPHILIA; HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS; LIFE EXPECTANCY; HEPATITIS; NETHERLANDS	UNITED-STATES; DEATH	Objective: To determine causes of death and mortality rates in patients with hemophilia over a period of 20 years, to assess changes in mortality, and to distinguish between hemophilia-related death and recent death induced by viral infections. Design: Cohort study of 919 patients followed from January 1986 to June 1992. Results were compared with outcomes of previous follow-up from 1973 to 1986. Setting: Consecutive national questionnaire surveys on hemophilia, using patient registries of the Netherlands Hemophilia Society and Dutch hemophilia centers. Patients: 919 males with hemophilia A or B who participated in a national questionnaire survey on hemophilia in 1985. Median duration of follow-up was 6.4 years, which yielded 5753 person-years of follow-up. The mean age at study entry was 30 years (range, 1 to 85 years). Measurements: Standardized mortality ratios, causes of death, median life expectancy, age-adjusted relative risks associated with the type or severity of hemophilia, presence of inhibitors, prophylaxis, and human immunodeficiency virus infection. Results: 45 patients (5%) died between January 1986 and June 1992; 22.6 patients had been expected to die. Thus, the overall standardized mortality ratio was 2.0. The overall median life expectancy was 66 years for the cohort studied from 1973 to 1986 and 68 years for the cohort studied from 1986 to 1992. When deaths related to viral infection were excluded, the life expectancy almost equaled that of the general male population. Between 1986 and 1992, 1 patient died of ischemic heart disease compared with the 5.2 who were expected to die of this disease. Infection with HIV was the strongest independent predictor of death (relative risk, 27.5 [95% CI, 5.7 to 132.8]). After adjustment for HIV infection, no other hemophilia-related risk factors were associated with the risk for death. Conclusions: The acquired immunodeficiency syndrome and hepatitis strongly influence mortality in patients with hemophilia. In the absence of viral infections, the life expectancy of patients with hemophilia would almost equal that of the general male population.	LEIDEN UNIV HOSP, DEPT CLIN EPIDEMIOL, 2300 RC LEIDEN, NETHERLANDS; VRIJE UNIV AMSTERDAM, DEPT MED PSYCHOL, 1081 BT AMSTERDAM, NETHERLANDS; NETHERLANDS HEMOPHILIA SOC, 1171 GN BADHOEVEDORP, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Vrije Universiteit Amsterdam				Triemstra, Mattanja/0000-0001-7133-6028				ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ARONSON DL, 1988, AM J HEMATOL, V27, P7, DOI 10.1002/ajh.2830270103; CHORBA TL, 1994, AM J HEMATOL, V45, P112, DOI 10.1002/ajh.2830450204; Cox D. R., 1984, ANAL SURVIVAL DATA; EYSTER ME, 1993, J ACQ IMMUN DEF SYND, V6, P602; IKKALA E, 1982, BRIT J HAEMATOL, V52, P7, DOI 10.1111/j.1365-2141.1982.tb03856.x; JOHNSON RE, 1985, AM J EPIDEMIOL, V121, P797, DOI 10.1093/oxfordjournals.aje.a114051; JONES PK, 1991, ANN INTERN MED, V114, P641, DOI 10.7326/0003-4819-114-8-641; LARSSON SA, 1983, ACTA MED SCAND, V214, P199; LARSSON SA, 1985, BRIT J HAEMATOL, V59, P593, DOI 10.1111/j.1365-2141.1985.tb07353.x; MANN JM, 1992, AIDS WORLD 1992; MEADE TW, 1994, BRIT MED BULL, V50, P755, DOI 10.1093/oxfordjournals.bmb.a072924; PHILLIPS AN, 1994, BRIT MED J, V309, P309, DOI 10.1136/bmj.309.6950.309; RAMGREN O, 1962, ACTA MED SCAND, V171, P37; ROSENDAAL FR, 1990, BRIT J HAEMATOL, V75, P525, DOI 10.1111/j.1365-2141.1990.tb07793.x; ROSENDAAL FR, 1989, BRIT J HAEMATOL, V71, P71, DOI 10.1111/j.1365-2141.1989.tb06277.x; SMIT C, 1989, BRIT MED J, V298, P235, DOI 10.1136/bmj.298.6668.235; TELFER P, 1994, BRIT J HAEMATOL, V87, P555, DOI 10.1111/j.1365-2141.1994.tb08312.x; 1994, ETHICAL ASPECTS BIOM, P17; [No title captured]	20	149	152	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1995	123	11					823	+		10.7326/0003-4819-123-11-199512010-00002	http://dx.doi.org/10.7326/0003-4819-123-11-199512010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG209	7486463				2022-12-28	WOS:A1995TG20900002
J	NELSON, RJ; DEMAS, GE; HUANG, PL; FISHMAN, MC; DAWSON, VL; DAWSON, TM; SNYDER, SH				NELSON, RJ; DEMAS, GE; HUANG, PL; FISHMAN, MC; DAWSON, VL; DAWSON, TM; SNYDER, SH			BEHAVIORAL ABNORMALITIES IN MALE-MICE LACKING NEURONAL NITRIC-OXIDE SYNTHASE	NATURE			English	Article								Is addition to its role in blood vessel(1,2) and macrophage(3,4) function, nitric oxide (NO) is a neurotransmitter(5) found in high densities in emotion-regulating brain regions(6-8). Mice with targeted disruption of neuronal NO synthase (nNOS) display grossly normal appearance, locomotor activity, breeding(9), long-term potentiation and long-term depression(11). The nNOS(-) mice are resistant to neural stroke damage following middle cerebral artery ligation(12). Although CO2-induced cerebral vasodilatation in wild-type mice is NO-dependent, in nNOS(-) mice this vasodilation is unaffected by NOS inhibitors(13). Establishing a behavioural role for NO has, until now, not been feasible, as NOS inhibitor drugs can only be administered acutely and because their pronounced effects on blood pressure and other body functions obfuscate behavioural interpretations. We now report a large increase in aggressive behaviour and excess, inappropriate sexual behaviour in nNOS(-) mice.	JOHNS HOPKINS UNIV,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT PHYSIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT PSYCHOL,BEHAV NEUROENDOCRINOL GRP,BALTIMORE,MD 21218; MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,BOSTON,MA 02129	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Harvard University; Massachusetts General Hospital			Dawson, Valina/Y-9757-2019; Demas, Gregory/Y-1783-2019	Demas, Gregory/0000-0003-3914-0900; Nelson, Randy/0000-0002-8194-4016; Dawson, Valina/0000-0002-2915-3970				ALBERT DJ, 1984, NEUROSCI BIOBEHAV R, V8, P5, DOI 10.1016/0149-7634(84)90017-4; BRAIN PF, 1992, PSYCHONEUROENDOCRINO, V17, P537, DOI 10.1016/0306-4530(92)90014-X; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; CHEN C, 1994, SCIENCE, V266, P291, DOI 10.1126/science.7939668; DAWSON TM, 1994, J NEUROSCI, V14, P5147; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; IRIKURA K, 1995, P NATL ACAD SCI USA, V92, P6823, DOI 10.1073/pnas.92.15.6823; LINDEN DJ, 1995, J NEUROSCI, V15, P5098; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; ODELL TJ, 1994, SCIENCE, V265, P542, DOI 10.1126/science.7518615; OGAWA S, 1995, END SOC ABSTR; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; REZUANI AH, 1995, PHARM BIOCH BEHAV, V50, P265; RODRIGO J, 1994, PHILOS T R SOC B, V345, P175, DOI 10.1098/rstb.1994.0096; SALIS PJ, 1971, NATURE, V232, P400, DOI 10.1038/232400a0; SAUDOU F, 1994, SCIENCE, V265, P1875, DOI 10.1126/science.8091214; SQUADRITO F, 1994, EUR J PHARMACOL, V255, P51, DOI 10.1016/0014-2999(94)90081-7; VINCENT SR, 1992, NEUROSCIENCE, V4, P755	24	524	535	1	28	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 23	1995	378	6555					383	386		10.1038/378383a0	http://dx.doi.org/10.1038/378383a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477374				2022-12-28	WOS:A1995TF89300058
J	DESPOSITO, M; DETRE, JA; ALSOP, DC; SHIN, RK; ATLAS, S; GROSSMAN, M				DESPOSITO, M; DETRE, JA; ALSOP, DC; SHIN, RK; ATLAS, S; GROSSMAN, M			THE NEURAL BASIS OF THE CENTRAL EXECUTIVE SYSTEM OF WORKING-MEMORY	NATURE			English	Article							HUMAN BRAIN; CORTEX; ATTENTION; ANATOMY	Working memory refers to a system for temporary storage and manipulation of information in the brain, a function critical for a wide range of cognitive operations. It has been proposed that working memory includes a central executive system (CES) to control attention and information flow to and from verbal and spatial short-term memory buffers(1). Although the prefrontal cortex is activated during both verbal and spatial passive working memory tasks(2-8), the brain regions involved in the CES component of working memory have not been identified. We have used functional magnetic resonance imaging (fMRI) to examine brain activation during the concurrent performance of two tasks, which is expected to engage the CES. Activation of the prefrontal cortex was observed when both tasks are performed together, but not when they are performed separately. These results support the view that the prefrontal cortex is involved in human working memory.	UNIV PENN,MED CTR,DEPT RADIOL,PHILADELPHIA,PA 19104	University of Pennsylvania	DESPOSITO, M (corresponding author), UNIV PENN,MED CTR,DEPT NEUROL,PHILADELPHIA,PA 19104, USA.		Alsop, David C/J-5764-2013	Alsop, David C/0000-0002-8206-1995				BADDLEY AD, 1986, WORKING MEMORY; BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; Cohen J D, 1994, Hum Brain Mapp, V1, P293, DOI 10.1002/hbm.460010407; CORBETTA M, 1991, J NEUROSCI, V11, P2383; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; DESPOSITO M, IN PRESS NEUROPSYCHO; FUSTER JM, 1971, SCIENCE, V173, P652, DOI 10.1126/science.173.3997.652; Goldman-Rakic P.S., 2011, HDB PHYSL, P373, DOI DOI 10.1002/CPHY.CP010509; GOLDMANRAKIC PS, 1988, ANNU REV NEUROSCI, V11, P137, DOI 10.1146/annurev.neuro.11.1.137; GOLDMANRAKIC PS, 1993, BRAIN MECHANISMS OF PERCEPTION AND MEMORY: FROM NEURON TO BEHAVIOR, P445; HAXBY JV, 1991, P NATL ACAD SCI USA, V88, P1621, DOI 10.1073/pnas.88.5.1621; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; MCCARTHY G, 1994, P NATL ACAD SCI USA, V91, P8690, DOI 10.1073/pnas.91.18.8690; OGAWA S, 1993, BIOPHYS J, V64, P803, DOI 10.1016/S0006-3495(93)81441-3; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; SWARTZ BE, 1995, CEREB CORTEX, V3, P205; Talairach J., 1988, COPLANAR STEREOTAXIC; VANDERLINDEN M, 1992, COGNITIVE NEUROPSYCH, V9, P301, DOI 10.1080/02643299208252063	22	1098	1109	7	112	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 16	1995	378	6554					279	281		10.1038/378279a0	http://dx.doi.org/10.1038/378279a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477346				2022-12-28	WOS:A1995TE85800048
J	MERCER, BM; ARHEART, KL				MERCER, BM; ARHEART, KL			ANTIMICROBIAL THERAPY IN EXPECTANT MANAGEMENT OF PRETERM PREMATURE RUPTURE OF THE MEMBRANES	LANCET			English	Review							PLACEBO-CONTROLLED TRIAL; ANTIBIOTIC-THERAPY; RANDOMIZED TRIAL; DOUBLE-BLIND; GESTATIONAL-AGE; AMNIOTIC-FLUID; BIRTH-WEIGHT; ERYTHROMYCIN; PROPHYLAXIS; INFECTION	We review the impact of antimicrobial treatment on maternal and fetal outcome during expectant management of preterm premature rupture of the membranes, Relevant studies were retrieved from Medline (1966 to August, 1994) with the search term fetal-membrane-premature-rupture and antibiotics or antimicrobial, Excerpta Medica (1972 to August, 1994) with the search term premature fetus, membrane rupture, and antibiotic or antimicrobial therapy, and the Cochrane database of systemic reviews with the criterion antibiotics and prelabour rupture of membranes. We also obtained unpublished data from a randomised clinical trial of ceftizoxime versus placebo, The selected studies were randomised controlled trials of systemic antimicrobial therapy for prolongation of gestation in non-labouring women after preterm premature rupture of the membranes. Data extraction was done by a single reviewer. Studies were evaluated for post randomisation exclusion and other confounding variables that might introduce analytical bias. Analysis was done with SAS statistical software by a blinded investigator. Antimicrobial therapy after preterm premature rupture of the membranes is associated with a reduced number of women delivering within 1 week (62 vs 76%; OR 0.51, 95% CI 0.41-0.68), and reduced diagnosis of maternal morbidity including chorioamnionitis (12 vs 23%; 0.45, 0.33-0.60) and postpartum infection (8 vs 12%; 0.63, 0.41-0.97). Fetal morbidity, including confirmed sepsis (5 vs 9%; 0.57, 0.36-0.88), pneumonia (1 vs 3%; 0.32, 0.11-0.96), and intraventricular haemorrhage (9 vs 14%; 0.65, 0.45-0.92) were less often diagnosed after antimicrobial therapy, Separate analysis of the six placebo-controlled trials revealed similar or improved odds of pregnancy prolongation, chorioamnionitis, neonatal sepsis, postpartum infection, positive infant blood cultures, and pneumonia. Antimicrobial therapy, when used in the expectant management of preterm premature rupture of the membranes is associated with prolongation of pregnancy and a reduction in the diagnosis of maternal and infant morbidity, Further study should be directed towards determination of optimal antimicrobial therapy, increasing pregnancy prolongation, and enhancement of corticosteroid therapy for induction of pulmonary maturity after preterm premature rupture of the membranes.	UNIV TENNESSEE,DEPT OBSTET & GYNECOL,DIV MATERNAL FETAL MED,MEMPHIS,TN 38103; UNIV TENNESSEE,DEPT PREVENT MED,DIV BIOSTAT,MEMPHIS,TN 38103	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center								AMON E, 1988, AM J OBSTET GYNECOL, V159, P539, DOI 10.1016/S0002-9378(88)80002-4; BERGOGNEBEREZIN E, 1979, J GYNECOL OBST BIO R, V8, P359; Blanco J., 1993, American Journal of Obstetrics and Gynecology, V168, P378; BRELJE MC, 1966, AM J OBSTET GYNECOL, V94, P889, DOI 10.1016/0002-9378(66)90021-4; CARLO WA, 1992, NEONATAL PERINATAL M, P831; CHRISTMAS JT, 1992, OBSTET GYNECOL, V80, P759; COPPER RL, 1993, AM J OBSTET GYNECOL, V168, P78, DOI 10.1016/S0002-9378(12)90889-3; CROWLEY P, 1994, PREGNANCY CHILDBIRTH; DEBODINANCE P, 1990, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V19, P533; DUNLOP PDM, 1986, J OBSTET GYNAECOL, V7, P92, DOI 10.3109/01443618609112279; ERNEST JM, 1994, AM J OBSTET GYNECOL, V170, P516, DOI 10.1016/S0002-9378(94)70220-9; Ferrari B., 1992, Clinical and Experimental Obstetrics and Gynecology, V19, P253; Fortunato S J, 1990, J Perinatol, V10, P252; FORTUNATO SJ, 1988, AM J OBSTET GYNECOL, V159, P570, DOI 10.1016/S0002-9378(88)80010-3; FORTUNATO SJ, 1992, DRUG INVEST, V4, P21; GIBBS RS, 1992, AM J OBSTET GYNECOL, V166, P1515, DOI 10.1016/0002-9378(92)91628-N; GORDON M, 1974, CONTROVERSY OBSTETRI, V2, P42; HUFF RW, 1977, J REPROD MED, V19, P79; JOHNSTON MM, 1990, AM J OBSTET GYNECOL, V163, P743, DOI 10.1016/0002-9378(90)91060-P; KANAYAMA N, 1985, AM J OBSTET GYNECOL, V153, P899, DOI 10.1016/0002-9378(85)90703-3; KURKI T, 1992, AM J PERINAT, V9, P11, DOI 10.1055/s-2007-994661; LEBHERZ TB, 1963, AM J OBSTET GYNECOL, V87, P218; LOCKWOOD CJ, 1993, AM J OBSTET GYNECOL, V169, P970, DOI 10.1016/0002-9378(93)90037-J; MAIN DM, 1985, AM J OBSTET GYNECOL, V151, P892, DOI 10.1016/0002-9378(85)90667-2; MATSUDA Y, 1993, GYNECOL OBSTET INVES, V36, P102, DOI 10.1159/000292605; MATSUDA Y, 1993, NIPPON SANKA FUJINHA, V10, P1109; MCCAUL JF, 1992, INT J GYNECOL OBSTET, V38, P19, DOI 10.1016/0020-7292(92)90724-W; MCGREGOR J A, 1988, Obstetrical and Gynecological Survey, V43, P1; MCGREGOR JA, 1987, OBSTET GYNECOL, V69, P167; MCGREGOR JA, 1991, AM J OBSTET GYNECOL, V165, P632, DOI 10.1016/0002-9378(91)90299-7; MERCER BM, 1993, AM J OBSTET GYNECOL, V169, P775, DOI 10.1016/0002-9378(93)90004-3; MERCER BM, 1992, AM J OBSTET GYNECOL, V166, P794, DOI 10.1016/0002-9378(92)91336-9; MERCER BM, 1993, AM J OBSTET GYNECOL, V168, P1467, DOI 10.1016/S0002-9378(11)90783-2; MONIF GRG, 1983, AM J OBSTET GYNECOL, V146, P334, DOI 10.1016/0002-9378(83)90759-7; MORALES WJ, 1989, OBSTET GYNECOL, V73, P721; NORRI L, 1991, 13TH P WORLD C GYN O, P80; OWEN J, 1993, AM J OBSTET GYNECOL, V169, P976, DOI 10.1016/0002-9378(93)90038-K; PHILIPSON A, 1973, NEW ENGL J MED, V288, P1219, DOI 10.1056/NEJM197306072882307; PHILIPSON A, 1976, CLIN PHARMACOL THER, V19, P68; Prevost Rebecca R., 1992, Pharmacotherapy, V12, P503; ROBERTSON PA, 1992, AM J OBSTET GYNECOL, V166, P1629, DOI 10.1016/0002-9378(92)91551-K; ROMERO R, 1988, SEMIN PERINATOL, V12, P262; ROMERO R, 1986, OBSTET GYNECOL, V67, pS15, DOI 10.1097/00006250-198603001-00005; ROMERO R, 1988, AM J OBSTET GYNECOL, V159, P661, DOI 10.1016/S0002-9378(88)80030-9; Spitzer D., 1993, International Journal of Experimental and Clinical Chemotherapy, V6, P35; 1993, AM J OBSTET GYNECOL, V169, P352	46	148	150	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1271	1279		10.1016/S0140-6736(95)91868-X	http://dx.doi.org/10.1016/S0140-6736(95)91868-X			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475723	Bronze			2022-12-28	WOS:A1995TE14500016
J	GLEASON, SC				GLEASON, SC			HEALTH SYSTEM DEREGULATION - SOME ASPECTS OF HEALTH-CARE SYSTEM REFORM NEED NOT BE HELD HOSTAGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									MAYO CLIN & MAYO FDN,MAYO MED SCH,DEPT FAMILY MED,ROCHESTER,MN 55905; MERCY CLIN INC,DES MOINES,IA	Mayo Clinic	GLEASON, SC (corresponding author), NATL HLTH POLICY COUNCIL,OFF CHAIRMAN,1050 CONNECTICUT AVE NW,SUITE 700,WASHINGTON,DC 20036, USA.							CLINTON WJ, 1995, NATL PERFORMANCE JUL, P4; GLEASON SC, 1994, HLTH CARE REFORM EXA; MARTIN J, 1994, 15TH NAT HLTH LAW AS; 1993, WORKGROUP ELECTRONIC	4	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	1995	274	18					1483	1486						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TC477	7474198				2022-12-28	WOS:A1995TC47700034
J	ALADJEM, MI; GROUDINE, M; BRODY, LL; DIEKEN, ES; FOURNIER, REK; WAHL, GM; EPNER, EM				ALADJEM, MI; GROUDINE, M; BRODY, LL; DIEKEN, ES; FOURNIER, REK; WAHL, GM; EPNER, EM			PARTICIPATION OF THE HUMAN BETA-GLOBIN LOCUS-CONTROL REGION IN INITIATION OF DNA-REPLICATION	SCIENCE			English	Article							ACTIVATION REGION; CHROMATIN STRUCTURE; GENE DOMAIN; ORIGIN; CELLS; CHROMOSOMES; TRANSCRIPTION; EXPRESSION; HYBRIDS	The human beta-globin locus control region (LCR) controls the transcription, chromatin structure, and replication timing of the entire locus. DNA replication was found to initiate in a transcription-independent manner within a region located 50 kilobases downstream of the LCR in human, mouse, and chicken cells containing the entire human beta-globin locus. However, DNA replication did not initiate within a deletion mutant locus lacking the sequences that encompass the LCR. This mutant locus replicated in the 3' to 5' direction. Thus, interactions between distantly separated sequences can be required for replication initiation, and factors mediating this interaction appear to be conserved in evolution.	SALK INST,GENE EXPRESS LAB,SAN DIEGO,CA 92037; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98195; UNIV WASHINGTON,SEATTLE,WA 98195	Salk Institute; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle			Aladjem, Mirit/G-2169-2010	Aladjem, Mirit/0000-0002-1875-3110				ALADJEM MI, UNPUB; BABA T, 1989, VIROLOGY, V144, P139; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BREAM GL, 1992, J VIROL, V66, P7319, DOI 10.1128/JVI.66.12.7319-7327.1992; BREWER BJ, 1994, CURR OPIN GENET DEV, V4, P196, DOI 10.1016/S0959-437X(05)80045-0; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; CADDLE MS, 1992, NUCLEIC ACIDS RES, V20, P5971, DOI 10.1093/nar/20.22.5971; CARROLL SM, 1993, MOL CELL BIOL, V13, P2971, DOI 10.1128/MCB.13.5.2971; CROSSLEY M, 1993, CURR OPIN GENET DEV, V3, P232, DOI 10.1016/0959-437X(93)90028-N; Depamphilis Melvin L., 1993, Trends in Cell Biology, V3, P161, DOI 10.1016/0962-8924(93)90137-P; DEPAMPHILIS ML, 1993, J BIOL CHEM, V268, P1; DHAR V, 1989, MOL CELL BIOL, V9, P3524, DOI 10.1128/MCB.9.8.3524; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; DOBBS DL, 1994, NUCLEIC ACIDS RES, V22, P2479, DOI 10.1093/nar/22.13.2479; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; EPNER E, 1988, P NATL ACAD SCI USA, V85, P8081, DOI 10.1073/pnas.85.21.8081; EPNER E, 1992, TRENDS GENET, V2, P262; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; GILBERT DM, 1993, COLD SPRING HARB SYM, V58, P475, DOI 10.1101/SQB.1993.058.01.054; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GUO ZS, 1992, MOL CELL BIOL, V12, P2514, DOI 10.1128/MCB.12.6.2514; HAMLIN JL, 1995, CURR OPIN GENET DEV, V5, P153, DOI 10.1016/0959-437X(95)80002-6; HANDELI S, 1989, CELL, V57, P909, DOI 10.1016/0092-8674(89)90329-2; KELLY RE, 1995, MOL CELL BIOL, V15, P4136; KIM CG, 1992, GENE DEV, V6, P928, DOI 10.1101/gad.6.6.928; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; LI R, 1994, P NATL ACAD SCI USA, V91, P7051, DOI 10.1073/pnas.91.15.7051; LUGO TG, 1987, MOL CELL BIOL, V7, P2814, DOI 10.1128/MCB.7.8.2814; NONET GH, 1993, SOMAT CELL MOLEC GEN, V19, P171, DOI 10.1007/BF01233532; TRASK BJ, 1993, COLD SPRING HARB SYM, V58, P767, DOI 10.1101/SQB.1993.058.01.084; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; YOON Y, 1995, MOL CELL BIOL, V15, P2482	37	188	191	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 3	1995	270	5237					815	819		10.1126/science.270.5237.815	http://dx.doi.org/10.1126/science.270.5237.815			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC712	7481774				2022-12-28	WOS:A1995TC71200046
J	BENNETT, MB; TAYLOR, GC				BENNETT, MB; TAYLOR, GC			SCALING OF ELASTIC STRAIN-ENERGY IN KANGAROOS AND THE BENEFITS OF BEING BIG	NATURE			English	Article							TERRESTRIAL LOCOMOTION; COST; MECHANICS; WALLABY; TENDONS	LARGE kangaroos are unique among mammals in their ability to uncouple aerobic metabolic energy costs from the speed of locomotion(1,2), making hopping an economical gait. During the first half of the ground-contact phase, kinetic energy lost from the body is stored as elastic strain energy, predominantly in the hind limbs(3-5). The subsequent recoil returns kinetic and potential energy to the body. Here we show that the allometry of structures in the legs and feet of Macropodoidea is different from that of quadrupedal eutherian mammals. The potential for elastic energy storage in hoppers is shown to stale with strong positive allometry. This is a function of the structural properties of muscle-tendon units in the distal hind limbs and the postures adopted by hopping kangaroos. Our findings demonstrate how the use of tissue elasticity is strongly mass dependent and help explain the observed energetic phenomena.			BENNETT, MB (corresponding author), UNIV QUEENSLAND,DEPT ANAT SCI,ST LUCIA,QLD 4072,AUSTRALIA.		Bennett, Michael/A-7218-2012; Bennett, Michael/L-4483-2019	Bennett, Michael/0000-0001-8051-0040				ALEXANDER RM, 1979, J ZOOL, V187, P169; ALEXANDER RM, 1975, J ZOOL, V177, P265, DOI 10.1111/j.1469-7998.1975.tb05983.x; ALEXANDER RM, 1988, ELASTIC MECHANISMS A; BAUDINETTE RV, 1992, AM J PHYSIOL, V262, pR771, DOI 10.1152/ajpregu.1992.262.5.R771; BENNETT MB, 1987, J ZOOL, V212, P457, DOI 10.1111/j.1469-7998.1987.tb02916.x; BENNETT MB, 1986, J ZOOL, V209, P537, DOI 10.1111/j.1469-7998.1986.tb03609.x; BENNETT MB, 1995, J ZOOL, V235, P33, DOI 10.1111/j.1469-7998.1995.tb05125.x; BIEWENER AA, 1990, SCIENCE, V250, P1097, DOI 10.1126/science.2251499; CAVAGNA GA, 1977, AM J PHYSIOL, V233, pR243, DOI 10.1152/ajpregu.1977.233.5.R243; DAWSON TJ, 1973, NATURE, V246, P313, DOI 10.1038/246313a0; FARLEY CT, 1993, J EXP BIOL, V185, P71; HERZOG W, 1993, J BIOMECH, V26, P945, DOI 10.1016/0021-9290(93)90056-K; KER RF, 1986, J ZOOL, V208, P417; Murray Peter, 1991, P1071; POLLOCK CM, 1994, AM J PHYSIOL, V266, pR1022, DOI 10.1152/ajpregu.1994.266.3.R1022; THOMPSON SD, 1980, NATURE, V287, P223, DOI 10.1038/287223a0; WINDSOR DE, 1971, J ZOOL LOND, V153, P165	17	76	77	0	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 2	1995	378	6552					56	59		10.1038/378056a0	http://dx.doi.org/10.1038/378056a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477284				2022-12-28	WOS:A1995TC46900047
J	SCHEIFFELE, P; PERANEN, J; SIMONS, K				SCHEIFFELE, P; PERANEN, J; SIMONS, K			N-GLYCANS AS APICAL SORTING SIGNALS IN EPITHELIAL-CELLS	NATURE			English	Article							CANINE KIDNEY-CELLS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; MDCK CELLS; PLASMA-MEMBRANE; PROTEINS; SECRETION; SURFACE; EXPRESSION; GLYCOSYLATION; TRANSPORT	IN epithelial Madin-Darby canine kidney (MDCK) cells newly synthesized molecules are sorted in the trans-Golgi network and directly delivered to their apical and basolateral surface destinations(1). Sorting is mediated by signals in the cytoplasmic domains of basolateral transmembrane proteins whereas glycosylphosphatidylinositol-linked proteins have apical sorting information in their glycolipid tails(5,6). Signals for apical transmembrane proteins are thought to reside in their ectodomains, because truncated forms lacking the cytoplasmic tail and the membrane anchor are secreted apically(7,8). Here we demonstrate that carbohydrates act as an apical targeting signal for secretory proteins. Growth hormone, which is non-glycosylated and secreted from both sides of MDCK cell lagers(9), is secreted from the apical side when glycosylated. Thus glycans not only play a general role in protein folding(10) but also appear to function in protein sorting in biosynthetic traffic.	EUROPEAN MOLEC BIOL LAB,CELL BIOL PROGRAMME,D-69112 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)				Simons, Kai/0000-0002-9231-9996				BALCAROVASTANDE.J, 1984, EMBO J, V3, P2687; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CAPLAN MJ, 1987, NATURE, V329, P632, DOI 10.1038/329632a0; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CORBEIL D, 1992, J BIOL CHEM, V267, P2798; CUNNINGHAM BC, 1991, SCIENCE, V253, P545, DOI 10.1126/science.1907025; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1995, CELL, V81, P1; GONZALEZ A, 1993, J BIOL CHEM, V268, P6662; GOTTLIEB TA, 1986, P NATL ACAD SCI USA, V83, P2100, DOI 10.1073/pnas.83.7.2100; GREEN RF, 1981, J CELL BIOL, V89, P230, DOI 10.1083/jcb.89.2.230; GUAN JL, 1985, CELL, V42, P489, DOI 10.1016/0092-8674(85)90106-0; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HUNZIKER W, 1991, CELL, V66, P1; KITAGAWA Y, 1994, EXP CELL RES, V213, P449, DOI 10.1006/excr.1994.1222; KONDORKOCH C, 1985, CELL, V43, P297, DOI 10.1016/0092-8674(85)90035-2; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MEISS HK, 1982, MOL CELL BIOL, V2, P1287, DOI 10.1128/MCB.2.10.1287; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOSTOV KE, 1987, J CELL BIOL, V105, P2031, DOI 10.1083/jcb.105.5.2031; MUSTO NA, 1993, EXP CELL RES, V209, P271, DOI 10.1006/excr.1993.1311; RAGNO P, 1992, EXP CELL RES, V203, P236, DOI 10.1016/0014-4827(92)90060-L; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VOGEL LK, 1992, J BIOL CHEM, V267, P2794; VOGEL LK, 1993, FEBS LETT, V330, P293, DOI 10.1016/0014-5793(93)80891-W; WAGNER M, 1995, EUR J CELL BIOL, V67, P84; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987	30	408	411	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 2	1995	378	6552					96	98		10.1038/378096a0	http://dx.doi.org/10.1038/378096a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477300				2022-12-28	WOS:A1995TC46900059
J	BAXT, WG				BAXT, WG			APPLICATION OF ARTIFICIAL NEURAL NETWORKS TO CLINICAL MEDICINE	LANCET			English	Article							ST-T SEGMENTS; MYOCARDIAL-INFARCTION; PATTERN-RECOGNITION; BREAST-CANCER; DIAGNOSIS; ELECTROENCEPHALOGRAM; CLASSIFICATION; EMERGENCY; PREDICT				BAXT, WG (corresponding author), UNIV PENN,MED CTR,DEPT EMERGENCY MED,PHILADELPHIA,PA 19104, USA.							Agyei-Mensah Stephan O., 1992, Australasian Physical and Engineering Sciences in Medicine, V15, P186; ANDERER P, 1994, ELECTROEN CLIN NEURO, V91, P108, DOI 10.1016/0013-4694(94)90032-9; ASTION ML, 1992, CLIN CHEM, V38, P34; ASTION ML, 1994, ARTHRITIS RHEUM, V37, P760, DOI 10.1002/art.1780370522; BANKMAN IN, 1992, IEEE T BIO-MED ENG, V39, P1305, DOI 10.1109/10.184707; Bat WG, 1990, NEURAL COMPUT, V2, P480, DOI 10.1162/neco.1990.2.4.480; BAXT WG, 1991, ANN INTERN MED, V115, P843, DOI 10.7326/0003-4819-115-11-843; BAXT WG, IN PRESS LANCET; BORTOLAN G, 1993, J ELECTROCARDIOL, V26, P75; BOUNDS DG, 1990, NEURAL NETWORKS, V3, P583, DOI 10.1016/0893-6080(90)90008-9; BUCHMAN TG, 1994, CRIT CARE MED, V22, P750, DOI 10.1097/00003246-199405000-00008; BURKE HB, 1994, SEMIN SURG ONCOL, V10, P73, DOI 10.1002/ssu.2980100111; CHAN KH, 1994, J NUCL MED, V35, P771; CLAYTON RH, 1994, MED BIOL ENG COMPUT, V32, P217, DOI 10.1007/BF02518922; CROSS SS, 1995, LANCET, V346, P1075, DOI 10.1016/S0140-6736(95)91746-2; Datz F L, 1993, J Digit Imaging, V6, P67; DATZ FL, 1993, J DIGIT IMAGING, V6, P240; DEVINE B, 1993, MED BIOL ENG COMPUT, V31, P343, DOI 10.1007/BF02446686; Doig G S, 1993, Proc Annu Symp Comput Appl Med Care, P361; DOYLE HR, 1994, ANN SURG, V219, P408, DOI 10.1097/00000658-199404000-00012; DYBOWSKI R, IN PRESS LANCET; EBELL MH, 1993, J FAM PRACTICE, V36, P297; EBERHART RC, 1991, 4TH P ANN IEEE S COM, P298; EDENBRANDT L, 1992, J ELECTROCARDIOL, V25, P167, DOI 10.1016/0022-0736(92)90001-G; EDENBRANDT L, 1993, EUR HEART J, V14, P464, DOI 10.1093/eurheartj/14.4.464; EDENBRANDT L, 1993, J ELECTROCARDIOL, V26, P74; EVANS SJL, 1994, PACE, V17, P611, DOI 10.1111/j.1540-8159.1994.tb02398.x; FARRUGIA S, 1993, PACE, V16, P228, DOI 10.1111/j.1540-8159.1993.tb01567.x; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; GRIGSBY J, 1994, ARCH PHYS MED REHAB, V75, P1077, DOI 10.1016/0003-9993(94)90081-7; GROSS GW, 1990, INVEST RADIOL, V25, P1017, DOI 10.1097/00004424-199009000-00013; GUO Z, 1994, MED BIOL ENG COMPUT, V32, P311, DOI 10.1007/BF02512528; HARE BJ, 1994, J BIOMOL NMR, V4, P35; HARRISON RF, 1991, P INT JOINT C NEURAL, V1, P1; HART A, 1990, MED INFORM, V15, P229, DOI 10.3109/14639239009025270; HU YH, 1993, J ELECTROCARDIOL, V26, P66, DOI 10.1088/0022-3727/26/1/011; JANDO G, 1993, ELECTROEN CLIN NEURO, V86, P100, DOI 10.1016/0013-4694(93)90082-7; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; KAPPEN HJ, 1993, ANN ONCOL         S4, V4, pS31; Katz A S, 1993, J Heart Valve Dis, V2, P504; Katz S, 1994, J Heart Valve Dis, V3, P49; KIPPENHAN JS, 1994, J NUCL MED, V35, P7; KIPPENHAN JS, 1992, J NUCL MED, V33, P1459; KLOPPEL B, 1994, NEUROPSYCHOBIOLOGY, V29, P39, DOI 10.1159/000119061; Lin J S, 1993, Proc Annu Symp Comput Appl Med Care, P434; Lo S C, 1993, J Digit Imaging, V6, P48; Masic N, 1993, Artif Intell Med, V5, P503, DOI 10.1016/0933-3657(93)90040-A; MULSANT GH, 1988, 12 ANN S COMP APPL M, P245; NARAYANAN MN, 1993, METHOD INFORM MED, V32, P55, DOI 10.1055/s-0038-1634888; PATIL S, 1993, CHEST, V104, P1685, DOI 10.1378/chest.104.6.1685; RAVDIN PM, 1992, BREAST CANCER RES TR, V22, P285, DOI 10.1007/BF01840841; REINUS WR, 1994, INVEST RADIOL, V29, P606, DOI 10.1097/00004424-199406000-00002; SNOW PB, 1994, J UROLOGY, V152, P1923, DOI 10.1016/S0022-5347(17)32416-3; SOMOZA E, 1993, MED DECIS MAKING, V13, P273, DOI 10.1177/0272989X9301300402; SUZUKI Y, 1992, MED BIOL ENG COMPUT, V30, P2, DOI 10.1007/BF02446186; Tu J V, 1992, Proc Annu Symp Comput Appl Med Care, P666; VENGPEDERSEN P, 1993, J PHARM SCI, V82, P918, DOI 10.1002/jps.2600820910; WEINSTEIN NJ, 1994, STEM CELLS, V12, P13; WILDING P, 1994, CANCER LETT, V77, P145, DOI 10.1016/0304-3835(94)90097-3; WU YZ, 1993, RADIOLOGY, V187, P81, DOI 10.1148/radiology.187.1.8451441; Yoon Y. O., 1989, J NEURAL NETWORK SUM, P43; [No title captured]	62	470	480	1	49	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 28	1995	346	8983					1135	1138		10.1016/S0140-6736(95)91804-3	http://dx.doi.org/10.1016/S0140-6736(95)91804-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB549	7475607	hybrid			2022-12-28	WOS:A1995TB54900014
J	CHOW, LC; DITTRICH, HC; SHABETAI, R				CHOW, LC; DITTRICH, HC; SHABETAI, R			ENDOMYOCARDIAL BIOPSY IN PATIENTS WITH UNEXPLAINED CONGESTIVE HEART-FAILURE	ANNALS OF INTERNAL MEDICINE			English	Article									VET ADM MED CTR, 3350 LA JOLLA VILLAGE DR, SAN DIEGO, CA 92161 USA; UNIV CALIF SAN DIEGO, MED CTR, SAN DIEGO, CA 92103 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego					NHLBI NIH HHS [HL 07444] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007444] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aretz T., 1986, AM J CARDIOVASC PATH, V1, P3; BAANDRUP U, 1981, BRIT HEART J, V45, P487; BILLINGHAM M, 1987, BRIT HEART J, V58, P6; CASSLING RS, 1985, AM HEART J, V110, P713, DOI 10.1016/0002-8703(85)90447-8; DALY K, 1984, BRIT HEART J, V51, P30, DOI 10.1136/hrt.51.1.30; Das J P, 1981, Indian Heart J, V33, P18; DEC GW, 1985, NEW ENGL J MED, V312, P885, DOI 10.1056/NEJM198504043121404; FENOGLIO JJ, 1983, NEW ENGL J MED, V308, P12, DOI 10.1056/NEJM198301063080103; FIGULLA HR, 1985, CIRCULATION, V71, P1095, DOI 10.1161/01.CIR.71.6.1095; FOWLES RE, 1982, ANN INTERN MED, V97, P885, DOI 10.7326/0003-4819-97-6-885; HOSENPUD JD, 1985, J AM COLL CARDIOL, V6, P797, DOI 10.1016/S0735-1097(85)80485-X; MALL G, 1982, VIRCHOWS ARCH A, V397, P67, DOI 10.1007/BF00430894; MASON JW, 1980, AM J CARDIOL, V45, P1037, DOI 10.1016/0002-9149(80)90174-5; MASON JW, 1985, CIRCULATION, V71, P185, DOI 10.1161/01.CIR.71.2.185; NIPPOLDT TB, 1982, MAYO CLIN PROC, V57, P407; NODA S, 1980, JPN CIRC J, V44, P95, DOI 10.1253/jcj.44.95; OCONNELL JB, 1984, CIRCULATION, V70, P58, DOI 10.1161/01.CIR.70.1.58; OCONNELL JB, 1985, POSTGRAD MED J, V61, P1127, DOI 10.1136/pgmj.61.722.1127; OCONNELL JB, 1986, CURR PROB CARDIOLOGY, V8, P445; PARRILLO JE, 1984, CIRCULATION, V69, P93, DOI 10.1161/01.CIR.69.1.93; SCHOENFELD MH, 1987, CIRCULATION, V75, P1012, DOI 10.1161/01.CIR.75.5.1012; SCHWARZ F, 1983, AM J CARDIOL, V51, P501, DOI 10.1016/S0002-9149(83)80088-5; SEKIGUCHI M, 1985, CIRCULATION, V72, P109; UNVERFERTH BJ, 1983, HUM PATHOL, V14, P974, DOI 10.1016/S0046-8177(83)80177-4; UNVERFERTH DV, 1983, CIRCULATION, V68, P1194, DOI 10.1161/01.CIR.68.6.1194; ZEECHENG CS, 1984, J AM COLL CARDIOL, V3, P63, DOI 10.1016/S0735-1097(84)80431-3	26	63	63	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1988	109	7					535	539		10.7326/0003-4819-109-7-535	http://dx.doi.org/10.7326/0003-4819-109-7-535			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q4157	3421562				2022-12-28	WOS:A1988Q415700005
J	LAKEBAKAAR, G; TOM, W; LAKEBAKAAR, D; GUPTA, N; BEIDAS, S; ELSAKR, M; STRAUS, E				LAKEBAKAAR, G; TOM, W; LAKEBAKAAR, D; GUPTA, N; BEIDAS, S; ELSAKR, M; STRAUS, E			GASTROPATHY AND KETOCONAZOLE MALABSORPTION IN THE ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)	ANNALS OF INTERNAL MEDICINE			English	Article									ASTRA RES CTR,S-15185 SODERTALJE,SWEDEN		LAKEBAKAAR, G (corresponding author), SUNY HLTH SCI CTR,BOX 1196,450 CLARKSON AVE,BROOKLYN,NY 11203, USA.							BRASS C, 1979, ANTIMICROB AGENTS CH, V15, P763, DOI 10.1128/AAC.15.6.763; DANESHMEND TK, 1984, ANTIMICROB AGENTS CH, V25, P1, DOI 10.1128/AAC.25.1.1; DANESHMEND TK, 1981, J ANTIMICROB CHEMOTH, V8, P299, DOI 10.1093/jac/8.4.299; HOLBROOK WP, 1979, POSTGRAD MED J, V55, P692, DOI 10.1136/pgmj.55.647.692; KOTLER DP, 1984, ANN INTERN MED, V101, P421, DOI 10.7326/0003-4819-101-4-421; LAKEBAKAAR G, 1988, ANN INTERN MED, V109, P471, DOI 10.7326/0003-4819-109-6-471; LAKEBAKAAR G, 1987, GASTROENTEROLOGY, V92, P1488; LELAWONGS P, 1988, CLIN PHARMACY, V7, P228; MAKSYMIUK AW, 1982, ANTIMICROB AGENTS CH, V22, P43, DOI 10.1128/AAC.22.1.43; TAVITIAN A, 1986, GASTROENTEROLOGY, V90, P443, DOI 10.1016/0016-5085(86)90946-7; 1985, PHYSICIANS DESK REFE, P1038; 1985, MMWR, V34, P373	12	188	188	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	SEP 15	1988	109	6					471	473		10.7326/0003-4819-109-6-471	http://dx.doi.org/10.7326/0003-4819-109-6-471			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q2568	3415107				2022-12-28	WOS:A1988Q256800007
J	TOFT, I; BONAA, KH; INGEBRETSEN, OC; NORDOY, A; JENSSEN, T				TOFT, I; BONAA, KH; INGEBRETSEN, OC; NORDOY, A; JENSSEN, T			EFFECTS OF N-3 POLYUNSATURATED FATTY-ACIDS ON GLUCOSE-HOMEOSTASIS AND BLOOD-PRESSURE IN ESSENTIAL-HYPERTENSION - A RANDOMIZED, CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						BLOOD GLUCOSE; FATTY ACIDS, UNSATURATED; HYPERTENSION; FISH OILS; INSULIN	FISH-OIL SUPPLEMENTATION; CORONARY HEART-DISEASE; DEPENDENT DIABETIC-PATIENTS; LIPID-METABOLISM; EICOSAPENTAENOIC ACID; INSULIN RESISTANCE; LIPOPROTEIN METABOLISM; GLYCEMIC CONTROL; PLASMA; SECRETION	Objective: To determine whether dietary supplementation with fish oil adversely affects glycemic control in patients with hypertension. Design: Randomized, double-blind, placebo-controlled study. Patients: 78 persons with untreated hypertension recruited from a population survey. Intervention: Participants were randomly assigned to receive eicosapentaenoic and docosahexaenoic acids, 4 g/d, or corn oil placebo, 4 g/d, for 16 weeks. Measurements: An oral glucose tolerance test; assessments of insulin release, glucose disposal, and insulin sensitivity done using the hyperglycemic clamp technique to keep plasma glucose levels at 10 mmol/L for 180 minutes; assessment of insulin sensitivity done using a euglycemic hyperinsulinemic clamp technique (infusing insulin and glucose to keep plasma glucose levels at 5 mmol/L); assessments of lipid levels and blood pressure. Measurements were done before and after intervention. Results: Changes in integrated glucose and insulin response after the oral glucose challenge did not differ between the fish oil and corn oil groups after intervention (-0.6 +/- 0.7 compared with -1.0 +/- 0.6 mmol/L [P > 0.3] for integrated glucose and 143 +/- 76 compared with 169 +/- 84 pmol/L [P > 0.3] for insulin response). Changes in first-phase insulin release (34 +/- 72 pmol/L in the fish oil group compared with 191 +/- 112 pmol/L in the corn oil group [P > 0.3]), second-phase insulin release (179 +/- 66 pmol/L compared with 257 +/- 122 pmol/L [P > 0.3]), and insulin sensitivity index (-0.03 +/- 0.01 compared with -0.01 +/- 0.01 [mu mol/kg . min divided by pmol/L]; P > 0.3) were also similar in both groups after treatment. Fish oil lowered systolic blood pressure by 3.8 mm Hg more than control (P = 0.04) and lowered diastolic blood pressure by 2.0 mm Hg more than control (P = 0.10). After fish oil treatment, triglyceride levels decreased by 0.28 +/- 0.08 mmol/L more than control (P = 0.01), and very-low-density lipoprotein cholesterol levels decreased by 0.13 +/- 0.04 mmol/L more than control (P = 0.01). Conclusion: Fish oil, in doses that reduce blood pressure and lipid levels in hypertensive persons, does not adversely affect glucose metabolism.	UNIV TROMSO, INST COMMUNITY MED, N-9037 TROMSO, NORWAY; UNIV TROMSO HOSP, DEPT CLIN CHEM, N-9038 TROMSO, NORWAY	UiT The Arctic University of Tromso; UiT The Arctic University of Tromso; University Hospital of North Norway	TOFT, I (corresponding author), UNIV TROMSO HOSP, DEPT INTERNAL MED, N-9038 TROMSO, NORWAY.							ANNUZZI G, 1991, ATHEROSCLEROSIS, V87, P65, DOI 10.1016/0021-9150(91)90233-S; APPEL LJ, 1993, ARCH INTERN MED, V153, P1429, DOI 10.1001/archinte.153.12.1429; BANG HO, 1971, LANCET, V1, P1143, DOI 10.1016/S0140-6736(71)91658-8; BJORNTORP P, 1991, DIABETES CARE, V14, P1132, DOI 10.2337/diacare.14.12.1132; BONAA KH, 1990, NEW ENGL J MED, V322, P795, DOI 10.1056/NEJM199003223221202; BONAA KH, 1992, CIRCULATION, V86, P394; BORKMAN M, 1989, DIABETES, V38, P1314, DOI 10.2337/diabetes.38.10.1314; BURR ML, 1989, LANCET, V2, P757; BURSTEIN M, 1970, J LIPID RES, V11, P583; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CONNOR WE, 1993, ANN NY ACAD SCI, V683, P337; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; Diabetes mellitus, 1985, WHO TECHNICAL REPORT, V727; DYERBERG J, 1978, LANCET, V2, P117, DOI 10.1016/s0140-6736(78)91505-2; ESCHWEGE E, 1985, HORM METAB RES, V15, P41; FASCHING P, 1991, DIABETES, V40, P583, DOI 10.2337/diabetes.40.5.583; FERRANNINI E, 1991, DIABETOLOGIA, V34, P416, DOI 10.1007/BF00403180; FESKENS EJM, 1991, DIABETES CARE, V14, P935, DOI 10.2337/diacare.14.11.935; FOLCH J, 1957, J BIOL CHEM, V226, P497; FOX PL, 1988, SCIENCE, V241, P453, DOI 10.1126/science.3393911; FRIDAY KE, 1989, DIABETES CARE, V12, P276, DOI 10.2337/diacare.12.4.276; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FRIER BM, 1977, DIABETES, V26, P369; GLAUBER H, 1988, ANN INTERN MED, V108, P663, DOI 10.7326/0003-4819-108-5-663; HARRIS WS, 1990, J LIPID RES, V31, P1549; HARRIS WS, 1989, J LIPID RES, V30, P785; HENDRA TJ, 1990, DIABETES CARE, V13, P821, DOI 10.2337/diacare.13.8.821; HOWARD WJ, 1993, ANN NY ACAD SCI, V683, P341; JORDE R, 1981, SCAND J GASTROENTERO, V16, P109; KALUZNY MA, 1985, J LIPID RES, V26, P135; KASIM SE, 1988, J CLIN ENDOCR METAB, V67, P1, DOI 10.1210/jcem-67-1-1; KESTIN M, 1990, AM J CLIN NUTR, V51, P1028, DOI 10.1093/ajcn/51.6.1028; KINSELLA JE, 1990, AM J CLIN NUTR, V52, P1; KNAPP HR, 1989, NEW ENGL J MED, V320, P1037, DOI 10.1056/NEJM198904203201603; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; LAWSON DL, 1991, EICOSANOIDS, V4, P217; LOCHER R, 1991, SCAND J CLIN LAB INV, V51, P541, DOI 10.3109/00365519109104563; MCGUIRE EAH, 1976, J APPL PHYSIOL, V41, P565, DOI 10.1152/jappl.1976.41.4.565; MITRAKOU A, 1992, J CLIN ENDOCR METAB, V75, P379, DOI 10.1210/jc.75.2.379; MORRIS MC, 1993, CIRCULATION, V88, P523, DOI 10.1161/01.CIR.88.2.523; NESTEL PJ, 1990, ANNU REV NUTR, V10, P149, DOI 10.1146/annurev.nu.10.070190.001053; NEWMAN WP, 1993, LANCET, V341, P1056, DOI 10.1016/0140-6736(93)92413-N; PARKS JS, 1990, J LIPID RES, V31, P455; PELIKANOVA T, 1993, ANN NY ACAD SCI, V683, P272; POLLARE T, 1990, METABOLISM, V39, P167, DOI 10.1016/0026-0495(90)90071-J; POPPSNIJDERS C, 1987, DIABETES RES CLIN EX, V4, P141; PYORALA K, 1985, ACTA MED SCAND, P38; REAVEN GM, 1991, AM HEART J, V121, P1283, DOI 10.1016/0002-8703(91)90434-J; ROBERTSON R P, 1986, Diabetes Metabolism Reviews, V2, P261; ROBERTSON RP, 1979, DIABETES, V28, P943; RUSTAN AC, 1988, J LIPID RES, V29, P1417; SCHECTMAN G, 1988, DIABETES, V37, P1567, DOI 10.2337/diabetes.37.11.1567; SCHMIDT EB, 1992, SCAND J CLIN LAB INV, V52, P229, DOI 10.3109/00365519209088790; STACPOOLE PW, 1988, METABOLISM, V37, P944, DOI 10.1016/0026-0495(88)90151-5; STACPOOLE PW, 1989, METABOLISM, V38, P946, DOI 10.1016/0026-0495(89)90004-8; STORLIEN LH, 1987, SCIENCE, V237, P885, DOI 10.1126/science.3303333; TURK J, 1988, DIABETES, V37, P992, DOI 10.2337/diabetes.37.7.992; VESSBY B, 1992, DIABETIC MED, V9, P126, DOI 10.1111/j.1464-5491.1992.tb01748.x; VONHOUWELINGEN R, 1987, AM J CLIN NUTR, V46, P424, DOI 10.1093/ajcn/46.3.424; WEISSER B, 1990, KLIN WOCHENSCHR, V68, P49; WESTERVELD HT, 1993, DIABETES CARE, V16, P683, DOI 10.2337/diacare.16.5.683; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; WING LMH, 1990, J HYPERTENS, V8, P339, DOI 10.1097/00004872-199004000-00007; WONG S, 1987, ATHEROSCLEROSIS, V64, P139, DOI 10.1016/0021-9150(87)90239-5; YAMAZAKI RK, 1987, BIOCHIM BIOPHYS ACTA, V920, P62, DOI 10.1016/0005-2760(87)90311-0; 1989, STATISTICAL GRAPHICS; 1987, SAS STAT GUIDE PERSO	67	137	144	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1995	123	12					911	+		10.7326/0003-4819-123-12-199512150-00003	http://dx.doi.org/10.7326/0003-4819-123-12-199512150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK120	7486485				2022-12-28	WOS:A1995TK12000003
J	MANNING, HL; SCHWARTZSTEIN, RM				MANNING, HL; SCHWARTZSTEIN, RM			MECHANISMS OF DISEASE - PATHOPHYSIOLOGY OF DYSPNEA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							OBSTRUCTIVE PULMONARY-DISEASE; CHEST-WALL VIBRATION; AIR HUNGER; VENTILATED QUADRIPLEGICS; AIRWAYS DISEASE; REDUCES DYSPNEA; PINK PUFFERS; BREATHLESSNESS; EXERCISE; STIMULATION		BETH ISRAEL HOSP,DEPT MED,DIV EMERGENCY MED,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT MED,DIV PULM & CRIT CARE MED,BOSTON,MA 02215; DARTMOUTH HITCHCOCK MED CTR,PULM & CRIT CARE MED SECT,LEBANON,NH; DARTMOUTH COLL SCH MED,LEBANON,NH; HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Dartmouth College; Dartmouth College; Harvard University; Harvard Medical School			Schwartzstein, Richard/AGO-8549-2022; Schwartzstein, Richard/L-4420-2019; Binazzi, Barbara/AAA-6522-2020	Binazzi, Barbara/0000-0002-7871-0243	NHLBI NIH HHS [HL-19170] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL019170] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS L, 1985, CLIN SCI, V69, P663, DOI 10.1042/cs0690663; AITKEN RCB, 1969, P ROY SOC MED, V62, P989, DOI 10.1177/003591576906201005; BANZETT RB, 1990, RESP PHYSIOL, V81, P1, DOI 10.1016/0034-5687(90)90065-7; BANZETT RB, 1989, RESP PHYSIOL, V76, P53, DOI 10.1016/0034-5687(89)90017-0; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; BURKI NK, 1987, LUNG, V165, P269, DOI 10.1007/BF02714443; CAMPBELL EJ, 1963, BRIT MED BULL, V19, P36, DOI 10.1093/oxfordjournals.bmb.a070002; CAMPBELL EJ, 1969, CLIN SCI, V36, P323; CAMPBELL EJM, 1981, LUNG BIOL HLTH DISEA, V17, P1181; Casaburi R, 1993, PRINCIPLES PRACTICE; CHONAN T, 1987, J APPL PHYSIOL, V63, P1822, DOI 10.1152/jappl.1987.63.5.1822; CHRONOS N, 1988, CLIN SCI, V74, P531, DOI 10.1042/cs0740531; Comroe Jr JH, 1966, BREATHLESSNESS, P1; DAVIES SF, 1987, AM REV RESPIR DIS, V136, P184, DOI 10.1164/ajrccm/136.1.184; DEAN NC, 1992, AM REV RESPIR DIS, V146, P941, DOI 10.1164/ajrccm/146.4.941; DEMEDIUK BH, 1992, AM REV RESPIR DIS, V146, P1222, DOI 10.1164/ajrccm/146.5_Pt_1.1222; ELLIOTT MW, 1991, AM REV RESPIR DIS, V144, P826, DOI 10.1164/ajrccm/144.4.826; Gescheider G. A., 1976, PSYCHOPHYSICS METHOD; GUZ A, 1970, BREATHING HERINGBREU, P315; GUZ A, 1970, BREATHING HERING BRE, P17; HAMILTON RD, 1987, J APPL PHYSIOL, V63, P2286, DOI 10.1152/jappl.1987.63.6.2286; HARVER A, 1989, ANN INTERN MED, V111, P117, DOI 10.7326/0003-4819-111-2-117; Harver A., 1990, DYSPNEA, P1; HOMMA I, 1984, J APPL PHYSIOL, V56, P8, DOI 10.1152/jappl.1984.56.1.8; JOHNSON MA, 1983, BRIT MED J, V286, P675, DOI 10.1136/bmj.286.6366.675; KILLIAN KJ, 1984, J APPL PHYSIOL, V57, P686, DOI 10.1152/jappl.1984.57.3.686; LANE R, 1987, CLIN SCI, V72, P693, DOI 10.1042/cs0720693; MAHLER DA, 1985, AM REV RESPIR DIS, V131, P22; MAHLER DA, 1990, DYSPNEA; MANNING HL, 1995, AM J RESP CRIT CARE, V151, P751; MANNING HL, 1992, RESP PHYSIOL, V90, P19, DOI 10.1016/0034-5687(92)90131-F; MANNING HL, 1991, J APPL PHYSIOL, V71, P175, DOI 10.1152/jappl.1991.71.1.175; MCCLOSKEY DI, 1981, HDB PHYSL NERVOUS SY, V2, P1415; MITHOEFER JC, 1953, J APPL PHYSIOL, V5, P797, DOI 10.1152/jappl.1953.5.12.797; MURRAY JF, 1986, NORMAL LUNG BASIS DI, P69; NOBLE MIM, 1970, BREATHING, P233; Nocturnal Oxygen Therapy Trial Group, 1980, ANN INTERN MED, V93, P391; OCONNELL JM, 1976, THORAX, V31, P669, DOI 10.1136/thx.31.6.669; ODONNELL DE, 1987, AM REV RESPIR DIS, V135, P912, DOI 10.1164/arrd.1987.135.4.912; REMMERS JE, 1968, RESP PHYSIOL, V4, P78, DOI 10.1016/0034-5687(68)90009-1; RICE KL, 1987, BRIT J DIS CHEST, V81, P287, DOI 10.1016/0007-0971(87)90163-X; SCHWARTZSTEIN R, 1991, AM REV RESPIR  SA596, V143; SCHWARTZSTEIN RM, 1989, AM REV RESPIR DIS, V139, P1231, DOI 10.1164/ajrccm/139.5.1231; SCHWARTZSTEIN RM, 1987, AM REV RESPIR DIS, V136, P58, DOI 10.1164/ajrccm/136.1.58; SCHWARTZSTEIN RM, 1990, LUNG, V168, P185, DOI 10.1007/BF02719692; SHAPIRO SH, 1992, LANCET, V340, P1425, DOI 10.1016/0140-6736(92)92620-U; SIBUYA M, 1994, AM J RESP CRIT CARE, V149, P1235, DOI 10.1164/ajrccm.149.5.8173764; SIMON PM, 1990, AM REV RESPIR DIS, V142, P1009, DOI 10.1164/ajrccm/142.5.1009; SIMON PM, 1989, AM REV RESPIR DIS, V140, P1021, DOI 10.1164/ajrccm/140.4.1021; SIMON PM, 1991, AM REV RESPIR DIS, V144, P419, DOI 10.1164/ajrccm/144.2.419; SMITH K, 1992, AM REV RESPIR DIS, V145, P533, DOI 10.1164/ajrccm/145.3.533; SPENCE DPS, 1993, CHEST, V103, P693, DOI 10.1378/chest.103.3.693; Stevens SS, 1975, PSYCHOPHYSICS INTRO, pxiv; SWINBURN CR, 1991, AM REV RESPIR DIS, V143, P913, DOI 10.1164/ajrccm/143.5_Pt_1.913; SWINBURN CR, 1984, CLIN SCI, V67, P515, DOI 10.1042/cs0670515; TAGUCHI O, 1991, J APPL PHYSIOL, V71, P2183, DOI 10.1152/jappl.1991.71.6.2183; WASSERMAN K, 1988, ANNU REV MED, V39, P503, DOI 10.1146/annurev.med.39.1.503; WOODCOCK AA, 1981, BRIT MED J, V283, P343, DOI 10.1136/bmj.283.6287.343	58	292	302	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 7	1995	333	23					1547	1553		10.1056/NEJM199512073332307	http://dx.doi.org/10.1056/NEJM199512073332307			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH157	7477171				2022-12-28	WOS:A1995TH15700007
J	BONE, RC				BONE, RC			ANOTHER TASTE OF LEMONADE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	1995	274	21					1656	1656		10.1001/jama.274.21.1656	http://dx.doi.org/10.1001/jama.274.21.1656			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH151	7474255				2022-12-28	WOS:A1995TH15100001
J	FINE, JD				FINE, JD			DRUG-THERAPY - MANAGEMENT OF ACQUIRED BULLOUS SKIN DISEASES	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							STEVENS-JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; GLUTEN-FREE DIET; RECURRENT ERYTHEMA MULTIFORME; TERM FOLLOW-UP; DOSE INTRAVENOUS IMMUNOGLOBULINS; DERMATITIS-HERPETIFORMIS; PEMPHIGUS-VULGARIS; PLASMA-EXCHANGE; CLINICAL-RESPONSE		UNIV N CAROLINA,DEPT EPIDEMIOL,CHAPEL HILL,NC 27599; NATL EPIDERMOLYSIS BULLOSA REGISTRY,CHAPEL HILL,NC	University of North Carolina; University of North Carolina Chapel Hill	FINE, JD (corresponding author), UNIV N CAROLINA,DEPT DERMATOL,SUITE 3100,THURSTON BLDG,CB 7287,CHAPEL HILL,NC 27599, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [N01AR022200, R01AR034861] Funding Source: NIH RePORTER; NIAMS NIH HHS [N01 AR22200, R01 AR34861, AR22201] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABERER W, 1987, J AM ACAD DERMATOL, V16, P527, DOI 10.1016/S0190-9622(87)70069-3; ADOUE D, 1987, PRESSE MED, V16, P1625; AHMED AR, 1987, J AM ACAD DERMATOL, V17, P437, DOI 10.1016/S0190-9622(87)70226-6; AUERBACH R, 1979, ARCH DERMATOL, V115, P728, DOI 10.1001/archderm.115.6.728; AUFDEMORTE TB, 1985, ORAL SURG ORAL MED O, V59, P256, DOI 10.1016/0030-4220(85)90162-8; BAHMER FA, 1982, ACTA DERM-VENEREOL, V62, P449; BARTHELEMY H, 1988, J AM ACAD DERMATOL, V18, P1262, DOI 10.1016/S0190-9622(88)70132-2; BARTHELEMY H, 1986, ANN DERMATOL VENER, V113, P309; BERBIS P, 1989, ANN DERMATOL VENER, V116, P301; BERK MA, 1986, ARCH DERMATOL, V122, P670, DOI 10.1001/archderm.122.6.670; Bunger P, 1968, Z Haut Geschlechtskr, V43, P853; BURTON JL, 1974, BRIT J DERMATOL, V91, P103, DOI 10.1111/j.1365-2133.1974.tb06725.x; CAZZOLA G, 1986, HELV PAEDIATR ACTA, V41, P87; COLEMAN MD, 1992, BRIT J CLIN PHARMACO, V34, P244, DOI 10.1111/j.1365-2125.1992.tb04131.x; CROSBY SS, 1986, CLIN PHARMACY, V5, P682; DAVIES P, 1983, INTENS CARE MED, V9, P87, DOI 10.1007/BF01699263; DOWNHAM TF, 1978, ARCH DERMATOL, V114, P1639, DOI 10.1001/archderm.114.11.1639; DUHRA P, 1988, BRIT J DERMATOL, V118, P731, DOI 10.1111/j.1365-2133.1988.tb02583.x; EBRINGER A, 1969, ANN INTERN MED, V71, P125, DOI 10.7326/0003-4819-71-1-125; EULER HH, 1987, ARCH DERMATOL, V123, P1205, DOI 10.1001/archderm.123.9.1205; FINE JD, 1988, ARCH DERMATOL, V124, P236, DOI 10.1001/archderm.124.2.236; FINE JD, 1993, BULLOUS DISEASES; FIVENSON DP, 1994, ARCH DERMATOL, V130, P753, DOI 10.1001/archderm.130.6.753; FRODIN T, 1981, ACTA DERM-VENEREOL, V61, P405; FRY L, 1982, BRIT J DERMATOL, V107, P631, DOI 10.1111/j.1365-2133.1982.tb00520.x; FRY L, 1981, BRIT J DERMATOL, V105, P83, DOI 10.1111/j.1365-2133.1981.tb00886.x; GARVEY MP, 1992, CLIN EXP DERMATOL, V17, P443, DOI 10.1111/j.1365-2230.1992.tb00256.x; GINSBURG CM, 1982, PEDIATR INFECT DIS J, V1, P155, DOI 10.1097/00006454-198205000-00005; Godard W, 1985, Ann Intern Med, V103, P964; GOLLNICK HPM, 1993, J AM ACAD DERMATOL, V28, P122, DOI 10.1016/S0190-9622(08)80854-7; GRANDO SA, 1990, INT J ARTIF ORGANS, V13, P181, DOI 10.1177/039139889001300309; GUILLAUME JC, 1993, ARCH DERMATOL, V129, P49, DOI 10.1001/archderm.129.1.49; GUILLAUME JC, 1988, ARCH DERMATOL, V124, P1659, DOI 10.1001/archderm.124.11.1659; GUILLOT B, 1986, ACTA DERM-VENEREOL, V66, P73; GUILLOT B, 1983, PRESSE MED, V12, P1855; HALBEDIAN PH, 1986, ANN SURG, V204, P503; HALL RP, 1987, ARCH DERMATOL, V123, pA1378, DOI 10.1001/archderm.123.10.1378a; HALL RP, 1982, ANN INTERN MED, V97, P165, DOI 10.7326/0003-4819-97-2-165; HARRINGTON CI, 1977, BRIT MED J, V1, P872, DOI 10.1136/bmj.1.6065.872; HENG MCY, 1991, J AM ACAD DERMATOL, V25, P778, DOI 10.1016/S0190-9622(08)80969-3; HORNSTEN P, 1990, ARCH DERMATOL, V126, P919, DOI 10.1001/archderm.126.7.919; HUFF JC, 1988, J AM ACAD DERMATOL, V18, P197, DOI 10.1016/S0190-9622(88)70027-4; HUFF JC, 1988, SEMIN DERMATOL, V7, P212; HUFF JC, 1993, BULLOUS DISEASES, P163; HYMES SR, 1992, ARCH DERMATOL, V128, P1462, DOI 10.1001/archderm.128.11.1462; JONES RR, 1981, BRIT J DERMATOL, V105, P465, DOI 10.1111/j.1365-2133.1981.tb00780.x; KADUNCE DP, 1991, J INVEST DERMATOL, V97, P175, DOI 10.1111/1523-1747.ep12479517; KAUR S, 1990, INT J DERMATOL, V29, P371, DOI 10.1111/j.1365-4362.1990.tb04767.x; LAPIDOTH M, 1994, J AM ACAD DERMATOL, V30, P752, DOI 10.1016/S0190-9622(08)81506-X; LEONARD JN, 1991, CLIN DERMATOL, V9, P403, DOI 10.1016/0738-081X(91)90032-G; LEVER WF, 1972, ARCH DERMATOL, V106, P491, DOI 10.1001/archderm.106.4.491; LEVER WF, 1984, ARCH DERMATOL, V120, P44, DOI 10.1001/archderm.120.1.44; LEVER WF, 1977, ARCH DERMATOL, V113, P1236, DOI 10.1001/archderm.113.9.1236; LJUNGHALL K, 1983, ARCH DERMATOL, V119, P970, DOI 10.1001/archderm.119.12.970; LOZADA F, 1982, ORAL SURG ORAL MED O, V53, P28, DOI 10.1016/0030-4220(82)90482-0; LOZADA F, 1982, ORAL SURG ORAL MED O, V54, P161, DOI 10.1016/0030-4220(82)90212-2; LOZADANUR F, 1992, ORAL SURG ORAL MED O, V74, P294, DOI 10.1016/0030-4220(92)90062-U; MARVIN JA, 1984, ARCH SURG-CHICAGO, V119, P601; McCord ML, 1993, BULLOUS DIS TOPICS C, P97; MCFADDEN JP, 1989, BRIT J DERMATOL, V121, P759, DOI 10.1111/j.1365-2133.1989.tb08218.x; MEGAHED M, 1994, ARCH DERMATOL RES, V286, P35, DOI 10.1007/BF00375841; MEIER F, 1993, J AM ACAD DERMATOL, V29, P334, DOI 10.1016/0190-9622(93)70189-Z; MILLER JL, 1995, BRIT J DERMATOL, V133, P467, DOI 10.1111/j.1365-2133.1995.tb02680.x; MOISSON YF, 1992, BRIT J DERMATOL, V126, P92, DOI 10.1111/j.1365-2133.1992.tb08415.x; MOREL P, 1984, ANN DERMATOL VENER, V111, P925; PANDYA AG, 1992, ARCH DERMATOL, V128, P1626, DOI 10.1001/archderm.128.12.1626; PAQUET P, 1991, ACTA DERM-VENEREOL, V71, P534; PARSONS JM, 1992, INT J DERMATOL, V31, P749, DOI 10.1111/j.1365-4362.1992.tb04238.x; PASRICHA JS, 1975, BRIT J DERMATOL, V93, P573, DOI 10.1111/j.1365-2133.1975.tb02251.x; PASRICHA JS, 1988, BRIT J DERMATOL, V119, P73, DOI 10.1111/j.1365-2133.1988.tb07104.x; PATTERSON R, 1994, ANN ALLERGY, V73, P27; PENNEYS NS, 1973, ARCH DERMATOL, V108, P56, DOI 10.1001/archderm.108.1.56; PENNEYS NS, 1976, ARCH DERMATOL, V112, P185, DOI 10.1001/archderm.112.2.185; PEOPLES D, 1992, J AM ACAD DERMATOL, V26, P498, DOI 10.1016/S0190-9622(08)80585-3; PIAMPHONGSANT T, 1991, INT J DERMATOL, V30, P139, DOI 10.1111/j.1365-4362.1991.tb04229.x; PRASAD JK, 1986, J TRAUMA, V26, P945, DOI 10.1097/00005373-198610000-00016; PRENDIVILLE JS, 1989, J PEDIATR-US, V115, P881, DOI 10.1016/S0022-3476(89)80736-X; PRUSSICK R, 1992, ARCH DERMATOL, V128, P210; RASMUSSEN JE, 1976, BRIT J DERMATOL, V95, P181, DOI 10.1111/j.1365-2133.1976.tb00824.x; RATNAM KV, 1990, INT J DERMATOL, V29, P363, DOI 10.1111/j.1365-4362.1990.tb04765.x; RENFRO L, 1989, PEDIATR DERMATOL, V6, P43, DOI 10.1111/j.1525-1470.1989.tb00266.x; RENFRO L, 1989, INT J DERMATOL, V28, P441, DOI 10.1111/j.1365-4362.1989.tb02502.x; REUNALA T, 1978, BRIT J DERMATOL, V98, P69, DOI 10.1111/j.1365-2133.1978.tb07335.x; REUNALA T, 1977, BRIT J DERMATOL, V97, P473, DOI 10.1111/j.1365-2133.1977.tb14122.x; ROGERS RS, 1982, J AM ACAD DERMATOL, V6, P215, DOI 10.1016/S0190-9622(82)70014-3; ROHRER TE, 1991, INT J DERMATOL, V30, P457, DOI 10.1111/j.1365-4362.1991.tb04861.x; ROOK AH, 1990, ANN INTERN MED, V112, P303, DOI 10.7326/0003-4819-112-4-303; ROSENBERG FR, 1976, ARCH DERMATOL, V112, P962, DOI 10.1001/archderm.112.7.962; ROUJEAU JC, 1988, SEMIN DERMATOL, V7, P195; ROUJEAU JC, 1990, J AM ACAD DERMATOL, V23, P1039, DOI 10.1016/0190-9622(90)70333-D; SAKELLARIOU G, 1991, INT J ARTIF ORGANS, V14, P634, DOI 10.1177/039139889101401006; SALOMON D, 1986, DERMATOLOGICA, V172, P310, DOI 10.1159/000249367; SAMS WM, 1971, BRIT J DERMATOL, V84, P7; SANDERS SW, 1986, ARZNEIMITTEL-FORSCH, V36-1, P146; SCHOFIELD JK, 1993, BRIT J DERMATOL, V128, P542, DOI 10.1111/j.1365-2133.1993.tb00232.x; SHELLEY WB, 1980, BRIT J DERMATOL, V103, P663, DOI 10.1111/j.1365-2133.1980.tb01689.x; SIEGEL J, 1984, ARCH DERMATOL, V120, P1157, DOI 10.1001/archderm.120.9.1157; SINGER L, 1989, ANN OPHTHALMOL, V21, P209; SNOW JL, 1995, ARCH DERMATOL, V131, P193, DOI 10.1001/archderm.131.2.193; STENVELD HJ, 1993, J AM ACAD DERMATOL, V28, P1014, DOI 10.1016/S0190-9622(08)80657-3; SWANSON DL, 1981, J AM ACAD DERMATOL, V4, P325, DOI 10.1016/S0190-9622(81)70033-1; TAPPEINER G, 1989, J AM ACAD DERMATOL, V20, P684, DOI 10.1016/S0190-9622(89)80148-3; THOMAS I, 1993, J AM ACAD DERMATOL, V28, P74, DOI 10.1016/0190-9622(93)70013-J; TING HC, 1984, DERMATOLOGICA, V169, P175, DOI 10.1159/000249598; VAINIO E, 1985, ACTA DERM-VENEREOL, V65, P291; VANDERMEER JB, 1991, CURR PROBL DERMATOL, V20, P176; VENNING VA, 1989, BRIT J DERMATOL, V120, P83, DOI 10.1111/j.1365-2133.1989.tb07769.x; VINCENT SD, 1993, ORAL SURG ORAL MED O, V76, P453, DOI 10.1016/0030-4220(93)90012-S; WILKEL CS, 1990, ARCH DERMATOL, V126, P397, DOI 10.1001/archderm.1990.01670270129025; Wojnarowska FT, 1990, MANAGEMENT BLISTERIN; ZEEDIJK N, 1986, ACTA DERM-VENEREOL, V66, P316; ZEMTSOV A, 1993, J AM ACAD DERMATOL, V28, P505, DOI 10.1016/S0190-9622(08)81769-0	112	72	74	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 30	1995	333	22					1475	1484		10.1056/NEJM199511303332207	http://dx.doi.org/10.1056/NEJM199511303332207			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG445	7477149				2022-12-28	WOS:A1995TG44500007
J	ITOH, K; STEVENS, B; SCHACHNER, M; FIELDS, RD				ITOH, K; STEVENS, B; SCHACHNER, M; FIELDS, RD			REGULATED EXPRESSION OF THE NEURAL CELL-ADHESION MOLECULE L1 BY SPECIFIC PATTERNS OF NEURAL IMPULSES	SCIENCE			English	Article							MONOCLONAL-ANTIBODY; NERVOUS-SYSTEM; SCHWANN-CELLS; SURFACE; GROWTH; NEURONS; STEP; ACID	Development of the mammalian nervous system is regulated by neural impulse activity, but the molecular mechanisms are not well understood. If cell recognition molecules [for example, L1 and the neural cell adhesion molecule (NCAM)] were influenced by specific patterns of impulse activity, cell-cell interactions controlling nervous system structure could be regulated by nervous system function at critical stages of development. Low frequency electrical pulses delivered to mouse sensory neurons in culture (0.1 hertz for 5 days) down-regulated expression of L1 messenger RNA and protein (but not NCAM). Fasciculation of neurites, adhesion of neuroblastoma cells, and the number of Schwann cells on neurites was reduced after 0.1-hertz stimulation, but higher frequencies or stimulation after synaptogenesis were without effect.	NICHHD,NEUROCYTOL & PHYSIOL UNIT,BETHESDA,MD 20892; ETH HONGGERBERG,DEPT NEUROBIOL,CH-8093 ZURICH,SWITZERLAND	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Swiss Federal Institutes of Technology Domain; ETH Zurich								BAILEY CH, 1992, SCIENCE, V256, P645, DOI 10.1126/science.1585177; BOCK E, 1985, EMBO J, V4, P2765, DOI 10.1002/j.1460-2075.1985.tb04001.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Fields R. Douglas, 1992, P67; FIELDS RD, 1991, J NEUROSCI, V11, P134; FIELDS RD, 1992, INT REV NEUROBIOL, V34, P133, DOI 10.1016/S0074-7742(08)60098-7; FITZGERALD M, 1987, NATURE, V326, P603, DOI 10.1038/326603a0; Fitzgerald M, 1992, SENSORY NEURONS DIVE, P287; ITOH K, 1995, J NEUROSCI, V15, P2504, DOI 10.1523/JNEUROSCI.15-03-02504.1995; LAWSON SN, 1984, J COMP NEUROL, V228, P263, DOI 10.1002/cne.902280211; MOOS M, 1989, NATURE, V334, P701; MOSCOSO LM, 1995, J COMP NEUROL, V352, P321, DOI 10.1002/cne.903520302; RATHJEN FG, 1984, EMBO J, V3, P1; RUTISHAUSER U, 1991, TRENDS NEUROSCI, V14, P528, DOI 10.1016/0166-2236(91)90006-G; SCHACHNER M, 1990, MORPHOREGULATORY MOL, P443; SEILHEIMER B, 1988, J CELL BIOL, V107, P341, DOI 10.1083/jcb.107.1.341; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SPRINKLE TJ, 1987, BRAIN RES, V426, P349, DOI 10.1016/0006-8993(87)90888-2; SWEADNER KJ, 1983, J NEUROSCI, V3, P2504; WONG EV, 1995, TRENDS NEUROSCI, V18, P168, DOI 10.1016/0166-2236(95)93896-6; WOOD P, 1990, ANN NY ACAD SCI, V605, P1, DOI 10.1111/j.1749-6632.1990.tb42376.x; XIAONAN G, 1995, NATURE, V375, P784	22	152	153	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 24	1995	270	5240					1369	1372		10.1126/science.270.5240.1369	http://dx.doi.org/10.1126/science.270.5240.1369			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF899	7481827				2022-12-28	WOS:A1995TF89900042
J	BRANNIGAN, JA; DODSON, G; DUGGLEBY, HJ; MOODY, PCE; SMITH, JL; TOMCHICK, DR; MURZIN, AG				BRANNIGAN, JA; DODSON, G; DUGGLEBY, HJ; MOODY, PCE; SMITH, JL; TOMCHICK, DR; MURZIN, AG			A PROTEIN CATALYTIC FRAMEWORK WITH AN N-TERMINAL NUCLEOPHILE IS CAPABLE OF SELF-ACTIVATION	NATURE			English	Article							GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE; ESCHERICHIA-COLI K-12; PENICILLIN ACYLASE; TRANSPEPTIDASE; CYSTEINE; GENE	THE crystal structures of three amidohydrolases have been determined recently(1-3): glutamine PRPP amidotransferase (GAT), penicillin acylase, and the proteasome. These enzymes use the side chain of the amino-terminal residue, incorporated in a beta-sheet, as the nucleophile in the catalytic attack at the carbonyl carbon. The nucleophile is cysteine in GAT, serine in penicillin acylase, and threonine in the proteasome. Here we show that all three enzymes share an unusual fold in which the nucleophile and other catalytic groups occupy equivalent sites. This fold provides both the capacity for nucleophilic attack and the possibility of autocatalytic processing. We suggest the name Ntn (N-terminal nucleophile) hydrolases for this structural superfamily of enzymes which appear to be evolutionarily related but which have diverged beyond any recognizable sequence similarity.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND; PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907; MRC,CTR PROT ENGN,CAMBRIDGE CB2 2QH,ENGLAND	MRC National Institute for Medical Research; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Cambridge	BRANNIGAN, JA (corresponding author), UNIV YORK,DEPT CHEM,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Moody, Peter/A-6832-2008; Tomchick, Diana/HGV-2018-2022	Moody, Peter/0000-0003-1762-9238; Tomchick, Diana/0000-0002-7529-4643	NIDDK NIH HHS [R37 DK042303] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK042303] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGGRAWAL AK, 1995, CURR OPINION STRUCT, V5, P11; BRUNS W, 1985, J MOL APPL GENET, V3, P36; CHOTHIA C, 1981, P NATL ACAD SCI-BIOL, V78, P4146, DOI 10.1073/pnas.78.7.4146; COLSTON MJ, 1994, MOL MICROBIOL, V12, P359, DOI 10.1111/j.1365-2958.1994.tb01025.x; DODSON GG, 1992, FARADAY DISCUSS, V93, P95, DOI 10.1039/fd9929300095; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; GALLAGHER T, 1993, J MOL BIOL, V230, P516, DOI 10.1006/jmbi.1993.1168; KAARTINEN V, 1991, J BIOL CHEM, V266, P5860; KUMAGAI H, 1993, J MOL BIOL, V234, P1259, DOI 10.1006/jmbi.1993.1677; LOUGH TJ, 1992, PLANT MOL BIOL, V19, P391, DOI 10.1007/BF00023386; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MANTSALA P, 1984, J BIOL CHEM, V259, P4230; MATSUDA A, 1987, J BACTERIOL, V169, P5821, DOI 10.1128/jb.169.12.5821-5826.1987; MONONEN I, 1993, FASEB J, V7, P1247, DOI 10.1096/fasebj.7.13.8405810; OINONEN C, IN PRESS NATURE STRU; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; SEEMULLER E, 1995, FEBS LETT, V359, P173, DOI 10.1016/0014-5793(95)00036-9; SIZMANN D, 1990, EUR J BIOCHEM, V192, P143, DOI 10.1111/j.1432-1033.1990.tb19207.x; Smith JL, 1995, BIOCHEM SOC T, V23, P894, DOI 10.1042/bst0230894; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; SMITH TK, 1995, P NATL ACAD SCI USA, V92, P2360, DOI 10.1073/pnas.92.6.2360; SOUCIET JL, 1988, J BIOL CHEM, V263, P3323; SUZUKI H, 1989, J BACTERIOL, V171, P5169, DOI 10.1128/jb.171.9.5169-5172.1989; TARENTINO AL, 1995, ARCH BIOCHEM BIOPHYS, V316, P399, DOI 10.1006/abbi.1995.1053; TATE SS, 1985, METHOD ENZYMOL, V113, P400; WALLACE CJA, 1993, PROTEIN SCI, V2, P697, DOI 10.1002/pro.5560020501; XU MQ, 1993, CELL, V75, P1371, DOI 10.1016/0092-8674(93)90623-X; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203; ZHOU G, 1992, J BIOL CHEM, V267, P7936; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765	31	545	552	3	39	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 23	1995	378	6555					416	419		10.1038/378416a0	http://dx.doi.org/10.1038/378416a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477383				2022-12-28	WOS:A1995TF89300067
J	LI, XJ; LI, SH; SHARP, AH; NUCIFORA, FC; SCHILLING, G; LANAHAN, A; WORLEY, P; SNYDER, SH; ROSS, CA				LI, XJ; LI, SH; SHARP, AH; NUCIFORA, FC; SCHILLING, G; LANAHAN, A; WORLEY, P; SNYDER, SH; ROSS, CA			A HUNTINGTIN-ASSOCIATED PROTEIN ENRICHED IN BRAIN WITH IMPLICATIONS FOR PATHOLOGY	NATURE			English	Article							TRINUCLEOTIDE REPEAT; DISEASE GENE; LENGTH; EXPRESSION; TISSUES; CLONING; IT-15; ONSET; YEAST; AGE	HUNTINGTON'S disease (HD) is an autosomal dominant neurodegenerative disorder caused by an expanding polyglutamine repeat in the IT15 or huntingtin gene(1). Although this gene is widely expressed(2-9) and is required for normal development(10-12), the pathology of HD is restricted to the brain, for reasons that remain poorly understood. The huntingtin gene product is expressed at similar levels in patients and controls, and the genetics of the disorder(13,14) suggest that the expansion of the polyglutamine repeat induces a toxic gain of function, perhaps through interactions with other cellular proteins(15-18). Here we report the identification of a protein (huntingtin-associated protein (HAP)-1) that binds to huntingtin. This binding is enhanced by an expanded polyglutamine repeat, the length of which is also known to correlate with the age of disease onset(19-21). The HAP-1 protein is enriched in the brain, suggesting a possible basis for the selective brain pathology of HD.	JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	LI, XJ (corresponding author), JOHNS HOPKINS UNIV,SCH MED,MOLEC NEUROBIOL LAB,BALTIMORE,MD 21205, USA.		Ross, Christopher A/H-8395-2013; NUCIFORA, FREDERICK/X-2364-2019					ALBIN RL, 1995, TRENDS NEUROSCI, V18, P11, DOI 10.1016/0166-2236(95)93943-R; AMBROSE CM, 1995, SOMAT CELL MOLEC GEN, V20, P27; ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GUSELLA JF, 1993, ARCH NEUROL-CHICAGO, V50, P1157, DOI 10.1001/archneur.1993.00540110037003; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; LI SH, 1993, NEURON, V11, P985, DOI 10.1016/0896-6273(93)90127-D; LI SH, 1993, GENOMICS, V16, P572, DOI 10.1006/geno.1993.1232; LI XJ, 1994, P NATL ACAD SCI USA, V91, P1814, DOI 10.1073/pnas.91.5.1814; MARGOLIS RL, IN PRESS MOL BRAIN R; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; PERSICHETTI F, 1995, MOL MED, V1, P374, DOI 10.1007/BF03401575; ROSS CA, 1993, TRENDS NEUROSCI, V16, P254, DOI 10.1016/0166-2236(93)90175-L; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; SCHILLING G, 1995, HUM MOL GENET, V4, P1365, DOI 10.1093/hmg/4.8.1365; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; STINE OC, 1993, HUM MOL GENET, V2, P1547, DOI 10.1093/hmg/2.10.1547; STRONG TV, 1993, NAT GENET, V5, P259, DOI 10.1038/ng1193-259; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; WEXLER NS, 1987, NATURE, V326, P194, DOI 10.1038/326194a0; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155; 1993, CELL, V72, P971	31	522	549	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 23	1995	378	6555					398	402		10.1038/378398a0	http://dx.doi.org/10.1038/378398a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477378				2022-12-28	WOS:A1995TF89300062
J	ORAHILLY, S; GRAY, H; HUMPHREYS, PJ; KROOK, A; POLONSKY, KS; WHITE, A; GIBSON, S; TAYLOR, K; CARR, C				ORAHILLY, S; GRAY, H; HUMPHREYS, PJ; KROOK, A; POLONSKY, KS; WHITE, A; GIBSON, S; TAYLOR, K; CARR, C			IMPAIRED PROCESSING OF PROHORMONES ASSOCIATED WITH ABNORMALITIES OF GLUCOSE-HOMEOSTASIS AND ADRENAL-FUNCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							2-SITE IMMUNORADIOMETRIC ASSAY; INSULIN-GENE; PROINSULIN CONVERSION; PROPOSED DEFECT; HUMAN-PLASMA; HYPERPROINSULINEMIA; ADRENOCORTICOTROPIN; WAKAYAMA; MUTATION; SEQUENCE		UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV MANCHESTER,HOPE HOSP,DEPT MED,SALFORD M6 8HD,LANCS,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Chicago; University of Manchester	ORAHILLY, S (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2QR,ENGLAND.		White, Anne/C-3753-2011; O'Rahilly, Stephen/ABF-6509-2020; White, Anne/G-7717-2015; Krook, Anna/K-1192-2015	O'Rahilly, Stephen/0000-0003-2199-4449; White, Anne/0000-0002-7686-2884; Krook, Anna/0000-0002-0891-0258	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CHAN SJ, 1987, P NATL ACAD SCI USA, V84, P2194, DOI 10.1073/pnas.84.8.2194; CLARK PMS, 1994, DIABETES METAB REV, V10, P79, DOI 10.1002/dmr.5610100203; CROSBY SR, 1988, J CLIN ENDOCR METAB, V67, P1272, DOI 10.1210/jcem-67-6-1272; ELBEIN SC, 1985, DIABETES, V34, P821, DOI 10.2337/diabetes.34.8.821; FRIEDMAN TC, 1994, ENDOCRINOLOGY, V135, P854, DOI 10.1210/en.135.3.854; GIVEN BD, 1985, J CLIN INVEST, V76, P1398, DOI 10.1172/JCI112116; GRUPPUSO PA, 1984, NEW ENGL J MED, V311, P629, DOI 10.1056/NEJM198409063111003; HANEDA M, 1984, NEW ENGL J MED, V310, P1288, DOI 10.1056/NEJM198405173102004; HOLST JJ, 1980, BIOCHEM J, V187, P337, DOI 10.1042/bj1870337; KROOK A, 1994, DIABETES, V43, P357, DOI 10.2337/diabetes.43.3.357; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; NANJO K, 1986, J CLIN INVEST, V77, P514, DOI 10.1172/JCI112331; NANJO K, 1987, DIABETOLOGIA, V30, P87; NUSSEY SS, 1993, CLIN ENDOCRINOL, V39, P381, DOI 10.1111/j.1365-2265.1993.tb02381.x; REVERS RR, 1984, DIABETES, V33, P762, DOI 10.2337/diabetes.33.8.762; RHODES CJ, 1994, DIABETES, V43, P511, DOI 10.2337/diabetes.43.4.511; ROBBINS DC, 1984, NEW ENGL J MED, V310, P1165, DOI 10.1056/NEJM198405033101807; ROUILLE Y, 1994, P NATL ACAD SCI USA, V91, P3242, DOI 10.1073/pnas.91.8.3242; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STEINER DF, 1990, DIABETES CARE, V13, P600, DOI 10.2337/diacare.13.6.600; STEWART PM, 1994, CLIN ENDOCRINOL, V40, P199, DOI 10.1111/j.1365-2265.1994.tb02468.x; WHITE A, 1987, CLIN ENDOCRINOL, V26, P41, DOI 10.1111/j.1365-2265.1987.tb03637.x; WILLIAMS T, 1984, NEW ENGL J MED, V311, P1403, DOI 10.1056/NEJM198411293112203; YANO H, 1992, J CLIN INVEST, V89, P1902, DOI 10.1172/JCI115795	27	178	184	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 23	1995	333	21					1386	1390		10.1056/NEJM199511233332104	http://dx.doi.org/10.1056/NEJM199511233332104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF521	7477119				2022-12-28	WOS:A1995TF52100004
J	ROLFE, IE; PEARSON, S; POWIS, DA; SMITH, AJ				ROLFE, IE; PEARSON, S; POWIS, DA; SMITH, AJ			TIME FOR A REVIEW OF ADMISSION TO MEDICAL-SCHOOL	LANCET			English	Article							PERFORMANCE; RESIDENTS; STUDENTS; SELECTION; SKILLS; PREDICTORS; AUSTRALIA; SCIENCE	Appropriate selection of medical students is a fundamental prerequisite if medical schools are to produce competent and caring doctors. The selection criteria for entry to the medical degree course at the University of Newcastle, New South Wales, are unique in Australia. The purpose of this study was to identify admission criteria that may predict performance in the first postgraduate (intern) year. Performance ratings were obtained from the clinical supervisors of two graduating classes of Newcastle University medical students during their five terms in internship (first postgraduate year). At least one rating was obtained for 93% of interns. A subset analysis of interns with multiple ratings (57%) showed that combining previous study in both humanities and science before medical school entry was predictive of higher intern performance ratings. These interns were rate more favourably than those who had earlier studied science alone. Moreover, students who had earlier studied both humanities and science were twice as likely to complete their medical degree as those who had studied science alone. Age, gender, admission interview results, written psychometric test scores, academic marks, and whether previous tertiary study had been undertaken prior to medical school entry were not predictive of intern performance ratings. Subject spread, including a background in humanities, is important for effective medical practice, at least in the immediate postgraduate period. Perhaps it is time to evaluate the admission criteria by which medical students are selected.			ROLFE, IE (corresponding author), UNIV NEWCASTLE,FAC MED & HLTH SCI,NEWCASTLE,NSW 2308,AUSTRALIA.		Powis, David A/C-1956-2008; Smith, Ashley/GZB-0298-2022					BARNSLEY L, 1994, TEACH LEARN MED, V6, P179; BUTTERFIELD PS, 1991, J GEN INTERN MED, V6, P155, DOI 10.1007/BF02598316; DAY SC, 1989, J GEN INTERN MED, V4, P309, DOI 10.1007/BF02597403; DICKMAN RL, 1980, JAMA-J AM MED ASSOC, V243, P2506, DOI 10.1001/jama.243.24.2506; DUFFY DL, 1980, ANN INTERN MED, V93, P354, DOI 10.7326/0003-4819-93-2-354; FELETTI GI, 1985, MED EDUC, V19, P276, DOI 10.1111/j.1365-2923.1985.tb01321.x; GEFFEN LB, 1991, MED J AUSTRALIA, V155, P737, DOI 10.5694/j.1326-5377.1991.tb94022.x; GUNZBURGER LK, 1987, J MED EDUC, V62, P379; HUXHAM GJ, 1989, MED EDUC, V23, P2; JOHNSON ML, 1971, BR J MED ED, V5, P260; KAMIEN M, 1990, MED J AUSTRALIA, V153, P105, DOI 10.5694/j.1326-5377.1990.tb136804.x; LIPTON A, 1984, MED EDUC, V18, P203, DOI 10.1111/j.1365-2923.1984.tb01011.x; MCPHERSON J, 1986, SOC RES HIGHER ED EV, V10, P5; NEAME RLB, 1992, MED EDUC, V26, P433, DOI 10.1111/j.1365-2923.1992.tb00202.x; POWIS DA, 1988, BRIT MED J, V296, P765, DOI 10.1136/bmj.296.6624.765; PRICE PB, 1971, J MED EDUC, V46, P229; ROLFE IE, 1994, MED J AUSTRALIA, V161, P667, DOI 10.5694/j.1326-5377.1994.tb126914.x; ROLFE IE, 1995, MED EDUC, V29, P225, DOI 10.1111/j.1365-2923.1995.tb02835.x; ROTER DL, 1990, J GEN INTERN MED, V5, P347, DOI 10.1007/BF02600404; SEFTON AJ, 1993, ANZAME B, V20, P3; Sheldrake P, 1975, Br J Med Educ, V9, P91; STILLMAN P, 1991, ANN INTERN MED, V114, P393, DOI 10.7326/0003-4819-114-5-393; VERHULST SJ, 1986, J MED EDUC, V61, P132; WINGARD JR, 1973, J MED EDUC, V48, P311; WOODWARD CA, 1983, CAN MED ASSOC J, V129, P567; WOODWARD CA, 1980, PERFORMANCE MCMASTER; WOODWARD CA, 1981, 20TH P ANN C RES MED, V20, P149	27	57	57	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 18	1995	346	8986					1329	1333		10.1016/S0140-6736(95)92344-6	http://dx.doi.org/10.1016/S0140-6736(95)92344-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE916	7475772				2022-12-28	WOS:A1995TE91600010
J	BRUNET, M; BEAUVILAIN, A; COPPENS, Y; HEINTZ, E; MOUTAYE, AHE; PILBEAM, D				BRUNET, M; BEAUVILAIN, A; COPPENS, Y; HEINTZ, E; MOUTAYE, AHE; PILBEAM, D			THE FIRST AUSTRALOPITHECINE 2,500 KILOMETERS WEST OF THE RIFT-VALLEY (CHAD)	NATURE			English	Article								The first sites with Pliocene and Pleistocene mammals west of the Rift Valley in Central Africa in northern Chad mere reported in 1959 (ref. 1), and documented the presence of mixed savannah and woodland habitats. Further sites(2) and a probable Homo erectus cranio-facial fragment(3) mere subsequently discovered. In 1993 a survey of Pliocene and Pleistocene formations in the Borkou-Ennedi-Tibesti Province of Chad (B.E.T.) led to the discovery of 17 new sites in the region of Bahr el Ghazal (classical Arabic for River of the Gazelles) near Koro Toro. One site, KT 12 (15 degrees 58'10'' N, 18 degrees 52'46'' E) yielded an australopithecine mandible associated with a fauna biochronologically estimated to be 3.0-3.5 Myr old. Australopithecine species described since 1925 are known from southern Africa and from sites spread along the eastern Rift Valley from Tanzania to Ethiopia (Fig. 1). This new find from Chad, which is most similar in morphology to Australopithecus afarensis(4), documents the presence of an early hominid a considerable distance, 2,500 km, west of the Rift Valley.	CNAR, NDJAMENA, CHAD; COLL FRANCE, CHAIRE PALEOANTHROPOL & PREHIST, F-75005 PARIS, FRANCE; CNRS, F-75794 PARIS 16, FRANCE; DRGM, NDJAMENA, CHAD; HARVARD UNIV, DEPT ANTHROPOL, CAMBRIDGE, MA 02138 USA	UDICE-French Research Universities; PSL Research University Paris; College de France; Centre National de la Recherche Scientifique (CNRS); Harvard University	BRUNET, M (corresponding author), UNIV POITIERS, FAC SCI JE 273 MST, GEOBIOL BIOCHRONOL & PALEONTOL HUMAINE, 40 AVE RECTEUR PINEAU, F-86022 POITIERS, FRANCE.		Lund, Laura/H-7335-2012; Klein, Richard G/B-5910-2009					ABADLE J, 1959, CR HEBD ACAD SCI, V248, P3329; Beden M, 1985, ENV HOMINIDES PLIO P, P21; BRAGA JC, 1995, THESIS U BORDEAUX; COOKE HBS, 1985, ENV HOMINIDES PLIO P, P101; COPPENS Y, 1965, CR HEBD ACAD SCI, V260, P2869; COPPENS Y, 1983, SINGE AFRIQUE HOMME, P1; COPPENS YVES, 1967, P89; EISENMANN U, 1993, KOOBI FORA PROJECT, P156; EISENMANN V, 1976, Geobios (Villeurbanne), V9, P577, DOI 10.1016/S0016-6995(76)80025-3; GEZE R, 1980, THESIS U PARIS; Geze R., 1985, ENV HOMINIDES PLIO P, P81; Groves C.P., 1986, P187; GRUPP P, 1993, PIGS PECCARIES HIPPO, P66; Guerin C., 1979, Bulletin de la Societe Geologique de France, V21, P283; HARRIS JM, 1979, T AM PHILOS SOC, V69, P5; HARRIS JM, 1983, KOOBI FORA RES PROJE, V2, P215; JOHANSON DC, 1982, AM J PHYS ANTHROPOL, V57, P545, DOI 10.1002/ajpa.1330570406; Jolly Clifford J., 1993, P67; KORTLANDT A, 1972, NEW PERSPECTIVES APE, P9; LEAKEY MD, 1976, NATURE, V262, P460, DOI 10.1038/262460a0; MORIN PA, 1994, SCIENCE, V265, P1193, DOI 10.1126/science.7915048; Pickford M., 1990, Human Evolution, V5, P1, DOI 10.1007/BF02436472; RUVOLO M, 1994, P NATL ACAD SCI USA, V91, P8900, DOI 10.1073/pnas.91.19.8900; SCHNEIDER JL, 1989, THESIS U AVIGNON; SCHNEIDER JL, 1992, DOCUMENT BRGM, V209; UCHIDA A, 1993, AM J PHYS ANTHR S, V16, P198; WHITE TD, 1994, NATURE, V371, P306, DOI 10.1038/371306a0; WOOD BA, 1992, CAMBRIDGE ENCY HUMAN, P231	28	178	185	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 16	1995	378	6554					273	275		10.1038/378273a0	http://dx.doi.org/10.1038/378273a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477344				2022-12-28	WOS:A1995TE85800046
J	GAUS, CR; CLANCY, CM				GAUS, CR; CLANCY, CM			RESEARCH AT THE INTERFACE OF PRIMARY AND SPECIALTY CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1995, JAMA-J AM MED ASSOC, V274, P1436	1	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	1995	274	18					1419	1419		10.1001/jama.274.18.1419	http://dx.doi.org/10.1001/jama.274.18.1419			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC477	7474177				2022-12-28	WOS:A1995TC47700005
J	CHAMBERS, HF; MILLER, RT; NEWMAN, MD				CHAMBERS, HF; MILLER, RT; NEWMAN, MD			RIGHT-SIDED STAPHYLOCOCCUS-AUREUS ENDOCARDITIS IN INTRAVENOUS DRUG-ABUSERS - 2-WEEK COMBINATION THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article									UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	CHAMBERS, HF (corresponding author), SAN FRANCISCO GEN HOSP, 5H22 MED SERV, SAN FRANCISCO, CA 94110 USA.							ABRAMS B, 1979, ANN INTERN MED, V90, P789, DOI 10.7326/0003-4819-90-5-789; BAYER AS, 1988, CHEST, V93, P247, DOI 10.1378/chest.93.2.247; BAYER AS, 1982, ARCH INTERN MED, V142, P1169, DOI 10.1001/archinte.142.6.1169; CATES JE, 1951, Q J MED, V20, P93; CHAMBERS HF, 1983, MEDICINE, V62, P170, DOI 10.1097/00005792-198305000-00004; DRAKE TA, 1983, ANTIMICROB AGENTS CH, V24, P653, DOI 10.1128/AAC.24.5.653; GRINZTON LE, 1982, AM J CARDIOL, V49, P1853; IANNINI PB, 1976, ANN INTERN MED, V84, P558, DOI 10.7326/0003-4819-84-5-558; KARCHMER AW, 1985, AM J MED, V78, P116, DOI 10.1016/0002-9343(85)90374-2; KORZENIOWSKI O, 1982, ANN INTERN MED, V97, P496, DOI 10.7326/0003-4819-97-4-496; MENDA KB, 1973, ANN INTERN MED, V78, P25, DOI 10.7326/0003-4819-78-1-25; NOLAN CM, 1976, AM J MED, V60, P495, DOI 10.1016/0002-9343(76)90715-4; REISBERG BE, 1979, PROG CARDIOVASC DIS, V22, P193, DOI 10.1016/0033-0620(79)90023-9; ROBBINS MJ, 1986, AM J MED, V80, P165, DOI 10.1016/0002-9343(86)90004-5; SANDE MA, 1976, J LAB CLIN MED, V88, P118; SANDE MA, 1980, ANN INTERN MED, V92, P390, DOI 10.7326/0003-4819-92-3-390; SHEAGREN JN, 1984, NEW ENGL J MED, V310, P1437, DOI 10.1056/NEJM198405313102206; SHEAGREN JN, 1984, NEW ENGL J MED, V310, P1368, DOI 10.1056/NEJM198405243102107; WATANAKUNAKORN C, 1982, ANTIMICROB AGENTS CH, V22, P903, DOI 10.1128/AAC.22.5.903; WATANAKUNAKORN C, 1977, AM J MED SCI, V273, P133, DOI 10.1097/00000441-197703000-00002; WILSON R, 1957, AM J MED, V22, P437, DOI 10.1016/0002-9343(57)90099-2; WILSON WR, 1978, CIRCULATION, V57, P1158, DOI 10.1161/01.CIR.57.6.1158; ZAR JH, 1974, BIOSTAT ANAL, P295	23	166	169	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1988	109	8					619	624		10.7326/0003-4819-109-8-619	http://dx.doi.org/10.7326/0003-4819-109-8-619			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q6974	3421575				2022-12-28	WOS:A1988Q697400007
J	GROSS, MD; SHAPIRO, B; BOUFFARD, JA; GLAZER, GM; FRANCIS, IR; WILTON, GP; KHAFAGI, F; SONDA, LP				GROSS, MD; SHAPIRO, B; BOUFFARD, JA; GLAZER, GM; FRANCIS, IR; WILTON, GP; KHAFAGI, F; SONDA, LP			DISTINGUISHING BENIGN FROM MALIGNANT EUADRENAL MASSES	ANNALS OF INTERNAL MEDICINE			English	Article									UNIV MICHIGAN, MED CTR, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	GROSS, MD (corresponding author), VET ADM MED CTR, NUCL MED SERV 115, 2215 FULLER RD, ANN ARBOR, MI 48105 USA.				NCI NIH HHS [CA-09015, R01-CA-43300-01] Funding Source: Medline; NIADDK NIH HHS [R01-AM-2147702] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM021477] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043300] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABECASSIS M, 1985, AM J SURG, V149, P783, DOI 10.1016/S0002-9610(85)80186-0; ABRAMS HL, 1959, J UROLOGY, V81, P711; BAKER ME, 1987, RADIOLOGY, V163, P669, DOI 10.1148/radiology.163.3.3575711; BEIERWALTES WH, 1974, J NUCL MED, V15, P246; BELLDEGRUN A, 1986, SURG GYNECOL OBSTET, V163, P203; BERKMAN WA, 1984, CANCER, V53, P2098, DOI 10.1002/1097-0142(19840515)53:10<2098::AID-CNCR2820531018>3.0.CO;2-0; BERLINER L, 1982, J COMPUT ASSIST TOMO, V6, P281, DOI 10.1097/00004728-198204000-00009; BERNARDINO ME, 1985, AM J ROENTGENOL, V144, P67, DOI 10.2214/ajr.144.1.67; CHARBONNEL B, 1981, J NUCL MED, V22, P1059; COOK B, 1987, J ENDOCRINOL, V113, P331, DOI 10.1677/joe.0.1130331; COPELAND PM, 1983, ANN INTERN MED, V98, P940, DOI 10.7326/0003-4819-98-6-940; DELAMONTE SM, 1984, AM J PATHOL, V114, P131; DUNNICK NR, 1982, J COMPUT ASSIST TOMO, V6, P978, DOI 10.1097/00004728-198210000-00020; FRANCIS IR, 1988, RADIOLOGY, V166, P353, DOI 10.1148/radiology.166.2.3336710; FREITAS JE, 1978, J NUCL MED, V19, P149; GLAZER GM, 1986, RADIOLOGY, V158, P73, DOI 10.1148/radiology.158.1.3940402; GLAZER HS, 1982, AM J ROENTGENOL, V139, P81, DOI 10.2214/ajr.139.1.81; GROSS MD, 1987, J NUCL MED, V28, P1401; GROSS MD, 1981, J CLIN ENDOCR METAB, V52, P1062, DOI 10.1210/jcem-52-6-1062; GROSS MD, 1984, CLIN NUCL MED, V9, P264, DOI 10.1097/00003072-198405000-00005; GROSS MD, 1983, J CLIN ENDOCR METAB, V57, P477, DOI 10.1210/jcem-57-3-477; GUERIN CK, 1983, AM J MED, V75, P653, DOI 10.1016/0002-9343(83)90452-7; GUERRERO LA, 1985, UROLOGY, V26, P435, DOI 10.1016/0090-4295(85)90149-9; HEASTON DK, 1982, AM J ROENTGENOL, V138, P1143, DOI 10.2214/ajr.138.6.1143; HEDELAND H, 1968, ACTA MED SCAND, V184, P211; HUSSAIN S, 1986, EUR J RADIOL, V6, P127; HUSSAIN S, 1985, AM J ROENTGENOL, V144, P61, DOI 10.2214/ajr.144.1.61; KATZ RL, 1985, CANCER, V55, P1995, DOI 10.1002/1097-0142(19850501)55:9<1995::AID-CNCR2820550928>3.0.CO;2-0; MITNICK JS, 1983, RADIOLOGY, V148, P495, DOI 10.1148/radiology.148.2.6867348; MITTY HA, 1983, AM J ROENTGENOL, V141, P727, DOI 10.2214/ajr.141.4.727; NEVILLE AM, 1978, INVEST CELL PATHOL, V1, P99; OLIVER TW, 1984, RADIOLOGY, V153, P217, DOI 10.1148/radiology.153.1.6473783; PRINZ RA, 1982, JAMA-J AM MED ASSOC, V248, P701, DOI 10.1001/jama.248.6.701; QURAISHI MA, 1981, CANCER, V48, P714, DOI 10.1002/1097-0142(19810801)48:3<714::AID-CNCR2820480309>3.0.CO;2-#; REINIG JW, 1986, RADIOLOGY, V158, P81, DOI 10.1148/radiology.158.1.3940403; REMINGTON RD, 1970, STATISTICS APPLICATI, P183; RIZZA RA, 1978, J NUCL MED, V19, P458; SCHAMBELAN M, 1981, NEW ENGL J MED, V304, P1047; SCHWARTZ AN, 1986, AM J ROENTGENOL, V146, P553, DOI 10.2214/ajr.146.3.553; SHAMMA A H, 1958, J Chronic Dis, V8, P587, DOI 10.1016/0021-9681(58)90051-1; SHAPIRO B, 1983, J NUCL MED, V24, P732; SIEKAVIZZA JL, 1981, UROLOGY, V18, P625, DOI 10.1016/0090-4295(81)90476-3; THRALL JH, 1978, SEMIN NUCL MED, V8, P23, DOI 10.1016/S0001-2998(78)80005-1; WEISS LM, 1984, AM J SURG PATHOL, V8, P163, DOI 10.1097/00000478-198403000-00001; YANKASKAS BC, 1986, INVEST RADIOL, V21, P325, DOI 10.1097/00004424-198604000-00006	45	99	99	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1988	109	8					613	618		10.7326/0003-4819-109-8-613	http://dx.doi.org/10.7326/0003-4819-109-8-613			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q6974	3421574				2022-12-28	WOS:A1988Q697400006
J	POLLAK, VE				POLLAK, VE			ADVERSE-EFFECTS AND PYROGENIC REACTIONS DURING HEMODIALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											POLLAK, VE (corresponding author), UNIV CINCINNATI,MED CTR,CINCINNATI,OH 45267, USA.							ALTER MJ, 1988, JAMA-J AM MED ASSOC, V260, P2073, DOI 10.1001/jama.260.14.2073; ALTER MJ, 1986, J INFECT DIS, V153, P1149, DOI 10.1093/infdis/153.6.1149; CHAROENPANICH R, 1987, ARTIF ORGANS, V11, P123, DOI 10.1111/j.1525-1594.1987.tb02642.x; DAUGIRDAS JT, 1985, ARCH INTERN MED, V145, P489, DOI 10.1001/archinte.145.3.489; GORDON SM, 1988, JAMA-J AM MED ASSOC, V260, P2077, DOI 10.1001/jama.260.14.2077; KANT KS, 1981, KIDNEY INT, V19, P728, DOI 10.1038/ki.1981.73; PETERSEN NJ, 1981, T AM SOC ART INT ORG, V27, P155; POLLAK VE, 1986, NEPHRON, V42, P217, DOI 10.1159/000183670; POLLAK VE, 1985, JAMA-J AM MED ASSOC, V253, P62; POLLAK VE, 1988, KIDNEY INT S24, V33, pS49; ROBSON MD, 1986, AM J NEPHROL, V6, P101, DOI 10.1159/000167063	11	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1988	260	14					2106	2107						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q3421	3418877				2022-12-28	WOS:A1988Q342100031
J	LARSON, JS; SCHUETZ, TJ; KINGSTON, RE				LARSON, JS; SCHUETZ, TJ; KINGSTON, RE			ACTIVATION INVITRO OF SEQUENCE-SPECIFIC DNA-BINDING BY A HUMAN REGULATORY FACTOR	NATURE			English	Article									HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital								ANATHAN J, 1986, SCIENCE, V232, P522; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Beckwith J. R., 1970, LACTOSE OPERON; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HOLMGREN R, 1979, CELL, V18, P1359, DOI 10.1016/0092-8674(79)90246-0; KINGSTON RE, 1987, MOL CELL BIOL, V7, P1530, DOI 10.1128/MCB.7.4.1530; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MIRAULT ME, 1982, EMBO J, V1, P1279, DOI 10.1002/j.1460-2075.1982.tb00025.x; MUNRO S, 1985, NATURE, V317, P477, DOI 10.1038/317477a0; NOVER L, 1984, HEAT SHOCK RESPONSE; PELHAM H, 1985, TRENDS GENET, V1, P31, DOI 10.1016/0168-9525(85)90012-5; PELHAM HRB, 1982, EMBO J, V1, P1473, DOI 10.1002/j.1460-2075.1982.tb01340.x; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; RITOSSA F, 1962, EXPERIENTIA, V18, P571, DOI 10.1007/BF02172188; SEGUIN C, 1987, SCIENCE, V235, P1383, DOI 10.1126/science.3103216; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; VERJEE ZHM, 1969, EUR J BIOCHEM, V9, P439, DOI 10.1111/j.1432-1033.1969.tb00628.x; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; WURM FM, 1986, P NATL ACAD SCI USA, V83, P5415; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	29	226	228	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 22	1988	335	6188					372	375		10.1038/335372a0	http://dx.doi.org/10.1038/335372a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q1373	3419505				2022-12-28	WOS:A1988Q137300066
J	OTWINOWSKI, Z; SCHEVITZ, RW; ZHANG, RG; LAWSON, CL; JOACHIMIAK, A; MARMORSTEIN, RQ; LUISI, BF; SIGLER, PB				OTWINOWSKI, Z; SCHEVITZ, RW; ZHANG, RG; LAWSON, CL; JOACHIMIAK, A; MARMORSTEIN, RQ; LUISI, BF; SIGLER, PB			CRYSTAL-STRUCTURE OF TRP REPRESSOR OPERATOR COMPLEX AT ATOMIC RESOLUTION	NATURE			English	Article									UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,920 E 58 ST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT CHEM,CHICAGO,IL 60637	University of Chicago; University of Chicago			Otwinowski, Zbyszek/F-3665-2011	Otwinowski, Zbyszek/0000-0003-3640-8545; Lawson, Catherine/0000-0002-3261-7035				AGARWAL RC, 1978, ACTA CRYSTALLOGR A, V34, P791, DOI 10.1107/S0567739478001618; ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; BASS S, 1987, GENE DEV, V1, P565, DOI 10.1101/gad.1.6.565; BOSSI L, 1984, CELL, V39, P643, DOI 10.1016/0092-8674(84)90471-9; CALLADINE CR, 1986, J MOL BIOL, V192, P907, DOI 10.1016/0022-2836(86)90036-7; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; CARUTHERS MH, 1986, PROTEIN STRUCTURE FO, P221; CHOTHIA C, 1976, P NATL ACAD SCI USA, V73, P3793, DOI 10.1073/pnas.73.11.3793; DICKERSON RE, 1981, J MOL BIOL, V149, P761, DOI 10.1016/0022-2836(81)90357-0; DICKERSON RE, 1985, BIOL MACROMOL, V2, P38; DREW HR, 1987, J MOL BIOL, V195, P143, DOI 10.1016/0022-2836(87)90333-0; EBRIGHT RH, 1984, P NATL ACAD SCI-BIOL, V81, P7274, DOI 10.1073/pnas.81.23.7274; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FREDERICK CA, 1984, NATURE, V309, P327, DOI 10.1038/309327a0; GOTOH O, 1981, BIOPOLYMERS, V20, P1033, DOI 10.1002/bip.1981.360200513; HARAN TE, 1984, J BIOMOL STRUCT DYN, V2, P397, DOI 10.1080/07391102.1984.10507575; HARRISON SC, 1988, B I PASTEUR, V86, P55; HENDRICKSON WA, 1981, STRUCTURE CONFORMATI, V1, P43; JANIN J, 1978, 12TH FEBS M DRESD, V52, P227; JOACHIMIAK A, 1987, J BIOL CHEM, V262, P4917; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KELLEY RL, 1985, P NATL ACAD SCI USA, V82, P483, DOI 10.1073/pnas.82.2.483; KLUG A, 1979, J MOL BIOL, V131, P669, DOI 10.1016/0022-2836(79)90196-7; KUMAMOTO AA, 1987, GENE DEV, V1, P556, DOI 10.1101/gad.1.6.556; LAWSON CL, 1988, PROTEINS, V3, P18, DOI 10.1002/prot.340030103; LAWSON CL, 1988, NATURE, V233, P869; LEFEVRE JF, 1987, BIOCHEMISTRY-US, V26, P5076, DOI 10.1021/bi00390a029; LOMONOSSOFF GP, 1981, J MOL BIOL, V149, P745, DOI 10.1016/0022-2836(81)90356-9; MARINI JC, 1982, P NATL ACAD SCI-BIOL, V79, P7664, DOI 10.1073/pnas.79.24.7664; MARMORSTEIN RQ, 1987, J BIOL CHEM, V262, P4922; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; OHLENDORF DH, 1983, J MOL EVOL, V19, P109, DOI 10.1007/BF02300748; ORNSTEIN RL, 1978, BIOPOLYMERS, V17, P2341, DOI 10.1002/bip.1978.360171005; PABO CO, 1982, NATURE, V298, P441, DOI 10.1038/298441a0; RECORD MT, 1988, UNUSUAL DNA STRUCTUR, P237; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SCHEVITZ RW, 1985, NATURE, V317, P782, DOI 10.1038/317782a0; SNYDER M, 1986, NATURE, V324, P87, DOI 10.1038/324087a0; SOMERVILLE RL, 1983, AMINO ACIDS BIOSYNTH, P351; STENZEL TT, 1987, CELL, V49, P709, DOI 10.1016/0092-8674(87)90547-2; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; TRAVERS AA, 1987, PHILOS T ROY SOC B, V317, P537, DOI 10.1098/rstb.1987.0080; VONHIPPEL PH, 1986, P NATL ACAD SCI USA, V83, P1608; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZAHN K, 1987, SCIENCE, V236, P416, DOI 10.1126/science.2951850; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0	48	899	907	1	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 22	1988	335	6188					321	329		10.1038/335321a0	http://dx.doi.org/10.1038/335321a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q1373	3419502				2022-12-28	WOS:A1988Q137300049
J	KEMP, BE; RYLATT, DB; BUNDESEN, PG; DOHERTY, RR; MCPHEE, DA; STAPLETON, D; COTTIS, LE; WILSON, K; JOHN, MA; KHAN, JM; DINH, DP; MILES, S; HILLYARD, CJ				KEMP, BE; RYLATT, DB; BUNDESEN, PG; DOHERTY, RR; MCPHEE, DA; STAPLETON, D; COTTIS, LE; WILSON, K; JOHN, MA; KHAN, JM; DINH, DP; MILES, S; HILLYARD, CJ			AUTOLOGOUS RED-CELL AGGLUTINATION ASSAY FOR HIV-1 ANTIBODIES - SIMPLIFIED TEST WITH WHOLE-BLOOD	SCIENCE			English	Article									AGEN BIOMED LTD,BRISBANE 4000,AUSTRALIA; FAIRFIELD HOSP,MCFARLANE BURNET CTR MED RES,NH & MRC SPECIAL UNIT AIDS VIROL,FAIRFIELD 3078,AUSTRALIA		KEMP, BE (corresponding author), UNIV MELBOURNE,REPATRIAT GEN HOSP,DEPT MED,HEIDELBERG,VIC 3081,AUSTRALIA.		Kemp, Bruce/G-9602-2019; McPhee, Dale A/D-1825-2011; Doherty, Richard/GVT-7356-2022; Kemp, Bruce E/L-2633-2014	Kemp, Bruce/0000-0001-6735-5082; Kemp, Bruce E/0000-0001-6735-5082; Doherty, Richard/0000-0002-3141-0083				BLOMBERG J, 1985, LEUKEMIA RES, V9, P1111, DOI 10.1016/0145-2126(85)90100-6; BURKE DS, 1987, J CLIN MICROBIOL, V25, P81, DOI 10.1128/JCM.25.1.81-84.1987; CHIODI F, 1987, AIDS RES HUM RETROV, V3, P165, DOI 10.1089/aid.1987.3.165; COOMBS RRA, 1987, J IMMUNOL METHODS, V101, P1, DOI 10.1016/0022-1759(87)90209-2; GAINES H, 1987, LANCET, V1, P1249; GNANN JW, 1987, J INFECT DIS, V156, P261, DOI 10.1093/infdis/156.2.261; GNANN JW, 1987, SCIENCE, V237, P1346, DOI 10.1126/science.2888192; GOEDERT JJ, 1984, LANCET, V2, P711; LITCHFIELD WJ, 1984, CLIN CHEM, V30, P1489; MASKILL W, 1986, J VIROL METHODS, V13, P273, DOI 10.1016/0166-0934(86)90051-0; RIGGIN CH, 1987, J CLIN MICROBIOL, V25, P1772, DOI 10.1128/JCM.25.9.1772-1773.1987; RYLATT, UNPUB; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; SARNGADHARAN MG, 1984, SCIENCE, V224, P506, DOI 10.1126/science.6324345; SCHUPBACH J, 1984, SCIENCE, V224, P503, DOI 10.1126/science.6200937; STEWART JM, 1966, SOLID PHASE PEPTIDE, P44; WANG JJG, 1986, P NATL ACAD SCI USA, V83, P6159, DOI 10.1073/pnas.83.16.6159; WELLING GW, 1985, FEBS LETT, V188, P215, DOI 10.1016/0014-5793(85)80374-4; WHICHER JT, 1984, CLIN BIOCH ANAL, V14; YOSHIDA T, 1986, JPN J CANCER RES, V77, P1211	20	64	77	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 9	1988	241	4871					1352	1354		10.1126/science.3413497	http://dx.doi.org/10.1126/science.3413497			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	P9812	3413497				2022-12-28	WOS:A1988P981200031
J	CHETCUTI, P; MYERS, NA; PHELAN, PD; BEASLEY, SW				CHETCUTI, P; MYERS, NA; PHELAN, PD; BEASLEY, SW			ADULTS WHO SURVIVED REPAIR OF CONGENITAL ESOPHAGEAL ATRESIA AND TRACHEO-OESOPHAGEAL FISTULA	BRITISH MEDICAL JOURNAL			English	Article									ROYAL CHILDRENS HOSP,DEPT GEN SURG,PARKVILLE,VIC 3052,AUSTRALIA; ROYAL CHILDRENS HOSP,DEPT THORAC MED,PARKVILLE,VIC 3052,AUSTRALIA; UNIV MELBOURNE,DEPT PAEDIAT,PARKVILLE,VIC 3052,AUSTRALIA	Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; University of Melbourne								AYRES JG, 1986, THORAX, V41, P106, DOI 10.1136/thx.41.2.106; AYRES JG, 1986, THORAX, V41, P111, DOI 10.1136/thx.41.2.111; CRISPIN AR, 1966, THORAX, V81, P104; DUDLEY NE, 1976, ARCH DIS CHILD, V51, P279, DOI 10.1136/adc.51.4.279; EMERY JL, 1971, ARCH DIS CHILD, V46, P236, DOI 10.1136/adc.46.247.236; HOLDER TM, 1981, SURG CLIN N AM, V61, P1051; HOLDER TM, 1964, PEDIATRICS, V34, P542; HUKS LM, 1981, J THORAC CARDIOVASC, V81, P358; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P724; KOOP CE, 1975, Z KINDERCHIR, V17, P125; Ladd WE, 1944, NEW ENGL J MED, V230, P625, DOI 10.1056/NEJM194405252302101; LAKS H, 1972, J PEDIATR SURG, V7, P591, DOI 10.1016/0022-3468(72)90218-7; LESOUEF PN, 1987, J PEDIATR SURG, V22, P918, DOI 10.1016/S0022-3468(87)80589-4; LEVEN NL, 1936, J THORACIC SURG, V6, P30; LISTER J, 1964, ARCH DIS CHILD, V39, P131, DOI 10.1136/adc.39.204.131; MILLIGAN DWA, 1979, J PEDIATR-US, V95, P24, DOI 10.1016/S0022-3476(79)80076-1; Myers N A, 1977, Prog Pediatr Surg, V10, P5; MYERS NA, 1974, ANN ROY COLL SURG, V54, P277; MYERS NA, 1979, CAUSES POSTOPERATIVE, P141; NAKAZATO Y, 1986, J PEDIATR SURG, V21, P831, DOI 10.1016/S0022-3468(86)80002-1; NEBEL OT, 1976, AM J DIG DIS, V21, P953, DOI 10.1007/BF01071906; SPITZ L, 1987, J PEDIATR SURG, V22, P103, DOI 10.1016/S0022-3468(87)80420-7; WAILOO MP, 1979, HISTOPATHOLOGY, V3, P329, DOI 10.1111/j.1365-2559.1979.tb03014.x; WATERSON DJ, 1962, LANCET, V1, P819; 1983, AUSTR SMOKING RATES	26	57	57	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1988	297	6644					344	346		10.1136/bmj.297.6644.344	http://dx.doi.org/10.1136/bmj.297.6644.344			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P4527	3416169	Bronze, Green Published			2022-12-28	WOS:A1988P452700029
J	ROIZMAN, B				ROIZMAN, B			MOLECULAR AND GENETIC-ENGINEERING - THE PRINCIPLES, THE POWER, AND THE PROMISE	SCIENCE			English	Article											ROIZMAN, B (corresponding author), UNIV CHICAGO,MARJORIE B KOVLER VIRAL ONCOL LABS,CHICAGO,IL 60637, USA.								0	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1988	239		2				G110	&						0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	M0210	3422518				2022-12-28	WOS:A1988M021000007
J	SURKS, MI; SIEVERT, R				SURKS, MI; SIEVERT, R			DRUG-THERAPY - DRUGS AND THYROID-FUNCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HORMONE-BINDING PROTEINS; FUNCTION TESTS; FREE-THYROXINE; THYROTROPIN SECRETION; FREE TRIIODOTHYRONINE; HYPOTHYROID PATIENTS; ANABOLIC-STEROIDS; LITHIUM TREATMENT; HUMAN-SERUM; HYPERTHYROIDISM		ALBERT EINSTEIN COLL MED, BRONX, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine	SURKS, MI (corresponding author), MONTEFIORE MED CTR, DEPT MED, DIV ENDOCRINOL, 111 E 210TH ST, BRONX, NY 10467 USA.							AGNER T, 1986, J CLIN ENDOCR METAB, V62, P778, DOI 10.1210/jcem-62-4-778; ARAFAH BM, 1994, ANN INTERN MED, V121, P247, DOI 10.7326/0003-4819-121-4-199408150-00002; AZIZI F, 1974, ANN INTERN MED, V80, P194, DOI 10.7326/0003-4819-80-2-194; BARTALENA L, 1990, ENDOCR REV, V11, P47, DOI 10.1210/edrv-11-1-47; BARTALENA L, 1994, J CLIN ENDOCR METAB, V78, P423, DOI 10.1210/jc.78.2.423; BARTALENA L, 1992, THYROID, V2, P237, DOI 10.1089/thy.1992.2.237; BAUDIN E, 1993, CLIN ENDOCRINOL, V39, P657, DOI 10.1111/j.1365-2265.1993.tb02423.x; BECKPECCOZ P, 1985, NEW ENGL J MED, V312, P1085, DOI 10.1056/NEJM198504253121703; BEEX L, 1977, CANCER TREAT REP, V61, P1291; BENRAFAEL Z, 1987, FERTIL STERIL, V48, P318; BENTSEN KD, 1983, ACTA NEUROL SCAND, V67, P235, DOI 10.1111/j.1600-0404.1983.tb04569.x; BERTHERAT J, 1992, J CLIN ENDOCR METAB, V75, P540, DOI 10.1210/jc.75.2.540; BISHNOI A, 1994, AM J MED, V96, P235, DOI 10.1016/0002-9343(94)90148-1; BLACKSHEAR JL, 1983, ANN INTERN MED, V99, P341, DOI 10.7326/0003-4819-99-3-341; BOCCHETTA A, 1991, ACTA PSYCHIAT SCAND, V83, P193, DOI 10.1111/j.1600-0447.1991.tb05523.x; BOESGAARD S, 1990, CLIN ENDOCRINOL, V32, P423, DOI 10.1111/j.1365-2265.1990.tb00882.x; BRABANT A, 1989, ACTA ENDOCRINOL-COP, V121, P95, DOI 10.1530/acta.0.1210095; BRABANT G, 1991, J CLIN ENDOCR METAB, V72, P145, DOI 10.1210/jcem-72-1-145; BRAVERMAN LE, 1990, ACTA MED AUST, V17, P29; CAMPBELL BA, 1994, ANN INTERN MED, V121, P152, DOI 10.7326/0003-4819-121-2-199407150-00024; CAMPBELL NRC, 1992, ANN INTERN MED, V117, P1010, DOI 10.7326/0003-4819-117-12-1010; CASHINHEMPHILL L, 1987, ANN INTERN MED, V107, P324, DOI 10.7326/0003-4819-107-2-324; CAVALIERI RR, 1973, J CLIN ENDOCR METAB, V37, P308, DOI 10.1210/jcem-37-2-308; CHOPRA IJ, 1975, J CLIN ENDOCR METAB, V41, P911, DOI 10.1210/jcem-41-5-911; CHRISTENSEN SE, 1992, METABOLISM, V41, P44, DOI 10.1016/0026-0495(92)90030-E; Cooper D S, 1982, Am J Med, V73, P867; COOPER DS, 1983, CLIN ENDOCRINOL, V18, P265, DOI 10.1111/j.1365-2265.1983.tb03211.x; CURRAN PG, 1991, ENDOCR REV, V12, P135, DOI 10.1210/edrv-12-2-135; DEGROOT LJ, 1976, J CLIN ENDOCR METAB, V42, P976, DOI 10.1210/jcem-42-5-976; DEYSSIG R, 1993, J CLIN ENDOCR METAB, V76, P1069, DOI 10.1210/jc.76.4.1069; DHOPESH VP, 1991, AM J DRUG ALCOHOL AB, V17, P423, DOI 10.3109/00952999109001601; DOWSETT M, 1991, EUR J CANCER, V27, P846, DOI 10.1016/0277-5379(91)90131-V; DUICK DS, 1974, J CLIN ENDOCR METAB, V39, P1151, DOI 10.1210/jcem-39-6-1151; ENGLER D, 1984, ENDOCR REV, V5, P151, DOI 10.1210/edrv-5-2-151; ENGLISH TN, 1988, CLIN CHEM, V34, P2202; FABER J, 1993, CLIN CHIM ACTA, V223, P159, DOI 10.1016/0009-8981(93)90072-C; FIGG WD, 1994, ARCH INTERN MED, V154, P1023, DOI 10.1001/archinte.154.9.1023; FIGGE HL, 1990, J CLIN PHARMACOL, V30, P588, DOI 10.1002/j.1552-4604.1990.tb01861.x; GAMSTEDT A, 1981, ACTA ENDOCRINOL-COP, V96, P484, DOI 10.1530/acta.0.0960484; GEOLA FL, 1980, J CLIN ENDOCR METAB, V51, P620, DOI 10.1210/jcem-51-3-620; GRAHAM RL, 1980, OBSTET GYNECOL, V55, P395, DOI 10.1097/00006250-198003000-00028; GUPTA A, 1992, CLIN PHARMACOL THER, V51, P56, DOI 10.1038/clpt.1992.8; HARMON SM, 1991, ANN INTERN MED, V115, P658, DOI 10.7326/0003-4819-115-8-658_2; HAVRANKOVA J, 1992, ANN INTERN MED, V117, P445, DOI 10.7326/0003-4819-117-5-445_3; HAVRANKOVA J, 1993, ANN INTERN MED, V118, P398; HAYS MT, 1988, ENDOCR RES, V14, P203, DOI 10.3109/07435808809032986; HERMAN R, 1991, BIOL PSYCHIAT, V29, P779, DOI 10.1016/0006-3223(91)90197-T; HERSHMAN JM, 1972, J CLIN ENDOCR METAB, V34, P574, DOI 10.1210/jcem-34-3-574; HOLLANDER CS, 1967, J CLIN ENDOCR METAB, V27, P1219, DOI 10.1210/jcem-27-8-1219; HORIMOTO M, 1995, J CLIN ENDOCR METAB, V80, P1124, DOI 10.1210/jc.80.4.1124; ISLEY WL, 1987, ANN INTERN MED, V107, P517, DOI 10.7326/0003-4819-107-4-517; ISOJARVI JIT, 1989, ARCH NEUROL-CHICAGO, V46, P1175, DOI 10.1001/archneur.1989.00520470029021; KABADI UM, 1987, J AM GERIATR SOC, V35, P255, DOI 10.1111/j.1532-5415.1987.tb02319.x; KERR DJ, 1987, CLIN SCI, V72, P737, DOI 10.1042/cs0720737; KHAN F, 1993, ANN INTERN MED, V118, P317, DOI 10.7326/0003-4819-118-4-199302150-00027; KNOPP RH, 1985, OBSTET GYNECOL, V66, P682; KRISTENSEN BO, 1977, CLIN PHARMACOL THER, V22, P864; KRUIT WHJ, 1993, J CLIN ONCOL, V11, P921, DOI 10.1200/JCO.1993.11.5.921; KUHL H, 1993, CONTRACEPTION, V47, P55, DOI 10.1016/0010-7824(93)90109-K; KUNG AWC, 1990, J CLIN ENDOCR METAB, V71, P1230, DOI 10.1210/jcem-71-5-1230; LARSEN PR, 1972, J CLIN INVEST, V51, P1125, DOI 10.1172/JCI106905; LIEL Y, 1994, AM J MED, V97, P363, DOI 10.1016/0002-9343(94)90303-4; LIEWENDAHL K, 1985, CLIN CHEM, V31, P1993; LOPRESTI JS, 1989, J CLIN INVEST, V84, P1650, DOI 10.1172/JCI114343; MALARKEY WB, 1991, AM J OBSTET GYNECOL, V165, P1385; MAMBY CC, 1995, J CLIN ONCOL, V13, P854, DOI 10.1200/JCO.1995.13.4.854; MANDEL SJ, 1990, NEW ENGL J MED, V323, P91, DOI 10.1056/NEJM199007123230204; MARTIN FIR, 1993, AM J MED, V95, P78, DOI 10.1016/0002-9343(93)90235-H; MCCONNELL RJ, 1992, JAMA-J AM MED ASSOC, V267, P1242, DOI 10.1001/jama.267.9.1242; MENDEL CM, 1986, J CLIN ENDOCR METAB, V63, P1394, DOI 10.1210/jcem-63-6-1394; MENDEL CM, 1987, J CLIN ENDOCR METAB, V65, P1259, DOI 10.1210/jcem-65-6-1259; NEWNHAM HH, 1987, CLIN ENDOCRINOL, V26, P423, DOI 10.1111/j.1365-2265.1987.tb00799.x; NOVICK DM, 1989, CLIN CHEM, V35, P1807; OBRIEN T, 1992, MAYO CLIN PROC, V67, P465, DOI 10.1016/S0025-6196(12)60393-0; OPPENHEIMER JH, 1968, J CLIN INVEST, V47, P1399, DOI 10.1172/JCI105831; PAGLIACCI MC, 1991, HORM METAB RES, V23, P196, DOI 10.1055/s-2007-1003651; PERRILD H, 1983, CLIN ENDOCRINOL, V18, P139, DOI 10.1111/j.1365-2265.1983.tb03196.x; PERRILD H, 1990, AM J PSYCHIAT, V147, P1518; PHILIPPOU G, 1992, CLIN ENDOCRINOL, V36, P573, DOI 10.1111/j.1365-2265.1992.tb02267.x; PRIMO J, 1993, AM J GASTROENTEROL, V88, P1976; REEVES RA, 1985, CLIN PHARMACOL THER, V37, P157, DOI 10.1038/clpt.1985.28; SAMUELS MH, 1994, J CLIN ENDOCR METAB, V78, P211, DOI 10.1210/jc.78.1.211; SCHULTZ M, 1989, LANCET, V1, P1452; SHAKIR KMM, 1993, ANN INTERN MED, V118, P112, DOI 10.7326/0003-4819-118-2-199301150-00006; SHAKIR KMM, 1995, MAYO CLIN PROC, V70, P556; SMITH PJ, 1984, ENDOCR REV, V5, P514, DOI 10.1210/edrv-5-4-514; SPAULDING SW, 1972, J CLIN ENDOCR METAB, V35, P905, DOI 10.1210/jcem-35-6-905; SPERBER AD, 1992, ARCH INTERN MED, V152, P183, DOI 10.1001/archinte.152.1.183; STEINGOLD KA, 1991, J CLIN ENDOCR METAB, V73, P275, DOI 10.1210/jcem-73-2-275; STOCKIGT JR, 1985, J CLIN ENDOCR METAB, V60, P1025, DOI 10.1210/jcem-60-5-1025; STOCKIGT JR, 1989, ARCH INTERN MED, V149, P973, DOI 10.1001/archinte.149.4.973; TRIP MD, 1991, AM J MED, V91, P507, DOI 10.1016/0002-9343(91)90187-3; VANSETERS AP, 1991, ACTA ENDOCRINOL-COP, V124, P526, DOI 10.1530/acta.0.1240526; VANSETERS AP, 1991, ACTA ENDOCRINOL-COP, V125, P336; VASSILOPOULOUSELLIN R, 1992, HORM METAB RES, V24, P434, DOI 10.1055/s-2007-1003353; WITZTUM JL, 1978, J CLIN ENDOCR METAB, V46, P838, DOI 10.1210/jcem-46-5-838	96	232	242	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 21	1995	333	25					1688	1694		10.1056/NEJM199512213332507	http://dx.doi.org/10.1056/NEJM199512213332507			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL401	7477223				2022-12-28	WOS:A1995TL40100007
J	AUGENBRAUN, M; FELDMAN, J; CHIRGWIN, K; ZENILMAN, J; CLARKE, L; DEHOVITZ, J; LANDESMAN, S; MINKOFF, H				AUGENBRAUN, M; FELDMAN, J; CHIRGWIN, K; ZENILMAN, J; CLARKE, L; DEHOVITZ, J; LANDESMAN, S; MINKOFF, H			INCREASED GENITAL SHEDDING OF HERPES-SIMPLEX VIRUS TYPE-2 IN HIV-SEROPOSITIVE WOMEN	ANNALS OF INTERNAL MEDICINE			English	Note							ACQUIRED IMMUNODEFICIENCY; RISK-FACTORS; INFECTION; TRANSMISSION; ACQUISITION; FREQUENCY; PARTNER; HISTORY	Objective: To compare the prevalence of genital herpes simplex virus type 2 (HSV-2) shedding in human immunodeficiency virus (HIV)-seropositive women and HIV-seronegative women. Design: Cross-sectional study Setting: A major inner-city medical center. Patients: 106 women who were HIV-seropositive and HSV-2-seropositive and 70 women who were HIV-seronegative and HSV-2-seropositive were enrolled from various primary care settings. Measurements: Herpes simplex virus type 2 antibody determinations were done for all patients. Regardless of symptoms, vulvar and cervical HSV cultures were obtained from all HIV-seropositive women and from a randomly selected subgroup of HIV-seronegative women. Results: The prevalence of HSV-2 shedding was nearly four times greater in HIV-seropositive than in HIV-seronegative women (13.2% compared with 3.6%; P = 0.04; odds ratio, 4.1 [95% CI, 1.0 to 27.4]) when the serum antibody for HSV-2 was present. Seventy-nine percent of viral shedding among HIV-seropositive women was asymptomatic. Overall viral shedding increased significantly as the CD4 cell count decreased. Conclusions: Women with HIV infection, particularly those with low CD4 cell counts, shed HSV-2 from the vulva and cervix more commonly than women not infected with HIV. Most of this shedding is asymptomatic.	JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA	Johns Hopkins University	AUGENBRAUN, M (corresponding author), SUNY HLTH SCI CTR, 450 CLARKSON AVE, BOX 56, BROOKLYN, NY 11203 USA.			DeHovitz, Jack/0000-0001-7307-0614	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031834, N01AI095014, U01AI031834] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-95014, AI31834-03] Funding Source: Medline; BHP HRSA HHS [CSA-92-100] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); BHP HRSA HHS		ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BROCK BV, 1990, JAMA-J AM MED ASSOC, V263, P418, DOI 10.1001/jama.263.3.418; BROWN ZA, 1985, AM J OBSTET GYNECOL, V153, P24, DOI 10.1016/0002-9378(85)90584-8; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; CONE RW, 1994, JAMA-J AM MED ASSOC, V272, P792, DOI 10.1001/jama.272.10.792; DEHOVITZ JA, 1994, AM J EPIDEMIOL, V140, P1125, DOI 10.1093/oxfordjournals.aje.a117212; ERLICH KS, 1989, NEW ENGL J MED, V320, P293, DOI 10.1056/NEJM198902023200506; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; RATTRAY MC, 1978, BRIT J VENER DIS, V54, P262; ROONEY JF, 1986, NEW ENGL J MED, V314, P1561, DOI 10.1056/NEJM198606123142407; SAFRIN S, 1991, AIDS, V5, P1107, DOI 10.1097/00002030-199109000-00008; SIEGAL FP, 1981, NEW ENGL J MED, V305, P1439, DOI 10.1056/NEJM198112103052403; STENZELPOORE MP, 1987, SEX TRANSM DIS, V14, P17, DOI 10.1097/00007435-198701000-00004; WHITLEY RJ, 1980, PEDIATRICS, V66, P489; YEAGER AS, 1984, PEDIATRICS, V73, P188; 1987, MMWR-MORBID M      S, V36, P1	18	162	165	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1995	123	11					845	847		10.7326/0003-4819-123-11-199512010-00006	http://dx.doi.org/10.7326/0003-4819-123-11-199512010-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG209	7486467				2022-12-28	WOS:A1995TG20900006
J	GORMAN, JM				GORMAN, JM			RESPIRATION DISORDERS IN PANIC ATTACKS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											GORMAN, JM (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,NEW YORK,NY 10032, USA.							Barlow DH., 2002, ANXIETY ITS DISORDER, VSecond; KLEIN DF, 1993, ARCH GEN PSYCHIAT, V50, P306; PAPP LA, 1993, AM J PSYCHIAT, V150, P1149	3	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	1995	274	19					1504	1504						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD571	7474206				2022-12-28	WOS:A1995TD57100010
J	ZHOU, JN; HOFMAN, MA; GOOREN, LJG; SWAAB, DF				ZHOU, JN; HOFMAN, MA; GOOREN, LJG; SWAAB, DF			A SEX DIFFERENCE IN THE HUMAN BRAIN AND ITS RELATION TO TRANSSEXUALITY	NATURE			English	Article							BED NUCLEUS; STRIA TERMINALIS; GONADAL-STEROIDS; RAT; ANDROGEN; IMMUNOREACTIVITY; FOREBRAIN; SEPTUM; AREA	TRANSSEXUALS have the strong feeling, often from childhood onwards, of having been born the wrong sex. The possible psychogenic or biological aetiology of transsexuality has been the subject of debate for many years(1,2). Here we show that the volume of the central subdivision of the bed nucleus of the stria terminalis (BSTc), a brain area that is essential for sexual behaviour(3,4), is larger in men than in women. A female-sized BSTc was found in male-to-female transsexuals. The size of the BSTc was not influenced by sex hormones in adulthood and was independent of sexual orientation. Our study is the first to show a female brain structure in genetically male transsexuals and supports the hypothesis that gender identity develops as a result of an interaction between the developing brain and sex hormones(5,6).	NETHERLANDS INST BRAIN RES,GRAD SCH NEUROSCI,1105 AZ AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT ENDOCRINOL,1007 MB AMSTERDAM,NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER			Zhou, JiangNing/N-3374-2013; Hofman, Michel A./ABG-7621-2020; Oostenbruggen, Belle/D-7966-2012	Swaab, Dick/0000-0002-9665-7845				ALLEN LS, 1990, J COMP NEUROL, V302, P697, DOI 10.1002/cne.903020402; ARLUISON M, 1994, BRAIN RES BULL, V34, P319, DOI 10.1016/0361-9230(94)90026-4; BLEIER R, 1982, J COMP NEUROL, V212, P118, DOI 10.1002/cne.902120203; CLARO F, 1995, BRAIN RES BULL, V36, P1, DOI 10.1016/0361-9230(94)00118-K; COMMINS D, 1985, J COMP NEUROL, V231, P473, DOI 10.1002/cne.902310406; DELABRIL A, 1987, DEV BRAIN RES, V32, P295, DOI 10.1016/0165-3806(87)90110-6; DEOLMOS JS, 1990, HUMAN NERVOUS SYSTEM, P597; DEVRIES GJN, 1990, NEUROENDOCRINOLOGY, V20, P1; EIDEN LE, 1985, NEUROSCIENCE, V15, P999, DOI 10.1016/0306-4522(85)90249-0; EMERY DE, 1976, PHYSIOL BEHAV, V17, P803, DOI 10.1016/0031-9384(76)90044-5; GOOREN L, 1990, PSYCHONEUROENDOCRINO, V15, P3, DOI 10.1016/0306-4530(90)90041-7; GUILLAMON A, 1988, DEV BRAIN RES, V44, P281, DOI 10.1016/0165-3806(88)90226-X; JAKAB RL, 1993, J STEROID BIOCHEM, V44, P481, DOI 10.1016/0960-0760(93)90253-S; KAWAKAMI M, 1974, ENDOCRINOL JAPON, V21, P125; MONEY J, 1984, PSYCHONEUROENDOCRINO, V9, P405, DOI 10.1016/0306-4530(84)90048-9; Money J, 1970, Int J Psychiatry, V9, P249; PILGRIM C, 1992, HORM METAB RES, V24, P353, DOI 10.1055/s-2007-1003334; SHERIDAN PJ, 1979, ENDOCRINOLOGY, V104, P130, DOI 10.1210/endo-104-1-130; SIMERLY RB, 1990, TRENDS NEUROSCI, V13, P104, DOI 10.1016/0166-2236(90)90186-E; SIMERLY RB, 1987, P NATL ACAD SCI USA, V84, P2087, DOI 10.1073/pnas.84.7.2087; SWAAB DF, 1995, TRENDS NEUROSCI, V18, P264, DOI 10.1016/0166-2236(95)93913-I; SWAAB DF, 1990, BRAIN RES, V537, P141, DOI 10.1016/0006-8993(90)90350-K; SWAAB DF, 1994, BRAIN RES, V7, P249; WALTER A, 1991, J CHEM NEUROANAT, V4, P281, DOI 10.1016/0891-0618(91)90019-9; WOODHAMS PL, 1983, NEUROSCIENCE, V8, P677, DOI 10.1016/0306-4522(83)90003-9; ZHOU JN, 1995, BRAIN RES, V672, P285, DOI 10.1016/0006-8993(94)01430-P; ZHOU JN, 1995, NEUROBIOL AGING, V16, P571, DOI 10.1016/0197-4580(95)00043-E; 1991, LANCET, V338, P603	28	451	458	2	130	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 2	1995	378	6552					68	70		10.1038/378068a0	http://dx.doi.org/10.1038/378068a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477289	Green Submitted			2022-12-28	WOS:A1995TC46900051
J	EICHLER, HG				EICHLER, HG			HAZARDS OF MISGUIDED ETHICS COMMITTEES	LANCET			English	Editorial Material							URODILATIN; THERAPY				EICHLER, HG (corresponding author), UNIV VIENNA,DEPT CLIN PHARMACOL,WAEHRINGER GUERTEL 18,VIENNA,AUSTRIA.							Freedman B, 1992, J Clin Ethics, V3, P231; HELLMAN S, 1991, NEW ENGL J MED, V324, P1585, DOI 10.1056/NEJM199105303242208; HUMMEL M, 1992, CLIN INVESTIGATOR, V70, P674; HUMMEL M, 1993, J HEART LUNG TRANSPL, V12, P209; PENN ZJ, 1995, BRIT J OBSTET GYNAEC, V102, P1, DOI 10.1111/j.1471-0528.1995.tb09015.x; Spilker B., 1991, GUIDE CLIN TRIALS; 1991, GOOD CLIN PRACTICE T	7	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 28	1995	346	8983					1115	1116		10.1016/S0140-6736(95)91796-9	http://dx.doi.org/10.1016/S0140-6736(95)91796-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TB549	7475599				2022-12-28	WOS:A1995TB54900006
J	MILLS, SL; MASSEY, SC				MILLS, SL; MASSEY, SC			DIFFERENTIAL PROPERTIES OF 2 GAP JUNCTIONAL PATHWAYS MADE BY AII AMACRINE CELLS	NATURE			English	Article							ROD BIPOLAR CELLS; RABBIT RETINA; NITRIC-OXIDE; 2-AMINO-4-PHOSPHONOBUTYRIC ACID; MAMMALIAN RETINA; TARGET-CELLS; CAT RETINA; GLUTAMATE; PERMEABILITY; CHANNELS	THE retina is sensitive to light stimuli varying over more than 12 log units in intensity. It accomplishes this, in part, by switching between rod-dominated circuits designed for maximum utilization of scarce photons and cone circuits designed for greater acuity. Rod signals are integrated into the cone pathways through AII amacrine cells, which are connected by gap junctions both to other AII amacrine cells and to cone bipolar cells. To determine the relative permeabilities of the two junctional pathways, we have measured the distribution of biotinylated tracers across this heterologous cell assembly after injecting a single An amacrine cell. We found that neurobiotin (relative molecular mass, 286) passed easily through both types of gap junctions, but that biotin-X cadaverine (relative molecular mass, 442) passed through AII/bipolar cell gap junctions poorly compared to AII/AII gap junctions. Thus, the AII/bipolar cell channel has a lower permeability to large molecules than does the AII/AII amacrine cell channel. The two pathways are also regulated differently. Dopamine and cyclic AMP agonists, known to diminish AII-AII coupling(1), did not change the relative labelling intensity of AII to bipolar cells. However, nitric oxide and cGMP agonists selectively reduced labelling in bipolar cells relative to AII amacrine cells, perhaps by acting at the bipolar side of this gap junction. This suggests that increased cGMP controls the network switching between rod and cone pathways associated with light adaptation.			MILLS, SL (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT OPHTHALMOL & VISUAL SCI,HOUSTON,TX 77030, USA.		Massey, Stephen/A-7217-2009					BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BEYER EC, 1990, J MEMBRANE BIOL, V116, P187, DOI 10.1007/BF01868459; BRINK PR, 1980, NATURE, V285, P101, DOI 10.1038/285101a0; BRUZZONE R, 1994, J CELL SCI, V107, P955; FLAGGNEWTON J, 1979, SCIENCE, V205, P406; HAMPSON ECGM, 1992, J NEUROSCI, V12, P4911; KOISTINAHO J, 1993, NEUROSCIENCE, V57, P587, DOI 10.1016/0306-4522(93)90008-4; KOLB H, 1974, SCIENCE, V186, P47, DOI 10.1126/science.186.4158.47; MASSEY SC, 1993, INVEST OPHTH VIS SCI, V34, P1382; MILLS SL, 1991, J COMP NEUROL, V304, P491, DOI 10.1002/cne.903040312; NAWY S, 1990, NATURE, V346, P269, DOI 10.1038/346269a0; NOMURA A, 1994, CELL, V77, P361, DOI 10.1016/0092-8674(94)90151-1; Rae J L, 1979, Curr Top Eye Res, V1, P37; SHIELLS R, 1992, NEUROREPORT, V3, P845, DOI 10.1097/00001756-199210000-00006; SHIELLS RA, 1990, P ROY SOC B-BIOL SCI, V242, P91, DOI 10.1098/rspb.1990.0109; SLAUGHTER MM, 1981, SCIENCE, V211, P182, DOI 10.1126/science.6255566; STERLING P, 1983, ANNU REV NEUROSCI, V6, P149, DOI 10.1146/annurev.ne.06.030183.001053; STRETTOI E, 1992, J COMP NEUROL, V325, P152, DOI 10.1002/cne.903250203; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; TIAN N, 1994, J NEUROPHYSIOL, V71, P2258, DOI 10.1152/jn.1994.71.6.2258; TORK I, 1979, BRAIN RES, V169, P261, DOI 10.1016/0006-8993(79)91029-1; VANEY DI, 1994, PROG RETIN EYE RES, V13, P301, DOI 10.1016/1350-9462(94)90014-0; VEENSTRA RD, 1994, CIRC RES, V75, P483, DOI 10.1161/01.RES.75.3.483; VOIGT T, 1987, J NEUROSCI, V7, P4115; WERNER R, 1989, P NATL ACAD SCI USA, V86, P5380, DOI 10.1073/pnas.86.14.5380; WITKOVSKY P, 1991, PROG RETIN RES, V11, P247, DOI 10.1016/0278-4327(91)90031-V; YAMAMOTO R, 1993, NEUROSCIENCE, V54, P189, DOI 10.1016/0306-4522(93)90393-T; YAMASHITA M, 1991, J NEUROSCI, V11, P2372; ZIMMERMAN AL, 1985, J MEMBRANE BIOL, V84, P269, DOI 10.1007/BF01871390	29	299	305	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 26	1995	377	6551					734	737		10.1038/377734a0	http://dx.doi.org/10.1038/377734a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB469	7477263				2022-12-28	WOS:A1995TB46900057
J	DANDOY, S				DANDOY, S			HAVE YOU EVER PRACTICED MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1988	260	14					2113	2113						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q3421	3418879				2022-12-28	WOS:A1988Q342100033
J	BRUCCOLERI, RE; HABER, E; NOVOTNY, J				BRUCCOLERI, RE; HABER, E; NOVOTNY, J			STRUCTURE OF ANTIBODY HYPERVARIABLE LOOPS REPRODUCED BY A CONFORMATIONAL SEARCH ALGORITHM	NATURE			English	Article									MASSACHUSETTS GEN HOSP,CELLULAR & MOLEC RES LAB,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School								BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUCCOLERI RE, 1987, BIOPOLYMERS, V26, P137, DOI 10.1002/bip.360260114; BRUCCOLERI RE, 1985, MACROMOLECULES, V18, P2767, DOI 10.1021/ma00154a069; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1986, SCIENCE, V233, P755, DOI 10.1126/science.3090684; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DELAPAZ P, 1986, EMBO J, V5, P415, DOI 10.1002/j.1460-2075.1986.tb04227.x; DYSON HJ, 1985, NATURE, V318, P480; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FINE R M, 1986, Proteins Structure Function and Genetics, V1, P342, DOI 10.1002/prot.340010408; Go N., 1970, MACROMOLECULES, V3, P178, DOI DOI 10.1021/MA60014A012; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; KABAT EA, 1972, P NATL ACAD SCI USA, V69, P960, DOI 10.1073/pnas.69.4.960; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; MOULT J, 1986, Proteins Structure Function and Genetics, V1, P146, DOI 10.1002/prot.340010207; NOVOTNY J, 1985, P NATL ACAD SCI USA, V82, P4592, DOI 10.1073/pnas.82.14.4592; NOVOTNY J, 1984, J MOL BIOL, V177, P787, DOI 10.1016/0022-2836(84)90049-4; OOI T, 1987, P NATL ACAD SCI USA, V84, P3086, DOI 10.1073/pnas.84.10.3086; PINCUS MR, 1982, P NATL ACAD SCI USA, V79, P5107, DOI 10.1073/pnas.79.16.5107; RASHIN AA, 1984, BIOPOLYMERS, V23, P1605, DOI 10.1002/bip.360230813; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SHIH HHL, 1985, P NATL ACAD SCI USA, V82, P1697, DOI 10.1073/pnas.82.6.1697; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; SMITHGILL SJ, 1987, J MOL BIOL, V194, P713, DOI 10.1016/0022-2836(87)90249-X; SNOW ME, 1986, PROTEIN-STRUCT FUNCT, V1, P276; WU TT, 1970, J EXP MED, V132, P211, DOI 10.1084/jem.132.2.211	30	176	184	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1988	335	6190					564	568		10.1038/335564a0	http://dx.doi.org/10.1038/335564a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q3412	3419534				2022-12-28	WOS:A1988Q341200061
J	ROBINSON, JC; CASALINO, LP				ROBINSON, JC; CASALINO, LP			THE GROWTH OF MEDICAL GROUPS PAID THROUGH CAPITATION IN CALIFORNIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNIVERSAL HEALTH-INSURANCE; MANAGED COMPETITION; PROMOTE QUALITY; ECONOMY; 1990S; PLAN	Background. In California, it is common for health maintenance organizations (HMOs) to contract with large medical groups that are paid through capitation and are responsible for managing a full spectrum of medical services. Methods. We studied six large medical groups in California - Bristol Park Medical, Friendly Hills HealthCare Network, HealthCare Partners Medical Group, Mullikin Medical Centers, Palo Alto Medical Foundation, and San Jose Medical Group - that are paid through capitation and that are growing as a result of contracts with managed-care organizations. We conducted interviews and obtained data on factors such as patient enrolment, capitation and other revenue, numbers of days spent by enrollees in the hospital, and numbers of visits to physicians per enrollee. Results Between 1990 and 1994, the number of HMO enrollees whose care was paid for through capitation in the six medical groups increased by 91 percent, from 398,359 to 759,474. In 1994, the mean number of hospital days per 1000 HMO enrollees ranged from 120 to 149 for non-Medicare patients and from 643 to 936 days for Medicare patients. By comparison, in 1993 the mean numbers of hospital days per 1000 HMO enrollees not covered by Medicare were 232 for California and 297 for the United States; for HMO enrollees covered by Medicare, the numbers were 1337 for California and 1698 for the United States. In 1994, the average annual number of visits to physicians for HMO patients in the six groups not covered by Medicare ranged from 3.1 to 3.9; for Medicare patients, it ranged from 6.8 to 9.3; these rates were slightly lower than statewide and national rates. Four of the groups have sold their assets (such as facilities, supplies, equipment, and patients' charts) to outside investors; the physicians remain employed by physician-owned professional corporations. Conclusions. Medical groups paid through capitation offer a model for the status of physicians in managed-care systems that differs from the employee status offered by staff-model HMOs and the subcontractor status offered by HMOs that negotiate directly with individual physicians. Despite their growth, such medical groups in California face substantial challenges, such as obtaining the financial assets necessary to sustain rapid growth.			ROBINSON, JC (corresponding author), UNIV CALIF BERKELEY,SCH PUBL HLTH,418 WARREN HALL,BERKELEY,CA 94720, USA.		Casalino, Lawrence/ABE-1245-2020	Casalino, Lawrence/0000-0002-7927-7859				ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; ENTHOVEN AC, 1993, HEALTH AFFAIR, V12, P24, DOI 10.1377/hlthaff.12.suppl_1.24; HODAPP TE, 1994, HMOS 1995 RIGHT PLAC; KRONICK R, 1993, NEW ENGL J MED, V328, P148, DOI 10.1056/NEJM199301143280225; MORRISON EM, 1995, CONSOLIDATION PROVID; 1994, MARION MERRELL DOW M; 1994, CAPITATION STRATEGY	8	131	132	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 21	1995	333	25					1684	1687		10.1056/NEJM199512213332506	http://dx.doi.org/10.1056/NEJM199512213332506			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL401	7477222				2022-12-28	WOS:A1995TL40100006
J	DIBISCEGLIE, AM; CONJEEVARAM, HS; FRIED, MW; SALLIE, R; PARK, Y; YURDAYDIN, C; SWAIN, M; KLEINER, DE; MAHANEY, K; HOOFNAGLE, JH; WRIGHT, D				DIBISCEGLIE, AM; CONJEEVARAM, HS; FRIED, MW; SALLIE, R; PARK, Y; YURDAYDIN, C; SWAIN, M; KLEINER, DE; MAHANEY, K; HOOFNAGLE, JH; WRIGHT, D			RIBAVIRIN AS THERAPY FOR CHRONIC HEPATITIS-C - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						RIBAVIRIN; HEPATITIS C; HEPATITIS C VIRUSES; AMINOTRANSFERASES; RNA, VIRAL	RECOMBINANT INTERFERON-ALFA; ALPHA-INTERFERON; FOLLOW-UP; LIVER; RNA	Objective: To evaluate ribavirin, an oral antiviral agent, as therapy for chronic hepatitis C. Design: Randomized, double-blind, placebo-controlled study. Setting: Clinical Center of the National Institutes of Health, a tertiary referral research hospital. Patients: 29 patients with chronic hepatitis C who received oral ribavirin (600 mg twice daily) for 12 months and 29 controls with chronic hepatitis C who received placebo for 12 months. Measurements: Effects of therapy were evaluated by measuring serum aminotransferase and hepatitis C virus (HCV) RNA levels before, during, and for 6 months after therapy and by histologic examination of liver specimens before and at the end of treatment. Results: Patients treated with ribavirin had a prompt decrease in serum aminotransferase levels (54% overall) compared with levels before treatment and levels in controls (5% decrease). Serum aminotransferase levels became normal or nearly normal in 10 patients treated with ribavirin (35% [95% CI, 18% to 54%]) but in no controls (0% [CI, 0% to 12%]). Aminotransferase levels remained normal in only 2 patients after ribavirin therapy was discontinued (7% [CI, 1% to 23%]). Serum HCV RNA levels did not change during or after therapy. Liver biopsy specimens showed a decrease in hepatic inflammation and necrosis among ribavirin-treated patients whose aminotransferase levels became normal. Conclusions: Ribavirin has beneficial effects on serum aminotransferase levels and histologic findings in the liver in patients with chronic hepatitis C, but these effects are not accompanied by changes in HCV RNA levels and are not sustained when ribavirin therapy is discontinued. Thus, ribavirin alone for periods as long as 12 months is unlikely to be of value as therapy for chronic hepatitis C.	NIDDKD,LIVER DIS SECT,DIGEST DIS BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Kleiner, David E/N-2770-2013	Kleiner, David E/0000-0003-3442-4453				ALTER MJ, 1994, VIRAL HEPATITIS LIVE, P439; ASCHER NL, 1994, HEPATOLOGY, V20, pS24; BRILLANTI S, 1994, GASTROENTEROLOGY, V107, P812, DOI 10.1016/0016-5085(94)90131-7; CAMPS J, 1993, J HEPATOL, V19, P408, DOI 10.1016/S0168-8278(05)80550-1; CHEMELLO L, 1994, J HEPATOL, P21; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; DIBISCEGLIE AM, 1992, HEPATOLOGY, V16, P649, DOI 10.1002/hep.1840160307; DIBISCEGLIE AM, 1993, GASTROENTEROLOGY, V105, P858, DOI 10.1016/0016-5085(93)90905-R; DIBISCEGLIE AM, 1994, J HEPATOL, V21, P109; GILBERT BE, 1986, ANTIMICROB AGENTS CH, V30, P201, DOI 10.1128/AAC.30.2.201; HEAGY W, 1991, J CLIN INVEST, V87, P1916, DOI 10.1172/JCI115217; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; LAI MY, 1993, HEPATOLOGY, V18, pA93, DOI 10.1016/0270-9139(93)91900-D; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; MAHANEY K, 1994, HEPATOLOGY, V20, P1405, DOI 10.1002/hep.1840200605; PAGLIARO L, 1994, HEPATOLOGY, V19, P820, DOI 10.1002/hep.1840190404; REALDI G, 1982, GUT, V23, P270, DOI 10.1136/gut.23.4.270; REICHARD O, 1991, LANCET, V337, P1058, DOI 10.1016/0140-6736(91)91707-2; SCHULMAN NR, 1984, CLIN APPL RIBAVIRIN, P79; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; STUYVER L, 1994, VIRAL HEPATITIS LIVE, P317	24	299	311	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	DEC 15	1995	123	12					897	&		10.7326/0003-4819-123-12-199512150-00001	http://dx.doi.org/10.7326/0003-4819-123-12-199512150-00001			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK120	7486483				2022-12-28	WOS:A1995TK12000001
J	OLSEN, JH; BOICE, JD; SEERSHOLM, N; BAUTZ, A; FRAUMENI, JF				OLSEN, JH; BOICE, JD; SEERSHOLM, N; BAUTZ, A; FRAUMENI, JF			CANCER IN THE PARENTS OF CHILDREN WITH CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOFT-TISSUE SARCOMA; CHILDHOOD-CANCER; BREAST-CANCER; RETINOBLASTOMA PATIENTS; RELATIVES; RISK; MORTALITY; SURVIVORS; FAMILIES; MOTHERS	Background. Certain types of cancer in children and young adults have been linked with an increased risk of cancer in close relatives. However, the relation between childhood cancer and familial risk remains to be fully assessed in population-based studies. Methods. We conducted a nationwide study in Denmark of 11,380 parents of children with cancer. The children were identified from records in the Danish Cancer Registry; their parents were identified from population registers. The occurrence and rate of cancer in the parents were determined with use of the Cancer Registry's files and compared with national incidence rates for various categories of tumor. Results. Overall, 1445 cancers were diagnosed in the parents, as compared with 1496 expected from national incidence rates, to yield standardized incidence ratios of 1.0 (95 percent confidence interval, 0.9 to 1.0) for all parents, 1.0 for mothers, and 0.9 for fathers. The lower rate of cancer among fathers reflected their lower standardized incidence ratio for lung cancer (0.8; 95 percent confidence interval, 0.6 to 0.9), as calculated from 114 observations. Conclusions. Genetic determinants are important in several types of childhood cancer, but the genetic susceptibility to tumors does not generally extend to the parents of children with cancer, nor do the patterns of incidence point to the influence of shared environmental factors. Thus, cancer in children should not be viewed as a general marker for an increased risk of cancer in the patients' parents.	NCI,EPIDEMIOL & BIOSTAT PROGRAM,BETHESDA,MD	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	OLSEN, JH (corresponding author), DANISH CANC SOC,DIV CANC EPIDEMIOL,STRANDBOULEVARDEN 49,DK-2100 COPENHAGEN,DENMARK.			Olsen, Jorgen Helge/0000-0001-9633-5662				[Anonymous], 1976, INT CLASSIFICATION D; BATAILLE V, 1995, BRIT J DERMATOL, V132, P134, DOI 10.1111/j.1365-2133.1995.tb08639.x; BIRCH JM, 1987, INT J CANCER, V40, P620, DOI 10.1002/ijc.2910400508; BIRCH JM, 1984, BRIT J CANCER, V49, P325, DOI 10.1038/bjc.1984.51; BIRCH JM, 1990, CANCER-AM CANCER SOC, V66, P2239, DOI 10.1002/1097-0142(19901115)66:10<2239::AID-CNCR2820661034>3.0.CO;2-Q; BROWN PD, 1989, INT J EPIDEMIOL, V18, P546, DOI 10.1093/ije/18.3.546; BURKE E, 1991, CANCER-AM CANCER SOC, V67, P1467, DOI 10.1002/1097-0142(19910301)67:5<1467::AID-CNCR2820670535>3.0.CO;2-4; DERKINDEREN DJ, 1988, INT J CANCER, V41, P499, DOI 10.1002/ijc.2910410405; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; EWERTZ M, 1990, INT J CANCER, V46, P597, DOI 10.1002/ijc.2910460408; FARWELL J, 1984, NEW ENGL J MED, V311, P749, DOI 10.1056/NEJM198409203111201; GARBER JE, 1991, CANCER RES, V51, P6094; GRUNDY GW, 1973, JNCI-J NATL CANCER I, V51, P767, DOI 10.1093/jnci/51.3.767; HARTLEY AL, 1993, CANCER, V72, P923, DOI 10.1002/1097-0142(19930801)72:3<923::AID-CNCR2820720343>3.0.CO;2-Y; HARTLEY AL, 1986, BRIT J CANCER, V54, P819, DOI 10.1038/bjc.1986.245; HAYASAKA S, 1986, BRIT J OPHTHALMOL, V70, P107, DOI 10.1136/bjo.70.2.107; Jensen O M, 1985, Natl Cancer Inst Monogr, V68, P245; KNUDSON AG, 1985, CANCER RES, V45, P1437; LI FP, 1982, JAMA-J AM MED ASSOC, V247, P2692, DOI 10.1001/jama.247.19.2692; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; MATTHIESSEN PC, 1984, GROWTH POPULATION CA; MOUTOU C, 1994, J MED GENET, V31, P429, DOI 10.1136/jmg.31.6.429; OLSEN JH, 1990, HUM GENET, V85, P283; PASTORE G, 1987, CANCER LETT, V37, P17, DOI 10.1016/0304-3835(87)90141-8; PERSHAGEN G, 1992, INT J EPIDEMIOL, V21, P1, DOI 10.1093/ije/21.1.1; ROTHMAN K, 1979, DHHS NIH791649 PUBL; SEVERSON RK, 1993, CANCER EPIDEM BIOMAR, V2, P433; STRONG LC, 1984, J NATL CANCER I, V73, P303, DOI 10.1093/jnci/73.2.303; STRONG LC, 1987, JNCI-J NATL CANCER I, V79, P1213; THOMPSON EN, 1988, BRIT J CANCER, V57, P127, DOI 10.1038/bjc.1988.25; 1957, MANUAL INT STATISTIC	32	77	79	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 14	1995	333	24					1594	1599		10.1056/NEJM199512143332403	http://dx.doi.org/10.1056/NEJM199512143332403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK065	7477194				2022-12-28	WOS:A1995TK06500003
J	FRIGO, P; LANG, C				FRIGO, P; LANG, C			OSTEOPOROSIS IN A WOMAN OF THE EARLY BRONZE-AGE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											FRIGO, P (corresponding author), UNIV HOSP VIENNA,A-1090 VIENNA,AUSTRIA.								0	6	6	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 30	1995	333	22					1468	1468		10.1056/NEJM199511303332205	http://dx.doi.org/10.1056/NEJM199511303332205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG445	7477147				2022-12-28	WOS:A1995TG44500005
J	DINCHUK, JE; CAR, BD; FOCHT, RJ; JOHNSTON, JJ; JAFFEE, BD; COVINGTON, MB; CONTEL, NR; ENG, VM; COLLINS, RJ; CZERNIAK, PM; GORRY, SA; TRZASKOS, JM				DINCHUK, JE; CAR, BD; FOCHT, RJ; JOHNSTON, JJ; JAFFEE, BD; COVINGTON, MB; CONTEL, NR; ENG, VM; COLLINS, RJ; CZERNIAK, PM; GORRY, SA; TRZASKOS, JM			RENAL ABNORMALITIES AND AN ALTERED INFLAMMATORY RESPONSE IN MICE LACKING CYCLOOXYGENASE-II	NATURE			English	Article							RAT PREOVULATORY FOLLICLES; PROSTAGLANDIN SYNTHASE; HORMONAL-REGULATION; ARACHIDONIC-ACID; MESSENGER-RNA; H SYNTHASE; CELLS; MOUSE; EXPRESSION; INDUCTION	PROSTAGLANDINS have wide-ranging effects in the body and are thought to be important mediators of inflammation. Cyclooxygenase (COX) plays a keg regulatory role in prostaglandin synthesis, and occurs in both constitutive (COX-1) and inducible (COX-2) isoforms(1,2). COX-1 is thought to provide cytoprotective effects(3), whereas COX-2 is both inducible and the major isoform of inflammatory cells(4), Reduction of prostaglandin production by inhibition of cyclooxygenases appears to be the main mechanism of action of most non-steroidal anti-inflammatory drugs (NSAIDS)(5), Here we present an animal model of COX-2 deficiency that was generated by gene targeting. Defects in null mice correlating with reduced viability included renal alterations, characteristic of renal dysplasia (100% penetrance), and cardiac fibrosis (50% penetrance). Female Cox-2 -/- mice were infertile, COX-2 deficiency failed to alter inflammatory responses in several standard models, but striking mitigation of endotoxin-induced hepatocellular cytotoxicity was observed.	UNIV PENN, ANIM RESOURCES LAB, PHILADELPHIA, PA 19104 USA; DUPONT MERCK PHARMACEUT CO, WILMINGTON, DE 19880 USA	University of Pennsylvania; DuPont	DINCHUK, JE (corresponding author), DUPONT MERCK PHARMACEUT CO, GLENOLDEN, PA 19036 USA.							ABRAMSON SB, 1989, ARTHRITIS RHEUM, V32, P1, DOI 10.1002/anr.1780320102; ARIASNEGRETE S, 1995, BIOCHEM BIOPH RES CO, V208, P582, DOI 10.1006/bbrc.1995.1378; CALHOUN W, 1987, AGENTS ACTIONS, V21, P306, DOI 10.1007/BF01966499; CAR BD, 1994, J EXP MED, V179, P1437, DOI 10.1084/jem.179.5.1437; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; DEWITT DL, 1993, AM J MED S, V40, pS40; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; GANS KR, 1990, J PHARMACOL EXP THER, V254, P180; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; GOULET JL, 1994, P NATL ACAD SCI USA, V91, P12852, DOI 10.1073/pnas.91.26.12852; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; KINKAIDSMITH P, 1993, DISEASES KIDNEY, P1099; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTIN M, 1994, KIDNEY INT, V45, P150, DOI 10.1038/ki.1994.18; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PETERS T, 1990, EUR J BIOCHEM, V191, P583, DOI 10.1111/j.1432-1033.1990.tb19161.x; RAMIREZSOLIS R, 1993, GUIDE TECHNIQUES MOU, P855; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SIROIS J, 1993, J BIOL CHEM, V268, P12199; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; TIEGS G, 1988, BIOCHEM PHARMACOL, V37, P2569, DOI 10.1016/0006-2952(88)90248-1; WONG WYL, 1992, ENDOCRINOLOGY, V130, P3512, DOI 10.1210/en.130.6.3512; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOUNG JM, 1984, J INVEST DERMATOL, V82, P367, DOI 10.1111/1523-1747.ep12260709	30	845	859	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 23	1995	378	6555					406	409		10.1038/378406a0	http://dx.doi.org/10.1038/378406a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477380				2022-12-28	WOS:A1995TF89300064
J	CAO, WX; TYKODI, SS; ESSER, MT; BRACIALE, VL; BRACIALE, TJ				CAO, WX; TYKODI, SS; ESSER, MT; BRACIALE, VL; BRACIALE, TJ			PARTIAL ACTIVATION OF CD8(+) T-CELLS BY A SELF-DERIVED PEPTIDE	NATURE			English	Article							LIGAND	T cells are normally activated when the peptide for which they are specific is presented to them in the context of the appropriate major histocompatibility complex (MHC) (class I and Class II for CD8(+) and CD4(+) T cells, respectively). An increasing body of evidence indicates that structural homologues of the immunogenic peptide can partially activate or antagonize CD4(+) T cells(1-3). CD8(+) T cells may also be partially antagonized by such peptides(4,5), and self-derived peptides of this type may play a role in CD8(+) T cell selection in the thymus(6-8). Activated CD8(+) T cells lyse their targets by perforin-dependent granule exocytosis(9,10) and by inducing apoptosis mediated bs CD95 (also known as Fas or APO1) with its ligand (CD95L)(11-15). Here we show that a clone of K-d-restricted CD8(+) T cells specific for influenza haemagglutinin, which can also be activated in a crossreactive manner by a peptide derived from a myeloma tumour immunoglobulin heavy-chain variable region (IgVH) to kill by both routes(16), kills only by the CD95-CD95L pathway when stimulated by the corresponding germline IgVH peptide. As this germline IgVH peptide differs from the tumour peptide only at a single position buried in the MHC-binding be triggered independently of the perforin-mediated pathway, and can be selectively affected by changes in MHC conformation.	UNIV VIRGINIA,HLTH SCI CTR,BELRNE B CARTER CTR IMMUNOL RES,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,CHARLOTTESVILLE,VA 22908; WASHINGTON UNIV,SCH MED,DIV BIOL & BIOMED SCI,PROGRAM IMMUNOL,ST LOUIS,MO 63110	University of Virginia; University of Virginia; University of Virginia; Washington University (WUSTL)								BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; BODMER HC, 1988, CELL, V52, P253, DOI 10.1016/0092-8674(88)90514-4; CAO WX, 1994, J EXP MED, V179, P195, DOI 10.1084/jem.179.1.195; CHATTOPADHYAY S, 1993, J EXP MED, V179, P213; CRISPE IN, 1994, IMMUNITY, V1, P347; EVAVOLD BD, 1992, J IMMUNOL, V148, P347; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; HENKART PA, 1994, IMMUNITY, V1, P343, DOI 10.1016/1074-7613(94)90063-9; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; ITO N, 1991, CELL, V66, P233; JAMESON SC, 1994, NATURE, V369, P750, DOI 10.1038/369750a0; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OSTERGAARD HL, 1987, NATURE, V330, P71, DOI 10.1038/330071a0; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; SHERMAN LA, 1993, ANNU REV IMMUNOL, V11, P385, DOI 10.1146/annurev.immunol.11.1.385; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SPAIN LM, 1994, J IMMUNOL, V152, P1709; STAIDER T, 1994, J IMMUNOL, V152, P1127; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; WALSH CM, 1994, J IMMUNOL, V153, P2506	29	90	90	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 16	1995	378	6554					295	298		10.1038/378295a0	http://dx.doi.org/10.1038/378295a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477351				2022-12-28	WOS:A1995TE85800053
J	HYRIEN, O; MARIC, C; MECHALI, M				HYRIEN, O; MARIC, C; MECHALI, M			TRANSITION IN SPECIFICATION OF EMBRYONIC METAZOAN DNA-REPLICATION ORIGINS	SCIENCE			English	Article							RIBOSOMAL-RNA GENES; SACCHAROMYCES-CEREVISIAE; EGG EXTRACTS; 3' END; INITIATION; SITES; DOMAIN; SPACER	In early Xenopus embryos, in which ribosomal RNA genes (rDNA) are not transcribed, rDNA replication initiates and terminates at 9- to 12-kilobase pair intervals, with no detectable dependence on specific DNA sequences. Resumption of ribosomal RNA (rRNA) synthesis at late blastula and early gastrula is accompanied by a specific repression of replication initiation within transcription units; the frequency of initiation within intergenic spacers remains as high as in early blastula, These results demonstrate that for rRNA genes, circumscribed zones of replication initiation emerge in intergenic DNA during the time in metazoan development when the chromatin is remodeled to allow gene transcription.			HYRIEN, O (corresponding author), INST JACQUES MONOD, F-75251 PARIS 05, FRANCE.		Hyrien, Olivier/R-5108-2017	Hyrien, Olivier/0000-0001-8879-675X				BENARD M, 1995, NUCLEIC ACIDS RES, V23, P1447, DOI 10.1093/nar/23.9.1447; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1994, CURR OPIN GENET DEV, V4, P196, DOI 10.1016/S0959-437X(05)80045-0; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; CALLAN HG, 1972, PROC R SOC SER B-BIO, V181, P19, DOI 10.1098/rspb.1972.0039; Depamphilis Melvin L., 1993, Trends in Cell Biology, V3, P161, DOI 10.1016/0962-8924(93)90137-P; DEWINTER RFJ, 1986, NUCLEIC ACIDS RES, V14, P6041, DOI 10.1093/nar/14.15.6041; DIJKWEL PA, 1994, NUCLEIC ACIDS RES, V22, P4989, DOI 10.1093/nar/22.23.4989; DIJKWEL PA, 1991, MOL CELL BIOL, V11, P3850, DOI 10.1128/MCB.11.8.3850; DIJKWEL PA, 1995, MOL CELL BIOL, V15, P3023; GILBERT DM, 1995, MOL CELL BIOL, V15, P2942; HAASE SB, 1994, MOL CELL BIOL, V14, P2516, DOI 10.1128/MCB.14.4.2516; HAMLIN JL, 1995, CURR OPIN GENET DEV, V5, P153, DOI 10.1016/0959-437X(95)80002-6; HERNANDEZ P, 1993, EMBO J, V12, P1475, DOI 10.1002/j.1460-2075.1993.tb05791.x; HYRIEN O, 1992, NUCLEIC ACIDS RES, V20, P1463, DOI 10.1093/nar/20.7.1463; HYRIEN O, 1993, EMBO J, V12, P4511, DOI 10.1002/j.1460-2075.1993.tb06140.x; KELLY RE, 1995, MOL CELL BIOL, V15, P4136; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; LABHART P, 1986, CELL, V45, P431, DOI 10.1016/0092-8674(86)90329-6; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LINSKENS MHK, 1990, NUCLEIC ACIDS RES, V18, P647, DOI 10.1093/nar/18.3.647; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; LUCCHINI R, 1992, MOL CELL BIOL, V12, P4288, DOI 10.1128/MCB.12.10.4288; MAHBUBANI HM, 1992, NUCLEIC ACIDS RES, V20, P1457, DOI 10.1093/nar/20.7.1457; PAN WJ, 1995, MOL CELL BIOL, V15, P3372; REEDER RH, 1990, TRENDS GENET, V6, P390, DOI 10.1016/0168-9525(90)90298-K; SHIOKAWA K, 1981, DEV GROWTH DIFFER, V23, P579; SNYDER M, 1988, MOL CELL BIOL, V8, P2184, DOI 10.1128/MCB.8.5.2184; TASHEVA ES, 1994, MOL CELL BIOL, V14, P5628, DOI 10.1128/MCB.14.9.5628; VAUGHN JP, 1990, CELL, V61, P1075, DOI 10.1016/0092-8674(90)90071-L; WIESENDANGER B, 1994, NUCLEIC ACIDS RES, V22, P5038, DOI 10.1093/nar/22.23.5038; WU CL, 1993, BIOCHIM BIOPHYS ACTA, V1174, P258, DOI 10.1016/0167-4781(93)90194-I; YOON Y, 1995, MOL CELL BIOL, V15, P2482	34	265	266	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 10	1995	270	5238					994	997		10.1126/science.270.5238.994	http://dx.doi.org/10.1126/science.270.5238.994			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD878	7481806				2022-12-28	WOS:A1995TD87800051
J	RAETZ, CRH; RODERICK, SL				RAETZ, CRH; RODERICK, SL			A LEFT-HANDED PARALLEL BETA-HELIX IN THE STRUCTURE OF UDP-N-ACETYLGLUCOSAMINE ACYLTRANSFERASE	SCIENCE			English	Article							LIPID-A BIOSYNTHESIS; ESCHERICHIA-COLI; ENDOTOXIN BIOSYNTHESIS; 1ST STEP; PROTEIN; GENE; CONFORMATION; REFINEMENT; SHEETS; LPXA	UDP-N-acetylglucosamine 3-O-acyltransferase (LpxA) catalyzes the transfer of (R)-3-hydroxymyristic acid from its acyl carrier protein thioester to UDP-N-acetylglucosamine. LpxA is the first enzyme in the lipid A biosynthetic pathway and is a target for the design of antibiotics. The x-ray crystal structure of LpxA has been determined to 2.6 angstrom resolution and reveals a domain motif composed of parallel beta strands, termed a left-handed parallel beta helix (L beta H). This unusual fold displays repeated violations of the protein folding constraint requiring right-handed crossover connections between strands of parallel beta sheets and may be present in other enzymes that share amino acid sequence homology to the repeated hexapeptide motif of LpxA.	ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Yeshiva University; Albert Einstein College of Medicine; Duke University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38328] Funding Source: Medline; NIGMS NIH HHS [GM51310] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLIGNET J, 1995, ANTIMICROB AGENTS CH, V39, P2027, DOI 10.1128/AAC.39.9.2027; ANDERSON MS, 1993, J BIOL CHEM, V268, P19858; ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; CHOTHIA C, 1973, J MOL BIOL, V75, P295, DOI 10.1016/0022-2836(73)90022-3; CHOU KC, 1987, J MOL BIOL, V205, P241; COLEMAN J, 1988, J BACTERIOL, V170, P1268, DOI 10.1128/jb.170.3.1268-1274.1988; CROWELL DN, 1986, J BACTERIOL, V168, P152, DOI 10.1128/jb.168.1.152-159.1986; DICKER IB, 1992, MOL MICROBIOL, V6, P817, DOI 10.1111/j.1365-2958.1992.tb01532.x; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUREY W, 1995, AM CRYSTALLOGRAPHIC, P73; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KELLY TM, 1993, J BIOL CHEM, V268, P19866; NAGANO K, 1977, J MOL BIOL, V109, P235, DOI 10.1016/S0022-2836(77)80032-6; PARENT R, 1992, J BACTERIOL, V174, P2891, DOI 10.1128/JB.174.9.2891-2897.1992; PFITZNER U, 1995, PROTEINS, V22, P191, DOI 10.1002/prot.340220212; PICKERSGILL R, 1994, NAT STRUCT BIOL, V1, P717, DOI 10.1038/nsb1094-717; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, UNPUB; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RICHARDSON JS, 1976, P NATL ACAD SCI USA, V73, P2619, DOI 10.1073/pnas.73.8.2619; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; STERNBERG MJE, 1977, J MOL BIOL, V110, P269, DOI 10.1016/S0022-2836(77)80072-7; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VUORIO R, 1992, ANTIMICROB AGENTS CH, V36, P826, DOI 10.1128/AAC.36.4.826; VUORIO R, 1991, FEBS LETT, V292, P90, DOI 10.1016/0014-5793(91)80841-P; VUORIO R, 1994, FEBS LETT, V337, P289, DOI 10.1016/0014-5793(94)80211-4; YODER MD, 1995, FASEB J, V9, P335, DOI 10.1096/fasebj.9.5.7896002; YODER MD, 1993, STRUCTURE, V1, P241, DOI 10.1016/0969-2126(93)90013-7; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994; YOUNG K, 1991, J BACTERIOL, V173, P3609, DOI 10.1128/JB.173.12.3609-3614.1991; YOUNG K, 1993, FED PROC, V7, P1252	33	297	303	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 10	1995	270	5238					997	1000		10.1126/science.270.5238.997	http://dx.doi.org/10.1126/science.270.5238.997			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD878	7481807				2022-12-28	WOS:A1995TD87800052
J	JORGENSEN, EM; HARTWIEG, E; SCHUSKE, K; NONET, ML; JIN, YS; HORVITZ, HR				JORGENSEN, EM; HARTWIEG, E; SCHUSKE, K; NONET, ML; JIN, YS; HORVITZ, HR			DEFECTIVE RECYCLING OF SYNAPTIC VESICLES IN SYNAPTOTAGMIN MUTANTS OF CAENORHABDITIS-ELEGANS	NATURE			English	Article							C-ELEGANS; MEMBRANE-PROTEIN; DOCKING; UNC-104; TISSUE	SYNAPTOTAGMIN, an integral membrane protein of the synaptic vesicle(1,2), binds calcium and interacts with proteins of the plasma membrane(4-6). These observations suggest several possible functions for synaptotagmin in synaptic vesicle dynamics: it could facilitate exocytosis by promoting calcium-dependent fusion(3), inhibit exocytosis by preventing fusion(7), or facilitate endocytosis of synaptic vesicles from the plasma membrane by acting as a receptor for the endocytotic proteins of the clathrin AP2 complex(8). Here we show that synaptic vesicles are depleted at synaptic terminals in synaptotagmin mutants of the nematode Caenorhabditis elegans. This depletion is not caused by a defect in transport or by increased synaptic vesicle release, but rather by a defect in retrieval of synaptic vesicles from the plasma membrane. Thus we propose that, as well as being involved in exocytosis, synaptotagmin functions in vesicular recycling.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139; WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Washington University (WUSTL)	JORGENSEN, EM (corresponding author), UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112, USA.			Jin, Yishi/0000-0002-9371-9860				AVERY L, 1993, GENETICS, V133, P897; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CLARK SG, 1994, GENETICS, V137, P987; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MILLER TM, 1984, J CELL BIOL, V98, P685, DOI 10.1083/jcb.98.2.685; MUNDIGL O, 1994, CURR OPIN CELL BIOL, V6, P561, DOI 10.1016/0955-0674(94)90077-9; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; RAIZEN DM, 1994, NEURON, V12, P483, DOI 10.1016/0896-6273(94)90207-0; RAND JB, 1985, PSYCHOPHARMACOL BULL, V21, P623; RAND JB, 1984, GENETICS, V106, P227; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	26	263	273	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 9	1995	378	6553					196	199		10.1038/378196a0	http://dx.doi.org/10.1038/378196a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD759	7477324				2022-12-28	WOS:A1995TD75900057
J	HIRSCHL, RB; PRANIKOFF, T; GAUGER, P; SCHREINER, RJ; DECHERT, R; BARTLETT, RH				HIRSCHL, RB; PRANIKOFF, T; GAUGER, P; SCHREINER, RJ; DECHERT, R; BARTLETT, RH			LIQUID VENTILATION IN ADULTS, CHILDREN, AND FULL-TERM NEONATES	LANCET			English	Note								We evaluated the safety and efficacy of partial liquid ventilation in a series of 19 adults, children, and neonates who were in respiratory failure and on extracorporeal life support. During partial liquid ventilation, the alveolar-arterial oxygen difference decreased from 590 (SE 25) to 471 (42) mm Hg (p=0 . 0002) and static pulmonary compliance increased from 0 . 18 (0 . 04) to 0 . 29 (0 . 04) mL cm H2O-1 kg(-1) (p=0 . 0002). 11 patients (58%) survived. These preliminary data suggest that partial liquid ventilation can be safely used in patients with severe respiratory failure and may improve lung function.	UNIV MICHIGAN, DEPT SURG, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan			Gauger, Paul/W-8176-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD015434] Funding Source: NIH RePORTER; NICHD NIH HHS [R01HD15434] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARTLETT RH, 1990, CURR PROB SURG, V27, P623; FUHRMAN BP, 1991, CRIT CARE MED, V19, P712, DOI 10.1097/00003246-199105000-00019; GATTINONI L, 1993, JAMA-J AM MED ASSOC, V269, P2122, DOI 10.1001/jama.269.16.2122; GREENSPAN JS, 1990, J PEDIATR-US, V117, P106, DOI 10.1016/S0022-3476(05)82457-6; HIRSCHL RB, 1994, SURGERY, V116, P159; HIRSCHL RB, 1995, CHEST, V108, P500, DOI 10.1378/chest.108.2.500; LOWE CA, 1986, J APPL PHYSIOL, V60, P154, DOI 10.1152/jappl.1986.60.1.154; SHAFFER TH, 1992, PEDIATR PULM, V14, P102, DOI 10.1002/ppul.1950140208	8	157	162	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 4	1995	346	8984					1201	1202		10.1016/S0140-6736(95)92903-7	http://dx.doi.org/10.1016/S0140-6736(95)92903-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC976	7475663				2022-12-28	WOS:A1995TC97600013
J	MATZEL, KE; STADELMAIER, U; HOHENFELLNER, M; GALL, FP				MATZEL, KE; STADELMAIER, U; HOHENFELLNER, M; GALL, FP			ELECTRICAL-STIMULATION OF SACRAL SPINAL NERVES FOR TREATMENT OF FECAL INCONTINENCE	LANCET			English	Article							CONTINENCE; MANAGEMENT; SPHINCTER	Functional deficits of the striated anal sphincteric muscles without any apparent gross defect often result in a lack of ability to postpone defaecation by intention or in faecal incontinence in response to increased intra-abdominal or intra-rectal pressure. We applied electrostimulation to the sacral spinal nerves to increase function of the striated muscles of the anal sphincter. Of three patients followed for 6 months, two gained full continence and one improved from gross incontinence to minor soiling. Closure pressure of the anal canal increased in all. Preliminary data indicate that anal closure pressure increases with the duration of stimulation. Continuous stimulation of sacral spinal nerves can help some patients with faecal incontinence. It may be possible to promote continence with intermittent stimulation.	UNIV WITTEN HERDECKE KLINIKUM, KLINIKUM WUPPERTAL, UROL & KINDERUROL KLIN, WUPPERTAL, GERMANY		MATZEL, KE (corresponding author), UNIV ERLANGEN NURNBERG, CHIRURG KLIN & POLIKLIN, W-8520 ERLANGEN, GERMANY.							BAETEN CGMI, 1991, LANCET, V338, P1163, DOI 10.1016/0140-6736(91)92030-6; CHRISTIANSEN J, 1989, DIS COLON RECTUM, V32, P432, DOI 10.1007/BF02563699; CORMAN ML, 1985, BRIT J SURG, V72, pS21, DOI 10.1002/bjs.1800721314; GASTON EA, 1948, SURG GYNECOL OBSTET, V87, P280; GOLIGHER JC, 1951, LANCET, V260, P543; LAURBERG S, 1990, BRIT J SURG, V77, P519, DOI 10.1002/bjs.1800770515; LONDONOSCHIMMER EE, 1994, INT J COLORECTAL DIS, V9, P110, DOI 10.1007/BF00699424; MATZEL KE, 1990, DIS COLON RECTUM, V33, P666, DOI 10.1007/BF02150742; PARKS A. G., 1962, DIS COLON AND RECTUM, V5, P407, DOI 10.1007/BF02616644; PERCY JP, 1981, LANCET, V1, P16; PETTE D, 1992, REV PHYSIOL BIOCH P, V120, P115, DOI 10.1007/BFb0036123; PICKRELL KL, 1952, ANN SURG, V135, P853, DOI 10.1097/00000658-195206000-00010; READ NW, 1983, GASTROENTEROLOGY, V85, P105; SALMONS S, 1981, MUSCLE NERVE, V4, P94, DOI 10.1002/mus.880040204; SCHMIDT RA, 1990, J UROLOGY, V143, P779, DOI 10.1016/S0022-5347(17)40092-9; SNOOKS SJ, 1986, ANN ROY COLL SURG, V68, P45; TANAGHO EA, 1988, J UROLOGY, V140, P1331, DOI 10.1016/S0022-5347(17)42038-6; TANAGHO EA, 1989, J UROLOGY, V142, P340, DOI 10.1016/S0022-5347(17)38751-7	18	396	410	3	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 28	1995	346	8983					1124	1127		10.1016/S0140-6736(95)91799-3	http://dx.doi.org/10.1016/S0140-6736(95)91799-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB549	7475602				2022-12-28	WOS:A1995TB54900009
J	FILICE, G; CEREDA, PM; VARNIER, OE				FILICE, G; CEREDA, PM; VARNIER, OE			INFECTION OF RABBITS WITH HUMAN IMMUNODEFICIENCY VIRUS	NATURE			English	Article									SCH MED,INST MICROBIOL,I-27100 PAVIA,ITALY; SCH MED,INST MICROBIOL,HUMAN RETROVIROL LAB,I-16132 GENOVA,ITALY		FILICE, G (corresponding author), IST RICOVERO & CURA CARATTERE SCI SAN MATTEO,INST INFECT DIS,I-27100 PAVIA,ITALY.							ALTER HJ, 1984, SCIENCE, V226, P549, DOI 10.1126/science.6093251; ASJO B, 1987, VIROLOGY, V157, P359, DOI 10.1016/0042-6822(87)90278-9; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; CEREDA PM, 1984, MICROBIOLOGICA, V7, P107; CLAPHAM PR, 1987, VIROLOGY, V158, P44, DOI 10.1016/0042-6822(87)90236-4; DAVIS LG, 1986, BASIC METHODS MOL BI, P44; DESROSIERS RC, 1987, REV INFECT DIS, V9, P438; FULTZ PN, 1986, J INFECT DIS, V154, P896, DOI 10.1093/infdis/154.5.896; FULTZ PN, 1986, J VIROL, V58, P116, DOI 10.1128/JVI.58.1.116-124.1986; GAJDUSEK DC, 1985, LANCET, V1, P55; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; KOTANI S, 1986, INT J CANCER, V37, P843, DOI 10.1002/ijc.2910370608; KULAGA H, 1988, P NATL ACAD SCI USA, V85, P4455, DOI 10.1073/pnas.85.12.4455; MATTHEWS TJ, 1987, AIDS RES HUM RETROV, V3, P197, DOI 10.1089/aid.1987.3.197; MORROW WJW, 1987, J GEN VIROL, V68, P2253, DOI 10.1099/0022-1317-68-8-2253; MULLER N, 1986, J ORG CHEM, V51, P263, DOI 10.1021/jo00352a032; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935	19	99	103	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 22	1988	335	6188					366	369		10.1038/335366a0	http://dx.doi.org/10.1038/335366a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q1373	3419504				2022-12-28	WOS:A1988Q137300064
J	KOEHLER, JE; LEBOIT, PE; EGBERT, BM; BERGER, TG				KOEHLER, JE; LEBOIT, PE; EGBERT, BM; BERGER, TG			CUTANEOUS VASCULAR-LESIONS AND DISSEMINATED CAT-SCRATCH DISEASE IN PATIENTS WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) AND AIDS-RELATED COMPLEX	ANNALS OF INTERNAL MEDICINE			English	Article									UNIV CALIF SAN FRANCISCO, MED CTR, DEPT PATHOL, SAN FRANCISCO, CA 94143 USA; SAN FRANCISCO GEN HOSP, DEPT DERMATOL, SAN FRANCISCO, CA 94110 USA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center	KOEHLER, JE (corresponding author), UNIV CALIF SAN FRANCISCO, DIV INFECT DIS, C443, BOX 0654, SAN FRANCISCO, CA 94143 USA.							ARIASSTELLA J, 1986, AM J SURG PATHOL, V10, P595, DOI 10.1097/00000478-198609000-00002; BLACK JR, 1986, ARCH INTERN MED, V146, P394, DOI 10.1001/archinte.146.2.394; CARITHERS HA, 1985, AM J DIS CHILD, V139, P1124, DOI 10.1001/archpedi.1985.02140130062031; COCKERELL CJ, 1988, LANCET, V1, P1334; COCKERELL CJ, 1987, LANCET, V2, P654; ENGLISH CK, 1988, JAMA-J AM MED ASSOC, V259, P1347, DOI 10.1001/jama.259.9.1347; GREENBAUM B, 1986, J PEDIATR-US, V108, P428, DOI 10.1016/S0022-3476(86)80889-7; GREGORY DW, 1986, AM J MED SCI, V292, P389, DOI 10.1097/00000441-198612000-00010; JOHNSON JF, 1985, RADIOLOGY, V156, P373, DOI 10.1148/radiology.156.2.4011899; KATNER HP, 1986, CHEST, V89, P302, DOI 10.1378/chest.89.2.302; KNOBLER EH, 1988, JAMA-J AM MED ASSOC, V260, P524, DOI 10.1001/jama.260.4.524; LEBOIT PE, 1988, LANCET, V1, P960; LEWIS DW, 1986, PEDIATRICS, V77, P714; MARGILETH AM, 1987, J INFECT DIS, V155, P390, DOI 10.1093/infdis/155.3.390; MARGILETH AW, 1984, JAMA-J AM MED ASSOC, V252, P928, DOI 10.1001/jama.252.7.928; MILLERCATCHPOLE R, 1986, AM J SURG PATHOL, V10, P276, DOI 10.1097/00000478-198604000-00006; MUSZYNSKI MJ, 1987, PEDIATR INFECT DIS J, V6, P199, DOI 10.1097/00006454-198702000-00011; ROCCO VK, 1985, GASTROENTEROLOGY, V89, P1400, DOI 10.1016/0016-5085(85)90661-4; STOLER MH, 1983, AM J CLIN PATHOL, V80, P714, DOI 10.1093/ajcp/80.5.714; WALDO E, 1983, AM J DERMATOPATH, V5, P525, DOI 10.1097/00000372-198312000-00003; WEAR DJ, 1985, OPHTHALMOLOGY, V92, P1282; WEAR DJ, 1983, SCIENCE, V221, P1403, DOI 10.1126/science.6612349	22	150	149	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1988	109	6					449	455		10.7326/0003-4819-109-6-449	http://dx.doi.org/10.7326/0003-4819-109-6-449			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q2568	3415105				2022-12-28	WOS:A1988Q256800003
J	COLQUHOUN, MC				COLQUHOUN, MC			USE OF DEFIBRILLATORS BY GENERAL-PRACTITIONERS	BRITISH MEDICAL JOURNAL			English	Article																		ARMSTRONG A, 1972, BRIT HEART J, V34, P67; COBB LA, 1975, CIRCULATION       S3, V51, P223; CUMMINS RO, 1985, BRIT MED J, V291, P1401, DOI 10.1136/bmj.291.6506.1401; PAI GR, 1987, BRIT MED J, V294, P352, DOI 10.1136/bmj.294.6568.352; RAWLINS DC, 1981, BRIT MED J, V282, P1677, DOI 10.1136/bmj.282.6277.1677	5	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1988	297	6644					336	336		10.1136/bmj.297.6644.336	http://dx.doi.org/10.1136/bmj.297.6644.336			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P4527	3416166	Green Published, Bronze			2022-12-28	WOS:A1988P452700025
J	MOSS, C; HAMILTON, PJ				MOSS, C; HAMILTON, PJ			THROMBOCYTOPENIA IN SYSTEMIC LUPUS-ERYTHEMATOSUS RESPONSIVE TO DAPSONE	BRITISH MEDICAL JOURNAL			English	Article											MOSS, C (corresponding author), ROYAL VICTORIA INFIRM,DERMATOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							COBURN PR, 1982, BRIT J DERMATOL, V106, P105, DOI 10.1111/j.1365-2133.1982.tb00910.x; KATZ SI, 1976, J INVEST DERMATOL, V67, P688, DOI 10.1111/1523-1747.ep12598565; MCCORMACK LS, 1984, J AM ACAD DERMATOL, V11, P397, DOI 10.1016/S0190-9622(84)70180-0; RUZICKA T, 1981, BRIT J DERMATOL, V104, P53, DOI 10.1111/j.1365-2133.1981.tb01711.x; STENDAHL O, 1978, J CLIN INVEST, V62, P214, DOI 10.1172/JCI109109	5	23	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1988	297	6643					266	266		10.1136/bmj.297.6643.266	http://dx.doi.org/10.1136/bmj.297.6643.266			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P4266	3416146	Bronze, Green Published			2022-12-28	WOS:A1988P426600021
J	[Anonymous]				[Anonymous]			ARE GERM-LINES SPECIAL	NATURE			English	Editorial Material																		WEATHERALL DJ, 1988, NATURE, V331, P13, DOI 10.1038/331013a0	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 14	1988	331	6152					100	100						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	L6688	3422342				2022-12-28	WOS:A1988L668800003
J	WILCOX, AJ; WEINBERG, CR; BAIRD, DD				WILCOX, AJ; WEINBERG, CR; BAIRD, DD			TIMING OF SEXUAL INTERCOURSE IN RELATION TO OVULATION - EFFECTS ON THE PROBABILITY OF CONCEPTION, SURVIVAL OF THE PREGNANCY, AND SEX OF THE BABY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							URINARY ESTROGEN; NORMAL MEN; TEMPERATURE; SPERMATOZOA; SPERM	Background. The timing of sexual intercourse in relation to ovulation strongly influences the chance of conception, although the actual number of fertile days in a woman's menstrual cycle is uncertain. The timing of intercourse may also be associated with the sex of the baby. Methods. We recruited 221 healthy women who were planning to become pregnant. At the same time the women stopped using birth-control methods, they began collecting daily urine specimens and keeping daily records of whether they had sexual intercourse. We measured estrogen and progesterone metabolites in urine to estimate the day of ovulation. Results. In a total of 625 menstrual cycles for which the dates of ovulation could be estimated, 192 pregnancies were initiated, as indicated by increases in the urinary concentration of human chorionic gonadotropin around the expected time of implantation. Two thirds (n=129) ended in live births. Conception occurred only when intercourse took place during a six-day period that ended on the estimated day of ovulation. The probability of conception ranged from 0.10 when intercourse occurred five days before ovulation to 0.33 when it occurred on the day of ovulation itself. There was no evident relation between the age of sperm and the viability of the conceptus, although only 6 percent of the pregnancies could be firmly attributed to sperm that were three or more days old. Cycles producing male and female babies had similar patterns of intercourse in relation to ovulation. Conclusions. Among healthy women trying to conceive, nearly all pregnancies can be attributed to intercourse during a six-day period ending on the day of ovulation. For practical purposes, the timing of sexual intercourse in relation to ovulation has no influence on the sex of the baby.	NIEHS,STAT & BIOMATH BRANCH,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	WILCOX, AJ (corresponding author), NIEHS,EPIDEMIOL BRANCH,RES TRIANGLE PK,NC 27709, USA.		Baird, Donna D/D-5214-2017; Wilcox, Allen J/C-7723-2019	Baird, Donna D/0000-0002-5544-2653; Wilcox, Allen J/0000-0002-3376-1311; Weinberg, Clarice/0000-0002-7713-8556				ARMSTRONG EG, 1984, J CLIN ENDOCR METAB, V59, P867, DOI 10.1210/jcem-59-5-867; BAIRD DD, 1991, STAT MED, V10, P255, DOI 10.1002/sim.4780100209; BAIRD DD, 1995, EPIDEMIOLOGY, V6, P547, DOI 10.1097/00001648-199509000-00015; BAKER RJ, 1978, GLIM SYSTEM; BARRETT JC, 1969, POP STUD-J DEMOG, V23, P455, DOI 10.1080/00324728.1969.10405297; Bongaarts J., 1983, DETERMINANTS FERTILI, V1, P103; Campbell K L, 1985, Res Front Fertil Regul, V3, P1; CHECK JH, 1989, AM J OBSTET GYNECOL, V160, P598, DOI 10.1016/S0002-9378(89)80036-5; COHEN J, 1985, FERTIL STERIL, V44, P254; COLLINS WP, 1983, CURRENT TOPICS REPRO, V3, P49; FRANCE JT, 1992, INT J FERTIL, V37, P244; FREUND M, 1962, J REPROD FERTIL, V4, P143; Glezerman M, 1993, INFERTILITY MALE FEM; GUERREROV R, 1975, NEW ENGL J MED, V293, P573; KESNER JS, 1994, STEROIDS, V59, P205, DOI 10.1016/0039-128X(94)90029-9; MACLEOD J, 1952, FERTIL STERIL, V3, P297; PERLOFF WH, 1964, AM J OBSTET GYNECOL, V88, P439; POLAND ML, 1985, FERTIL STERIL, V44, P396; POTTER RG, 1961, MILBANK FUND Q, V39, P132, DOI 10.2307/3348639; ROYSTON JP, 1982, BIOMETRICS, V38, P397, DOI 10.2307/2530453; SARNARAJEEWA P, 1979, J STEROID BIOCHEM, V11, P1165; SCHWARTZ D, 1980, POP STUD-J DEMOG, V34, P397, DOI 10.1080/00324728.1980.10410398; SHETTLES LB, 1984, CHOOSE SEX YOUR BABY; SIMPSON J L, 1988, Advances in Contraception, V4, P247, DOI 10.1007/BF01849266; WEINBERG CR, 1994, BIOMETRICS, V50, P358, DOI 10.2307/2533379; WEINBERG CR, 1995, HUM REPROD, V10, P304, DOI 10.1093/oxfordjournals.humrep.a135932; WEINBERG CR, IN PRESS PONTIFICAL; Wilcox A J, 1990, Epidemiology, V1, P382, DOI 10.1097/00001648-199009000-00008; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; WILCOX AJ, 1985, FERTIL STERIL, V44, P366; WRIGHT K, 1978, STEROIDS, V31, P407, DOI 10.1016/0039-128X(78)90053-3; ZARUTSKIE PW, 1989, FERTIL STERIL, V52, P891; 1983, FERTIL STERIL, V40, P773; 1984, FERTIL STERIL, V41, P593	34	720	738	3	65	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 7	1995	333	23					1517	1521		10.1056/NEJM199512073332301	http://dx.doi.org/10.1056/NEJM199512073332301			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH157	7477165				2022-12-28	WOS:A1995TH15700001
J	WILSON, WR; KARCHMER, AW; DAJANI, AS; TAUBERT, KA; BAYER, A; KAYE, D; BISNO, AL; FERRIERI, P; SHULMAN, ST; DURACK, DT				WILSON, WR; KARCHMER, AW; DAJANI, AS; TAUBERT, KA; BAYER, A; KAYE, D; BISNO, AL; FERRIERI, P; SHULMAN, ST; DURACK, DT			ANTIBIOTIC-TREATMENT OF ADULTS WITH INFECTIVE ENDOCARDITIS DUE TO STREPTOCOCCI, ENTEROCOCCI, STAPHYLOCOCCI, AND HACEK MICROORGANISMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COAGULASE-NEGATIVE STAPHYLOCOCCI; PROSTHETIC VALVE ENDOCARDITIS; INTRAVENOUS-DRUG-USERS; AUREUS ENDOCARDITIS; STREPTOMYCIN-RESISTANT; VIRIDANS STREPTOCOCCI; ANTIMICROBIAL THERAPY; PENICILLIN; COMBINATION; VANCOMYCIN	Objective.-To provide guidelines for the treatment of endocarditis in adults caused by the following microorganisms: viridans streptococci and other streptococci, enterococci, staphylococci, and fastidious gram-negative bacilli of the HACEK group. Participants.-An ad hoc writing group appointed by the American Heart Association under the auspices of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young. Evidence.-Published studies of the treatment of patients with endocarditis and the collective clinical experience of this group of experts. Consensus Process.-The recommendations were formulated during meetings of the working group and were prepared by a writing committee after the group had agreed on the specific therapeutic regimens. The consensus statement was subsequently reviewed by standing committees of the American Heart Association and by a group of experts not affiliated with the working group. Conclusions.-Sufficient evidence has been published that recommendations regarding treatment of the most common microbiological causes of endocarditis (viridans streptococci, enterococci, Streptococcus bovis, staphylococci, and the HACEK organisms) are justified. There are insufficient published data to make a strong statement regarding the efficacy of specific therapeutic regimens for cases of endocarditis due to microorganisms that uncommonly cause endocarditis. As a useful aid to the practicing clinician, the writing group developed a consensus opinion regarding management of endocarditis caused by the most commonly encountered microorganisms and regarding those cases due to infrequent causes of endocarditis.	AMER HEART ASSOC, COUNCIL CARDIOVASC DIS YOUNG, COMM RHEUMAT FEVER ENDOCARDITIS & KAWASAKI DIS, DALLAS, TX USA									BALDASSARRE JS, 1992, INFECTIVE ENDOCARDIT, P169; BAYER AS, 1993, CLIN INFECT DIS, V17, P313, DOI 10.1093/clinids/17.3.313; BISNO AL, 1989, JAMA-J AM MED ASSOC, V261, P1471, DOI 10.1001/jama.261.10.1471; CALDERWOOD SB, 1986, J THORAC CARDIOV SUR, V92, P776; CAPUTO GM, 1987, AM J MED, V83, P619, DOI 10.1016/0002-9343(87)90889-8; CHAMBERS HF, 1993, INFECT DIS CLIN N AM, V7, P69; CHAMBERS HF, 1988, ANN INTERN MED, V109, P619, DOI 10.7326/0003-4819-109-8-619; CHUARD C, 1991, ANTIMICROB AGENTS CH, V35, P2611, DOI 10.1128/AAC.35.12.2611; DINUBILE MJ, 1994, EUR J CLIN MICROBIOL, V13, P533, DOI 10.1007/BF01971302; Douglas JL, 1992, INFECT ENDOCARDITIS, P397; DWORKIN RJ, 1989, LANCET, V2, P1071; Eliopoulos GM, 1992, INFECT ENDOCARDITIS, P209; ELIOPOULOS GM, 1993, MED CLIN N AM, V17, P117; ENZLER MJ, 1987, J INFECT DIS, V155, P954, DOI 10.1093/infdis/155.5.954; FANTIN B, 1992, ANTIMICROB AGENTS CH, V36, P907, DOI 10.1128/AAC.36.5.907; FRAIMOV HS, 1996, INFECT DIS CLIN N AM, V9, P497; FRANCIOLI P, 1992, JAMA-J AM MED ASSOC, V267, P264, DOI 10.1001/jama.267.2.264; FRANCIOLI P, IN PRESS CLIN INFECT; FRANCIOLI PB, 1993, INFECT DIS CLIN N AM, V17, P313; GERACI JE, 1982, MAYO CLIN PROC, V57, P145; GILBERT DN, 1991, ANTIMICROB AGENTS CH, V35, P79, DOI 10.1128/AAC.35.1.79; HENDERSHOT EF, 1995, INFECT DIS CLIN N AM, V9, P715; HENRY NK, 1986, ANTIMICROB AGENTS CH, V30, P465, DOI 10.1128/AAC.30.3.465; Karchmer Adolf W., 1994, P213; KARCHMER AW, 1983, ANN INTERN MED, V98, P447, DOI 10.7326/0003-4819-98-4-447; KARCHMER AW, 1991, ANN INTERN MED, V115, P739, DOI 10.7326/0003-4819-115-9-739; KARCHMER AW, 1979, JAMA-J AM MED ASSOC, V241, P1801, DOI 10.1001/jama.241.17.1801; KLEIN RS, 1979, ANN INTERN MED, V91, P560, DOI 10.7326/0003-4819-91-4-560; KORZENIOWSKI O, 1982, ANN INTERN MED, V97, P496, DOI 10.7326/0003-4819-97-4-496; LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307; LEVINE DP, 1991, ANN INTERN MED, V115, P674, DOI 10.7326/0003-4819-115-9-674; MURPHY JG, 1993, INFECT DIS CLIN N AM, V7, P153; MURRAY BE, 1983, J CLIN INVEST, V72, P1168, DOI 10.1172/JCI111042; NAHASS RG, 1990, J INFECT DIS, V162, P967, DOI 10.1093/infdis/162.4.967; RICE LB, 1991, REV INFECT DIS, V13, P1; Roberts R, 1992, INFECTIVE ENDOCARDIT, P191; ROBERTS SA, 1993, INFECT DIS CLIN PRAC, V2, P191, DOI 10.1097/00019048-199305000-00006; STAMBOULIAN D, 1991, REV INFECT DIS, V13, pS160; TORRESTORTOSA M, 1994, EUR J CLIN MICROBIOL, V13, P559, DOI 10.1007/BF01971306; WHITENER C, 1993, INFECT DIS CLIN N AM, V7, P81; WILSON WR, 1984, ANN INTERN MED, V100, P816, DOI 10.7326/0003-4819-100-6-816; WILSON WR, 1985, J INFECT DIS, V151, P1028, DOI 10.1093/infdis/151.6.1028; WILSON WR, 1981, JAMA-J AM MED ASSOC, V245, P360, DOI 10.1001/jama.245.4.360	43	341	352	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	1995	274	21					1706	1713		10.1001/jama.274.21.1706	http://dx.doi.org/10.1001/jama.274.21.1706			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH151	7474277				2022-12-28	WOS:A1995TH15100029
J	MORLEY, JE; SILVER, AJ				MORLEY, JE; SILVER, AJ			NUTRITIONAL ISSUES IN NURSING-HOME CARE	ANNALS OF INTERNAL MEDICINE			English	Article							GERIATRIC REHABILITATION PATIENTS; PROTEIN-CALORIE UNDERNUTRITION; II DIABETES-MELLITUS; VITAMIN-C; ELDERLY PATIENTS; COBALAMIN DEFICIENCY; ALZHEIMERS-DISEASE; SELECT POPULATION; PRESSURE SORES; FRACTURED NECK	The most common nutritional problems in nursing home residents are weight loss and concomitant protein energy undernutrition. Although the causes of weight loss in these patients can usually be treated, they are rarely identified in the nursing home. Depression and adverse drug effects are the most common causes of weight loss. We discuss the appropriate use of feeding tubes in the nursing home and the early use of enteral feeding to prevent the development of severe protein energy undernutrition. Vitamin deficiencies, especially folate and pyridoxine deficiencies, frequently develop in nursing home residents. Hip fractures are often associated with vitamin D deficiency. Trace mineral deficiencies (for example, zinc deficiency) can aggravate immune deficiency and slow wound healing. Inadequate fluid intake leads to dehydration, hypotension, and, in persons with diabetes mellitus, hyperosmolarity. Finally, food intake itself can cause postprandial hypotension (which in turn may precipitate falls), produce electrolyte shifts, and result in aspiration pneumonia. Physical activity programs are an important component of nursing home care that may have an effect on nutritional status, and simple, cost-effective programs may be as beneficial as high-technology programs. Careful attention to the nutritional intake of nursing home residents is both a clinical and a quality-of-life issue.	DEPT VET AFFAIRS, ST LOUIS, MO USA		MORLEY, JE (corresponding author), ST LOUIS UNIV, SCH MED, DIV GERIATR MED, 1402 S GRAND BLVD, ROOM M-238, ST LOUIS, MO 63104 USA.		morley, john e/F-9177-2011; Morley, John Edward/K-1570-2019	morley, john e/0000-0001-6444-2965; 				ABBASI AA, 1993, J AM GERIATR SOC, V41, P117, DOI 10.1111/j.1532-5415.1993.tb02043.x; ALTMAN H, 1973, J AM GERIATR SOC, V21, P249, DOI 10.1111/j.1532-5415.1973.tb01684.x; ARTHUR G, 1967, BRIT MED J, V1, P732, DOI 10.1136/bmj.1.5542.732; ASPLUND R, 1991, J INTERN MED, V229, P131, DOI 10.1111/j.1365-2796.1991.tb00320.x; BASTOW MD, 1983, BRIT MED J, V287, P1589, DOI 10.1136/bmj.287.6405.1589; BERTHELEMY P, 1992, J AM GERIATR SOC, V40, P365, DOI 10.1111/j.1532-5415.1992.tb02136.x; BLAUM CS, 1995, J GERONTOL A-BIOL, V50, pM162, DOI 10.1093/gerona/50A.3.M162; BRESLOW RA, 1993, J AM GERIATR SOC, V41, P357, DOI 10.1111/j.1532-5415.1993.tb06940.x; BROCKLEHURST JC, 1968, GERONTOL CLIN, V10, P309, DOI 10.1159/000245198; BUCKLER DA, 1994, J AM GERIATR SOC, V42, P1100, DOI 10.1111/j.1532-5415.1994.tb06216.x; BUSH LS, 1995, NURSING HOME MED, V3, P3; CHANDRA RK, 1992, LANCET, V340, P1124, DOI 10.1016/0140-6736(92)93151-C; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; CONRIGHT KC, 1990, J AM GERIATR SOC, V38, P1267, DOI 10.1111/j.1532-5415.1990.tb01515.x; COULSTON AM, 1990, AM J CLIN NUTR, V51, P67, DOI 10.1093/ajcn/51.1.67; DAVIS KM, 1992, JAMA-J AM MED ASSOC, V267, P2625, DOI 10.1001/jama.267.19.2625; DELMI M, 1990, LANCET, V335, P1013, DOI 10.1016/0140-6736(90)91073-J; DRINKA PJ, 1991, J AM GERIATR SOC, V39, P1008, DOI 10.1111/j.1532-5415.1991.tb04050.x; DURNIN JVGA, 1992, NESTLE NUTR WORKS SE, V29, P51; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; FERGUSON RP, 1993, J AM GERIATR SOC, V41, P545, DOI 10.1111/j.1532-5415.1993.tb01893.x; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; FIATARONE MA, 1989, J GERONTOL, V44, pM37, DOI 10.1093/geronj/44.2.M37; FITTEN LJ, 1989, J AM GERIATR SOC, V37, P459, DOI 10.1111/j.1532-5415.1989.tb02645.x; FORETTE B, 1989, LANCET, V1, P868; GOODE HF, 1992, BRIT MED J, V305, P925, DOI 10.1136/bmj.305.6859.925; GOODWIN JS, 1983, JAMA-J AM MED ASSOC, V249, P2917, DOI 10.1001/jama.249.21.2917; HAUSKEN T, 1994, SCAND J GASTROENTERO, V29, P23, DOI 10.3109/00365529409090432; HEALTON EB, 1991, MEDICINE, V70, P229, DOI 10.1097/00005792-199107000-00001; HORN JV, 1994, SPEC CARE DENTIST, V14, P108; HUGHES VA, 1993, AM J PHYSIOL, V264, pE855, DOI 10.1152/ajpendo.1993.264.6.E855; IKEDA T, 1990, ACTA PSYCHIAT SCAND, V82, P327, DOI 10.1111/j.1600-0447.1990.tb01395.x; JIROVEC MM, 1991, INT J NURS STUD, V28, P145, DOI 10.1016/0020-7489(91)90004-M; KAHN R, 1995, J AM GERIATR SOC, V43, P83, DOI 10.1111/j.1532-5415.1995.tb06254.x; KAISER FE, 1991, J AM GERIATR SOC, V39, P235, DOI 10.1111/j.1532-5415.1991.tb01643.x; KATZ RW, 1993, J CLIMATE, V6, P151, DOI 10.1175/1520-0442(1993)006<0151:DCLRDM>2.0.CO;2; KELLER HH, 1993, J AM GERIATR SOC, V41, P1212, DOI 10.1111/j.1532-5415.1993.tb07305.x; KINLAW WB, 1983, AM J MED, V75, P273, DOI 10.1016/0002-9343(83)91205-6; LEDERLE FA, 1991, JAMA-J AM MED ASSOC, V265, P94, DOI 10.1001/jama.265.1.94; LINDENBAUM J, 1988, NEW ENGL J MED, V318, P1720, DOI 10.1056/NEJM198806303182604; MASTER AM, 1960, JAMA-J AM MED ASSOC, V172, P658, DOI 10.1001/jama.1960.03020070016005; MCLEAN KA, 1992, AGE AGEING, V21, P56, DOI 10.1093/ageing/21.1.56; MCLEOD RD, 1972, AGE AGEING, V1, P99; MILLER A, 1992, AM J HEMATOL, V40, P163, DOI 10.1002/ajh.2830400302; MILLER DK, 1991, J AM GERIATR SOC, V39, P462, DOI 10.1111/j.1532-5415.1991.tb02490.x; MOORADIAN AD, 1988, J AM GERIATR SOC, V36, P391, DOI 10.1111/j.1532-5415.1988.tb02376.x; MOORADIAN AD, 1987, AM J CLIN NUTR, V45, P877, DOI 10.1093/ajcn/45.5.877; MORGAN RE, 1993, LANCET, V341, P75, DOI 10.1016/0140-6736(93)92556-9; MORLEY GK, 1984, AM J MED, V77, P79, DOI 10.1016/0002-9343(84)90439-X; MORLEY JE, 1991, J AM GERIATR SOC, V39, P1139, DOI 10.1111/j.1532-5415.1991.tb02884.x; MORLEY JE, 1990, J AM GERIATR SOC, V38, P605, DOI 10.1111/j.1532-5415.1990.tb02417.x; MORLEY JE, 1991, LIFE SCI, V49, P707, DOI 10.1016/0024-3205(91)90102-H; MORLEY JE, 1988, NEUROBIOL AGING, V9, P9, DOI 10.1016/S0197-4580(88)80004-6; MORLEY JE, 1994, J AM GERIATR SOC, V42, P583, DOI 10.1111/j.1532-5415.1994.tb06853.x; MORLEY JE, 1986, AM J MED, V81, P679, DOI 10.1016/0002-9343(86)90557-7; MORLEY JE, 1994, NURSING HOME MED, V2, P11; MUNCIE HL, 1982, J FAM PRACTICE, V14, P1061; NASO F, 1990, ARCH PHYS MED REHAB, V71, P241; NELSON ME, 1994, JAMA-J AM MED ASSOC, V272, P1909, DOI 10.1001/jama.272.24.1909; NIEWOEHNER CB, 1986, AM J MED, V81, P63, DOI 10.1016/0002-9343(86)90183-X; NIIRANEN A, 1990, AM J CLIN ONCOL-CANC, V13, P113, DOI 10.1097/00000421-199004000-00005; PENNYPACKER LC, 1990, J AM GERIATR SOC, V38, pA9; PIERRON RL, 1990, J AM GERIATR SOC, V38, P1339, DOI 10.1111/j.1532-5415.1990.tb03458.x; PINCHCOFSKYDEVIN GD, 1986, J AM GERIATR SOC, V34, P435, DOI 10.1111/j.1532-5415.1986.tb03411.x; PIRTTILA T, 1993, ACTA NEUROL SCAND, V87, P161; POEHLMAN ET, 1993, J AM GERIATR SOC, V41, P552, DOI 10.1111/j.1532-5415.1993.tb01895.x; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; RUDMAN D, 1988, JPEN-PARENTER ENTER, V12, P155, DOI 10.1177/0148607188012002155; RUDMAN D, 1987, JPEN-PARENTER ENTER, V11, P360, DOI 10.1177/0148607187011004360; RUDMAN D, 1989, J AM GERIATR SOC, V37, P173, DOI 10.1111/j.1532-5415.1989.tb05880.x; RUDMAN D, 1993, J AM GERIATR SOC, V41, P1317, DOI 10.1111/j.1532-5415.1993.tb06482.x; SANDMAN PO, 1987, J AM GERIATR SOC, V35, P31, DOI 10.1111/j.1532-5415.1987.tb01316.x; SAUVAGE LR, 1992, AM J PHYS MED REHAB, V71, P333, DOI 10.1097/00002060-199212000-00005; SCHORAH CJ, 1981, AM J CLIN NUTR, V34, P871, DOI 10.1093/ajcn/34.5.871; SCHORAH CJ, 1979, LANCET, V1, P403; SHAVER HJ, 1980, JPEN-PARENTER ENTER, V4, P367, DOI 10.1177/0148607180004004367; Shephard Roy J., 1995, P303; SIEBENS H, 1986, J AM GERIATR SOC, V34, P192, DOI 10.1111/j.1532-5415.1986.tb04202.x; SILVER AJ, 1988, J AM GERIATR SOC, V36, P487, DOI 10.1111/j.1532-5415.1988.tb04017.x; SILVER AJ, 1992, J AM GERIATR SOC, V40, P556, DOI 10.1111/j.1532-5415.1992.tb02102.x; SMIDT LJ, 1991, J GERONTOL, V46, pM16, DOI 10.1093/geronj/46.1.M16; SULLIVAN DH, 1990, AM J CLIN NUTR, V51, P749, DOI 10.1093/ajcn/51.5.749; SULLIVAN DH, 1993, J AM GERIATR SOC, V41, P725, DOI 10.1111/j.1532-5415.1993.tb07461.x; SULLIVAN DH, 1992, J AM GERIATR SOC, V40, P792, DOI 10.1111/j.1532-5415.1992.tb01851.x; SWAN GE, 1992, ARCH NEUROL-CHICAGO, V49, P476, DOI 10.1001/archneur.1992.00530290058012; THOMAS DR, 1991, JPEN-PARENTER ENTER, V15, P400, DOI 10.1177/0148607191015004400; THOMSON W M, 1992, New Zealand Dental Journal, V88, P51; TOLONEN M, 1988, INT J VITAM NUTR RES, V58, P73; VIGILD M, 1989, COMMUNITY DENT ORAL, V17, P102, DOI 10.1111/j.1600-0528.1989.tb00598.x; WHITTAKER JS, 1990, AM REV RESPIR DIS, V142, P283, DOI 10.1164/ajrccm/142.2.283	90	180	188	0	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1995	123	11					850	859		10.7326/0003-4819-123-11-199512010-00008	http://dx.doi.org/10.7326/0003-4819-123-11-199512010-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TG209	7486469				2022-12-28	WOS:A1995TG20900008
J	MISHKIN, B				MISHKIN, B			URGENTLY NEEDED - POLICIES ON ACCESS TO DATA BY ERSTWHILE COLLABORATORS	SCIENCE			English	Editorial Material											MISHKIN, B (corresponding author), HOGAN & HARTSON LTD LIABIL PARTNERS,555 13TH ST NW,WASHINGTON,DC 20004, USA.							ANDERSON C, 1993, SCIENCE, V262, P23, DOI 10.1126/science.8211122; BELSHEIM DJ, 1986, AM J PHARM EDUC, V50, P139; BRADLEY SG, 1991, ASM NEWS, V57, P60; FISHBEIN EA, 1991, ACAD MED, V66, P129, DOI 10.1097/00001888-199103000-00002; LANMAN RB, 1994, COMMUNICATION   0325, P2; MARSHALL E, 1995, SCIENCE, V268, P792, DOI 10.1126/science.7754362; MISHKIN B, 1994, CHRONICLE HIGHE 0223, pB1; TAUBES G, 1995, SCIENCE, V268, P1125, DOI 10.1126/science.7794410; 1990, GUIDELINES CONDUCT R; 1991, FED REG         0618, V56, P28003; 1994, GUIDELINES CONDUCT R; 1995, DHHS1994 OFF RES INT, P28; 1995, NIH GUIDE GRANTS CON, V24; 1990, PUBLIC HLTH SERVICE, P8; 1992, RESPONSIBLE SCI ENSU, V1, P138; 1995, PROFESSIONAL ETHICS, V8; 1993, RESPONSIBLE SCI ENSU, V2, P127	17	4	4	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 10	1995	270	5238					927	928		10.1126/science.270.5238.927	http://dx.doi.org/10.1126/science.270.5238.927			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD878	7481793				2022-12-28	WOS:A1995TD87800029
J	NAKASHIMA, K; IKEMATSU, H; HAYASHI, J; KISHIHARA, Y; MITSUTAKE, A; KASHIWAGI, S				NAKASHIMA, K; IKEMATSU, H; HAYASHI, J; KISHIHARA, Y; MITSUTAKE, A; KASHIWAGI, S			INTRAFAMILIAL TRANSMISSION OF HEPATITIS-C VIRUS AMONG THE POPULATION OF AN ENDEMIC AREA OF JAPAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							POLYMERASE CHAIN-REACTION; NON-B-HEPATITIS; NON-A; GENOME; SEQUENCE; PRIMERS; RNA	Objectives.-To assess the role of intrafamilial transmission of hepatitis C virus (HCV) among general populations. Design and Setting.-Cross-sectional study in an HCV-endemic area of Japan. Participants.-A total of 1122 residents (mean age, 41.7 years; range, 0 to 80 years), including 359 mother-child pairs and 234 pairs of spouses. Main Outcome Measures.-Antibody to HCV (anti-HCV) was examined using second-generation anti-HCV testing by passive hemagglutination assay. Hepatitis C virus RNA was detected by polymerase chain reaction with primers deduced from the 5'-noncoding region and HCV genotypes by reaction with type-specific primers deduced from the HCV core gene. Results.-Prevalence of anti-HCV was 14.1% (158/1122), and HCV RNA was detected in 82.9% of those who tested positive for anti-HCV. Prevalence of anti-HCV increased with advancing age, but no anti-HCV was found among 312 persons younger than 20 years. Of the 53 children with anti-HCV-positive mothers, three were positive for anti-HCV, all were older than 20 years, and all had a history of surgical treatment. Hepatitis C virus RNA was found in one mother-child pair but with different HCV genotypes. Both spouses were positive for anti-HCV in 17 of 234 pairs. Of the 11 pairs of spouses in whom the HCV genotypes of both were determined, five had different HCV genotypes. Conclusions.-While HCV is highly endemic in this area, neither vertical nor horizontal transmission between spouses seems to play an important role in its spread. The incidence of intrafamilial transmission of HCV seems to be low.			NAKASHIMA, K (corresponding author), KYUSHU UNIV HOSP 71,DEPT GEN MED,HIGASHI KU,FUKUOKA 812,JAPAN.							CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; HAYASHI J, 1995, AM J GASTROENTEROL, V90, P794; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; NAKASHIMA K, 1992, AM J EPIDEMIOL, V136, P1132, DOI 10.1093/oxfordjournals.aje.a116579; NAKASHIMA K, 1994, J EPIDEMIOL, V4, P14; OHTO H, 1994, NEW ENGL J MED, V330, P744, DOI 10.1056/NEJM199403173301103; OKAMOTO H, 1990, JPN J EXP MED, V60, P215; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; OKAMOTO H, 1992, VIROLOGY, V188, P331, DOI 10.1016/0042-6822(92)90762-E; OKAMOTO H, 1991, J GEN VIROL, V72, P2697, DOI 10.1099/0022-1317-72-11-2697; TAJIMA K, 1991, LANCET, V337, P1410, DOI 10.1016/0140-6736(91)93089-R	12	62	65	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	1995	274	18					1459	1461		10.1001/jama.274.18.1459	http://dx.doi.org/10.1001/jama.274.18.1459			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC477	7474193				2022-12-28	WOS:A1995TC47700029
J	JASS, JR; COTTIER, DS; JEEVARATNAM, P; POKOS, V; HOLDAWAY, KM; BOWDEN, ML; VANDEWATER, NS; BROWETT, PJ				JASS, JR; COTTIER, DS; JEEVARATNAM, P; POKOS, V; HOLDAWAY, KM; BOWDEN, ML; VANDEWATER, NS; BROWETT, PJ			DIAGNOSTIC USE OF MICROSATELLITE INSTABILITY IN HEREDITARY NONPOLYPOSIS COLORECTAL-CANCER	LANCET			English	Note							DINUCLEOTIDE REPEAT POLYMORPHISMS	50 families with a history of colorectal cancer were divided according to whether criteria for hereditary non-polyposis colorectal cancer (HNPCC) were fulfilled totally (A, n=19) or partly (B, n=31) and stratified by the demonstration that at least half the cancers tested per family were positive for DNA replication errors (RER+). Accepted clinical and pathological characteristics of HNPCC were found to cluster within 12 A/RER+ families in which the mean number of affected individuals per family was 10 . 1. Reliance upon clinical data alone may result in over-diagnosis of HNPCC, in small families who just meet the minimum criteria, whereas underdiagnosis is rare. The criteria could be refined by inclusion of RER status.	UNIV AUCKLAND,SCH MED,DEPT MOLEC MED,AUCKLAND,NEW ZEALAND	University of Auckland	JASS, JR (corresponding author), UNIV AUCKLAND,SCH MED,DEPT PATHOL,PRIVATE BAG 92019,AUCKLAND,NEW ZEALAND.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD015434] Funding Source: NIH RePORTER; NICHD NIH HHS [R01HD15434] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AALTONEN LA, 1994, CANCER RES, V54, P1645; EASTON DF, 1993, AM J HUM GENET, V52, P678; Jones Michael H., 1992, Human Molecular Genetics, V1, P131, DOI 10.1093/hmg/1.2.131; KIM HG, 1994, AM J PATHOL, V145, P148; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; MAKELA TP, 1992, HUM MOL GENET, V1, P217, DOI 10.1093/hmg/1.3.217-a; NYSTROMLAHTI M, 1994, P NATL ACAD SCI USA, V91, P6054, DOI 10.1073/pnas.91.13.6054; RISINGER JI, 1991, HUM MOL GENET, V1, P657; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	11	87	87	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 4	1995	346	8984					1200	1201		10.1016/S0140-6736(95)92902-9	http://dx.doi.org/10.1016/S0140-6736(95)92902-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC976	7475662	Bronze			2022-12-28	WOS:A1995TC97600012
J	WACHTER, KW				WACHTER, KW			DISTURBED BY META-ANALYSIS	SCIENCE			English	Editorial Material											WACHTER, KW (corresponding author), UNIV CALIF BERKELEY,DEMOG & STAT,BERKELEY,CA 94720, USA.							COOPER H, 1986, SOCIAL PSYCHOL APPLI; Glass G.V., 1976, ED RES, V5, P3, DOI [DOI 10.3102/0013189X005010003, 10.2307/1174772ISSN0536-1036]; Hedges L, 1985, STATISTICAL METHODS; IYENGAR S, IN PRESS STAT SCI; LIGHT RJ, 1984, SUMMING UP SCI REV R; Rosenthal R., 1984, EDUC RESEARCHER; ROTTON J, 1986, MERCURY, V15, P73; Wolf F.M., 1986, METAANALYSIS QUANTIT	8	83	83	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 16	1988	241	4872					1407	1408		10.1126/science.3420397	http://dx.doi.org/10.1126/science.3420397			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q0479	3420397				2022-12-28	WOS:A1988Q047900002
J	WARD, JW; HOLMBERG, SD; ALLEN, JR; COHN, DL; CRITCHLEY, SE; KLEINMAN, SH; LENES, BA; RAVENHOLT, O; DAVIS, JR; QUINN, MG; JAFFE, HW				WARD, JW; HOLMBERG, SD; ALLEN, JR; COHN, DL; CRITCHLEY, SE; KLEINMAN, SH; LENES, BA; RAVENHOLT, O; DAVIS, JR; QUINN, MG; JAFFE, HW			TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) BY BLOOD-TRANSFUSIONS SCREENED AS NEGATIVE FOR HIV ANTIBODY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									DENVER DIS CONTROL SERV,DENVER,CO; AMER RED CROSS,BLOOD SERV,ATLANTA,GA; AMER RED CROSS,BLOOD SERV,LOS ANGELES,CA; AMER RED CROSS,BLOOD SERV,MIAMI,FL	American Red Cross; American Red Cross; American Red Cross	WARD, JW (corresponding author), CTR DIS CONTROL,CTR INFECT DIS,AIDS PROGRAM,BLDG 6-285,MAILSTOP G22,ATLANTA,GA 30333, USA.							ALLAIN JP, 1986, LANCET, V2, P1233; BOVE JR, 1987, NEW ENGL J MED, V317, P242, DOI 10.1056/NEJM198707233170411; BREO DL, 1987, AM MED NEWS     1106, P10; COOPER DA, 1985, LANCET, V1, P1537; ESTEBAN JI, 1985, LANCET, V2, P1083; GAINES H, 1987, LANCET, V1, P1249; GOUDSMIT J, 1986, LANCET, V2, P177; HO DD, 1985, ANN INTERN MED, V103, P880, DOI 10.7326/0003-4819-103-6-880; KUMAR P, 1987, ANN INTERN MED, V106, P244, DOI 10.7326/0003-4819-106-2-244; NIGHTINGALE S, 1987, JAMA-J AM MED ASSOC, V257, P1289; PETERMAN TA, 1987, TRANSFUSION, V27, P371, DOI 10.1046/j.1537-2995.1987.27587320525.x; RANKI A, 1987, LANCET, V2, P589; SCHORR JB, 1985, NEW ENGL J MED, V313, P384, DOI 10.1056/NEJM198508083130610; WARD JW, 1986, JAMA-J AM MED ASSOC, V256, P357, DOI 10.1001/jama.256.3.357; WARD JW, 1987, ANN INTERN MED, V106, P61, DOI 10.7326/0003-4819-106-1-61; WARD JW, IN PRESS TRANSFUSION; YASKANIN D, 1987, TRANSFUSION, V6, P549; ZUCK TF, 1987, TRANSFUSION, V27, P447, DOI 10.1046/j.1537-2995.1987.27688071691.x; 1986, MMWR, V35, P284; 1985, MMWR, V34, P1; 1983, MMWR, V32, P101; 1980, 80 AM BLOOD COMM SPE; 1986, MMWR, V35, P389; 1985, MMWR, V34, P547; 1987, MMWR, V36, P137	25	397	407	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1988	318	8					473	478		10.1056/NEJM198802253180803	http://dx.doi.org/10.1056/NEJM198802253180803			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M1574	3422337				2022-12-28	WOS:A1988M157400003
J	ROSA, F; ROBERTS, AB; DANIELPOUR, D; DART, LL; SPORN, MB; DAWID, IB				ROSA, F; ROBERTS, AB; DANIELPOUR, D; DART, LL; SPORN, MB; DAWID, IB			MESODERM INDUCTION IN AMPHIBIANS - THE ROLE OF TGF-BETA-2-LIKE FACTORS	SCIENCE			English	Article									NCI,DIV CANC ETIOL,CHEMOPREVENT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	ROSA, F (corresponding author), NICHHD,MOLEC GENET LAB,BETHESDA,MD 20892, USA.		Rosa, Frederic/L-5990-2017					ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GIMLICH RL, 1986, DEV BIOL, V115, P340, DOI 10.1016/0012-1606(86)90254-X; GURDON JB, 1984, CELL, V38, P691, DOI 10.1016/0092-8674(84)90264-2; IKEDA T, 1987, BIOCHEMISTRY-US, V26, P2406, DOI 10.1021/bi00383a002; KELLER RE, 1976, DEV BIOL, V51, P118, DOI 10.1016/0012-1606(76)90127-5; KELLER RE, 1975, DEV BIOL, V42, P222, DOI 10.1016/0012-1606(75)90331-0; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; LAWRENCE D, 1985, BIOCHEM BIOPH RES CO, V133, P1026, DOI 10.1016/0006-291X(85)91239-2; MARQUARDT H, 1987, J BIOL CHEM, V262, P12127; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; NAKAMURA O, 1971, P JPN ACAD, V47, P407, DOI 10.2183/pjab1945.47.407; NAKAMURA O, 1970, P JPN ACAD, V46, P694, DOI 10.2183/pjab1945.46.694; Nieuwkoop P D, 1973, Adv Morphog, V10, P1; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; PUDNEY M, 1973, EXPERIENTIA, V29, P466, DOI 10.1007/BF01926785; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; SARGENT TD, 1986, DEV BIOL, V114, P238, DOI 10.1016/0012-1606(86)90399-4; SEGARINI PR, 1987, J BIOL CHEM, V262, P14655; SEYEDIN SM, 1987, J BIOL CHEM, V262, P1946; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1987, DEVELOPMENT, V99, P3; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; SUDARWAT.S, 1971, ROUX ARCH DEV BIOL, V166, P189, DOI 10.1007/BF00650029; TIEDEMANN H, 1982, BIOCH DIFFERENTIATIO, V33, P275; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; WAKEFIELD L, UNPUB; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7	32	416	424	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1988	239	4841					783	785		10.1126/science.3422517	http://dx.doi.org/10.1126/science.3422517			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	M0209	3422517				2022-12-28	WOS:A1988M020900034
J	FELBER, BK; PAVLAKIS, GN				FELBER, BK; PAVLAKIS, GN			A QUANTITATIVE BIOASSAY FOR HIV-1 BASED ON TRANS-ACTIVATION	SCIENCE			English	Article											FELBER, BK (corresponding author), NCI,FREDERICK CANC RES FACIL,BIONET RES INC,BASIC RES PROGRAM,POB B,FREDERICK,MD 21701, USA.				NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; ARYA SK, 1987, NATURE, V328, P548, DOI 10.1038/328548a0; BARIN F, 1985, LANCET, V2, P1387; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; CLAVEL F, 1986, NATURE, V324, P691, DOI 10.1038/324691a0; COFFIN J, 1986, SCIENCE, V232, P697, DOI 10.1126/science.3008335; CONE RD, 1984, P NATL ACAD SCI-BIOL, V81, P6349, DOI 10.1073/pnas.81.20.6349; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FISHER AG, 1985, NATURE, V316, P262, DOI 10.1038/316262a0; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; GOH WC, 1986, J VIROL, V59, P181, DOI 10.1128/JVI.59.1.181-184.1986; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HIRSCH V, 1987, CELL, V49, P307, DOI 10.1016/0092-8674(87)90283-2; JHAPPAN C, 1986, J VIROL, V60, P750, DOI 10.1128/JVI.60.2.750-753.1986; KANKI PJ, 1985, SCIENCE, V230, P951, DOI 10.1126/science.2997923; KANKI PJ, 1985, LANCET, V1, P1330; KANKI PJ, 1985, SCIENCE, V228, P1199, DOI 10.1126/science.3873705; KANKI PJ, 1986, SCIENCE, V232, P238, DOI 10.1126/science.3006256; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; KNIGHT DM, 1987, SCIENCE, V236, P837, DOI 10.1126/science.3033827; KORNFELD H, 1987, NATURE, V326, P610, DOI 10.1038/326610a0; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; LIFSON JD, 1986, SCIENCE, V232, P1123, DOI 10.1126/science.3010463; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MITSUYA H, 1987, NATURE, V325, P773, DOI 10.1038/325773a0; MITSUYA H, 1987, P NATL ACAD SCI USA, V84, P2033, DOI 10.1073/pnas.84.7.2033; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; MITSUYA H, 1986, P NATL ACAD SCI US, V83, P1919; MOSCA JD, 1987, NATURE, V325, P67, DOI 10.1038/325067a0; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; NEWMANN JR, 1987, BIOTECHNIQUES, V5, P444; PAVLAKIS GN, 1988, P UCLA S HUMAN RETRO, V71; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; PUTNEY SD, 1986, SCIENCE, V234, P1392, DOI 10.1126/science.2431482; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; SARNGADHARAN MG, 1984, SCIENCE, V224, P506, DOI 10.1126/science.6324345; SHAW W, 1975, METHOD ENZYMOL, V53, P737; SIEGEL L, 1986, VIROLOGY, V148, P228; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; SODROSKI J, 1985, SCIENCE, V229, P74, DOI 10.1126/science.2990041; STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WRIGHT CM, 1986, SCIENCE, V234, P988, DOI 10.1126/science.3490693	58	179	200	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 8	1988	239	4836					184	187		10.1126/science.3422113	http://dx.doi.org/10.1126/science.3422113			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	L5256	3422113				2022-12-28	WOS:A1988L525600036
J	PARISI, VM; MEYER, BA				PARISI, VM; MEYER, BA			TO STAY OR NOT TO STAY - THAT IS THE QUESTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DISCHARGE				PARISI, VM (corresponding author), SUNY STONY BROOK,MED CTR,STONY BROOK,NY 11794, USA.							ANNAS GJ, 1995, NEW ENGL J MED, V333, P1647, DOI 10.1056/NEJM199512143332420; CONRAD PD, 1989, AM J DIS CHILD, V143, P98, DOI 10.1001/archpedi.1989.02150130108026; WILLIAMS JW, 1912, JAMA-J AM MED ASSOC, V58, P7; WILLIAMS JW, 1912, JAMA-J AM MED ASSOC, V58, P4; YANOVER MJ, 1976, NEW ENGL J MED, V294, P702, DOI 10.1056/NEJM197603252941306; 1992, GUIDELINES PERINATAL; 1995, PEDIATRICS, V96, P788	7	30	30	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 14	1995	333	24					1635	1637		10.1056/NEJM199512143332412	http://dx.doi.org/10.1056/NEJM199512143332412			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK065	7477203				2022-12-28	WOS:A1995TK06500012
J	DANNER, SA; CARR, A; LEONARD, JM; LEHMAN, LM; GUDIOL, F; GONZALES, J; RAVENTOS, A; RUBIO, R; BOUZA, E; PINTADO, V; AGUADO, AG; DELOMAS, JG; DELGADO, R; BORLEFFS, JCC; HSU, A; VALDES, JM; BOUCHER, CAB; COOPER, DA; GIMENO, C; CLOTET, B; TOR, J; FERRER, E; MARTINEZ, PL; MORENO, S; ZANCADA, G; ALCAMI, J; NORIEGA, AR; PULIDO, F; GLASSMAN, HN				DANNER, SA; CARR, A; LEONARD, JM; LEHMAN, LM; GUDIOL, F; GONZALES, J; RAVENTOS, A; RUBIO, R; BOUZA, E; PINTADO, V; AGUADO, AG; DELOMAS, JG; DELGADO, R; BORLEFFS, JCC; HSU, A; VALDES, JM; BOUCHER, CAB; COOPER, DA; GIMENO, C; CLOTET, B; TOR, J; FERRER, E; MARTINEZ, PL; MORENO, S; ZANCADA, G; ALCAMI, J; NORIEGA, AR; PULIDO, F; GLASSMAN, HN			A SHORT-TERM STUDY OF THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF RITONAVIR, AN INHIBITOR OF HIV-1 PROTEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS	Background. Reverse-transcriptase inhibitors have only moderate clinical efficacy against the human immunodeficiency virus type 1 (HIV-1). Ritonavir is an inhibitor of HIV-1 pretease with potent in vitro anti-HIV properties and good oral bioavailability. Methods. We evaluated the antiviral activity and safety of ritonavir in a double-blind, randomized, placebo-controlled phase 1 and 2 study of 84 HIV-positive patients with 50 or more CD4+ lymphocytes per cubic millimeter. The patients were randomly assigned to one of four regimens of ritonavir therapy, or to placebo for four weeks and then (by random assignment) to one of the ritonavir regimens. Results. During the first 4 weeks, increases in CD4+ lymphocyte counts and reductions in the log number of copies of HIV-1 RNA per milliliter of plasma were similar among the four dosage groups, but in the three lower-dosage groups there was a return to base-line levels by 16 weeks. After 32 weeks, in the seven patients in the highest-dosage group (600 mg of ritonavir every 12 hours), the median increase from base line in the CD4+ lymphocyte count was 230 cells per cubic millimeter, and the mean decrease in the plasma concentration of HIV-1 RNA (as measured by a branched-chain DNA assay) was 0.81 log (95 percent confidence interval, 0.40 to 1.22). In a subgroup of 17 patients in the two higher-dosage groups, RNA was also measured with an assay based on the polymerase chain reaction, and after eight weeks of treatment there was a mean maximal decrease in viral RNA of 1.94 log (95 percent confidence interval, 1.37 to 2.51). Adverse events included nausea, circumoral paresthesia, elevated hepatic aminotransferase levels, and elevated triglyceride levels. Ten withdrawals from the study were judged to be related to ritonavir treatment. Conclusions. In this short-term study, ritonavir was well tolerated and had potent activity against HIV-1, but its clinical benefits remain to be established.	ST VINCENTS HOSP,SYDNEY,NSW,AUSTRALIA; ABBOTT LABS,ABBOTT PK,IL; HOSP BELLVITGE PRINCIPES DE ESPANA,BARCELONA,SPAIN; HOSP LA PAZ,MADRID,SPAIN; HOSP GERMANS TRIAS & PUJOL,BARCELONA,SPAIN; HOSP 12 OCTUBRE,MADRID,SPAIN; HOSP GEN GREGORIO MARANON,MADRID,SPAIN; HOSP RAMON Y CAJAL,MADRID,SPAIN; HOSP CLIN VALENCIA,VALENCIA,SPAIN; UNIV UTRECHT HOSP,UTRECHT,NETHERLANDS	St Vincents Hospital Sydney; Abbott Laboratories; Hospital Universitario La Paz; Hospital Germans Trias i Pujol; Hospital Universitario 12 de Octubre; General University Gregorio Maranon Hospital; Hospital Universitario Ramon y Cajal; Utrecht University; Utrecht University Medical Center	DANNER, SA (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DIV INFECT DIS,MEIBERGDREEF 9,1105 AZ AMSTERDAM,NETHERLANDS.		Bouza, Emilio/D-8661-2014; Delgado, Rafael/C-4910-2016; Alcami, Pepe/T-2242-2018; Pulido, Federico/B-8417-2009; DELGADO, RAFAEL/A-2938-2012	Bouza, Emilio/0000-0001-6967-9267; Delgado, Rafael/0000-0002-6912-4736; Alcami, Pepe/0000-0003-0023-7377; Pulido, Federico/0000-0002-7414-8812; Rubio Garcia, Rafael/0000-0001-8132-4303				BILELLO JA, IN PRESS J CLIN INVE; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; DAQUILA RT, 1995, ANN INTERN MED, V122, P401, DOI 10.7326/0003-4819-122-6-199503150-00001; DEBOUCK C, 1992, AIDS RES HUM RETROV, V8, P153, DOI 10.1089/aid.1992.8.153; HAVLIR D, 1995, J INFECT DIS, V171, P537, DOI 10.1093/infdis/171.3.537; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; JURRIAANS S, 1995, AIDS RES HUM RETROV, V11, P473, DOI 10.1089/aid.1995.11.473; KATLAMA C, 1995, 2 NAT C HUM RETR REL, P29; KATZENSTEIN DA, 1994, J INFECT DIS, V169, P416, DOI 10.1093/infdis/169.2.416; KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484; KITCHEN VS, 1995, LANCET, V345, P952, DOI 10.1016/S0140-6736(95)90699-1; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; LOVEDAY C, 1995, LANCET, V345, P820, DOI 10.1016/S0140-6736(95)92963-0; MARKOWITZ M, 1995, J VIROL, V69, P701, DOI 10.1128/JVI.69.2.701-706.1995; MOLLA A, 1995, 4TH INT WORKSH HIV D, P69; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; NORBECK D, 1995, 4 INT WORKSH HIV DRU, P70; PACHL C, 1995, J ACQ IMMUN DEF SYND, V8, P446, DOI 10.1097/00042560-199504120-00003; REEDIJK M, 1995, ANTIMICROB AGENTS CH, V39, P1559, DOI 10.1128/AAC.39.7.1559; RICHMAN DD, 1993, ANTIMICROB AGENTS CH, V37, P1207, DOI 10.1128/AAC.37.6.1207; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; STASZEWSKI S, 1995, 2ND NAT C HUM RETR R, P29; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	23	503	510	2	46	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 7	1995	333	23					1528	1533		10.1056/NEJM199512073332303	http://dx.doi.org/10.1056/NEJM199512073332303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH157	7477167	Green Published			2022-12-28	WOS:A1995TH15700003
J	WEISS, M; LOPRINZI, CL; CREAGAN, ET; DALTON, RJ; NOVOTNY, P; OFALLON, JR				WEISS, M; LOPRINZI, CL; CREAGAN, ET; DALTON, RJ; NOVOTNY, P; OFALLON, JR			UTILITY OF FOLLOW-UP TESTS FOR DETECTING RECURRENT DISEASE IN PATIENTS WITH MALIGNANT MELANOMAS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							BREAST-CANCER; GUIDELINES; POLICY	Objective.-To determine the effectiveness of follow-up tests for signaling recurrences in patients with intermediate- and high-risk malignant melanomas treated with curative intention. Design.-Retrospective analysis of prospectively collected data. Setting.-North Central Cancer Treatment Group. Patients.-A total of 261 patients with resected local (greater than or equal to 1.69 mm) and regional nodal malignant melanomas who were enrolled in a single prospective adjuvant trial were studied. All patients were scheduled to be followed up monthly for 2 months, then every 2 months for the first year, every 4 months the second year, every 6 months the next 3 years, and annually thereafter, with each visit consisting of a history, physical examination, complete blood cell count, blood chemistry panel, and a chest x-ray. Results.-Of the 145 evaluable patients who developed recurrent melanomas, 99 patients (68%) developed symptoms that signaled the diagnosis of recurrent disease. Physical examination of asymptomatic patients led to the diagnosis of recurrent disease in 37 patients (26%). The other nine patients (6%) with recurrent disease had abnormal chest x-rays. Laboratory results were never a sole indicator of recurrent disease. Conclusion.-The majority of recurrences following resection of primary melanomas are discovered by history and/or physical examination despite the frequent use of other follow-up tests. The present data indicate that routine blood analyses and chest x-rays have limited value in the postoperative follow-up of patients with resected intermediate- and high-risk melanomas.	MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA; DULUTH COMMUNITY CLIN ONCOL PROGRAM, DULUTH, MN USA	Mayo Clinic					NATIONAL CANCER INSTITUTE [U10CA025224, P30CA015083, U10CA037404] Funding Source: NIH RePORTER; NCI NIH HHS [CA-37404, CA-15083, CA-25224] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baughan C A, 1993, Clin Oncol (R Coll Radiol), V5, P174, DOI 10.1016/S0936-6555(05)80321-8; BRANDT SE, 1990, J SURG ONCOL, V43, P157, DOI 10.1002/jso.2930430307; BROWMAN GP, 1995, J CLIN ONCOL, V13, P502, DOI 10.1200/JCO.1995.13.2.502; BROYN T, 1982, ACTA CHIR SCAND, V148, P401; COLLINS CD, 1993, BRIT J RADIOL, V66, P117, DOI 10.1259/0007-1285-66-782-117; DELTURCO MR, 1994, JAMA-J AM MED ASSOC, V271, P1593, DOI 10.1001/jama.1994.03510440053032; DEMBROW VD, 1986, FUNDAMENTALS SURGICA, P141; DRAKE LA, 1993, J AM ACAD DERMATOL, V28, P638, DOI 10.1016/S0190-9622(08)81784-7; HALL WH, 1992, JAMA-J AM MED ASSOC, V268, P1314, DOI 10.1001/jama.1992.03490100112037; JILLELLA A, 1995, P AN M AM SOC CLIN, V14, P413; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KATTLOVE H, 1995, JAMA-J AM MED ASSOC, V273, P142, DOI 10.1001/jama.273.2.142; KAUFMANN P M, 1992, Aktuelle Radiologie, V2, P81; LOPRINZI CL, 1994, J CLIN ONCOL, V12, P881, DOI 10.1200/JCO.1994.12.5.881; MARTINI L, 1994, TUMORI, V80, P188, DOI 10.1177/030089169408000305; MCCARTHY WH, 1988, SURG GYNECOL OBSTET, V166, P497; MCEWAN L, 1990, PLAST RECONSTR SURG, V86, P527, DOI 10.1097/00006534-199009000-00024; PANDYA KJ, 1985, CANCER, V55, P202, DOI 10.1002/1097-0142(19850101)55:1<202::AID-CNCR2820550132>3.0.CO;2-X; PEARLMAN NW, 1992, AM J SURG, V164, P458, DOI 10.1016/S0002-9610(05)81180-8; ROMERO JB, 1994, J DERMATOL SURG ONC, V20, P175, DOI 10.1111/j.1524-4725.1994.tb00462.x; SCANLON EF, 1980, CANCER, V46, P977, DOI 10.1002/1097-0142(19800815)46:4+<977::AID-CNCR2820461320>3.0.CO;2-0; SCHAPIRA DV, 1991, JAMA-J AM MED ASSOC, V265, P380, DOI 10.1001/jama.265.3.380; SLINGLUFF CL, 1992, CANCER-AM CANCER SOC, V70, P1917, DOI 10.1002/1097-0142(19921001)70:7<1917::AID-CNCR2820700719>3.0.CO;2-5; TAHERY DP, 1992, INT J DERMATOL, V31, P629, DOI 10.1111/j.1365-4362.1992.tb03980.x; WINCHESTER DP, 1979, CANCER, V43, P956, DOI 10.1002/1097-0142(197903)43:3<956::AID-CNCR2820430326>3.0.CO;2-L; ZWAVELING A, 1987, J SURG ONCOL, V34, P194, DOI 10.1002/jso.2930340314; 1994, JAMA-J AM MED ASSOC, V271, P1587	27	119	119	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	1995	274	21					1703	1705		10.1001/jama.274.21.1703	http://dx.doi.org/10.1001/jama.274.21.1703			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH151	7474276				2022-12-28	WOS:A1995TH15100028
J	REES, JH; SOUDAIN, SE; GREGSON, NA; HUGHES, RAC				REES, JH; SOUDAIN, SE; GREGSON, NA; HUGHES, RAC			CAMPYLOBACTER-JEJUNI INFECTION AND GUILLAIN-BARRE-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEUROPATHY	Background. Although infection with Campylobacter jejuni is recognized as a common antecedent of the Guillain-Barre syndrome, the clinical and epidemiologic features of this association are not well understood. Methods. We performed a prospective case-control study in a cohort of patients with Guillajn-Barre syndrome (96 patients) or Miller Fisher syndrome (7 patients) who were admitted to hospitals throughout England and Wales between November 1992 and April 1994. Bacteriologic and serologic techniques were used to diagnose preceding C. jejuni infection. Results. There was evidence of recent C. jejuni infection in 26 percent of the patients with Guillain-Barre or Miller Fisher syndrome, as compared with 2 percent of household controls and 1 percent of age-matched hospital controls (P<0.001). Of the 27 patients with C. jejuni infection, 19 (70 percent) reported having had a diarrheal illness within 12 weeks before the onset of the neurologic illness. No specific serotypes were associated with Guillain-Barre syndrome. C. jejuni infection was slightly more common in men (P=0.14) and was more likely to be associated with a pure motor syndrome and a slower recovery (P=0.03). The patients with preceding C. jejuni infection were more likely to have acute axonal neuropathy or axonal degeneration in association with acute inflammatory demyelinating polyradiculoneuropathy, and they had greater disability after one year (P=0.02). C. jejuni infection was significantly associated with a poor outcome even after correction for other factors associated with a poor prognosis. Conclusions. Infection with C. jejuni often precedes the Guillain-Barre syndrome and is associated with axonal degeneration, slow recovery, and severe residual disability.	UNITED MED & DENT SCH,GUYS HOSP,DEPT NEUROL,LONDON SE1 9RT,ENGLAND; UNITED MED & DENT SCH,GUYS HOSP,DIV ANAT & CELL BIOL,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London			Rees, Jeremy/AAH-4382-2019					ALBERS JW, 1985, MUSCLE NERVE, V8, P528, DOI 10.1002/mus.880080609; ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707; BLASER MJ, 1984, INFECT IMMUN, V44, P292, DOI 10.1128/IAI.44.2.292-298.1984; DYCK PJ, 1993, NEUROLOGY, V43, P1277, DOI 10.1212/WNL.43.7.1277; ENDERS U, 1993, ANN NEUROL, V34, P136, DOI 10.1002/ana.410340208; FISHER M, 1956, NEW ENGL J MED, V255, P57, DOI 10.1056/NEJM195607122550201; GREGSON NA, 1993, Q J MED, V86, P111; KALDOR J, 1984, BRIT MED J, V288, P1867, DOI 10.1136/bmj.288.6434.1867; KUROKI S, 1993, ANN NEUROL, V33, P243, DOI 10.1002/ana.410330304; MCKHANN GM, 1993, ANN NEUROL, V33, P333, DOI 10.1002/ana.410330402; MISHU B, 1993, ANN INTERN MED, V118, P947, DOI 10.7326/0003-4819-118-12-199306150-00006; Palace J A, 1994, Eur J Neurol, V1, P21, DOI 10.1111/j.1468-1331.1994.tb00046.x; REES JH, 1993, Q J MED, V86, P623, DOI 10.1093/qjmed/86.10.623; ROBERTS T, 1987, J NEUROL NEUROSUR PS, V50, P1557, DOI 10.1136/jnnp.50.11.1557; ROPPER AH, 1992, NEW ENGL J MED, V326, P1130, DOI 10.1056/NEJM199204233261706; SKIRROW MB, 1987, EPIDEMIOL INFECT, V99, P647, DOI 10.1017/S0950268800066504; WINER JB, 1988, J NEUROL NEUROSUR PS, V51, P613, DOI 10.1136/jnnp.51.5.613; WROE SJ, 1985, J NEUROL NEUROSUR PS, V48, P593, DOI 10.1136/jnnp.48.6.593; YUKI N, 1993, J EXP MED, V178, P1771, DOI 10.1084/jem.178.5.1771	19	533	546	0	23	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 23	1995	333	21					1374	1379		10.1056/NEJM199511233332102	http://dx.doi.org/10.1056/NEJM199511233332102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF521	7477117	Bronze			2022-12-28	WOS:A1995TF52100002
J	VANHERWERDEN, L; HARRAP, SB; WONG, ZYH; ABRAMSON, MJ; KUTIN, JJ; FORBES, AB; RAVEN, J; LANIGAN, A; WALTERS, EH				VANHERWERDEN, L; HARRAP, SB; WONG, ZYH; ABRAMSON, MJ; KUTIN, JJ; FORBES, AB; RAVEN, J; LANIGAN, A; WALTERS, EH			LINKAGE OF HIGH-AFFINITY IGE RECEPTOR GENE WITH BRONCHIAL HYPERREACTIVITY, EVEN IN ABSENCE OF ATOPY	LANCET			English	Article							CHROMOSOME-11Q; HYPERRESPONSIVENESS; ASTHMA	Asthma is a manifestation of bronchial hyperreactivity (BHR) and forms part of the spectrum of atopic diease. Some pedigree studies of atopy have suggested linkage with the high-affinity IgE receptor (Fc epsilon RI beta) gene on chromosome 11q13, but others find no linkage. The molecular genetics of asthma and BHR have not been studied in the general population. We examined the genetic linkage of the Fc epsilon RI beta gene with clinical asthma and the underlying phenotypes of BHR (to methacholine) and atopy (defined by skinprick testing) in 123 affected sibling-pairs recruited from the general population. We found evidence of significant linkage of a highly polymorphic microsatellite marker in the fifth intron of the Fc epsilon RI beta gene to a diagnosis of asthma (18.0% excess of shared alleles, p=0.002) and to SHR (21.7% excess of shared alleles, p=0.001). Significant linkage was also observed in siblings sharing BHR when those with atopy were excluded (32.8% excess of shared alleles, p=0.004). Atopy in the absence of BHR did not show significant linkage to the Fc epsilon RI beta gene (7.2% excess of shared alleles, p=0.124). These findings suggest that mutations in the Fc epsilon RI beta gene or a closely linked gene influence the BHR underlying asthma, even in the absence of atopy.	MONASH UNIV SCH MED,DEPT SOCIAL & PREVENT MED,PRAHRAN,VIC,AUSTRALIA; ALFRED HOSP,DEPT RESP MED,PRAHRAN,VIC,AUSTRALIA	Monash University; Florey Institute of Neuroscience & Mental Health			WALTERS, Eugene/AAL-2264-2021; Abramson, Michael/AAQ-2671-2020; van Herwerden, Lynne/I-1087-2012	Abramson, Michael/0000-0002-9954-0538; van Herwerden, Lynne/0000-0001-6717-8995; Harrap, Stephen/0000-0003-2907-6714; Kutin, Jozica Johanna/0000-0002-3812-0417; Forbes, Andrew/0000-0003-4269-914X				ABRAMSON MJ, 1991, J ASTHMA, V28, P129, DOI 10.3109/02770909109082737; AMELUNG PJ, 1992, CLIN EXP ALLERGY, V22, P1077, DOI 10.1111/j.1365-2222.1992.tb00133.x; BOOTH H, 1995, AM J RESP CRIT CARE, V152, P45, DOI 10.1164/ajrccm.152.1.7599861; BRERETON HM, 1994, CLIN EXP ALLERGY, V24, P868, DOI 10.1111/j.1365-2222.1994.tb01809.x; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; DANIELS SE, 1994, HUM MOL GENET, V3, P213, DOI 10.1093/hmg/3.1.213; HIZAWA N, 1992, CLIN EXP ALLERGY, V22, P1065, DOI 10.1111/j.1365-2222.1992.tb00131.x; HOLGATE ST, 1987, CLIN SCI, V73, P561, DOI 10.1042/cs0730561; HOLMANS P, 1993, AM J HUM GENET, V52, P362; JEANPIERRE M, 1987, NUCLEIC ACIDS RES, V15, P961; LANGE K, 1986, ANN HUM GENET, V50, P283, DOI 10.1111/j.1469-1809.1986.tb01049.x; LYMPANY P, 1992, CLIN EXP ALLERGY, V22, P1085, DOI 10.1111/j.1365-2222.1992.tb00134.x; LYMPANY P, 1992, J ALLERGY CLIN IMMUN, V89, P619, DOI 10.1016/0091-6749(92)90330-5; MARSH DG, 1992, NAT GENET, V2, P252, DOI 10.1038/ng1292-252; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MOFFATT MF, 1992, CLIN EXP ALLERGY, V22, P1046, DOI 10.1111/j.1365-2222.1992.tb00128.x; MORTON NE, 1992, CLIN EXP ALLERGY, V22, P1041, DOI 10.1111/j.1365-2222.1992.tb00126.x; NEELY JD, 1994, J ALLERGY CLIN IMMUN, V93, P220; PLATTSMILLS TAE, 1991, INT ARCH ALLER A IMM, V94, P339, DOI 10.1159/000235398; RAVETCH JV, 1994, NAT GENET, V7, P117, DOI 10.1038/ng0694-117; RICH SS, 1992, CLIN EXP ALLERGY, V22, P1070, DOI 10.1111/j.1365-2222.1992.tb00132.x; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; SHIRAKAWA T, 1991, CYTOGENET CELL GENET, V58, P1070; SIBBALD B, 1980, THORAX, V35, P671, DOI 10.1136/thx.35.9.671	26	121	122	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1262	1265		10.1016/S0140-6736(95)91863-9	http://dx.doi.org/10.1016/S0140-6736(95)91863-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475718				2022-12-28	WOS:A1995TE14500011
J	DENOOIJ, JC; HARIHARAN, IK				DENOOIJ, JC; HARIHARAN, IK			UNCOUPLING CELL FATE DETERMINATION FROM PATTERNED CELL-DIVISION IN THE DROSOPHILA EYE	SCIENCE			English	Article							C-ELEGANS EMBRYOS; COMPOUND EYE; CYCLIN-A; EXPRESSION; PROTEIN; HOMOLOG; MELANOGASTER; INHIBITOR; MUTANTS; KINASES	Cell proliferation and cell fate specification are under strict spatiotemporal control in the developing Drosophila eye. Cells excluded from five-cell preclusters synchronously enter a single additional cell cycle, the second mitotic wave, after which the remaining cells are sequentially recruited. When the second mitotic wave was blocked with the human cyclin-dependent kinase inhibitor p21(CIP1/WAF1), each cell type was still specified. Hence, cell fate determination is regulated independently of the division pattern of precursor cells. However, the second mitotic wave is needed to generate appropriate numbers of each cell type. Moreover, p21 can arrest precursor cell proliferation and allow appropriate fate choice in vivo.	MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School								BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; Campos-Ortega J A, 1980, Curr Top Dev Biol, V15 Pt 1, P347; DENOOIJ JC, UNPUB; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLIS MC, 1993, DEVELOPMENT, V119, P855; FOE VE, 1989, DEVELOPMENT, V107, P1; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARIHARAN IK, 1995, EMBO J, V14, P292, DOI 10.1002/j.1460-2075.1995.tb07003.x; HARPER JW, 1993, CELL, V75, P805; HAY BA, 1994, DEVELOPMENT, V120, P2121; JIANG HP, 1994, ONCOGENE, V9, P3397; JIMENEZ J, 1990, EMBO J, V9, P3565, DOI 10.1002/j.1460-2075.1990.tb07567.x; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; RICHARDSON HE, 1993, DEVELOPMENT, V119, P673; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; TOMLINSON A, 1987, DEV BIOL, V120, P336; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; WOLFF T, 1991, DEVELOPMENT, V113, P841; WOLFF T, 1991, DEVELOPMENT, V113, P825; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	28	117	118	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 10	1995	270	5238					983	985		10.1126/science.270.5238.983	http://dx.doi.org/10.1126/science.270.5238.983			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD878	7481802				2022-12-28	WOS:A1995TD87800047
J	SCHULZ, KF				SCHULZ, KF			SUBVERTING RANDOMIZATION IN CONTROLLED TRIALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-TRIALS; BIAS	Recent empirical evidence supports the importance of adequate randomization in controlled trials. Trials with inadequate allocation concealment have been associated with larger treatment effects compared with trials in which authors reported adequate allocation concealment. While that provides empirical evidence of bias being interjected into trials, trial investigators rarely document the sensitive details of subverting the intended purpose of randomization. This article relates anonymous accounts of deciphering assignment sequences before allocation based on experiences acquired from epidemiologic workshops for physicians. These accounts run the gamut from simple to intricate operations, from transillumination of envelopes to searching for code in the office files of the principal investigator. They indicate that deciphering is something more frequent than a rare occurrence. These accounts prompt some methodological recommendations to help prevent deciphering. Randomized controlled trials appear to annoy human nature-if properly conducted, indeed they should.			SCHULZ, KF (corresponding author), CTR DIS CONTROL & PREVENT,DIV SEXUALLY TRANSMITTED DIS PREVENT,MAIL STOP E-02,ATLANTA,GA 30333, USA.							ALTMAN DG, 1991, BRIT MED J, V302, P1481, DOI 10.1136/bmj.302.6791.1481; ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; BULPITT CJ, 1983, RANDOMIZED CONTROLLE; CARLETON RA, 1960, NEW ENGL J MED, V263, P1002, DOI 10.1056/NEJM196011172632006; CHALMERS TC, 1983, NEW ENGL J MED, V309, P1358, DOI 10.1056/NEJM198312013092204; CHALMERS TC, 1987, STAT MED, V6, P315, DOI 10.1002/sim.4780060320; Meinert CL., 1986, CLIN TRIALS DESIGN C; POCOCK SJ, 1982, STATISTICIAN, V31, P1; Pocock SJ., 2013, CLIN TRIALS PRACTICA; RENNIE D, 1995, JAMA-J AM MED ASSOC, V273, P1054, DOI 10.1001/jama.273.13.1054; SCHULZ KF, 1994, JAMA-J AM MED ASSOC, V272, P125, DOI 10.1001/jama.272.2.125; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; WILDE O, 1985, PICTURE D GRAY, P41; 1988, CONTROL CLIN TRIALS, V9, P287; 1995, JAMA-J AM MED ASSOC, V273, P776; 1994, JAMA-J AM MED ASSOC, V272, P1926; 1994, ANN INTERN MED, V121, P894	17	321	325	1	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	1995	274	18					1456	1458						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC477	7474192				2022-12-28	WOS:A1995TC47700028
J	BHANJI, S				BHANJI, S			COOKE,WILLIAM OF EXETER - APOTHECARY, SURGEON, AND GRAVE-ROBBER	LANCET			English	Article											BHANJI, S (corresponding author), POSTGRAD MED SCH, BARRACK RD, EXETER EX2 5DW, DEVON, ENGLAND.							COOKE W, 1827, LANCET, V1, P940; COOKE W, 1827, LANCET, V1, P272; HEWSON J, 1927, LANCET, V1, P274; PICKERING D, 1765, STATUTES LARGE 23RD, P380; Richardson Ruth, 1987, DEATH DISSECTION DES; 1862, GENTLEMANS MAG, V213, P364; 1826, EXETER PLYMOUTH 1111; 1826, LANCET, V12, P758; 1826, LANCET, V12, P306; 1826, LANCET, V12, P241; 1828, J HOUSE COMMONS, V83, P259; 1826, LANCET, V12, P787; 1827, EXETER PLYMOUTH 0526; 1827, LANCET, V1, P327	14	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 4	1995	346	8984					1212	1214		10.1016/S0140-6736(95)92907-X	http://dx.doi.org/10.1016/S0140-6736(95)92907-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC976	7475667				2022-12-28	WOS:A1995TC97600017
J	SCHWARER, AP; OPAT, SS; WATSON, AL; COLESINCLAIR, MF				SCHWARER, AP; OPAT, SS; WATSON, AL; COLESINCLAIR, MF			CLOBAZAM FOR SEIZURE PROPHYLAXIS DURING BUSULFAN CHEMOTHERAPY	LANCET			English	Letter											SCHWARER, AP (corresponding author), ALFRED HOSP,CLIN HAEMATOL & BMT UNIT,MELBOURNE,VIC 3181,AUSTRALIA.			Opat, Stephen/0000-0002-0308-6458				FEELY M, 1984, J NEUROL NEUROSUR PS, V47, P1279, DOI 10.1136/jnnp.47.12.1279; FITZSIMMONS WE, 1990, CANCER CHEMOTH PHARM, V27, P226, DOI 10.1007/BF00685717; OPENSHAW H, 1994, BONE MARROW TRANSPL, P488	3	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 4	1995	346	8984					1238	1238		10.1016/S0140-6736(95)92951-7	http://dx.doi.org/10.1016/S0140-6736(95)92951-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC976	7475702				2022-12-28	WOS:A1995TC97600066
J	THOMIS, DC; GURNIAK, CB; TIVOL, E; SHARPE, AH; BERG, LJ				THOMIS, DC; GURNIAK, CB; TIVOL, E; SHARPE, AH; BERG, LJ			DEFECTS IN B-LYMPHOCYTE MATURATION AND T-LYMPHOCYTE ACTIVATION IN MICE LACKING JAK3	SCIENCE			English	Article							RECEPTOR; IDENTIFICATION; MUTATION; MOUSE	Biochemical studies of signaling mediated by many cytokine and growth factor receptors have implicated members of the Jak family of tyrosine kinases in these pathways. Specifically, Jak3 has been shown to be associated with the interleukin-2 (IL-2) receptor gamma chain, a component of the receptors for IL-2, IL-4, IL-7, IL-9, and IL-15. Mice lacking Jak3 showed a severe block in B cell development at the pre-B stage in the bone marrow. In contrast, although the thymuses of these mice were small, T cell maturation progressed relatively normally. In response to mitogenic signals, peripheral T cells in Jak3-deficient mice did not proliferate and secreted small amounts of IL-2. These data demonstrate that Jak3 is critical for the progression of B cell development in the bone marrow and for the functional competence of mature T cells.	HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007627] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR042689] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32HLO7627] Funding Source: Medline; NIAMS NIH HHS [1PO30AR42689] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIERER BE, 1994, CHEM IMMUNOL, V59, P128; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; GROSS JA, 1992, J IMMUNOL, V149, P380; GURNIAK CB, UNPUB; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KIRKEN RA, 1994, J BIOL CHEM, V269, P19136; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MUSSO T, 1995, J EXP MED, V181, P1425, DOI 10.1084/jem.181.4.1425; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; RANE SG, 1994, ONCOGENE, V9, P2415; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SCOLLAY R, 1995, IMMUNOL TODAY, V16, P268, DOI 10.1016/0167-5699(95)80179-0; TAKAHASHI T, 1994, FEBS LETT, V342, P124, DOI 10.1016/0014-5793(94)80485-0; THOMIS DC, UNPUB; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0	25	450	469	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 3	1995	270	5237					794	797		10.1126/science.270.5237.794	http://dx.doi.org/10.1126/science.270.5237.794			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC712	7481767				2022-12-28	WOS:A1995TC71200039
J	ORTON, P				ORTON, P			CARING AND SHARING	LANCET			English	Editorial Material																		BAILEY J, 1990, BRIT MED J, V308, P1083; ORTON P, 1994, LANCET, V344, P1413; VIERHOUT WPM, 1995, LANCET, V346, P990, DOI 10.1016/S0140-6736(95)91686-5; WARNER M, 1995, WELSH PLANNING FORUM	4	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 14	1995	346	8981					984	984		10.1016/S0140-6736(95)91682-2	http://dx.doi.org/10.1016/S0140-6736(95)91682-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475588				2022-12-28	WOS:A1995RZ59900005
J	YOCHEM, J; WESTON, K; GREENWALD, I				YOCHEM, J; WESTON, K; GREENWALD, I			THE CAENORHABDITIS-ELEGANS LIN-12 GENE ENCODES A TRANSMEMBRANE PROTEIN WITH OVERALL SIMILARITY TO DROSOPHILA-NOTCH	NATURE			English	Article									MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology	YOCHEM, J (corresponding author), PRINCETON UNIV,DEPT BIOL,PRINCETON,NJ 08544, USA.							AKAM M, 1986, NATURE, V319, P447, DOI 10.1038/319447a0; APPELLA E, 1987, J BIOL CHEM, V262, P4437; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BENDER W, 1985, CELL, V43, P559, DOI 10.1016/0092-8674(85)90224-7; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HARTLEY DA, 1987, EMBO J, V6, P3407, DOI 10.1002/j.1460-2075.1987.tb02664.x; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MANIATIS T, 1982, MOL CLONING LABORATO; OKUDA A, 1987, J BIOL CHEM, V262, P3858; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STERNBERG P, 1988, NATURE, V335; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6	28	264	277	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1988	335	6190					547	550		10.1038/335547a0	http://dx.doi.org/10.1038/335547a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q3412	3419531				2022-12-28	WOS:A1988Q341200055
J	RIDLEY, MG; WOLFE, CS; ASHERSON, RA; HUGHES, GRV				RIDLEY, MG; WOLFE, CS; ASHERSON, RA; HUGHES, GRV			RECURRENT OTITIS-MEDIA AND PULMONARY-INFILTRATES AS PRESENTING FEATURES IN WEGENERS GRANULOMATOSIS	BRITISH MEDICAL JOURNAL			English	Article									UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT RHEUMATOL,LONDON SE1 7EH,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,LUPUS ARTHRITIS RES UNIT,LONDON SE1 7EH,ENGLAND	University of London; King's College London; University of London; King's College London								CARRINGTON CB, 1966, AM J MED, V41, P497, DOI 10.1016/0002-9343(66)90214-2; FAUCI AS, 1973, MEDICINE, V52, P535, DOI 10.1097/00005792-197311000-00002; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; HELLMANN D, 1987, ANN RHEUM DIS, V46, P628, DOI 10.1136/ard.46.8.628; HOLLANDER D, 1967, ANN INTERN MED, V67, P393, DOI 10.7326/0003-4819-67-2-393; SERGENT JS, 1974, ANN INTERN MED, V81, P195, DOI 10.7326/0003-4819-81-2-195; SHAH IA, 1984, PATHOL RES PRACT, V178, P407, DOI 10.1016/S0344-0338(84)80042-4; WALTON EW, 1958, BRIT MED J, V2, P265, DOI 10.1136/bmj.2.5091.265; WOLFF SM, 1974, ANN INTERN MED, V81, P836	9	13	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1988	297	6644					352	353		10.1136/bmj.297.6644.352	http://dx.doi.org/10.1136/bmj.297.6644.352			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P4527	3416170	Green Published, Bronze			2022-12-28	WOS:A1988P452700032
J	JENKINSON, D; DAVISON, J; JONES, S; HAWTIN, P				JENKINSON, D; DAVISON, J; JONES, S; HAWTIN, P			COMPARISON OF EFFECTS OF A SELF MANAGEMENT BOOKLET AND AUDIOCASSETTE FOR PATIENTS WITH ASTHMA	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM,SCH MED,DEPT COMMUNITY MED & EPIDEMIOL,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham								ANDERSON JE, 1980, BRIT MED J, V281, P924, DOI 10.1136/bmj.281.6245.924; BLUM ML, 1968, IND PSYCHOL THEORETI, P306; FIREMAN P, 1981, PEDIATRICS, V68, P341; HARDING JM, 1985, J ROY COLL GEN PRACT, V35, P226; HILTON S, 1986, LANCET, V1, P26; LEWIS CE, 1984, PEDIATRICS, V74, P478; LEY P, 1976, PSYCHOL MED, V6, P599, DOI 10.1017/S0033291700018237; MAIMAN LA, 1979, JAMA-J AM MED ASSOC, V241, P1919; MAZZUCA SA, 1982, J CHRON DIS, V35, P521, DOI 10.1016/0021-9681(82)90071-6; MCCULLOCH DK, 1983, BRIT MED J, V287, P1858, DOI 10.1136/bmj.287.6408.1858; MODELL M, 1983, BRIT MED J, V286, P2027, DOI 10.1136/bmj.286.6383.2027; MORRELL DC, 1980, BRIT MED J, V280, P769, DOI 10.1136/bmj.280.6216.769	12	69	70	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1988	297	6643					267	270		10.1136/bmj.297.6643.267	http://dx.doi.org/10.1136/bmj.297.6643.267			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P4266	3416147	Green Published, Bronze			2022-12-28	WOS:A1988P426600022
J	MAHER, ER; DUTOIT, SH; BAILLOD, RA; SWENY, P; MOORHEAD, JF				MAHER, ER; DUTOIT, SH; BAILLOD, RA; SWENY, P; MOORHEAD, JF			GASTROINTESTINAL COMPLICATIONS OF DIALYSIS RELATED AMYLOIDOSIS	BRITISH MEDICAL JOURNAL			English	Article									ROYAL FREE HOSP & SCH MED,DEPT HISTOPATHOL,LONDON NW3 2QG,ENGLAND	University of London; University College London	MAHER, ER (corresponding author), ROYAL FREE HOSP & SCH MED,DEPT NEPHROL,LONDON NW3 2QG,ENGLAND.		Moorhead, John/M-7404-2014; Dutoit, Stephen Hamilton/E-1815-2013; MAHER, EAMONN R/A-9507-2008	MAHER, EAMONN R/0000-0002-6226-6918; Hamilton-Dutoit, Stephen/0000-0003-2158-3885				Bardin T, 1986, Nephrol Dial Transplant, V1, P151; BRANDT K, 1968, AM J MED, V44, P955, DOI 10.1016/0002-9343(68)90095-8; BROWN EA, 1986, BMJ-BRIT MED J, V292, P163, DOI 10.1136/bmj.292.6514.163; MUNOZGOMEZ J, 1985, ANN RHEUM DIS, V44, P729, DOI 10.1136/ard.44.11.729; THEAKER JM, 1987, J CLIN PATHOL, V40, P1247, DOI 10.1136/jcp.40.10.1247	5	53	53	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1988	297	6643					265	266		10.1136/bmj.297.6643.265	http://dx.doi.org/10.1136/bmj.297.6643.265			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P4266	3416145	Bronze, Green Published			2022-12-28	WOS:A1988P426600020
J	CLARK, SS; MCLAUGHLIN, J; TIMMONS, M; PENDERGAST, AM; BEN-NERIAH, Y; DOW, LW; CRIST, W; ROVERA, G; SMITH, SD; WITTE, ON				CLARK, SS; MCLAUGHLIN, J; TIMMONS, M; PENDERGAST, AM; BEN-NERIAH, Y; DOW, LW; CRIST, W; ROVERA, G; SMITH, SD; WITTE, ON			EXPRESSION OF A DISTINCTIVE BCR-ABL ONCOGENE IN PH1-POSITIVE ACUTE LYMPHOCYTIC-LEUKEMIA (ALL)	SCIENCE			English	Article									UNIV CALIF LOS ANGELES, INST MOLEC BIOL, DEPT MICROBIOL, LOS ANGELES, CA 90024 USA; UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38101 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA; HEBREW UNIV JERUSALEM, HADASSAH MED SCH, LAUTENBERG CTR GEN & TUMOR IMMUNOL, IL-91010 JERUSALEM, ISRAEL; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38101 USA; WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP STANFORD, DEPT PEDIAT, PALO ALTO, CA 94304 USA	University of California System; University of California Los Angeles; University of Tennessee System; University of Tennessee Health Science Center; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Hebrew University of Jerusalem; St Jude Children's Research Hospital; The Wistar Institute			Ben-Neriah, Yinon/L-6285-2019	Pendergast, Ann Marie/0000-0002-1250-6880	NCI NIH HHS [CA-21765, CA-34233, CA-20180] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA020180, P01CA034233, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BERK AJ, 1978, P NATL ACAD SCI USA, V75, P1274, DOI 10.1073/pnas.75.3.1274; CANAANI E, 1984, LANCET, V1, P593; CATOVSKY D, 1979, BRIT J HAEMATOL, V42, P493, DOI 10.1111/j.1365-2141.1979.tb01161.x; CHAMBERL.M, 1973, J BIOL CHEM, V248, P2235; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CLARK SJ, UNPUB; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; COLLINS SJ, 1984, SCIENCE, V225, P72, DOI 10.1126/science.6587568; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; ERIKSON J, 1986, P NATL ACAD SCI USA, V83, P1807, DOI 10.1073/pnas.83.6.1807; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; GALE RP, 1984, P NATL ACAD SCI-BIOL, V81, P5648, DOI 10.1073/pnas.81.18.5648; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; LANGE B, 1987, BLOOD, V70, P192; LEIBOWITZ D, 1985, BLOOD, V65, P526; LEIBOWITZ D, 1985, BLOOD, V66, P243; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MAXWELL S, 1985, CANCER RES, V47, P1731; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; NAUMOVSKI L, UNPUB; NOWELL PC, 1960, SCIENCE, V132, P1497; PENDERGAST AM, UNPUB; RODENHUIS S, 1985, NEW ENGL J MED, V313, P51; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; WALKER LC, 1987, NATURE, V329, P851, DOI 10.1038/329851a0; WESTBROOK CG, 1987, J CELL BIOCH A S, V11, P200; 1981, CANCER GENET CYTOGEN, V4, P95	40	232	241	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 12	1988	239	4841					775	777		10.1126/science.3422516	http://dx.doi.org/10.1126/science.3422516			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	M0209	3422516				2022-12-28	WOS:A1988M020900031
J	ROSS, JM; SOX, HC				ROSS, JM; SOX, HC			IF AT FIRST YOU DONT SUCCEED	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											ROSS, JM (corresponding author), DARTMOUTH HITCHCOCK MED CTR,DEPT MED,LEBANON,NH 03756, USA.							BAYES T, 1991, M D COMPUT, V8, P157; CROOKS J, 1959, Q J MED, V52, P211; Kassirer JP., 2009, LEARNING CLIN REASON; SOX HC, 1988, MED DECIS MAKING, P27; VOYTOVICH AE, 1985, J MED EDUC, V60, P302	5	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 7	1995	333	23					1557	1560		10.1056/NEJM199512073332309	http://dx.doi.org/10.1056/NEJM199512073332309			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH157	7477173				2022-12-28	WOS:A1995TH15700009
J	MERMEL, LA; PARENTEAU, S; TOW, SM				MERMEL, LA; PARENTEAU, S; TOW, SM			THE RISK OF MIDLINE CATHETERIZATION IN HOSPITALIZED-PATIENTS - A PROSPECTIVE-STUDY	ANNALS OF INTERNAL MEDICINE			English	Note							CYSTIC-FIBROSIS	Objective: To assess the risk associated with midline catheter use in hospitalized patients. Design: Prospective, consecutive enrollment. Setting: A 719-bed university-affiliate hospital. Patients: Patients were enrolled if they were likely to require at least 7 days of intravascular catheterization while hospitalized. Measurements: Patients were monitored for adverse reactions, Catheter segment, insertion site, hub, infusate, and blood cultures were assessed. Results: From February 1993 through June 1994, 251 Landmark midline catheters were inserted in 238 patients, One hundred forty catheter cultures were obtained from 130 patients who remained hospitalized for the duration of catheterization. For these 130 patients, the mean duration of catheterization was 9 days, the incidence of catheter colonization was 5.0 per 1000 catheter days, and the incidence of catheter-related bloodstream infection was 0.8 per 1000 catheter days. During the study period, two severe, unexpected adverse reactions occurred that may have been associated with the use of Landmark midline catheters; no such reactions were associated with the insertion of 58 580 Teflon peripheral catheters (P < 0.00001; exact 95% lower bound of the odds ratio, 68.9). Fifty-three similar reactions associated with Landmark midline catheters, including two deaths, have been reported to the Food and Drug Administration through June 1994. Conclusion: The risk for midline catheter-related infection is low. However, Landmark midline catheters are associated with life-threatening adverse reactions that are probably attributable to the catheter material itself.	RHODE ISL HOSP, DEPT INFECT CONTROL, PROVIDENCE, RI 02903 USA; RHODE ISL HOSP, DEPT NURSING, PROVIDENCE, RI 02903 USA; BROWN UNIV, SCH MED, PROVIDENCE, RI USA	Lifespan Health Rhode Island; Rhode Island Hospital; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University	MERMEL, LA (corresponding author), RHODE ISL HOSP, DIV INFECT DIS, 593 EDDY ST, PROVIDENCE, RI 02903 USA.		Mermel, Leonard/Z-1475-2019					Blum D Y, 1995, J Intraven Nurs, V18, P116; BRIARS G, 1993, LANCET, V342, P118, DOI 10.1016/0140-6736(93)91320-L; BROSS JE, 1995, INFECT CONTROL HO S2, V16, P38; COBB DK, 1992, NEW ENGL J MED, V327, P1062, DOI 10.1056/NEJM199210083271505; FAN ST, 1988, J HOSP INFECT, V12, P191, DOI 10.1016/0195-6701(88)90006-0; Fontaine P J, 1991, J Intraven Nurs, V14, P91; HARWOOD IR, 1992, PEDIATR PULM, V12, P233, DOI 10.1002/ppul.1950120407; LESSER E, 1993, CLIN RES, V41, pA604; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; MERMEL LA, 1996, IN PRESS ASS PROFESS; Pauley S Y, 1993, J Intraven Nurs, V16, P50; Rogan D H, 1993, J Intraven Nurs, V16, P118; SHERERTZ RJ, 1990, J CLIN MICROBIOL, V28, P76, DOI 10.1128/JCM.28.1.76-82.1990; STENZEL JP, 1989, CRIT CARE MED, V17, P984, DOI 10.1097/00003246-198910000-00003; [No title captured]; 1994, ADVERSE MED DEVICE E	16	49	49	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1995	123	11					841	844		10.7326/0003-4819-123-11-199512010-00005	http://dx.doi.org/10.7326/0003-4819-123-11-199512010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG209	7486466				2022-12-28	WOS:A1995TG20900005
J	DAVIDSON, EH; PETERSON, KJ; CAMERON, RA				DAVIDSON, EH; PETERSON, KJ; CAMERON, RA			ORIGIN OF BILATERIAN BODY PLANS - EVOLUTION OF DEVELOPMENTAL REGULATORY MECHANISMS	SCIENCE			English	Article							MARINE-INVERTEBRATES; LARVAL DEVELOPMENT; PATTERN-FORMATION; HOX CODE; DROSOPHILA; HINDBRAIN; PHYLOGENY; EMBRYOS; GENES; EXPRESSION	An argument is proposed to explain the origin of large metazoans, based on the regulatory processes that underlie the morphogenetic organization of pattern in modern animals. Genetic regulatory systems similar to those used in modern, indirectly developing marine invertebrates are considered to indicate the Precambrian regulatory platform on which were erected innovations that underlie the development of macroscopic body plans. Those systems are genetic regulatory programs that produce groups of unspecified ''set-aside cells'' and hierarchical regulatory programs that initially define regions of morphogenetic space in terms of domains of transcription factor expression, These ideas affect interpretation of the development of arthropods and chordates as well as interpretation of the role of the genes of the homeotic complex in embryogenesis.	UNIV CALIF LOS ANGELES,DEPT EARTH & SPACE SCI,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles	DAVIDSON, EH (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.		Peterson, Kevin J/A-2188-2009	Cameron, R. Andrew/0000-0003-3947-6041	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005753, R37HD005753] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006591] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-06591] Funding Source: Medline; NICHD NIH HHS [HD-05753] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHLBERG PE, 1994, NATURE, V368, P507, DOI 10.1038/368507a0; BALSER EJ, 1990, ACTA ZOOL-STOCKHOLM, V71, P235, DOI 10.1111/j.1463-6395.1990.tb01082.x; BENGTSON S., 1986, PROBLEMATIC FOSSIL T, P3; Berrill N.J., 1955, ORIGIN VERTEBRATES; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; BOWRING SA, 1993, SCIENCE, V261, P1293, DOI 10.1126/science.11539488; BRITTEN RJ, 1971, QUART REV BIOL, V46, P111; Brusca R.C., 1990, INVERTEBRATES; CAMERON R A, 1989, Molecular Reproduction and Development, V1, P149, DOI 10.1002/mrd.1080010302; CAMERON RA, 1987, GENE DEV, V1, P75, DOI 10.1101/gad.1.1.75; CAMERON RA, 1989, DEVELOPMENT, V113, P1085; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CARROLL SB, 1994, DEVELOPMENT, P217; Coffman JA, 1992, CURR OPIN GENET DEV, V2, P260, DOI 10.1016/S0959-437X(05)80283-7; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; Cohen S. M., 1993, DEV DROSOPHILA MELAN, P747; CZIHAK G, 1965, ROUX ARCH ENTW MECH, V155, P709; DAMEN P, 1994, DEV BIOL, V162, P364, DOI 10.1006/dbio.1994.1094; Dan, 1968, INVERTEBRATE EMBRYOL; DAVIDSON EH, 1990, DEVELOPMENT, V108, P365; DAVIDSON EH, 1993, DEVELOPMENT, V118, P665; DAVIDSON EH, 1991, DEVELOPMENT, V113, P1; DAVIDSON EH, 1994, BIOESSAYS, V16, P603, DOI 10.1002/bies.950160903; DAVIDSON EH, 1986, GENE ACTIVITY EARLY, pCH3; EDGAR LG, 1994, DEVELOPMENT, V120, P443; EMLET RB, 1995, DEV BIOL, V167, P405, DOI 10.1006/dbio.1995.1037; FEDONKIN MA, 1994, NOBEL S, V84, P370; GARCIABELLIDO A, 1994, P NATL ACAD SCI USA, V91, P10222, DOI 10.1073/pnas.91.21.10222; GEHLING JG, 1991, MEMOIRS GEOLOGICAL S, V20, P181; GONZALEZGAITAN M, 1994, MECH DEVELOP, V40, P183; Gould S. J., 1989, WONDERFUL LIFE BURGE; GOULD SJ, 1992, ORIGIN EARLY EVOLUTI; Hadfield M.G., 1975, P185; HALANYCH KM, 1995, SCIENCE, V267, P1641, DOI 10.1126/science.7886451; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HASZPRUNAR G, 1995, ACTA ZOOL-STOCKHOLM, V76, P141, DOI 10.1111/j.1463-6395.1995.tb00988.x; HOLLAND LZ, 1989, MAR BIOL, V101, P83, DOI 10.1007/BF00393481; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; Hyman L. H., 1959, INVERTEBRATES SMALLE, VV; IZPISUABELMONTE JC, 1992, DEV BIOL, V152, P26, DOI 10.1016/0012-1606(92)90153-8; Jagersten G, 1972, EVOLUTION METAZOAN L; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LEAHY PS, 1994, MECH DEVELOP, V45, P255, DOI 10.1016/0925-4773(94)90012-4; MacBride EW, 1903, PHILOS T R SOC LON B, V195, P285, DOI 10.1098/rstb.1903.0006; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MILEIKOVSKY SA, 1971, MAR BIOL, V10, P193, DOI 10.1007/BF00352809; MOLVEN A, 1990, DEVELOPMENT, V109, P279; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; MORGAN BA, 1994, DEVELOPMENT, P181; MORRIS SC, 1995, PHILOS T ROY SOC B, V347, P305, DOI 10.1098/rstb.1995.0029; MORRIS SC, 1993, NATURE, V361, P219, DOI 10.1038/361219a0; MORRIS SC, 1993, PALAEONTOLOGY, V36, P593; MORRIS SC, 1994, DEVELOPMENT S, V1; NIELSEN C, 1985, BIOL J LINN SOC, V25, P243, DOI 10.1111/j.1095-8312.1985.tb00396.x; Pearse JS, 1991, REPRODUCTION MARINE, P514; PETERSON KJ, 1995, LETHAIA, V28, P25, DOI 10.1111/j.1502-3931.1995.tb01591.x; QUIRING R, 1994, SCIENCE, V265, P85; RAFF RA, 1987, DEV BIOL, V119, P6, DOI 10.1016/0012-1606(87)90201-6; RAFF RA, 1994, ANNU REV ECOL SYST, V25, P351, DOI 10.1146/annurev.es.25.110194.002031; RAFF RA, 1994, NOB S, V84, P489; REUTER R, 1990, DEVELOPMENT, V109, P289; REUTER R, 1994, DEVELOPMENT, V120, P1123; RUNNEGAR B, 1982, ALCHERINGA, V6, P223, DOI 10.1080/03115518208565415; RUNNEGAR B, 1982, J GEOL SOC AUST, V29, P395, DOI 10.1080/00167618208729222; Runnegar Bruce, 1995, Neues Jahrbuch fuer Geologie und Palaeontologie Abhandlungen, V195, P303; SCHELTEMA AH, 1993, BIOL BULL, V171, P57; SCHNEIDERMAUNOU.S, 1993, CELL, V0075; Sepkoski J.J. Jr, 1992, P1171; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; STRATHMANN RR, 1978, EVOLUTION, V32, P894, DOI 10.1111/j.1558-5646.1978.tb04642.x; STRATHMANN RR, 1985, ANNU REV ECOL SYST, V16, P339, DOI 10.1146/annurev.es.16.110185.002011; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; THORSON G, 1950, BIOL REV, V25, P1, DOI 10.1111/j.1469-185X.1950.tb00585.x; VALENTINE JW, 1994, NOBEL S, V84, P401; WADA H, 1994, P NATL ACAD SCI USA, V91, P1801, DOI 10.1073/pnas.91.5.1801; WEIGUO S, 1994, NOBLE S, V84, P358; WHEELER WC, 1993, CLADISTICS, V9, P1, DOI 10.1111/j.1096-0031.1993.tb00207.x; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; WILLIAMS JA, 1993, BIOESSAYS, V15, P567, DOI 10.1002/bies.950150902; WRAY GA, 1994, DEVELOPMENT, P97; WRAY GA, 1994, AM ZOOL, V34, P353; [No title captured]	83	308	315	0	44	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 24	1995	270	5240					1319	1325		10.1126/science.270.5240.1319	http://dx.doi.org/10.1126/science.270.5240.1319			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF899	7481819				2022-12-28	WOS:A1995TF89900028
J	JAMPEL, HD				JAMPEL, HD			PATCHING FOR CORNEAL ABRASIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CONTACT				JAMPEL, HD (corresponding author), JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21218, USA.							ANDERSON C, 1991, CORNEA, V10, P478, DOI 10.1097/00003226-199111000-00003; ASWAD MI, 1989, ARCH OPHTHALMOL-CHIC, V107, P1667, DOI 10.1001/archopht.1989.01070020745040; COHEN EJ, 1987, OPHTHALMOLOGY, V94, P109; SCHEIN OD, 1993, AM J EMERG MED, V11, P606, DOI 10.1016/0735-6757(93)90012-Z	4	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	1995	274	19					1504	1504						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD571	7474205				2022-12-28	WOS:A1995TD57100009
J	FERSTER, D; SPRUSTON, N				FERSTER, D; SPRUSTON, N			CRACKING THE NEURONAL CODE	SCIENCE			English	Editorial Material							RESPONSES; CORTEX; CELLS				FERSTER, D (corresponding author), NORTHWESTERN UNIV,DEPT PHYSIOL & NEUROBIOL,EVANSTON,IL 60208, USA.			Spruston, Nelson/0000-0003-3118-1636				ABELES M, 1993, J NEUROPHYSIOL, V70, P1629, DOI 10.1152/jn.1993.70.4.1629; ADRIAN ED, 1937, J PHYSL, V61, P151; BUZSAKI G, 1995, CURR OPIN NEUROBIOL, V5, P504, DOI 10.1016/0959-4388(95)80012-3; DECHARMS RC, UNPUB; ERLANGER J, 1937, ELECTRICAL SIGNS NER; FETZ EE, 1983, J PHYSIOL-LONDON, V341, P387, DOI 10.1113/jphysiol.1983.sp014812; GAWNE TJ, 1991, J NEUROPHYSIOL, V66, P379, DOI 10.1152/jn.1991.66.2.379; GERSTEIN GL, 1964, BIOPHYS J, V4, P41, DOI 10.1016/S0006-3495(64)86768-0; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; HOPFIELD JJ, 1995, NATURE, V376, P33, DOI 10.1038/376033a0; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; MEISTER M, IN PRESS SCIENCE; Muller J., 1840, HDB PHYSIOLOGIE MENS; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; Shadlen M N, 1995, Curr Opin Neurobiol, V5, P248, DOI 10.1016/0959-4388(95)80033-6; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; SOFTKY W, 1994, NEUROSCIENCE, V58, P13, DOI 10.1016/0306-4522(94)90154-6; Softky W R, 1995, Curr Opin Neurobiol, V5, P239, DOI 10.1016/0959-4388(95)80032-8; SOFTKY WR, 1993, J NEUROSCI, V13, P334; VAADIA E, 1995, NATURE, V373, P515, DOI 10.1038/373515a0; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520	21	109	115	0	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 3	1995	270	5237					756	757		10.1126/science.270.5237.756	http://dx.doi.org/10.1126/science.270.5237.756			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC712	7481761				2022-12-28	WOS:A1995TC71200028
J	MARICQ, AV; PECKOL, E; DRISCOLL, M; BARGMANN, CI				MARICQ, AV; PECKOL, E; DRISCOLL, M; BARGMANN, CI			MECHANOSENSORY SIGNALING IN C-ELEGANS MEDIATED BY THE GLR-1 GLUTAMATE-RECEPTOR	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; NERVOUS-SYSTEM; GENE; NEURODEGENERATION; ACETYLCHOLINE; EXPRESSION; SEQUENCE; CLONING; FAMILY; SET	NEURONAL signalling across synapses involves activation of many neurotransmitter receptors on postsynaptic cells. glr-1 encodes a potential glutamate receptor in the nematode Caenorhabditis elegans which is most similar to vertebrate AMPA-type ionotropic glutamate receptors(1). glr-1 is expressed in motor neurons and interneurons, including interneurons implicated in the control of locomotion(2). Here we investigate the contribution of glr-1 to the normal signalling of these neurons, by generating a deletion mutation in glr-1. We find that mutant worms are deficient in their ability to withdraw backwards when mechanically stimulated, but they withdraw normally in response to chemical repellents. The ASH sensory neurons mediate withdrawal responses both to mechanical stimuli and to chemical repellents(3,4), and ASH makes chemical synapses with glr-1-expressing interneurons. Our results suggest that postsynaptic interneurons use different neurotransmitter receptors to process two sensory stimuli detected by one sensory neuron.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, PROGRAM DEV BIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT ANAT, PROGRAM NEUROSCI, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT ANAT, GENET PROGRAM, SAN FRANCISCO, CA 94143 USA; RUTGERS STATE UNIV, CTR ADV BIOTECHNOL & MED, DEPT MOLEC BIOL & BIOCHEM, PISCATAWAY, NJ 08855 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Rutgers State University New Brunswick				Bargmann, Cornelia/0000-0002-8484-0618				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARGMANN CI, 1990, COLD SPRING HARB SYM, V55, P529; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BOCHET P, 1994, NEURON, V12, P383, DOI 10.1016/0896-6273(94)90279-8; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1985, J NEUROSCI, V5, P956; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHURCH PJ, 1993, J NEUROSCI, V13, P2790; CULOTTI JG, 1978, GENETICS, V90, P243; Darlison Mark G., 1993, V63, P48; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVRIES SH, 1993, CELL, V72, P139, DOI 10.1016/S0092-8674(05)80033-9; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; HART AC, 1995, NATURE, V378, P82, DOI 10.1038/378082a0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; JONAS P, 1994, NEURON, V12, P1281, DOI 10.1016/0896-6273(94)90444-8; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; OMALLEY DM, 1992, J NEUROSCI, V12, P1394; SCHOTLAND J, 1995, NATURE, V374, P266, DOI 10.1038/374266a0; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; ULTSCH A, 1992, P NATL ACAD SCI USA, V89, P10484, DOI 10.1073/pnas.89.21.10484; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	31	274	282	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 2	1995	378	6552					78	81		10.1038/378078a0	http://dx.doi.org/10.1038/378078a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477293				2022-12-28	WOS:A1995TC46900054
J	ANDERSON, HV				ANDERSON, HV			INTRAVENOUS THROMBOLYSIS IN REFRACTORY UNSTABLE ANGINA-PECTORIS	LANCET			English	Editorial Material							TRIAL; PLACEBO		HERMANN HOSP,HOUSTON,TX		ANDERSON, HV (corresponding author), UNIV TEXAS,HLTH SCI CTR,HOUSTON,TX 77225, USA.							ANDERSON HV, IN PRESS J AM COLL C; BAR FW, 1992, CIRCULATION, V86, P131, DOI 10.1161/01.CIR.86.1.131; DUVVURI S, 1994, J MYOCARD ISCHEMIA, V6, P11; FREEMAN MR, 1992, CIRCULATION, V85, P150, DOI 10.1161/01.CIR.85.1.150; GRAVES EJ, 1993, NATIONAL CTR HLTH 13, V114; GURKFINKEL E, 1995, J AM COLL CARDIOL, pA420; ROMEO F, 1995, J AM COLL CARDIOL, V25, P1295, DOI 10.1016/0735-1097(95)00002-L; SCHREIBER TL, 1992, CIRCULATION, V86, P1407, DOI 10.1161/01.CIR.86.5.1407; Theroux P, 1993, Curr Probl Cardiol, V18, P157	9	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 28	1995	346	8983					1113	1114						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB549	7475596				2022-12-28	WOS:A1995TB54900003
J	JACOBS, TP; WHITLOCK, RT; EDSALL, J; HOLUB, DA				JACOBS, TP; WHITLOCK, RT; EDSALL, J; HOLUB, DA			ADDISONIAN CRISIS WHILE TAKING HIGH-DOSE GLUCOCORTICOIDS - AN UNUSUAL PRESENTATION OF PRIMARY ADRENAL FAILURE IN 2 PATIENTS WITH UNDERLYING INFLAMMATORY DISEASES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note									COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University								BOSCH EP, 1977, NEUROLOGY, V27, P1178; CHRISTY NP, 1971, HUMAN ADRENAL CORTEX, P395; DINGMAN JF, 1960, J CLIN INVEST, V39, P1851, DOI 10.1172/JCI104209; GAMBERTOGLIO JG, 1980, J PHARMACOKINET BIOP, V8, P1, DOI 10.1007/BF01059447; GUILLEVIN L, 1978, ANN MED INTERNE, V129, P255; Haynes Jr RC, 1985, PHARMACOL BASIS THER, P1459; JENKINS JS, 1967, BRIT MED J, V2, P205, DOI 10.1136/bmj.2.5546.205; KARLISH AJ, 1970, LANCET, V2, P330; KNOWLTON AI, 1971, HUMAN ADRENAL CORTEX, P329; NEUFELD M, 1981, MEDICINE, V60, P355, DOI 10.1097/00005792-198109000-00003; PICKUP ME, 1979, CLIN PHARMACOKINET, V4, P111, DOI 10.2165/00003088-197904020-00004; POWELL LW, 1972, GUT, V13, P690, DOI 10.1136/gut.13.9.690; PRUNTY FTG, 1964, CHEM TREATMENT ADREN, P37; RICKARDS AG, 1954, Q J MED, V23, P403; SCHRIER RW, 1980, MINER ELECTROL METAB, V4, P1; SEINFELD ED, 1983, J ROY SOC MED, V76, P883, DOI 10.1177/014107688307601015; SPITAL A, 1982, SOUTHERN MED J, V75, P581, DOI 10.1097/00007611-198205000-00018; STOCKIGT JR, 1979, AM J MED, V66, P915, DOI 10.1016/0002-9343(79)90445-5; THOMPSON DG, 1979, CLIN ENDOCRINOL, V10, P499, DOI 10.1111/j.1365-2265.1979.tb02107.x; Wilson JD, 1985, WILLIAMS TXB ENDOCRI	20	13	13	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1988	260	14					2082	2084		10.1001/jama.260.14.2082	http://dx.doi.org/10.1001/jama.260.14.2082			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q3421	3418873				2022-12-28	WOS:A1988Q342100022
J	BODY, JJ; DEMEESTERMIRKINE, N; CORVILAIN, J				BODY, JJ; DEMEESTERMIRKINE, N; CORVILAIN, J			CALCITONIN DEFICIENCY AFTER RADIOACTIVE IODINE TREATMENT	ANNALS OF INTERNAL MEDICINE			English	Note									HOP UNIV BRUGMANN, SERV MED, B-1020 BRUSSELS, BELGIUM		BODY, JJ (corresponding author), INST JULES BORDET, SERV MED, UNITE ENDOCRINOL, 1 RUE HEGER BORDET, B-1000 BRUSSELS, BELGIUM.		Body, Jean-Jacques/G-9785-2015					AUSTIN LA, 1981, NEW ENGL J MED, V304, P269, DOI 10.1056/NEJM198101293040505; BODY JJ, 1983, J CLIN ENDOCR METAB, V57, P897, DOI 10.1210/jcem-57-5-897; BODY JJ, 1986, J CLIN ENDOCR METAB, V62, P700; COINDRE JM, 1986, ARCH INTERN MED, V146, P48, DOI 10.1001/archinte.146.1.48; GRAHAM GD, 1986, ANN INTERN MED, V105, P900, DOI 10.7326/0003-4819-105-6-900; KENDALLTAYLOR P, 1984, BRIT MED J, V289, P361, DOI 10.1136/bmj.289.6441.361; NUSYNOWITZ ML, 1982, J NUCL MED, V23, P143; REFETOFF S, 1977, J NUCL MED ALLIED S, V21, P23; THURSTON V, 1982, ACTA ENDOCRINOL-COP, V99, P72, DOI 10.1530/acta.0.0990072; TIEGS RD, 1986, J BONE MINER RES, V1, P339	10	10	10	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1988	109	7					590	591		10.7326/0003-4819-109-7-590	http://dx.doi.org/10.7326/0003-4819-109-7-590			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q4157	3421566				2022-12-28	WOS:A1988Q415700012
J	REYNEN, K				REYNEN, K			CARDIAC MYXOMAS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LEFT ATRIAL-MYXOMA; TWO-DIMENSIONAL ECHOCARDIOGRAPHY; LEFT-VENTRICULAR MYXOMA; SEPTAL ANEURYSM MIMICKING; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; CLINICAL-EXPERIENCE; CORONARY ANGIOGRAPHY; SURGICAL-TREATMENT; RAPID GROWTH; DIAGNOSIS				REYNEN, K (corresponding author), UNIV ERLANGEN NURNBERG, DEPT INTERNAL MED 2, OSTLICHE STADTMAUERSTR 29, D-91054 ERLANGEN, GERMANY.							ALDRIDGE HE, 1960, BRIT HEART J, V22, P189; BALK AHM, 1979, AM J CARDIOL, V44, P767, DOI 10.1016/0002-9149(79)90300-X; BATEMAN TM, 1983, J THORAC CARDIOV SUR, V86, P601; BENJAMIN HS, 1939, ARCH PATHOL, V27, P950; Blondeau P, 1990, Thorac Cardiovasc Surg, V38 Suppl 2, P192, DOI 10.1055/s-2007-1014065; BOUGH EW, 1983, AM J CARDIOL, V52, P1365, DOI 10.1016/0002-9149(83)90610-0; BULKLEY BH, 1979, AM HEART J, V97, P639, DOI 10.1016/0002-8703(79)90193-5; BURNS ER, 1982, AM J MED SCI, V284, P17, DOI 10.1097/00000441-198209000-00003; CARNEY JA, 1986, MAYO CLIN PROC, V61, P165, DOI 10.1016/S0025-6196(12)61843-6; CARTER AB, 1960, BRIT HEART J, V22, P502; CASALE L, 1991, AM HEART J, V122, P1474, DOI 10.1016/0002-8703(91)90596-A; CHIARI H, 1931, ZBL ALLG PATH PATH A, V52, P241; CHIN WW, 1988, AM HEART J, V116, P562, DOI 10.1016/0002-8703(88)90636-9; CLEVELAND DC, 1983, JAMA-J AM MED ASSOC, V249, P2799, DOI 10.1001/jama.249.20.2799; COHEN AI, 1963, AM J CARDIOL, V11, P802, DOI 10.1016/0002-9149(63)90109-7; CRAFOORD C, 1955, H FORD HOSP INT S CA, P202; CRAWFORD FA, 1978, ANN SURG, V188, P240, DOI 10.1097/00000658-197808000-00018; DEGROAT TS, 1985, AM J CARDIOL, V56, P827, DOI 10.1016/0002-9149(85)91160-9; DEIN JR, 1987, J THORAC CARDIOV SUR, V93, P502; DEMARIA AN, 1975, AM J MED, V59, P713, DOI 10.1016/0002-9343(75)90232-6; DEMORAIS CF, 1988, ARCH PATHOL LAB MED, V112, P185; DEPACE NL, 1981, AM J CARDIOL, V48, P954, DOI 10.1016/0002-9149(81)90364-7; DESOUSA AL, 1978, J NEUROL NEUROSUR PS, V41, P1119, DOI 10.1136/jnnp.41.12.1119; DIFLO T, 1992, SURGERY, V111, P352; DITTMANN H, 1989, AM HEART J, V118, P172, DOI 10.1016/0002-8703(89)90088-4; EFFERT S, 1959, DEUT MED WOCHENSCHR, V84, P6, DOI 10.1055/s-0028-1113531; EMANUEL RW, 1962, BRIT HEART J, V24, P796; ENGBERDING R, 1993, EUR HEART J, V14, P1223, DOI 10.1093/eurheartj/14.9.1223; FANG BR, 1990, INT J CARDIOL, V29, P335, DOI 10.1016/0167-5273(90)90123-M; FEIGENBAUM H, 1994, ECHOCARDIOGR-J CARD, P589; FITZPATRICK AP, 1986, BRIT HEART J, V55, P592; FUEREDI GA, 1989, AM J ROENTGENOL, V152, P737, DOI 10.2214/ajr.152.4.737; GERBODE F, 1967, SURGERY, V61, P94; GERTNER E, 1992, J RHEUMATOL, V19, P1293; GLADDEN JR, 1983, AM J CARDIOL, V52, P1364, DOI 10.1016/0002-9149(83)90609-4; GOLDBERG HP, 1952, CIRCULATION, V6, P762, DOI 10.1161/01.CIR.6.5.762; GOLDSCHL.A, 1972, AM J CARDIOL, V29, P82, DOI 10.1016/0002-9149(72)90130-0; GONZALEZ A, 1980, AM J MED, V69, P795, DOI 10.1016/0002-9343(80)90455-6; GOODWIN JF, 1963, LANCET, V1, P464; GOODWIN JF, 1968, AM J CARDIOL, V21, P307, DOI 10.1016/0002-9149(68)90135-5; GOPALAKRISHNAIAH GUPTA K, 1956, Indian J Pediatr, V23, P210, DOI 10.1007/BF02756838; GRAHAM HV, 1976, AM J CARDIOL, V38, P658, DOI 10.1016/S0002-9149(76)80017-3; GRAY IR, 1985, BRIT HEART J, V53, P645; GREENWOOD WF, 1968, AM J CARDIOL, V21, P367, DOI 10.1016/0002-9149(68)90141-0; GRIFFITHS CC, 1965, PROGR CARDIOVASC DIS, V7, P465; GROSS BH, 1983, AM J ROENTGENOL, V140, P903, DOI 10.2214/ajr.140.5.903; HALL RJ, 1990, HEART ARTERIES VEINS, P1382; HANNAH H, 1982, AM HEART J, V104, P881, DOI 10.1016/0002-8703(82)90031-X; HANSON EC, 1985, J THORAC CARDIOV SUR, V89, P298; HEATH D, 1968, AM J CARDIOL, V21, P315, DOI 10.1016/0002-9149(68)90136-7; HUDSON REB, 1965, TUMOURS PERICARDIUM, V2, P1563; HUSTON KA, 1978, MAYO CLIN PROC, V53, P752; JOSEPH P, 1980, CHEST, V78, P340, DOI 10.1378/chest.78.2.340; KAMINSKY ME, 1979, CHEST, V75, P92, DOI 10.1378/chest.75.1.93; KAUFMANN G, 1961, AM J CARDIOL, V8, P350, DOI 10.1016/0002-9149(61)90153-9; King TW, 1845, LANCET, V46, P428, DOI DOI 10.1016/S0140-6736(02)87782-0; Kirklin JW, 1993, CARDIAC SURG, P1635; KOHLER E, 1981, Z KARDIOL, V70, P571; KRIKLER DM, 1992, BRIT HEART J, V67, P89; LANE GE, 1994, AM HEART J, V127, P1629, DOI 10.1016/0002-8703(94)90398-0; LAZARIDES D P, 1985, Journal of Cardiovascular Surgery, V26, P364; LEVINSON JP, 1961, NEW ENGL J MED, V264, P1187, DOI 10.1056/NEJM196106082642304; LIE JT, 1989, ARCH PATHOL LAB MED, V113, P724; LIEBLER GA, 1976, J THORAC CARDIOV SUR, V71, P605; LIU HY, 1983, CHEST, V84, P62, DOI 10.1378/chest.84.1.62; LIVI U, 1984, THORAC CARDIOV SURG, V32, P143, DOI 10.1055/s-2007-1023371; LUND JT, 1989, AM J ROENTGENOL, V152, P469, DOI 10.2214/ajr.152.3.469; MALEKZADEH S, 1989, AM J CARDIOL, V64, P1075, DOI 10.1016/0002-9149(89)90819-9; MANNS M, 1986, DEUT MED WOCHENSCHR, V111, P1106, DOI 10.1055/s-2008-1068591; MARKEL ML, 1986, AM HEART J, V111, P409, DOI 10.1016/0002-8703(86)90161-4; MARTIN LW, 1987, ANN THORAC SURG, V44, P77, DOI 10.1016/S0003-4975(10)62362-4; McAllister H., 1978, TUMORS CARDIOVASCULA, P1; MCCARTHY PM, 1986, J THORAC CARDIOV SUR, V91, P389; MELLER J, 1977, AM J MED, V63, P816; METZKURSCHEL U, 1989, DEUT MED WOCHENSCHR, V114, P181, DOI 10.1055/s-2008-1066573; MUGGE A, 1991, CIRCULATION, V83, P70, DOI 10.1161/01.CIR.83.1.70; OBEID AI, 1989, AM J CARDIOL, V63, P1006, DOI 10.1016/0002-9149(89)90162-8; OHSHIMA H, 1993, EUR HEART J, V14, P132, DOI 10.1093/eurheartj/14.1.132; PANIDIS IP, 1984, AM HEART J, V107, P745, DOI 10.1016/0002-8703(84)90324-7; PASTERNAK RC, 1976, BRIT HEART J, V38, P1209, DOI 10.1136/hrt.38.11.1209; PETERS MN, 1974, JAMA-J AM MED ASSOC, V230, P695, DOI 10.1001/jama.230.5.695; PINDYCK F, 1972, AM J CARDIOL, V30, P569, DOI 10.1016/0002-9149(72)90052-5; POCHIS WT, 1991, AM HEART J, V122, P1781, DOI 10.1016/0002-8703(91)90303-Y; POHOST GM, 1977, CIRCULATION, V55, P88, DOI 10.1161/01.CIR.55.1.88; POOLE GV, 1984, J CARDIOVASC SURG, V25, P5; POWERS JC, 1979, J THORAC CARDIOV SUR, V77, P782; PRICHARD RW, 1951, AMA ARCH PATHOL, V51, P98; QUINN TJ, 1984, AM J CARDIOL, V53, P381, DOI 10.1016/0002-9149(84)90482-X; RAHILLY GT, 1981, AM HEART J, V101, P237, DOI 10.1016/0002-8703(81)90677-3; RATH S, 1984, AM J CARDIOL, V54, P1392, DOI 10.1016/S0002-9149(84)80117-4; READ RC, 1974, J THORAC CARDIOV SUR, V68, P857; REYNEN K, 1993, Z KARDIOL, V82, P658; ROSENZWEIG A, 1989, AM HEART J, V117, P962, DOI 10.1016/0002-8703(89)90636-4; ROUDAUT R, 1987, BRIT HEART J, V58, P413; SAJI T, 1991, AM HEART J, V122, P579, DOI 10.1016/0002-8703(91)91022-F; SAMDARSHI TE, 1992, J THORAC CARDIOV SUR, V103, P471; SANDRASAGRA FA, 1979, BRIT HEART J, V42, P221; SANNERSTEDT R, 1962, AM HEART J, V64, P243, DOI 10.1016/0002-8703(62)90336-8; SCHANZ U, 1984, SCHWEIZ MED WSCHR, V114, P850; SCHARTL M, 1983, Z KARDIOL, V72, P334; SCHWARZ F, 1972, DEUT MED WOCHENSCHR, V97, P1550, DOI 10.1055/s-0028-1107601; SCHWEIGER MJ, 1980, AM HEART J, V99, P630, DOI 10.1016/0002-8703(80)90738-3; SCHWEIZERCAGIANUT M, 1982, VIRCHOWS ARCH A, V397, P183, DOI 10.1007/BF00442388; SEINO Y, 1993, BRIT HEART J, V69, P565; SHAPIRO MR, 1983, AM HEART J, V105, P325, DOI 10.1016/0002-8703(83)90535-5; SHARMA SC, 1991, J THORAC CARDIOV SUR, V101, P938; SHELDON RS, 1987, CHEST, V92, P937, DOI 10.1378/chest.92.5.937; SILVERMAN J, 1962, CIRCULATION, V26, P99, DOI 10.1161/01.CIR.26.1.99; SILVERMAN NA, 1980, ANN SURG, V191, P127, DOI 10.1097/00000658-198002000-00001; SMITH AJ, 1990, AM HEART J, V120, P714, DOI 10.1016/0002-8703(90)90040-5; STRAUS R, 1945, ARCH PATHOL, V39, P74; SUTTON MGSJ, 1980, MAYO CLIN PROC, V55, P371; SYBERS HD, 1971, ARCH PATHOL, V91, P179; THOMAS AC, 1980, BRIT HEART J, V44, P541; THOMAS KE, 1967, J THORAC CARDIOV SUR, V53, P535, DOI 10.1016/S0022-5223(19)43181-4; THOMAS MH, 1981, J RHEUMATOL, V8, P133; TUNICK PA, 1990, AM HEART J, V119, P679, DOI 10.1016/S0002-8703(05)80297-2; TWAY KP, 1981, AM J MED, V71, P896, DOI 10.1016/0002-9343(81)90394-6; UNTERBERG C, 1989, Z KARDIOL, V78, P745; VUOPIO P, 1966, AM J CARDIOL, V17, P585, DOI 10.1016/0002-9149(66)90251-7; WADA A, 1993, CARDIOLOGY, V83, P208, DOI 10.1159/000175971; WAGNER WL, 1988, Z KARDIOL, V77, P251; WALLER DA, 1989, THORAC CARDIOV SURG, V37, P226, DOI 10.1055/s-2007-1020322; WITTENSTEIN GJ, 1959, SURGERY, V45, P981; WOLD LE, 1980, AM J PATHOL, V101, P217; WRISLEY D, 1991, AM HEART J, V121, P1554, DOI 10.1016/0002-8703(91)90171-D; YEOH JK, 1991, AM J CARDIOL, V68, P827, DOI 10.1016/0002-9149(91)90671-7; YOUNG RD, 1947, ARCH PATHOL, V43, P86	128	817	874	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 14	1995	333	24					1610	1617		10.1056/NEJM199512143332407	http://dx.doi.org/10.1056/NEJM199512143332407			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK065	7477198				2022-12-28	WOS:A1995TK06500007
J	YU, BD; HESS, JL; HORNING, SE; BROWN, GAJ; KORSMEYER, SJ				YU, BD; HESS, JL; HORNING, SE; BROWN, GAJ; KORSMEYER, SJ			ALTERED HOX EXPRESSION AND SEGMENTAL IDENTITY IN MLL-MUTANT MICE	NATURE			English	Article							DROSOPHILA-TRITHORAX; ACUTE LEUKEMIAS; ALL-1 GENE; MOUSE; TRANSFORMATIONS; REGULATOR; MUTATION; DOMAINS; MOTIF	THE mixed-lineage leukaemia gene (MLL/HRX/ALL-1) is disrupted by chromosomal translocation in human acute leukaemias that often display mixed lymphoid-myeloid phenotypes and present in infancy(1-4). MLL possesses a highly conserved SET domain also found in Drosophila trithorax (trx) and Polycomb group (Pc-G) genes, which are known to regulate homeotic genes (HOM-C) in a positive or negative fashion, respectively(5). Mll was targeted in mice by homologous recombination in embryonic stem (ES) cells to assess its role in pattern development. MII heterozygous (+/-) mice had retarded growth, displayed haematopoietic abnormalities, and demonstrated bidirectional homeotic transformations of the axial skeleton as well as sternal malformations. Mll deficiency (-/-) was embryonic lethal. Anterior boundaries of Hoxa-7 and Noxc-9 expression were shifted posteriorly in Mll +/- embryos, but their expression was abolished in Mll -/- embryos. Thus Mll is required for proper segment identity in mammals, displays haplo-insufficiency, and positively regulates Hox gene expression.	WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MED,DIV MOLEC ONCOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT PATHOL,DIV MOLEC ONCOL,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)				Yu, Benjamin/0000-0001-6663-6616				ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; BREEN TR, 1991, MECH DEVELOP, V35, P113, DOI 10.1016/0925-4773(91)90062-B; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; DUBOULE D, 1994, DEVELOPMENT, P135; ERSELIUS JR, 1990, DEVELOPMENT, V110, P629; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hogan B, 1994, MANIPULATING MOUSE E; INGHAM P, 1980, MOL GEN GENET, V179, P607, DOI 10.1007/BF00271751; JEANNOTTE L, 1993, GENE DEV, V7, P2085, DOI 10.1101/gad.7.11.2085; Kaufman M.H., 1992, ATLAS MOUSE DEV; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KNITTEL T, 1995, DEVELOPMENT, V121, P1077; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; PARO R, 1995, TRENDS GENET, V11, P295, DOI 10.1016/S0168-9525(00)89081-2; PoPeSKo P, 1992, COLOUR ATLAS ANATOMY, V2; REEVES R, 1990, J BIOL CHEM, V265, P8573; ROWLEY JD, 1993, SEMIN CANCER BIOL, V4, P377; SEDKOV Y, 1994, DEVELOPMENT, V120, P1907; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; SINGH PB, 1994, J CELL SCI, V107, P2653; TAM PPL, 1994, ANAT EMBRYOL, V189, P275; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361	29	688	709	0	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					505	508		10.1038/378505a0	http://dx.doi.org/10.1038/378505a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477409				2022-12-28	WOS:A1995TH05400075
J	DALY, MJ; MINTON, KW				DALY, MJ; MINTON, KW			RESISTANCE TO RADIATION	SCIENCE			English	Editorial Material											DALY, MJ (corresponding author), UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20814, USA.							DALY MJ, 1994, J BACTERIOL, V176, P3508, DOI 10.1128/JB.176.12.3508-3517.1994; DALY MJ, 1995, J BACTERIOL, V177, P7506; MATTIMORE V, IN PRESS J BACTERIOL; MINTON KW, 1994, MOL MICROBIOL, V13, P9, DOI 10.1111/j.1365-2958.1994.tb00397.x; MINTON KW, 1995, BIOESSAYS, V17, P457, DOI 10.1002/bies.950170514	5	29	32	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 24	1995	270	5240					1318	1318		10.1126/science.270.5240.1318	http://dx.doi.org/10.1126/science.270.5240.1318			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF899	7481818				2022-12-28	WOS:A1995TF89900027
J	GINZBERG, E				GINZBERG, E			A CAUTIONARY NOTE ON MARKET REFORMS IN HEALTH-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GINZBERG, E (corresponding author), COLUMBIA UNIV,EISENHOWER CTR CONSERVAT HUMAN RESOURCES,475 RIVERSIDE DR,SUITE 248,NEW YORK,NY 10115, USA.							GINZBERG E, 1985, AM MED POWER SHIFT, P65; LAWRENCE DK, 1994, CRITICAL ISSUES US H, pCH8	2	13	13	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	1995	274	20					1633	1634		10.1001/jama.274.20.1633	http://dx.doi.org/10.1001/jama.274.20.1633			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE738	7474252				2022-12-28	WOS:A1995TE73800032
J	DECELIS, G; MIR, J; CASAL, J; GOMEZ, D				DECELIS, G; MIR, J; CASAL, J; GOMEZ, D			31-YEAR-OLD WOMAN WITH AN ENLARGED TENDER LIVER	LANCET			English	Note							PORTAL-VEIN THROMBOSIS		HOSP NOSTRA SENYORA MERITXELL,DEPT RADIOL,ESCALDES ENGORDANY,SPAIN; HOSP NOSTRA SENYORA MERITXELL,DEPT MICROBIOL,ESCALDES ENGORDANY,SPAIN		DECELIS, G (corresponding author), HOSP NOSTRA SENYORA MERITXELL,DEPT INTERNAL MED,FITER & ROSSELL 1-15,ESCALDES ENGORDANY,SPAIN.							COHEN J, 1992, AM J MED, V92, P173, DOI 10.1016/0002-9343(92)90109-O; GIBSON JA, 1973, P ROY SOC MED, V66, P502, DOI 10.1177/003591577306600603; PARVEY HR, 1994, AM J ROENTGENOL, V162, P77, DOI 10.2214/ajr.162.1.8273695; RELLER LB, 1973, LANCET, V1, P20; SCHWERK WB, 1986, GASTROINTEST RADIOL, V11, P312, DOI 10.1007/BF02035098	5	26	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1270	1270		10.1016/S0140-6736(95)91867-1	http://dx.doi.org/10.1016/S0140-6736(95)91867-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475722				2022-12-28	WOS:A1995TE14500015
J	HEATH, SL; TEW, JG; TEW, JG; SZAKAL, AK; BURTON, GF				HEATH, SL; TEW, JG; TEW, JG; SZAKAL, AK; BURTON, GF			FOLLICULAR DENDRITIC CELLS AND HUMAN-IMMUNODEFICIENCY-VIRUS INFECTIVITY	NATURE			English	Article							MONOCLONAL-ANTIBODY; HIV-INFECTION; EXPRESSION; RETENTION; TISSUE; CLONE; AIDS	LARGE amounts of human immunodeficiency virus (HIV) localize on follicular dendritic cells (FDC) in the follicles of secondary lymploid tissues following viral infection(1,2). During clinical latency, active viral infection occurs primarily at these sites(3,4). As HIV on FDC is in the form of immune complexes(5), some of which may be formed with neutralizing antibody, we investigated whether HIV on FDC is infectious. We report here that HIV on FDC is highly infectious. Furthermore, FDC can convert neutralized HIV into an infectious form even in the presence of a vast excess of neutralizing antibody. Thus FDC may provide a mechanism whereby HIV infection can continue in the presence of neutralizing antibody.	VIRGINIA COMMONWEALTH UNIV, DEPT MICROBIOL & IMMUNOL, DIV IMMUNOBIOL, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, DEPT ANAT, RICHMOND, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University								BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; BIBERFELD P, 1988, CANCER DETECT PREV, V12, P217; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; BURTON GF, 1993, J IMMUNOL, V150, P31; BUTCH AW, 1994, CELL IMMUNOL, V155, P27, DOI 10.1006/cimm.1994.1099; BUTCH AW, 1993, J IMMUNOL, V150, P39; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; CHESEBRO B, 1988, J VIROL, V62, P3779, DOI 10.1128/JVI.62.10.3779-3788.1988; CLOUSE KA, 1989, J IMMUNOL, V142, P431; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; FOX CH, 1992, IMMUNOL TODAY, V13, P353, DOI 10.1016/0167-5699(92)90171-3; GELDERBLOM HR, 1987, VIROLOGY, V156, P171, DOI 10.1016/0042-6822(87)90449-1; GRAY D, 1991, INT IMMUNOL, V3, P141, DOI 10.1093/intimm/3.2.141; KOSCO MH, 1992, J IMMUNOL, V148, P2331; MANDEL TE, 1980, IMMUNOL REV, V53, P29, DOI 10.1111/j.1600-065X.1980.tb01039.x; MANN DL, 1989, AIDS RES HUM RETROV, V5, P253, DOI 10.1089/aid.1989.5.253; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PINCUS SH, 1989, J IMMUNOL, V142, P3070; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; POSNER MR, 1991, J IMMUNOL, V146, P4325; POSNER MR, 1995, J ACQU IMMUN DEFIC S, V6, P7; Racz P, 1989, APMIS Suppl, V8, P16; SZAKAL AK, 1983, J IMMUNOL, V131, P1714; TENNERRACZ K, 1991, ACCESSORY CELLS IN HIV AND OTHER RETROVIRAL INFECTIONS, P83; TEW JG, 1976, CELL IMMUNOL, V26, P141, DOI 10.1016/0008-8749(76)90358-0; TEW JG, 1979, AUST J EXP BIOL MED, V57, P401, DOI 10.1038/icb.1979.40; TEW JG, IN PRESS HDB EXPT IM	29	252	259	0	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 26	1995	377	6551					740	744		10.1038/377740a0	http://dx.doi.org/10.1038/377740a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB469	7477265				2022-12-28	WOS:A1995TB46900059
J	ALTER, MJ; FAVERO, MS; MILLER, JK; COLEMAN, PJ; BLAND, LA				ALTER, MJ; FAVERO, MS; MILLER, JK; COLEMAN, PJ; BLAND, LA			REUSE OF HEMODIALYZERS - RESULTS OF NATIONWIDE SURVEILLANCE FOR ADVERSE-EFFECTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									CTR DIS CONTROL,CTR INFECT DIS,NOSOCOMIAL INFECT LAB BRANCH,HOSP INFECT PROGRAM,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	ALTER, MJ (corresponding author), CTR DIS CONTROL,CTR INFECT DIS,DIV VIRAL DIS,HEPATITIS BRANCH,BLDG 6,ROOM 154,ATLANTA,GA 30333, USA.							ALTER MJ, 1986, J INFECT DIS, V153, P1149, DOI 10.1093/infdis/153.6.1149; ALTER MJ, 1983, DIALYSIS TRANSPLANT, V12, P860; Bland L, 1985, Trans Am Soc Artif Intern Organs, V31, P556; BOK DV, 1980, P DIAL TRANSPLANT FO, V19, P92; BOLAN G, 1985, J INFECT DIS, V152, P1013, DOI 10.1093/infdis/152.5.1013; BRESLOW NE, 1980, ANAL CASE CONTROL ST, P136; DEANE N, 1986, GUIDE REPROCESSING H, P3; Dixon WJ, 1969, INTRO STATISTICAL AN, P237; FAVERO MS, 1975, HEALTH LAB SCI, V12, P321; FAVERO MS, 1981, JAMA-J AM MED ASSOC, V245, P166, DOI 10.1001/jama.245.2.166; Favero MS., 1985, HOSPITAL INFECTIONS, P267; FAVERO MS, 1986, GUIDE REPROCESSING H, P63; GAZENFIELDGAZIT E, 1969, ISRAEL J MED SCI, V5, P1032; KANT KS, 1981, KIDNEY INT, V19, P728, DOI 10.1038/ki.1981.73; MURPHY J, 1987, AM SOC ARTIF INTERN, V16, P51; PETERSEN NJ, 1981, T AM SOC ART INT ORG, V27, P155; RAIJ L, 1973, KIDNEY INT, V4, P47; SNYDMAN DR, 1977, J INFECT DIS, V135, P687, DOI 10.1093/infdis/135.4.687; 1977, CONTROL MEASURES HEP; 1986, MMWR, V35, P417; 1986, AAMI RECOMMENDED PRA	21	32	32	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1988	260	14					2073	2076		10.1001/jama.260.14.2073	http://dx.doi.org/10.1001/jama.260.14.2073			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q3421	3418871				2022-12-28	WOS:A1988Q342100020
J	MANU, P; LANE, TJ; MATTHEWS, DA				MANU, P; LANE, TJ; MATTHEWS, DA			THE FREQUENCY OF THE CHRONIC FATIGUE SYNDROME IN PATIENTS WITH SYMPTOMS OF PERSISTENT FATIGUE	ANNALS OF INTERNAL MEDICINE			English	Article									VET ADM MED CTR, NEWINGTON, CT 06111 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	MANU, P (corresponding author), UNIV CONNECTICUT, CTR HLTH, SCH MED, DIV GEN MED, AM-028, FARMINGTON, CT 06032 USA.							ACHESON ED, 1959, AM J MED, V26, P569, DOI 10.1016/0002-9343(59)90280-3; ANTHONY JC, 1985, ARCH GEN PSYCHIAT, V42, P667; BEHAN PO, 1985, J INFECTION, V10, P211, DOI 10.1016/S0163-4453(85)92488-0; BENDER CE, 1962, JAMA-J AM MED ASSOC, V182, P156; BUCHWALD D, 1987, JAMA-J AM MED ASSOC, V257, P2303, DOI 10.1001/jama.257.17.2303; DUBOIS RE, 1984, SOUTHERN MED J, V77, P1376, DOI 10.1097/00007611-198411000-00007; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; HELZER JE, 1985, ARCH GEN PSYCHIAT, V42, P657; HENDERSON DA, 1959, NEW ENGL J MED, V260, P757, DOI 10.1056/NEJM195904092601506; HOLMES GP, 1987, JAMA-J AM MED ASSOC, V257, P2297, DOI 10.1001/jama.257.17.2297; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; ISAACS R, 1948, BLOOD, V3, P858, DOI 10.1182/blood.V3.8.858.858; Robins L.N., 1985, DIAGNOSTIC INTERVIEW; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Robins LN, 1981, NIMH DIAGNOSTIC INTE; TOBI M, 1982, LANCET, V1, P61; 1978, DHEW PHS791787 PUBL	17	125	125	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1988	109	7					554	556		10.7326/0003-4819-109-7-554	http://dx.doi.org/10.7326/0003-4819-109-7-554			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q4157	3421564				2022-12-28	WOS:A1988Q415700008
J	FRY, J; SANDLER, G				FRY, J; SANDLER, G			DOMICILIARY CONSULTATIONS - SOME FACTS AND QUESTIONS	BRITISH MEDICAL JOURNAL			English	Article									BARNSLEY DIST GEN HOSP,BARNSLEY,ENGLAND									COUPLAND AI, 1985, BRIT MED J, V290, P1399, DOI 10.1136/bmj.290.6479.1399; LITTLEJOHNS PC, 1986, J ROY COLL GEN PRACT, V36, P313; MULLEY GP, 1988, BMJ-BRIT MED J, V296, P515, DOI 10.1136/bmj.296.6621.515; SMITH MV, 1971, UPDATE PLUS, V1, P135; 1983, PRESENT STATE FUTURE; 1979, PRESENT STATE FUTURE, V13; 1981, NATIONAL HLTH SERVIC	7	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1988	297	6644					337	338		10.1136/bmj.297.6644.337	http://dx.doi.org/10.1136/bmj.297.6644.337			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P4527	3416167	Green Published, Bronze			2022-12-28	WOS:A1988P452700026
J	CNATTINGIUS, S; HAGLUND, B; MEIRIK, O				CNATTINGIUS, S; HAGLUND, B; MEIRIK, O			CIGARETTE-SMOKING AS RISK FACTOR FOR LATE FETAL AND EARLY NEONATAL DEATH	BMJ-BRITISH MEDICAL JOURNAL			English	Article									WHO, HUMAN REPROD PROGRAMME, CH-1211 GENEVA 27, SWITZERLAND	World Health Organization	CNATTINGIUS, S (corresponding author), UNIV HOSP UPPSALA, CTR PRIMARY CARE RES, S-75185 UPPSALA, SWEDEN.							Bakketeig L. S., 1984, PERINATAL EPIDEMIOLO, P99; BUTLER NR, 1963, 1ST REPORT BRIT PERI, P14; CNATTINGIUS S, 1985, OBSTET GYNECOL, V66, P449; ERICSON A, 1984, ACTA PAEDIATR SCAND, V73, P69, DOI 10.1111/j.1651-2227.1984.tb09900.x; FREDRICK J, 1978, BRIT J OBSTET GYNAEC, V85, P1; KARLBERG P, 1980, PERINATAL AUDIT SURV, P221; KLEINMAN JC, 1988, AM J EPIDEMIOL, V127, P274, DOI 10.1093/oxfordjournals.aje.a114803; KRUSE J, 1986, OBSTET GYNECOL, V67, P627, DOI 10.1097/00006250-198605000-00005; KULLANDER S, 1971, ACTA OBSTET GYN SCAN, V50, P83, DOI 10.3109/00016347109157292; MCCORMICK MC, 1984, AM J PUBLIC HEALTH, V74, P18, DOI 10.2105/AJPH.74.1.18; MCILWAINE GM, 1979, BMJ-BRIT MED J, V2, P1103, DOI 10.1136/bmj.2.6198.1103; McIntosh I D, 1984, Public Health Rev, V12, P29; MEYER MB, 1974, AM J EPIDEMIOL, V100, P443, DOI 10.1093/oxfordjournals.aje.a112056; MEYER MB, 1976, AM J EPIDEMIOL, V103, P464, DOI 10.1093/oxfordjournals.aje.a112248; ROOTH G, 1979, LANCET, V2, P1170; Schlesselman J., 1982, CASE CONTROL STUDIES, P354; SEXTON M, 1984, JAMA-J AM MED ASSOC, V251, P911, DOI 10.1001/jama.251.7.911; WERLER MM, 1985, TERATOLOGY, V32, P473, DOI 10.1002/tera.1420320316; 1985, SAS USERS GUIDE BASI, P1290	19	157	159	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 23	1988	297	6643					258	261		10.1136/bmj.297.6643.258	http://dx.doi.org/10.1136/bmj.297.6643.258			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P4266	3416144	Green Published, Bronze			2022-12-28	WOS:A1988P426600018
J	JHA, P; FLATHER, M; LONN, E; FARKOUH, M; YUSUF, S				JHA, P; FLATHER, M; LONN, E; FARKOUH, M; YUSUF, S			ANTIOXIDANT VITAMINS AND CARDIOVASCULAR-DISEASE - A CRITICAL-REVIEW OF EPIDEMIOLOGIC AND CLINICAL-TRIAL DATA	ANNALS OF INTERNAL MEDICINE			English	Review							LOW-DENSITY-LIPOPROTEIN; CORONARY HEART-DISEASE; BETA-CAROTENE; PLASMA-CONCENTRATIONS; E SUPPLEMENTATION; ALPHA-TOCOPHEROL; E CONSUMPTION; FOLLOW-UP; C INTAKE; RISK	Purpose: To review prospective epidemiologic studies and randomized trials regarding the role of antioxidant vitamins (vitamins E and C and beta-carotene) in the prevention of cardiovascular disease, with emphasis on differences in results obtained by these two types of studies. Data Sources: Computerized and manual searches of the literature on antioxidant vitamins and cardiovascular disease. Study Selection: Prospective epidemiologic studies and randomized trials that included 100 or more participants and provided quantified estimates of antioxidant vitamin intake. Data Synthesis: Comparisons of relative risk reductions (RRR) across observational studies and randomized trials, including assessment of dose-response relations. Results: All three large epidemiologic cohort studies of vitamin E noted that high-level vitamin E intake or supplementation was associated with a significant reduction in cardiovascular disease (RRR range, 31% to 65%), as measured by various fatal and nonfatal cardiovascular end points. To obtain these reductions, vitamin E supplementation must last at least 2 years. Less consistent reductions were seen in studies of beta-carotene (RRR range, -2% to 46%) and vitamin C (RRR range, -25% to 51%). Considerable biases in observational studies, such as different health behaviors of persons using antioxidants, may account for the observed benefit. By contrast, none of the completed randomized trials showed any clear reduction in cardiovascular disease with vitamin E, vitamin C, or beta-carotene supplementation. The trials were not specifically designed to assess cardiovascular disease, did not provide data on nonfatal cardiovascular end points, may have had insufficient treatment durations, and used suboptimal vitamin E doses. The completed trials were of adequate size to indicate that the true therapeutic benefit of vitamin E and other antioxidants in reducing fatal cardiovascular disease (a survival benefit as long as 5 years) is probably more modest than the epidemiologic data suggest. Conclusion: The epidemiologic data suggest that antioxidant vitamins reduce cardiovascular disease, with the dearest effect for vitamin E; however, completed randomized trials do not support this finding. Much of this controversy should be resolved by the ongoing large-scale and long-term randomized trials designed specifically to evaluate effects on cardiovascular disease.	MCMASTER UNIV, HAMILTON GEN HOSP, DIV CARDIOL, HGH MCMASTER CLIN, HAMILTON, ON L8L 2X2, CANADA	McMaster University	JHA, P (corresponding author), WORLD BANK, DEPT HUMAN DEV, 1818 H ST NW, WASHINGTON, DC 20433 USA.			Yusuf, Salim/0000-0003-4776-5601				BENDICH A, 1988, AM J CLIN NUTR, V48, P612, DOI 10.1093/ajcn/48.3.612; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; BULPITT CJ, 1995, BRIT MED J, V310, P1548, DOI 10.1136/bmj.310.6994.1548; Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; CHISOLM GM, 1991, CLIN CARDIOL, V14, P25, DOI 10.1002/clc.4960141304; COMSTOCK GW, 1993, CLIN CHEM, V39, P1075; DEMAIO SJ, 1992, J AM COLL NUTR, V11, P68; DRISKELL WJ, 1984, CLIN CHEM, V30, P1171; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; ENSTROM JE, 1986, AM J PUBLIC HEALTH, V76, P1124, DOI 10.2105/AJPH.76.9.1124; FARRELL PM, 1975, AM J CLIN NUTR, V28, P1381, DOI 10.1093/ajcn/28.12.1381; GALE CR, 1995, BRIT MED J, V310, P1563, DOI 10.1136/bmj.310.6994.1563; GAZIANO J M, 1992, Journal of the American College of Cardiology, V19, p377A; Gaziano J.M., 1992, CURR OPIN LIPIDOL, V3, P291, DOI [DOI 10.1097/00041433-199208000-00008, 10.1097/00041433-199208000-00008]; GAZIANO JM, 1990, CIRCULATION, V82, P201; GEY KF, 1993, AM J CLIN NUTR, V57, P787; GREEN J, 1962, VITAM HORM, V20, P485, DOI 10.1016/S0083-6729(08)60731-1; GREENBERG ER, 1990, NEW ENGL J MED, V323, P789, DOI 10.1056/NEJM199009203231204; HARRIS WS, 1992, CLIN CARDIOL, V15, P636, DOI 10.1002/clc.4960150904; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; HENNEKENS CH, 1985, PREV MED, V14, P165, DOI 10.1016/0091-7435(85)90031-3; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; JACQUES PF, 1992, J AM COLL NUTR, V11, P139; JESSUP W, 1990, BIOCHEM J, V265, P399, DOI 10.1042/bj2650399; JIALAL I, 1991, BIOCHIM BIOPHYS ACTA, V1086, P134, DOI 10.1016/0005-2760(91)90164-D; KEANEY JF, 1993, P NATL ACAD SCI USA, V90, P11880, DOI 10.1073/pnas.90.24.11880; KHAW KT, 1995, BRIT MED J, V310, P1559, DOI 10.1136/bmj.310.6994.1559; KNEKT P, 1994, AM J EPIDEMIOL, V139, P1180, DOI 10.1093/oxfordjournals.aje.a116964; KOK FJ, 1987, AM J CLIN NUTR, V45, P462, DOI 10.1093/ajcn/45.2.462; LAPIDUS L, 1986, AM J CLIN NUTR, V44, P444, DOI 10.1093/ajcn/44.4.444; MORRIS DL, 1994, JAMA-J AM MED ASSOC, V272, P1439, DOI 10.1001/jama.272.18.1439; REAVEN PD, 1993, ARTERIOSCLER THROMB, V13, P590, DOI 10.1161/01.ATV.13.4.590; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; ROTHMAN K, 1987, MODERN EPIDEMIOLOGY, P31; SALONEN JT, 1985, AM J CARDIOL, V56, P226, DOI 10.1016/0002-9149(85)90839-2; SATO K, 1990, ARCH BIOCHEM BIOPHYS, V279, P402, DOI 10.1016/0003-9861(90)90508-V; SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413; STAMLER J, 1993, 34TH ANN C CARD DIS; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINBERG D, 1992, CIRCULATION, V85, P2338, DOI 10.1161/01.CIR.85.6.2337; STEINBERG D, 1995, LANCET, V346, P36, DOI 10.1016/S0140-6736(95)92657-7; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STREET DA, 1991, AM J EPIDEMIOL, V134, P719; THORNQUIST MD, 1993, CONTROL CLIN TRIALS, V14, P308, DOI 10.1016/0197-2456(93)90228-6; TROUT DL, 1991, AM J CLIN NUTR, V53, pS322, DOI 10.1093/ajcn/53.1.322S; WILLETT WC, 1983, AM J CLIN NUTR, V38, P559, DOI 10.1093/ajcn/38.4.559; WILSON T S, 1973, Age and Ageing, V2, P163, DOI 10.1093/ageing/2.3.163; ZIEGLER RG, 1992, CANCER RES, V52, pS2060; ZIEGLER RG, 1989, J NUTR, V119, P116, DOI 10.1093/jn/119.1.116; 1993, 1993 HEART STROKE FA, P2; 1993, 1993 WORLD BANK WORL, P26; 1990, TREATMENT EARLY BREA, V1, P8; 1995, IN PRESS CAN J CARDI	55	322	330	1	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1995	123	11					860	872		10.7326/0003-4819-123-11-199512010-00009	http://dx.doi.org/10.7326/0003-4819-123-11-199512010-00009			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG209	7486470				2022-12-28	WOS:A1995TG20900009
J	BARONE, MV; COURTNEIDGE, S				BARONE, MV; COURTNEIDGE, S			MYC BUT NOT FOS RESCUE OF PDGF SIGNALING BLOCK CAUSED BY KINASE INACTIVE SRC	NATURE			English	Article							C-MYC; GROWTH-FACTOR; CELL-PROLIFERATION; PROTO-ONCOGENE; 3T3 CELLS; TYROSINE KINASES; ANTISENSE RNA; MESSENGER-RNA; GENE; EXPRESSION	GROWTH factors such as platelet-derived growth factor (PDGF) elicit the transcriptional activation of a large number of immediate early genes (many of which encode transcription factors), and ultimately DNA synthesis(1). Both AP1 and Myc are activated in fibroblasts in response to growth factor stimulation(2-5), and various experiments suggest their importance in proliferation(6-10). Src family kinases are required for PDGF (and other growth factors) to induce DNA synthesis(11,12). We have examined which transcription factors, when constitutively expressed, 'rescue' the block elicited by dominant negative Src. We report here that Myc, but not Fos and/or Jun, was able to rescue the block. In contrast, Fos and Jun, but not Myc, rescued the block induced by dominant negative Ras. Our data suggest that Src kinases control the transcriptional activation of Myc.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69012 HEIDELBERG,GERMANY; SUGEN INC,REDWOOD CITY,CA 94063	European Molecular Biology Laboratory (EMBL)				BARONE, Maria Vittoria/0000-0001-6190-4917				ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BARONE MV, 1989, EMBO J, V8, P1079, DOI 10.1002/j.1460-2075.1989.tb03476.x; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KUCHINO Y, 1985, JPN J CANCER RES, V76, P75; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOVOVA V, 1993, INT J CANCER, V53, P983; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; WELHAM MJ, 1990, ONCOGENE, V5, P161; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581	30	290	292	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					509	512		10.1038/378509a0	http://dx.doi.org/10.1038/378509a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477410				2022-12-28	WOS:A1995TH05400076
J	ZISCHLER, H; GEISERT, H; VONHAESELER, A; PAABO, S				ZISCHLER, H; GEISERT, H; VONHAESELER, A; PAABO, S			A NUCLEAR FOSSIL OF THE MITOCHONDRIAL D-LOOP AND THE ORIGIN OF MODERN HUMANS	NATURE			English	Article							DNA SEQUENCES; EVOLUTION	MAMMALIAN mitochondrial DNA sequences evolve more rapidly than nuclear sequences(1). Although the rapid rate of evolution is an advantage for the study of closely related species and populations, it presents a problem in situations where related species, used as outgroups in phylogenetic analyses, have accumulated so much change that multiple substitutions obliterate the phylogenetic information(2). However, mitochondrial DNA sequences are frequently inserted into the nuclear genome(3), where they presumably evolve as nuclear pseudogene sequences and therefore more slowly than their mitochondrial counterparts. Such sequences thus represent molecular 'fossils' that could shed light on the evolution of the mitochondrial genome and could be used as outgroups in situations where no appropriate outgroup species exist. Here we show that human chromosome 11 carries a recent integration of the mitochondrial control region that can be used to gain further insight into the origin of the human mitochondrial gene pool.			ZISCHLER, H (corresponding author), UNIV MUNICH,INST ZOOL,POB 202136,LUISENSTR 14,D-80021 MUNICH,GERMANY.		von Haeseler, Arndt/HCI-9958-2022	von Haeseler, Arndt/0000-0002-3366-4458; Zischler, Hans/0000-0002-3440-8376				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BROWN WM, 1982, J MOL EVOL, V18, P225, DOI 10.1007/BF01734101; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; DODA JN, 1981, P NATL ACAD SCI-BIOL, V78, P6116, DOI 10.1073/pnas.78.10.6116; FELSENSTEIN J, 1994, PHYLIP VERSION 3 5P; GILL P, 1985, NATURE, V318, P577, DOI 10.1038/318577a0; HEDGES SB, 1992, SCIENCE, V255, P737, DOI 10.1126/science.1738849; LUNDSTROM R, 1992, P NATL ACAD SCI USA, V89, P5961, DOI 10.1073/pnas.89.13.5961; MADDISON DR, 1991, SYST ZOOL, V40, P355, DOI 10.2307/2992327; MADDISON DR, 1992, SYST BIOL, V41, P111, DOI 10.2307/2992510; MORIN PA, 1994, SCIENCE, V265, P1193, DOI 10.1126/science.7915048; Nei M., 1987, MOL EVOLUTIONARY GEN; PENA SDJ, 1994, P NATL ACAD SCI USA, V91, P1946, DOI 10.1073/pnas.91.5.1946; PULT I, 1994, BIOL CHEM H-S, V375, P837; RUVOLO M, 1991, P NATL ACAD SCI USA, V88, P1570, DOI 10.1073/pnas.88.4.1570; Sambrook J, 1989, MOL CLONING LABORATO; TAPPER DP, 1981, J BIOL CHEM, V256, P5106; TEMPLETON AR, 1992, SCIENCE, V255, P737, DOI 10.1126/science.1590849; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; WARD RH, 1991, P NATL ACAD SCI USA, V88, P8720, DOI 10.1073/pnas.88.19.8720; ZULLO S, 1991, J MOL BIOL, V221, P1123	21	176	181	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					489	492		10.1038/378489a0	http://dx.doi.org/10.1038/378489a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477404				2022-12-28	WOS:A1995TH05400070
J	BALDWIN, LM; HART, LG; LLOYD, M; FORDYCE, M; ROSENBLATT, RA				BALDWIN, LM; HART, LG; LLOYD, M; FORDYCE, M; ROSENBLATT, RA			DEFENSIVE MEDICINE AND OBSTETRICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MALPRACTICE LITIGATION; NONSUED PHYSICIANS	Objective.-To test the hypothesis that physicians with greater malpractice claims exposure, either through personal experience or in their practice environment, will use more prenatal resources and have a higher cesarean delivery rate than physicians with lesser claims exposure. Design.-Retrospective cohort study using county malpractice defendant rate data from the Washington State Physicians Insurance and Exchange Association and prenatal care, delivery method, and self-reported obstetric suit experience data from the Content of Obstetrical Care Study database. Setting.-Washington State obstetric practices. Participants.-Stratified random samples of obstetrician-gynecologists and family physicians. Main Outcome Measures.-The rates of obstetric ultrasound use, referral and consultation, prenatal care resource use, and cesarean delivery. Results.-After controlling for patient, physician, and sociodemographic characteristics, we found no difference in prenatal resource use or cesarean delivery rate for low-risk patients between physicians with more and less exposure to malpractice claims. Conclusions.-This study does not support an association between the malpractice experience or exposure of individual physicians and an increase in the use of prenatal resources or cesarean deliveries for the care of low-risk obstetric patients,	WASHINGTON STATE PHYSICIANS INSURANCE EXCHANGE,SEATTLE,WA		BALDWIN, LM (corresponding author), UNIV WASHINGTON,SCH MED,DEPT FAMILY MED,BOX 355304,SEATTLE,WA 98195, USA.				AHRQ HHS [R01 HS06166] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BALDWIN LM, 1994, OBSTET GYNECOL, V84, P549; BUTLER MA, 1990, USDA9028 AGR RUR EC; CHARLES SC, 1985, AM J PSYCHIAT, V142, P437; DOBIE SA, 1994, OBSTET GYNECOL, V84, P557; GOYERT GL, 1989, NEW ENGL J MED, V320, P706, DOI 10.1056/NEJM198903163201106; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2538, DOI 10.1001/jama.258.18.2538; LOCALIO AR, 1993, JAMA-J AM MED ASSOC, V269, P366, DOI 10.1001/jama.269.3.366; REYNOLDS RA, 1987, JAMA-J AM MED ASSOC, V257, P2776, DOI 10.1001/jama.257.20.2776; ROCK SM, 1988, PUBLIC HEALTH REP, V103, P459; SHAPIRO RS, 1989, ARCH INTERN MED, V149, P2190, DOI 10.1001/archinte.149.10.2190; SLOAN FA, 1989, HLTH INSUR ASS A MAY, P1; SLORA EJ, 1988, SOCIOECONOMIC CHARAC, P18; WEISMAN CS, 1989, MED CARE, V27, P16, DOI 10.1097/00005650-198901000-00002; Zuckerman S, 1984, Health Aff (Millwood), V3, P128, DOI 10.1377/hlthaff.3.3.128; 1991, FACTS FAMILY PRACTIC; 1990, AM MED DIRECTORY DIR; 1985, SOCIOECONOMIC REPO 2, P25; 1988, PROFESSIONAL LIABILI; 1985, PROFESSIONAL LIABILI; 1994, OTAH602 US C OFF TEC	20	81	81	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	1995	274	20					1606	1610		10.1001/jama.274.20.1606	http://dx.doi.org/10.1001/jama.274.20.1606			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE738	7474245				2022-12-28	WOS:A1995TE73800025
J	MORRIS, RE; BROWN, BW				MORRIS, RE; BROWN, BW			TACROLIMUS FOR PREVENTION OF LIVER ALLOGRAFT-REJECTION - CLINICAL-TRIALS AND TRIBULATIONS	LANCET			English	Editorial Material							FK-506; TRANSPLANTATION		STANFORD UNIV,SCH MED,DEPT HLTH RES POLICY,STANFORD,CA 94305	Stanford University	MORRIS, RE (corresponding author), STANFORD UNIV,SCH MED,DEPT CARDIOTHORAC SURG,TRANSPLANTAT IMMUNOL LAB,STANFORD,CA 94305, USA.							FUNG J, 1991, TRANSPLANT P, V23, P2977; Kahan B D, 1994, Ther Immunol, V1, P33; Klintmalm G., 1994, TRANSPLANT REV, V8, P53, DOI [10.1016/S0955-470X(05)80015-1, DOI 10.1016/S0955-470X(05)80015-1]; NOSSAL GJV, 1991, TRANSPLANT P, V23, P3371; STARZL TE, 1989, LANCET, V2, P1000; STARZL TE, 1991, TRANSPLANT P, V22, P113; STEINMULLER DR, 1994, FK506 ORGAN TRANSPLA, P1; TODO S, 1991, TRANSPLANT P, V23, P1397; 1994, LANCET, V344, P423; 1994, NEW ENGL J MED, V331, P1110; 1995, LANCET, V346, P1346	11	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 18	1995	346	8986					1310	1311		10.1016/S0140-6736(95)92336-5	http://dx.doi.org/10.1016/S0140-6736(95)92336-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE916	7475764				2022-12-28	WOS:A1995TE91600002
J	VONKONIG, CHW; POSTELSMULTANI, S; BOCK, HL; SCHMITT, HJ				VONKONIG, CHW; POSTELSMULTANI, S; BOCK, HL; SCHMITT, HJ			PERTUSSIS IN ADULTS - FREQUENCY OF TRANSMISSION AFTER HOUSEHOLD EXPOSURE	LANCET			English	Article							WHOOPING-COUGH; INFECTION; ERYTHROMYCIN; PREVENTION; EFFICACY	Although pertussis in adults is well documented, opinions differ about incidence of adult disease and about the role of adults as reservoirs of infection. We made use of a prospective household contact study of an acellular pertussis vaccine to collect data about pertussis in adults. All members of families with an index case of pertussis were monitored for respiratory symptoms, and pertussis was confirmed by laboratory tests. In 122 households, 104 children (85%) and 18 adults (15%) were the source of pertussis. These households consisted of 265 adults (aged 19-83 years), in 84 of whom (31%) pertussis was confirmed. Of these 84, 81% had respiratory symptoms for 21 days or more. The spread of pertussis was independent of whether a child (74/104) or an adult (14/18) was the index case. Most adult index cases had no pertussis recall (odds ratio 11.8). The overall attack rate in adult contacts was 0.267 and was independent of the social status and the size of the family and of a pertussis recall, although it differed significantly between women and men (p<0.05). Erythromycin treatment of the index case reduced the attack rate significantly (p<0.05). Patients whose first pertussis episode dated back more than 20 years had similar symptoms and attack rates to patients without a recall. We conclude that adults are often involved in the spread of pertussis, and that they can be susceptible to reinfection 20 years after a first pertussis episode.	UNIV MAINZ,KINDERKLIN,W-6500 MAINZ,GERMANY; SMITHKLINE BEECHAM PHARMA,CLIN RES,MUNICH,GERMANY	Johannes Gutenberg University of Mainz; GlaxoSmithKline	VONKONIG, CHW (corresponding author), STADT KRANKENANSTALTEN,INST HYG & LAB MED,LUTHERPL 40,D-47805 KREFELD,GERMANY.							AOYAMA T, 1992, AM J DIS CHILD, V146, P163, DOI 10.1001/archpedi.1992.02160140029015; BASS JW, 1986, PEDIATR INFECT DIS J, V5, P154, DOI 10.1097/00006454-198601000-00051; CROMER BA, 1993, AM J DIS CHILD, V147, P575, DOI 10.1001/archpedi.1993.02160290081031; FARIZO KM, 1992, CLIN INFECT DIS, V14, P708, DOI 10.1093/clinids/14.3.708; FEER E, 1914, MED KLIN, V10, P837; GIAMMANCO A, 1991, REV INFECT DIS, V13, P1216; GORDON JE, 1951, AM J MED SCI, V222, P333, DOI 10.1097/00000441-195109000-00011; GROB PR, 1981, LANCET, V1, P772; HE QS, 1994, J INFECT DIS, V170, P705, DOI 10.1093/infdis/170.3.705; ISACSON J, 1993, PEDIATR INFECT DIS J, V12, P284, DOI 10.1097/00006454-199304000-00005; MacLean D W, 1982, J R Coll Gen Pract, V32, P298; MINK CM, 1992, CLIN INFECT DIS, V14, P464, DOI 10.1093/clinids/14.2.464; MINK CM, 1994, ARCH PEDIAT ADOL MED, V148, P153, DOI 10.1001/archpedi.1994.02170020039006; MORSE SI, 1968, ANN INTERN MED, V68, P953, DOI 10.7326/0003-4819-68-4-953; MORTIMER EA, 1990, J INFECT DIS, V161, P473, DOI 10.1093/infdis/161.3.473; NELSON JD, 1978, AM J DIS CHILD, V132, P371, DOI 10.1001/archpedi.1978.02120290043006; SCHMITT HJ, IN PRESS JAMA; SCHMITZ M, 1994, MONATSSCHR KINDERH, V142, P41; STEKETEE RW, 1988, J INFECT DIS, V157, P434, DOI 10.1093/infdis/157.3.434; STORSAETER J, 1992, AM J DIS CHILD, V146, P167, DOI 10.1001/archpedi.1992.02160140033016; TROLLFORS B, 1981, BRIT MED J, V283, P696, DOI 10.1136/bmj.283.6293.696; VONKONIG CHW, 1991, DEUT MED WOCHENSCHR, V116, P649, DOI 10.1055/s-2008-1063661; VONKONIG CHW, 1992, METHODEN MIKROBIOLOG; WRIGHT SW, 1995, JAMA-J AM MED ASSOC, V273, P1044, DOI 10.1001/jama.273.13.1044; Ziegler R, 1988, Offentl Gesundheitswes, V50, P25; 1992, LANCET, V339, P526	26	151	156	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 18	1995	346	8986					1326	1329						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE916	7475771				2022-12-28	WOS:A1995TE91600009
J	KATAN, MB				KATAN, MB			EXIT TRANS-FATTY-ACIDS	LANCET			English	Editorial Material											KATAN, MB (corresponding author), AGR UNIV WAGENINGEN,DEPT HUMAN NUTR,WAGENINGEN,NETHERLANDS.							ALMENDINGEN K, 1995, J LIPID RES, V36, P1370; ARO A, 1995, LANCET, V345, P273, DOI 10.1016/S0140-6736(95)90273-2; GILLMAN MW, 1995, CIRCULATION, V91, P925; KATAN MB, 1995, ANNU REV NUTR, V15, P473, DOI [10.1146/annurev.nu.15.070195.002353, 10.1146/annurev.nutr.15.1.473]; Kris-Etherton P. M., 1995, American Journal of Clinical Nutrition, V62, p655S; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; ROBERTS TL, 1995, LANCET, V345, P278, DOI 10.1016/S0140-6736(95)90274-0; SENTI FRE, 1988, HLTH ASPECTS DIETARY; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; ZOCK PL, 1995, AM J CLIN NUTR, V61, P617, DOI 10.1093/ajcn/61.3.617; 1995, TRANS FATTY ACIDS	11	32	34	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1245	1246		10.1016/S0140-6736(95)91858-2	http://dx.doi.org/10.1016/S0140-6736(95)91858-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475713	Green Accepted			2022-12-28	WOS:A1995TE14500006
J	GREENFIELD, S; ROGERS, W; MANGOTICH, M; CARNEY, MF; TARLOV, AR				GREENFIELD, S; ROGERS, W; MANGOTICH, M; CARNEY, MF; TARLOV, AR			OUTCOMES OF PATIENTS WITH HYPERTENSION AND NON-INSULIN-DEPENDENT DIABETES-MELLITUS TREATED BY DIFFERENT SYSTEMS AND SPECIALTIES - RESULTS FROM THE MEDICAL OUTCOMES STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FUNCTIONAL STATUS; CARE; QUALITY; THERAPY; LIFE; MEN	Objective.-To compare the outcomes of patients with hypertension and non-insulin-dependent diabetes mellitus (NIDDM) who were cared for in three different systems of care and by generalist and subspecialist physicians. Design.-An observational study with follow-up at three periods: (1) a 2-year study of 532 patients with hypertension and 170 patients with NIDDM who had entrance and exit histories, physical examinations, and laboratory tests; (2) a 4-year follow-up of 1044 patients with hypertension and 317 patients with NIDDM based on patient-reported functional status; and (3) 7-year mortality for 1296 patients with hypertension and 424 patients with NIDDM. Setting and Participants.-Patients sampled from health maintenance organizations, large multispecialty groups, and solo or single-specialty group practices in Boston, Mass, Los Angeles, Calif, and Chicago, III. Patients were designated as belonging to one of three systems of care: fee for service; prepaid patients in solo or small single-specialty groups or in large multispecialty group practices, referred to as independent practice associations; and staff-model health maintenance organizations. The principal providers were family practitioners, general internists, cardiologists, or endocrinologists. Main Outcome Measures.-Physiological, functional, and mortality. For hypertension, we measured blood pressure and stroke incidence. For NIDDM, we measured blood pressure, glycosylated hemoglobin level, visual function, vibration sense, ulcers and infections in the feet, and albumin excretion rate. Functional outcomes were assessed using the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). Mortality was assessed for the 7 years following the entrance examination. Results.-We found no evidence that any one system of care or physician specialty achieved consistently better e-year or 4-year outcomes than others for patients with NIDDM or hypertension, Endocrinologists appeared to achieve better foot-ulcer and infection outcomes for patients with NIDDM, particularly when compared with family practitioners, However, no other specialist differences were found in any individual measures for either condition. Moreover, no adjusted mortality differences among systems or among physician specialties were observed in the 7-year follow-up period. Conclusion.-No meaningful differences were found in the mean health outcomes for patients with hypertension or NIDDM, whether they were treated by different care systems or by different physician specialists. Although prepaid medicine relies more heavily on generalist physicians than does fee for service, there is no evidence from these analyses that the quality of care of moderately ill patients with these two common diseases was adversely affected, These findings must be viewed in light of the historically higher costs of fee-for-service medicine and of subspecialty physician practice.	TUFTS UNIV, SCH MED, DEPT MED, BOSTON, MA 02111 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; VALUE HLTH SCI, SANTA MONICA, CA USA; RAND CORP, SANTA MONICA, CA USA	Tufts University; Harvard University; Harvard T.H. Chan School of Public Health; RAND Corporation	GREENFIELD, S (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, INST HLTH, 750 WASHINGTON ST, BOX 345, BOSTON, MA 02111 USA.			Greenfield, Sheldon/0000-0003-4628-1998				[Anonymous], 1992, Am J Hypertens, V5, P207; BLOOM S, 1984, BRIT MED J, V288, P1793, DOI 10.1136/bmj.288.6433.1793; CAPUTO GM, 1994, NEW ENGL J MED, V331, P854, DOI 10.1056/NEJM199409293311307; CARLISLE DM, 1992, AM J PUBLIC HEALTH, V82, P1626, DOI 10.2105/AJPH.82.12.1626; GEFFNER DL, 1992, DIABETES CARE, V15, P44, DOI 10.2337/diacare.15.1.S44; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1969, DOI 10.1001/jama.264.15.1969; KRAVITZ RL, 1992, JAMA-J AM MED ASSOC, V267, P1617, DOI 10.1001/jama.267.12.1617; LOGERFO JP, 1978, MED CARE, V16, P488, DOI 10.1097/00005650-197806000-00005; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; MOLITCH ME, 1994, DIABETES CARE, V17, P756, DOI 10.2337/diacare.17.7.756; MURRAY JP, 1992, MED CARE, V30, P252, DOI 10.1097/00005650-199203000-00007; NEWHOUSE JP, 1993, HLTH INSURANCE MED C; RETCHIN SM, 1992, HEALTH SERV RES, V27, P651; ROGERS W, 1992, MEASURING FUNCTIONAL, P27; ROST KM, 1991, DIABETES CARE, V14, P881, DOI 10.2337/diacare.14.10.881; RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835; SAFRAN DG, 1994, JAMA-J AM MED ASSOC, V271, P1579, DOI 10.1001/jama.271.20.1579; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHERWIN RS, 1988, JAMA-J AM MED ASSOC, V260, P37; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; Stewart AL, 1992, MEASURING FUNCTIONIN, P67; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; TESTA MA, 1993, NEW ENGL J MED, V328, P907, DOI 10.1056/NEJM199304013281302; TIU SC, 1993, DIABETES CARE, V16, P616, DOI 10.2337/diacare.16.4.616; WARE JE, 1995, MED CARE, V33, pAS264, DOI 10.1097/00005650-199501001-00005; WARE JE, 1992, MEASURING FUNCTIONIN, P3; Ware JE, 1993, SF36 HLTH SURVEY MAN; YELIN EH, 1985, NEW ENGL J MED, V312, P962, DOI 10.1056/NEJM198504113121506; YELIN EH, 1986, MED CARE, V24, P236, DOI 10.1097/00005650-198603000-00006	35	308	310	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	1995	274	18					1436	1444						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TC477	7474189				2022-12-28	WOS:A1995TC47700025
J	NOSAKA, T; VANDEURSEN, JMA; TRIPP, RA; THIERFELDER, WE; WITTHUHN, BA; MCMICKLE, AP; DOHERTY, PC; GROSVELD, GC; IHLE, JN				NOSAKA, T; VANDEURSEN, JMA; TRIPP, RA; THIERFELDER, WE; WITTHUHN, BA; MCMICKLE, AP; DOHERTY, PC; GROSVELD, GC; IHLE, JN			DEFECTIVE LYMPHOID DEVELOPMENT IN MICE LACKING JAK3	SCIENCE			English	Article							RECEPTOR	The Janus tyrosine kinases (Jaks) play a central role in signaling through cytokine receptors. Although Jak1, Jak2, and Tyk2 are widely expressed, Jak3 is predominantly expressed in hematopoietic cells and is known to associate only with the common gamma (gamma(c)) chain of the interleukin (IL)-2, IL-4, IL-7, IL-9, and IL-15 receptors. Homozygous mutant mice in which the Jak3 gene had been disrupted were generated by gene targeting. Jak3-deficient mice had profound reductions in thymocytes and severe B cell and T cell lymphopenia similar to severe combined immunodeficiency disease (SCID), and the residual T cells and B cells were functionally deficient. Thus, Jak3 plays a critical role in gamma(c) signaling and lymphoid development.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT GENET, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT IMMUNOL, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital			witthuhn, bruce/GSE-3193-2022; Tripp, Ralph/F-5218-2011; Doherty, Peter Charles/C-4185-2013	Tripp, Ralph/0000-0002-2924-9956; Doherty, Peter Charles/0000-0002-5028-3489	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL53749] Funding Source: Medline; NIDDK NIH HHS [R01 DK/HL42932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOSAKA T, UNPUB; OUELLE FW, 1995, MOL CELL BIOL, V15, P3336; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; ROSEN FS, 1984, NEW ENGL J MED, V311, P235, DOI 10.1056/NEJM198407263110406; ROSEN FS, 1995, NEW ENGL J MED, V333, P431, DOI 10.1056/NEJM199508173330707; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SECKINGER P, 1994, J IMMUNOL, V153, P97; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VENKITARAMAN AR, 1992, P NATL ACAD SCI USA, V89, P12083, DOI 10.1073/pnas.89.24.12083; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	23	549	574	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 3	1995	270	5237					800	802		10.1126/science.270.5237.800	http://dx.doi.org/10.1126/science.270.5237.800			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC712	7481769				2022-12-28	WOS:A1995TC71200041
J	YOSHIBA, M; OKAMOTO, H; MISHIRO, S				YOSHIBA, M; OKAMOTO, H; MISHIRO, S			DETECTION OF THE GBV-C HEPATITIS-VIRUS GENOME IN SERUM FROM PATIENTS WITH FULMINANT-HEPATITIS OF UNKNOWN ETIOLOGY	LANCET			English	Note								Hepatitis viruses A, B, C, D, and E have not accounted for all cases of hepatitis, hence ''non A-E'' agent(s) might be implicated. A set of new viruses (GBV-A, -B, and -C) whose genomes have been sequenced, are being investigated as possible causes of non A-E hepatitis. We investigated six cases of fulminant hepatitis of unknown aetiology for the presence of GBV-C genome in their serum, and three showed positive signals by semi-nested PCR using primers derived from the NS3/helicase region. Nucleotide sequence analyses confirmed these signals to be derived from a GBV-C sequence. The results suggest the importance of GBV-C in the aetiology of fulminant hepatitis.	TOSHIBA GEN HOSP, DEPT MED SCI, SHINAGAWA KU, TOKYO 140, JAPAN; SHOWA UNIV, FUJIGAOKA HOSP, SCH MED, DEPT GASTROENTEROL, YOKOHAMA, KANAGAWA 227, JAPAN; JICHI MED SCH, DIV IMMUNOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN	Toshiba Corporation; Showa University; Jichi Medical University			Okamoto, Hiroaki/H-4371-2011	Okamoto, Hiroaki/0000-0003-0827-0964; Mishiro, Shunji/0000-0001-9618-6468				DEINHARDT F, 1967, J EXP MED, V125, P673, DOI 10.1084/jem.125.4.673; FAGAN EA, 1992, J MED VIROL, V38, P71, DOI 10.1002/jmv.1890380115; OKAMOTO H, 1994, HEPATOLOGY, V20, P1131, DOI 10.1002/hep.1840200505; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; SUZUKI H, 1994, VIRAL HEPATITIS LIVE, P426; YOSHIBA M, 1994, HEPATOLOGY, V19, P829	7	474	484	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 28	1995	346	8983					1131	1132		10.1016/S0140-6736(95)91802-7	http://dx.doi.org/10.1016/S0140-6736(95)91802-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB549	7475605				2022-12-28	WOS:A1995TB54900012
J	MOORMAN, JR; ACKERMAN, SJ; KOWDLEY, GC; GRIFFIN, MP; MOUNSEY, JP; CHEN, ZH; CALA, SE; OBRIAN, JJ; SZABO, G; JONES, LR				MOORMAN, JR; ACKERMAN, SJ; KOWDLEY, GC; GRIFFIN, MP; MOUNSEY, JP; CHEN, ZH; CALA, SE; OBRIAN, JJ; SZABO, G; JONES, LR			UNITARY ANION CURRENTS THROUGH PHOSPHOLEMMAN CHANNEL MOLECULES	NATURE			English	Article							PROTEIN; TAURINE; MYOCARDIUM; EXPRESSION; TRANSPORT; CLONING; HEART; ISK; K+	PHOSPHOLEMMAN (PLM) is a 72-amino-acid peptide with a single transmembrane domain(1-3), the expression of which induces chloride currents in Xenopus oocytes(4-6). It has remained unknown whether PLM is an ion channel or acts as a channel regulator. Here we show, by measuring unitary anion currents across planar phospholipid bilayers to which immunoaffinity-purified recombinant PLM was added, that it does indeed form ion channels. Excised patches of oocytes expressing PLM had similar currents. Of the ions tested, the sulphonic amino acid taurine was the most permeant, and expression of PLM increased fluxes of radiolabelled taurine in oocytes. Phospholemman is the smallest protein in cell membranes known to form an ion channel and the taurine selectivity suggests that it is involved in cell volume regulation.	UNIV VIRGINIA, HLTH SCI CTR, DEPT MOLEC PHYSIOL & BIOL PHYS, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT PEDIAT, DIV NEONATOL, CHARLOTTESVILLE, VA 22908 USA; INDIANA UNIV, SCH MED, KRANNERT INST CARDIOL, DEPT INTERNAL MED, INDIANAPOLIS, IN 46202 USA; DUPONT MERCK PHARMACEUT CO, WILMINGTON, DE 19898 USA	University of Virginia; University of Virginia; Indiana University System; Indiana University-Purdue University Indianapolis; DuPont	MOORMAN, JR (corresponding author), UNIV VIRGINIA, HLTH SCI CTR, DEPT INTERNAL MED, DIV CARDIOVASC, CHARLOTTESVILLE, VA 22908 USA.		Moorman, J Randall/ABG-9946-2020					ATLAS M, 1984, J MOL CELL CARDIOL, V16, P311, DOI 10.1016/S0022-2828(84)80602-1; ATTALI B, 1993, NATURE, V365, P850, DOI 10.1038/365850a0; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; BANDERALI U, 1992, AM J PHYSIOL, V263, pC1200, DOI 10.1152/ajpcell.1992.263.6.C1200; CALA SE, 1994, BIOPHYS J, V66, pA226; DIAMOND JM, 1969, PHYSIOL REV, V49, P581; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; GOLDSTEIN L, 1994, AM J PHYSIOL, V267, pR426, DOI 10.1152/ajpregu.1994.267.2.R426; HARLOW E, 1988, ANTIBODIES LABORATOR; HAUSDORFF SF, 1991, BIOCHEMISTRY-US, V30, P3341, DOI 10.1021/bi00227a025; Hille B., 1992, IONIC CHANNELS EXCIT; HUXTABLE R, 1977, SCIENCE, V198, P409, DOI 10.1126/science.198879; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; JACKSON PS, 1993, AM J PHYSIOL, V265, pC1489, DOI 10.1152/ajpcell.1993.265.6.C1489; KIRK K, 1992, J BIOL CHEM, V267, P23475; KOWDLEY GC, 1994, J GEN PHYSIOL, V103, P217, DOI 10.1085/jgp.103.2.217; LINDEMANN JP, 1986, J BIOL CHEM, V261, P4860; MOORMAN JR, 1992, J BIOL CHEM, V267, P14551; MORRISON BW, 1994, ONCOGENE, V9, P3417; MORRISON BW, 1995, J BIOL CHEM, V270, P2176, DOI 10.1074/jbc.270.5.2176; MOUNSEY JP, 1995, J CLIN INVEST, V95, P2379, DOI 10.1172/JCI117931; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PRESTI CF, 1985, J BIOL CHEM, V260, P3860; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754	25	128	131	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 26	1995	377	6551					737	740		10.1038/377737a0	http://dx.doi.org/10.1038/377737a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB469	7477264				2022-12-28	WOS:A1995TB46900058
J	KAKKAR, AK; DERUVO, N; CHINSWANGWATANAKUL, V; TEBBUTT, S; WILLIAMSON, RCN				KAKKAR, AK; DERUVO, N; CHINSWANGWATANAKUL, V; TEBBUTT, S; WILLIAMSON, RCN			EXTRINSIC-PATHWAY ACTIVATION IN CANCER WITH HIGH FACTOR VIIA AND TISSUE FACTOR	LANCET			English	Note								Thromboembolic complications are common in patients with malignant disease. We studied the activation of coagulation in 106 patients with solid tumours and 72 healthy volunteers by measuring plasma levels of tissue factor, factor VIIa, factor XIIa, thrombin-antithrombin complex, and prothrombin fragments 1+2. Tissue factor was 67% higher in cancer patients (median 582 vs 349 pg/mL, p=0.0006) and factor VIIa was 46% higher (100 vs 69 mU/mL, p=0.0002), indicating extrinsic pathway activation. Modest activation of the intrinsic pathway (elevated factor XIIa) was seen only in patients with advanced disease or those receiving chemotherapy. Excess thrombin generation was manifested by elevations in thrombin-antithrombin complex and prothrombin fragments 1+2. Tissue factor pathway is clearly implicated in the hypercoagulable state of cancer.	ROYAL POSTGRAD MED SCH,DEPT SURG,LONDON W12 0NN,ENGLAND	Imperial College London								BASTIDA E, 1994, BLOOD, V64, P177; BERRETTINI M, 1992, J BIOL CHEM, V267, P19833; CARVALHO MG, 1993, THROMB HAEMOSTASIS, V69, P601; DONATI MB, 1994, HAEMOSTASIS, V24, P128; GORDON SG, 1992, HEMATOL ONCOL CLIN N, V6, P1359, DOI 10.1016/S0889-8588(18)30280-6; KAKKAR AK, 1995, BRIT J SURG, V82, P1101, DOI 10.1002/bjs.1800820831; KAKKAR VV, 1994, BRIT MED BULL, V50, P871, DOI 10.1093/oxfordjournals.bmb.a072931; RAO LVM, 1995, BLOOD, V85, P121, DOI 10.1182/blood.V85.1.121.bloodjournal851121; RICKLES FR, 1992, CANCER METAST REV, V11, P237, DOI 10.1007/BF01307180; WRIGHT SD, 1994, BAILLIERE CLIN HAEM, V7, P591, DOI 10.1016/S0950-3536(05)80101-5	10	180	191	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 14	1995	346	8981					1004	1005		10.1016/S0140-6736(95)91690-3	http://dx.doi.org/10.1016/S0140-6736(95)91690-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475548				2022-12-28	WOS:A1995RZ59900012
J	KOBER, L; TORPPEDERSEN, C; CARLSEN, JE; BAGGER, H; ELIASEN, P; LYNGBORG, K; VIDEBEK, J; COLE, DS; AUCLERT, L; PAULY, NC; ALIOT, E; PERSSON, S; CAMM, AJ				KOBER, L; TORPPEDERSEN, C; CARLSEN, JE; BAGGER, H; ELIASEN, P; LYNGBORG, K; VIDEBEK, J; COLE, DS; AUCLERT, L; PAULY, NC; ALIOT, E; PERSSON, S; CAMM, AJ			A CLINICAL-TRIAL OF THE ANGIOTENSIN-CONVERTING-ENZYME INHIBITOR TRANDOLAPRIL IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MORTALITY; SURVIVAL	Background. Treatment with angiotensin-converting-enzyme (ACE) inhibitors reduces mortality among survivors of acute myocardial infarction, but whether to use ACE inhibitors in all patients or only in selected patients is uncertain. Methods. We screened 6676 consecutive patients with 7001 myocardial infarctions confirmed by enzyme studies. A total of 2606 patients had echocardiographic evidence of left ventricular systolic dysfunction (ejection fraction, less than or equal to 35 percent). On days 3 to 7 after infarction, 1749 patients were randomly assigned to receive oral trandolapril (876 patients) or placebo (873 patients). The duration of follow-up was 24 to 50 months. Results. During the study period, 304 patients (34.7 percent) in the trandolapril group died, as compared with 369 (42.3 percent) in the placebo group (P=0.001). The relative risk of death in the trandolapril group, as compared with the placebo group, was 0.78 (95 percent confidence interval, 0.67 to 0.91). Trandolapril also reduced the risk of death from cardiovascular causes (relative risk, 0.75; 95 percent confidence interval, 0.63 to 0.89; P=0.001) and sudden death (relative risk, 0.76; 95 percent confidence interval, 0.59 to 0.98; P=0.03). Progression to severe heart failure was less frequent in the trandolapril group (relative risk, 0.71; 95 percent confidence interval, 0.56 to 0.89; P=0.003). In contrast, the risk of recurrent myocardial infarction (fatal or nonfatal) was not significantly reduced (relative risk, 0.86; 95 percent confidence interval, 0.66 to 1.13; P=0.29). Conclusions. Long-term treatment with trandolapril in patients with reduced left ventricular function soon after myocardial infarction significantly reduced the risk of overall mortality, mortality from cardiovascular causes, sudden death, and the development of severe heart failure. That mortality was reduced in a randomized study enrolling 25 percent of consecutive patients screened should encourage the selective use of ACE inhibition after myocardial infarction.	GENTOFTE UNIV HOSP, DEPT CARDIOL, COPENHAGEN, DENMARK; ESBJERG CENT HOSP, ESBJERG, DENMARK; SLAGELSE HOSP, SLAGELSE, DENMARK; FREDERIKSBERG UNIV HOSP, FREDERIKSBERG, DENMARK; BISPEBJERG HOSP, DK-2400 COPENHAGEN, DENMARK; KNEBWORTH CONSULTANCY, KNEBWORTH, ENGLAND; HOP CENT NANCY, NANCY, FRANCE; ROUSSEL UCLAF, ROMAINVILLE, FRANCE; UNIV HOSP MALMO, MALMO, SWEDEN; UNIV LONDON ST GEORGES HOSP, SCH MED, LONDON SW17 0RE, ENGLAND	University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Bispebjerg Hospital; CHU de Nancy; Lund University; Skane University Hospital; St Georges University London	KOBER, L (corresponding author), TRACE STUDY OFF, SVANEMOLLEVEJ 2, DK-2100 COPENHAGEN, DENMARK.		Torp-Pedersen, Christian/E-5931-2013	Kober, Lars/0000-0002-6635-1466				AMBROSIONI E, 1995, NEW ENGL J MED, V332, P80, DOI 10.1056/NEJM199501123320203; BALL SG, 1993, LANCET, V342, P821; BALL SG, 1995, J AM COLL CARDIOL, V25, pS42; BERNING J, 1990, AM J CARDIOL, V65, P567, DOI 10.1016/0002-9149(90)91032-2; BERNING J, 1992, CARDIOLOGY, V80, P257, DOI 10.1159/000175011; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; COLLINS R, 1995, LANCET, V345, P669; DEVITA C, 1994, LANCET, V343, P1115; EMANUELSSON H, 1994, EUR HEART J, V15, P761, DOI 10.1093/oxfordjournals.eurheartj.a060583; HEGER JJ, 1980, CIRCULATION, V61, P1113, DOI 10.1161/01.CIR.61.6.1113; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KOBER L, 1995, AM J CARDIOL, V76, P1, DOI 10.1016/S0002-9149(99)80791-7; KOBER L, 1994, EUR HEART J, V15, P1616; LIU LS, 1995, LANCET, V345, P686; MANTEL N, 1959, J NATL CANCER I, V22, P719; MULLER CA, 1994, EUR HEART J, V15, P988, DOI 10.1093/oxfordjournals.eurheartj.a060620; PACKER M, 1992, CIRCULATION, V85, P50; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; STEVENSON R, 1993, BMJ-BRIT MED J, V307, P349, DOI 10.1136/bmj.307.6900.349; STEVENSON R, 1993, BRIT MED J, V307, P909; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; VIDEBAEK J, 1994, AM J CARDIOL, V73, pC44; 1993, NEW ENGL J MED, V329, P1204	23	1328	1374	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 21	1995	333	25					1670	1676		10.1056/NEJM199512213332503	http://dx.doi.org/10.1056/NEJM199512213332503			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL401	7477219				2022-12-28	WOS:A1995TL40100003
J	HAMMER, MF				HAMMER, MF			A RECENT COMMON ANCESTRY FOR HUMAN-Y-CHROMOSOMES	NATURE			English	Article							EVOLUTION; POLYMORPHISM; POPULATIONS; SEQUENCES	THE male-specific portion of the Y chromosome is especially useful for studies of human origins. Patterns of nucleotide variation that are neutral with respect to fitness should permit estimates of when and where ancestral Y chromosomes existed(1). However, variation on the human Y chromosome has been observed to be greatly reduced relative to the autosomes and the X chromosome(2-5). One explanation is that selection for a favourable mutation on the nonrecombining portion of the Y chromosome has resulted in the recent fixation of a single Y haplotype(5,6). A 2.6-kilobase fragment encompassing a polymorphic Alu insertion was sequenced from 16 human and four chimpanzee Y chromosomes. Patterns of nucleotide sequence diversity and divergence provide no evidence for a recent, strong selective sweep on the human Y chromosome. The time back to a common ancestral human Y chromosome is estimated to be 188,000 years, with a 95% confidence interval from 51,000 to 411,000 years. These results are consistent with autosomal and mitochondrial DNA studies that suggest a long-term human effective population size of 10,000 and a sex ratio of 1 (ref. 7). These inferences contradict predictions of the multiregional hypothesis(8) positing a widespread transformation of Homo erectus populations into Homo sapiens.			HAMMER, MF (corresponding author), UNIV ARIZONA,MOLEC SYSTEMAT & EVOLUT LAB,BIOSCI W,TUCSON,AZ 85721, USA.		Klein, Richard G/B-5910-2009					DORIT RL, 1995, SCIENCE, V268, P1183, DOI 10.1126/science.7761836; ELLIS N, 1990, CELL, V63, P977, DOI 10.1016/0092-8674(90)90501-5; FULLERTON SM, 1994, P NATL ACAD SCI USA, V91, P1805, DOI 10.1073/pnas.91.5.1805; GOLDMAN N, 1992, NATURE, V367, P440; HAMMER MF, 1994, MOL BIOL EVOL, V11, P749; HAMMER MF, 1995, AM J HUM GENET, V56, P951; HARPENDING HC, 1993, CURR ANTHROPOL, V34, P483, DOI 10.1086/204195; HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532; HUDSON RR, 1987, GENETICS, V116, P153; JAKUBICZKA S, 1989, HUM GENET, V84, P86, DOI 10.1007/BF00210680; KOCHER TD, 1991, EVOLUTION OF LIFE, P391; KREITMAN M, 1991, GENETICS, V127, P565; LI WH, 1991, GENETICS, V129, P513; MALASPINA P, 1990, ANN HUM GENET, V54, P297, DOI 10.1111/j.1469-1809.1990.tb00385.x; MAYNARDSMITH J, 1990, NATURE, V344, P591; Nei M., 1987, MOL EVOLUTIONARY GEN; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROGERS AR, 1992, MOL BIOL EVOL, V9, P552; RUVOLO M, 1993, MOL BIOL EVOL, V10, P1115; STONEKING M, 1993, EVOLUTIONARY ANTHR, V2, P60; STRINGER CB, 1988, SCIENCE, V158, P1263; TAJIMA F, 1983, GENETICS, V105, P437; TAKAHATA N, 1993, MOL BIOL EVOL, V10, P2; TEMPLETON AR, 1993, AM ANTHROPOL, V95, P51, DOI 10.1525/aa.1993.95.1.02a00030; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; WOLPOFF MH, 1989, HUMAN REVOLUTIONS BE, P123	26	297	304	1	34	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 23	1995	378	6555					376	378		10.1038/378376a0	http://dx.doi.org/10.1038/378376a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477371				2022-12-28	WOS:A1995TF89300055
J	SCHOENENBERGER, RA; TANASIJEVIC, MJ; JHA, A; BATES, DW				SCHOENENBERGER, RA; TANASIJEVIC, MJ; JHA, A; BATES, DW			APPROPRIATENESS OF ANTIEPILEPTIC DRUG LEVEL MONITORING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHENYTOIN; EPILEPSY; MANAGEMENT; PHYSICIAN; IMPACT	Objectives.-To develop explicit, reliable appropriateness criteria for antiepileptic drug level monitoring and to assess the appropriateness of monitoring in one tertiary care institution. Design.-Appropriateness criteria derived from the literature and through expert opinion were used to evaluate a stratified random sample of antiepileptic drug level determinations obtained from chart review. Setting.-Tertiary care center performing more than 10 000 antiepileptic drug level determinations per year. Patients.-A total of 330 inpatients in whom antiepileptic drug levels were measured a total of 855 times. Methods.-Drug levels were assessed at least 200 times for each of four antiepileptic drugs (phenytoin, carbamazepine, phenobarbital, and valproic acid). Main Outcome Measures.-The proportion of antiepileptic drug levels with an appropriate indication and, of those, the proportion sampled appropriately. Results.-Overall, 27% (95% confidence interval, 24% to 30%) of levels had an appropriate indication. Interrater agreement for appropriateness was substantial (kappa=0.61). There was no significant difference in the appropriateness rate among the four drugs (range, 25% to 29%), Of the 624 antiepileptic drug level determinations considered inappropriate (73%), only four (0.6%) were more than 20% higher than the upper limit of normal, and none of the four patients had clinical signs of drug toxicity, A median of six levels (range, one through 69) was determined per patient, and the median interval between level determinations was 24 hours. Of the 27% of level determinations with an appropriate indication, 51% were sampled correctly, resulting in an overall appropriateness rate of 14%. Conclusions.-Only 27% of antiepileptic drug level determinations had an appropriate indication, and half of these were not sampled correctly. Routine daily monitoring without pharmacological justification accounted for most of the inappropriate drug level determinations. Efforts to decrease inappropriate monitoring may result in substantial cost reductions without missing important clinical results.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV GEN MED & PRIMARY CARE,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV CLIN EPIDEMIOL,BOSTON,MA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital					AHRQ HHS [R01-HS07107-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Bates D W, 1994, Qual Manag Health Care, V2, P18; BEARDSLEY RS, 1983, EPILEPSIA, V24, P330, DOI 10.1111/j.1528-1157.1983.tb04896.x; BRODIE MJ, 1988, BRIT MED J, V296, P1110, DOI 10.1136/bmj.296.6629.1110; BUSSEY HI, 1983, THER DRUG MONIT, V5, P245, DOI 10.1097/00007691-198309000-00002; CHADWICK DW, 1987, BRIT MED J, V294, P723, DOI 10.1136/bmj.294.6574.723; CHOONARA IA, 1990, CLIN PHARMACOKINET, V18, P318, DOI 10.2165/00003088-199018040-00004; Feinstein A.R., 1985, CLIN EPIDEMIOLOGY; FINEBERG HV, 1979, DHEW PHS793216 PUBL, P144; Fleiss JL, 1981, STAT METHODS RATES P; FROESCHER W, 1981, J NEUROL, V224, P193; FROESCHER W, 1992, WIEN KLIN WOCHEN S15, V19, P15; GARDNER MJ, 1989, BRIT MED J; HOLFORD NHG, 1987, AVERYS DRUG TREATMEN, P195; JOHANNESSEN SI, 1991, COMPREHENSIVE EPILEP, P505; KNOTT C, 1990, CLIN PHARMACOKINET, V19, P425, DOI 10.2165/00003088-199019060-00002; KUTT H, 1985, RECENT ADV EPILEPSY, P183; LEVIN B, 1981, AM J HOSP PHARM, V38, P845, DOI 10.1093/ajhp/38.6.845; LEVINE M, 1988, THER DRUG MONIT, V10, P50, DOI 10.1097/00007691-198801000-00009; LOTT R, 1988, APPL THER, P1371; LUNDBERG GD, 1983, JAMA-J AM MED ASSOC, V249, P639, DOI 10.1001/jama.249.5.639; MALONEY TW, 1979, NEW ENGL J MED, V301, P1413; MCDONALD CJ, 1994, JAMA-J AM MED ASSOC, V271, P872, DOI 10.1001/jama.271.11.872; MCINNES GT, 1989, BRIT J CLIN PHARMACO, V27, P281, DOI 10.1111/j.1365-2125.1989.tb05365.x; MCKEE PJW, 1993, THER DRUG MONIT, V15, P83, DOI 10.1097/00007691-199304000-00003; NORTH JB, 1983, J NEUROSURG, V58, P672, DOI 10.3171/jns.1983.58.5.0672; PANZER RJ, 1987, J GEN INTERN MED, V2, P365, DOI 10.1007/BF02596179; PATSALOS PN, 1987, LANCET, V2, P39; PEARCE GA, 1990, THER DRUG MONIT, V12, P250, DOI 10.1097/00007691-199005000-00007; PITTERLE ME, 1985, AM J HOSP PHARM, V42, P1547, DOI 10.1093/ajhp/42.7.1547; PORTER RJ, 1989, ANTIEPILEPTIC DRUGS, P117; RICHENS A, 1992, TXB EPILEPSY, P535; RIED LD, 1989, AM J HOSP PHARM, V46, P945, DOI 10.1093/ajhp/46.5.945; RUBENSTEIN KE, 1972, BIOCHEM BIOPH RES CO, V47, P846, DOI 10.1016/0006-291X(72)90570-0; SPECTOR R, 1988, CLIN PHARMACOL THER, V43, P345, DOI 10.1038/clpt.1988.42; THEODORE WH, 1992, PHARMACOL THERAPEUT, V54, P297, DOI 10.1016/0163-7258(92)90004-J; TOMSON T, 1994, EPILEPSIA, V35, P122, DOI 10.1111/j.1528-1157.1994.tb02921.x; TRISOLINI MG, 1987, MED CARE, V25, P286, DOI 10.1097/00005650-198704000-00003; TROUPIN AS, 1984, ANN INTERN MED, V100, P854, DOI 10.7326/0003-4819-100-6-854; VOZEH S, 1980, EUR J CLIN PHARMACOL, V17, P33, DOI 10.1007/BF00561674; VOZEH S, 1987, CLIN PHARMACOKINET, V13, P131; WING DS, 1989, THER DRUG MONIT, V11, P32, DOI 10.1097/00007691-198901000-00007; 1993, EPILEPSIA, V34, P585; 1989, LANCET, V2, P1190	43	76	77	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	1995	274	20					1622	1626		10.1001/jama.274.20.1622	http://dx.doi.org/10.1001/jama.274.20.1622			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE738	7474249				2022-12-28	WOS:A1995TE73800029
J	ALLISON, JP; KRUMMEL, MF				ALLISON, JP; KRUMMEL, MF			THE YIN AND YANG OF T-CELL COSTIMULATION	SCIENCE			English	Editorial Material							CTLA-4; CD28		UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV IMMUNOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	ALLISON, JP (corresponding author), UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720, USA.			Allison, James/0000-0001-8980-5697				ALLISON JP, 1994, CURR OPIN IMMUNOL, V6, P414, DOI 10.1016/0952-7915(94)90120-1; ALLISON JP, IN PRESS CURR OPIN I; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; CHEN LP, 1993, IMMUNOL TODAY, V14, P483, DOI 10.1016/0167-5699(93)90262-J; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; GREEN JM, 1994, IMMUNITY, V1, P501, DOI 10.1016/1074-7613(94)90092-2; HARPER K, 1991, J IMMUNOL, V147, P1037; JENKINS MK, 1994, IMMUNITY, V1, P443, DOI 10.1016/1074-7613(94)90086-8; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KEARNEY ER, 1995, J IMMUNOL, V155, P1033; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; LENSCHOW DJ, 1993, CURR OPIN IMMUNOL, V5, P747, DOI 10.1016/0952-7915(93)90132-C; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; LINSLEY PS, 1995, J EXP MED, V182, P289, DOI 10.1084/jem.182.2.289; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, J EXP MED, V176, P1595, DOI 10.1084/jem.176.6.1595; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985	21	154	189	1	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 10	1995	270	5238					932	933		10.1126/science.270.5238.932	http://dx.doi.org/10.1126/science.270.5238.932			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD878	7481795				2022-12-28	WOS:A1995TD87800032
J	MYERS, MP; WAGERSMITH, K; WESLEY, CS; YOUNG, MW; SEHGAL, A				MYERS, MP; WAGERSMITH, K; WESLEY, CS; YOUNG, MW; SEHGAL, A			POSITIONAL CLONING AND SEQUENCE-ANALYSIS OF THE DROSOPHILA CLOCK GENE, TIMELESS	SCIENCE			English	Article							MESSENGER-RNA LEVELS; PERIOD GENE; AH-RECEPTOR; NUCLEAR-PROTEIN; VISUAL-SYSTEM; NOTCH LOCUS; MELANOGASTER; PRODUCT; MUTATIONS; MUTANTS	The Drosophila genes timeless (tim) and period (per) interact, and both are required for production of circadian rhythms. Here the positional cloning and sequencing of tim are reported. The tim gene encodes a previously uncharacterized protein of 1389 amino acids, and possibly another protein of 1122 amino acids. The arrhythmic mutation tim(01) is a 64-base pair deletion that truncates TIM to 749 amino acids. Absence of sequence similarity to the PER dimerization motif (PAS) indicates that direct interaction between PER and TIM would require a heterotypic protein association.	ROCKEFELLER UNIV,CTR BIOL TIMING,HOWARD HUGHES MED INST,NATL SCI FDN SCI & TECHNOL,NEW YORK,NY 10021; ROCKEFELLER UNIV,GENET LAB,NEW YORK,NY 10021; UNIV PENN,SCH MED,DEPT NEUROSCI,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,CTR SLEEP & RESP NEUROBIOL,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Rockefeller University; Rockefeller University; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine			, 机智的马小跳和机智的羊不愁/ABC-5169-2020					BAYLIES MK, 1987, NATURE, V326, P390, DOI 10.1038/326390a0; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; COHEN SA, COMMUNICATION; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; HAMILTON BA, 1991, NUCLEIC ACIDS RES, V19, P1951, DOI 10.1093/nar/19.8.1951; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, EMBO J, V11, P1; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HARDIN PE, 1994, MOL CELL BIOL, V14, P7211, DOI 10.1128/MCB.14.11.7211; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUANG ZJ, 1995, SCIENCE, V267, P1169, DOI 10.1126/science.7855598; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; JACKSON FR, 1986, NATURE, V320, P185, DOI 10.1038/320185a0; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1983, CELL, V34, P421, DOI 10.1016/0092-8674(83)90376-8; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LIU X, 1992, J NEUROSCI, V12, P2735; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; MYERS M, UNPUB; Pirrotta V., 1986, DROSOPHILA PRACTICAL, P83; PRICE JL, 1995, EMBO J, V14, P4044, DOI 10.1002/j.1460-2075.1995.tb00075.x; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; ROTHENFLUHHILFI.A, UNPUB; SAEZ L, 1988, MOL CELL BIOL, V8, P5378, DOI 10.1128/MCB.8.12.5378; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SHUBO Z, 1995, EMBO J, V14, P2884; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; WESLEY CS, 1994, NUCLEIC ACIDS RES, V22, P538, DOI 10.1093/nar/22.3.538; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; YU Q, 1987, P NATL ACAD SCI USA, V84, P784, DOI 10.1073/pnas.84.3.784; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; ZERR DM, 1990, J NEUROSCI, V10, P2749	40	211	220	1	18	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 3	1995	270	5237					805	808		10.1126/science.270.5237.805	http://dx.doi.org/10.1126/science.270.5237.805			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC712	7481771				2022-12-28	WOS:A1995TC71200043
J	WORTON, R				WORTON, R			MUSCULAR-DYSTROPHIES - DISEASES OF THE DYSTROPHIN-GLYCOPROTEIN COMPLEX	SCIENCE			English	Editorial Material									UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A8,CANADA	University of Toronto	WORTON, R (corresponding author), HOSP SICK CHILDREN,RES INST,DEPT GENET,555 UNIV AVE,TORONTO,ON M5G 1X8,CANADA.							ARAHATA K, 1993, P JPN ACAD B-PHYS, V69, P259, DOI 10.2183/pjab.69.259; BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; IBRAGHINOVBESKR, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; LJUNGGREN A, 1995, ANN NEUROL, V38, P367, DOI 10.1002/ana.410380305; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; PASSOSBUENO MR, 1995, HUM MOL GENET, V4, P1163; PICCOLO F, 1995, NAT GENET, V10, P243, DOI 10.1038/ng0695-243; RICHARD I, 1995, CELL, V87, P27; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; SUZUKI A, 1992, FEBS LETT, V308, P154, DOI 10.1016/0014-5793(92)81265-N; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276; YOSIDA M, 1994, EUR J BIOCHEM, V222, P1055	16	156	164	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 3	1995	270	5237					755	756		10.1126/science.270.5237.755	http://dx.doi.org/10.1126/science.270.5237.755			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC712	7481760				2022-12-28	WOS:A1995TC71200027
J	WANG, XQ; MERZENICH, MM; SAMESHIMA, K; JENKINS, WM				WANG, XQ; MERZENICH, MM; SAMESHIMA, K; JENKINS, WM			REMODELING OF HAND REPRESENTATION IN ADULT CORTEX DETERMINED BY TIMING OF TACTILE STIMULATION	NATURE			English	Article							SOMATOSENSORY CORTEX; OWL MONKEYS; TOPOGRAPHIC REORGANIZATION; FUNCTIONAL REORGANIZATION; SQUIRREL-MONKEYS; DIGIT AMPUTATION; AREA-3B; PLASTICITY; DEAFFERENTATION; DENERVATION	THE primate somatosensory cortex, which processes tactile stimuli, contains a topographic representation of the signals it receives, but the way in which such maps are maintained is poorly understood. Previous studies of cortical plasticity(1-20) indicated that changes in cortical representation during learning arise largely as a result of hebbian synaptic change mechanisms. Here we show, using adult owl monkeys trained to respond to specific stimulus sequence events, that serial application of stimuli to the fingers results in changes to the neuronal response specificity and maps of the hand surfaces in the true primary somatosensory cortical field (S1 area 3b). In this representational remodelling stimuli applied sychronously to the fingers resulted in these fingers being integrated in their representation, whereas fingers to which stimuli were applied asynchronously were segregated in their representation. Ventroposterior thalamus response maps derived in these monkeys were not equivalently reorganized. This representational plasticity appears to be cortical in origin.	UNIV CALIF SAN FRANCISCO,COLEMAN LAB,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,KECK CTR INTEGRAT NEUROSCI,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Sameshima, Koichi/AHA-5593-2022; Sameshima, Koichi/C-2857-2012	Sameshima, Koichi/0000-0002-0290-2927; Sameshima, Koichi/0000-0002-0290-2927				ARMSTRONGJAMES M, 1994, J NEUROSCI, V14, P6978; CALFORD MB, 1988, NATURE, V332, P446, DOI 10.1038/332446a0; CLARK SA, 1988, NATURE, V332, P444, DOI 10.1038/332444a0; CODE RA, 1992, EXP BRAIN RES, V88, P341, DOI 10.1007/BF02259109; DIAMOND ME, 1994, SCIENCE, V265, P1885, DOI 10.1126/science.8091215; DIAMOND ME, 1993, P NATL ACAD SCI USA, V90, P2082, DOI 10.1073/pnas.90.5.2082; GARRAGHTY PE, 1991, P NATL ACAD SCI USA, V88, P6976, DOI 10.1073/pnas.88.16.6976; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82, DOI 10.1152/jn.1990.63.1.82; KAAS JH, 1983, ANNU REV NEUROSCI, V6, P325, DOI 10.1146/annurev.ne.06.030183.001545; KALASKA J, 1979, J NEUROPHYSIOL, V42, P618, DOI 10.1152/jn.1979.42.2.618; MERZENICH MM, 1987, J COMP NEUROL, V258, P281, DOI 10.1002/cne.902580208; MERZENICH MM, 1978, J COMP NEUROL, V181, P41, DOI 10.1002/cne.901810104; MERZENICH MM, 1983, NEUROSCIENCE, V10, P639, DOI 10.1016/0306-4522(83)90208-7; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; MERZENICH MM, 1983, NEUROSCIENCE, V8, P33, DOI 10.1016/0306-4522(83)90024-6; MERZENICH MM, 1991, COLD SPRING HARB SYM, V55, P873; MOGILNER A, 1993, P NATL ACAD SCI USA, V90, P3593, DOI 10.1073/pnas.90.8.3593; PASCUALLEONE A, 1993, BRAIN, V116, P39, DOI 10.1093/brain/116.1.39; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; RASMUSSON DD, 1982, J COMP NEUROL, V205, P313, DOI 10.1002/cne.902050402; RECANZONE GH, 1991, BEHAV RES METH INS C, V23, P357, DOI 10.3758/BF03203397; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1031, DOI 10.1152/jn.1992.67.5.1031; STRYKER MP, 1987, J COMP NEUROL, V258, P297, DOI 10.1002/cne.902580209; SUR M, 1980, J NEUROPHYSIOL, V44, P295, DOI 10.1152/jn.1980.44.2.295; WALL JT, 1983, SCIENCE, V221, P771, DOI 10.1126/science.6879175; XERRI C, 1994, J NEUROSCI, V14, P1710, DOI 10.1523/JNEUROSCI.14-03-01710.1994; YANG TT, 1994, NEUROREPORT, V5, P701, DOI 10.1097/00001756-199402000-00010	27	349	352	0	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 2	1995	378	6552					71	75		10.1038/378071a0	http://dx.doi.org/10.1038/378071a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477291				2022-12-28	WOS:A1995TC46900052
J	HEIN, L; BARSH, GS; PRATT, RE; DZAU, VJ; KOBILKA, BK				HEIN, L; BARSH, GS; PRATT, RE; DZAU, VJ; KOBILKA, BK			BEHAVIORAL AND CARDIOVASCULAR EFFECTS OF DISRUPTING THE ANGIOTENSIN-II TYPE-2 RECEPTOR GENE IN MICE	NATURE			English	Article							RAT-BRAIN; WATER-INTAKE; EXPRESSION; INJECTION; MECHANISMS; SUBTYPES; APPETITE; DRINKING; CLONING; FETUS	ANGIOTENSIN II, a potent regulator of blood pressure and of water and electrolyte balance, binds to two different G-protein-coupled receptors. The type-1 receptor (AT(1)) mediates the vasopressive and aldosterone-secreting effects of angiotensin II, but the function of the type-2 receptor (AT(2); refs 1, 2) is unknown, although it is expressed in both adult(3) and embryonic(4) life. To address this question, we have generated mice lacking the gene encoding the AT(2) receptor. Mutant mice develop normally, but have an impaired drinking response to water deprivatian as well as a reduction in spontaneous movements. Their baseline blood pressure is normal, but they show an increased vasopressor response to injection of angiotensin II. Thus, although the AT(2) receptor is not required for embryonic development, it plays a role in the central nervous system and cardiovascular functions that are mediated by the renin-angiotensin system.	STANFORD UNIV, FALK CARDIOVASC RES CTR, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT MED, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT PEDIAT, STANFORD, CA 94305 USA; STANFORD UNIV, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University				Kobilka, Brian/0000-0001-5958-3990				CHAASSAGNE C, 1995, GENOMICS, V25, P601, DOI 10.1016/0888-7543(95)80072-T; COONEY AS, 1993, EXP PHYSIOL, V78, P767, DOI 10.1113/expphysiol.1993.sp003724; DOURISH CT, 1992, EUR J PHARMACOL, V211, P113, DOI 10.1016/0014-2999(92)90271-5; FEUILLAN PP, 1993, REGUL PEPTIDES, V44, P159, DOI 10.1016/0167-0115(93)90239-5; GEORGIEV V, 1991, METHOD FIND EXP CLIN, V13, P5; GEORGIEV V, 1990, POL J PHARMACOL PHAR, V42, P553; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; GRADY EF, 1993, REGUL PEPTIDES, V44, P171, DOI 10.1016/0167-0115(93)90240-9; HOGARTY DC, 1992, BRAIN RES, V586, P289, DOI 10.1016/0006-8993(92)91638-U; HUANG Y, 1987, J NEUROCHEM, V49, P1541, DOI 10.1111/j.1471-4159.1987.tb01025.x; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KOIKE G, 1994, BIOCHEM BIOPH RES CO, V203, P1842, DOI 10.1006/bbrc.1994.2402; LOPEZ JJ, 1994, AM J PHYSIOL, V267, pH844, DOI 10.1152/ajpheart.1994.267.2.H844; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NAKAJIMA M, 1993, BIOCHEM BIOPH RES CO, V197, P393, DOI 10.1006/bbrc.1993.2492; NIO Y, 1995, J CLIN INVEST, V95, P46, DOI 10.1172/JCI117675; PETKOVA B, 1991, Acta Physiologica et Pharmacologica Bulgarica, V17, P84; ROWE BP, 1992, NEUROENDOCRINOLOGY, V55, P563, DOI 10.1159/000126177; ROWLAND NE, 1992, BRAIN RES BULL, V29, P389, DOI 10.1016/0361-9230(92)90073-7; ROWLAND NE, 1993, BRAIN RES BULL, V32, P391, DOI 10.1016/0361-9230(93)90205-P; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUMNERS C, 1983, AM J PHYSIOL, V244, pR257, DOI 10.1152/ajpregu.1983.244.2.R257; TSUTSUMI K, 1992, MOL PHARMACOL, V41, P290; VISWANATHAN M, 1992, J CLIN INVEST, V90, P1707, DOI 10.1172/JCI116043; WOOD SA, 1993, NATURE, V365, P87, DOI 10.1038/365025a0; WRIGHT JW, 1994, NEUROSCI BIOBEHAV R, V18, P21, DOI 10.1016/0149-7634(94)90034-5; XU M, 1994, CELL, V79, P945, DOI 10.1016/0092-8674(94)90026-4; ZHUO, 1995, HYPERTENSION PATHOPH, P1739	30	646	657	0	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 26	1995	377	6551					744	747		10.1038/377744a0	http://dx.doi.org/10.1038/377744a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB469	7477266				2022-12-28	WOS:A1995TB46900060
J	COLLER, BS; SCUDDER, LE; BERGER, HJ; IULIUCCI, JD				COLLER, BS; SCUDDER, LE; BERGER, HJ; IULIUCCI, JD			INHIBITION OF HUMAN-PLATELET FUNCTION INVIVO WITH A MONOCLONAL-ANTIBODY - WITH OBSERVATIONS ON THE NEWLY DEAD AS EXPERIMENTAL SUBJECTS	ANNALS OF INTERNAL MEDICINE			English	Article									CENTOCOR, MALVERN, PA USA	Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc	COLLER, BS (corresponding author), SUNY STONY BROOK, DIV HEMATOL, HSC T-15-040, STONY BROOK, NY 11794 USA.				PHS HHS [19278] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CAVAGNARO J, 1987, BLOOD S, V70, pA349; CAVAGNARO J, 1987, BLOOD S, V70, pA337; COLLER BS, 1987, THROMB HAEMOSTASIS, V58, P244; COLLER BS, 1985, BLOOD, V66, P1456; COLLER BS, 1986, BLOOD, V68, P783; COLLER BS, 1983, BLOOD, V61, P99; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; COLLER BS, 1979, BLOOD, V53, P325; GAYLIN W, 1974, HARPERS          SEP, P23; GOLD HK, 1988, CIRCULATION, V77, P670, DOI 10.1161/01.CIR.77.3.670; Robertson John A, 1980, IRB, V2, P4, DOI 10.2307/3563921; YASUDA T, 1988, J CLIN INVEST, V81, P1284, DOI 10.1172/JCI113446	12	48	48	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1988	109	8					635	638		10.7326/0003-4819-109-8-635	http://dx.doi.org/10.7326/0003-4819-109-8-635			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q6974	3421576				2022-12-28	WOS:A1988Q697400010
J	GARRY, RF; WITTE, MH; GOTTLIEB, A; ELVINLEWIS, M; GOTTLIEB, MS; WITTE, CL; ALEXANDER, SS; COLE, WR; DRAKE, WL				GARRY, RF; WITTE, MH; GOTTLIEB, A; ELVINLEWIS, M; GOTTLIEB, MS; WITTE, CL; ALEXANDER, SS; COLE, WR; DRAKE, WL			DOCUMENTATION OF AN AIDS VIRUS-INFECTION IN THE UNITED-STATES IN 1968	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note									TULANE UNIV,SCH MED,DEPT MED,NEW ORLEANS,LA 70112; UNIV ARIZONA,COLL MED,DEPT SURG,TUCSON,AZ 85721; IMREG INC,NEW ORLEANS,LA; WASHINGTON UNIV,SCH DENT MED,DEPT MICROBIOL,ST LOUIS,MO 63130; BIOTECH RES LABS INC,ROCKVILLE,MD; UNIV MISSOURI,MED CTR,SCH MED,DEPT SURG,COLUMBIA,MO 65201; MISSOURI BAPTIST HOSP,ST LOUIS,MO; DEACONESS HOSP,ST LOUIS,MO	Tulane University; University of Arizona; Washington University (WUSTL); University of Missouri System; University of Missouri Columbia	GARRY, RF (corresponding author), TULANE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,1430 TULANE AVE,NEW ORLEANS,LA 70112, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022720] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 22720] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIGGAR RJ, 1985, LANCET, V2, P520; BIGGAR RJ, 1986, LANCET, V1, P79; CURRAN JW, 1985, SCIENCE, V229, P1352, DOI 10.1126/science.2994217; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; ELVINLEWIS M, 1973, LYMPHOLOGY, V6, P113; GALLO R C, 1987, Scientific American, V256, P47; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; GOUDSMIT J, 1986, LANCET, V2, P177; KATNER HP, 1987, J NATL MED ASSOC, V79, P1068; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MASUR H, 1981, NEW ENGL J MED, V305, P1431, DOI 10.1056/NEJM198112103052402; NAHMIAS AJ, 1986, LANCET, V1, P1279; QUINN TC, 1986, SCIENCE, V234, P955, DOI 10.1126/science.3022379; SARNGADHARAN MG, 1984, SCIENCE, V224, P506, DOI 10.1126/science.6324345; SAXINGER WC, 1985, SCIENCE, V227, P1036, DOI 10.1126/science.2983417; SHAW GM, 1985, SCIENCE, V227, P177, DOI 10.1126/science.2981429; SIEGAL FP, 1981, NEW ENGL J MED, V305, P1439, DOI 10.1056/NEJM198112103052403; WITTE MH, 1984, JAMA-J AM MED ASSOC, V251, P2657, DOI 10.1001/jama.1984.03340440017005; WONGSTAAL F, 1985, NATURE, V317, P395, DOI 10.1038/317395a0; ZAGURY JF, 1988, P NATL ACAD SCI USA, V85, P5941, DOI 10.1073/pnas.85.16.5941; 1981, MMWR, V30, P305; [No title captured]	22	41	42	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1988	260	14					2085	2087		10.1001/jama.260.14.2085	http://dx.doi.org/10.1001/jama.260.14.2085			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q3421	3418874				2022-12-28	WOS:A1988Q342100023
J	HEGARTY, JD; ABRAMS, EJ; HUTCHINSON, VE; NICHOLAS, SW; SUAREZ, MS; HEAGARTY, MC				HEGARTY, JD; ABRAMS, EJ; HUTCHINSON, VE; NICHOLAS, SW; SUAREZ, MS; HEAGARTY, MC			THE MEDICAL-CARE COSTS OF HUMAN IMMUNODEFICIENCY VIRUS - INFECTED CHILDREN IN HARLEM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											HEGARTY, JD (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,HARLEM HOSP CTR,DEPT PEDIAT,506 LENOX AVE,NEW YORK,NY 10037, USA.							Berger R, 1985, Md Med J, V34, P1173; BERNSTEIN LJ, 1985, J PEDIATR-US, V107, P352, DOI 10.1016/S0022-3476(85)80505-9; BERNSTEIN LJ, 1985, PEDIATR INFECT DIS J, V4, P472, DOI 10.1097/00006454-198509000-00005; EPSTEIN LG, 1986, PEDIATRICS, V78, P678; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; HARDY AM, 1986, JAMA-J AM MED ASSOC, V255, P209, DOI 10.1001/jama.255.2.209; Kaufman S L, 1982, Inquiry, V19, P167; LAMBERTSEN EC, 1984, PROJECTING REQUIREME; OBERG CN, 1987, PEDIATRICS, V79, P567; OSTERHOLM MT, 1987, JAMA-J AM MED ASSOC, V258, P2736; RUBINSTEIN A, 1983, JAMA-J AM MED ASSOC, V249, P2350, DOI 10.1001/jama.249.17.2350; RUBINSTEIN A, 1986, CURR PROBL PEDIATR, V16, P363; SCITOVSKY AA, 1987, PUBLIC HEALTH REP, V102, P5; SCITOVSKY AA, 1986, JAMA-J AM MED ASSOC, V256, P3103, DOI 10.1001/jama.256.22.3103; SCOTT GB, 1987, AIDS MODERN CONCEPTS, P245; SEAGE GR, 1986, JAMA-J AM MED ASSOC, V256, P3107, DOI 10.1001/jama.256.22.3107; SISK JE, 1987, HLTH AFF         SUM, P7; ULTMANN MH, 1985, DEV MED CHILD NEUROL, V27, P563, DOI 10.1111/j.1469-8749.1985.tb14127.x; 1987, HRSDMC871 US DEP HLT; 1987, MMWR S, V36, P801; 1988, AIDS SURVEILLANCE UP; 1987, MMWR, V36, P225; 1988, AIDS WEEKLY SURVEILL	23	36	36	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1988	260	13					1901	1905						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q2703	3418851				2022-12-28	WOS:A1988Q270300024
J	MYERS, TJ; KESSIMIAN, N; SCHWARTZ, S				MYERS, TJ; KESSIMIAN, N; SCHWARTZ, S			MEDIASTINAL GERM-CELL TUMOR ASSOCIATED WITH THE HEMOPHAGOCYTIC SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Note									PAWTUCKET MEM HOSP, PAWTUCKET, RI USA; BROWN UNIV, PROVIDENCE, RI 02912 USA	Brown University								DEMENT SH, 1985, AM J SURG PATHOL, V9, P23, DOI 10.1097/00000478-198501000-00006; GARNICK MB, 1983, ANN INTERN MED, V98, P926, DOI 10.7326/0003-4819-98-6-926; JAFFE ES, 1983, AM J MED, V75, P741, DOI 10.1016/0002-9343(83)90402-3; KORMAN LY, 1979, ANN INTERN MED, V91, P60, DOI 10.7326/0003-4819-91-1-60; MANOHARAN A, 1981, SCAND J HAEMATOL, V26, P5; NICHOLS CR, 1985, ANN INTERN MED, V102, P603, DOI 10.7326/0003-4819-102-5-603; RISDALL RJ, 1979, CANCER, V44, P993, DOI 10.1002/1097-0142(197909)44:3<993::AID-CNCR2820440329>3.0.CO;2-5; SCHUMACHER HR, 1979, LANCET, V1, P158; SKARIN AT, 1972, ARCH PATHOL, V93, P256; THEODORAKIS ME, 1983, MED PEDIATR ONCOL, V11, P20, DOI 10.1002/mpo.2950110105	10	24	25	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1988	109	6					504	505		10.7326/0003-4819-109-6-504	http://dx.doi.org/10.7326/0003-4819-109-6-504			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q2568	3415108				2022-12-28	WOS:A1988Q256800013
J	GARG, A; GRUNDY, SM				GARG, A; GRUNDY, SM			LOVASTATIN FOR LOWERING CHOLESTEROL LEVELS IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									UNIV TEXAS, SW MED CTR, CTR HUMAN NUTR, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; VET ADM MED CTR, DALLAS, TX 75216 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000633] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029252, R37HL029252] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR-00633] Funding Source: Medline; NHLBI NIH HHS [HL-29252] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS JJ, 1982, DIABETES, V31, P903, DOI 10.2337/diabetes.31.10.903; [Anonymous], 1985, Diabetologia, V28 Suppl, P615; BARRETTCONNOR E, 1982, AM J EPIDEMIOL, V115, P657, DOI 10.1093/oxfordjournals.aje.a113348; BILHEIMER DW, 1983, P NATL ACAD SCI-BIOL, V80, P4124, DOI 10.1073/pnas.80.13.4124; BROWN MS, 1983, J CLIN INVEST, V72, P743, DOI 10.1172/JCI111044; DUNN FL, 1984, METABOLISM, V33, P117, DOI 10.1016/0026-0495(84)90122-7; ENDO A, 1976, J ANTIBIOT, V29, P1346, DOI 10.7164/antibiotics.29.1346; GRUNDY SM, 1985, J LIPID RES, V26, P1464; GURIAN H, 1959, AM J MED SCI, V237, P12, DOI 10.1097/00000441-195901000-00003; HARRIS M, 1979, DIABETES, V28, P1039; HOEG JM, 1986, AM J CARDIOL, V57, P933, DOI 10.1016/0002-9149(86)90733-2; HOLLENBECK CB, 1986, J CLIN ENDOCR METAB, V62, P605, DOI 10.1210/jcem-62-3-605; HOWARD BV, 1985, AM J MED, V79, P78, DOI 10.1016/S0002-9343(85)80012-7; HOWARD BV, 1987, J LIPID RES, V28, P613; HOWARD BV, 1984, ARTERIOSCLEROSIS, V4, P462, DOI 10.1161/01.ATV.4.5.462; ILLINGWORTH DR, 1984, J CLIN INVEST, V74, P1972, DOI 10.1172/JCI111618; INGELFINGER JA, 1976, DIABETES, V25, P561, DOI 10.2337/diabetes.25.7.561; KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; KISSEBAH AH, 1983, J CLIN INVEST, V71, P655, DOI 10.1172/JCI110812; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1194, DOI 10.1073/pnas.78.2.1194; LAAKSO M, 1985, ATHEROSCLEROSIS, V56, P271, DOI 10.1016/0021-9150(85)90003-6; MABUCHI H, 1981, NEW ENGL J MED, V305, P478, DOI 10.1056/NEJM198108273050902; MARKS J, 1982, RES CLIN FORUMS, V4, P95; MYERS LH, 1976, J LAB CLIN MED, V88, P491; PAN XR, 1986, DIABETES CARE, V9, P395, DOI 10.2337/diacare.9.4.395; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; ROESCHLA.P, 1974, Z KLIN CHEM KLIN BIO, V12, P226; RUDERMAN NB, 1984, PROG CARDIOVASC DIS, V26, P373, DOI 10.1016/0033-0620(84)90011-2; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; TASKINEN MR, 1982, DIABETOLOGIA, V22, P46, DOI 10.1007/BF00253869; TASKINEN MR, 1986, DIABETES, V35, P1268, DOI 10.2337/diabetes.35.11.1268; TOBERT JA, 1987, CIRCULATION, V76, P534, DOI 10.1161/01.CIR.76.3.534; TOBERT JA, 1986, JAMA-J AM MED ASSOC, V256, P2829; VEGA GL, 1984, J LIPID RES, V25, P580; WAHLEFELD A., 1974, METHOD ENZYMAT AN, P1831; Winer BJ, 1971, STATISTICAL PRINCIPL, P261; YOSHINO G, 1986, Diabetes Research and Clinical Practice, V2, P179, DOI 10.1016/S0168-8227(86)80020-1; ZAR JH, 1984, BIOSTAT ANAL, P222; 1974, DHEW NIH75628 PUBL, V1; 1984, ARTERIOSCLEROSIS, V4, P296; 1979, DIABETES, V28, P1027	42	178	180	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1988	318	2					81	86		10.1056/NEJM198801143180204	http://dx.doi.org/10.1056/NEJM198801143180204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	L6001	3422105				2022-12-28	WOS:A1988L600100004
J	ALEXIEWICZ, JM; KUMAR, D; SMOGORZEWSKI, M; KLIN, M; MASSRY, SG				ALEXIEWICZ, JM; KUMAR, D; SMOGORZEWSKI, M; KLIN, M; MASSRY, SG			POLYMORPHONUCLEAR LEUKOCYTES IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS - ABNORMALITIES IN METABOLISM AND FUNCTION	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETES MELLITUS, NON-INSULIN-DEPENDENT; NEUTROPHILS; PHAGOCYTOSIS; CALCIUM CHANNELS; GLYBURIDE	INCREASES CYTOSOLIC CALCIUM; PROTEIN KINASE-C; PHOSPHATE-DEPLETION; IMPAIRED PHAGOCYTOSIS; PARATHYROID-HORMONE; PANCREATIC-ISLETS; CA-2+ TRANSPORT; RAT ADIPOCYTES; MECHANISM; SODIUM	Objective: To determine basal levels of cytosolic calcium ([Ca2+]i) and phagocytic activity in polymorphonuclear leukocytes (PMNLs) from patients with non-insulin-dependent diabetes (NIDDM). Design: Prospective cohort study. Setting: A university-county hospital. Measurements: Cytosolic calcium levels, adenosine triphosphate (ATP) content, and phagocytosis of PMNLs from patients with NIDDM and from controls. Intervention: In patients with NIDDM, we evaluated the effect of treatment with an oral hypoglycemic agent (glyburide) on [Ca2+]i levels, ATP content, and the phagocytosis of PMNLs. Patients: 22 controls and 34 patients with NIDDM were examined. Fifteen patients were studied before and after 3 months of treatment with glyburide. Results: Polymorphonuclear leukocytes from patients with NIDDM showed significantly elevated basal levels of [Ca2+]i (68 +/- 9.6 compared with 43 +/- 4.9 nmol/L; P < 0.01); reduced ATP content (1.30 +/- 0.58 compared with 2.35 +/- 0.45 nmol/10(6) PMNLs; P < 0.01); and impaired phagocytosis (117 +/- 21.0 compared with 145 +/- 17.4 mu g oil/10(7) PMNLs per minute; P < 0.01) compared with controls. There was a direct and significant correlation (P < 0.01, r = 0.80) between [Ca2+]i levels in PMNLs and serum glucose levels and an inverse correlation between phagocytic ability and [Ca2+]i levels (P < 0.01; r = 0.62) as well as between phagocytic activity and fasting serum glucose levels (P < 0.01, r = 0.54) in patients with NIDDM. Glyburide therapy resulted in significant reduction in fasting serum glucose levels; in PMNLs, this treatment resulted in a significant reduction in [Ca2+]i levels, a significant increase in ATP content, and a significant improvement of phagocytosis. Conclusions: Patients with NIDDM have elevated [Ca2+]i levels in PMNLs. This abnormality is probably induced by hyperglycemia and is primarily responsible for the impaired phagocytosis seen in these patients.	UNIV SO CALIF, SCH MED, DIV NEPHROL, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, DIV ENDOCRINOL DIABET & HYPERTENS, LOS ANGELES, CA 90033 USA	University of Southern California; University of Southern California			Kalra, D/H-6661-2019	Kalra, D/0000-0001-5254-4067	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029955, R55DK029955] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 29955] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXIEWICZ JM, 1991, AM J NEPHROL, V11, P102, DOI 10.1159/000168284; ALEXIEWICZ JM, 1995, AM J KIDNEY DIS, V25, P440, DOI 10.1016/0272-6386(95)90106-X; ALEXIEWICZ JM, 1992, AM J HYPERTENS, V5, P536, DOI 10.1093/ajh/5.8.536; ALLO SN, 1991, AM J PHYSIOL, V260, pC1165, DOI 10.1152/ajpcell.1991.260.6.C1165; BACZYNSKI R, 1985, KIDNEY INT, V27, P718, DOI 10.1038/ki.1985.71; BAGDADE JD, 1974, DIABETES, V23, P9, DOI 10.2337/diab.23.1.9; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CHERVU I, 1992, KIDNEY INT, V41, P1501, DOI 10.1038/ki.1992.219; CRADDOCK PR, 1974, NEW ENGL J MED, V290, P1403, DOI 10.1056/NEJM197406202902504; DENTON RM, 1985, AM J PHYSIOL, V249, pE543, DOI 10.1152/ajpendo.1985.249.6.E543; DOWD TL, 1993, J BIOL CHEM, V268, P991; DRAZNIN B, 1989, ENDOCRINOLOGY, V125, P2341, DOI 10.1210/endo-125-5-2341; DRAZNIN B, 1988, BIOCHEM BIOPH RES CO, V156, P570, DOI 10.1016/S0006-291X(88)80880-5; ERNE P, 1984, NEW ENGL J MED, V310, P1084, DOI 10.1056/NEJM198404263101705; FADDA GZ, 1990, AM J PHYSIOL, V258, pE975, DOI 10.1152/ajpendo.1990.258.6.E975; FERRANTE A, 1980, J IMMUNOL METHODS, V36, P109, DOI 10.1016/0022-1759(80)90036-8; GREENE DA, 1983, J CLIN INVEST, V72, P1058, DOI 10.1172/JCI111030; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARRIS M, 1979, DIABETES, V28, P1039; KIERSZTEJN M, 1992, J AM SOC NEPHROL, V2, P1484; KLIN M, 1994, AM J PHYSIOL-GASTR L, V267, pG754, DOI 10.1152/ajpgi.1994.267.5.G754; LEE TS, 1989, P NATL ACAD SCI USA, V86, P5141, DOI 10.1073/pnas.86.13.5141; LUNDIN A, 1986, METHOD ENZYMOL, V133, P27; MAKINO N, 1987, AM J PHYSIOL, V253, pE202, DOI 10.1152/ajpendo.1987.253.2.E202; MARHOFFER W, 1992, DIABETES CARE, V15, P256, DOI 10.2337/diacare.15.2.256; MASSRY SG, 1994, SEMIN NEPHROL, V14, P219; MASSRY SG, 1992, MINER ELECTROL METAB, V18, P133; MASSRY SG, 1991, AM J PHYSIOL, V260, pF12, DOI 10.1152/ajprenal.1991.260.1.F12; MAZZANTI L, 1990, DIABETES, V39, P850, DOI 10.2337/diabetes.39.7.850; OHARA T, 1991, DIABETES, V40, P1560, DOI 10.2337/diabetes.40.11.1560; OSHIMA T, 1987, JPN CIRC J, V51, P1184, DOI 10.1253/jcj.51.1184; RESNICK LM, 1991, HYPERTENSION, V17, P951, DOI 10.1161/01.HYP.17.6.951; SOUTHWICK FS, 1986, MANUAL CLIN LABORATO, P326; STOJCEVATANEVA O, 1993, NEPHRON, V64, P592, DOI 10.1159/000187406; STUDER RK, 1989, ENDOCRINOLOGY, V125, P2421, DOI 10.1210/endo-125-5-2421; TRIVELLI LA, 1971, NEW ENGL J MED, V284, P353, DOI 10.1056/NEJM197102182840703; TRUMP BE, 1987, ADV MOD ENV TOXICOL, V14, P27; TSCHOPE D, 1994, AM J MED, V96, P260; ZERNEL MB, 1990, METABOLISM, V39, P704; ZHANG YB, 1994, KIDNEY INT, V45, P1113, DOI 10.1038/ki.1994.148; ZHOU XJ, 1991, KIDNEY INT, V39, P120, DOI 10.1038/ki.1991.15	41	155	161	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1995	123	12					919	+		10.7326/0003-4819-123-12-199512150-00004	http://dx.doi.org/10.7326/0003-4819-123-12-199512150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK120	7486486				2022-12-28	WOS:A1995TK12000004
J	DALY, LE; KIRKE, PN; MOLLOY, A; WEIR, DG; SCOTT, JM				DALY, LE; KIRKE, PN; MOLLOY, A; WEIR, DG; SCOTT, JM			FOLATE LEVELS AND NEURAL-TUBE DEFECTS - IMPLICATIONS FOR PREVENTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOLIC-ACID; VITAMIN SUPPLEMENTATION; TRIAL	Using data from a recent case-control study, a woman's risk of having a child with a neural tube defect (NTD) was found to be associated with early pregnancy red cell folate levels in a continuous dose-response relationship. These findings were used to calculate the reduction in NTD cases that would be expected under two different strategies to raise folate levels. Targeting high-risk individuals has a small effect on the population prevalence but can substantially change an individual's risk. Targeting the population produces a small change in individual risk but has a large effect on the population prevalence. Supplementation of high-risk women would be the most efficient method to implement the high-risk strategy, while food fortification would be preferable for the population approach. The current guidelines for the prevention of NTD are for an increased folio acid intake of 0.4 mg per day. This would result in a 48% reduction in NTDs, which may be near optimal. The two intervention strategies should be considered complementary in prevention of NTDs.	HLTH RES BOARD,DUBLIN,IRELAND; TRINITY COLL DUBLIN,DEPT CLIN MED,DUBLIN,IRELAND; TRINITY COLL DUBLIN,DEPT BIOCHEM,DUBLIN,IRELAND	Health Research Board - Ireland; Trinity College Dublin; Trinity College Dublin	DALY, LE (corresponding author), UNIV DUBLIN TRINITY COLL,DEPT EPIDEMIOL & PUBL HLTH MED,EARLSFORT TERRACE,DUBLIN 2,IRELAND.			Molloy, Anne/0000-0002-1688-9049				BERESFORD SAA, 1994, AM J PUBLIC HEALTH, V84, P348, DOI 10.2105/AJPH.84.3.348; CLARK NAC, 1994, BRIT J OBSTET GYNAEC, V101, P709, DOI 10.1111/j.1471-0528.1994.tb13190.x; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; HESEKER H, 1987, J NUTR SCI VITAMINOL, V33, P163, DOI 10.3177/jnsv.33.163; HUBER AM, 1988, J AM DIET ASSOC, V88, P791; KIRKE PN, 1992, ARCH DIS CHILD, V67, P1442, DOI 10.1136/adc.67.12.1442; LAURENCE KM, 1981, BRIT MED J, V282, P1509, DOI 10.1136/bmj.282.6275.1509; OAKLEY GP, 1993, JAMA-J AM MED ASSOC, V269, P1292, DOI 10.1001/jama.269.10.1292; SCOTT J, 1994, Q J MED, V87, P705, DOI 10.1093/oxfordjournals.qjmed.a068887; SMITHELLS RW, 1983, LANCET, V1, P1027; TSUI JC, 1990, J AM DIET ASSOC, V90, P1551; WALD N, 1991, LANCET, V338, P131; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; WOTEKI CE, 1988, AM J CLIN NUTR, V47, P320, DOI 10.1093/ajcn/47.2.320; 1993, POSITION PAPER FOLIC; 1992, FOLIC ACID PREVENTIO	16	564	583	0	38	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	1995	274	21					1698	1702		10.1001/jama.274.21.1698	http://dx.doi.org/10.1001/jama.274.21.1698			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH151	7474275				2022-12-28	WOS:A1995TH15100027
J	GHOSH, P; AMAYA, M; MELLINS, E; WILEY, DC				GHOSH, P; AMAYA, M; MELLINS, E; WILEY, DC			THE STRUCTURE OF AN INTERMEDIATE IN CLASS-II MHC MATURATION - CLIP BOUND TO HLA-DR3	NATURE			English	Article							ANTIGEN-PROCESSING MUTANT; INVARIANT CHAIN PEPTIDES; HLA-DR MOLECULES; CELL LINE; ASSOCIATION; BINDING	A complex between HLA-DR3 and a fragment of invariant chain called CLIP was isolated from a human cell line defective in antigen presentation and its X-ray crystal structure determined. Previous data indicate that this complex is an intermediate in class II histocompatibility maturation, occurring between invariant chain-DR3 and antigenic peptide-DR3 complexes. The structure shows that the CLIP fragment binds to DR3 in a way almost identical to that in which antigenic peptides bind class II histocompatibility glycoproteins. The structure is the substrate for the loading of antigenic peptides by an exchange process catalysed by DM.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; UNIV PENN,CHILDRENS HOSP PHILADELPHIA,PHILADELPHIA,PA 19104; CHILDRENS SEASHORE HOUSE,PHILADELPHIA,PA 19104	Harvard University; Harvard University; Howard Hughes Medical Institute; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia								[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; BIJLMAKERS MJE, 1994, J EXP MED, V180, P623, DOI 10.1084/jem.180.2.623; BROWN JH, 1993, NATURE, V368, P33; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; FREISEWINKEL IM, 1993, P NATL ACAD SCI USA, V90, P9703, DOI 10.1073/pnas.90.20.9703; GAUTAM AM, 1995, P NATL ACAD SCI USA, V92, P335, DOI 10.1073/pnas.92.1.335; GELUK A, 1995, MOL IMMUNOL, V32, P975, DOI 10.1016/0161-5890(95)00058-M; GELUK A, 1994, J IMMUNOL, V152, P5742; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; GORGA JC, 1991, RES IMMUNOL, V142, P401, DOI 10.1016/0923-2494(91)90038-K; GORGA JC, 1987, J BIOL CHEM, V262, P16087; HUANG CC, 1991, J MOL GRAPHICS, V9, P230, DOI 10.1016/0263-7855(91)80016-S; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JASANOFF A, 1995, P NATL ACAD SCI USA, V92, P9900, DOI 10.1073/pnas.92.21.9900; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1978, ACTA CRYSTALLOGR A, V34, P827, DOI 10.1107/S0567739478001680; KIM JS, 1994, SCIENCE, V266, P1870, DOI 10.1126/science.7997880; KROPSHOFER H, 1995, P NATL ACAD SCI USA, V92, P8313, DOI 10.1073/pnas.92.18.8313; LEE C, 1995, P NATL ACAD SCI USA, V92, P8269, DOI 10.1073/pnas.92.18.8269; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MALCHEREK G, 1995, J EXP MED, V181, P527, DOI 10.1084/jem.181.2.527; MALCHEREK G, 1993, INT IMMUNOL, V5, P1229, DOI 10.1093/intimm/5.10.1229; MAURER D, 1991, J IMMUNOL, V146, P621; MELLINS E, 1994, J EXP MED, V179, P541, DOI 10.1084/jem.179.2.541; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MONJI T, 1994, J IMMUNOL, V153, P4468; MORKOWSKI S, 1995, J EXP MED, V182, P1403, DOI 10.1084/jem.182.5.1403; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PARK SJ, 1995, P NATL ACAD SCI USA, V92, P11289, DOI 10.1073/pnas.92.24.11289; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; ROMAGNOLI P, 1994, J EXP MED, V180, P1107, DOI 10.1084/jem.180.3.1107; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SETTE A, 1995, J EXP MED, V181, P677, DOI 10.1084/jem.181.2.677; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; URBAN RG, 1994, J EXP MED, V180, P751, DOI 10.1084/jem.180.2.751; XU MZ, 1994, MOL IMMUNOL, V31, P723, DOI 10.1016/0161-5890(94)90146-5	50	523	537	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					457	462		10.1038/378457a0	http://dx.doi.org/10.1038/378457a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477400				2022-12-28	WOS:A1995TH05400059
J	OLIVER, MF				OLIVER, MF			STATINS PREVENT CORONARY HEART-DISEASE	LANCET			English	Editorial Material											OLIVER, MF (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, NATL HEART & LUNG INST, LONDON, ENGLAND.							BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; BYINGTON RP, 1995, CIRCULATION, V92, P2419, DOI 10.1161/01.CIR.92.9.2419; DAYTON S, 1969, CIRCULATION S2, V39, P63; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; LORD I, 1992, J CLIN EPIDEMIOL, V45, P849, DOI 10.1016/0895-4356(92)90068-X; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OLIVER MF, 1994, LANCET, V344, P633; PEDERSEN TR, 1995, LANCET, V345, P1274; PEDERSEN TR, 1994, LANCET, V344, P1383; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; STROES ESG, 1995, LANCET, V346, P467, DOI 10.1016/S0140-6736(95)91322-X; WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959; 1993, MORTALITY STATIS DH2	16	26	26	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 25	1995	346	8987					1378	1379		10.1016/S0140-6736(95)92399-3	http://dx.doi.org/10.1016/S0140-6736(95)92399-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG207	7475814	Bronze			2022-12-28	WOS:A1995TG20700002
J	PERRY, IJ; REFSUM, H; MORRIS, RW; EBRAHIM, SB; UELAND, PM; SHAPER, AG				PERRY, IJ; REFSUM, H; MORRIS, RW; EBRAHIM, SB; UELAND, PM; SHAPER, AG			PROSPECTIVE-STUDY OF SERUM TOTAL HOMOCYSTEINE CONCENTRATION AND RISK OF STROKE IN MIDDLE-AGED BRITISH MEN	LANCET			English	Article							ISCHEMIC-HEART-DISEASE; PLASMA HOMOCYST(E)INE	Moderate hyperhomocysteinaemia is common in the general population and has been linked with cardiovascular disease. However, there are no data from prospective, population-based studies. We examined the association between serum total homocysteine (tHcy) concentration and stroke in a nested case-control study within the British Regional Heart Study cohort. Between 1978 and 1980 serum was saved from 5661 men, aged 40-59 years, randomly selected from the population of one general practice in each of 18 towns in the UK. During follow-up to December, 1991, there were 141 incident cases of stroke among men with no history of stroke at screening. Serum tHcy was measured in 107 cases and 118 control men (matched for age-group and town, without a history of stroke at screening, who did not develop a stroke or myocardial infarction during follow-up). tHcy concentrations were significantly higher in cases than controls (geometric mean 13.7 [95% CI 12.7-14.8] vs 11.9 [11.3-12.6] mu mol/L; p=0004). There was a graded increase in the relative risk of stroke in the second, third, and fourth quarters of the tHcy distribution (odds ratios 1.3, 1.9, 2.8; trend p=0.005) relative to the first. Adjustment for age-group, town, social class, body-mass index, hypertensive status, cigarette smoking, expiratory volume, packed-cell volume, alcohol diabetes, high-density-lipoprotein cholesterol, and serum creatinine did not attenuate the association. These findings suggest that tHcy is a strong and independent risk factor for stroke.	UNIV BERGEN,DEPT BIOL CLIN,DIV PHARMACOL,BERGEN,NORWAY	University of Bergen	PERRY, IJ (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH,LONDON NW3 2PF,ENGLAND.		Refsum, Helga/A-4073-2010; Ueland, Per M/C-7340-2013	Ueland, Per Magne/0000-0002-1903-0571; Morris, Richard/0000-0001-7240-4563; Perry, Ivan/0000-0002-4965-9792				ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BRATTSTROM L, 1994, J INTERN MED, V236, P633, DOI 10.1111/j.1365-2796.1994.tb00856.x; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; FISKERSTRAND T, 1993, CLIN CHEM, V39, P263; GUTTORMSEN AB, 1994, J NUTR, V124, P1934, DOI 10.1093/jn/124.10.1934; ISRAELSSON B, 1993, SCAND J CLIN LAB INV, V39, P263; LANDGREN F, 1995, J INTERN MED, V237, P381, DOI 10.1111/j.1365-2796.1995.tb01190.x; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; MALINOW MR, 1994, J INTERN MED, V236, P603, DOI 10.1111/j.1365-2796.1994.tb00854.x; MASSER PE, 1995, J IR COLL PHYS SURG, V24, P25; Mudd Sh, 1989, METABOLIC BASIS INHE, V1, P693; POCOCK SJ, 1989, J CLIN PATHOL, V42, P172, DOI 10.1136/jcp.42.2.172; REFSUM H, 1989, CLIN CHEM, V35, P1921; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; SHAPER AG, 1985, J EPIDEMIOL COMMUN H, V39, P197, DOI 10.1136/jech.39.3.197; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SHAPER AG, 1991, BRIT MED J, V302, P1111, DOI 10.1136/bmj.302.6785.1111; SHAPER AG, 1984, BRIT HEART J, V51, P595, DOI 10.1136/hrt.51.6.595; SHAPER AG, 1988, LANCET, V2, P1268; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; STAMPFER MJ, 1995, NEW ENGL J MED, V332, P328, DOI 10.1056/NEJM199502023320511; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; THELLE DS, 1984, BRIT HEART J, V49, P205; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924; WALKER M, 1984, J R COLL GEN PRACT, V34, P197; WANNAMETHEE G, 1994, J INTERN MED, V235, P163, DOI 10.1111/j.1365-2796.1994.tb01050.x	30	714	744	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 25	1995	346	8987					1395	1398		10.1016/S0140-6736(95)92407-8	http://dx.doi.org/10.1016/S0140-6736(95)92407-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG207	7475822	Bronze			2022-12-28	WOS:A1995TG20700010
J	FINE, PEM				FINE, PEM			VARIATION IN PROTECTION BY BCG - IMPLICATIONS OF AND FOR HETEROLOGOUS IMMUNITY	LANCET			English	Review							CHILDHOOD TUBERCULOSIS; VACCINATION PROGRAM; CALMETTE-GUERIN; MYCOBACTERIA; EFFICACY; NEWBORN; INFECTION; IDENTIFICATION; EVALUATE; LEPROSY	Besides being the world's most widely used vaccine, and being directed against the world's leading cause of infectious disease mortality, BCG is the most controversial vaccine in current use.(1,2) Estimates of protection imparted by BCG against pulmonary tuberculosis vary from nil to 80%. This variability has been attributed to strain variation in BCG preparations, to genetic or nutritional differences between populations, and to environmental influences such as sunlight exposure, poor cold-chain maintenance, or exposure to environmental mycobacterial infections. Evidence accumulated to date indicates that regional differences in environmental mycobacteria are responsible for much of the variation observed between populations in the efficacy of BCG against pulmonary tuberculosis. This paper reviews the evidence, and notes its broader implications for the epidemiology and control of mycobacterial diseases as well as for other infections and vaccines.			FINE, PEM (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,COMMUNICABLE DIS EPIDEMIOL UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.							ARONSON JD, 1948, AM REV TUBERC PULM, V58, P255; BERGGREN SA, 1981, BRIT VET J, V137, P88, DOI 10.1016/S0007-1935(17)31792-X; BLIN P, 1986, TUBERCLE, V67, P283, DOI 10.1016/0041-3879(86)90017-6; Bloom Barry R., 1994, P531; BROWN CA, 1985, TUBERCLE, V66, P251, DOI 10.1016/0041-3879(85)90062-5; BUDDLE B, 1995, MAR P VACC 95 C LORN, P61; CHAVIALITTAMRON.B, 1986, PEDIATR PULM, V2, P202; CHENG SH, 1993, INFECT IMMUN, V61, P4501, DOI 10.1128/IAI.61.10.4501-4503.1993; Coetzee A M, 1968, Proc Mine Med Off Assoc, V48, P41; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; COMSTOCK GW, 1969, AM REV RESPIR DIS, V100, P839; COMSTOCK GW, 1976, PUBLIC HEALTH REP, V91, P276; COMSTOCK GW, 1988, AM REV RESPIR DIS, V138, P479, DOI 10.1164/ajrccm/138.2.479; COMSTOCK GW, 1974, AM J PUBLIC HEALTH, V64, P283, DOI 10.2105/AJPH.64.3.283; EDWARDS LB, 1968, ARCH ENVIRON HEALTH, V17, P507, DOI 10.1080/00039896.1968.10665273; EDWARDS LB, 1973, AM REV RESPIR DIS, V108, P1334; EDWARDS LB, 1969, AM REV RESPIR DIS, V99, P1; EDWARDS ML, 1982, J INFECT DIS, V145, P733, DOI 10.1093/infdis/145.2.733; FALKINHAM JO, 1980, AM REV RESPIR DIS, V121, P931; FERGUSON RG, 1994, TUBERCLE, V30, P5; FINE PEM, 1990, LANCET, V335, P1016, DOI 10.1016/0140-6736(90)91074-K; FINE PEM, 1992, INT J LEPROSY, V60, P71; FINE PEM, 1994, LANCET, V344, P1245, DOI 10.1016/S0140-6736(94)90748-X; Frimodt-Moller J, 1973, Bull Int Union Tuberc, V48, P40; HART P. D'A., 1967, Tubercle, V48, P201, DOI 10.1016/S0041-3879(67)80024-2; HART PD, 1967, BRIT MED J, V1, P587, DOI 10.1136/bmj.1.5540.587; HART PD, 1977, BRIT MED J, V2, P293, DOI 10.1136/bmj.2.6082.293; HOUSTON S, 1986, AM J EPIDEMIOL, V131, P340; HYGE TAGE V., 1956, ACTA TUBERC SCAND, V32, P89; Jezek Z, 1988, HUMAN MONKEYPOX; JIN BW, 1989, TUBERCLE, V70, P241, DOI 10.1016/0041-3879(89)90018-4; KIM JJ, 1989, INFECT IMMUN, V57, P602, DOI 10.1128/IAI.57.2.602-608.1989; LEVINE MI, 1946, AM REV TUBERC PULM, V53, P517; MICELI I, 1988, INT J EPIDEMIOL, V17, P629, DOI 10.1093/ije/17.3.629; MURTAGH K, 1980, LANCET, V1, P423; MYINT TT, 1987, ANN TROP PAEDIATR, V7, P159, DOI 10.1080/02724936.1987.11748499; OREGE PA, 1994, INT J LEPROSY, V61, P542; ORME IM, 1984, INFECT IMMUN, V44, P28, DOI 10.1128/IAI.44.1.28-32.1984; PACKE GE, 1988, ARCH DIS CHILD, V63, P277, DOI 10.1136/adc.63.3.277; PADUNGCHAN S, 1986, B WORLD HEALTH ORGAN, V64, P247; PALMER CE, 1966, AM REV RESPIR DIS, V94, P553; PALMER CE, 1957, B INT UNION TUBERC, V27, P106; PALMER CE, 1968, JAMA-J AM MED ASSOC, V205, P117; PARAMASIVAN CN, 1985, TUBERCLE, V66, P9, DOI 10.1016/0041-3879(85)90048-0; PATEL A, 1991, B WORLD HEALTH ORGAN, V69, P425; PONNIGHAUS JM, 1992, LANCET, V339, P636, DOI 10.1016/0140-6736(92)90794-4; PUTRALI J, 1983, P E REGIONAL TUBERCU, P194; RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154; RODRIGUES LC, 1991, J EPIDEMIOL COMMUNIT, V45, P79; ROMANUS V, 1983, TUBERCLE, V64, P101, DOI 10.1016/0041-3879(83)90034-X; ROOK GAW, 1981, TUBERCLE, V62, P63, DOI 10.1016/0041-3879(81)90038-6; ROSENTHAL S, 1961, PEDIATRICS, V28, P622; SACK DA, 1994, LANCET, V343, P1413, DOI 10.1016/S0140-6736(94)92531-3; SHANNON A, 1991, EUR RESPIR J, V4, P778; SHAPIRO C, 1985, INT J EPIDEMIOL, V14, P441, DOI 10.1093/ije/14.3.441; SIRINAVIN S, 1991, PEDIATR INFECT DIS J, V10, P359, DOI 10.1097/00006454-199105000-00003; SJOGREN I, 1976, SCAND J RESPIR DIS, V57, P208; SMITH PG, 1976, T ROY SOC TROP MED H, V70, P449, DOI 10.1016/0035-9203(76)90128-0; SPRINGETT V H, 1969, Tubercle, V50, P159, DOI 10.1016/0041-3879(69)90021-X; STYBLO K, 1991, SELECT PAP ROY DUTCH, V24, P9; SUTHERLAND I, 1987, TUBERCLE, V68, P91; TIDJANI O, 1986, TUBERCLE, V67, P269, DOI 10.1016/0041-3879(86)90016-4; TRIPATHY SP, 1987, B INT UNION TUBERC L, V62, P69; TRNKA L, 1994, TUBERCLE LUNG DIS, V75, P348, DOI 10.1016/0962-8479(94)90080-9; TVERDAL A, 1988, TUBERCLE, V69, P119, DOI 10.1016/0041-3879(88)90074-8; VANDIVIERE HM, 1973, AM REV RESPIR DIS, V108, P301; WILSON ME, 1995, CLIN INFECT DIS, V20, P982, DOI 10.1093/clinids/20.4.982; YOUNG TK, 1986, AM J PUBLIC HEALTH, V76, P783, DOI 10.2105/AJPH.76.7.783; ZILBER N, 1984, ISRAEL J MED SCI, V20, P1150; 1980, INDIAN J MED RES S, V72, P1; 1975, TUBERCLE, V56, P129; 1980, BR J DIS CHEST, V74, P215	72	1017	1102	1	59	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 18	1995	346	8986					1339	1345		10.1016/S0140-6736(95)92348-9	http://dx.doi.org/10.1016/S0140-6736(95)92348-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE916	7475776				2022-12-28	WOS:A1995TE91600014
J	HUANG, WP; CIOCHON, R; GU, YM; LARICK, R; FANG, QR; SCHWARCZ, H; YONGE, C; DEVOS, J; RINK, W				HUANG, WP; CIOCHON, R; GU, YM; LARICK, R; FANG, QR; SCHWARCZ, H; YONGE, C; DEVOS, J; RINK, W			EARLY HOMO AND ASSOCIATED ARTIFACTS FROM ASIA	NATURE			English	Article							ORIGIN	The site of Longgupo Cave was discovered in 1984 and excavated in 1985-1988 by the Institute of Vertebrate Paleontology and Paleoanthropology (Beijing) and the Chongqing National Museum (Sichuan Province). Important finds include very archaic hominid dental fragments, Gigantopithecus teeth and primitive stone tools. Palaeomagnetic analysis and the presence of Ailuropoda microta (pygmy giant panda) suggested that the hominid-bearing levels dated to the earliest Pleistocene(1). In 1992, joint Chinese-American-Canadian geochronological research corroborated the age using electron spin resonance (ESR) analysis. We report here that the hominid dentition and stone tools from Longgupo Cave are comparable in age and morphology with early representives of the genus Homo (H. habilis and H. ergaster) and the Oldowan technology in East Africa. The Longgupo dentition is demonstrably more primitive than that seen in Asian Homo erectus. Longgupo's diverse and well preserved Plio-Pleistocene fauna of 116 species provide a sensitive contextual base for interpreting the early arrival of the genus Homo in Asia.	UNIV MASSACHUSETTS,DEPT ANTHROPOL,AMHERST,MA 01003; CHONGOING MUSEUM NAT HIST,CHONGQING 630013,PEOPLES R CHINA; UNIV CALGARY,DEPT PHYS & ASTRON,HAMILTON,ON L85 4M1,CANADA; NATL MUSEUM NAT HIST,2300 RA LEIDEN,NETHERLANDS; UNIV IOWA,DEPT PEDIAT DENT,IOWA CITY,IA 52242; ACAD SINICA,INST VERTEBRATE PALEONTOL & PALEOANTHROPOL,BEIJING 100044,PEOPLES R CHINA	University of Massachusetts System; University of Massachusetts Amherst; University of Calgary; University of Iowa; Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS	HUANG, WP (corresponding author), UNIV IOWA,DEPT ANTHROPOL,IOWA CITY,IA 52242, USA.							Brown Barbara, 1993, P161; CANDE SC, 1992, J GEOPHYS RES-SOL EA, V97, P13917, DOI 10.1029/92JB01202; CIOCHON R, IN PRESS P NATN ACAD; CLARKE RJ, 1990, J HUM EVOL, V19, P699, DOI 10.1016/0047-2484(90)90004-U; CLARKE RJ, 1988, WORLD ARCHAEOL, V21, P1; COLBERT EH, 1953, B AM MUS NAT HIST, V102, P1; Gao Jian, 1975, Vertebrata Palasiatica, V13, P81; GRUN R, 1987, CAN J EARTH SCI, V24, P1022, DOI 10.1139/e87-099; Harris J.W.K., 1983, AFR ARCHAEOL REV, V1, P3, DOI DOI 10.1007/BF01116770; HOWELL FC, 1994, ORIGINS ANATOMICALLY, P253; Huang W., 1991, WUSHAN HOMINID SITE; Huang Wanpo, 1993, Vertebrata Palasiatica, V31, P191; Leakey M.D., 1971, OLDUVAI GORGE, V3, P1960; Luo H., 1989, ACTA ANTHROPOL SIN, V8, P172; MATTHEW WD, 1923, B AM MUS NAT HIST, V46, P563; MCDOUGALL I, 1992, GEOPHYS RES LETT, V19, P2349, DOI 10.1029/92GL02714; Rightmire G. P., 1990, EVOLUTION HOMO ERECT; SCHWARCZ HP, 1994, J HUM EVOL, V26, P175, DOI 10.1006/jhev.1994.1010; SWISHER CC, 1994, SCIENCE, V263, P1118, DOI 10.1126/science.8108729; TOBIAS PV, 1991, OLDUVAL GORGE, V4; WANG L, 1982, VERTEBRAT PALASIATIC, V20, P255; WELDENREICH F, 1937, PALEONTOL SINICA D, V1, P1; Woo J. K., 1962, Palaeontologia Sinica New Ser D, V11, P1; WOOD B, 1992, NATURE, V355, P783, DOI 10.1038/355783a0; Wood B., 1991, HOMINID CRANIAL REMA, V4; Wood Bernard, 1993, P485; ZHANG YY, 1982, AM J PHYS ANTHROPOL, V59, P21; ZHENG SH, 1986, VERTEBRAT PALASIATIC, V24, P81; Zheng SH, 1993, QUATERNARY RODENTS S	29	178	214	2	43	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 16	1995	378	6554					275	278						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TE858	7477345				2022-12-28	WOS:A1995TE85800047
J	SPITZER, RL; KROENKE, K; LINZER, M; HAHN, SR; WILLIAMS, JBW; DEGRUY, FV; BRODY, D; DAVIES, M				SPITZER, RL; KROENKE, K; LINZER, M; HAHN, SR; WILLIAMS, JBW; DEGRUY, FV; BRODY, D; DAVIES, M			HEALTH-RELATED QUALITY-OF-LIFE IN PRIMARY-CARE PATIENTS WITH MENTAL-DISORDERS - RESULTS FROM THE PRIME-MD 1000 STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PANIC DISORDER; OF-LIFE; MEDICAL OUTCOMES; DISABILITY; DEPRESSION; MORBIDITY; POPULATION; COMMUNITY; WORK	Objective.-To determine if different mental disorders commonly seen in primary care are uniquely associated with distinctive patterns of impairment in the components of health-related quality of life (HRQL) and how this compares with the impairment seen in common medical disorders. Design.-Survey. Setting.-Four primary care clinics. Subjects.-A total of 1000 adult patients (369 selected by convenience and 631 selected by site-specific methods to avoid sampling bias) assessed by 31 primary care physicians using PRIME-MD (Primary Care Evaluation of Mental Disorders) to make diagnoses of mood, anxiety, alcohol, somatoform, and eating disorders. Main Outcome Measures.-The six scales of the Short-Form General Health Survey and self-reported disability days, adjusting for demographic variables as well as psychiatric and medical comorbidity. Results.-Mood, anxiety, somatoform, and eating disorders were associated with substantial impairment in HRQL, Impairment was also present in patients who only had subthreshold mental disorder diagnoses, such as minor depression and anxiety disorder not otherwise specified. Mental disorders, particularly mood disorders, accounted for considerably more of the impairment on all domains of HRQL than did common medical disorders. Finally, we found marked differences in the pattern of impairment among different groups of mental disorders just as others have reported unique patterns associated with different medical disorders. Whereas mood disorders had a pervasive effect on all domains of HRQL, anxiety, somatoform, and eating disorders affected only selected domains. Conclusions.-Mental disorders commonly seen in primary care are not only associated with more impairment in HRQL than common medical disorders, but also have distinct patterns of impairment. Primary care directed at improving HRQL needs to focus on the recognition and treatment of common mental disorders. Outcomes studies of mental disorders in both primary care and psychiatric settings should include multidimensional measures of HRQL.	COLUMBIA UNIV,DEPT PSYCHIAT,NEW YORK,NY; UNIFORMED SERV UNIV HLTH SCI,DEPT MED,BETHESDA,MD; UNIV WISCONSIN,SCH MED,DEPT MED,MADISON,WI; ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY; UNIV SO ALABAMA,COLL MED,DEPT FAMILY PRACTICE COMMUNITY MED,MOBILE,AL; MERCY CATHOLIC MED CTR,DEPT MED,DARBY,PA	Columbia University; Uniformed Services University of the Health Sciences - USA; University of Wisconsin System; University of Wisconsin Madison; Yeshiva University; Albert Einstein College of Medicine; University of South Alabama	SPITZER, RL (corresponding author), NEW YORK STATE PSYCHIAT INST & HOSP,DEPT BIOMETR RES,UNIT 74,722 W 168 ST,NEW YORK,NY 10032, USA.		anand, amit/A-7222-2009	Kroenke, Kurt/0000-0002-0114-4669				BERGNER M, 1989, MED CARE, V27, pS148, DOI 10.1097/00005650-198903001-00012; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; CALKINS DR, 1991, ANN INTERN MED, V114, P451, DOI 10.7326/0003-4819-114-6-451; CONNELLY JE, 1989, MED CARE, V27, pS99, DOI 10.1097/00005650-198903001-00009; ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766; ESCOBAR JI, 1987, AM J PUBLIC HEALTH, V77, P837, DOI 10.2105/AJPH.77.7.837; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; JOHNSON J, 1992, JAMA-J AM MED ASSOC, V267, P1478, DOI 10.1001/jama.267.11.1478; JOHNSON JG, 1995, J CONSULT CLIN PSYCH, V63, P133, DOI 10.1037/0022-006X.63.1.133; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; KESSLER LG, 1983, J FAM PRACTICE, V16, P319; KLERMAN GL, 1992, J CLIN PSYCHIAT, V53, P14; MARKOWITZ JS, 1989, ARCH GEN PSYCHIAT, V46, P984; MASSION AO, 1993, AM J PSYCHIAT, V150, P600; MCHORNEY CA, 1992, MED CARE, V30, pMS252; MINTZ J, 1992, ARCH GEN PSYCHIAT, V49, P761; MOSTELLER F, 1989, MED CARE, V27, pS282, DOI 10.1097/00005650-198903001-00022; MULROW CD, 1995, ANN INTERN MED, V122, P913, DOI 10.7326/0003-4819-122-12-199506150-00004; NELSON E C, 1989, Medical Care (Philadelphia), V27, pS77, DOI 10.1097/00005650-198903001-00007; OLDEHINKEL T, 1994, JAMA-J AM MED ASSOC, V272, P1741; PARKERSON GR, 1992, J CLIN EPIDEMIOL, V45, P1303, DOI 10.1016/0895-4356(92)90171-I; PARKERSON GR, 1995, MED CARE, V33, P53, DOI 10.1097/00005650-199501000-00005; Patrick D. L., 1993, HLTH STATUS HLTH POL; ROSENBLATT RA, 1983, NEW ENGL J MED, V309, P892, DOI 10.1056/NEJM198310133091505; SCHOR EL, 1995, ARCH INTERN MED, V155, P309, DOI 10.1001/archinte.155.3.309; SPITZER RL, 1993, INT J EAT DISORDER, V13, P137, DOI 10.1002/1098-108X(199303)13:2&lt;161::AID-EAT2260130204&gt;3.0.CO;2-R; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; STEWART AL, 1993, MEASURING FUNCTION W; USTUN TB, 1995, MENTAL ILLNESS GENER; VONKORFF M, 1992, ARCH GEN PSYCHIAT, V49, P91; WARE JE, 1994, INT J MENT HEALTH, V23, P49, DOI 10.1080/00207411.1994.11449283; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WARE JE, 1993, SF36 HTLH SURVEY MAN; WELLS KB, 1988, AM J PSYCHIAT, V145, P712; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WILLIAMS JW, 1995, J GEN INTERN MED, V10, P7, DOI 10.1007/BF02599568; WILSON IB, 1995, JAMA-J AM MED ASSOC, V273, P59, DOI 10.1001/jama.273.1.59; WOODWELL DA, 1992, ADV DATA VITAL HLTH, V209; 1994, DIAGNOSTIC STATISTIC; [No title captured]; 1993, DEPRESSION PRIMARY C, V2	44	657	671	0	36	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	1995	274	19					1511	1517		10.1001/jama.274.19.1511	http://dx.doi.org/10.1001/jama.274.19.1511			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TD571	7474219				2022-12-28	WOS:A1995TD57100027
J	JACOBSEN, SJ; KATUSIC, SK; BERGSTRALH, EJ; OESTERLING, JE; OHRT, D; KLEE, GG; CHUTE, CG; LIEBER, MM				JACOBSEN, SJ; KATUSIC, SK; BERGSTRALH, EJ; OESTERLING, JE; OHRT, D; KLEE, GG; CHUTE, CG; LIEBER, MM			INCIDENCE OF PROSTATE-CANCER DIAGNOSIS IN THE ERAS BEFORE AND AFTER SERUM PROSTATE-SPECIFIC ANTIGEN TESTING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To estimate the incidence of prostate cancer in Olmsted County, Minnesota, from 1983 through 1999 to describe the secular changes that have occurred since the introduction of serum prostate-specific antigen (PSA) testing to the community medical practice in 1987. Design.-Population-based, descriptive epidemiological study with ecologic and individual level comparisons over time. Study Setting.-Olmsted County, Minnesota, where the Rochester Epidemiology Project provides passive surveillance of the population for health outcomes. Subjects.-All 511 biopsy-proven incident cases of adenocarcinoma of the prostate diagnosed from 1983 through 1992. The community inpatient and outpatient medical records of all incident cases were reviewed to evaluate the presenting characteristics of men at the time of diagnosis. Results.-The age-adjusted incidence of biopsy-proven prostate cancer increased from 64 per 100 000 person-years in 1983 to 215 per 100 000 person-years in 1992. The increase occurred primarily between 1987 and 1988 and was predominately for organ-confined tumors. The age-specific incidence increased dramatically in this same period among men aged 50 years and older. Among men aged 70 years and older, however, prostate carcinoma incidence rates declined after 1990 following the initial increase. This decline among older men contrasted with community-based estimates of PSA utilization rates, which demonstrated consistent increases since 1987 to nearly 50% of the older population in 1992. Conclusion.-These results support the premise that the recent increase in prostate cancer is due in part to the increased utilization of serum PSA testing. Further, the increased incidence appears to be a transient phenomenon due to the depletion of previously undiagnosed cases from the prevalence pool. Finally, these data suggest that, in terms of stage at diagnosis, early detection efforts may be effective in identifying more early stage (smaller) cancers.	MAYO CLIN & MAYO FDN, BIOSTAT SECT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT HLTH SCI RES, DIV METAB & HEMATOL BIOCHEM, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT UROL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT LAB MED & PATHOL, ROCHESTER, MN 55905 USA; BLUE CROSS BLUE SHIELD MINNESOTA, ST PAUL, MN USA; MAYO CLIN & MAYO FDN, HLTH SERV EVALUAT SECT, ROCHESTER, MN USA; MAYO CLIN & MAYO FDN, MED INFORMAT RESOURCES SECT, ROCHESTER, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	JACOBSEN, SJ (corresponding author), MAYO CLIN & MAYO FDN, CLIN EPIDEMIOL SECT, 200 1ST ST SW, ROCHESTER, MN 55905 USA.			Jacobsen, Steven/0000-0002-8174-8533	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR30582] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BENDER AP, 1993, MINN CANCER SURVEILL, V6, P1; BENOIT RM, 1994, UROLOGY, V44, P795, DOI 10.1016/S0090-4295(94)80160-6; BERGSTRALH EJ, 1992, MAYO CLIN TECHNICAL, V49; BETSILL WL, 1975, CANCER, V36, P305, DOI 10.1002/1097-0142(197508)36:2<305::AID-CNCR2820360202>3.0.CO;2-D; BOSTWICK DG, 1994, SEMIN SURG ONCOL, V10, P60, DOI 10.1002/ssu.2980100110; BRAWLEY OW, 1994, UROLOGY, V43, P594, DOI 10.1016/0090-4295(94)90169-4; Breslow N. E., 1987, STATISTICAL METHODS, VII; Burks D A, 1992, Henry Ford Hosp Med J, V40, P89; CATALONA WJ, 1993, UROLOGY, V42, P113, DOI 10.1016/0090-4295(93)90632-K; CHISHOLM GD, 1993, BRIT J UROL, V71, P375, DOI 10.1111/j.1464-410X.1993.tb15975.x; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; CHODAK GW, 1993, UROLOGY, V42, P116, DOI 10.1016/0090-4295(93)90633-L; CORDER EH, 1994, CANCER CAUSE CONTROL, V5, P207, DOI 10.1007/BF01830238; DEMERS RY, 1994, ARCH INTERN MED, V154, P1211, DOI 10.1001/archinte.154.11.1211; DENIS LJ, 1992, PROSTATE, P63; FOWLER FJ, 1993, UROLOGY, V42, P622, DOI 10.1016/0090-4295(93)90524-E; GERBER GS, 1991, J NATL CANCER I, V83, P329, DOI 10.1093/jnci/83.5.329; GILLILAND F, 1994, CANCER EPIDEM BIOMAR, V3, P105; GILLILAND FD, 1994, CANCER, V73, P2192, DOI 10.1002/1097-0142(19940415)73:8<2192::AID-CNCR2820730826>3.0.CO;2-Y; GOHAGAN JK, 1994, AM J PREV MED, V10, P245, DOI 10.1016/S0749-3797(18)30600-7; GREENWALD P, 1995, CA-CANCER J CLIN, V45, P31, DOI 10.3322/canjclin.45.1.31; JONLER M, 1994, UROLOGY, V44, P876, DOI 10.1016/S0090-4295(94)80174-6; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; Kurland LT, 1970, COMMUNITY EPIDEMIOLO, P47; LANGE PH, 1995, JAMA-J AM MED ASSOC, V273, P336, DOI 10.1001/jama.273.4.336; LITWIN MS, 1995, JAMA-J AM MED ASSOC, V273, P129, DOI 10.1001/jama.273.2.129; LUYAO GL, 1994, LANCET, V343, P251, DOI 10.1016/S0140-6736(94)91109-6; LYON JL, 1977, AM J EPIDEMIOL, V105, P439, DOI 10.1093/oxfordjournals.aje.a112402; METTLIN C, 1994, J UROLOGY, V152, P1737, DOI 10.1016/S0022-5347(17)32373-X; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; MILLER BA, 1993, NIH932789 PUBL; MORGENSTERN H, 1982, AM J PUBLIC HEALTH, V72, P1336, DOI 10.2105/AJPH.72.12.1336; MORRISON AS, 1982, INT J EPIDEMIOL, V11, P261, DOI 10.1093/ije/11.3.261; MORTON RA, 1994, UROLOGY, V44, P637, DOI 10.1016/S0090-4295(94)80196-7; POTOSKY AL, 1995, JAMA-J AM MED ASSOC, V273, P548, DOI 10.1001/jama.273.7.548; SOX HC, 1994, AM J PREV MED, V10, P187, DOI 10.1016/S0749-3797(18)30589-0; TAYLOR JD, 1994, CANCER-AM CANCER SOC, V73, P1704, DOI 10.1002/1097-0142(19940315)73:6<1704::AID-CNCR2820730625>3.0.CO;2-Y; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; 1992, 1992 AM UR ASS POL S, V4, P20	39	185	193	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	1995	274	18					1445	1449		10.1001/jama.274.18.1445	http://dx.doi.org/10.1001/jama.274.18.1445			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC477	7474190				2022-12-28	WOS:A1995TC47700026
J	KOGAN, MD; ALEXANDER, GR; TEITELBAUM, MA; JACK, BW; KOTELCHUCK, M; PAPPAS, G				KOGAN, MD; ALEXANDER, GR; TEITELBAUM, MA; JACK, BW; KOTELCHUCK, M; PAPPAS, G			THE EFFECT OF GAPS IN HEALTH-INSURANCE ON CONTINUITY OF A REGULAR SOURCE OF CARE AMONG PRESCHOOL-AGED CHILDREN IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-CARE; AMERICAN CHILDREN; ACCESS; TERMINATION; SERVICES; POOR	Objective.-To estimate the prevalence and length of gaps in health insurance coverage and their effect on having a regular source of care in a national sample of preschool-aged children. Design.-Follow-up survey of a nationally representative sample of 3-year-old children in the US population by phone or personal interview. Participants.-A total of 8129 children whose mothers were interviewed for the 1991 Longitudinal Follow-up to the National Maternal and Infant Health Survey. Main Outcome Measures.-Report of any gap in health insurance for the children, the length of the gap, and the number of different sites where the children were taken for medical care as a measure of continuity of a regular source of care. Results.-About one quarter of US children were without health insurance for at least 1 month during their first 3 years of life, Over half of these children had a health insurance gap of more than 6 months. Less than half of US children had only one site of care during their first 3 years. Children with health insurance gaps of longer than 6 months were at increased risk of having more than one care site (odds ratio = 1.52; 95% confidence interval, 1.19 to 1.96). This risk further increased when an emergency treatment was discounted as a multiple site of care. Conclusions.-Having a gap in health insurance coverage is an important determinant for not having a regular source of care for preschool-aged children. This finding is of concern, given the sizable percentage of children in the United States who lacked continuous health care coverage during a critical period of development.	CHILDRENS DEF FUND,WASHINGTON,DC; BROWN UNIV,SCH MED,DEPT FAMILY MED,PROVIDENCE,RI 02912; UNIV N CAROLINA,DEPT MATERNAL & CHILD HLTH,CHAPEL HILL,NC; UNIV ALABAMA,DEPT MATERNAL & CHILD HLTH,BIRMINGHAM,AL	Brown University; University of North Carolina; University of North Carolina Chapel Hill; University of Alabama System; University of Alabama Birmingham	KOGAN, MD (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,6525 BELCREST RD,ROOM 840,HYATTSVILLE,MD 20782, USA.			Jack, Brian/0000-0002-6497-2437				ADAY LA, 1984, AM J PUBLIC HEALTH, V74, P1331, DOI 10.2105/AJPH.74.12.1331; ALPERT JJ, 1976, PEDIATRICS, V57, P917; [Anonymous], 1994, CURRENT POPULATION S; ATKINSON WL, 1992, ANNU REV MED, V43, P451, DOI 10.1146/annurev.med.43.1.451; BENNIFIELD RL, 1994, DYNAMICS EC WELL BEI, P70; BRAVEMAN P, 1989, NEW ENGL J MED, V321, P508, DOI 10.1056/NEJM198908243210805; BUTLER JA, 1985, PEDIATRICS, V76, P495; CORNELIUS LJ, 1993, J NATL MED ASSOC, V85, P281; Cunningham P J, 1994, Future Child, V4, P24, DOI 10.2307/1602433; CUNNINGHAM PJ, 1990, HLTH AFF MILLWOOD, V90, P76; DAVIS K, 1981, ANNU REV PUBL HEALTH, V2, P159, DOI 10.1146/annurev.pu.02.050181.001111; HAYWARD RA, 1988, NEW ENGL J MED, V318, P1507, DOI 10.1056/NEJM198806093182305; HUBBELL FA, 1989, AM J MED, V87, P127; Johansen A. S, 1994, ANAL CONCEPT PRIMARY; KOGAN MD, 1994, JAMA-J AM MED ASSOC, V272, P1025, DOI 10.1001/jama.272.13.1025; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; MARQUIS MS, 1992, JAMA-J AM MED ASSOC, V268, P3473; MAURER HM, 1993, AM J DIS CHILD, V147, P529, DOI 10.1001/archpedi.1993.02160290035015; MCDANIEL DB, 1975, PEDIATRICS, V56, P504; MONHEIT AC, 1984, FUTURE CHILD, V74, P1331; MOSCOVICE I, 1987, MED CARE, V25, P413, DOI 10.1097/00005650-198705000-00005; NEWACHECK PW, 1994, MATERNAL CHILD HLTH; ORR ST, 1991, MED CARE, V29, P283, DOI 10.1097/00005650-199103000-00009; PETER G, 1994, 1994 REDBOOK; RASK KJ, 1994, JAMA-J AM MED ASSOC, V271, P1931, DOI 10.1001/jama.271.24.1931; REICHEL W, 1981, JAMA-J AM MED ASSOC, V246, P2065, DOI 10.1001/jama.246.18.2065; SANDERSON M, 1991, BIRTH-ISS PERINAT C, V18, P26, DOI 10.1111/j.1523-536X.1991.tb00050.x; SPILLMAN BC, 1992, INQUIRY-J HEALTH CAR, V29, P457; Starfield B., 1992, PRIMARY CARE CONCEPT; SWARTZ K, 1990, INQUIRY-J HEALTH CAR, V27, P281; SWARTZ K, 1993, INQUIRY, V80, P64; SZILAGYI PG, 1993, PEDIATRICS, V91, P1; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; 1993, 1991 LONGITUDINAL FO; 1993, SURVEY DATA ANAL VER; 1994, MMWR MORB MORTAL WKL, V43; 1991, JAMA-J AM MED ASSOC, V266, P1547	38	129	129	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	1995	274	18					1429	1435		10.1001/jama.274.18.1429	http://dx.doi.org/10.1001/jama.274.18.1429			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TC477	7474188				2022-12-28	WOS:A1995TC47700024
J	YOUNGER, SJ				YOUNGER, SJ			WHO DEFINES FUTILITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									CASE WESTERN RESERVE UNIV,UNIV HOSP CLEVELAND,SCH MED,CTR BIOMED ETHICS,DEPT MED,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland	YOUNGER, SJ (corresponding author), CASE WESTERN RESERVE UNIV,UNIV HOSP CLEVELAND,SCH MED,CTR BIOMED ETHICS,DEPT PSYCHIAT,CLEVELAND,OH 44106, USA.							ANGELL M, 1985, JAMA-J AM MED ASSOC, V254, P1203, DOI 10.1001/jama.254.9.1203; BLENDON RJ, 1984, NEW ENGL J MED, V311, P613, DOI 10.1056/NEJM198408303110938; BLENDON RJ, 1988, JAMA-J AM MED ASSOC, V259, P3587, DOI 10.1001/jama.259.24.3587; CALLAHAN D, 1988, HASTINGS CENT REP, V18, P14, DOI 10.2307/3562403; Callahan D., 1987, MED GOALS AGEING SOC; Childress JF., 1970, SOUNDINGS, V53, P339; EVANS RW, 1983, JAMA-J AM MED ASSOC, V249, P2208, DOI 10.1001/jama.249.16.2208; EVANS RW, 1983, JAMA-J AM MED ASSOC, V249, P2047; MCQUILLEN MP, 1988, NEW ENGL J MED, V318, P1756; MURPHY DJ, 1988, JAMA-J AM MED ASSOC, V260, P2098, DOI 10.1001/jama.260.14.2098; NOLAN K, 1987, HASTINGS CENT REP, V17, P9, DOI 10.2307/3562663; RESCHER N, 1969, ETHICS, V79, P173, DOI 10.1086/291723; TOMLINSON T, 1988, NEW ENGL J MED, V318, P43, DOI 10.1056/NEJM198801073180109	13	227	228	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1988	260	14					2094	2095		10.1001/jama.260.14.2094	http://dx.doi.org/10.1001/jama.260.14.2094			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q3421	3418875				2022-12-28	WOS:A1988Q342100025
J	FOX, KM; SHAPIRO, LM				FOX, KM; SHAPIRO, LM			HEART-DISEASE IN ASIANS IN BRITAIN	BRITISH MEDICAL JOURNAL			English	Editorial Material									PAPWORTH HOSP,CAMBRIDGE CB3 8RE,ENGLAND	Papworth Hospital	FOX, KM (corresponding author), NATL HEART HOSP,LONDON W1M 8BA,ENGLAND.							BALARAJAN R, 1984, BRIT MED J, V289, P1185, DOI 10.1136/bmj.289.6453.1185; BECKLES GLA, 1986, LANCET, V1, P1298; BEEVERS DG, 1981, POSTGRAD MED J, V57, P763, DOI 10.1136/pgmj.57.674.763; CRUICKSHANK JK, 1980, BRIT MED J, V281, P1108, DOI 10.1136/bmj.281.6248.1108; DANARAJ TJ, 1959, AM HEART J, V58, P516, DOI 10.1016/0002-8703(59)90085-7; JACOBSON MS, 1987, LANCET, V2, P656, DOI 10.1016/S0140-6736(87)92443-3; LAWRENCE RE, 1985, BRIT MED J, V290, P1472, DOI 10.1136/bmj.290.6480.1472; LOWER PJ, 1982, BR HEART J; MARMOT MG, 1981, POSTGRAD MED J, V57, P760, DOI 10.1136/pgmj.57.674.760; MARMOT MG, 1984, LANCET, V1, P1455, DOI 10.1016/S0140-6736(84)91943-3; MCKEIGUE PM, 1985, LANCET, V2, P1086; PADHANI A, 1986, LANCET, V1, P213; SHAPER AG, 1959, LANCET, V2, P534; 1986, CORONARY HEART DISEA	14	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1988	297	6644					311	312		10.1136/bmj.297.6644.311	http://dx.doi.org/10.1136/bmj.297.6644.311			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P4527	3416160	Bronze, Green Published			2022-12-28	WOS:A1988P452700005
J	FINKELHOR, D; WOLAK, J				FINKELHOR, D; WOLAK, J			NONSEXUAL ASSAULTS TO THE GENITALS IN THE YOUTH POPULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FACE-TO-FACE; CHILD SEXUAL ABUSE; TELEPHONE; RELIABILITY; TRAUMA; BOYS	Objective.-To assess the frequency with which youth suffer nonsexual assaults to the genitals and their context and consequences. Design.-Telephone survey with follow-up interview 1 year later. Setting.-General population of the United States living in households with telephones. Participants.-Random sample of 1042 boys and 958 girls aged 10 through 16 years. Results.-A nonsexual assault to the genitals was experienced by 9.2% of the boys and 1.0% of the girls in the year prior to the initial interview and 9.1% of the boys and 2.2% of the girls in the year prior to the follow-up interview. Among the boys, about a quarter of the assaults involved some injury, but only one in 50 needed medical attention. The most common assailants were same-aged peers. The assaults occurred in a variety of contexts including gang attacks, peer fighting, bullying, and some situations in which girls retaliated against the genitals of harassing boys. Boy victims of nonsexual genital assault had significantly higher levels of posttraumatic and depression symptomatology than boys without such assaults. Conclusions.-Nonsexual genital violence needs additional clinical and research attention. Youth should be educated about its possible consequences. Clinicians should ask about nonsexual genital violence when taking a history, particularly with youth who have experienced other kinds of assaults.			FINKELHOR, D (corresponding author), UNIV NEW HAMPSHIRE,FAMILY RES LAB,126 HORTON SOCIAL SCI CTR,DURHAM,NH 03824, USA.							BAJOS N, 1992, AIDS, V6, P315; BAYS J, 1990, AM J DIS CHILD, V144, P1319, DOI 10.1001/archpedi.1990.02150360043017; BAYS J, 1993, CHILD ABUSE NEGLECT, V17, P91, DOI 10.1016/0145-2134(93)90011-S; BERMACK E, 1989, PSYCHOL REP, V65, P259, DOI 10.2466/pr0.1989.65.1.259; BONEYMCCOY S, 1995, J CONSULT CLIN PSYCH, V63, P726, DOI 10.1037/0022-006X.63.5.726; Czaja R, 1987, Int Q Community Health Educ, V8, P23, DOI 10.2190/XT6W-31CX-TD87-E643; EVANS C, 1993, J CONTEMP ETHNOGR, V22, P139, DOI 10.1177/089124193022002001; FINE GA, 1987, LITTLE LEAGUE BASEBA; FINKEL MA, 1989, PEDIATRICS, V84, P317; FINKELHOR D, 1994, PEDIATRICS, V94, P413; Finkelhor D, 1994, Future Child, V4, P31, DOI 10.2307/1602522; FINKELHOR D, 1995, CHILD ABUSE NEGL, V19, P137; FOA EB, 1993, J TRAUMA STRESS, V6, P459, DOI 10.1007/BF00974317; GROTH N, 1979, MEN RAPE; HARLEY J, 1995, JAN SAN DIEG C RESP; HAUSMAN AJ, 1992, J ADOLESCENT HEALTH, V13, P668, DOI 10.1016/1054-139X(92)90061-F; HERMANGIDDENS ME, 1987, PEDIATRICS, V80, P203; HERMANGIDDENS ME, 1989, JAMA-J AM MED ASSOC, V261, P577; HOBBS CJ, 1989, CHILD ABUSE NEGLECT, V13, P195, DOI 10.1016/0145-2134(89)90006-9; JOHNSON CF, 1985, CHILD ABUSE NEGLECT, V9, P207, DOI 10.1016/0145-2134(85)90013-4; KERNS DL, 1992, AM J DIS CHILD, V146, P494; MARIN G, 1989, HISPANIC J BEHAV SCI, V11, P330, DOI 10.1177/07399863890114003; MCCANN J, 1992, PEDIATRICS, V89, P307; MERRITT KA, 1994, PEDIATRICS, V94, P17; MORRISON L J, 1988, Journal of Emergency Medicine, V6, P521, DOI 10.1016/0736-4679(88)90412-X; MURAM D, 1989, CHILD ABUSE NEGLECT, V13, P211, DOI 10.1016/0145-2134(89)90007-0; POTTS MK, 1990, J PSYCHIATR RES, V24, P335, DOI 10.1016/0022-3956(90)90005-B; RIMZA ME, 1982, PEDIATRICS, V69, P8; SHAFFER D, 1992, NATIONAL I MENTAL HL; SLOSBERG EJ, 1978, AM J DIS CHILD, V132, P719, DOI 10.1001/archpedi.1978.02120320079019; SPENCER MJ, 1986, PEDIATRICS, V78, P133; STEWART WF, 1989, PSYCHOSOM MED, V51, P559, DOI 10.1097/00006842-198909000-00007; WEEKS MF, 1983, AM J PUBLIC HEALTH, V73, P1389, DOI 10.2105/AJPH.73.12.1389; WELLS KB, 1988, J PSYCHIAT RES, V22, P207, DOI 10.1016/0022-3956(88)90006-4; 1994, CRIMINAL VICTIMIZATI	35	17	17	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	1995	274	21					1692	1697		10.1001/jama.274.21.1692	http://dx.doi.org/10.1001/jama.274.21.1692			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TH151	7474274				2022-12-28	WOS:A1995TH15100026
J	HEROLD, AH				HEROLD, AH			ACADEMIC PHYSICIANS PARTICIPATION IN ORGANIZED MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								To study the relationship of state medical societies to their medical schools, two cross-sectional surveys were conducted. The first was a survey of the medical society executive directors of the 46 states and US sovereign territories that have medical schools within their borders. Directors were asked to compare academic and community physician participation (membership and member involvement) in the medical society and describe the characteristics of the medical society's medical school unit (eg, how formalized it is and its design, composition, and level of interaction). The unit's characteristics were compared with the amount of academic physician participation. Data about physician membership in state medical societies and the American Medical Association (AMA) were obtained from the AMA Physician Masterfile. Significantly fewer academic physicians than community physicians were members of the state medical society or the AMA (38.1% vs 52.0%, P<.001, and 32.8% vs 41.7%, P<.001, respectively). Academic physician members were less likely than community physician members to be involved in medical society activities. Twenty-eight (60.9%) of 46 medical societies had no formalized structure for the unit that represents academic physicians at the medical society. The unit's characteristics had no significant relationship to academic physician membership or member involvement. This first survey and the AMA data suggest that academic physicians were significantly less likely to participate in medical society activities or join the AMA than community physicians, and the way in which medical schools and medical societies interface did not appear to influence participation. The second survey was carried out at the four academ ic medical centers in Florida. All academic physicians were surveyed about their attitudes toward organized medicine. Academic physicians reported that the annual dues were not reasonable relative to the benefit derived, but other data in this study suggested that reducing dues would not necessarily increase membership. Academic physicians also reported that their administration did not reward their participation in organized medicine and thought participation was less relevant to academic physicians than community physicians, but admitted a knowledge deficit regarding organized medicine. These findings suggest that reducing dues may not be sufficient to increase academic physician participation in organized medicine, but that changing the reward system within the medical school and increasing academic physicians' awareness of organized medicine's value to them may be ways to influence participation.			HEROLD, AH (corresponding author), UNIV S FLORIDA,COLL MED,DEPT FAMILY MED,12901 BRUCE B DOWNS BLVD,MDC BOX 13,TAMPA,FL 33612, USA.							ADAY L, 1989, DESIGNING CONDUCTING; EVERDING TC, 1992, 1992 FACT BOOK; FRASEBLUNT M, 1995, AAMC REPORTER    AUG, V4, P3; Lind D, 1985, Iowa Med, V75, P156; Litwin M S, 1990, J Med Assoc Ga, V79, P167; NUMERALLY JC, 1978, PSYCHOMETRIC THEORY; SAVELA PD, 1993, HLTH ED EVALUATION M; TODD JS, 1995, LEGISLATIVE CALL ACT; UVA J, 1989, OHIO MED, V85, P894; 1995, SECTION MED SCH REPO; 1993, ACADEMIC PHYSICIAN S; 1990, CENSUS POPULATION 19; 1995, SEP SECT MED SCH AM, P5; 1991, HRSAPDM914 US DHHS P; 1992, JUN ANN M AM MED ASS; 1992, JAN ED SCI TRUST PEN; 1994, DEC AM MED ASS INT M; 1994, MAINTAINING ED QUALI; 1991, 1991 SURVEY GROUP PR; 1992, DEC AM MED ASS INT M	20	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	1995	274	21					1727	1732						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH151	7474281				2022-12-28	WOS:A1995TH15100034
J	LIBERMAN, UA; WEISS, SR; BROLL, J; MINNE, HW; QUAN, H; BELL, NH; RODRIGUEZPORTALES, J; DOWNS, RW; DEQUEKER, J; FAVUS, M; SEEMAN, E; RECKER, RR; CAPIZZI, T; SANTORA, AC; LOMBARDI, A; SHAH, RV; HIRSCH, LJ; KARPF, DB				LIBERMAN, UA; WEISS, SR; BROLL, J; MINNE, HW; QUAN, H; BELL, NH; RODRIGUEZPORTALES, J; DOWNS, RW; DEQUEKER, J; FAVUS, M; SEEMAN, E; RECKER, RR; CAPIZZI, T; SANTORA, AC; LOMBARDI, A; SHAH, RV; HIRSCH, LJ; KARPF, DB			EFFECT OF ORAL ALENDRONATE ON BONE-MINERAL DENSITY AND THE INCIDENCE OF FRACTURES IN POSTMENOPAUSAL OSTEOPOROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FLUORIDE TREATMENT; WOMEN; MASS; ETIDRONATE; BISPHOSPHONATES; PREVENTION; THERAPY; CALCIUM; RAT	Background. Postmenopausal osteoporosis is a serious health problem, and addit Methods. We studied the effects of oral alendronate, an aminobisphosphonate, on bone mineral density and the incidence of fractures and height loss in 994 women with postmenopausal osteoporosis. The women were treated with placebo or alendronate (5 or 10 mg daily for three years, or 20 mg for two years followed by 5 mg for one year); all the women received 500 mg of calcium daily. Bone mineral density was measured by dual-energy x-ray absorptiometry. The occurrence of new vertebral fractures and the progression of vertebral deformities were determined by an analysis of digitized radiographs, and loss of height was determined by sequential height measurements. Results. The women receiving alendronate had significant, progressive increases in bone mineral density at all skeletal sites, whereas those receiving placebo had decreases in bone mineral density. At three years, the mean (+/-SE) differences in bone mineral density between the women receiving 10 mg of alendronate daily and those receiving placebo were 8.8+/-0.4 percent in the spine, 5.9+/-0.5 percent in the femoral neck, 7.8+/-0.6 percent in the trochanter, and 2.5+/-0.3 percent in the total body (P<0.001 for all comparisons). The 5-mg dose was less effective than the 10-mg dose, and the regimen of 20 mg followed by 5 mg was similar in efficacy to the 10-mg dose. Overall, treatment with alendronate was associated with a 48 percent reduction in the proportion of women with new vertebral fractures (3.2 percent, vs. 6.2 percent in the placebo group; P=0.03), a decreased progression of vertebral deformities (33 percent, vs. 41 percent in the placebo group; P=0.028), and a reduced loss of height (P=0.005) and was well tolerated. Conclusions. Daily treatment with alendronate progressively increases the bone mass in the spine, hip, and total body and reduces the incidence of vertebral fractures, the progression of vertebral deformities, and height loss in postmenopausal women with osteoporosis.	SAN DIEGO ENDOCRINE & MED CLIN, SAN DIEGO, CA USA; KAISER FRANZ JOSEF HOSP, DEPT MED, VIENNA, AUSTRIA; KLIN FURSTENHOF, BAD PYRMONT, GERMANY; MERCK & CO INC, RES LABS, RAHWAY, NJ USA; VET AFFAIRS MED CTR, DEPT RES SERV, CHARLESTON, SC 29403 USA; CATHOLIC UNIV CHILE, SCH MED, DEPT ENDOCRINOL, SANTIAGO, CHILE; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT MED, RICHMOND, VA 23298 USA; CATHOLIC UNIV LEUVEN, DEPT RHEUMATOL, B-3000 LOUVAIN, BELGIUM; UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA; AUSTIN HOSP, DEPT ENDOCRINOL, HEIDELBERG, VIC 3084, AUSTRALIA; CREIGHTON UNIV, CTR OSTEOPOROSIS RES, OMAHA, NE 68178 USA	Kaiser-Franz-Josef Hospital; Merck & Company; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pontificia Universidad Catolica de Chile; Virginia Commonwealth University; KU Leuven; University of Chicago; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Creighton University	LIBERMAN, UA (corresponding author), TEL AVIV UNIV, BEILINSON MED CTR, DEPT METAB DIS, IL-49100 PETAH TIQWA, ISRAEL.		Seeman, Ego/AAC-3656-2019	Seeman, Ego/0000-0002-9692-048X				ARLOT MC, 1995, J BONE MINER RES, V10, pS199; AXELROD DW, 1994, J BONE MINER RES  S1, V9, pS136; BALENA R, 1993, J CLIN INVEST, V92, P2577, DOI 10.1172/JCI116872; BURGER H, 1994, BRIT MED J, V309, P991, DOI 10.1136/bmj.309.6960.991; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; CHESTNUT CH, 1995, AM J MED, V99, P144, DOI 10.1016/S0002-9343(99)80134-X; FLEISCH H, 1991, DRUGS, V42, P919, DOI 10.2165/00003495-199142060-00003; GARNERO P, 1994, J CLIN ENDOCR METAB, V79, P1693, DOI 10.1210/jc.79.6.1693; GUY JA, 1993, CALCIFIED TISSUE INT, V53, P283, DOI 10.1007/BF01320915; Kleerekoper M, 1991, Osteoporos Int, V1, P155, DOI 10.1007/BF01625446; LEICHTER I, 1982, CLIN ORTHOP RELAT R, P272; LUFKIN EG, 1994, OSTEOPOROSIS INT, V4, P320, DOI 10.1007/BF01622190; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MAMELLE N, 1988, LANCET, V2, P361, DOI 10.1016/S0140-6736(88)92834-6; MARCUS R, 1993, AM J MED, V95, P555, DOI 10.1016/0002-9343(93)90349-T; MELTON LJ, 1993, J BONE MINER RES, V8, P1227; MELTON LJ, 1993, OSTEOPOROSIS INT, V3, P113, DOI 10.1007/BF01623271; MINNE HW, 1988, BONE MINER, V3, P335; OVERGAARD K, 1992, BRIT MED J, V305, P556, DOI 10.1136/bmj.305.6853.556; PAK CYC, 1994, ANN INTERN MED, V120, P625, DOI 10.7326/0003-4819-120-8-199404150-00001; PECK WA, 1993, AM J MED, V94, P646; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; RIGGS BL, 1992, NEW ENGL J MED, V327, P620; ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003-4819-114-11-919; SCHENK R, 1986, CALCIFIED TISSUE INT, V38, P342, DOI 10.1007/BF02555748; SCHILLER JH, 1987, ARCH INTERN MED, V147, P963, DOI 10.1001/archinte.147.5.963; SHINODA H, 1983, CALCIFIED TISSUE INT, V35, P87, DOI 10.1007/BF02405012; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; TILYARD MW, 1992, NEW ENGL J MED, V326, P357, DOI 10.1056/NEJM199202063260601; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; WINDELER J, 1995, BRIT MED J, V310, P454, DOI 10.1136/bmj.310.6977.454	32	1877	1925	1	119	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 30	1995	333	22					1437	1443		10.1056/NEJM199511303332201	http://dx.doi.org/10.1056/NEJM199511303332201			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG445	7477143	Green Published			2022-12-28	WOS:A1995TG44500001
J	BRONNER, LL; KANTER, DS; MANSON, JE				BRONNER, LL; KANTER, DS; MANSON, JE			MEDICAL PROGRESS - PRIMARY PREVENTION OF STROKE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CORONARY HEART-DISEASE; MODERATE ALCOHOL-CONSUMPTION; CEREBRAL BLOOD-FLOW; CARDIOVASCULAR-DISEASE; ORAL-CONTRACEPTIVES; CIGARETTE-SMOKING; RISK-FACTORS; MYOCARDIAL-INFARCTION; DENSITY LIPOPROTEIN; PLATELET REACTIVITY		BRIGHAM & WOMENS HOSP, DIV PREVENT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, NEUROL NEUROSURG INTENS CARE UNIT, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DIV NEUROL, BOSTON, MA 02115 USA; HARVARD UNIV, COMMUNITY HLTH PLAN, PEABODY, MA 02138 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University				Kanter, Daniel/0000-0003-4929-4890	NHLBI NIH HHS [HL-34595, HL-34594] Funding Source: Medline; NIDDK NIH HHS [DK-36798] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595, R01HL034594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036798] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBOTT RD, 1994, AM J EPIDEMIOL, V139, P881, DOI 10.1093/oxfordjournals.aje.a117094; ABBOTT RD, 1994, STROKE, V25, P2370, DOI 10.1161/01.STR.25.12.2370; Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Amery A, 1991, Aging (Milano), V3, P287; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; [Anonymous], 1989, DIABETES CARE, V12, P573; ATKINS D, 1993, ANN INTERN MED, V119, P136, DOI 10.7326/0003-4819-119-2-199307150-00008; BARNETT HJM, 1995, NEW ENGL J MED, V332, P238, DOI 10.1056/NEJM199501263320408; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BENFANTE R, 1994, STROKE, V25, P814, DOI 10.1161/01.STR.25.4.814; Bierman E.L, 1981, TXB ENDOCRINOLOGY, P907; BJORNTORP P, 1992, OBESITY, P708; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; BURCHFIEL CM, 1994, STROKE, V25, P951, DOI 10.1161/01.STR.25.5.951; CAMARGO CA, 1985, JAMA-J AM MED ASSOC, V253, P2854; CAMARGO CA, 1989, STROKE, V20, P1611, DOI 10.1161/01.STR.20.12.1611; CARLSON LA, 1965, HANDB PHYSIOL, P625; CHAKRABARTI R, 1976, DIABETOLOGIA, V12, P383; CHANG WC, 1980, BIOCHIM BIOPHYS ACTA, V620, P472; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOPER R, 1990, STROKE, V21, P1274, DOI 10.1161/01.STR.21.9.1274; COTTON P, 1992, JAMA-J AM MED ASSOC, V267, P469; CRIQUI MH, 1980, CIRCULATION, V62, P70; CURB JD, 1991, AM J CLIN NUTR S, V153, pS1212; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DALEN JE, 1981, AM HEART J, V101, P626, DOI 10.1016/0002-8703(81)90231-3; DUNBABIN DW, 1990, STROKE, V21, P36; DWYER JT, 1992, OBESITY, P662; FIEBACH NH, 1989, AM J EPIDEMIOL, V130, P646; FINUCANE FF, 1993, ARCH INTERN MED, V153, P73, DOI 10.1001/archinte.153.1.73; FISCHER GM, 1981, ATHEROSCLEROSIS, V39, P463, DOI 10.1016/0021-9150(81)90004-6; GARRAWAY WM, 1983, MAYO CLIN PROC, V58, P520; GAZIANO JM, 1990, CIRCULATION, V82, P201; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; GILLMAN MW, 1995, JAMA-J AM MED ASSOC, V273, P1113, DOI 10.1001/jama.273.14.1113; GILLUM RF, 1988, STROKE, V19, P1; GORDON T, 1981, ARCH INTERN MED, V141, P1128, DOI 10.1001/archinte.141.9.1128; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; HANNAFORD PC, 1994, STROKE, V25, P935, DOI 10.1161/01.STR.25.5.935; Health. & N.R.C.U.C.o.D.a., 1989, DIET HLTH IMPLICATIO; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HERMAN B, 1982, STROKE, V13, P334, DOI 10.1161/01.STR.13.3.334; HEYDEN S, 1971, ARCH INTERN MED, V128, P956, DOI 10.1001/archinte.128.6.956; Higgins M, 1988, Acta Med Scand Suppl, V723, P23; HILLBOM M, 1985, STROKE, V16, P19, DOI 10.1161/01.STR.16.1.19; Hirai A, 1987, POLYUNSATURATED FATT, P9; HOLZBACH RL, 1990, J OCCUP ENVIRON MED, V32, P973; HORTON ES, 1981, INT J OBESITY, V5, P165; INMAN WHW, 1970, BMJ-BRIT MED J, V2, P203, DOI 10.1136/bmj.2.5703.203; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; JAKUBOWSKI JA, 1988, ARTERIOSCLEROSIS, V8, P436, DOI 10.1161/01.ATV.8.4.436; KATERNDAHL DA, 1992, J FAM PRACTICE, V35, P147; KAWACHI I, 1993, JAMA-J AM MED ASSOC, V269, P232, DOI 10.1001/jama.269.2.232; KELI SO, 1994, STROKE, V25, P328, DOI 10.1161/01.STR.25.2.328; KIELY DK, 1994, AM J EPIDEMIOL, V140, P608, DOI 10.1093/oxfordjournals.aje.a117298; KIELY DK, 1995, AM J EPIDEMIOL, V141, P178; KOK FJ, 1987, AM J CLIN NUTR, V45, P462, DOI 10.1093/ajcn/45.2.462; KRISETHERTON PM, 1988, J AM DIET ASSOC, V88, P1373; KUBOTA K, 1983, STROKE, V14, P720, DOI 10.1161/01.STR.14.5.720; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LAPIDUS L, 1985, ACTA MED SCAND, V217, P481; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LAPIDUS L, 1986, AM J CLIN NUTR, V44, P444, DOI 10.1093/ajcn/44.4.444; LEAF A, 1988, NEW ENGL J MED, V318, P549, DOI 10.1056/NEJM198803033180905; LINDSTED K, 1991, INT J OBESITY, V15, P397; LOBO RA, 1990, ANN NY ACAD SCI, V592, P286; LONGSTRETH W T JR, 1984, Stroke, V15, P747; MACMAHON S, 1987, HYPERTENSION, V9, P111, DOI 10.1161/01.HYP.9.2.111; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MACMAHON SW, 1986, PROG CARDIOVASC DIS, V29, P99, DOI 10.1016/0033-0620(86)90038-1; MANSON JE, 1991, JAMA-J AM MED ASSOC, V266, P521, DOI 10.1001/jama.266.4.521; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; MANSON JE, 1995, CIRCULATION, V91, P927; MANSOORI GA, 1993, FLUID PHASE EQUILIBR, V87, P1, DOI 10.1016/0378-3812(93)85015-E; MARCUS AJ, 1977, J CLIN INVEST, V59, P149, DOI 10.1172/JCI108613; MATHEW RJ, 1986, STROKE, V17, P1156, DOI 10.1161/01.STR.17.6.1156; MCGEE D, 1985, INT J EPIDEMIOL, V14, P97, DOI 10.1093/ije/14.1.97; MCGINNIS JM, 1995, JAMA-J AM MED ASSOC, V273, P1123, DOI 10.1001/jama.273.14.1123; MEADE TW, 1982, AM J OBSTET GYNECOL, V142, P776; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MOORE RD, 1986, MEDICINE, V65, P242, DOI 10.1097/00005792-198607000-00004; MORRIS MC, 1995, AM J EPIDEMIOL, V142, P166, DOI 10.1093/oxfordjournals.aje.a117615; OBERMAN A, 1988, HEART DISEASE TXB CA, V2, P1395; Ostfeld A M, 1980, Epidemiol Rev, V2, P136; PAFFENBARGER RS, 1990, EXERCISE, FITNESS, AND HEALTH, P33; PAFFENBARGER RS, 1971, AM J EPIDEMIOL, V94, P524, DOI 10.1093/oxfordjournals.aje.a121351; PAGANINIHILL A, 1989, BRIT MED J, V299, P1247, DOI 10.1136/bmj.299.6710.1247; PATSCH JR, 1987, J CLIN INVEST, V80, P341, DOI 10.1172/JCI113078; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; PHILLIPS SJ, 1992, ARCH INTERN MED, V152, P938, DOI 10.1001/archinte.152.5.938; PORTER JB, 1985, OBSTET GYNECOL, V66, P1; RAURAMAA R, 1986, CIRCULATION, V74, P939, DOI 10.1161/01.CIR.74.5.939; REALINI JP, 1985, AM J OBSTET GYNECOL, V152, P729, DOI 10.1016/S0002-9378(85)80001-6; REED DM, 1990, AM J EPIDEMIOL, V131, P579, DOI 10.1093/oxfordjournals.aje.a115542; RENAUD S, 1984, CLIN PHARMACOL THER, V36, P389, DOI 10.1038/clpt.1984.193; RHOADS GG, 1983, ARTERIOSCLEROSIS, V3, P316, DOI 10.1161/01.ATV.3.4.316; RHOADS GG, 1983, LANCET, V1, P492; ROCCELLA EJ, 1986, JAMA-J AM MED ASSOC, V256, P70; Rothman K, 1986, MODERN EPIDEMIOLOGY, P7; RUDERMAN NB, 1984, PROG CARDIOVASC DIS, V26, P373, DOI 10.1016/0033-0620(84)90011-2; SACCO RL, 1984, NEUROLOGY, V34, P847, DOI 10.1212/WNL.34.7.847; SALONEN JT, 1982, STROKE, V13, P327, DOI 10.1161/01.STR.13.3.327; SARAN M, 1990, FREE RADICAL RES COM, V10, P221, DOI 10.3109/10715769009149890; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; SHINTON R, 1991, J EPIDEMIOL COMMUN H, V45, P138, DOI 10.1136/jech.45.2.138; SIEFFERT GF, 1981, SURG FORUM, V32, P333; SMITH JR, 1978, NEW ENGL J MED, V298, P6, DOI 10.1056/NEJM197801052980102; SOLTERO I, 1978, STROKE, V9, P549, DOI 10.1161/01.STR.9.6.549; SPRANGER M, 1989, STROKE, V20, P34, DOI 10.1161/01.STR.20.1.34; STADEL BV, 1981, NEW ENGL J MED, V305, P672, DOI 10.1056/NEJM198109173051205; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P1313, DOI 10.1056/NEJM198811173192004; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STROMBLAD G, 1986, METABOLISM, V35, P323, DOI 10.1016/0026-0495(86)90148-4; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; TELL GS, 1988, STROKE, V19, P423, DOI 10.1161/01.STR.19.4.423; THORNTON JR, 1984, LANCET, V2, P1013; THOROGOOD M, 1992, AM J EPIDEMIOL, V136, P35, DOI 10.1093/oxfordjournals.aje.a116418; VANGIJN J, 1992, NEUROL CLIN, V10, P193, DOI 10.1016/S0733-8619(18)30241-X; VESSEY MP, 1984, BRIT MED J, V289, P530, DOI 10.1136/bmj.289.6444.530-a; WANNAMETHEE G, 1992, BRIT MED J, V304, P597, DOI 10.1136/bmj.304.6827.597; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WILLIAMS GD, 1988, PUBLIC HEALTH REP, V103, P592; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025; WOLF PA, 1992, STROKE PATHOPHYSIOLO, P3; YANO K, 1989, STROKE, V20, P1460, DOI 10.1161/01.STR.20.11.1460; 1991, HEART STROKE FACTS; 1994, STROKE CLIN UPDATES, V5, P9; 1992, J MYOCARDIAL ISCHEMI, V4, P30; 1994, BRIT MED J, V308, P1540; 1990, DHHS CDC908416 PUBL; 1994, MORBIDITY MORTALITY; 1989, DHHS CDC898411 PUBL; 1994, 1993 WORLD HLTH STAT; 1993, DHHS PHS9412321 PUBL; 1987, DHHS ADM871519 PUBL; 1992, HEART STROKE FACTS; 1988, STROKE FACTS	144	261	274	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 23	1995	333	21					1392	1400		10.1056/NEJM199511233332106	http://dx.doi.org/10.1056/NEJM199511233332106			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF521	7477121				2022-12-28	WOS:A1995TF52100006
J	GUMPERZ, JE; PARHAM, P				GUMPERZ, JE; PARHAM, P			THE ENIGMA OF THE NATURAL-KILLER-CELL	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; INTEGRAL MEMBRANE-PROTEINS; MARROW GRAFT-REJECTION; NK CELLS; ANTIGEN RECOGNITION; MULTIGENE FAMILY; GENE-COMPLEX; ALLOANTIGEN RECOGNITION; MOLECULAR-CLONING; LYMPHOCYTE-T	Natural killer (NK) cells are controlled by receptors specific for polymorphic determinants of class I molecules of the major histocompatibility complex (MHC). The contrasting properties of NK and cytotoxic T cell (CTL) class I receptors provide complementarity in the cytolytic lymphocyte response to viruses, tumours and transplants. Whereas human NK cell class I receptors consist of immunoglobulin domains, their mouse counterparts resemble C-type lectins. This difference may reflect the receptors' diverse and rapidly evolving class I ligands.	STANFORD UNIV, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA	Stanford University	GUMPERZ, JE (corresponding author), STANFORD UNIV, DEPT BIOL STRUCT, SHERMAN FAIRCHILD BLDG, STANFORD, CA 94305 USA.							ADAMKIEWICZ TV, 1994, IMMUNOGENETICS, V39, P218; BARBER LD, 1993, ANNU REV CELL BIOL, V9, P163; BARINAGA M, 1995, SCIENCE, V268, P367, DOI 10.1126/science.7716537; BEZOUSKA K, 1994, J BIOL CHEM, V269, P16945; BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; BIX M, 1991, NATURE, V349, P329, DOI 10.1038/349329a0; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BRENNAN J, 1994, J EXP MED, V180, P2287, DOI 10.1084/jem.180.6.2287; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; CELLA M, 1994, J EXP MED, V180, P1235, DOI 10.1084/jem.180.4.1235; CHAMBERS WH, 1993, GLYCOBIOLOGY, V3, P9, DOI 10.1093/glycob/3.1.9; CHANG C, IN PRESS EUR IMMUN; CICCONE E, 1992, J EXP MED, V175, P709, DOI 10.1084/jem.175.3.709; CICCONE E, 1990, J EXP MED, V172, P47, DOI 10.1084/jem.172.1.47; COLONNA M, 1992, P NATL ACAD SCI USA, V89, P7983, DOI 10.1073/pnas.89.17.7983; COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543; COLONNA M, 1993, SCIENCE, V260, P1121, DOI 10.1126/science.8493555; CORREA I, 1994, EUR J IMMUNOL, V24, P1323, DOI 10.1002/eji.1830240613; DANDREA A, 1995, J IMMUNOL, V155, P2306; DANIELS BF, 1994, IMMUNITY, V1, P785, DOI 10.1016/S1074-7613(94)80020-0; DANIELS BF, 1994, J EXP MED, V180, P687, DOI 10.1084/jem.180.2.687; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DELARBRE C, 1992, IMMUNOGENETICS, V37, P29; DRICKAMER K, 1993, PROG NUCLEIC ACID RE, V45, P207, DOI 10.1016/S0079-6603(08)60870-3; FERRINI S, 1994, EUR J IMMUNOL, V24, P2294, DOI 10.1002/eji.1830241005; GIORDA R, 1990, SCIENCE, V249, P1298, DOI 10.1126/science.2399464; GIORDA R, 1992, J IMMUNOL, V149, P1957; GUMPERZ JE, 1995, J EXP MED, V181, P1133, DOI 10.1084/jem.181.3.1133; HERBERMAN RB, 1986, ANNU REV IMMUNOL, V4, P651, DOI 10.1146/annurev.iy.04.040186.003251; HERBERMAN RB, 1981, SCIENCE, V214, P24, DOI 10.1126/science.7025208; HOUCHINS JP, 1991, J EXP MED, V173, P1017, DOI 10.1084/jem.173.4.1017; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; KANE KP, 1994, J EXP MED, V179, P1011, DOI 10.1084/jem.179.3.1011; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KAUFMAN DS, 1995, P NATL ACAD SCI USA, V92, P6484, DOI 10.1073/pnas.92.14.6484; KAUFMAN DS, 1993, J IMMUNOL, V150, P1429; KINDT TJ, 1987, IMMUNOL RES, V6, P57, DOI 10.1007/BF02918104; LANIER LL, 1986, J IMMUNOL, V137, P2735; LANIER LL, 1995, J IMMUNOL, V154, P3320; LANIER LL, 1994, J IMMUNOL, V153, P2417; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; LITWIN V, 1993, J EXP MED, V178, P1321, DOI 10.1084/jem.178.4.1321; LITWIN V, 1994, J EXP MED, V180, P537, DOI 10.1084/jem.180.2.537; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; LOPEZCABRERA M, 1993, J EXP MED, V178, P537, DOI 10.1084/jem.178.2.537; MELERO I, 1994, J IMMUNOL, V152, P1662; MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597; MORETTA A, 1990, J EXP MED, V171, P695, DOI 10.1084/jem.171.3.695; MORETTA A, 1990, J EXP MED, V172, P1589, DOI 10.1084/jem.172.6.1589; OHLEN C, 1989, SCIENCE, V246, P666, DOI 10.1126/science.2814488; OLSSON MY, 1995, P NATL ACAD SCI USA, V92, P1649, DOI 10.1073/pnas.92.5.1649; ORTALDO JR, 1984, ANNU REV IMMUNOL, V2, P359, DOI 10.1146/annurev.iy.02.040184.002043; Parham P, 1994, Semin Immunol, V6, P373, DOI 10.1006/smim.1994.1047; PARHAM P, 1995, IMMUNOL REV, V143, P141, DOI 10.1111/j.1600-065X.1995.tb00674.x; PHILLIPS JH, 1995, SCIENCE, V268, P403, DOI 10.1126/science.7716542; ROGERS JH, 1985, EMBO J, V4, P749, DOI 10.1002/j.1460-2075.1985.tb03692.x; ROLSTAD B, 1994, NATURAL IMMUNITY NOR, P99; RYAN JC, 1992, J IMMUNOL, V149, P1631; RYAN JC, 1991, J IMMUNOL, V147, P3244; SANCHEZ MJ, 1994, J EXP MED, V180, P569, DOI 10.1084/jem.180.2.569; SANCHEZ MJ, 1993, J EXP MED, V178, P1857, DOI 10.1084/jem.178.6.1857; SCALZO AA, 1992, J IMMUNOL, V149, P581; SENTMAN CL, 1994, J IMMUNOL, V153, P5482; SENTMAN CL, 1989, J EXP MED, V170, P191, DOI 10.1084/jem.170.1.191; SHIMIZU Y, 1989, EUR J IMMUNOL, V19, P447, DOI 10.1002/eji.1830190306; SMITH HRC, 1994, J IMMUNOL, V153, P1068; Sprent Jonathan, 1993, P75; STORKUS WJ, 1989, J IMMUNOL, V143, P3853; STORKUS WJ, 1991, P NATL ACAD SCI USA, V88, P5989, DOI 10.1073/pnas.88.14.5989; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; TRINCHIERI G, 1994, J EXP MED, V180, P417, DOI 10.1084/jem.180.2.417; VAAGE JT, 1994, J EXP MED, V180, P641, DOI 10.1084/jem.180.2.641; VERSTEEG R, 1992, IMMUNOL TODAY, V13, P244, DOI 10.1016/0167-5699(92)90003-P; WAGTMANN N, 1995, IMMUNITY, V2, P439, DOI 10.1016/1074-7613(95)90025-X; WAN AM, 1986, J IMMUNOL, V137, P3671; WATKINS DI, IN PRESS CRITICAL RE; WELSH RM, 1986, NAT IMMUN CELL GROW, V5, P169; WONG S, 1991, J IMMUNOL, V147, P1417; YABE T, 1993, IMMUNOGENETICS, V37, P455; YOKOYAMA WM, 1990, J IMMUNOL, V145, P2353; YOKOYAMA WM, 1989, J IMMUNOL, V143, P1379; YOKOYAMA WM, 1991, J IMMUNOL, V147, P3229; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145; YU YYL, 1994, INT IMMUNOL, V6, P1297, DOI 10.1093/intimm/6.9.1297; YU YYL, 1992, ANNU REV IMMUNOL, V10, P189, DOI 10.1146/annurev.iy.10.040192.001201; ZIEGLER SF, 1994, J IMMUNOL, V152, P1228	90	242	244	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 16	1995	378	6554					245	248		10.1038/378245a0	http://dx.doi.org/10.1038/378245a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477341				2022-12-28	WOS:A1995TE85800038
J	REINISCH, JM; SANDERS, SA; MORTENSEN, EL; RUBIN, DB				REINISCH, JM; SANDERS, SA; MORTENSEN, EL; RUBIN, DB			IN-UTERO EXPOSURE TO PHENOBARBITAL AND INTELLIGENCE DEFICITS IN ADULT MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-BIRTH-WEIGHT; CENTRAL-NERVOUS-SYSTEM; MATERNAL ALCOHOL-USE; EDUCATIONAL-LEVEL; FEBRILE SEIZURES; BEHAVIOR; CHILDREN; PREGNANCY; INFANTS; DRUGS	Objective.-To test whether exposure to phenobarbital in utero is associated with deficits in intelligence scores in adult men and whether the magnitude of the postnatal effect is mediated by exposure parameters and/or postnatal environmental factors. Design.-Two double-blind studies were conducted on independent samples of adult men prenatally exposed to phenobarbital and matched control samples using different measures of general intelligence, Based on data from control subjects, regression models were built relating intelligence scores to relevant pre-exposure matching variables and age at testing, Models generated predicted scores for each exposed subject, Group mean differences between the individually predicted and observed scores estimated exposure effects. Setting.-Copenhagen, Denmark. Participants.-Exposed subjects were adult men born at the largest hospital in Copenhagen between 1959 and 1961 who were exposed to phenobarbital during gestation via maternal medical treatment and whose mothers had no history of a central nervous system disorder and no treatment during pregnancy with any other psychopharmacological drug. Study 1 included 33 men and study 2, 81 men. Controls were unexposed members of the same birth cohort matched on a wide spectrum of maternal variables recorded prenatally and perinatally. Controls for studies 1 and 2 included 52 and 101 men, respectively. Main Outcome Measures.-In study 1: Wechsler Adult intelligence Scale (Danish version); in study 2: Danish Military Draft Board Intelligence Test (Borge Priens Prove). Result.-Men exposed prenatally to phenobarbital had significantly lower verbal intelligence scores (approximately 0.5 SD) than predicted, Lower socioeconomic status and being the offspring of an ''unwanted'' pregnancy increased the magnitude of the negative effects; Exposure that included the last trimester was the most detrimental. Conclusion.-Phenobarbital exposure during early development can have long-term deleterious effects on cognitive performance. Detrimental environmental conditions can interact with prenatal biological insult to magnify negative outcomes, Physicians are urged to use increased caution in prescribing such medications during pregnancy.	INST PREVENT MED, HOSP CORP, COPENHAGEN, DENMARK; HARVARD UNIV, DEPT STAT, CAMBRIDGE, MA USA	Harvard University	REINISCH, JM (corresponding author), INDIANA UNIV, KINSEY INST RES SEX GENDER & REPROD, MORRISON HALL, 3RD FLOOR, BLOOMINGTON, IN 47405 USA.				NICHD NIH HHS [HD 20263, HD 17655] Funding Source: Medline; NIDA NIH HHS [DA 05056] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017655, R01HD020263] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARAI Y, 1968, ENDOCRINOLOGY, V82, P1005, DOI 10.1210/endo-82-5-1005; ARAI Y, 1968, ENDOCRINOLOGY, V82, P1010, DOI 10.1210/endo-82-5-1010; ARMITAGE SG, 1952, J COMP PHYSIOL PSYCH, V45, P146, DOI 10.1037/h0062268; BRENT DA, 1990, PEDIATRICS, V85, P1086; CAMFIELD CS, 1979, J PEDIATR-US, V95, P361, DOI 10.1016/S0022-3476(79)80507-7; COCHRAN WG, 1973, SANKHYA SER A, V35, P417; DEVASCONCELOS AP, 1990, EXP NEUROL, V108, P176, DOI 10.1016/0014-4886(90)90025-N; DODSON WE, 1989, CLIN PERINATOL, V16, P339, DOI 10.1016/S0095-5108(18)30636-5; FARWELL JR, 1990, NEW ENGL J MED, V323, P485; FARWELL JR, 1990, NEW ENGL J MED, V322, P364, DOI 10.1056/NEJM199002083220604; Feingold C, 1994, J Pediatr Nurs, V9, P91; FISHMAN RHB, 1983, NEUROSCI BIOBEHAV R, V7, P19, DOI 10.1016/0149-7634(83)90004-0; FRIIS B, 1977, ARCH DIS CHILD, V52, P239, DOI 10.1136/adc.52.3.239; GAILY E, 1990, DEV MED CHILD NEUROL, V32, P403; Graffar M., 1960, MOD PROBL PADIAT, V5, P30; GROSS RT, 1990, JAMA-J AM MED ASSOC, V263, P3035; HESS G, 1974, WAIS ANVENDT PA 698; HILL TD, 1985, CLIN PSYCHOL REV, V5, P287, DOI 10.1016/0272-7358(85)90009-1; HIRTZ DG, 1986, AM J DIS CHILD, V140, P909, DOI 10.1001/archpedi.1986.02140230079037; JONES DC, 1992, IND LABOR RELAT REV, V45, P452, DOI 10.2307/2524272; KALTENBACH K, 1986, NEUROTOXICOL TERATOL, V8, P353; KILBEY MM, 1991, DHHSNIDA114 NAT I DR; KLIPSTEIN FA, 1964, BLOOD, V23, P68, DOI 10.1182/blood.V23.1.68.68; LIEWENDAHL K, 1978, CLIN ENDOCRINOL, V8, P185, DOI 10.1111/j.1365-2265.1978.tb01493.x; LITTLE R, 1987, STATISTICAL ANAL MIS; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; Martin J C, 1979, Neurobehav Toxicol, V1, P49; MARTIN JC, 1986, NEUROTOXICOL TERATOL, V8, P335; MIDDAUGH LD, 1986, NEUROTOXICOLOGY, V7, P287; MORALES WJ, 1986, OBSTET GYNECOL, V68, P295, DOI 10.1097/00006250-198609000-00001; MORTENSEN EL, 1989, SCAND J PSYCHOL, V30, P315, DOI 10.1111/j.1467-9450.1989.tb01094.x; PFEIFFER SI, 1990, PERCEPT MOTOR SKILL, V70, P1367, DOI 10.2466/PMS.70.3.1367-1378; Rayburn W, 1989, J Perinatol, V9, P268; RAYBURN W, 1988, AM J OBSTET GYNECOL, V159, P1491, DOI 10.1016/0002-9378(88)90580-7; REINISCH JM, 1982, NEUROSCI BIOBEHAV R, V6, P311, DOI 10.1016/0149-7634(82)90043-4; REINISCH JM, 1993, ACTA PSYCHIAT SCAND, V87, P54, DOI 10.1111/j.1600-0447.1993.tb05361.x; RODGERS B, 1978, DEV MED CHILD NEUROL, V20, P421, DOI 10.1111/j.1469-8749.1978.tb15242.x; ROSENBAUM PR, 1985, BIOMETRICS, V41, P103, DOI 10.2307/2530647; ROSENBAUM PR, 1985, AM STAT, V39, P33, DOI 10.2307/2683903; ROSENTHAL R, 1982, J EDUC PSYCHOL, V74, P708, DOI 10.1037/0022-0663.74.5.708; ROSENTHAL R, 1982, J EDUC PSYCHOL, V74, P166, DOI 10.1037/0022-0663.74.2.166; Rubin DB, 1984, WG COCHRANS IMPACT S, P37; RUSSELL M, 1991, ALCOHOL CLIN EXP RES, V15, P991, DOI 10.1111/j.1530-0277.1991.tb05200.x; Scarr S., 1981, RACE SOCIAL CLASS IN; SCHAIE KW, 1983, DEV PSYCHOL, V19, P531, DOI 10.1037/0012-1649.19.4.531; SCHRAEDER BD, 1986, NURS RES, V35, P237; SMITH I, 1991, ARCH DIS CHILD, V66, P311, DOI 10.1136/adc.66.3.311; Sobczyk W, 1977, Neurol Neurochir Pol, V11, P59; STREISSGUTH AP, 1989, DEV PSYCHOL, V25, P3, DOI 10.1037/0012-1649.25.1.3; TEASDALE TW, 1987, NATURE, V325, P119, DOI 10.1038/325119a0; TEASDALE TW, 1988, BRIT J EDUC PSYCHOL, V58, P307, DOI 10.1111/j.2044-8279.1988.tb00906.x; TEASDALE TW, 1991, HUM BIOL, V63, P19; VALAES T, 1980, PEDIATR RES, V14, P947, DOI 10.1203/00006450-198008000-00011; VANDERPOL MC, 1991, AM J OBSTET GYNECOL, V164, P121, DOI 10.1016/0002-9378(91)90640-D; VILLUMSEN AL, 1970, ENV FACTORS CONGENIT, P124; VINING EPG, 1987, PEDIATRICS, V80, P165; WALLIN A, 1984, ACTA PAEDIATR SCAND, V73, P488, DOI 10.1111/j.1651-2227.1984.tb09960.x; Wechsler D., 2008, WAIS 4 WECHSLER ADUL; Wesson D. R, 1977, BARBITURATES THEIR U; WILSON JT, 1971, CLIN PEDIATR, V10, P684, DOI 10.1177/000992287101001202; WITKIN HA, 1976, SCIENCE, V193, P547, DOI 10.1126/science.959813; Yaffe S J, 1980, Prog Clin Biol Res, V36, P157; YAFFE SJ, 1990, DEV PHARMACOL THERAP, V15, P215, DOI 10.1159/000457649; YANAI J, 1989, NEUROTOXICOLOGY, V10, P543; YANAI J, 1981, EXP NEUROL, V73, P199, DOI 10.1016/0014-4886(81)90055-8; ZACHAUCHRISTIAN.B, 1975, BABIES HUMAN DEV 1ST; ZEMP JW, 1975, ADDICT DIS, V2, P307; 1951, CLASSIFICATION OCCUP, P3	68	214	217	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	1995	274	19					1518	1525		10.1001/jama.274.19.1518	http://dx.doi.org/10.1001/jama.274.19.1518			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TD571	7474220				2022-12-28	WOS:A1995TD57100028
J	JONES, SN; ROE, AE; DONEHOWER, LA; BRADLEY, A				JONES, SN; ROE, AE; DONEHOWER, LA; BRADLEY, A			RESCUE OF EMBRYONIC LETHALITY IN MDM2-DEFICIENT MICE BY ABSENCE OF P53	NATURE			English	Article							WILD-TYPE P53; MDM-2 ONCOGENE; PROTEIN; MOUSE; GROWTH; GENE; TRANSACTIVATION; LINE	THE Mdm2 proto-oncogene was originally identified as one of several genes contained on a mouse double minute chromosome present in a transformed derivative of 3T3 cells(1). Overexpression of Mdm2 can immortalize primary cultures of rodent fibroblasts(2). Human MDM2 is amplified in 30-40% of sarcomas, and is overexpressed in leukaemic cells(3,4). The Mdm2 oncoprotein forms a complex with the p53 tumour-suppressor protein and inhibits p53-mediated transregulation of gene expression(5,6) Because Mdm2 expression increases in response to p53, Mdm2-p53 binding may autoregulate Mdm2 expression and modulate the activity of p53 in the cell(7,8). We have created Mdm2-null and Mdm2/p53-null mice to determine whether Mdm2 possesses developmental functions in addition to the ability to complex with p53, and to investigate the biological role of Mdm2-p53 complex formation in development. Mice deficient for Mdm2 die early in development. In contrast, mice deficient for both Mdm2 and p53 develop normally and are viable. These results suggest that a critical role of Mdm2 in development is the regulation of p53 function.	BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC VIROL,HOUSTON,TX 77030	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	JONES, SN (corresponding author), BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.			Bradley, Allan/0000-0002-2349-8839				BAKER SJ, 1990, SCIENCE, V253, P49; BUESORAMOS CE, 1993, BLOOD, V82, P2617; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN J, 1995, J MOL MED, V1, P142; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P2; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; RAMIREZSOLIS R, 1993, GUIDE TECHNIQUES MOU, P855; SCHMID P, 1991, DEVELOPMENT, V113, P857; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	23	1040	1060	1	36	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 9	1995	378	6553					206	208		10.1038/378206a0	http://dx.doi.org/10.1038/378206a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD759	7477327				2022-12-28	WOS:A1995TD75900060
J	LUNA, RMD; WAGNER, DS; LOZANO, G				LUNA, RMD; WAGNER, DS; LOZANO, G			RESCUE OF EARLY EMBRYONIC LETHALITY IN MDM2-DEFICIENT MICE BY DELETION OF P53	NATURE			English	Article							WILD-TYPE P53; MDM-2 ONCOGENE; PROTEIN; APOPTOSIS; PROTOONCOGENE; IRRADIATION; ACTIVATION; DISRUPTION; RADIATION; CELLS	THE gene p53 encodes a transcriptional activator(1,2) of genes involved in growth arrest(3,4), DNA repair(5) and apoptosis(6-8). Loss p53 function contributes to tumor development in vivo(9-11). The transcriptional activation function of p53 is inactivated by interaction with the mdm2 gene product(11-14). Amplification of mdm2 has been observed in 36% of human sarcomas, indicating that it may represent an alternative mechanism of preventing p53 function in tumor development(15). To study mdm2 function in vivo, we generated an mdm2 null allele by homologous recombination. Mdm2 null mice are not viable, and further analysis revealed embryonic lethality around implantation. To examine the importance of the interaction of MDM2 with p53 in vivo, we crossed mice heterozygous for mdm2 null alleles. Rescue of the mdm2(-/-) lethality in a p53 null background suggests that a critical in vivo function of MDM2 is the negative regulation of p53 activity.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC GENET, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT BIOCHEM & MOLEC BIOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Wagner, Daniel S/C-9379-2009	Wagner, Daniel S/0000-0002-0595-2436				CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARPER JW, 1993, CELL, V75, P805; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	27	1099	1116	0	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 9	1995	378	6553					203	206						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD759	7477326				2022-12-28	WOS:A1995TD75900059
J	HIETALA, J; SYVALAHTI, E; VUORIO, K; RAKKOLAINEN, V; BERGMAN, J; HAAPARANTA, M; SOLIN, O; KUOPPAMAKI, M; KIRVELA, O; RUOTSALAINEN, U; SALOKANGAS, RKR				HIETALA, J; SYVALAHTI, E; VUORIO, K; RAKKOLAINEN, V; BERGMAN, J; HAAPARANTA, M; SOLIN, O; KUOPPAMAKI, M; KIRVELA, O; RUOTSALAINEN, U; SALOKANGAS, RKR			PRESYNAPTIC DOPAMINE FUNCTION IN STRIATUM OF NEUROLEPTIC-NAIVE SCHIZOPHRENIC-PATIENTS	LANCET			English	Note							POSITRON EMISSION TOMOGRAPHY; ABNORMALITIES; RECEPTORS	Presynaptic dopamine function (6-[F-18]-fluorodopa uptake) in the brains of seven neuroleptic-naive first-admission schizophrenic patients and eight healthy controls was studied with positron emission tomography. The fluorodopa influx constant (K-i) in putamen was higher in the patients than in controls (average mean: 0.0149 vs 0.0129, p=0.034). The changes in caudate were smaller but significantly lateralised to the left caudate. There was one catatonic schizophrenic patient in our sample. This patient had lower striatal K-i than any control. Alterations in striatal presynaptic dopamine function may constitute a part of disrupted neural circuits that predispose to schizophrenic psychosis.	TURKU MED CYCLOTRON PET PROJECT,TURKU,FINLAND; TURKU CITY PSYCHIAT HOSP,TURKU,FINLAND; ABO AKAD UNIV,ACCELERATOR LAB,TURKU,FINLAND; TURKU UNIV HOSP,DEPT ANAESTHESIOL,SF-20520 TURKU,FINLAND; TURKU UNIV HOSP,DEPT PSYCHIAT,SF-20520 TURKU,FINLAND	Abo Akademi University; University of Turku; University of Turku	HIETALA, J (corresponding author), UNIV TURKU,DEPT PHARMACOL,KIINAMYLLYNKATU 10,SF-20520 TURKU,FINLAND.		Ruotsalainen, Ulla/J-5678-2014	Ruotsalainen, Ulla/0000-0001-7775-3412				Bergman J., 1994, Journal of Labelled Compounds and Radiopharmaceuticals, V35, P476; BILDER RM, 1994, AM J PSYCHIAT, V151, P1437; FARDE L, 1990, ARCH GEN PSYCHIAT, V47, P213; HIETALA J, 1994, ARCH GEN PSYCHIAT, V51, P116; PELLIZARI A, 1989, J COMPUT ASSIST TOMO, V13, P20; PILOWSKY LS, 1994, BRIT J PSYCHIAT, V164, P16, DOI 10.1192/bjp.164.1.16; REITH J, 1994, P NATL ACAD SCI USA, V91, P11651, DOI 10.1073/pnas.91.24.11651; SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; WONG DF, 1986, SCIENCE, V234, P1558, DOI 10.1126/science.2878495	10	262	266	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 28	1995	346	8983					1130	1131		10.1016/S0140-6736(95)91801-9	http://dx.doi.org/10.1016/S0140-6736(95)91801-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TB549	7475604				2022-12-28	WOS:A1995TB54900011
J	MONTAGUE, PR; DAYAN, P; PERSON, C; SEJNOWSKI, TJ				MONTAGUE, PR; DAYAN, P; PERSON, C; SEJNOWSKI, TJ			BEE FORAGING IN UNCERTAIN ENVIRONMENTS USING PREDICTIVE HEBBIAN LEARNING	NATURE			English	Article							BUMBLE BEES; HONEYBEES; CHOICE; BEHAVIOR; DOPAMINE; REWARD	RECENT work has identified a neuron with widespread projections to odour processing regions of the honeybee brain whose activity represents the reward value of gustatory stimuli(1,2). We have constructed a model of bee foraging in uncertain environments based on this type of neuron and a predictive form of hebbian synaptic plasticity. The model uses visual input from a simulated three-dimensional world and accounts for a wide range of experiments on bee learning during foraging, including risk aversion. The predictive model shows how neuromodulatory influences can be used to bias actions and control synaptic plasticity in a way that goes beyond standard correlational mechanisms. Although several behavioural models of conditioning in bees have been proposed(3-7), this model is based on the neural substrate and was tested in a simulation of bee flight.	MIT,DEPT BRAIN & COGNIT SCI,CBCL,CAMBRIDGE,MA 02139; SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego	MONTAGUE, PR (corresponding author), BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030, USA.		Sejnowski, Terrence/AAV-5558-2021	Dayan, Peter/0000-0003-3476-1839				BARTO AG, 1989, 8995 U MASS COMP INF; Berry D A, 1985, BANDIT PROBLEMS SEQU; COUVILLON PA, 1991, ANIM LEARN BEHAV, V19, P381, DOI 10.3758/BF03197899; COUVILLON PA, 1986, ANIM LEARN BEHAV, V14, P225, DOI 10.3758/BF03200062; COUVILLON PA, 1985, ANIM LEARN BEHAV, V13, P246, DOI 10.3758/BF03200017; GOLDSTEIN RS, 1991, J COMP PHYSIOL A, V168, P103, DOI 10.1007/BF00217108; GREGGERS U, 1993, BEHAV ECOL SOCIOBIOL, V32, P17, DOI 10.1007/BF00172219; Hammer M., 1994, Society for Neuroscience Abstracts, V20, P582; HAMMER M, 1993, NATURE, V366, P59, DOI 10.1038/366059a0; HAMMER M, 1995, NEUROSCIENCE, V15, P1617; HARDER LD, 1987, ECOLOGY, V68, P1104, DOI 10.2307/1938384; HARRISWARRICK RM, 1995, J NEUROSCI, V15, P342; HEBB DO, 1949, ORG BEHAVIOR; Konorski J., 1948, CONDITIONED REFLEXES; KREBS JR, 1978, NATURE, V275, P27, DOI 10.1038/275027a0; LOCKERY SR, 1991, J COMP PHYSIOL A, V168, P165, DOI 10.1007/BF00218409; Menzel Randolf, 1993, P79; Montague P. R., 1993, ADV NEURAL INFORMATI, V5, P969; MONTAGUE PR, 1994, LEARN MEMORY, V1, P1; REAL L, 1990, ECOLOGY, V71, P1625, DOI 10.2307/1938299; REAL LA, 1991, SCIENCE, V253, P980, DOI 10.1126/science.1887231; REAL LA, 1981, ECOLOGY, V62, P20, DOI 10.2307/1936663; Rescorla R., 1972, CLASSICAL CONDITION, P64; SAMUEL AL, 1956, IBM J RES DEV, V3, P211; SCHULTZ W, 1993, J NEUROSCI, V13, P900; SPUDICH JL, 1975, P NATL ACAD SCI USA, V72, P710, DOI 10.1073/pnas.72.2.710; Sutton R. S., 1988, Machine Learning, V3, P9, DOI 10.1023/A:1022633531479; SUTTON RS, 1981, PSYCHOL REV, V88, P135, DOI 10.1037/0033-295X.88.2.135; SUTTON RS, 1987, LEARNING COMPUTATION, P497; Widrow B., 1985, ADAPTIVE SIGNAL PROC	30	200	205	4	37	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 26	1995	377	6551					725	728		10.1038/377725a0	http://dx.doi.org/10.1038/377725a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TB469	7477260				2022-12-28	WOS:A1995TB46900054
J	WAGNER, M				WAGNER, M			A GLOBAL WITCH-HUNT	LANCET			English	Editorial Material																		BERG D, 1994, GEBURTSH FRAUENHEIK, V5, P131; JONSEN AR, 1983, NEW ENGL J MED, V308, P1531, DOI 10.1056/NEJM198306233082511; KORTE D, 1995, MOTHERING        FAL, P21; SAVAGE W, 1986, SAVAGE ENQUIRY; WOLFE S, 1994, OB GYN NEWS     0601	5	15	15	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 14	1995	346	8981					1020	1022		10.1016/S0140-6736(95)91696-2	http://dx.doi.org/10.1016/S0140-6736(95)91696-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475554				2022-12-28	WOS:A1995RZ59900018
J	LICHTENHELD, MG; OLSEN, KJ; LU, P; LOWREY, DM; HAMEED, A; HENGARTNER, H; PODACK, ER				LICHTENHELD, MG; OLSEN, KJ; LU, P; LOWREY, DM; HAMEED, A; HENGARTNER, H; PODACK, ER			STRUCTURE AND FUNCTION OF HUMAN PERFORIN	NATURE			English	Article									UNIV ZURICH,DEPT EXPTL PATHOL,CH-8006 ZURICH,SWITZERLAND	University of Zurich	LICHTENHELD, MG (corresponding author), UNIV MIAMI,SCH MED,DEPT MICROBIOL & IMMUNOL,MIAMI,FL 33101, USA.							BANKIER AT, 1983, NUCLEIC ACID BIOCH B, V508, P1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENNERT G, 1987, P NATL ACAD SCI USA, V84, P5004, DOI 10.1073/pnas.84.14.5004; DISCIPIO RG, 1988, J BIOL CHEM, V263, P549; DISCIPIO RG, 1984, P NATL ACAD SCI-BIOL, V81, P7298, DOI 10.1073/pnas.81.23.7298; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAEFLIGER JA, 1987, BIOCHEMISTRY-US, V26, P3551, DOI 10.1021/bi00386a045; HANSCH GM, 1981, P NATL ACAD SCI-BIOL, V78, P5118, DOI 10.1073/pnas.78.8.5118; HENKART PA, 1984, J EXP MED, V160, P75, DOI 10.1084/jem.160.1.75; HOWARD OMZ, 1987, BIOCHEMISTRY-US, V26, P3565, DOI 10.1021/bi00386a047; LACHMANN PJ, 1983, NATURE, V305, P473, DOI 10.1038/305473a0; LOWREY DM, 1987, ANN INST PASTEUR IMM, V138, P296, DOI 10.1016/S0769-2625(87)80082-X; LOWREY DM, 1988, CANCER RES, V48, P4681; Maniatis T, 1982, MOL CLONING LABORATO; MARTIN DE, 1988, P NATL ACAD SCI USA, V85, P213, DOI 10.1073/pnas.85.1.213; MARTIN DE, 1987, P NATL ACAD SCI USA, V84, P2946, DOI 10.1073/pnas.84.9.2946; OSTERGAARD HL, 1987, NATURE, V330, P71, DOI 10.1038/330071a0; PODACK ER, 1984, J EXP MED, V160, P695, DOI 10.1084/jem.160.3.695; PODACK ER, 1985, P NATL ACAD SCI USA, V82, P8629, DOI 10.1073/pnas.82.24.8629; PODACK ER, 1984, J BIOL CHEM, V259, P8641; PODACK ER, 1988, IMMUNOL REV, V103, P203, DOI 10.1111/j.1600-065X.1988.tb00756.x; RAO AG, 1987, BIOCHEMISTRY-US, V26, P3556, DOI 10.1021/bi00386a046; STANLEY KK, 1987, EMBO J, V6, P1951, DOI 10.1002/j.1460-2075.1987.tb02457.x; STANLEY KK, IN PRESS CURRENT TOP; TRENN G, 1987, NATURE, V330, P72, DOI 10.1038/330072a0; TSCHOPP J, 1986, NATURE, V322, P831, DOI 10.1038/322831a0; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; ZALMAN LS, 1986, P NATL ACAD SCI USA, V83, P5262, DOI 10.1073/pnas.83.14.5262	29	341	353	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 29	1988	335	6189					448	451		10.1038/335448a0	http://dx.doi.org/10.1038/335448a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q2364	3419519				2022-12-28	WOS:A1988Q236400054
J	NOSE, A; NAGAFUCHI, A; TAKEICHI, M				NOSE, A; NAGAFUCHI, A; TAKEICHI, M			EXPRESSED RECOMBINANT CADHERINS MEDIATE CELL SORTING IN MODEL SYSTEMS	CELL			English	Article											NOSE, A (corresponding author), KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN.		Takeichi, Masatoshi/G-5903-2012	Takeichi, Masatoshi/0000-0002-9931-3378				BRONNERFRASER M, 1985, J CELL BIOL, V101, P610, DOI 10.1083/jcb.101.2.610; CURTIS ASG, 1967, CELL SURFACE ITS MOL; EDELMAN GM, 1984, P NATL ACAD SCI-BIOL, V81, P1460, DOI 10.1073/pnas.81.5.1460; EDELMAN GM, 1987, P NATL ACAD SCI USA, V84, P8502, DOI 10.1073/pnas.84.23.8502; FREGIEN N, 1986, GENE, V48, P1, DOI 10.1016/0378-1119(86)90346-X; GALLIN WJ, 1987, P NATL ACAD SCI USA, V84, P2808, DOI 10.1073/pnas.84.9.2808; GIBRALTER D, 1985, DEV BIOL, V112, P292, DOI 10.1016/0012-1606(85)90400-2; HATTA K, 1986, NATURE, V320, P447, DOI 10.1038/320447a0; HATTA K, 1987, DEV BIOL, V120, P215, DOI 10.1016/0012-1606(87)90119-9; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; KATOH K, 1987, CELL STRUCT FUNCT, V12, P575, DOI 10.1247/csf.12.575; MOSCONA A, 1952, J ANAT, V86, P287; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NOSE A, 1987, EMBO J, V6, P3655, DOI 10.1002/j.1460-2075.1987.tb02698.x; NOSE A, 1986, J CELL BIOL, V103, P2649, DOI 10.1083/jcb.103.6.2649; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; SHIRAYOSHI Y, 1986, CELL STRUCT FUNCT, V11, P245, DOI 10.1247/csf.11.245; STEINBERG MS, 1963, SCIENCE, V141, P401, DOI 10.1126/science.141.3579.401; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; TAKEICHI M, 1987, TRENDS GENET, V3, P213, DOI 10.1016/0168-9525(87)90238-1; TAKEICHI M, 1981, DEV BIOL, V87, P340, DOI 10.1016/0012-1606(81)90157-3; TAKEICHI M, 1985, MOL DETERMINANTS ANI, P223; TOWNES PL, 1955, J EXP ZOOL, V128, P53, DOI 10.1002/jez.1401280105; VOLK T, 1987, CELL, V50, P987, DOI 10.1016/0092-8674(87)90525-3; VOLK T, 1986, J CELL BIOL, V103, P1441, DOI 10.1083/jcb.103.4.1441; Xie H, 1984, CELL STRUCT FUNCT, V8, P315	28	604	611	1	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 23	1988	54	7					993	1001		10.1016/0092-8674(88)90114-6	http://dx.doi.org/10.1016/0092-8674(88)90114-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	Q3063	3416359				2022-12-28	WOS:A1988Q306300012
J	LANDE, R				LANDE, R			GENETICS AND DEMOGRAPHY IN BIOLOGICAL CONSERVATION	SCIENCE			English	Article											LANDE, R (corresponding author), UNIV CHICAGO, DEPT ECOL & EVOLUT, CHICAGO, IL 60637 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027120] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27120] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allee W., 1949, PRINCIPLES ANIMAL EC; ALLENDORF FW, 1979, HEREDITAS, V91, P19; ANDREWARTHA HG, 1954, DISTRIBUTION ABUNDAN; [Anonymous], 1986, CONSERVATION BIOL SC; BROWN JL, 1975, EVOLUTION BEHAVIOR; BRYANT EH, 1986, GENETICS, V114, P1191; CHARLESWORTH B, 1984, PALEOBIOLOGY, V10, P319, DOI 10.1017/S0094837300008290; CHARLESWORTH D, 1987, ANNU REV ECOL SYST, V18, P237, DOI 10.1146/annurev.es.18.110187.001321; CONNER RN, 1987, RED COCKADED WOODPEC; DAWSON WR, 1987, CONDOR, V89, P205, DOI 10.2307/1368783; Ehrlich P.R., 1983, P152; ELLIOT DK, 1986, DYNAMICS EXTINCTION; Falconer D. S., 1981, INTRO QUANTITATIVE G; Foose T.J., 1980, International Zoo Yearbook, V20, P154, DOI 10.1111/j.1748-1090.1980.tb00959.x; Frankel OH, 1981, CONSERVATION EVOLUTI; Franklin I.R., 1980, CONSERVATION BIOL EV, P135; Goodman D., 1987, P11, DOI 10.1017/CBO9780511623400.003; GOODMAN D, 1980, CONSERVATION BIOL EV, P171; GOODNIGHT CJ, 1987, EVOLUTION, V41, P80, DOI 10.1111/j.1558-5646.1987.tb05772.x; HARRIS R B, 1987, Conservation Biology, V1, P72, DOI 10.1111/j.1523-1739.1987.tb00011.x; HILL WG, 1982, GENET RES, V40, P225; JABLONSKI D, 1986, SCIENCE, V231, P129, DOI 10.1126/science.231.4734.129; Janzen D.H., 1986, P286; KIERSTEAD H, 1953, J MAR RES, V12, P141; LANDE R, 1987, AM NAT, V130, P624, DOI 10.1086/284734; LANDE R, 1985, EVOLUTION, V39, P24, DOI [10.2307/2408514, 10.1111/j.1558-5646.1985.tb04077.x]; LANDE R, 1988, P NATL ACAD SCI USA, V85, P7418, DOI 10.1073/pnas.85.19.7418; LANDE R, 1988, OECOLOGIA, V75, P601, DOI 10.1007/BF00776426; LANDE R, 1980, AM NAT, V116, P463, DOI 10.1086/283642; LANDE R, 1975, GENET RES, V26, P221, DOI 10.1017/S0016672300016037; Lande R., 1987, P87, DOI 10.1017/CBO9780511623400.007; LEIGH EG, 1981, J THEOR BIOL, V90, P213; Leigh Jr EG, 1982, ECOLOGY TROPICAL FOR; LESLIE PH, 1966, J ANIM ECOL, V35, P291, DOI 10.2307/2396; LEVINS R, 1969, Bulletin of the Entomological Society of America, V15, P237; LEVINS R, 1970, SOME MATH QUESTIONS, V2, P75; LEWONTIN RC, 1974, GENETIC BASIS EVOLUT, P91; LIGON JD, 1986, AUK, V103, P848; Lovejoy T.E., 1986, P257; LYNCH M, 1985, EVOLUTION, V39, P804, DOI 10.1111/j.1558-5646.1985.tb00422.x; LYNCH M, 1988, GENET RES, V51, P137, DOI 10.1017/S0016672300024150; MAC ARTHUR ROBERT H., 1967; MYERS N, 1986, CONSERVATION BIOL SC, P444; OBRIEN SJ, 1983, SCIENCE, V221, P459, DOI 10.1126/science.221.4609.459; Okubo A., 1980, DIFFUSION ECOLOGICAL; OLDFIELD ML, 1984, VALUE CONSERVING GEN; PEASE CM, UNPUB; Pickett S. T. A., 1985, ECOLOGY NATURAL DIST; RALLS K, 1986, ZOO BIOL, V5, P81, DOI 10.1002/zoo.1430050202; Ralls K., 1983, P164; ROBERTSON ALAN, 1952, GENETICS, V37, P189; Schonewald-Cox C, 1983, GENETICS CONSERVATIO; SCHWARTZ OA, 1986, BIOL CONSERV, V37, P179, DOI 10.1016/0006-3207(86)90090-X; Seal U.S., 1984, Journal of the Minnesota Academy of Science, V49, P3; Senner J. W., 1980, Conservation Biology, P209; SHAFFER ML, 1981, BIOSCIENCE, V31, P131, DOI 10.2307/1308256; Simberloff D., 1986, P165; SIMMONS MJ, 1977, ANNU REV GENET, V11, P49, DOI 10.1146/annurev.ge.11.120177.000405; SIMPSON GG, 1953, MAJOR FEATURES EVOLU, P77; SLATKIN M, 1976, AM NAT, V110, P31, DOI 10.1086/283047; Soule M. E., 1980, CONSERVATION BIOL EV; SOULE ME, 1986, BIOL CONSERV, V35, P19, DOI 10.1016/0006-3207(86)90025-X; SOUTHWICK CH, 1983, GLOBAL ECOLOGY; TULJAPURKAR SD, 1982, THEOR POPUL BIOL, V21, P141, DOI 10.1016/0040-5809(82)90010-7; Wilcove D.S., 1986, P237; Wilcox B. A., 1980, Conservation biology. An evolutionary-ecological perspective., P95; WOLF EC, 1988, STATE WORLD 1988, P101; WRIGHT S, 1951, ANN EUGENIC, V15, P323; Wright S., 1969, THEORY GENE FREQUENC, V2, P520; Wright S., 1977, EVOLUTION GENETICS P, V3; 1985, RED COCKADED WOODPEC; 1986, ENV IMPACT STATEME S, V1; 1984, FINAL REGIONAL GUIDE	73	1623	1698	12	494	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 16	1988	241	4872					1455	1460		10.1126/science.3420403	http://dx.doi.org/10.1126/science.3420403			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q0479	3420403				2022-12-28	WOS:A1988Q047900028
J	SWARTZ, R; HOLMES, C				SWARTZ, R; HOLMES, C			MACROPHAGES	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									BAXTER HLTHCARE CORP,MCGAW PK,IL 60085	Baxter International Inc	SWARTZ, R (corresponding author), UNIV MICHIGAN HOSP,ANN ARBOR,MI 48109, USA.								0	1	1	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 7	1995	333	23					1546	1546		10.1056/NEJM199512073332306	http://dx.doi.org/10.1056/NEJM199512073332306			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH157	7477170				2022-12-28	WOS:A1995TH15700006
J	WRENN, K				WRENN, K			POSTMIDNIGHT REVERIE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											WRENN, K (corresponding author), VANDERBILT UNIV, MED CTR, 703 OXFORD HOUSE, NASHVILLE, TN 37232 USA.		Wrenn, Keith/AAI-7651-2020						0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1995	123	11					890	890		10.7326/0003-4819-123-11-199512010-00016	http://dx.doi.org/10.7326/0003-4819-123-11-199512010-00016			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG209	7486477				2022-12-28	WOS:A1995TG20900016
J	CHAPMAN, LE; FOLKS, TM; SALOMON, DR; PATTERSON, AP; EGGERMAN, TE; NOGUCHI, PD				CHAPMAN, LE; FOLKS, TM; SALOMON, DR; PATTERSON, AP; EGGERMAN, TE; NOGUCHI, PD			XENOTRANSPLANTATION AND XENOGENEIC INFECTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SIMIAN IMMUNODEFICIENCY VIRUS; CRIMEAN HEMORRHAGIC-FEVER; OUTBREAK; RETROVIRUSES; EVOLUTION; PHYLOGENY; DISEASE; AFRICA; HIV-2		SCRIPPS RES INST, LA JOLLA, CA 92037 USA; US FDA, BETHESDA, MD 20892 USA	Scripps Research Institute; US Food & Drug Administration (FDA)	CHAPMAN, LE (corresponding author), CTR DIS CONTROL, NATL CTR INFECT DIS, DIV AIDS STD & TB LAB RES, RETROVIRUS DIS BRANCH, ATLANTA, GA 30333 USA.		Salomon, Daniel/E-9380-2012					ALDHOUS P, 1990, NATURE, V347, P321, DOI 10.1038/347321c0; Allan Jonathan S., 1995, ILAR J, V37, P37; Beran GW, 1994, HDB ZOONOSES; BROWN P, 1992, LANCET, V340, P24, DOI 10.1016/0140-6736(92)92431-E; BURNEY MI, 1980, AM J TROP MED HYG, V29, P941, DOI 10.4269/ajtmh.1980.29.941; CHAPMAN LE, 1994, INFECT AGENT DIS, V3, P234; CHARI RS, 1994, NEW ENGL J MED, V331, P234, DOI 10.1056/NEJM199407283310404; CHILDS JE, 1994, J INFECT DIS, V169, P1271, DOI 10.1093/infdis/169.6.1271; COURGNAUD V, 1992, J VIROL, V66, P414, DOI 10.1128/JVI.66.1.414-419.1992; DEINHARDT F, 1980, VIRAL ONCOLOGY, P357; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; DOOLITTLE RF, 1990, CURR TOP MICROBIOL, V157, P1; DOOLITTLE RF, 1989, NATURE, V339, P338, DOI 10.1038/339338a0; DUNNING JJ, 1994, PATHOL BIOL, V42, P231; EASTLUND T, 1995, CELL TRANSPLANT, V4, P455, DOI 10.1016/0963-6897(95)00035-V; Fishman Jay A., 1994, Xenotransplantation, V1, P47, DOI 10.1111/j.1399-3089.1994.tb00049.x; FLUGEL RM, 1991, J ACQ IMMUN DEF SYND, V4, P739; FRANCHINI G, 1989, ANN NY ACAD SCI, V554, P81, DOI 10.1111/j.1749-6632.1989.tb22412.x; FRANCHINI G, 1994, AIDS RES HUM RETROV, V10, P1047, DOI 10.1089/aid.1994.10.1047; FRAZIER ME, 1985, ARCH VIROL, V83, P83, DOI 10.1007/BF01310966; GAO F, 1992, NATURE, V358, P495, DOI 10.1038/358495a0; HOLMES GP, 1995, CLIN INFECT DIS, V20, P421, DOI 10.1093/clinids/20.2.421; JIN MJ, 1994, J VIROL, V68, P8454, DOI 10.1128/JVI.68.12.8454-8460.1994; KALTER SS, 1976, HDB LABORATORY ANIMA, V3, P655; KANKI PJ, 1988, VET MICROBIOL, V17, P309, DOI 10.1016/0378-1135(88)90072-7; KHABBAZ RF, 1994, NEW ENGL J MED, V330, P172, DOI 10.1056/NEJM199401203300304; MARTINI GA, 1969, T ROY SOC TROP MED H, V63, P295, DOI 10.1016/0035-9203(69)90001-7; MCCLURE MA, 1988, P NATL ACAD SCI USA, V85, P2469, DOI 10.1073/pnas.85.8.2469; MICHAELS MG, 1994, TRANSPLANTATION, V57, P1, DOI 10.1097/00007890-199401000-00001; MOORE C, 1992, VET CLIN N AM-FOOD A, V8, P461, DOI 10.1016/S0749-0720(15)30698-8; MYERS G, 1992, RETROVIRIDAE, V1, P57; Nalesnik M A, 1994, Transplant Sci, V4, P61; NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615; NOWAK R, 1994, SCIENCE, V266, P1148, DOI 10.1126/science.7973690; PEETERS M, 1992, AIDS, V6, P447, DOI 10.1097/00002030-199205000-00002; PRUSINER SB, 1995, SCI AM, V272, P48, DOI 10.1038/scientificamerican0195-48; SHIIGI S, 1989, J MED PRIMATOL, V18, P185; Shortridge K F, 1992, Semin Respir Infect, V7, P11; SIMONDS RJ, 1993, AIDS, V7, pS35, DOI 10.1097/00002030-199311002-00008; SMITH DM, 1993, NEW ENGL J MED, V328, P142, DOI 10.1056/NEJM199301143280218; SULEIMAN MNEH, 1980, LANCET, V2, P939; SWANEPOEL R, 1987, AM J TROP MED HYG, V36, P120, DOI 10.4269/ajtmh.1987.36.120; VANIN EF, 1994, J VIROL, V68, P4241, DOI 10.1128/JVI.68.7.4241-4250.1994; WILSON ME, 1994, ANN NY ACAD SCI, V740, P1, DOI 10.1111/j.1749-6632.1994.tb19849.x; 1978, WHO ORG 1978, V56, P271; 1992, MMWR-MORBID MORTAL W, V41, P814	46	140	145	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 30	1995	333	22					1498	1501		10.1056/NEJM199511303332211	http://dx.doi.org/10.1056/NEJM199511303332211			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG445	7477153				2022-12-28	WOS:A1995TG44500011
J	KROPSHOFER, H; VOGT, AB; STERN, LJ; HAMMERLING, GJ				KROPSHOFER, H; VOGT, AB; STERN, LJ; HAMMERLING, GJ			SELF-RELEASE OF CLIP IN PEPTIDE LOADING OF HLA-DR MOLECULES	SCIENCE			English	Article							ANTIGEN-PROCESSING MUTANT; INVARIANT CHAIN PEPTIDES; CELL LINE; ASSOCIATION; CONTAINS; BINDING	The assembly and transport of major histocompatibility complex (MHC) class II molecules require interaction with the invariant chain. A fragment of the invariant chain, CLIP, occupies the peptide-binding groove of the class II molecule. At endosomal pH, the binding of CLIP to human MHC class II HLA-DR molecules was counteracted by its amino-terminal segment (residues 81 to 89), which facilitated rapid release. The CLIP(81-89) fragment also catalyzed the release of CLIP(90-105) and a subset of other self-peptides, probably by transient interaction with an effector site outside the groove. Thus, CLIP may facilitate peptide loading through an allosteric release mechanism.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	KROPSHOFER, H (corresponding author), GERMAN CANC RES CTR,DEPT MOLEC IMMUNOL,NEUENHEIMER FELD 280,D-69120 HEIDELBERG,GERMANY.							ADAMS S, 1995, EUR J IMMUNOL, V25, P1693, DOI 10.1002/eji.1830250632; AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BARNES KA, 1995, J EXP MED, V181, P1715, DOI 10.1084/jem.181.5.1715; BIJLMAKERS MJE, 1994, J EXP MED, V180, P623, DOI 10.1084/jem.180.2.623; BROOKS AG, 1994, J IMMUNOL, V153, P5382; CASTELLINO F, 1995, IMMUNITY, V2, P73, DOI 10.1016/1074-7613(95)90080-2; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; FREISEWINKEL IM, 1993, P NATL ACAD SCI USA, V90, P9703, DOI 10.1073/pnas.90.20.9703; GELUK A, 1992, J IMMUNOL, V149, P2864; Ghosh P., COMMUNICATION; GORGA JC, 1987, J BIOL CHEM, V262, P16087; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; KARLSSON L, 1994, SCIENCE, V266, P1569, DOI 10.1126/science.7985028; KROPSHOFER H, 1993, P NATL ACAD SCI USA, V90, P403, DOI 10.1073/pnas.90.2.403; KROPSHOFER H, 1995, P NATL ACAD SCI USA, V92, P8313, DOI 10.1073/pnas.92.18.8313; KROPSHOFER H, 1991, BIOCHEMISTRY-US, V30, P9177, DOI 10.1021/bi00102a008; LEE C, 1995, P NATL ACAD SCI USA, V92, P8269, DOI 10.1073/pnas.92.18.8269; MALCHEREK G, 1995, J EXP MED, V181, P527, DOI 10.1084/jem.181.2.527; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NELSON CA, 1993, P NATL ACAD SCI USA, V90, P1227, DOI 10.1073/pnas.90.4.1227; PINET V, 1995, NATURE, V375, P603, DOI 10.1038/375603a0; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROMAGNOLI P, 1994, J EXP MED, V180, P1107, DOI 10.1084/jem.180.3.1107; ROTHBARD JB, 1988, CELL, V52, P515, DOI 10.1016/0092-8674(88)90464-3; SANDERSON F, 1994, SCIENCE, V266, P1566, DOI 10.1126/science.7985027; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SETTE A, 1995, J EXP MED, V181, P677, DOI 10.1084/jem.181.2.677; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; STEBBINS CC, 1995, J EXP MED, V181, P223, DOI 10.1084/jem.181.1.223; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; STRUBIN M, 1986, EMBO J, V5, P3483, DOI 10.1002/j.1460-2075.1986.tb04673.x; URBAN RG, 1994, J EXP MED, V180, P751, DOI 10.1084/jem.180.2.751	40	93	98	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 24	1995	270	5240					1357	1359		10.1126/science.270.5240.1357	http://dx.doi.org/10.1126/science.270.5240.1357			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF899	7481823				2022-12-28	WOS:A1995TF89900038
J	BLENDON, RJ; ALTMAN, DE; BENSON, J; JAMES, M; ROWLAND, D; NEUMAN, P; LEITMAN, R; HYAMS, TS				BLENDON, RJ; ALTMAN, DE; BENSON, J; JAMES, M; ROWLAND, D; NEUMAN, P; LEITMAN, R; HYAMS, TS			THE PUBLICS VIEW OF THE FUTURE OF MEDICARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								As we reached the 30th anniversary of the enactment of Medicare, widespread national debate about the future of the program continues. The controversy involves strong disagreements over Medicare's short-term future as well as the shape the program should take in the next century. Health policy experts, national politicians, and opinion leaders have written and spoken extensively on this topic. But less attention has been paid to the views of the average citizen on the future of Medicare. This article seeks to fill that void. We attempt to answer three basic questions. First, how much do Americans know about Medicare and its problems? Second, what do they want to do about the program in the short term, particularly with regard to avoiding bankruptcy of the Medicare Hospital Trust Fund and achieving savings to help balance the federal budget? Last, what is the public's vision of the Medicare program in the next century, and what changes, if any, would they support in the long term? The answers to these questions are drawn from an in-depth analysis of the results of recent national opinion surveys. A special effort is made to identify the public's core attitudes and beliefs, which are likely to remain constant throughout the debate and which can be expected to influence the outcome.	HARVARD UNIV,KENNEDY SCH GOVT,CAMBRIDGE,MA; HENRY J KAISER FAMILY FDN,MENLO PK,CA; LOUIS HARRIS & ASSOCIATES,NEW YORK,NY	Harvard University	BLENDON, RJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.							BLENDON RJ, 1993, JAMA-J AM MED ASSOC, V269, P2573, DOI 10.1001/jama.269.19.2573; 1995, TIME            0510; 1995, WALL STREET J   0916; 1995, ANAL PRESIDENTS BUDG; 1995, WALL STREET J   0729; 1995, WALL STREET J   0421; 1995, STATISTICAL ABSTRACT; 1995, TIME            0823; 1995, WASHINGTON POST 0510	9	6	6	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	1995	274	20					1645	1648		10.1001/jama.274.20.1645	http://dx.doi.org/10.1001/jama.274.20.1645			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE738	7474254				2022-12-28	WOS:A1995TE73800039
J	NEWACHECK, PW; HUGHES, DC; ENGLISH, A; FOX, HB; PERRIN, J; HALFON, N				NEWACHECK, PW; HUGHES, DC; ENGLISH, A; FOX, HB; PERRIN, J; HALFON, N			THE EFFECT ON CHILDREN OF CURTAILING MEDICAID SPENDING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LOW-INCOME CHILDREN; HEALTH-SERVICES; POOR; CARE; POVERTY		UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PEDIAT,SAN FRANCISCO,CA 94109; NATL CTR YOUTH LAW,CHAPEL HILL,NC; FOX HLTH POLICY CONSULTANTS,WASHINGTON,DC; UNIV CALIF LOS ANGELES,DEPT PEDIAT,LOS ANGELES,CA 90024; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,BOSTON,MA 02115	University of California System; University of California San Francisco; University of California System; University of California Los Angeles; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	NEWACHECK, PW (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,1388 SUTTER ST,SUITE 1100,SAN FRANCISCO,CA 94109, USA.			Perrin, James/0000-0002-1810-3708				ANNEST J, 1984, VITAL HLTH STAT 233, V11; [Anonymous], [No title captured]; BENJAMIN AE, 1991, PEDIATRICS, V88, P75; BENSON V, 1994, VITAL HLTH STAT 189, V10; Cunningham P J, 1994, Future Child, V4, P24, DOI 10.2307/1602433; CURRIE J, 1995, J HUM RESOUR, V30, P135, DOI 10.2307/146194; DAVIS K, 1981, ANNU REV PUBL HEALTH, V2, P159, DOI 10.1146/annurev.pu.02.050181.001111; DUTTON DB, 1978, AM SOCIOL REV, V43, P348, DOI 10.2307/2094495; HALFON N, 1993, PEDIATRICS, V91, P56; KOVAR MG, 1982, PUBLIC HEALTH REP, V97, P3; KOVAR MG, 1981, US DHHS PUBLICATION, V5501; NEWACHECK P, 1994, J SCHOOL HEALTH, V64, P229, DOI 10.1111/j.1746-1561.1994.tb06191.x; NEWACHECK PW, 1988, AM J PUBLIC HEALTH, V78, P927, DOI 10.2105/AJPH.78.8.927; NEWACHECK PW, 1988, PEDIATRICS, V82, P462; NEWACHECK PW, 1995, HEALTH AFFAIR, V14, P244, DOI 10.1377/hlthaff.14.1.244; NEWACHECK PW, 1994, ARCH PEDIAT ADOL MED, V148, P1143, DOI 10.1001/archpedi.1994.02170110029005; OVERPECK MD, 1995, AM J PUBLIC HEALTH, V85, P402, DOI 10.2105/AJPH.85.3.402; ROBERTS J, 1977, VITAL HLTH STAT 201, V11; ROBERTS J, 1975, VITAL HLTH STAT 154, V11; ROBERTS J, 1973, VITAL HLTH STAT 129, V11; ROBERTS J, 1975, VITAL HLTH STAT 145, V11; ROBERTS J, 1975, VITAL HTLH STAT 157, V11; ROSENBACH ML, 1989, AM J PUBLIC HEALTH, V79, P1220, DOI 10.2105/AJPH.79.9.1220; SANCHEZ M, 1974, VITAL HLTH STAT 151, V11; SCHOENBORN CA, 1987, VITAL HLTH STAT 166, V10; SHORT PF, 1992, MED CARE, V30, P766, DOI 10.1097/00005650-199209000-00002; STARFIELD B, 1985, HEALTH SERV RES, V19, P817; Starfield B, 1982, J Public Health Policy, V3, P244, DOI 10.2307/3342443; STARFIELD B, 1992, FUTURE CHILD, V2, P25; SWARTZ K, 1990, WORKING POOR AM SOUR; WILSON RW, 1977, MED CARE, V15, P636, DOI 10.1097/00005650-197708000-00004; WISE PH, 1988, PEDIATR CLIN N AM, V35, P1169; 1995, MEDICAID MANAGED CAR; 1994, FY1988 AM AC PED MED; [No title captured]; 1995, HLTH NEEDS MED FINAN; 1995, 158 EMPL BEN RES I S; 1995, MEDICARE AM HLTH CAR; 1995, HOUSE SENATE MED BUD; 1995, MED PROGRAM GLANCE M; 1994, ANN REPORT C	41	15	15	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	1995	274	18					1468	1471		10.1001/jama.274.18.1468	http://dx.doi.org/10.1001/jama.274.18.1468			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TC477	7474195				2022-12-28	WOS:A1995TC47700031
J	SCHAEFER, EJ; LICHTENSTEIN, AH; LAMONFAVA, S; MCNAMARA, JR; SCHAEFER, MM; RASMUSSEN, H; ORDOVAS, JM				SCHAEFER, EJ; LICHTENSTEIN, AH; LAMONFAVA, S; MCNAMARA, JR; SCHAEFER, MM; RASMUSSEN, H; ORDOVAS, JM			BODY-WEIGHT AND LOW-DENSITY-LIPOPROTEIN CHOLESTEROL CHANGES AFTER CONSUMPTION OF A LOW-FAT AD-LIBITUM DIET	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; POLY-UNSATURATED FAT; SERUM-LIPIDS; CARBOHYDRATE INTAKE; TARAHUMARA INDIANS; MEN; PLASMA; TRIAL; WOMEN; POPULATIONS	Objective.-To assess the effects of a diet restricted in fat, saturated fat, and cholesterol, under weight-maintenance and ad libitum conditions on body weight and plasma lipid levels in hypercholesterolemic subjects. Design.-Dietary intervention study. Setting and Participants.-Twenty-seven free-living, healthy middle-aged and elderly men (n=13, age range, 41 to 81 years) and women (n=14, age range, 52 to 79 years) with moderate hypercholesterolemia (low-density lipoprotein cholesterol [LDL-C] greater than or equal to 3.36 mmol/L [130 mg/dL]) participated in the study. Intervention.-Subjects underwent three dietary phases. First, subjects were provided with a diet similar to the average US diet (baseline diet; 35.4% total fat, 13.8% to 14.1% saturated fat, and 30 to 35 mg/1000 kJ [128 to 147 mg/1000 kcal] cholesterol), During the second dietary phase, subjects consumed a low-fat diet (15.1% total fat, 5.0% saturated fat, 17 mg/1000 kJ [73 mg/1000 kcal] cholesterol). During the baseline and low-fat diet phases, which lasted 5 to 6 weeks each, the energy intake was adjusted to keep body weight constant. During the third diet phase (low-fat ad libitum diet) subjects were given the same low-fat diet for 10 to 12 weeks, but could adjust their intake between 66% and 133% of the energy required to maintain body weight. Main Outcome Measures.-Body weight and plasma lipid levels. Results.-Consumption of the low-fat diet underweight-maintenance conditions had significant lowering effects on plasma total cholesterol (TC), LDL-C, and high-density lipoprotein cholesterol (HDL-C) levels (mean change, -12.5%, -17.1%, and -22.8%, respectively). This diet significantly increased plasma triglyceride levels (+47.3%) and the TC/HDL-C ratio (+14.6%). In contrast, consumption of the low-fat ad libitum diet was accompanied by significant weight loss (-3.63 kg), by a mean decrease in LDL-C (-24.3%), and by mean triglyceride levels and TC/HDL-C ratio that were not significantly different from values obtained at baseline. Conclusions.-Our results indicate that a low-fat ad libitum diet promotes weight loss and LDL-C lowering without adverse effects on triglycerides or the TC/HDL-C ratio in middle-aged and elderly men and women with moderate hypercholesterolemia.	TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV ENDOCRINOL DIABET METAB & MOLEC MED,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111	Tufts Medical Center; Tufts University; Tufts University	SCHAEFER, EJ (corresponding author), TUFTS UNIV,JEAN MAYER USDA,HUMAN NUTR RES CTR AGING,LIPID METAB LAB,711 WASHINGTON ST,BOSTON,MA 02111, USA.		Ordovas, Jose/B-8727-2013	Ordovas, Jose/0000-0002-7581-5680	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039326] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL39326] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHESON KJ, 1982, METABOLISM, V31, P1234, DOI 10.1016/0026-0495(82)90010-5; ANTONIS A, 1961, LANCET, V1, P3; BARNARD RJ, 1991, ARCH INTERN MED, V151, P1389, DOI 10.1001/archinte.151.7.1389; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CONNOR SL, 1986, LANCET, V1, P1229; CONNOR WE, 1978, AM J CLIN NUTR, V31, P1131, DOI 10.1093/ajcn/31.7.1131; DATTILO AM, 1992, AM J CLIN NUTR, V56, P320, DOI 10.1093/ajcn/56.2.320; DAYTON S, 1969, CIRCULATION S2, V40, P11; DENKE MA, 1993, ARCH INTERN MED, V153, P1093, DOI 10.1001/archinte.153.9.1093; DOUGHERTY RM, 1988, AM J CLIN NUTR, V48, P970, DOI 10.1093/ajcn/48.4.970; FLATT JP, 1985, J CLIN INVEST, V76, P1019, DOI 10.1172/JCI112054; Friedewald W. T., 1972, CLIN CHEM, V18, P449; GINSBERG H, 1976, J CLIN ENDOCR METAB, V42, P729, DOI 10.1210/jcem-42-4-729; GRUNDY SM, 1990, J LIPID RES, V31, P1149; HOLME I, 1985, PREV MED, V14, P279, DOI 10.1016/0091-7435(85)90057-X; KANNEL W B, 1981, Progress in Lipid Research, V20, P339, DOI 10.1016/0163-7827(81)90067-9; KANNEL WB, 1986, AM HEART J, V112, P825, DOI 10.1016/0002-8703(86)90481-3; KASIM SE, 1993, AM J CLIN NUTR, V57, P146, DOI 10.1093/ajcn/57.2.146; KATO H, 1973, AM J EPIDEMIOL, V97, P372, DOI 10.1093/oxfordjournals.aje.a121518; KENDALL A, 1991, AM J CLIN NUTR, V53, P1124, DOI 10.1093/ajcn/53.5.1124; KNUIMAN JT, 1987, ARTERIOSCLEROSIS, V7, P612, DOI 10.1161/01.ATV.7.6.612; KUUSI T, 1985, J LIPID RES, V26, P360; LICHTENSTEIN AH, 1994, ARTERIOSCLER THROMB, V14, P1751, DOI 10.1161/01.ATV.14.11.1751; MCMURRY MP, 1991, NEW ENGL J MED, V325, P1704, DOI 10.1056/NEJM199112123252405; MCNAMARA JR, 1987, CLIN CHIM ACTA, V166, P1, DOI 10.1016/0009-8981(87)90188-4; MIETTINEN M, 1972, LANCET, V2, P835; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; ROBERTS SB, 1994, JAMA-J AM MED ASSOC, V272, P1601, DOI 10.1001/jama.272.20.1601; ROBERTSON TL, 1977, AM J CARDIOL, V39, P239, DOI 10.1016/S0002-9149(77)80197-5; ROBINSON D, 1979, BRIT MED J, V1, P1249, DOI 10.1136/bmj.1.6173.1249; SACKS FM, 1986, ARCH INTERN MED, V146, P1573, DOI 10.1001/archinte.146.8.1573; SCHAEFER EJ, 1981, AM J CLIN NUTR, V34, P1758, DOI 10.1093/ajcn/34.9.1758; SCHAEFER EJ, 1995, ARTERIOSCL THROM VAS, V15, P1079, DOI 10.1161/01.ATV.15.8.1079; SCHUTZ Y, 1989, AM J CLIN NUTR, V50, P307, DOI 10.1093/ajcn/50.2.307; SCHWARTZ RS, 1985, METABOLISM, V34, P285, DOI 10.1016/0026-0495(85)90014-9; SHEPPARD L, 1991, AM J CLIN NUTR, V54, P821, DOI 10.1093/ajcn/54.5.821; SIMS EAH, 1987, J CLIN INVEST, V79, P1019, DOI 10.1172/JCI112913; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; STEINBERG D, 1990, JAMA-J AM MED ASSOC, V264, P3047, DOI 10.1001/jama.264.23.3047; STUNKARD AJ, 1979, ARCH GEN PSYCHIAT, V36, P801, DOI 10.1001/archpsyc.1979.01780070079009; TRUSWELL AS, 1994, AM J CLIN NUTR, V59, p710S, DOI 10.1093/ajcn/59.3.710S; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WEST CE, 1990, AM J EPIDEMIOL, V131, P271, DOI 10.1093/oxfordjournals.aje.a115497; [No title captured]; 1983, DIETARY INTAKE SOURC, P48; 1975, US DHEW NIH75628 PUB; 1993, JAMA-J AM MED ASSOC, V269, P3015; 1994, HEART STROKE FACTS 1, P1	48	143	143	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	1995	274	18					1450	1455		10.1001/jama.274.18.1450	http://dx.doi.org/10.1001/jama.274.18.1450			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC477	7474191				2022-12-28	WOS:A1995TC47700027
J	RUSSELL, SM; TAYEBI, N; NAKAJIMA, H; RIEDY, MC; ROBERTS, JL; AMAN, MJ; MIGONE, TS; NOGUCHI, M; MARKERT, ML; BUCKLEY, RH; O'SHEA, JJ; LEONARD, WJ				RUSSELL, SM; TAYEBI, N; NAKAJIMA, H; RIEDY, MC; ROBERTS, JL; AMAN, MJ; MIGONE, TS; NOGUCHI, M; MARKERT, ML; BUCKLEY, RH; O'SHEA, JJ; LEONARD, WJ			MUTATION OF JAK3 IN A PATIENT WITH SCID - ESSENTIAL ROLE OF JAK3 IN LYMPHOID DEVELOPMENT	SCIENCE			English	Article							RECEPTOR GAMMA-CHAIN; FUNCTIONAL COMPONENT; IL-2 RECEPTOR	Males with X-linked severe combined immunodeficiency (XSCID) have defects in the common cytokine receptor gamma chain (gamma(c)) gene that encodes a shared, essential component of the receptors for interleukin-2 (IL-2), IL-4, IL-7, IL-9, and IL-15. The Janus family tyrosine kinase Jak3 is the only signaling molecule known to be associated with gamma(c), so it was hypothesized that defects in Jak3 might cause an XSCID-like phenotype. A girl with immunological features indistinguishable from those of XSCID was therefore selected for analysis. An Epstein-Barr virus (EBV)-transformed cell line derived from her lymphocytes had normal gamma(c) expression but lacked Jak3 protein and had greatly diminished Jak3 messenger RNA. Sequencing revealed a different mutation on each allele: a single nucleotide insertion resulting in a frame shift and premature termination in the Jak3 JH4 domain and a nonsense mutation in the Jak3 JH2 domain. The lack of Jak3 expression correlated with impaired B cell signaling, as demonstrated by the inability of IL-4 to activate Stat6 in the EBV-transformed cell line from the patient. These observations indicate that the functions of gamma(c) are dependent on Jak3 and that Jak3 is essential for lymphoid development and signaling.	NHLBI, MOLEC IMMUNOL LAB, BETHESDA, MD 20892 USA; NIMH, CLIN NEUROSCI BRANCH, CLIN GENET UNIT, BETHESDA, MD 20892 USA; NIAMSD, ARTHRITIS & RHEUMATISM BRANCH, BETHESDA, MD 20892 USA; DUKE UNIV, SCH MED, DEPT IMMUNOL, DURHAM, NC 27710 USA; DUKE UNIV, SCH MED, DEPT PEDIAT, DURHAM, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Duke University; Duke University			Russell, Sarah M/B-9341-2009; Leonard, Warren/AAA-1397-2022; Nakajima, Hiroshi/AFU-9313-2022; Buckley, Rebecca/AAB-1578-2019	Russell, Sarah M/0000-0001-5826-9641; Nakajima, Hiroshi/0000-0001-8595-9381; 	NATIONAL CANCER INSTITUTE [T32CA009058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018613] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09058] Funding Source: Medline; NCRR NIH HHS [M01-RR30] Funding Source: Medline; NIAID NIH HHS [R37AI18613-13] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Johnston J. C., UNPUB; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KIMURA Y, 1995, INT IMMUNOL, V7, P115, DOI 10.1093/intimm/7.1.115; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LEONARD WJ, 1994, IMMUNOL REV, V138, P61, DOI 10.1111/j.1600-065X.1994.tb00847.x; LEONARD WJ, IN PRESS ANN REV MED; LEONARD WJ, IN PRESS IMMUNOL REV; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; LOZANO F, 1994, EMBO J, V13, P4617, DOI 10.1002/j.1460-2075.1994.tb06783.x; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; NOSAKA, 1995, SCIENCE, V270, P800; PUCK JM, 1994, J CLIN IMMUNOL, V14, P81, DOI 10.1007/BF01541340; Qazilbash M H, 1995, J Hematother, V4, P91, DOI 10.1089/scd.1.1995.4.91; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; RUSSELL SM, UNPUB; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YIN TG, 1994, J BIOL CHEM, V269, P26614	31	600	629	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 3	1995	270	5237					797	800		10.1126/science.270.5237.797	http://dx.doi.org/10.1126/science.270.5237.797			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC712	7481768	Green Submitted			2022-12-28	WOS:A1995TC71200040
J	SEHGAL, A; ROTHENFLUHHILFIKER, A; HUNTERENSOR, M; CHEN, YF; MYERS, MP; YOUNG, MW				SEHGAL, A; ROTHENFLUHHILFIKER, A; HUNTERENSOR, M; CHEN, YF; MYERS, MP; YOUNG, MW			RHYTHMIC EXPRESSION OF TIMELESS - A BASIS FOR PROMOTING CIRCADIAN CYCLES IN PERIOD GENE AUTOREGULATION	SCIENCE			English	Article							MESSENGER-RNA LEVELS; DROSOPHILA-MELANOGASTER; MOSAIC ANALYSIS; MUTANTS	The clock gene timeless (tim) is required for circadian rhythmicity in Drosophila. The accumulation of tim RNA followed a circadian rhythm, and the phase and period of the tim RNA rhythm were indistinguishable from those that have been reported for per. The tim RNA oscillations were found to be dependent on the presence of PER and TIM proteins, which demonstrates feedback control of tim by a mechanism previously shown to regulate per expression. The cyclic expression of tim appears to dictate the timing of PER protein accumulation and nuclear localization, suggesting that tim promotes circadian rhythms of per and tim transcription by restricting per RNA and PER protein accumulation to separate times of day.	UNIV PENN,MED CTR,CTR SLEEP & RESP NEUROBIOL,PHILADELPHIA,PA 19104; ROCKEFELLER UNIV,CTR BIOL TIMING,HOWARD HUGHES MED INST,NATL SCI FDN SCI & TECHNOL,NEW YORK,NY 10021; ROCKEFELLER UNIV,GENET LAB,NEW YORK,NY 10021	University of Pennsylvania; Pennsylvania Medicine; Howard Hughes Medical Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Rockefeller University; Rockefeller University	SEHGAL, A (corresponding author), UNIV PENN,MED CTR,DEPT NEUROSCI,PHILADELPHIA,PA 19104, USA.		, 机智的马小跳和机智的羊不愁/ABC-5169-2020	Rothenfluh, Adrian/0000-0002-3813-5723				ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BAYLIES MK, 1993, MOL GENETICS BIOL RH, P123; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; EWER J, 1992, J NEUROSCI, V12, P3321; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, EMBO J, V11, P1; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HARDIN PE, 1994, MOL CELL BIOL, V14, P7211, DOI 10.1128/MCB.14.11.7211; KONOPKA R, 1983, MOL GEN GENET, V190, P284, DOI 10.1007/BF00330652; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; PRICE JL, 1995, EMBO J, V14, P4044, DOI 10.1002/j.1460-2075.1995.tb00075.x; ROTHENFLUHHILFI.A, UNPUB; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SEHGAL A, UNPUB; THERKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477; VOSSHALL LB, 1995, NEURON, V15, P345, DOI 10.1016/0896-6273(95)90039-X; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; ZATZ M, 1992, DISCUSS NEUROSCI, V8, P67; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x	24	294	306	5	35	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 3	1995	270	5237					808	810		10.1126/science.270.5237.808	http://dx.doi.org/10.1126/science.270.5237.808			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC712	7481772				2022-12-28	WOS:A1995TC71200044
J	BURKHOLDER, BT; TOOLE, MJ				BURKHOLDER, BT; TOOLE, MJ			EVOLUTION OF COMPLEX DISASTERS	LANCET			English	Article							REFUGEE; MORTALITY		MACFARLANE BURNET MED RES CTR, MELBOURNE, VIC, AUSTRALIA		BURKHOLDER, BT (corresponding author), CTR DIS CONTROL & PREVENT, INT HLTH PROGRAM OFF, MAILSTOP K-01, 4770 BUFORD HIGHWAY, ATLANTA, GA 30341 USA.							[Anonymous], 1995, Lancet, V345, P339; [Anonymous], MMWR; Burkle F M Jr, 1995, Prehosp Disaster Med, V10, P36; BUTTERWORTH R, 1981, DISASTERS, V5, P171; CHARTIER Y, 1993, UNHCR IMPROVED WATER; CURDY A, 1994, DEC WORKSH IMPR NUTR; GESSNER BD, 1994, JAMA-J AM MED ASSOC, V272, P382, DOI 10.1001/jama.272.5.382; Hansch S, 1994, LIVES LOST LIVES SAV; MAGAN AM, 1983, DISASTERS, V7, P94, DOI 10.1111/j.1467-7717.1983.tb00801.x; MOREN A, 1994, DEC WORKSH IMPR NUTR; NORTON R, 1994, DEC WORKSH IMPR NUTR; TOOLE M J, 1989, Bulletin of the World Health Organization, V67, P381; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; TOOLE MJ, 1993, JAMA-J AM MED ASSOC, V270, P600, DOI 10.1001/jama.270.5.600; TOOLE MJ, 1995, INFECT DIS CLIN N AM, V9, P353; TOOLE MJ, 1990, REV HLTH NUTRITION P; YIP R, 1993, JAMA-J AM MED ASSOC, V270, P587, DOI 10.1001/jama.270.5.587; 1982, HDB EMERGENCIES; 1993, 1993 WORLD BANK WORL; 1993, MMWR-MORBID MORTAL W, V972, P979; 1994, WORLD REFUGEE SURVEY	21	54	64	2	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 14	1995	346	8981					1012	1015		10.1016/S0140-6736(95)91694-6	http://dx.doi.org/10.1016/S0140-6736(95)91694-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475552				2022-12-28	WOS:A1995RZ59900016
J	MISTRY, PK				MISTRY, PK			GENOTYPE/PHENOTYPE CORRELATIONS IN GAUCHERS-DISEASE	LANCET			English	Editorial Material							GLUCOCEREBROSIDASE GENE; MUTATION				MISTRY, PK (corresponding author), ROYAL FREE HOSP,SCH MED,HEPATOBILIARY & LIVER TRANSPLANT UNIT,LONDON,ENGLAND.							ABRAHAMOV A, 1995, LANCET, V346, P1000, DOI 10.1016/S0140-6736(95)91688-1; BEUTLER E, 1993, P NATL ACAD SCI USA, V90, P5384, DOI 10.1073/pnas.90.12.5384; Beutler E., 1995, METABOLIC MOL BASES, P2641; BORNSTEIN P, 1995, P NATL ACAD SCI USA, V92, P4547, DOI 10.1073/pnas.92.10.4547; BRADY RO, 1993, ARCH NEUROL-CHICAGO, V50, P1212, DOI 10.1001/archneur.1993.00540110088009; CHABAS A, 1995, J MED GENET, V32, P740, DOI 10.1136/jmg.32.9.740; DAHL N, 1990, AM J HUM GENET, V47, P275; MISTRY PK, 1993, J MED GENET, V30, P889, DOI 10.1136/jmg.30.11.889; MISTRY PK, 1995, 1ST P WORKSH EUR WOR, P62; TSUJI S, 1987, NEW ENGL J MED, V316, P570, DOI 10.1056/NEJM198703053161002	10	24	25	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 14	1995	346	8981					982	983		10.1016/S0140-6736(95)91680-6	http://dx.doi.org/10.1016/S0140-6736(95)91680-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475586				2022-12-28	WOS:A1995RZ59900002
J	BLOOM, BS; KISSICK, WL				BLOOM, BS; KISSICK, WL			MARXISM, THE THEORY OF COMPLEMENTARITY, AND MEDICAL-CARE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											BLOOM, BS (corresponding author), UNIV PENN, PHILADELPHIA, PA 19104 USA.							BLENDON RJ, 1984, NEW ENGL J MED, V311, P613, DOI 10.1056/NEJM198408303110938; HIMMELSTEIN DU, 1988, ANN INTERN MED, V109, P494, DOI 10.7326/0003-4819-109-6-494	2	2	2	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1988	109	6					446	448		10.7326/0003-4819-109-6-446	http://dx.doi.org/10.7326/0003-4819-109-6-446			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q2568	3415104				2022-12-28	WOS:A1988Q256800002
J	EWY, GA				EWY, GA			THE ABDOMINOJUGULAR TEST - TECHNIQUE AND HEMODYNAMIC CORRELATES	ANNALS OF INTERNAL MEDICINE			English	Article											EWY, GA (corresponding author), UNIV ARIZONA, COLL MED, CARDIOL SECT, TUCSON, AZ 85724 USA.							BARRATTBOYES BG, 1958, J LAB CLIN MED, V51, P72; BRAUNWALD E, 1984, HEART DISEASE TXB CA, P496; BURCH GE, 1954, AM HEART J, V48, P373, DOI 10.1016/0002-8703(54)90025-3; COHN JN, 1982, PERICARDIAL DISEASE, P249; CONSTANT J, 1964, AM HEART J, V67, P701, DOI 10.1016/0002-8703(64)90343-6; DUCAS J, 1983, AM J CARDIOL, V52, P1299, DOI 10.1016/0002-9149(83)90592-1; EWY GA, 1985, SIGNS SYMPTOMS CARDI, P132; HULTGREN HN, 1950, AM HEART J, V39, P592, DOI 10.1016/0002-8703(50)90256-0; HURST JW, 1978, HEART ARTERIES VEINS, P200; MATTHEWS MB, 1958, LANCET, V1, P873; OROURKE RA, 1987, HARRISONS PRINCIPLES, P867; OROURKE RA, 1986, HEART ARTERIES VEINS, P147; PASTEUR W, 1885, LANCET, V2, P524; SINGH SP, 1973, POSTGRAD MED J, V49, P10, DOI 10.1136/pgmj.49.567.10	14	70	72	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1988	109	6					456	460		10.7326/0003-4819-109-6-456	http://dx.doi.org/10.7326/0003-4819-109-6-456			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q2568	3415106				2022-12-28	WOS:A1988Q256800004
J	SELIK, RM; CHU, SY; WARD, JW				SELIK, RM; CHU, SY; WARD, JW			TRENDS IN INFECTIOUS-DISEASES AND CANCERS AMONG PERSONS DYING OF HIV-INFECTION IN THE UNITED-STATES FROM 1987 TO 1992	ANNALS OF INTERNAL MEDICINE			English	Note							HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS PROPHYLAXIS; AIDS PATIENTS; SURVIVAL	Objective: To determine trends in the relative frequency of infectious diseases and cancers among U.S. residents dying of human immunodeficiency virus (HIV) infection. Data Source: National multiple-cause mortality data for 1987 to 1992 compiled from death certificates. Subjects: Deaths reported with HIV infection as the underlying cause and with nonunderlying causes that could be secondary to HIV infection. Data Analysis: Trends in the annual percentage of deaths associated with each infectious disease or cancer that accounted for at least 1.0% of all HIV-related deaths. Results: From 1987 to 1992, the percentage of HIV-related deaths associated with the following diseases decreased: pneumocystosis, from 32.5% to 13.8%; cryptococcosis, from 7.7% to 5.0%; and candidiasis, from 2.3% to 1.7%. The percentage of deaths associated with the following diseases increased: nontuberculous mycobacteriosis, from 6.7% to 12.2%; cytomegalovirus disease, from 5.2% to 9.9%; bacterial septicemia, from 9.0% to 11.5%; non-Hodgkin lymphoma, from 3.9% to 5.7%; tuberculosis, from 2.9% to 4.1%; progressive multifocal leukoencephalopathy, from 0.8% to 1.9%; bacterial pneumonia, from 1.2% to 2.1%; and cryptosporidiosis or isosporiasis, from 0.7% to 1.2%, The percentages of deaths associated with toxoplasmosis, Kaposi sarcoma, and pneumonia caused by unspecified organisms had no significant linear trends (ranges from 4.9% to 5.5%, 10.4% to 12.1%, and 17.6% to 18.6%, respectively). Conclusions: The percentage of HIV-related deaths associated with pneumocystosis has decreased dramatically, probably because of chemoprophylaxis and improved treatment. Pneumonia caused by unspecified organisms has now become the leading secondary cause of death among persons dying of HIV infection. Decreases in the percentages of HIV-related deaths associated with cryptococcosis and candidiasis may reflect the use of new antifungal agents such as fluconazole.			SELIK, RM (corresponding author), CTR DIS CONTROL & PREVENT, MAIL STOP E47, 1600 CLIFTON RD, ATLANTA, GA 30333 USA.							BEAMAN MH, 1992, ANN INTERN MED, V117, P163, DOI 10.7326/0003-4819-117-2-163; BUEHLER JW, 1990, AM J PUBLIC HEALTH, V80, P1080, DOI 10.2105/AJPH.80.9.1080; BUEHLER JW, 1992, AM J PUBLIC HEALTH, V82, P1500, DOI 10.2105/AJPH.82.11.1500; CHAISSON RE, 1992, ARCH INTERN MED, V152, P2009, DOI 10.1001/archinte.152.10.2009; HARRIS JE, 1990, JAMA-J AM MED ASSOC, V263, P397, DOI 10.1001/jama.263.3.397; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; ISRAEL RA, 1986, AM J EPIDEMIOL, V124, P161, DOI 10.1093/oxfordjournals.aje.a114375; KATZ MH, 1994, J INFECT DIS, V170, P198, DOI 10.1093/infdis/170.1.198; KOCHANEK KD, 1995, MONTHLY VITAL STATIS, V43, P70; MASUR H, 1993, NEW ENGL J MED, V329, P898, DOI 10.1056/NEJM199309163291228; MOORE RD, 1994, NEW ENGL J MED, V330, P763, DOI 10.1056/NEJM199403173301107; MUNOZ A, 1993, AM J EPIDEMIOL, V137, P423, DOI 10.1093/oxfordjournals.aje.a116691; NELSON MR, 1994, AIDS, V8, P651, DOI 10.1097/00002030-199405000-00011; PARENTE F, 1994, AM J GASTROENTEROL, V89, P416; SAAH AJ, 1995, JAMA-J AM MED ASSOC, V273, P1197, DOI 10.1001/jama.273.15.1197; SAMET JH, 1994, AM J MED, V97, P347, DOI 10.1016/0002-9343(94)90301-8; SELIK RM, 1987, AIDS, V1, P175; 1989, SAS P243 SAS I INC T, P1351; [No title captured]; 1994, MMWR-MORBID MORTAL W, V43, P826	20	105	105	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1995	123	12					933	936		10.7326/0003-4819-123-12-199512150-00006	http://dx.doi.org/10.7326/0003-4819-123-12-199512150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK120	7486488				2022-12-28	WOS:A1995TK12000006
J	SILLITO, AM; GRIEVE, KL; JONES, HE; CUDEIRO, J; DAVIS, J				SILLITO, AM; GRIEVE, KL; JONES, HE; CUDEIRO, J; DAVIS, J			VISUAL CORTICAL MECHANISMS DETECTING FOCAL ORIENTATION DISCONTINUITIES	NATURE			English	Article							DEPENDENT NEURONAL OSCILLATIONS; CROSS-CORRELATION ANALYSIS; CAT STRIATE CORTEX; RECEPTIVE-FIELDS; HYPERCOMPLEX CELLS; PATTERNS; RESPONSES; DISCRIMINATION; INHIBITION	NEURONS in the primary visual cortex (V1) respond in well defined ways to stimuli within their classical receptive field, but these responses can be modified by stimuli overlying the surrounding area(1-7). For example patch-suppressed cells respond to gratings of a specific orientation within their classical receptive field, but the response diminishes if the grating is expanded to cover the surrounding area(1-7). We report here more complex effects in many such cells. When stimulated at their optimal orientation, introducing a surrounding field at a significantly different (for example, orthogonal) orientation enhanced their output by both a disinhibitory mechanism and an active facilitatory mechanism producing 'supra-optimal' responses. Importantly, some cells responded well if the orientations of centre and surround stimuli were swapped. The output reflected the discontinuity because neither stimulus component alone was effective. Under these stimulus conditions simultaneously recorded cells with orthogonally oriented receptive fields showed correlated firing consistent with neuronal binding to the configuration. We propose a mechanism integrating orientation-dependent information over adjacent areas of visual space to represent focal orientation discontinuities such as junctions or corners.	UNIV LA CORUNA,HOSP JUAN CANALEJO,UNIDAD CIRUGAI,DEPT CIENCAS SALUD 1,EL FERROL,SPAIN	Complejo Hospitalario Universitario A Coruna; Universidade da Coruna	SILLITO, AM (corresponding author), INST OPHTHALMOL,DEPT VISUAL SCI,BATH ST,LONDON EC1V 9EL,ENGLAND.			Cudeiro, Javier/0000-0002-6597-6077				ABELES M, 1988, J NEUROPHYSIOL, V60, P909, DOI 10.1152/jn.1988.60.3.909; ABELES M, 1982, J NEUROSCI METH, V5, P317, DOI 10.1016/0165-0270(82)90002-4; BERGEN JR, 1983, NATURE, V303, P696, DOI 10.1038/303696a0; BERGEN JR, 1983, IEEE T SYST MAN CYB, V13, P857, DOI 10.1109/TSMC.1983.6313080; BORN RT, 1991, P NATL ACAD SCI USA, V88, P7071, DOI 10.1073/pnas.88.16.7071; DEANGELIS GC, 1992, J NEUROPHYSIOL, V68, P144, DOI 10.1152/jn.1992.68.1.144; DEANGELIS GC, 1994, J NEUROPHYSIOL, V71, P347, DOI 10.1152/jn.1994.71.1.347; ENGEL AK, 1990, EUR J NEUROSCI, V2, P588, DOI 10.1111/j.1460-9568.1990.tb00449.x; FRIES W, 1977, VISION RES, V17, P1001, DOI 10.1016/0042-6989(77)90002-5; GILBERT CD, 1990, VISION RES, V30, P1689, DOI 10.1016/0042-6989(90)90153-C; GRAY CM, 1990, EUR J NEUROSCI, V2, P607, DOI 10.1111/j.1460-9568.1990.tb00450.x; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; GRINVALD A, 1994, J NEUROSCI, V14, P2545; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P229, DOI 10.1152/jn.1965.28.2.229; KEEBLE DRT, 1995, VISION RES, V35, P1991, DOI 10.1016/0042-6989(94)00284-S; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; MAFFEI L, 1976, VISION RES, V16, P1131, DOI 10.1016/0042-6989(76)90253-4; NELSON JI, 1978, BRAIN RES, V139, P359, DOI 10.1016/0006-8993(78)90937-X; ORBAN GA, 1979, J NEUROPHYSIOL, V42, P818, DOI 10.1152/jn.1979.42.3.818; ORBAN GA, 1979, J NEUROPHYSIOL, V42, P833, DOI 10.1152/jn.1979.42.3.833; PALM G, 1988, BIOL CYBERN, V59, P1, DOI 10.1007/BF00336885; SILLITO AM, 1993, EXP BRAIN RES, V93, P6; SILLITO AM, 1977, J PHYSIOL-LONDON, V273, P791, DOI 10.1113/jphysiol.1977.sp012124; TSO DY, 1986, J NEUROSCI, V6, P1160	24	474	486	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					492	496		10.1038/378492a0	http://dx.doi.org/10.1038/378492a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477405				2022-12-28	WOS:A1995TH05400071
J	CARLSTEDT, T; GRANE, P; HALLIN, RG; NOREN, G				CARLSTEDT, T; GRANE, P; HALLIN, RG; NOREN, G			RETURN OF FUNCTION AFTER SPINAL-CORD IMPLANTATION OF AVULSED SPINAL NERVE ROOTS	LANCET			English	Article							REINNERVATION	Avulsion of nerve roots from the spinal cord is widely regarded as an untreatable injury. However, a series of experiments in animals has shown that, if continuity is restored between spinal cord and ventral roots, axons from spinal motor neurons can regrow into the peripheral nerves with recovery of motor function. These observations were applied in the treatment of a man with avulsion of the 6th cervical (C6) to 1st thoracic roots due to brachial plexus injury. Two ventral roots were implanted into the spinal cord through slits in the pia mater, C6 directly and C7 via sural nerve grafts. Voluntary activity in proximal arm muscles was detected electromyographically after nine months and clinically after one year. After three years the patient had voluntary activity (with some co-contraction) in the deltoid, biceps, and triceps muscles. To determine whether the improvement was due to spontaneous recovery from C5, the C5 root was blocked pharmacologically, and the results indicated that the repaired roots were contributing substantially to motor function. Repair of spinal nerve roots deserves further exploration in management of brachial plexus injury.	KAROLINSKA HOSP,DEPT NEURORADIOL,S-17176 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,DEPT NEUROSURG,S-17176 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,DEPT NEUROSCI,S-17176 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	CARLSTEDT, T (corresponding author), KAROLINSKA HOSP,DEPT ORTHOPAED,S-17176 STOCKHOLM,SWEDEN.							ALNOT JY, 1984, CLIN PLAST SURG, V11, P127; BONNEY G, 1954, BRAIN, V77, P588, DOI 10.1093/brain/77.4.588; CARLSTEDT T, 1986, ACTA PHYSIOL SCAND, V128, P645, DOI 10.1111/j.1748-1716.1986.tb08024.x; CARLSTEDT T, 1995, PARALYSIES PLEXUS BR, P290; CARLSTEDT TP, 1993, J NEUROL NEUROSUR PS, V56, P649, DOI 10.1136/jnnp.56.6.649; CULLHEIM S, 1989, NEUROSCIENCE, V29, P725, DOI 10.1016/0306-4522(89)90144-9; Jamieson AM, 1980, INT J MICROSURG, V2, P75; KAAS JH, 1991, ANNU REV NEUROSCI, V14, P137, DOI 10.1146/annurev.neuro.14.1.137; KLINE DG, 1992, J NEUROSURG, V76, P459, DOI 10.3171/jns.1992.76.3.0459; LINDA H, 1993, THESIS KAROLINSKA I; RISLING M, 1993, BRAIN RES BULL, V30, P405, DOI 10.1016/0361-9230(93)90272-D; RISLING M, 1983, BRAIN RES, V280, P15, DOI 10.1016/0006-8993(83)91169-1; [No title captured]	13	169	178	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 18	1995	346	8986					1323	1325		10.1016/S0140-6736(95)92342-X	http://dx.doi.org/10.1016/S0140-6736(95)92342-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE916	7475770				2022-12-28	WOS:A1995TE91600008
J	COOPER, RA				COOPER, RA			PERSPECTIVES ON THE PHYSICIAN WORKFORCE TO THE YEAR 2020	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; HEALTH-CARE; MEDICINE; DOCTOR; COSTS	Physician supply and demand for the period extending to 2020 were assessed from three perspectives: physician utilization in group- and staff-model health maintenance organizations, physician distribution, and the future supply of nonphysician clinicians. The national norm for physician demand in 1993 was estimated to be 205 per 100 000 population. Demand is projected to increase 18% by 2020, because of both an expansion in beneficial services and a reduction in physician work effort. Supply initially will increase more rapidly, resulting in a surplus of 31 000 physicians (5% of patient care physicians) in the year 2000 and increasing to 62 000 physicians (8%) in 2010, after which the gap will narrow. Similar results were obtained when previous studies that had projected surpluses of 73 000 to 165 000 physicians (15% to 30%) in the year 2000 were reevaluated. However, physician distribution is not homogeneous, and the number of physicians per capita currently varies by more than twofold among states. Relative to the national norm, surpluses already exist in some states and shortages in others. In addition, the supply of nonphysician clinicians with independent practice authority is increasing. Their numbers are projected to double by 2010, equaling 60% of the number of patient care physicians. Measured as physician equivalents, their growth will equal the growth in physician supply. Thus, in terms of physicians alone, there is no evidence of a major impending national surplus. Local surpluses will be influenced principally by how physicians distribute themselves geographically. The major determinant of overall physician surpluses in the future will be the extent to which patients continue to seek physicians for services that also will be offered by an expanded workforce of nonphysician clinicians. Policy is needed that encompasses the universe of clinicians who will be providing care to patients in the next century.			COOPER, RA (corresponding author), MED COLL WISCONSIN,INST HLTH POLICY,MILWAUKEE,WI 53226, USA.							Brimelow P., 1995, ALIEN NATION COMMON; Cooper R A, 1995, Trans Am Clin Climatol Assoc, V106, P188; COOPER RA, 1994, JAMA-J AM MED ASSOC, V272, P680, DOI 10.1001/jama.272.9.680; DEANGELIS CD, 1994, JAMA-J AM MED ASSOC, V271, P868, DOI 10.1001/jama.271.11.868; DIAL TH, 1995, HEALTH AFFAIR, V14, P168, DOI 10.1377/hlthaff.14.2.168; Donaldson M, 1994, DEFINING PRIMARY CAR; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; FEIL EC, 1993, JAMA-J AM MED ASSOC, V269, P2659, DOI 10.1001/jama.269.20.2659; FOWKES V, 1993, ASSESSMENT PHYSICIAN; GAMLIEL S, 1995, HEALTH AFFAIR, V14, P131, DOI 10.1377/hlthaff.14.2.131; HART LG, 1995, WILL GROWTH MANAGED; HOLMES SA, 1995, NY TIMES        1020, pA1; JACOBSEN SJ, 1987, HEALTH AFFAIR, V6, P48, DOI 10.1377/hlthaff.6.2.48; JONAS HS, 1994, JAMA-J AM MED ASSOC, V272, P694; JONES PE, 1994, JAMA-J AM MED ASSOC, V271, P1266, DOI 10.1001/jama.271.16.1266; KAUFMAN JL, 1995, JAMA-J AM MED ASSOC, V273, P112, DOI 10.1001/jama.1995.03520260031017; KLETKE PR, 1995, JAMA-J AM MED ASSOC, V273, P111, DOI 10.1001/jama.1995.03520260031016; KLETKE PR, 1990, AM J PUBLIC HEALTH, V80, P300, DOI 10.2105/AJPH.80.3.300; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V273, P1534, DOI 10.1001/jama.273.19.1534; LEMANN N, 1995, NY TIMES BOOK REV, V144, P3; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; LUND M, 1995, NEW YORKER, V71, P107; MILLIS JS, 1966, GRADUATE ED PHYSICIA; MOFFET HH, 1994, ALTERNATIVE COMPLEME, V1, P14; MULHAUSEN R, 1989, JAMA-J AM MED ASSOC, V261, P1930, DOI 10.1001/jama.261.13.1930; MULLAN F, 1995, JAMA-J AM MED ASSOC, V273, P1521, DOI 10.1001/jama.273.19.1521; Peabody FW, 1927, J AMER MED ASSOC, V88, P0877, DOI 10.1001/jama.1927.02680380001001; PETERSDORF RG, 1993, ACAD MED, V68, P113, DOI 10.1097/00001888-199302000-00001; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1074, DOI 10.1001/jama.270.9.1074; SCHROEDER SA, 1993, NEW ENGL J MED, V328, P961, DOI 10.1056/NEJM199304013281312; SCHROEDER SA, 1994, INQUIRY, V28, P266; SCHWARTZ WB, 1990, JAMA-J AM MED ASSOC, V263, P557; SCHWARTZ WB, 1988, JAMA-J AM MED ASSOC, V259, P233, DOI 10.1001/jama.259.2.233; SEKSCENSKI ES, 1994, NEW ENGL J MED, V331, P1266, DOI 10.1056/NEJM199411103311905; SHINE KI, 1995, JAMA-J AM MED ASSOC, V273, P1057, DOI 10.1001/jama.273.13.1057; STODDARD JJ, 1994, JAMA-J AM MED ASSOC, V272, P53, DOI 10.1001/jama.272.1.53; Tarlov A R, 1986, Health Aff (Millwood), V5, P23, DOI 10.1377/hlthaff.5.1.23; TARLOV AR, 1983, NEW ENGL J MED, V308, P1235, DOI 10.1056/NEJM198305193082028; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WEINER JP, 1995, HRSA94576P US DEP HL; WENNBERG JE, 1993, HEALTH AFFAIR, V12, P89, DOI 10.1377/hlthaff.12.2.89; WILLIAMS AP, 1983, NEW ENGL J MED, V309, P958, DOI 10.1056/NEJM198310203091606; 1993, PHYSICIAN CHARACTERI; 1994, HMO IND PROFILE 1993; 1990, 6TH UD DEP HLTH HUM; 1994, BOOK STATES 1994 199, V30; 1992, POPULATION PROJEJCTI; 1989, POPULATION PROJECTIO; 1992, IMPROVING ACCESS HLT; 1992, HLTH PERSONNEL US 19; 1994, TRACKING CENSUS SAIM; 1995, AOA YB DIRECTORY 199; 1995, SOCIOECONOMIC CHARAC; 1994, 192643 NAT LEAG NURS; 1995, OVERVIEW LEGISLATIVE; 1994, RECOMMENDATIONS IMPR; 1993, POPULATION PROJECTIO; 1994, MED SCH GRADUATION Q; 1995, STATISTICAL INFORMAT; 1995, DOCTORATE RECIPIENTS; 1994, POLICYR ES PERSPECTI; 1981, HSA81651 US DEP HLTH; 1994, 1995 STATE MANAGED L; 1977, POPULATION PROJECTIO; 1994, STATISTICAL ABSTRACT	65	116	116	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	1995	274	19					1534	1543		10.1001/jama.274.19.1534	http://dx.doi.org/10.1001/jama.274.19.1534			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD571	7474222				2022-12-28	WOS:A1995TD57100030
J	THOMPSON, C				THOMPSON, C			THALIDOMIDE EFFECTIVE FOR AIDS-RELATED ORAL ULCERS	LANCET			English	Editorial Material																			0	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1289	1289		10.1016/S0140-6736(95)91884-1	http://dx.doi.org/10.1016/S0140-6736(95)91884-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475726				2022-12-28	WOS:A1995TE14500031
J	BOURNE, HR				BOURNE, HR			TRIMERIC G-PROTEINS - SURPRISE WITNESS TELLS A TALE	SCIENCE			English	Editorial Material							GAMMA		UNIV CALIF SAN FRANCISCO,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	BOURNE, HR (corresponding author), UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT CELLULAR & MOLEC PHARMACOL & MED,SAN FRANCISCO,CA 94143, USA.							COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; GARCIA PD, IN PRESS EMBO J; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; WHITEWAY M, 1994, MOL CELL BIOL, V14, P3223, DOI 10.1128/MCB.14.5.3223	10	10	10	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 10	1995	270	5238					933	934		10.1126/science.270.5238.933	http://dx.doi.org/10.1126/science.270.5238.933			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD878	7481796				2022-12-28	WOS:A1995TD87800033
J	HAN, S; ELTIS, LD; TIMMIS, KN; MUCHMORE, SW; BOLIN, JT				HAN, S; ELTIS, LD; TIMMIS, KN; MUCHMORE, SW; BOLIN, JT			CRYSTAL-STRUCTURE OF THE BIPHENYL-CLEAVING EXTRADIOL DIOXYGENASE FROM A PCB-DEGRADING PSEUDOMONAD	SCIENCE			English	Article							PROTEIN; DEGRADATION; MECHANISM; PATHWAY	Polychlorinated biphenyls (PCBs) typify a class of stable aromatic pollutants that are targeted by bioremediation strategies. In the aerobic degradation of biphenyl by bacteria, the key step of ring cleavage is catalyzed by an Fe(II)-dependent extradiol dioxygenase. The crystal structure of 2,3-dihydroxybiphenyl 1,2-dioxygenase from a PCB-degrading strain of Pseudomonas cepacia has been determined at 1.9 angstrom resolution, The monomer comprises amino- and carboxyl-terminal domains, Structural homology between and within the domains reveals evolutionary relationships within the extradiol dioxygenase family. The iron atom has five ligands in square pyramidal geometry: one glutamate and two histidine side chains, and two water molecules.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907; UNIV LAVAL,DEPT BIOCHEM,ST FOY,PQ G1K 7P4,CANADA; GESELL BIOTECHNOL FORSCH MBH,BEREICH MIKROBIOL,D-38124 BRAUNSCHWEIG,GERMANY	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Laval University; Gesellschaft fur Biotechnologische Forschung mbH			Eltis, Lindsay D/J-8272-2015	Eltis, Lindsay D/0000-0002-6774-8158	NIGMS NIH HHS [GM 52831] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052831] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOWICZ DA, 1990, CRIT REV BIOTECHNOL, V10, P241, DOI 10.3109/07388559009038210; ARCIERO DM, 1985, J BIOL CHEM, V260, P4035; ARCIERO DM, 1985, J BIOL CHEM, V260, P2170; ASTURIAS JA, 1994, J BIOL CHEM, V269, P7807; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BERTINI I, 1994, BIOCHEMISTRY-US, V33, P10777, DOI 10.1021/bi00201a027; BOLDT YR, 1995, J BACTERIOL, V177, P1225, DOI 10.1128/jb.177.5.1225-1232.1995; BOLIN JT, UNPUB; BOLIN JT, 1993, MAY ANN M AM CRYST A; BOPP LH, 1986, J IND MICROBIOL, V1, P23, DOI 10.1007/BF01569413; BRUNGER AT, 1992, X PLOR; CCP4, 1979, CCP4 SUITE PROGRAMS; CERDAN P, 1994, J BACTERIOL, V176, P6074, DOI 10.1128/jb.176.19.6074-6081.1994; CHAN AWE, 1993, PROTEIN SCI, V2, P1574, DOI 10.1002/pro.5560021004; ELTIS LD, 1993, J BIOL CHEM, V268, P2727; HARAYAMA S, 1992, ANNU REV MICROBIOL, V46, P565, DOI 10.1146/annurev.mi.46.100192.003025; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HOFER B, 1993, GENE, V130, P47, DOI 10.1016/0378-1119(93)90345-4; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOLM L, 1994, NUCLEIC ACIDS RES, V22, P3600; HOLM L, 1992, PROTEIN SCI, V1, P1691, DOI 10.1002/pro.5560011217; HORI K, 1973, J BIOCHEM, V74, P375; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MABROUK PA, 1991, J AM CHEM SOC, V113, P4053, DOI 10.1021/ja00011a001; MINOR W, 1993, XDIS PLAYF; OHLENDORF DH, 1988, NATURE, V336, P403, DOI 10.1038/336403a0; OHLENDORF DH, 1994, J MOL BIOL, V244, P586, DOI 10.1006/jmbi.1994.1754; OTWINOWSKI Z, 1991, P CCP4 STUDY WEEKEND, P56; RAMOS JL, 1987, SCIENCE, V235, P593, DOI 10.1126/science.3468623; SCARROW RC, 1994, BIOCHEMISTRY-US, V33, P15023, DOI 10.1021/bi00254a011; SHU LJ, 1995, BIOCHEMISTRY-US, V34, P6649, DOI 10.1021/bi00020a010; SINGH J, 1992, ATLAS PROTEIN SIDECH; SUGIYAMA K, 1995, P JPN ACAD B-PHYS, V71, P32, DOI 10.2183/pjab.71.32; TIMMIS KN, 1994, ANNU REV MICROBIOL, V48, P525, DOI 10.1146/annurev.mi.48.100194.002521; WASSERFALLEN A, 1991, BIO-TECHNOL, V9, P296, DOI 10.1038/nbt0391-296	39	309	313	2	44	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 10	1995	270	5238					976	980		10.1126/science.270.5238.976	http://dx.doi.org/10.1126/science.270.5238.976			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD878	7481800				2022-12-28	WOS:A1995TD87800045
J	SMITH, CK; REGAN, L				SMITH, CK; REGAN, L			GUIDELINES FOR PROTEIN DESIGN - THE ENERGETICS OF BETA-SHEET SIDE-CHAIN INTERACTIONS	SCIENCE			English	Article							HELIX-FORMING TENDENCIES; TERTIARY STRUCTURE; AMINO-ACIDS; STABILITY; PEPTIDES	To determine the interaction energy between cross-strand pairs of side chains on an antiparallel beta sheet, pairwise amino acid substitutions were made on the solvent-exposed face of the B1 domain of streptococcal protein G, The measured interaction energies were substantial (1.8 kilocalories per mole) and comparable to the magnitude of the beta sheet propensities. The experimental results paralleled the statistical frequency with which the residue pairs are found in beta sheets of known structure.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520	Yale University								BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; CHAKRABARTTY A, 1993, P NATL ACAD SCI USA, V90, P11337; CHOU PY, 1973, BIOCHEMISTRY-US, V13, P211; GARRATT RC, 1991, FEBS LETT, V280, P141, DOI 10.1016/0014-5793(91)80223-P; GRONENBORN AM, 1991, SCIENCE, V253, P657, DOI 10.1126/science.1871600; HUNTER CA, 1991, J MOL BIOL, V218, P837, DOI 10.1016/0022-2836(91)90271-7; KIM CWA, 1993, NATURE, V362, P267, DOI 10.1038/362267a0; LIFSON S, 1980, J MOL BIOL, V139, P627, DOI 10.1016/0022-2836(80)90052-2; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MINOR DL, 1994, NATURE, V371, P264, DOI 10.1038/371264a0; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PADMANABHAN S, 1994, J MOL BIOL, V241, P706, DOI 10.1006/jmbi.1994.1545; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; PADMANABHAN S, 1995, PROTEIN SCI, V3, P1992; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SALEMME FR, 1983, PROG BIOPHYS MOL BIO, V42, P95, DOI 10.1016/0079-6107(83)90005-6; SERRANO L, 1991, J MOL BIOL, V218, P465, DOI 10.1016/0022-2836(91)90725-L; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; von Heijne G, 1977, J Mol Biol, V117, P821, DOI 10.1016/0022-2836(77)90073-0; WOUTERS MA, 1995, PROTEINS, V22, P119, DOI 10.1002/prot.340220205	23	235	254	0	23	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 10	1995	270	5238					980	982		10.1126/science.270.5238.980	http://dx.doi.org/10.1126/science.270.5238.980			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD878	7481801				2022-12-28	WOS:A1995TD87800046
J	SAUCIER, D; CAIN, DP				SAUCIER, D; CAIN, DP			SPATIAL-LEARNING WITHOUT NMDA RECEPTOR-DEPENDENT LONG-TERM POTENTIATION	NATURE			English	Article							WATER-MAZE; SELECTIVE IMPAIRMENT; SYNAPTIC PLASTICITY; ANTAGONIST; MEMORY; RAT; BLOCKADE; ACQUISITION; MECHANISMS; NPC-17742	HIPPOCAMPAL lesions impair spatial learning in the watermaze(1). Drugs that antagonize N-methyl-D-aspartate (NMDA)-receptor activity, which is required for long-term potentiation (LTP) at various hippocampal synapses(2-4), block LTP and impair watermaze learning(4-6). This has led to the hypothesis that NMDA receptors, through their involvement in LTP, may be necessary for spatial(4-11) and other forms of learning(12,13). We examined this hypothesis using NPC17742 (2R,4R,5S-2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptano acid), a potent and specific antagonist of NMDA receptors(14-17). Here we report that NPC17742 completely blocked dentate gyrus LTP but did not prevent normal spatial learning in rats that had been made familiar with the general task requirements by non-spatial pretraining. Although these results do not rule out a contribution of NMDA-mediated dentate LTP to spatial learning, they indicate that this form of LTP is not required for normal spatial learning in the watermaze.	UNIV WESTERN ONTARIO,GRAD PROGRAM NEUROSCI,LONDON,ON N6A 5C2,CANADA	Western University (University of Western Ontario)	SAUCIER, D (corresponding author), UNIV WESTERN ONTARIO,DEPT PSYCHOL,LONDON,ON N6A 5C2,CANADA.							BARNES CA, 1988, TRENDS NEUROSCI, V11, P163, DOI 10.1016/0166-2236(88)90143-9; BAUDRY M, 1988, LONG TERM POTENTIATI; BOBELIS DJ, 1993, J PHARMACOL EXP THER, V264, P845; BROWN TH, 1988, SCIENCE, V242, P724, DOI 10.1126/science.2903551; CAIN DP, 1993, HIPPOCAMPUS, V3, P153, DOI 10.1002/hipo.450030208; CAIN DP, IN PRESS BEHAV NEURO; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; COTMAN CW, 1988, ANNU REV NEUROSCI, V11, P61, DOI 10.1146/annurev.neuro.11.1.61; DAVIS S, 1992, J NEUROSCI, V12, P21; FERKANY JW, 1993, J PHARMACOL EXP THER, V264, P256; HARGREAVES EL, 1990, J NEUROSCI, V10, P1472; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; JEFFERY KJ, 1993, HIPPOCAMPUS, V3, P133, DOI 10.1002/hipo.450030205; KEITH JR, 1990, PSYCHOBIOLOGY, V18, P251; KOROL DL, 1993, HIPPOCAMPUS, V3, P127, DOI 10.1002/hipo.450030204; MISERENDINO MJD, 1990, NATURE, V345, P716, DOI 10.1038/345716a0; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; OLNEY J, 1993, NEUROBIOLOGY CINGULA; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; SAUCIER D, IN PRESS BEHAV NEURO; SCHWARTZ JH, 1987, ANNU REV NEUROSCI, V10, P459; STAUBLI U, 1989, BEHAV NEUROSCI, V103, P54, DOI 10.1037/0735-7044.103.1.54; SUTHERLAND RJ, 1993, HIPPOCAMPUS, V3, P141, DOI 10.1002/hipo.450030206; WILEY JL, 1994, PSYCHOPHARMACOLOGY, V116, P266, DOI 10.1007/BF02245327; WILLETTS J, 1993, J PHARMACOL EXP THER, V265, P1055	28	280	289	1	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 9	1995	378	6553					186	189		10.1038/378186a0	http://dx.doi.org/10.1038/378186a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD759	7477321				2022-12-28	WOS:A1995TD75900054
J	SILBERSWEIG, DA; STERN, E; FRITH, C; CAHILL, C; HOLMES, A; GROOTOONK, S; SEAWARD, J; MCKENNA, P; CHUA, SE; SCHNORR, L; JONES, T; FRACKOWIAK, RSJ				SILBERSWEIG, DA; STERN, E; FRITH, C; CAHILL, C; HOLMES, A; GROOTOONK, S; SEAWARD, J; MCKENNA, P; CHUA, SE; SCHNORR, L; JONES, T; FRACKOWIAK, RSJ			A FUNCTIONAL NEUROANATOMY OF HALLUCINATIONS IN SCHIZOPHRENIA	NATURE			English	Article							CEREBRAL BLOOD-FLOW; AUDITORY HALLUCINATIONS; AREA; PET	HALLUCINATIONS, perceptions in the absence of external stimuli, are prominent among the core symptoms of schizophrenia. The neural correlates of these brief, involuntary experiences are not well understood, and have not been imaged selectively. We have used new positron emission tomography (PET) methods(1,2) to study the brain state associated with the occurrence of hallucinations in six schizophrenic patients. Here we present a group study of five patients with classic auditory verbal hallucinations despite medication, demonstrating activations in subcortical nuclei (thalamic, striatal), limbic structures (especially hippocampus), and paralimbic regions (parahippocampal and cingulate gyri, as well as orbito-frontal cortex). We also present a case study of a unique, drug-naive patient with visual as well as auditory verbal hallucinations, demonstrating activations in visual and auditory/linguistic association cortices as part of a distributed cortical-subcortical network. Activity in deep brain structures, identified with group analysis, may generate or modulate hallucinations, and the particular neocortical regions entrained in individual patients may affect their specific perceptual content. The interaction of these distributed neural systems provides a biological basis for the bizarre reports of schizophrenic patients.	HAMMERSMITH HOSP, INST NEUROL, WELLCOME DEPT COGNIT NEUROL, LONDON W12 0NN, ENGLAND; NEW YORK HOSP, CORNELL MED CTR, FUNCT NEUROIMAGING LAB, NEW YORK, NY 10021 USA; FULBOURNE HOSP, FULBOURN CB1 5EF, ENGLAND	Imperial College London; University of London; University College London; Cornell University; NewYork-Presbyterian Hospital	SILBERSWEIG, DA (corresponding author), HAMMERSMITH HOSP, MRC, CYCLOTRON UNIT, DUCANE RD, LONDON W12 0NN, ENGLAND.		Frackowiak, Richard/H-4383-2011; Stern, Emily/E-6035-2011; Frith, Chris D/A-2171-2009; Frackowiak, Richard S/I-1809-2013	Frackowiak, Richard/0000-0002-3151-822X; Frith, Chris D/0000-0002-8665-0690; McKenna, Peter/0000-0001-5474-1144				ANDREASEN NC, 1994, SCIENCE, V266, P294, DOI 10.1126/science.7939669; BARBUR JL, 1993, BRAIN, V116, P1293, DOI 10.1093/brain/116.6.1293; BOGERTS B, 1993, SCHIZOPHRENIA BULL, V19, P431, DOI 10.1093/schbul/19.2.431; CLEGHORN JM, 1992, AM J PSYCHIAT, V149, P1062; CLEGHORN JM, 1990, BRIT J PSYCHIAT, V157, P562, DOI 10.1192/bjp.157.4.562; CSERNANSKY JG, 1991, BIOL PSYCHIAT, V30, P383, DOI 10.1016/0006-3223(91)90295-W; DELISI LE, 1989, BIOL PSYCHIAT, V25, P835, DOI 10.1016/0006-3223(89)90263-1; DOLAN RJ, 1995, HUMAN BRAIN MAPPIN S, V1, P417; FARAH MJ, 1989, TRENDS NEUROSCI, V12, P395, DOI 10.1016/0166-2236(89)90079-9; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; FRISTON KJ, 1992, BRAIN, V115, P367, DOI 10.1093/brain/115.2.367; FRISTON KJ, IN PRESS BIOL SCHIZO; KURACHI M, 1985, EUR NEUROL, V24, P176, DOI 10.1159/000115791; LLINAS RR, 1991, NEUROSCIENCE, V44, P521, DOI 10.1016/0306-4522(91)90075-Y; MARSH L, 1994, SCHIZOPHR RES, V11, P225, DOI 10.1016/0920-9964(94)90016-7; MATSUDA H, 1988, CLIN NUCL MED, V13, P53, DOI 10.1097/00003072-198801000-00015; MCGUIRE PK, 1993, LANCET, V342, P703, DOI 10.1016/0140-6736(93)91707-S; MCGUIRE PK, IN PRESS PSYCHOL MED; Mesulam M. M., 1985, PRINCIPLES BEHAVIORA, P1; MUSALEK M, 1989, COMPR PSYCHIAT, V30, P99, DOI 10.1016/0010-440X(89)90123-5; NOTARDONATO H, 1989, CLIN NUCL MED, V14, P319, DOI 10.1097/00003072-198905000-00001; OLNEY JW, 1995, BIOL PSYCHIAT, V37, P667, DOI 10.1016/0006-3223(95)94677-O; SILBERSWEIG DA, 1994, J CEREBR BLOOD F MET, V14, P771, DOI 10.1038/jcbfm.1994.98; SILBERSWEIG DA, 1993, J CEREBR BLOOD F MET, V13, P617, DOI 10.1038/jcbfm.1993.80; TALAIRACH J, 1989, CO PLANAR STEREOTAXI; Trimble MR, 1991, PSYCHOSES EPILEPSY; VOLKOW ND, 1987, AM J PSYCHIAT, V144, P151; WEINBERGER DR, 1994, J NEUROPSYCH CLIN N, V6, P419; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; ZEKI S, 1991, J NEUROSCI, V11, P641	30	717	729	1	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 9	1995	378	6553					176	179		10.1038/378176a0	http://dx.doi.org/10.1038/378176a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD759	7477318				2022-12-28	WOS:A1995TD75900051
J	ARTENSTEIN, AW; COPPOLA, J; BROWN, AE; CARR, JK; SANDERSBUELL, E; GALBARINI, E; MASCOLA, JR; VANCOTT, TC; SCHONBROOD, P; MCCUTCHAN, FE; BURKE, DS				ARTENSTEIN, AW; COPPOLA, J; BROWN, AE; CARR, JK; SANDERSBUELL, E; GALBARINI, E; MASCOLA, JR; VANCOTT, TC; SCHONBROOD, P; MCCUTCHAN, FE; BURKE, DS			MULTIPLE INTRODUCTIONS OF HIV-1 SUBTYPE-E INTO THE WESTERN-HEMISPHERE	LANCET			English	Note								There are nine recognised genetic subtypes of HIV-1, and the epidemic in Southeast Asia is largely due to subtype E. We have investigated HIV-1 viral subtypes in 11 Uruguayan military personnel, six with infection acquired during a United Nations deployment to Cambodia and five with infection acquired in South America. We found subtype E in five of the six infections acquired in Southeast Asia, and subtype B in all five of the domestically acquired cases. These findings document multiple introductions of HIV-1 subtype E into the western hemisphere and mean that the genetic diversity of the global HIV-1 pandemic must be considered in strategies for epidemic control.	NATL HLTH DIRECTORATE ARMED FORCES,MONTEVIDEO,URUGUAY; HENRY M JACKSON FDN,ROCKVILLE,MD	Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc	ARTENSTEIN, AW (corresponding author), WALTER REED ARMY INST RES,DIV RETROVIROL,ROCKVILLE,MD 20850, USA.		Mascola, John/AAI-7193-2021	/0000-0002-5704-8094				ARTENSTEIN AW, 1995, J INFECT DIS, V171, P805, DOI 10.1093/infdis/171.4.805; BERRIOLO R, 1992, AIDS, V6, P884; GAO F, 1994, AIDS RES HUM RETROV, V10, P625, DOI 10.1089/aid.1994.10.625; KUNANUSONT C, 1995, LANCET, V345, P1078, DOI 10.1016/S0140-6736(95)90818-8; LOUWAGIE J, 1994, AIDS RES HUM RETROV, V10, P561, DOI 10.1089/aid.1994.10.561; MASCOLA JR, 1994, J INFECT DIS, V169, P48, DOI 10.1093/infdis/169.1.48; MCCUTCHAN FE, 1992, AIDS RES HUM RETROV, V8, P1887, DOI 10.1089/aid.1992.8.1887; MORGADO MG, 1994, AIDS RES HUM RETROV, V10, P569, DOI 10.1089/aid.1994.10.569; MYERS G, 1994, HUMAN RETROVIRUSES A; QUINN TC, 1994, P NATL ACAD SCI USA, V91, P2407, DOI 10.1073/pnas.91.7.2407	10	76	76	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 4	1995	346	8984					1197	1198		10.1016/S0140-6736(95)92900-2	http://dx.doi.org/10.1016/S0140-6736(95)92900-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC976	7475660	Bronze			2022-12-28	WOS:A1995TC97600010
J	POCOCK, SJ; HENDERSON, RA; RICKARDS, AF; HAMPTON, JR; KING, SB; HAMM, CW; PUEL, J; HUEB, W; GOY, JJ; RODRIGUEZ, A				POCOCK, SJ; HENDERSON, RA; RICKARDS, AF; HAMPTON, JR; KING, SB; HAMM, CW; PUEL, J; HUEB, W; GOY, JJ; RODRIGUEZ, A			METAANALYSIS OF RANDOMIZED TRIALS COMPARING CORONARY ANGIOPLASTY WITH BYPASS-SURGERY	LANCET			English	Article							DIRECTIONAL ATHERECTOMY; ARTERY; SURVIVAL; DISEASE; GRAFT	A patient with severe angina will often be eligible for either angioplasty (PTCA) or bypass surgery (CABG). Results from eight published randomised trials have been combined in a collaborative meta-analysis of 3371 patients (1661 CABG, 1710 PTCA) with a mean follow-up of 2 . 7 years. The total deaths in the CABG and PTCA groups were 73 and 79, respectively, with a relative risk (RR) of 1 . 08 (95% CI 0 . 79-1 . 50). The combined endpoint of cardiac death and non-fatal myocardial infarction occurred in 169 PTCA patients and 154 CABG patients (RR 1 . 10 [0 . 89-1 . 37]). Amongst patients randomised to PTCA 17 . 8% required additional CABG within a year, while in subsequent years the need for additional CABG was around 2% per annum. The rate of additional non-randomised interventions (PTCA and/or CABG) in the first year of follow-up was 33 . 7% and 3 . 3% in patients randomised to PTCA and CABG, respectively. The prevalence of angina after one year was considerably higher in the PTCA group (RR 1 . 56 [1 . 30-1 . 88]) but at 3 years this difference had attenuated (RR 1 . 22 [0 . 99-1 . 54]). Overall there was substantial similarity in outcome across the trials. Separate analyses for the 732 single-vessel and 2639 multivessel disease patients were largely compatible, though the rates of mortality, additional intervention, and prevalent angina were slightly lower in single vessel disease. The combined evidence comparing PTCA with CABG shows no difference in prognosis between these two initial revascularisation strategies. However, the treatments differ markedly in the subsequent requirement for additional revascularisation procedures and in the relief of angina. These results will influence the choice of revascularisation procedure in future patients with angina.	WYTHENSHAWE HOSP, MANCHESTER M23 9LT, LANCS, ENGLAND; ROYAL BROMPTON HOSP, LONDON SW3 6LY, ENGLAND; UNIV NOTTINGHAM HOSP, NOTTINGHAM NG7 2UH, ENGLAND; EMORY UNIV, SCH MED, ATLANTA, GA USA; UNIV HAMBURG, HOSP EPPENDORF, D-20246 HAMBURG, GERMANY; CTR HOSP PURPAN, TOULOUSE, FRANCE; UNIV SAO PAULO, BR-05508 SAO PAULO, BRAZIL; CHU VAUDOIS, CH-1011 LAUSANNE, SWITZERLAND; ANCHORENA HOSP, BUENOS AIRES, DF, ARGENTINA	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Royal Brompton Hospital; University of Nottingham; Emory University; University of Hamburg; CHU de Toulouse; Universidade de Sao Paulo; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	POCOCK, SJ (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, KEPPEL ST, LONDON WC1E 7HT, ENGLAND.		Hamm, Christian W./I-3155-2017; Hueb, Whady/A-7919-2013	Hamm, Christian W./0000-0001-6763-4161; Hueb, Whady/0000-0002-3166-6054				ADELMAN AG, 1993, NEW ENGL J MED, V329, P228, DOI 10.1056/NEJM199307223290402; [Anonymous], 1995, Lancet, V346, P1179; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; FITZGIBBON GM, 1991, J AM COLL CARDIOL, V17, P1075, DOI 10.1016/0735-1097(91)90834-V; GOY JJ, 1994, LANCET, V343, P1449, DOI 10.1016/S0140-6736(94)92579-8; HAMM CW, 1995, NEW ENGL J MED, V332, P889; HAMM CW, 1994, NEW ENGL J MED, V331, P1037, DOI 10.1056/NEJM199410203311601; HUEB W, IN PRESS J AM COLL C; KING SB, 1995, AM J CARDIOL, V75, pC42; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; King SB, 1993, J AM COLL CARDIOL, V22, P353, DOI 10.1016/0735-1097(93)90037-2; LAIRDMEETER K, 1987, BRIT HEART J, V57, P427; LITVACK F, 1994, J AM COLL CARDIOL, V23, P323, DOI 10.1016/0735-1097(94)90414-6; LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101; LYTLE BW, 1987, J THORAC CARDIOV SUR, V93, P847; PUEL J, 1992, CIRCULATION, V86, P372; RODRIGUEZ A, 1993, J AM COLL CARDIOL, V22, P1060, DOI 10.1016/0735-1097(93)90416-X; SCULPHER MJ, 1994, LANCET, V344, P927, DOI 10.1016/S0140-6736(94)92274-8; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; STEWART M, 1994, LANCET, V344, P416, DOI 10.1016/S0140-6736(94)91448-6; TOPOL EJ, 1993, NEW ENGL J MED, V329, P221, DOI 10.1056/NEJM199307223290401; WEBB JG, 1990, J AM COLL CARDIOL, V16, P812, DOI 10.1016/S0735-1097(10)80327-4; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; 1991, CIRCULATION S5, V84, P1; 1993, LANCET, V343, P573	27	406	416	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 4	1995	346	8984					1184	1189		10.1016/S0140-6736(95)92897-9	http://dx.doi.org/10.1016/S0140-6736(95)92897-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC976	7475657				2022-12-28	WOS:A1995TC97600007
J	SHORTRIDGE, KF				SHORTRIDGE, KF			THE NEXT PANDEMIC INFLUENZA-VIRUS	LANCET			English	Editorial Material							A VIRUSES				SHORTRIDGE, KF (corresponding author), UNIV HONG KONG,DEPT MICROBIOL,PATHOL BLDG,QUEEN MARY HOSP CPDS,HONG KONG,HONG KONG.							CASTRUCCI MR, 1993, VIROLOGY, V193, P503, DOI 10.1006/viro.1993.1155; MURPHY BR, 1990, VIROLOGY, P1091; REICHELDELFER P, 1989, 1ST P AS PAC C MED V, P412; SCHOLTISSEK C, 1987, MOSBACH C, V38, P39; SCHOLTISSEK C, 1985, VIROLOGY, V147, P278; Shortridge K F, 1992, Semin Respir Infect, V7, P11; SHORTRIDGE KF, 1982, B WORLD HEALTH ORGAN, V60, P129; SHORTRIDGE KF, 1982, LANCET, V2, P812; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992; WEBSTER RG, 1975, INFLUENZA VIRUSES IN, P269	10	35	36	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 4	1995	346	8984					1210	1212		10.1016/S0140-6736(95)92906-1	http://dx.doi.org/10.1016/S0140-6736(95)92906-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC976	7475666				2022-12-28	WOS:A1995TC97600016
J	NOGUCHI, S; MCNALLY, EM; BENOTHMANE, K; HAGIWARA, Y; MIZUNO, Y; YOSHIDA, M; YAMAMOTO, H; BONNEMANN, CG; GUSSONI, E; DENTON, PH; KYRIAKIDES, T; MIDDLETON, L; HENTATI, F; BENHAMIDA, M; NONAKA, I; VANCE, JM; KUNKEL, LM; OZAWA, E				NOGUCHI, S; MCNALLY, EM; BENOTHMANE, K; HAGIWARA, Y; MIZUNO, Y; YOSHIDA, M; YAMAMOTO, H; BONNEMANN, CG; GUSSONI, E; DENTON, PH; KYRIAKIDES, T; MIDDLETON, L; HENTATI, F; BENHAMIDA, M; NONAKA, I; VANCE, JM; KUNKEL, LM; OZAWA, E			MUTATIONS IN THE DYSTROPHIN-ASSOCIATED PROTEIN GAMMA-SARCOGLYCAN IN CHROMOSOME-13 MUSCULAR-DYSTROPHY	SCIENCE			English	Article							GLYCOPROTEIN COMPLEX; GENE; ORGANIZATION; DOMAIN; ACTIN; CDNA	Severe childhood autosomal recessive muscular dystrophy (SCARMD) is a progressive muscle-wasting disorder common in North Africa that segregates with microsatellite markers at chromosome 13q12. Here, it is shown that a mutation in the gene encoding the 35-kilodalton dystrophin-associated glycoprotein, gamma-sarcoglycan, is likely to be the primary genetic defect in this disorder. The human gamma-sarcoglycan gene was mapped to chromosome 13q12, and deletions that alter its reading frame were identified in three families and one of four sporadic cases of SCARMD. These mutations not only affect gamma-sarcoglycan but also disrupt the integrity of the entire sarcoglycan complex.	CHILDRENS HOSP, DIV GENET, BOSTON, MA 02155 USA; CHILDRENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02155 USA; DUKE UNIV, MED CTR, DEPT MED, DIV NEUROL, DURHAM, NC 27710 USA; CYPRUS INST NEUROL & GENET, NICOSIA, CYPRUS; INST NEUROL, TUNIS, TUNISIA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Duke University; Universite de Tunis-El-Manar; Institut National de Neurologie	NOGUCHI, S (corresponding author), NATL CTR NEUROL & PSYCHIAT, NATL INST NEUROSCI, 4-1-1 OGAWA HIGASHI CHO, KODAIRA, TOKYO 187, JAPAN.		Gussoni, Emanuela/AAL-6150-2021; McNally, Elizabeth/W-4909-2019	Gussoni, Emanuela/0000-0002-9915-3677; McNally, Elizabeth/0000-0002-1221-719X; Vance, Jeffery/0000-0003-3815-8199	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS026630, R01NS023740] Funding Source: NIH RePORTER; NINDS NIH HHS [P01-NS26630, NS23740] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AZIBI K, 1993, HUM MOL GENET, V2, P1423; AZIBI K, 1991, CYTOGENET CELL GENET, V58, P1907; BENOTHMANE K, 1992, NAT GENET, V2, P315, DOI 10.1038/ng1292-315; BENOTHMANE K, 1995, AM J HUM GENET, V57, P732; BENOTHMANE K, UNPUB; BONNEMANN CG, IN PRESS NATURE GENE; BUENO MRP, 1994, AMJ HUM GENET, V55, pA199; BURGHES AHM, 1987, NATURE, V328, P434, DOI 10.1038/328434a0; BUSHBY KMD, 1995, NEUROMUSCULAR DISORD, V5, P337, DOI 10.1016/0960-8966(95)00005-8; ELKERCH F, 1994, J MED GENET, V31, P342, DOI 10.1136/jmg.31.4.342; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; FARAG TI, 1990, AM J MED GENET, V37, P290, DOI 10.1002/ajmg.1320370229; HAMIDA MB, 1983, MUSCLE NERVE, V6, P469, DOI 10.1002/mus.880060702; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; LEVINE BA, 1990, FEBS LETT, V263, P159, DOI 10.1016/0014-5793(90)80728-2; LIM LE, IN PRESS NATURE GENE; LJUNGGREN A, 1995, ANN NEUROL, V38, P367, DOI 10.1002/ana.410380305; MCNALLY EM, 1994, P NATL ACAD SCI USA, V91, P9690, DOI 10.1073/pnas.91.21.9690; MCNALLY EM, UNPUB; MIZUNO Y, 1994, BIOCHEM BIOPH RES CO, V203, P979, DOI 10.1006/bbrc.1994.2278; MIZUNO Y, UNPUB; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; NOGUCHI S, UNPUB; OZAWA E, IN PRESS HUM MOL GEN; PICCOLO F, 1995, NAT GENET, V10, P243, DOI 10.1038/ng0695-243; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; SUZUKI A, 1992, FEBS LETT, V308, P154, DOI 10.1016/0014-5793(92)81265-N; YAMAMOTO H, 1994, J BIOCHEM-TOKYO, V115, P162, DOI 10.1093/oxfordjournals.jbchem.a124294; YOSHIDA M, 1994, EUR J BIOCHEM, V222, P1055, DOI 10.1111/j.1432-1033.1994.tb18958.x; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276; ZATZ M, 1995, HUM MOL GENET, V4, P401, DOI 10.1093/hmg/4.3.401; ZATZ M, 1989, AM J MED GENET, V32, P407, DOI 10.1002/ajmg.1320320328	35	466	476	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 3	1995	270	5237					819	822		10.1126/science.270.5237.819	http://dx.doi.org/10.1126/science.270.5237.819			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC712	7481775				2022-12-28	WOS:A1995TC71200047
J	EASTWOOD, M				EASTWOOD, M			THE DILEMMA OF LAXATIVE ABUSE	LANCET			English	Editorial Material											EASTWOOD, M (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT MED,GASTROINTESTINAL UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							MORTON J, 1987, ANN CLIN BIOCHEM, V24, P107, DOI 10.1177/000456328702400116; NEIMS DM, 1995, INT J EAT DISORDER, V17, P211, DOI 10.1002/1098-108X(199504)17:3<211::AID-EAT2260170302>3.0.CO;2-I; PHILLIPS S, 1995, ANN INTERN MED, V123, P97, DOI 10.7326/0003-4819-123-2-199507150-00003; READ NW, 1980, GASTROENTEROLOGY, V78, P264; WELTZIN TE, 1995, INT J EAT DISORDER, V17, P141, DOI 10.1002/1098-108X(199503)17:2<141::AID-EAT2260170206>3.0.CO;2-5	5	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 28	1995	346	8983					1115	1115		10.1016/S0140-6736(95)91795-0	http://dx.doi.org/10.1016/S0140-6736(95)91795-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TB549	7475598				2022-12-28	WOS:A1995TB54900005
J	JUNGERS, P; HOUILLIER, P; FORGET, D; LABRUNIE, M; SKHIRI, H; GIATRAS, I; DESCAMPSLATSCHA, B				JUNGERS, P; HOUILLIER, P; FORGET, D; LABRUNIE, M; SKHIRI, H; GIATRAS, I; DESCAMPSLATSCHA, B			INFLUENCE OF PREGNANCY ON THE COURSE OF PRIMARY CHRONIC GLOMERULONEPHRITIS	LANCET			English	Article							GLOMERULAR-DISEASE; RENAL-DISEASE; WOMEN	According to some nephrologists, pregnancy has damaging effects on renal function in primary glomerulonephritis, but the evidence is conflicting. We evaluated the effect of pregnancy on the occurrence of end-stage renal failure (ESRF) in 360 patients with various histological forms of primary glomerulonephritis but with normal renal function (serum creatinine less than or equal to 0.11 mmol/L) at presentation. In actuarial analyses, overall ESRF-free survival did not significantly differ between women who became pregnant after clinical onset of renal disease (n=171) and those who did not conceive (n=189). Furthermore, in a case-control study pregnancy did not emerge as a risk factor for progression to ESRF (odds ratio 1.15 [95% CI 0.61-2.18]), whereas the type of glomerulonephritis and hypertension were major determinants. We conclude that pregnancy does not affect the course of renal disease in patients who have normal renal function al conception.	HOP NECKER ENFANTS MALAD,INSERM,U25,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	JUNGERS, P (corresponding author), HOP NECKER ENFANTS MALAD,DEPT NEPHROL,149 RUE SEVRES,F-75015 PARIS,FRANCE.		Houillier, Pascal/AAD-4903-2019	Houillier, Pascal/0000-0003-4953-6917				ABE S, 1985, AM J OBSTET GYNECOL, V153, P508, DOI 10.1016/0002-9378(85)90463-6; ABE S, 1994, CLIN NEPHROL, V41, P61; BARCELO P, 1986, KIDNEY INT, V30, P914, DOI 10.1038/ki.1986.272; HOU SH, 1985, AM J MED, V78, P185, DOI 10.1016/0002-9343(85)90425-5; IMBASCIATI E, 1986, AM J NEPHROL, V6, P193, DOI 10.1159/000167114; Jungers P, 1986, Adv Nephrol Necker Hosp, V15, P103; KATZ AI, 1980, KIDNEY INT, V18, P192, DOI 10.1038/ki.1980.128; PACKHAM DK, 1989, Q J MED, V266, P537; SURIAN M, 1984, NEPHRON, V36, P101, DOI 10.1159/000183126; 1989, LANCET, V2, P253	10	64	69	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 28	1995	346	8983					1122	1124		10.1016/S0140-6736(95)91798-5	http://dx.doi.org/10.1016/S0140-6736(95)91798-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB549	7475601				2022-12-28	WOS:A1995TB54900008
J	VANITERSON, M; VANDERWAART, FJM; ERDMANN, W; TROUWBORST, A				VANITERSON, M; VANDERWAART, FJM; ERDMANN, W; TROUWBORST, A			SYSTEMIC HEMODYNAMICS AND OXYGENATION DURING HEMODILUTION IN CHILDREN	LANCET			English	Article							HEMODILUTION ANESTHESIA; BLOOD-TRANSFUSION; JEHOVAH WITNESSES; SURGERY; RESECTION	Transfusion of homologous blood should be avoided when possible, and one technique that diminishes perioperative requirement for donor blood is haemodilution. In children its effects on systemic haemodynamics and systemic oxygenation have not been reported. Six children aged 4-12 yr were anaesthetised for major surgery and blood was withdrawn to reduce packed cell volume to 25%. Cardiac index increased from 3.1 (SD 0.5) L min(-1) m(-2) at baseline to 4.4 (0.5) L min(-1) m(-2) at the end of surgery, when packed cell volume was 16 (1)%; this change, compensating for the decline in oxygen carrying capacity, was associated with a fall in systemic vascular resistance and a rise in stroke volume. Oxygen extraction from haemoglobin rose from 0.22 (0.05) to 0.33 (0.06). Perioperative blood loss was 40% of circulating blood volume; however, owing to reinfusion of autologous blood (and use of a cell saver in three patients), the haemoglobin one day after operation was only 19% lower than preoperatively (9.9 [1.5] vs 12.5 [2.5] g/dL). In this study, children seemed at least as able as adults to compensate for the effects of haemodilution, which allowed major surgery without transfusion of homologous blood.	UNIV AMSTERDAM, ACAD MED CTR, DEPT ANAESTHESIOL, 1105 AZ AMSTERDAM, NETHERLANDS; ERASMUS UNIV ROTTERDAM, DEPT ANAESTHESIOL, ROTTERDAM, NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; Erasmus University Rotterdam								ADZICK NS, 1985, J PEDIATR SURG, V20, P372, DOI 10.1016/S0022-3468(85)80222-0; BERKMAN SA, 1988, BLOOD REV, V2, P206, DOI 10.1016/0268-960X(88)90026-4; BLUMBERG N, 1989, TRANSFUSION, V29, P236, DOI 10.1046/j.1537-2995.1989.29389162731.x; CUTLER BS, 1984, SURGERY, V95, P717; DESA VP, 1991, ANESTH ANALG, V72, P645; HENDERSON AM, 1986, ANAESTHESIA, V41, P748, DOI 10.1111/j.1365-2044.1986.tb12846.x; HENLING CE, 1985, J THORAC CARDIOV SUR, V89, P914; KRAFT M, 1981, ANAESTHESIA, V36, P402, DOI 10.1111/j.1365-2044.1981.tb10247.x; LICHTIGER B, 1982, ANESTH ANALG, V61, P618; MESSMER K, 1986, EUR SURG RES, V18, P254, DOI 10.1159/000128533; NADLER SB, 1962, SURGERY, V51, P224; SCHALLER RT, 1983, AM J SURG, V146, P79, DOI 10.1016/0002-9610(83)90263-5; SCHALLER RT, 1984, J PEDIATR SURG, V19, P705, DOI 10.1016/S0022-3468(84)80356-5; SPAHN DR, 1994, ANESTH ANALG, V78, P1000; TOY PTCY, 1987, NEW ENGL J MED, V316, P517, DOI 10.1056/NEJM198702263160906; TROUWBORST A, 1990, LANCET, V336, P1295, DOI 10.1016/0140-6736(90)92973-L; TROUWBORST A, 1990, ANESTH ANALG, V70, P523; ZETTERSTROM H, 1986, ACTA ANAESTH SCAND, V30, P300, DOI 10.1111/j.1399-6576.1986.tb02418.x	18	23	24	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 28	1995	346	8983					1127	1129		10.1016/S0140-6736(95)91800-0	http://dx.doi.org/10.1016/S0140-6736(95)91800-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB549	7475603				2022-12-28	WOS:A1995TB54900010
J	CARSON, DA; LOIS, A				CARSON, DA; LOIS, A			CANCER PROGRESSION AND P53	LANCET			English	Review							PROTEIN; MICE	In a complex organism, somatic cells are under intermittent selection pressure for the emergence of mutants that can survive environmental insults and that can grow autonomously despite adverse conditions. Repeated rounds of mutation, selection, and proliferation may lead to cancer. The organism prevents malignant transformation by assuring accurate DNA repair before cell division, by forcing the death of cells with excessive DNA damage, and by placing limits on the replicative lifespans of most somatic cells. The p53 gene is a ''guardian of the genome''-it regulates multiple components of the DNA damage control response and promotes cellular senescence. Disabling mutations and deletions of p53 occur in 50% of human tumours, p53-deficient cancers are often unstable, aggressive, and resistant to therapy.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego	CARSON, DA (corresponding author), UNIV CALIF SAN DIEGO,SAM & ROSE STEIN INST RES AGING,9500 GILMAN DR,LA JOLLA,CA 92093, USA.							BOND JA, 1994, ONCOGENE, V9, P1885; CANNON CE, 1995, GENE DEV, V9, P600; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FREBOURG T, 1995, AM J HUM GENET, V56, P608; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HARVEY M, 1993, ONCOGENE, V8, P2457; HASSAPOGLIDOU S, 1993, ONCOGENE, V8, P1501; HESKETH R, 1995, ONCOGENE FACTS BOOK; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; XIONG Y, 1993, NATURE, V366, P401; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	23	152	163	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 14	1995	346	8981					1009	1011		10.1016/S0140-6736(95)91693-8	http://dx.doi.org/10.1016/S0140-6736(95)91693-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475551				2022-12-28	WOS:A1995RZ59900015
J	VIERHOUT, WPM; KNOTTNERUS, JA; VANOOIJ, A; CREBOLDER, HFJM; POP, P; WESSELINGHMEGENS, AMK; BEUSMANS, GHMI				VIERHOUT, WPM; KNOTTNERUS, JA; VANOOIJ, A; CREBOLDER, HFJM; POP, P; WESSELINGHMEGENS, AMK; BEUSMANS, GHMI			EFFECTIVENESS OF JOINT CONSULTATION SESSIONS OF GENERAL-PRACTITIONERS AND ORTHOPEDIC SURGEONS FOR LOCOMOTOR-SYSTEM DISORDERS	LANCET			English	Article							ORTHOPEDIC OUTPATIENT REFERRALS; SICKNESS IMPACT PROFILE; CARE; FAMILY	Joint consultation sessions between general practitioners (GPs) and specialists to examine patients for whom decisions about referral are difficult are thought to be helpful, but their effects have not been evaluated. In a randomised, controlled trial we studied the effects of joint sessions of GPs and orthopaedic surgeons on referral and intervention rates. During 1.5 years, 12 GPs (in groups of three) held monthly joint consultation sessions with four participating orthopaedic surgeons: patients were seen by one orthopaedic surgeon in the presence of three GPs. Patients were included in the trial if the GP was uncertain about the diagnostic or therapeutic management and if referral was considered; and excluded if referral was urgently necessary or if there was some other clear indication for referral. By a randomised consent design, patients were assigned to joint consultation sessions (n=144) or a usual-care control group (n=128). A year later the patients were examined by an independent orthopaedic surgeon. There were significantly fewer referrals (51/144 [35%] vs 87/128 [68%], p<0.01) and diagnostic actions in the intervention group than in the control group, without negative effects on health or functional status. More patients in the intervention group were symptom-free at 1 year (35% vs 24%, p<0.05). Joint consultation sessions of GPs and orthopaedic surgeons within the framework of general practice resulted in more efficient care, with better targeted examination, treatment, and referrals.	ACAD HOSP MAASTRICHT,DEPT ORTHOPAED,MAASTRICHT,NETHERLANDS; ACAD HOSP MAASTRICHT,CTR TRANSMURAL MED,MAASTRICHT,NETHERLANDS	Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC)	VIERHOUT, WPM (corresponding author), UNIV LIMBURG,POB 616,6200 MD MAASTRICHT,NETHERLANDS.		Knottnerus, Johannes A/A-3829-2009; Knottnerus, Andre/F-4866-2013					ARMSTRONG D, 1991, BRIT MED J, V302, P1186, DOI 10.1136/bmj.302.6786.1186; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; FELSON DT, 1985, ARTHRITIS RHEUM, V28, P1156, DOI 10.1002/art.1780281012; FLEMING D, 1993, THESIS U LIMBURG MAA; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; FROM J, 1984, J FAM PRACTICE, V18, P623; GERRITSMA JGM, 1982, WERKWIJSZE HUISARTS; GILSON BS, 1975, AM J PUBLIC HEALTH, V65, P1304, DOI 10.2105/AJPH.65.12.1304; HALPIN SFS, 1991, BRIT MED J, V303, P813, DOI 10.1136/bmj.303.6806.813; JOOSTEN J, 1987, GEZONDHEID SAMENLEVI, V10, P251; KNOTTNERUS JA, 1991, FAM PRACT, V8, P305, DOI 10.1093/fampra/8.4.305; KNOTTNERUS JA, 1990, BRIT J GEN PRACT, V40, P178; KNOTTNERUS JA, 1987, HUISARTS WET, V30, P116; KNOTTNERUS JA, 1987, HUISARTS WET, V30, P49; KNOTTNERUS JA, 1987, HUISARTS WET, V30, P72; LAMBERTS H, 1991, HUIS HUISARTS VERSLA; Lamberts H., 1987, ICPC INT CLASSIFICAT; MOLD JW, 1986, NEW ENGL J MED, V314, P512, DOI 10.1056/NEJM198602203140809; Nachemson AL, 1976, SPINE, V1, P9; NEWTON J, 1991, FAM PRACT, V8, P308, DOI 10.1093/fampra/8.4.308; REYNOLDS GA, 1991, BMJ-BRIT MED J, V302, P1250, DOI 10.1136/bmj.302.6787.1250; ROCKLY PH, 1978, J FAM PRACTICE, V3, P455; ROLAND MO, 1991, BRIT MED J, V302, P1124, DOI 10.1136/bmj.302.6785.1124; ROSS AK, 1983, BRIT MED J, V287, P1439, DOI 10.1136/bmj.287.6403.1439; SCHNEEWEISS R, 1989, JAMA-J AM MED ASSOC, V262, P370; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203; 1992, JB ZIEKENHUIZEN	28	58	59	2	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 14	1995	346	8981					990	994		10.1016/S0140-6736(95)91686-5	http://dx.doi.org/10.1016/S0140-6736(95)91686-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475592				2022-12-28	WOS:A1995RZ59900008
J	SCHIEDERMAYER, DL				SCHIEDERMAYER, DL			THE DECISION TO FORGO CPR IN THE ELDERLY PATIENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									MED COLL WISCONSIN,DIV GEN INTERNAL MED,MILWAUKEE,WI 53226	Medical College of Wisconsin	SCHIEDERMAYER, DL (corresponding author), MED COLL WISCONSIN,CTR STUDY BIOETH,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226, USA.							BASS E, 1985, ANN INTERN MED, V103, P920, DOI 10.7326/0003-4819-103-6-920; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; CALLAHAN D, 1987, SETTING LIMITS MED G, P170; DANS PE, 1988, NEW ENGL J MED, V318, P1272; GORDON M, 1984, J AM GERIATR SOC, V32, P930, DOI 10.1111/j.1532-5415.1984.tb00895.x; JOHNSON AL, 1967, AM J CARDIOL, V20, P831, DOI 10.1016/0002-9149(67)90397-9; NOLAN K, 1987, HASTINGS CENT REP, V17, P9, DOI 10.2307/3562663; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; TOMLINSON R, 1988, N ENGL J MED, V318, P43; YOUNGNER SJ, 1987, HASTINGS CENT REP, V17, P24, DOI 10.2307/3562438; 1987, GUIDELINES TERMINATI, P46; 1987, OTABA306 US C OFF TE, P167	14	36	36	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1988	260	14					2096	2097		10.1001/jama.260.14.2096	http://dx.doi.org/10.1001/jama.260.14.2096			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q3421	3418876				2022-12-28	WOS:A1988Q342100026
J	LOELIGER, EA				LOELIGER, EA			DIPYRIDAMOLE AS AN ANTITHROMBOTIC DRUG	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											LOELIGER, EA (corresponding author), UNIV HOSP LEIDEN,2300 RC LEIDEN,NETHERLANDS.							FITZGERALD GA, 1987, NEW ENGL J MED, V316, P1247; LOELIGER EA, 1985, THROMB HAEMOSTASIS, V53, P437; RANHOSKY A, 1987, NEW ENGL J MED, V317, P1734; SULLIVAN JM, 1971, NEW ENGL J MED, V284, P1391, DOI 10.1056/NEJM197106242842501	4	1	1	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 6	1988	319	14					951	952						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q2854	3419462				2022-12-28	WOS:A1988Q285400021
J	STERNBERG, PW				STERNBERG, PW			LATERAL INHIBITION DURING VULVAL INDUCTION IN CAENORHABDITIS-ELEGANS	NATURE			English	Article											STERNBERG, PW (corresponding author), CALTECH,DIV BIOL 156-29,PASADENA,CA 91125, USA.			Sternberg, Paul/0000-0002-7699-0173				AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BRENNER S, 1974, GENETICS, V77, P71; CAMPOSORTEGA JA, 1985, TRENDS NEUROSCI, V8, P245, DOI 10.1016/0166-2236(85)90097-9; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; TECHNAU G M, 1986, Wilhelm Roux's Archives of Developmental Biology, V195, P445; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; Wigglesworth VB, 1940, J EXP BIOL, V17, P180; WILCOX M, 1973, J CELL SCI, V12, P707; YOCHEM J, 1988, NATURE, V335	19	197	206	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1988	335	6190					551	554		10.1038/335551a0	http://dx.doi.org/10.1038/335551a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q3412	3419532				2022-12-28	WOS:A1988Q341200056
J	BATEMAN, E; PAULE, MR				BATEMAN, E; PAULE, MR			PROMOTER OCCLUSION DURING RIBOSOMAL-RNA TRANSCRIPTION	CELL			English	Article											BATEMAN, E (corresponding author), COLORADO STATE UNIV,DEPT BIOCHEM,FT COLLINS,CO 80523, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022580] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22580] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1982, CELL, V29, P939, DOI 10.1016/0092-8674(82)90456-1; BAKER SM, 1986, CELL, V47, P839, DOI 10.1016/0092-8674(86)90795-6; BATEMAN E, 1986, CELL, V47, P445, DOI 10.1016/0092-8674(86)90601-X; BATEMAN E, 1988, MOL CELL BIOL, V8, P1940, DOI 10.1128/MCB.8.5.1940; BATEMAN E, 1985, P NATL ACAD SCI USA, V82, P8004, DOI 10.1073/pnas.82.23.8004; BROWN DD, 1984, CELL, V37, P359, DOI 10.1016/0092-8674(84)90366-0; DEWINTER RFJ, 1986, NUCLEIC ACIDS RES, V14, P6041, DOI 10.1093/nar/14.15.6041; GAY NJ, 1986, BIOCHEM J, V234, P111, DOI 10.1042/bj2340111; GRUMMT I, 1985, CELL, V43, P801, DOI 10.1016/0092-8674(85)90253-3; GRUMMT I, 1986, CELL, V47, P901, DOI 10.1016/0092-8674(86)90805-6; HENDERSON S, 1986, CELL, V47, P891, DOI 10.1016/0092-8674(86)90804-4; HOROWITZ H, 1982, NUCLEIC ACIDS RES, V10, P5447, DOI 10.1093/nar/10.18.5447; IIDA CT, 1985, P NATL ACAD SCI USA, V82, P1668, DOI 10.1073/pnas.82.6.1668; KOWNIN P, 1985, NUCLEIC ACIDS RES, V13, P6237, DOI 10.1093/nar/13.17.6237; KOWNIN P, 1988, MOL CELL BIOL, V8, P747, DOI 10.1128/MCB.8.2.747; KOWNIN P, 1987, CELL, V50, P693, DOI 10.1016/0092-8674(87)90327-8; LABHART P, 1987, CELL, V50, P51, DOI 10.1016/0092-8674(87)90661-1; LABHART P, 1986, CELL, V45, P431, DOI 10.1016/0092-8674(86)90329-6; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LOSA R, 1987, CELL, V50, P801, DOI 10.1016/0092-8674(87)90338-2; MANIATIS T, 1982, MOL CLONING LABORATO; MCSTAY B, 1986, CELL, V47, P913, DOI 10.1016/0092-8674(86)90806-8; MITCHELSON K, 1987, NUCLEIC ACIDS RES, V15, P9577, DOI 10.1093/nar/15.22.9577; MOSS T, 1983, NATURE, V302, P223, DOI 10.1038/302223a0; MURTIF VL, 1985, NUCLEIC ACIDS RES, V13, P3221, DOI 10.1093/nar/13.9.3221; PROUDFOOT NJ, 1986, NATURE, V322, P562, DOI 10.1038/322562a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.bi.55.070186.004101; SPINDLER SR, 1978, J BIOL CHEM, V253, P4669; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; WOLFFE AP, 1986, CELL, V47, P217, DOI 10.1016/0092-8674(86)90444-7; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	33	104	104	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 23	1988	54	7					985	992		10.1016/0092-8674(88)90113-4	http://dx.doi.org/10.1016/0092-8674(88)90113-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	Q3063	3416358				2022-12-28	WOS:A1988Q306300011
J	PEARSON, SD; GOULARTFISHER, D; LEE, TH				PEARSON, SD; GOULARTFISHER, D; LEE, TH			CRITICAL PATHWAYS AS A STRATEGY FOR IMPROVING CARE - PROBLEMS AND POTENTIAL	ANNALS OF INTERNAL MEDICINE			English	Article							PRACTICE GUIDELINES; EXPENDITURES; SERVICES; COSTS	In an era of increasing competition in medical care, critical pathway guidelines have emerged as one of the most popular new initiatives intended to reduce costs while maintaining or even improving the quality of care. Developed primarily for high-volume hospital diagnoses, critical pathways display goals for patients and provide the corresponding ideal sequence and timing of staff actions for achieving those goals with optimal efficiency. Despite the rapid dissemination of critical pathway programs in hospitals throughout the United States, many uncertainties remain about their development, implementation, and evaluation. In addition, serious concerns have been raised about their effect on patient outcomes and satisfaction with care, physician autonomy, malpractice risks, and the teaching and research missions of many hospitals. Underlying these concerns is the absence of data from controlled trials to evaluate the effects of critical pathways. Physicians should understand the potential benefits and problems associated with critical pathways because physicians are increasingly being asked to provide leadership for pathway programs. Physicians and other health service investigators should also develop methods to study pathways in evolving health care settings. Although the promise of reduced costs and improved quality is enticing, the gaps in our knowledge about critical pathways are extensive; therefore, like any new health care technology, pathway programs should be fully evaluated in order to understand the conditions under which that promise may be fulfilled.	PARTNERS COMMUNITY HLTHCARE INC, BOSTON, MA 02199 USA; HARVARD PILGRIM HLTH CARE, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA 02215 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, BOSTON, MA 02115 USA	Harvard Pilgrim Health Care; Harvard University; Brigham & Women's Hospital; Harvard Medical School								AUDET AM, 1990, ANN INTERN MED, V113, P709, DOI 10.7326/0003-4819-113-9-709; BROOK RH, 1989, JAMA-J AM MED ASSOC, V262, P3027, DOI 10.1001/jama.262.21.3027; Bueno M M, 1993, Nurs Manage, V24, P51; BUFFA ES, 1969, MODERN PRODUCTION MA; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; Coffey R J, 1992, Qual Manag Health Care, V1, P45; Coffey R J, 1995, Qual Manag Health Care, V3, P14; Crummer M B, 1993, J Cardiovasc Nurs, V7, P30; DiJerome L, 1992, Comput Nurs, V10, P250, DOI 10.1097/00024665-199211000-00005; Ethridge P, 1989, Nurs Manage, V20, P30; Falconer J A, 1993, QRB Qual Rev Bull, V19, P8; Farley K, 1995, Qual Manag Health Care, V3, P43; FELDSTEIN PJ, 1988, NEW ENGL J MED, V318, P1310, DOI 10.1056/NEJM198805193182006; GARNICK DW, 1991, JAMA-J AM MED ASSOC, V266, P2856, DOI 10.1001/jama.266.20.2856; Giuliano K K, 1991, Nurs Manage, V22, P52; GREENE JH, 1974, PRODUCTION INVENTORY; HAMPTON DC, 1993, J NURS ADMIN, V23, P21, DOI 10.1097/00005110-199323050-00007; HLFFMAN PA, 1993, JOINT COMM J QUAL IM, V19, P235; Holoweiko M, 1989, Med Econ, V66, P118; Holoweiko M., 1989, MED ECON, V66, P125; Holoweiko M., 1989, MED ECON, V66, P130; HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; HYAMS AL, 1995, ANN INTERN MED, V122, P450, DOI 10.7326/0003-4819-122-6-199503150-00008; JONES DA, 1985, AM J CARDIOL, V56, pC40, DOI 10.1016/S0002-9149(85)80008-4; Korycan T, 1995, Qual Manag Health Care, V3, P71; LING K, 1993, NURSING ADM Q, V17, P54; LOCKYET K, 1991, CRITICAL PATH ANAL O; LONDON M, 1993, HEALTH PROG, P36; Lord J, 1993, Manag Care Q, V1, P43; Luttman R J, 1995, Qual Manag Health Care, V3, P1; MODER T, 1983, PROJECT MANAGEMENT C; Nolin C E, 1995, Qual Manag Health Care, V3, P65; PEARSON SD, 1994, J GEN INTERN MED, V9, P227, DOI 10.1007/BF02600130; Robinson J A, 1992, ANNA J, V19, P182; Rudisill P T, 1994, J Nurs Care Qual, V8, P27; Schriefer J, 1995, Qual Manag Health Care, V3, P30; SPATH PL, 1994, CLIN PATHS TOOLS OUT; STETLER C, 1987, CASE MANAGEMENT PLAN; STOECKLE JD, 1992, ANN INTERN MED, V116, P407, DOI 10.7326/0003-4819-116-5-407; Trubo R, 1993, Med Econ, V70, P69; Trubo R., 1993, MED ECON, V70, P80; Trubo R, 1993, MED ECON, V70, P77; WEINGARTEN SR, 1994, ANN INTERN MED, V120, P257, DOI 10.7326/0003-4819-120-4-199402150-00001; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; WICKIZER TM, 1992, HEALTH SERV RES, V27, P104; WILLIAMSON J, 1991, HLTH CARE QUALITY MA; Yandell B, 1995, Qual Manag Health Care, V3, P55; ZANDER K, 1993, NURSING CASE MANAGEM; Zander K., 1991, NEW DEFINITION, V6, P1; Zander K, 1992, NEW DEFINITION, V7, P1; ZAUDER K, 1991, NEW DEFINITION, V6, P1	52	365	382	0	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1995	123	12					941	948		10.7326/0003-4819-123-12-199512150-00008	http://dx.doi.org/10.7326/0003-4819-123-12-199512150-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK120	7486490				2022-12-28	WOS:A1995TK12000008
J	ANNAS, GJ				ANNAS, GJ			WOMEN AND CHILDREN FIRST	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				KIPLING R, 1940, COMPLETE VERSE DEFIN, P432; KRAUTHAMMER C, 1995, WASHINGTON POST 0203, pA19; MAIER T, 1995, NEWSDAY         0622, P6; NORDHEIMER J, 1995, NY TIMES        0606, pB1; PARISI VM, 1995, NEW ENGL J MED, V333, P1635, DOI 10.1056/NEJM199512143332412; ROVNER J, 1995, LANCET, V346, P171, DOI 10.1016/S0140-6736(95)91219-3; SIMPSON AWB, 1984, CANNIBALISM COMMON L, P97; WERTZ RW, 1977, LYING IN HIST CHILDB; 1995, HOSPITAL LENGTH STAY; 1995, AM MED NEWS     0807, P13; 1995, MMWR-MORBID MORTAL W, V44, P335	11	44	45	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 14	1995	333	24					1647	1651		10.1056/NEJM199512143332420	http://dx.doi.org/10.1056/NEJM199512143332420			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK065	7477216				2022-12-28	WOS:A1995TK06500032
J	ROUJEAU, JC; KELLY, JP; NALDI, L; RZANY, B; STERN, RS; ANDERSON, T; AUQUIER, A; BASTUJIGARIN, S; CORREIA, O; LOCATI, F; MOCKENHAUPT, M; PAOLETTI, C; SHAPIRO, S; SHEAR, N; SCHOPF, E; KAUFMAN, DW				ROUJEAU, JC; KELLY, JP; NALDI, L; RZANY, B; STERN, RS; ANDERSON, T; AUQUIER, A; BASTUJIGARIN, S; CORREIA, O; LOCATI, F; MOCKENHAUPT, M; PAOLETTI, C; SHAPIRO, S; SHEAR, N; SCHOPF, E; KAUFMAN, DW			MEDICATION USE AND THE RISK OF STEVENS-JOHNSON SYNDROME OR TOXIC EPIDERMAL NECROLYSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ERYTHEMA MULTIFORME; DRUG-USE; CORTICOSTEROIDS; CARBAMAZEPINE; PROPHYLAXIS; SULFADOXINE	Background. Toxic epidermal necrolysis and Stevens-Johnson syndrome are rare, life-threatening, drug-induced cutaneous reactions. We conducted a case-control study to quantify the risks associated with the use of specific drugs. Methods. Data were obtained through surveillance networks in France, Germany, Italy, and Portugal. Drug use before the onset of disease was compared in 245 people who were hospitalized because of toxic epidermal necrolysis or Stevens-Johnson syndrome and 1147 patients hospitalized for other reasons (controls). Crude relative risks were calculated and adjusted for confounding by multivariate methods when numbers were large enough. Results. Among drugs usually used for short periods, the risks were increased for trimethoprim-sulfamethoxazole and other sulfonamide antibiotics (crude relative risk, 172; 95 percent confidence interval, 75 to 396), chlormezanone (crude relative risk, 62; 21 to 188), aminopenicillins (multivariate relative risk, 6.7; 2.5 to 18), quinolones (multivariate relative risk, 10; 2.6 to 38), and cephalosporins (multivariate relative risk, 14; 3.2 to 59). For acetaminophen, the multivariate relative risk was 0.6 (95 percent confidence interval, 0.2 to 1.3) in France but 9.3 (3.9 to 22) in the other countries. Among drugs usually used for months or years, the increased risk was confined largely to the first two months of treatment, when crude relative risks were as follows: carbamazepine, 90 (95 percent confidence interval, 19 to infinity); phenobarbital, 45 (19 to 108); phenytoin, 53 (11 to infinity); valproic acid, 25 (4.3 to infinity); oxicam nonsteroidal antiinflammatory drugs (NSAIDs), 72 (25 to 209); allopurinol, 52 (16 to 167); and corticosteroids, 54 (23 to 124). For many drugs, including thiazide diuretics and oral hypoglycemic agents, there was no significant increase in risk. Conclusions. The use of antibacterial sulfonamides, anticonvulsant agents, oxicam NSAIDs, allopurinol, chlormezanone, and corticosteroids is associated with large increases in the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. But for none of the drugs does the excess risk exceed five cases per million users per week.	UNIV PARIS 13, DEPT PUBL HLTH, CRETEIL, FRANCE; BOSTON UNIV, SCH MED, SLONE EPIDEMIOL UNIT, BOSTON, MA 02118 USA; UNIV MILAN, DEPT DERMATOL, ITALIANO STUDI EPIDEMIOL DERMATOL GRP, BERGAMO, ITALY; UNIV FREIBURG, DOLUMENTAT ZENTRUM SCHWERER HAUTREAKT, FREIBURG, GERMANY; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT DERMATOL, BOSTON, MA 02215 USA; INST GUSTAVE ROUSSY, DEPT BIOSTAT & EPIDEMIOL, INSERM, U351, VILLEJUIF, FRANCE; HOSP SAO JOAO, FAC MED, DEPT DERMATOL & IMMUNOL, PORTUGUES ELYS GRP, OPORTO, PORTUGAL; SUNNYBROOK HLTH SCI CTR, DEPT PHARMACOL, TORONTO, ON, CANADA	Universite Paris 13; Boston University; University of Milan; University of Freiburg; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Sao Joao Hospital; Universidade do Porto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center			Naldi, Luigi/AFM-8982-2022; Bastuji-Garin, Sylvie/R-3479-2018; Naldi, Luigi/K-6343-2016	Naldi, Luigi/0000-0002-3160-2835; Bastuji-Garin, Sylvie/0000-0001-9855-5183; Naldi, Luigi/0000-0002-3160-2835				ASKMARK H, 1990, ACTA NEUROL SCAND, V81, P131; AUBOCK J, 1985, BMJ-BRIT MED J, V290, P1969, DOI 10.1136/bmj.290.6486.1969; BASTUJIGARIN S, 1993, ARCH DERMATOL, V129, P92, DOI 10.1001/archderm.129.1.92; BERGOEND H, 1968, ANN DERMATOL SYPHIL, V95, P481; CANS C, 1991, REV EPIDEMIOL SANTE, V39, P515; CHAN HL, 1990, ARCH DERMATOL, V126, P43, DOI 10.1001/archderm.126.1.43; CORREIA O, 1993, DERMATOLOGY, V186, P32, DOI 10.1159/000247299; DOOMSGOOSSENS AE, 1989, J AM ACAD DERMATOL, V21, P538, DOI 10.1016/S0190-9622(89)70222-X; FLECHET ML, 1985, LANCET, V2, P499; GARATTINI S, 1993, LANCET, V342, P1191, DOI 10.1016/0140-6736(93)92181-R; GUILLAUME JC, 1987, ARCH DERMATOL, V123, P1166, DOI 10.1001/archderm.123.9.1166; HERNBORG A, 1985, LANCET, V2, P1072; HIRJI KF, 1989, AM STAT, V43, P7, DOI 10.2307/2685158; KAUFMAN DW, 1991, MONOGRAPHYS EPIDEMIO, V18; KELLY JP, 1995, J CLIN EPIDEMIOL, V48, P1099, DOI 10.1016/0895-4356(95)00004-N; LAPORTE JR, 1991, LANCET, V337, P85, DOI 10.1016/0140-6736(91)90744-A; LASSER EC, 1987, NEW ENGL J MED, V317, P845, DOI 10.1056/NEJM198710013171401; LAUERMA AI, 1991, J AM ACAD DERMATOL, V24, P182, DOI 10.1016/0190-9622(91)70024-V; LYELL A, 1979, BRIT J DERMATOL, V100, P69, DOI 10.1111/j.1365-2133.1979.tb03571.x; MATTSON RH, 1992, NEW ENGL J MED, V327, P765, DOI 10.1056/NEJM199209103271104; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MILLER KD, 1986, AM J TROP MED HYG, V35, P451, DOI 10.4269/ajtmh.1986.35.451; NALDI L, 1990, ARCH DERMATOL, V126, P1103, DOI 10.1001/archderm.1990.01670320127028; NOBILI A, 1992, PHARMACOEPIDEM DR S, V1, P65; PARIENTE P, 1992, PSYCHOL MED, V22, P181, DOI 10.1017/S0033291700032839; PATTRICK M, 1993, BRIT J RHEUMATOL, V32, P55; ROUJEAU JC, 1990, ARCH DERMATOL, V126, P37, DOI 10.1001/archderm.126.1.37; ROUJEAU JC, 1994, NEW ENGL J MED, V331, P1272, DOI 10.1056/NEJM199411103311906; RUIZMALDONADO R, 1985, J AM ACAD DERMATOL, V13, P623, DOI 10.1016/S0190-9622(85)70207-1; RZANY B, 1991, ACTA DERM-VENEREOL, V71, P171; RZANY B, 1990, IN PRESS J CLIN EPID; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SCHOPF E, 1991, ARCH DERMATOL, V127, P839, DOI 10.1001/archderm.127.6.839; SERFATY D, 1992, GYNECOLOGIE, V43, P366; SOLINAS A, 1988, J AM ACAD DERMATOL, V18, P1165, DOI 10.1016/S0190-9622(88)70117-6; STERN RS, 1989, J AM ACAD DERMATOL, V21, P317, DOI 10.1016/S0190-9622(89)70176-6; THOMAS DG, 1971, APPLIED STATISTICS, V20, P105, DOI DOI 10.2307/2346643; YETIV JZ, 1980, SOUTH MED J, V73, P599, DOI 10.1097/00007611-198005000-00015; YOLA M, 1994, J CLIN EPIDEMIOL, V47, P731, DOI 10.1016/0895-4356(94)90170-8	39	985	1027	0	65	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 14	1995	333	24					1600	1607		10.1056/NEJM199512143332404	http://dx.doi.org/10.1056/NEJM199512143332404			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK065	7477195				2022-12-28	WOS:A1995TK06500004
J	PHILIP, T; GUGLIELMI, C; HAGENBEEK, A; SOMERS, R; VANDERLELIE, H; BRON, D; SONNEVELD, P; GISSELBRECHT, C; CAHN, JY; HAROUSSEAU, JL; COIFFIER, B; BIRON, P; MANDELLI, F; CHAUVIN, F				PHILIP, T; GUGLIELMI, C; HAGENBEEK, A; SOMERS, R; VANDERLELIE, H; BRON, D; SONNEVELD, P; GISSELBRECHT, C; CAHN, JY; HAROUSSEAU, JL; COIFFIER, B; BIRON, P; MANDELLI, F; CHAUVIN, F			AUTOLOGOUS BONE-MARROW TRANSPLANTATION AS COMPARED WITH SALVAGE CHEMOTHERAPY IN RELAPSES OF CHEMOTHERAPY-SENSITIVE NON-HODGKINS-LYMPHOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PARMA INTERNATIONAL PROTOCOL; STEM-CELL TRANSPLANTATION; HIGH-DOSE CHEMOTHERAPY; MALIGNANT-LYMPHOMA; THERAPY; REGIMEN; DISEASE; COMBINATION; DHAP	Background. High-dose chemotherapy followed by autologous bone marrow transplantation is a therapeutic option for patients with chemotherapy-sensitive non-Hodgkin's lymphoma who have relapses. In this report we describe a prospective randomized study of such treatment. Methods. A total of 215 patients with relapses of non-Hodgkin's lymphoma were treated between July 1987 and June 1994. All patients received two courses of conventional chemotherapy. The 109 patients who had a response to chemotherapy were randomly assigned to receive four courses of chemotherapy plus radiotherapy (54 patients) or radiotherapy plus intensive chemotherapy and autologous bone marrow transplantation (55 patients). Results. The overall rate of response to conventional chemotherapy was 58 percent; among patients with relapses after chemotherapy, the response rate was 64 percent, and among those with relapses during chemotherapy, the response rate was 21 percent. There were three deaths from toxic effects among the patients in the transplantation group, and none among those in the group receiving chemotherapy without transplantation. The two groups did not differ in terms of prognostic factors. The median follow-up time was 63 months. The response rate was 84 percent after bone marrow transplantation and 44 percent after chemotherapy without transplantation. At five years, the rate of event-free survival was 46 percent in the transplantation group and 12 percent in the group receiving chemotherapy without transplantation (P = 0.001), and the rate of overall survival was 53 and 32 percent, respectively (P = 0.038). Conclusions. As compared with conventional chemotherapy, treatment with high-dose chemotherapy and autologous bone marrow transplantation increases event-free and overall survival in patients with chemotherapy-sensitive non-Hodgkin's lymphoma in relapse.	CTR LEON BERARD,DEPT MED ONCOL,BONE MARROW TRANSPLANTAT & BIOSTAT UNIT,LYON,FRANCE; UNIV ROMA LA SAPIENZA,ROME,ITALY; ANTONI VAN LEEUWENHOEK HUIS,NETHERLANDS CANC CTR INST,ROTTERDAM,NETHERLANDS; ACAD MED CTR,AMSTERDAM,NETHERLANDS; INST JULES BORDET,BRUSSELS,BELGIUM; UNIV HOSP DIJKZIGT,ROTTERDAM,NETHERLANDS; HOP ST LOUIS,PARIS,FRANCE; HOP JEAN MINJOZ,BESANCON,FRANCE; CHU NANTES,HOP HOTEL DIEU,NANTES,FRANCE; CHU LYON SUD,PIERRE BENITE,FRANCE	UNICANCER; Centre Leon Berard; Sapienza University Rome; University of Amsterdam; Academic Medical Center Amsterdam; Institut Jules Bordet; Erasmus University Rotterdam; Erasmus MC; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Franche-Comte; CHU Besancon; Nantes Universite; CHU de Nantes; CHU Lyon								ANDERSON JE, 1993, J CLIN ONCOL, V11, P2342, DOI 10.1200/JCO.1993.11.12.2342; APPELBAUM FR, 1978, BLOOD, V52, P85; ARMITAGE JO, 1993, NEW ENGL J MED, V328, P1023; BARTLETT NL, 1994, J CLIN ONCOL, V12, P1349, DOI 10.1200/JCO.1994.12.7.1349; BONADONNA G, 1994, ANN ONCOL         S2, V5, P5; BOSLY A, 1992, J CLIN ONCOL, V10, P1615, DOI 10.1200/JCO.1992.10.10.1615; CABANILLAS F, 1987, J CLIN ONCOL, V5, P407, DOI 10.1200/JCO.1987.5.3.407; CABANILLAS F, 1982, BLOOD, V60, P693; CARBONE PP, 1971, CANCER RES, V31, P1860; CHOPRA R, 1992, J CLIN ONCOL, V10, P1690, DOI 10.1200/JCO.1992.10.11.1690; FREEDMAN AS, 1993, J CLIN ONCOL, V11, P1841, DOI 10.1200/JCO.1993.11.10.1841; FREEMAN D, 1987, STATISTICS TXB MONOG, V79; GISSELBRECHT C, 1993, ANN ONCOL         S1, V4, P7; International Non-Hodgkin's Lymphoma Prognostic Factors Project, 1993, NEW ENGL J MED, V329, P987; JONES HM, 1994, J CLIN ONCOL, V12, P1693, DOI 10.1200/JCO.1994.12.8.1693; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEWIS JA, 1993, BRIT J CANCER, V68, P647, DOI 10.1038/bjc.1993.402; MANTEL N, 1966, CANCER CHEMOTHERAPY, V50, P163, DOI DOI 10.1073/PNAS.0308531101; PETERSON BA, 1994, J CLIN ONCOL, V12, P2524, DOI 10.1200/JCO.1994.12.12.2524; PHILIP T, 1984, LANCET, V1, P391; PHILIP T, 1987, NEW ENGL J MED, V316, P1493, DOI 10.1056/NEJM198706113162401; PHILIP T, 1991, ANN ONCOL, V2, P57, DOI 10.1093/annonc/2.suppl_1.57; PHILIP T, 1991, BLOOD, V77, P1587; PHILIP T, 1991, EUR J CANCER, V27, P320, DOI 10.1016/0277-5379(91)90538-O; RAPOPORT AP, 1993, J CLIN ONCOL, V11, P2351, DOI 10.1200/JCO.1993.11.12.2351; RATANATHARATHORN V, 1994, BLOOD, V84, P1050; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P1541, DOI 10.1056/NEJM198706113162409; SAEZ R, 1994, HEMATOL ONCOL, V12, P75, DOI 10.1002/hon.2900120205; SHIPP MA, 1994, BLOOD, V83, P1165; VELASQUEZ WS, 1994, J CLIN ONCOL, V12, P1169, DOI 10.1200/JCO.1994.12.6.1169; VELASQUEZ WS, 1988, BLOOD, V71, P117; VOSE JM, 1993, J CLIN ONCOL, V11, P1846, DOI 10.1200/JCO.1993.11.10.1846; WEAVER CH, 1994, J CLIN ONCOL, V12, P2559, DOI 10.1200/JCO.1994.12.12.2559	33	1813	1879	0	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 7	1995	333	23					1540	1545		10.1056/NEJM199512073332305	http://dx.doi.org/10.1056/NEJM199512073332305			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH157	7477169	Bronze			2022-12-28	WOS:A1995TH15700005
J	CHRISTIAN, MC; MCCABE, MS; KORN, EL; ABRAMS, JS; KAPLAN, RS; FRIEDMAN, MA				CHRISTIAN, MC; MCCABE, MS; KORN, EL; ABRAMS, JS; KAPLAN, RS; FRIEDMAN, MA			THE NATIONAL-CANCER-INSTITUTE AUDIT OF THE NATIONAL-SURGICAL-ADJUVANT-BREAST-AND-BOWEL-PROJECT-PROTOCOL-B-06	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPARING TOTAL MASTECTOMY	Background. The National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-06, a clinical trial sponsored by the National Cancer Institute (NCI), has provided evidence of the value of lumpectomy and breast irradiation for treating women with breast cancer in an early stage, Publicity generated by the discovery that the study included fraudulent data on patients enrolled by St. Luc Hospital in Montreal aroused concern about the overall accuracy of the data and conclusions. To address this concern, the NCI conducted an audit of other participating institutions. Methods. In 1994, data on 1554 of the 1809 randomized patients (85.9 percent) enrolled by centers other than St, Luc Hospital were audited at 37 clinical sites in North America, The audit included data on eligibility, survival, disease-free survival, the length of time to a recurrence of cancer in the ipsilateral breast, and documentation of signed informed consent. Results. End points were assessed for all 1554 patients, and eligibility was assessed for 1507 patients; 47 patients were excluded because their forms were not complete or not returned. A total of 1429 patients had their eligibility status verified. Of a total of 7770 data points examined with respect to the number of positive nodes at base line, treatment characteristics, first events (excluding death), recurrence of cancer in the ipsilateral breast, and survival, 7577 (97.5 percent) were verified, 123 (1.6 percent) could not be verified, and 70 (0.9 percent) were discrepant with the NSABP file. Of the 1554 patients, 1340 (86.2 percent) had all audited items (including eligibility) verified, 69 (4.4 percent) had at least one discrepant item, and 113 (7.3 percent) had at least one unverified item (as a result of missing or incomplete data); 32 (2.1 percent) were not assessed for eligibility but had no other discrepant or unverifiable items. Written informed consent was documented for 1098 patients before surgery and 210 after surgery; no date appeared on the signed form for 137. The informed-consent status was not verified for 71 patients and could not be determined for 38. The rates of verification of end-point data and documentation of written informed consent were similar among the total-mastectomy group, the lumpectomy group, and the group treated by lumpectomy and breast irradiation. Conclusions. The audit confirms the adequacy of the data on which the reanalysis of Protocol B-06 and the results after 12 years of follow-up are based.			CHRISTIAN, MC (corresponding author), NCI,DIV CANC TREATMENT,CANC THERAPY EVALUAT PROGRAM,6130 EXECUT BLVD,RM 715,ROCKVILLE,MD 20892, USA.			Kaplan, Richard S./0000-0002-0189-8348				ABRAMS J, 1994, J NATL CANCER I, V86, P1672, DOI 10.1093/jnci/86.22.1672; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; FISHER B, 1995, NEW ENGL J MED, V333, P1456, DOI 10.1056/NEJM199511303332203; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; MAUER JK, 1985, CANCER TREAT REP, V69, P1177; STABLEIN DM, 1994, REANALYSIS NSABP PRO; SUNDERLAND M, 1990, P AN M AM SOC CLIN, V9, P60; WEISS RB, 1993, JAMA-J AM MED ASSOC, V270, P459, DOI 10.1001/jama.270.4.459; 1994, EXPERT PANELS REPORT; 1995, NEW ENGL J MED, V333, P144; 1992, NCI MONOGRAPHS, V11, P1	11	48	53	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 30	1995	333	22					1469	1474		10.1056/NEJM199511303332206	http://dx.doi.org/10.1056/NEJM199511303332206			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG445	7477148				2022-12-28	WOS:A1995TG44500006
J	KOSSLYN, SM; THOMPSON, WL; KIM, IJ; ALPERT, NM				KOSSLYN, SM; THOMPSON, WL; KIM, IJ; ALPERT, NM			TOPOGRAPHICAL REPRESENTATIONS OF MENTAL IMAGES IN PRIMARY VISUAL-CORTEX	NATURE			English	Article								WE report here the use of positron emission tomography (PET) to reveal that the primary visual cortex is activated when subjects close their eyes and visualize objects. The size of the image is systematically related to the location of maximal activity, which is as expected because the earliest visual areas are spatially organized(1-5). These results were only evident, however, when imagery conditions were compared to a non-imagery baseline in which the same auditory cues were presented (and hence the stimuli were controlled); when a resting baseline was used (and hence brain activation was uncontrolled), imagery activation was obscured because of activation in visual cortex during the baseline condition. These findings resolve a debate in the literature about whether imagery activates early visual cortex(6-11) and indicate that visual mental imagery involves 'depictive' representations, not solely language-like descriptions(12-14). Moreover, the fact that stored visual information can affect processing in even the earliest visual areas suggests that knowledge can fundamentally bias what one sees.	MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT RADIOL,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	KOSSLYN, SM (corresponding author), HARVARD UNIV,DEPT PSYCHOL,33 KIRKLAND ST,CAMBRIDGE,MA 02138, USA.		Park, Irene J. K./D-1798-2010					[Anonymous], 1993, BRAIN ACTIVATION; CHARLOT V, 1992, NEUROPSYCHOLOGIA, V30, P565, DOI 10.1016/0028-3932(92)90059-U; Damasio H., 1993, Society for Neuroscience Abstracts, V19, P1603; DANIEL PM, 1961, J PHYSIOL-LONDON, V159, P203, DOI 10.1113/jphysiol.1961.sp006803; Douglas K. L., 1992, Society for Neuroscience Abstracts, V18, P390; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FOX PT, 1986, NATURE, V323, P806, DOI 10.1038/323806a0; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; KOPS ER, 1990, J COMPUT ASSIST TOMO, V14, P437, DOI 10.1097/00004728-199005000-00022; Kosslyn S.M., 1994, IMAGE BRAIN RESOLUTI; KOSSLYN SM, 1993, J COGNITIVE NEUROSCI, V5, P263, DOI 10.1162/jocn.1993.5.3.263; KOSSLYN SM, 1977, COGNITIVE PSYCHOL, V9, P52, DOI 10.1016/0010-0285(77)90004-4; LEBIHAN D, 1993, P NATL ACAD SCI USA, V5, P11802; MENON R, 1993, FUNCTIONAL MRI BRAIN; PYLYSHYN ZW, 1973, PSYCHOL BULL, V80, P1, DOI 10.1037/h0034650; ROLAND PE, 1995, CEREB CORTEX, V5, P79, DOI 10.1093/cercor/5.1.79; ROLAND PE, 1985, J NEUROPHYSIOL, V53, P1219, DOI 10.1152/jn.1985.53.5.1219; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; TALAIRACH J, 1988, COOPLANAR STREOTAXIC; TOOTELL RBH, 1982, SCIENCE, V218, P902, DOI 10.1126/science.7134981	20	480	494	0	29	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					496	498		10.1038/378496a0	http://dx.doi.org/10.1038/378496a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477406				2022-12-28	WOS:A1995TH05400072
J	STAYTON, PS; SHIMOBOJI, T; LONG, C; CHILKOTI, A; CHEN, GH; HARRIS, JM; HOFFMAN, AS				STAYTON, PS; SHIMOBOJI, T; LONG, C; CHILKOTI, A; CHEN, GH; HARRIS, JM; HOFFMAN, AS			CONTROL OF PROTEIN-LIGAND RECOGNITION USING A STIMULI-RESPONSIVE POLYMER	NATURE			English	Article							POLY(N-ISOPROPYLACRYLAMIDE); IMMUNOASSAY; MEMBRANE; RELEASE; GELS	STIMULI-responsive polymers exhibit reversible phase changes in response to changes in environmental factors such as pH or temperature(1-14). Conjugating such polymers to antibodies and proteins provides molecular systems for applications such as affinity separations, immunoassays and enzyme recovery and recycling(15-25). Here we show that conjugating a temperature-sensitive polymer to a genetically engineered site on a protein allows the protein's ligand binding affinity to be controlled. We synthesized a mutant of the protein streptavidin to enable site-specific conjugation of the responsive polymer near the protein's binding site. Normal binding of biotin to the modified protein occurs below 32 degrees C, whereas above this temperature the polymer collapses and blocks binding. The collapse of the polymer and thus the enabling and disabling of binding, is reversible. Such environmentally triggered control of binding may find many applications in biotechnology and biomedicine, such as the control of enzyme reaction rates and of biosensor activity, and the controlled release of drugs.	UNIV ALABAMA,DEPT CHEM,HUNTSVILLE,AL 35899	University of Alabama System; University of Alabama Huntsville	STAYTON, PS (corresponding author), UNIV WASHINGTON,CTR BIOENGN,SEATTLE,WA 98195, USA.		Stayton, Patrick/C-1975-2018	Stayton, Patrick/0000-0001-6939-6371				BRANNONPEPPAS L, 1989, J CONTROL RELEASE, V8, P267, DOI 10.1016/0168-3659(89)90048-5; BURNS JA, 1991, J ORG CHEM, V56, P2648, DOI 10.1021/jo00008a014; Chen G.H., 1992, POLYM PREPR-ACS, V33, P468; CHEN GH, 1994, J BIOMAT SCI-POLYM E, V5, P371; CHEN GH, 1993, BIOCONJUGATE CHEM, V4, P509, DOI 10.1021/bc00024a013; CHEN GH, 1995, NATURE, V373, P49, DOI 10.1038/373049a0; CHEN GH, 1995, MACROMOL CHEM PHYS, V196, P1251, DOI 10.1002/macp.1995.021960424; CHEN JP, 1990, BIOMATERIALS, V11, P625, DOI 10.1016/0142-9612(90)90019-M; CHIIKOTI A, 1994, BIOCONJ CHEM, V5, P504; CHILKOTI A, 1995, P NATL ACAD SCI USA, V92, P1754, DOI 10.1073/pnas.92.5.1754; CUSSLER EL, 1984, AICHE J, V30, P578, DOI 10.1002/aic.690300408; Heskins M., 1968, J MACROMOL SCI CHEM, V2, P1441, DOI DOI 10.1080/10601326808051910; HOFFMAN A S, 1987, Journal of Controlled Release, V6, P297, DOI 10.1016/0168-3659(87)90083-6; HOFFMAN AS, 1995, ARTIF ORGANS, V19, P458, DOI 10.1111/j.1525-1594.1995.tb02359.x; IRIE M, 1990, ADV POLYM SCI, V94, P28; ISHIHARA K, 1984, POLYM J, V16, P625, DOI 10.1295/polymj.16.625; KABRA BG, 1991, POLYM COMMUN, V32, P322; KOKUFUTA E, 1994, J BIOMAT SCI-POLYM E, V6, P35, DOI 10.1163/156856295X00733; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KWON IC, 1991, NATURE, V354, P291, DOI 10.1038/354291a0; MONJI N, 1987, APPL BIOCHEM BIOTECH, V14, P107, DOI 10.1007/BF02798429; MONJI N, 1994, J BIOMAT SCI-POLYM E, V5, P407, DOI 10.1163/156856294X00112; MONJI N, 1990, BIOCHEM BIOPH RES CO, V172, P652, DOI 10.1016/0006-291X(90)90724-2; OKUZAKI H, 1994, J BIOMAT SCI-POLYM E, V5, P485, DOI 10.1163/156856294X00167; STAYTON PS, 1988, J BIOL CHEM, V267, P13544; TAKEI YG, 1993, BIOCONJUGATE CHEM, V4, P42, DOI 10.1021/bc00019a006; TANAKA T, 1981, SCI AM, V244, P124, DOI 10.1038/scientificamerican0181-124; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; YANG HJ, 1990, J POLYM SCI POL CHEM, V28, P219, DOI 10.1002/pola.1990.080280116; YOSHIDA R, 1995, NATURE, V374, P240, DOI 10.1038/374240a0	30	582	601	2	222	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					472	474		10.1038/378472a0	http://dx.doi.org/10.1038/378472a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477401				2022-12-28	WOS:A1995TH05400064
J	BEZRUKOV, SM; VODYANOY, I				BEZRUKOV, SM; VODYANOY, I			NOISE-INDUCED ENHANCEMENT OF SIGNAL-TRANSDUCTION ACROSS VOLTAGE-DEPENDENT ION CHANNELS	NATURE			English	Article							ALAMETHICIN; CONDUCTANCE	THE presence of noise in a signal transduction system usually interferes with its ability to transfer information reliably. But many nonlinear systems can use noise to enhance performance(1), and this phenomenon, called stochastic resonance, may underlie the extraordinary ability of some biological systems to detect and amplify small signals in noisy environments(2-5). Previous work has demonstrated the occurrence of stochastic resonance in a complex system of biological transducers and neural signal pathways(6), but the possibility that it could occur at the sub-cellular level has remained open. Here we report the observation of stochastic resonance in a system of voltage-dependent ion channels formed by the peptide alamethicin. A hundred-fold increase in signal transduction induced by external noise is accompanied by a growth in the output signal-to-noise ratio. The system of ion channels considered here represents the simplest biological system yet known to exhibit stochastic resonance.	OFF NAVAL RES, LONDON NW1 5TH, ENGLAND; ST PETERSBURG NUCL PHYS INST, GATCHINA 188350, RUSSIA; UCL, LONDON, ENGLAND	National Research Centre - Kurchatov Institute; Petersburg Nuclear Physics Institute; University of London; University College London	BEZRUKOV, SM (corresponding author), NIH, DIV COMP RES & TECHNOL, BETHESDA, MD 20892 USA.			Vodyanoy, Vitaly/0000-0003-3092-6245				BEZRUKOV SM, 1993, BIOPHYS J, V64, P16, DOI 10.1016/S0006-3495(93)81336-5; BLOCK SM, 1992, SOC GEN PHY, V47, P1; BULSARA AR, 1994, PHYS REV E, V49, P4989, DOI 10.1103/PhysRevE.49.4989; COLLINS JJ, 1995, NATURE, V376, P236, DOI 10.1038/376236a0; DOUGLASS JK, 1993, NATURE, V365, P337, DOI 10.1038/365337a0; EISENBERG M, 1973, J MEMBRANE BIOL, V14, P143, DOI 10.1007/BF01868075; HALL JE, 1984, BIOPHYS J, V45, P233, DOI 10.1016/S0006-3495(84)84151-X; Hille B., 1992, IONIC CHANNELS EXCIT; KALMIJN AJ, 1982, SCIENCE, V218, P916, DOI 10.1126/science.7134985; Makeyev V. M., 1993, Biophysics (English Translation of Biofizika), V38, P189; PANTAZELOU E, 1995, INT J BIFURCAT CHAOS, V5, P101, DOI 10.1142/S0218127495000089; PETRACCHI D, 1994, BIOPHYS J, V66, P1844, DOI 10.1016/S0006-3495(94)80978-6; POLK C, 13TH P A M NAT COUNC; WIESENFELD K, 1995, NATURE, V373, P33, DOI 10.1038/373033a0	14	338	341	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 23	1995	378	6555					362	364		10.1038/378362a0	http://dx.doi.org/10.1038/378362a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477370				2022-12-28	WOS:A1995TF89300049
J	STARZL, TE; DONNER, A; ELIASZIW, M; STITT, L; MEIER, P; FUNG, JJ; MCMICHAEL, JP; TODO, S				STARZL, TE; DONNER, A; ELIASZIW, M; STITT, L; MEIER, P; FUNG, JJ; MCMICHAEL, JP; TODO, S			RANDOMIZED TRIALOMANIA - THE MULTICENTER LIVER-TRANSPLANT TRIALS OF TACROLIMUS	LANCET			English	Editorial Material							ALLOGRAFT RECIPIENTS; CYCLOSPORIN-A; FK-506; KIDNEY; IMMUNOSUPPRESSION; PHARMACOKINETICS; CONVERSION; ORGANS; FK506		UNIV WESTERN ONTARIO,DEPT EPIDEMIOL & BIOSTAT,LONDON,ON N6A 3K7,CANADA; COLUMBIA UNIV,DEPT STAT,NEW YORK,NY; UNIV PITTSBURGH,CTR MED,PITTSBURGH TRANSPLANTAT INST,PITTSBURGH,PA	Western University (University of Western Ontario); Columbia University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			FUNG, John Julian/A-2679-2012	FUNG, John Julian/0000-0002-3038-0441	NIDDK NIH HHS [DK 29961, R01 DK029961-19] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029961, R37DK029961] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUELMAGD K, 1991, TRANSPLANTATION, V52, P71, DOI 10.1097/00007890-199107000-00015; Ahrens E.H., 1992, CRISIS CLIN RES OVER; ANGELL M, 1990, NEW ENGL J MED, V322, P1462, DOI 10.1056/NEJM199005173222011; CALNE RY, 1979, LANCET, V2, P1033; CALNE RY, 1994, NEW ENGL J MED, V331, P1154, DOI 10.1056/NEJM199410273311711; FUNG J, 1991, TRANSPLANT P, V23, P2977; FUNG JJ, 1991, TRANSPLANT P, V23, P14; FUNG JJ, 1990, TRANSPLANT P, V22, P6; GJERTSON DW, IN PRESS TRANSPLANTA; JAIN AB, 1990, TRANSPLANT P, V22, P57; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; STARZL TE, 1982, SURG GYNECOL OBSTET, V154, P819; STARZL TE, 1971, SURG GYNECOL OBSTETR, V133, P981; STARZL TE, 1989, LANCET, V2, P1000; STARZL TE, 1963, SURG GYNECOL OBSTET, V117, P385; STARZL TE, 1982, HEPATOLOGY, V2, P614; STARZL TE, 1991, TRANSPLANT P, V23, P914; STARZL TE, 1980, SURG GYNECOL OBSTET, V151, P17; STARZL TE, 1992, PUZZLE PEOPLE, P231; STARZL TE, 1985, KIDNEY INT, V28, pS31; STARZL TE, 1992, PUZZLE PEOPLE, P288; STARZL TE, 1994, JAMA-J AM MED ASSOC, V264, P63; TODO S, 1990, ANN SURG, V212, P295, DOI 10.1097/00000658-199009000-00008; TODO S, 1994, ANN SURG, V220, P297, DOI 10.1097/00000658-199409000-00006; 1995, LANCET, V346, P1310; 1994, LANCET, V344, P423; 1994, NEW ENGL J MED, V331, P1110; 1994, JAMA-J AM MED ASSOC, V272, P1926	29	50	51	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 18	1995	346	8986					1346	1350		10.1016/S0140-6736(95)92349-7	http://dx.doi.org/10.1016/S0140-6736(95)92349-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE916	7475777	Green Accepted, hybrid			2022-12-28	WOS:A1995TE91600015
J	RUSSIAN, DA; KOVACS, JA				RUSSIAN, DA; KOVACS, JA			PNEUMOCYSTIS-CARINII IN AFRICA - AN EMERGING PATHOGEN	LANCET			English	Editorial Material							HIV-INFECTION; PNEUMONIA; CHILDREN				RUSSIAN, DA (corresponding author), NIH,CTR CLIN,DEPT CRIT CARE MED,BETHESDA,MD 20892, USA.		Kovacs, Joseph/AAU-6105-2021	Kovacs, Joseph/0000-0002-5191-9880				ABOUYA YL, 1992, AM REV RESPIR DIS, V145, P617, DOI 10.1164/ajrccm/145.3.617; BATUNGWANAYO J, 1994, AM J RESP CRIT CARE, V149, P1591, DOI 10.1164/ajrccm.149.6.8004318; KAMANFU G, 1993, AM REV RESPIR DIS, V147, P658, DOI 10.1164/ajrccm/147.3.658; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; MILLER RF, 1992, LANCET, V339, P747, DOI 10.1016/0140-6736(92)90650-R; SIMONDS RJ, 1993, JAMA-J AM MED ASSOC, V270, P470, DOI 10.1001/jama.270.4.470; SMULIAN AG, 1993, J INFECT DIS, V167, P1243, DOI 10.1093/infdis/167.5.1243; WAKEFIELD AE, 1990, T ROY SOC TROP MED H, V84, P800, DOI 10.1016/0035-9203(90)90087-U; 1991, GUIDELINES CLIN MANA	9	22	22	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1242	1243		10.1016/S0140-6736(95)91854-X	http://dx.doi.org/10.1016/S0140-6736(95)91854-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475709				2022-12-28	WOS:A1995TE14500002
J	BRYSON, JW; BETZ, SF; LU, HS; SUICH, DJ; ZHOU, HXX; ONEIL, KT; DEGRADO, WF				BRYSON, JW; BETZ, SF; LU, HS; SUICH, DJ; ZHOU, HXX; ONEIL, KT; DEGRADO, WF			PROTEIN DESIGN - A HIERARCHICAL APPROACH	SCIENCE			English	Review							ALPHA-HELIX STABILITY; ASSEMBLED SYNTHETIC PROTEINS; 4-HELIX BUNDLE PROTEIN; MOLTEN GLOBULE STATE; GCN4 LEUCINE-ZIPPER; DENOVO DESIGN; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; COILED-COILS; ELECTRON-TRANSFER	The de novo design of peptides and proteins has recently emerged as an approach for investigating protein structure and function. Designed, helical peptides provide model systems for dissecting and quantifying the multiple interactions that stabilize secondary structure formation. De novo design is also useful for exploring the features that specify the stoichiometry and stability of alpha-helical coiled coils and for defining the requirements for folding into structures that resemble native, functional proteins. The design process often occurs in a series of discrete steps. Such steps reflect the hierarchy of forces required for stabilizing tertiary structures, beginning with hydrophobic forces and adding more specific interactions as required to achieve a unique, functional protein.	DUPONT MERCK PHARMACEUT CO, WILMINGTON, DE 19880 USA	DuPont			Zhou, Huan-Xiang/AAH-9836-2020	Zhou, Huan-Xiang/0000-0001-9020-0302				AKERFELDT KS, 1992, J AM CHEM SOC, V114, P9656, DOI 10.1021/ja00050a054; ANGLOS D, 1994, J CHEM SOC CHEM COMM, P213, DOI 10.1039/c39940000213; ARMSTRONG KM, 1993, P NATL ACAD SCI USA, V90, P11337, DOI 10.1073/pnas.90.23.11337; AURORA R, 1994, SCIENCE, V264, P1126, DOI 10.1126/science.8178170; BASU G, 1993, BIOCHEMISTRY-US, V32, P3067, DOI 10.1021/bi00063a018; BEAUREGARD M, 1991, PROTEIN ENG, V4, P745, DOI 10.1093/protein/4.7.745; BELL JA, 1992, BIOCHEMISTRY-US, V31, P3590, DOI 10.1021/bi00129a006; BENSON DR, 1995, J AM CHEM SOC, V117, P8502, DOI 10.1021/ja00138a002; BETZ JW, IN PRESS CURR OPIN S; BETZ S, 1995, PHILOS T ROY SOC B, V348, P81, DOI 10.1098/rstb.1995.0048; BETZ SF, 1993, CURR OPIN STRUC BIOL, V3, P601, DOI 10.1016/0959-440X(93)90090-8; BIANCHI E, 1994, J MOL BIOL, V236, P649, DOI 10.1006/jmbi.1994.1174; BLABER M, 1994, J MOL BIOL, V235, P600, DOI 10.1006/jmbi.1994.1016; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; BLONDELLE SE, 1995, TRAC-TREND ANAL CHEM, V14, P83, DOI 10.1016/0165-9936(95)91476-9; BOWIE JU, 1989, P NATL ACAD SCI USA, V86, P2152, DOI 10.1073/pnas.86.7.2152; BOWIE JU, 1993, CURR OPIN STRUC BIOL, V3, P437, DOI 10.1016/S0959-440X(05)80118-6; BRACKEN C, 1994, J AM CHEM SOC, V116, P6431, DOI 10.1021/ja00093a052; BRUCH MD, 1991, PROTEINS, V10, P130, DOI 10.1002/prot.340100206; CHAKRABARTTY A, 1994, PROTEIN SCI, V3, P843; CHIN TM, 1992, J AM CHEM SOC, V114, P2279, DOI 10.1021/ja00032a064; CHOMA CT, 1994, J AM CHEM SOC, V116, P856, DOI 10.1021/ja00082a005; CHOMA CT, 1994, TETRAHEDRON LETT, V35, P6191, DOI 10.1016/S0040-4039(00)73388-0; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11118; CIESLA DJ, 1991, J AM CHEM SOC, V113, P3957, DOI 10.1021/ja00010a043; COREY MJ, 1994, APPL BIOCHEM BIOTECH, V47, P199, DOI 10.1007/BF02787935; CREAMER TP, 1992, P NATL ACAD SCI USA, V89, P5937, DOI 10.1073/pnas.89.13.5937; CREAMER TP, 1994, PROTEINS, V19, P85, DOI 10.1002/prot.340190202; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; DEGRADO WF, 1989, SCIENCE, V243, P622, DOI 10.1126/science.2464850; DEGRADO WF, 1993, NATURE, V365, P488, DOI 10.1038/365488a0; DEGRADO WF, UNPUB; DeGrado WF, 1991, CURR OPIN STRUC BIOL, V1, P984, DOI 10.1016/0959-440X(91)90095-B; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DESJARLAIS JR, IN PRESS PROTEIN SCI; DILL KA, 1995, PROTEIN SCI, V4, P561; DOIG AJ, 1995, PROTEIN SCI, V4, P1325, DOI 10.1002/pro.5560040708; DOIG AJ, 1994, BIOCHEMISTRY-US, V33, P3396, DOI 10.1021/bi00177a033; EISENBERG D, 1986, Proteins Structure Function and Genetics, V1, P16, DOI 10.1002/prot.340010105; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FARID RS, 1993, CURR OPIN STRUC BIOL, V3, P225, DOI 10.1016/S0959-440X(05)80157-5; FEDOROV AN, 1992, J MOL BIOL, V225, P927, DOI 10.1016/0022-2836(92)90092-X; FELIX AM, 1988, INT J PEPT PROT RES, V32, P441; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FEZOUI Y, 1994, P NATL ACAD SCI USA, V91, P3675, DOI 10.1073/pnas.91.9.3675; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; FOROOD B, 1993, P NATL ACAD SCI USA, V90, P838, DOI 10.1073/pnas.90.3.838; FUKUGITA M, 1991, CHEM LETT, P1279, DOI 10.1246/cl.1991.1279; GHADIRI MR, 1994, NATURE, V369, P301, DOI 10.1038/369301a0; GORAJ K, 1990, PROTEIN ENG, V3, P259, DOI 10.1093/protein/3.4.259; GROVE A, 1993, PROTEIN SCI, V2, P1918, DOI 10.1002/pro.5560021113; GUTTE B, 1979, NATURE, V281, P650, DOI 10.1038/281650a0; HAHN KW, 1990, SCIENCE, V248, P1544, DOI 10.1126/science.2360048; HANDEL T, 1990, J AM CHEM SOC, V112, P6710, DOI 10.1021/ja00174a039; HANDEL TM, 1993, SCIENCE, V261, P879, DOI 10.1126/science.8346440; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HARPER ET, 1993, BIOCHEMISTRY-US, V32, P7605, DOI 10.1021/bi00081a001; HARRIS NL, 1994, J MOL BIOL, V236, P1356, DOI 10.1016/0022-2836(94)90063-9; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; HELLINGA HW, 1994, P NATL ACAD SCI USA, V91, P5803, DOI 10.1073/pnas.91.13.5803; HERMANS J, 1992, BIOCHEMISTRY-US, V31, P5646, DOI 10.1021/bi00139a031; HILL CP, 1990, SCIENCE, V249, P543, DOI 10.1126/science.2382133; HO SP, 1987, J AM CHEM SOC, V109, P6751, DOI 10.1021/ja00256a032; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; HONIG B, 1995, ADV PROTEIN CHEM, V46, P27, DOI 10.1016/S0065-3233(08)60331-9; HOROVITZ A, 1992, J MOL BIOL, V227, P560, DOI 10.1016/0022-2836(92)90907-2; HOUBRECHTS A, 1995, PROTEIN ENG, V8, P249, DOI 10.1093/protein/8.3.249; HUFFMAN DL, 1994, THESIS U ILLINOIS UR; HUYGHUESDESPOINTES BMP, 1993, PROTEIN SCI, V2, P80; IWAMOTO T, 1994, INT J PEPT PROT RES, V43, P597, DOI 10.1111/j.1399-3011.1994.tb00562.x; JACKSON DY, 1991, J AM CHEM SOC, V113, P9391, DOI 10.1021/ja00024a067; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; JOHNSSON K, 1993, NATURE, V365, P530, DOI 10.1038/365530a0; KAMTEKAR S, 1993, SCIENCE, V262, P1680, DOI 10.1126/science.8259512; KAURNAYA PTP, 1990, BIOCHEMISTRY-US, V29, P13; KEMP DS, 1991, NATURE, V352, P451, DOI 10.1038/352451a0; KEMP DS, 1988, TETRAHEDRON LETT, V29, P5077, DOI 10.1016/S0040-4039(00)80683-8; KIENKER PK, 1994, P NATL ACAD SCI USA, V91, P4859, DOI 10.1073/pnas.91.11.4859; KIM CWA, 1993, NATURE, V362, P267, DOI 10.1038/362267a0; KITAKUNI E, 1994, PROTEIN SCI, V3, P831; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURODA Y, 1994, J MOL BIOL, V236, P862, DOI 10.1006/jmbi.1994.1194; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LECOMTE JTJ, 1991, J AM CHEM SOC, V113, P9663, DOI 10.1021/ja00025a037; LEE C, 1991, NATURE, V352, P448, DOI 10.1038/352448a0; LIM WA, 1991, J MOL BIOL, V219, P359, DOI 10.1016/0022-2836(91)90570-V; LOCKHART DJ, 1993, SCIENCE, V260, P198, DOI 10.1126/science.8469972; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; LUTGRING R, 1994, J AM CHEM SOC, V116, P6451, DOI 10.1021/ja00093a062; LYU PC, 1993, BIOCHEMISTRY-US, V32, P421, DOI 10.1021/bi00053a006; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; LYU PCC, 1992, J AM CHEM SOC, V114, P6560, DOI 10.1021/ja00042a047; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MCCAFFERTY DG, 1995, TETRAHEDRON, V51, P1093, DOI 10.1016/0040-4020(94)01018-U; MICHAEL SF, 1992, P NATL ACAD SCI USA, V89, P4796, DOI 10.1073/pnas.89.11.4796; MIHARA H, 1992, CHEM LETT, P1813, DOI 10.1246/cl.1992.1813; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MINOR DL, 1994, NATURE, V371, P264, DOI 10.1038/371264a0; MONERA OD, 1994, BIOCHEMISTRY-US, V33, P3862, DOI 10.1021/bi00179a010; MONERA OD, 1993, J BIOL CHEM, V268, P19218; MONTAL M, 1990, FASEB J, V4, P2623, DOI 10.1096/fasebj.4.9.1693348; MORII H, 1991, PROTEINS, V11, P133, DOI 10.1002/prot.340110206; MUNOZ V, 1994, PROTEINS, V20, P301, DOI 10.1002/prot.340200403; MUNOZ V, 1995, J MOL BIOL, V245, P275, DOI 10.1006/jmbi.1994.0023; MUNSON M, 1994, PROTEIN SCI, V3, P2015, DOI 10.1002/pro.5560031114; MURZIN AG, 1988, J MOL BIOL, V204, P749, DOI 10.1016/0022-2836(88)90366-X; MUTTER M, 1992, J AM CHEM SOC, V114, P1463, DOI 10.1021/ja00030a049; MUTTER M, 1989, ANGEW CHEM INT EDIT, V28, P535, DOI 10.1002/anie.198905353; MYSZKA DG, 1994, BIOCHEMISTRY-US, V33, P2363, DOI 10.1021/bi00175a003; NICHOLSON H, 1991, BIOCHEMISTRY-US, V30, P9816, DOI 10.1021/bi00105a002; NICHOLSON H, 1988, NATURE, V336, P651, DOI 10.1038/336651a0; NISHINO N, 1992, TETRAHEDRON LETT, V33, P5767, DOI 10.1016/0040-4039(92)89027-A; Nyanguile Origene, 1994, Letters in Peptide Science, V1, P9, DOI 10.1007/BF00132757; OLOFSSON S, 1995, J CHEM SOC P2, P1; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; ONUCHIC JN, 1995, P NATL ACAD SCI USA, V92, P3626, DOI 10.1073/pnas.92.8.3626; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSTERHOUT JJ, 1992, J AM CHEM SOC, V114, P331, DOI 10.1021/ja00027a043; OTZEN DE, 1995, BIOCHEMISTRY-US, V34, P5718, DOI 10.1021/bi00017a003; PADMANABHAN S, 1994, PROTEIN SCI, V3, P1992, DOI 10.1002/pro.5560031111; PARK SH, 1993, BIOCHEMISTRY-US, V32, P7048, DOI 10.1021/bi00078a033; PESSI A, 1993, NATURE, V362, P367, DOI 10.1038/362367a0; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; QUINN TP, 1994, P NATL ACAD SCI USA, V91, P8747, DOI 10.1073/pnas.91.19.8747; RALEIGH DP, 1995, J AM CHEM SOC, V117, P7558, DOI 10.1021/ja00133a035; RALEIGH DP, 1992, J AM CHEM SOC, V114, P10079, DOI 10.1021/ja00051a061; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; REGAN L, 1990, BIOCHEMISTRY-US, V29, P10878, DOI 10.1021/bi00501a003; REGAN L, 1988, SCIENCE, V241, P976, DOI 10.1126/science.3043666; RICHARDSON JS, 1989, TRENDS BIOCHEM SCI, V14, P304, DOI 10.1016/0968-0004(89)90070-4; RICHARDSON JS, 1992, BIOPHYS J, V63, P1186, DOI 10.1016/S0006-3495(92)81696-X; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; ROBERTSON DE, 1994, NATURE, V368, P425, DOI 10.1038/368425a0; ROBINSON CR, 1993, PROTEIN SCI, V2, P826, DOI 10.1002/pro.5560020512; SANCHO J, 1992, BIOCHEMISTRY-US, V31, P2253, DOI 10.1021/bi00123a006; SASAKI T, 1993, TETRAHEDRON, V49, P3677; SASAKI T, 1989, J AM CHEM SOC, V111, P380, DOI 10.1021/ja00183a065; SCHAFMEISTER CE, 1993, SCIENCE, V262, P734, DOI 10.1126/science.8235592; SCHNEIDER JP, IN PRESS CHEM REV; SCHOLTZ JM, 1993, BIOCHEMISTRY-US, V32, P9668, DOI 10.1021/bi00088a019; SCHOLTZ JM, 1991, J AM CHEM SOC, V113, P5102, DOI 10.1021/ja00013a079; SERRANO L, 1989, NATURE, V342, P296, DOI 10.1038/342296a0; SHAKHNOVICH EI, 1993, PROTEIN ENG, V6, P793, DOI 10.1093/protein/6.8.793; SHAKHNOVICH EI, 1993, P NATL ACAD SCI USA, V90, P7195, DOI 10.1073/pnas.90.15.7195; SHANG ZG, 1994, P NATL ACAD SCI USA, V91, P8373, DOI 10.1073/pnas.91.18.8373; SHERIDAN RP, 1980, BIOPHYS CHEM, V11, P133, DOI 10.1016/0301-4622(80)80015-9; SKOLNICK J, 1991, J MOL BIOL, V221, P499, DOI 10.1016/0022-2836(91)80070-B; SKOLNICK J, 1993, CURR BIOL, V3, P414, DOI 10.1016/0960-9822(93)90348-R; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; SRINIVASAN R, 1995, PROTEINS, V22, P81, DOI 10.1002/prot.340220202; STICKLE DF, 1992, J MOL BIOL, V226, P1143, DOI 10.1016/0022-2836(92)91058-W; TANAKA T, 1994, PROTEIN ENG, V7, P969, DOI 10.1093/protein/7.8.969; TANAKA T, 1994, BIOPHYS CHEM, V50, P47, DOI 10.1016/0301-4622(94)85019-4; TANAKA T, 1994, PROTEIN SCI, V3, P419; TSANG KY, 1994, J AM CHEM SOC, V116, P3988, DOI 10.1021/ja00088a039; Wada A, 1976, Adv Biophys, P1; WALDBURGER CD, 1995, NAT STRUCT BIOL, V2, P122, DOI 10.1038/nsb0295-122; WENDT H, 1995, BIOCHEMISTRY-US, V34, P4097, DOI 10.1021/bi00012a028; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344; YAN YB, 1994, PROTEIN SCI, V3, P1069, DOI 10.1002/pro.5560030709; YUE K, 1992, P NATL ACAD SCI USA, V89, P4163, DOI 10.1073/pnas.89.9.4163; YUE K, 1995, P NATL ACAD SCI USA, V92, P325, DOI 10.1073/pnas.92.1.325; YUN RH, 1991, PROTEIN ENG, V4, P761, DOI 10.1093/protein/4.7.761; ZHOU NE, 1993, BIOCHEMISTRY-US, V32, P3178, DOI 10.1021/bi00063a033; ZHUKOVSKY EA, 1994, BIOCHEMISTRY-US, V33, P9856, DOI 10.1021/bi00199a006	175	533	540	0	113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 10	1995	270	5238					935	941		10.1126/science.270.5238.935	http://dx.doi.org/10.1126/science.270.5238.935			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD878	7481798				2022-12-28	WOS:A1995TD87800035
J	REINSCHEID, RK; NOTHACKER, HP; BOURSON, A; ARDATI, A; HENNINGSEN, RA; BUNZOW, JR; GRANDY, DK; LANGEN, H; MONSMA, FJ; CIVELLI, O				REINSCHEID, RK; NOTHACKER, HP; BOURSON, A; ARDATI, A; HENNINGSEN, RA; BUNZOW, JR; GRANDY, DK; LANGEN, H; MONSMA, FJ; CIVELLI, O			ORPHANIN-FQ - A NEUROPEPTIDE THAT ACTIVATES AN OPIOID-LIKE G-PROTEIN-COUPLED RECEPTOR	SCIENCE			English	Article							FUNCTIONAL EXPRESSION; CLONING; BRAIN; CDNA	A heptadecapeptide was identified and purified from porcine brain tissue as a ligand for an orphan heterotrimeric GTP- binding protein (G protein)- coupled receptor (LC132) that is similar in sequence to opioid receptors. This peptide, orphanin FQ, has a primary structure reminiscent of that of opioid peptides. Nanomolar concentrations of orphanin FQ inhibited forskolin-stimulated adenylyl cyclase activity in cells transfected with LC132. This inhibitory activity was not affected by the addition of opioid ligands, nor did the peptide activate opioid receptors. Orphanin FQ bound to its receptor in a saturable manner and with high affinity. When injected intracerebroventricularly into mice, orphanin FQ caused a decrease in locomotor activity but did not induce analgesia in the hot-plate test. However, the peptide produced hyperalgesia in the tail-flick assay. Thus, orphanin FQ may act as a transmitter in the brain by modulating nociceptive and locomotor behavior.	HOFFMANN LA ROCHE AG,CNS RES,DIV PHARMA,CH-4002 BASEL,SWITZERLAND; OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201; HOFFMANN LA ROCHE AG,DIV PHARMA,GENE TECHNOL RES,CH-4002 BASEL,SWITZERLAND	Roche Holding; Oregon Health & Science University; Roche Holding			Civelli, Olivier/A-8392-2012		NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008562, R21DA009620] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 09620, DA 08562] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BOSWORTH N, 1989, NATURE, V341, P167, DOI 10.1038/341167a0; BOURSON A, UNPUB; BUNZOW JR, 1994, FEBS LETT, V347, P284, DOI 10.1016/0014-5793(94)00561-3; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CHEN Y, 1993, MOL PHARMACOL, V44, P8; CHEN Y, 1994, FEBS LETT, V347, P279, DOI 10.1016/0014-5793(94)00560-5; CIVELLI O, 1987, MOL NEUROBIOL, V1, P373, DOI 10.1007/BF02935742; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FUKUDA K, 1994, FEBS LETT, V343, P42, DOI 10.1016/0014-5793(94)80603-9; HALL ZW, 1987, TRENDS NEUROSCI, V10, P99, DOI 10.1016/0166-2236(87)90049-X; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; IRWIN S, 1968, PSYCHOPHARMACOLOGIA, V13, P222, DOI 10.1007/BF00401402; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; LACHOWICZ JE, 1995, J NEUROCHEM, V64, P34; LI CH, 1983, BIOCH CLIN ASPECTS N, P17; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; LYNCH DR, 1986, ANNU REV BIOCHEM, V55, P773, DOI 10.1146/annurev.bi.55.070186.004013; MOLLEREAU C, 1994, FEBS LETT, V341, P33, DOI 10.1016/0014-5793(94)80235-1; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NELSON N, 1987, ANAL BIOCHEM, V165, P287, DOI 10.1016/0003-2697(87)90271-5; REINSCHEID RK, UNPUB; STEVENS CF, 1987, NATURE, V328, P198, DOI 10.1038/328198b0; WANG JB, 1994, FEBS LETT, V348, P75, DOI 10.1016/0014-5793(94)00557-5; WICK MJ, 1994, MOL BRAIN RES, V27, P37, DOI 10.1016/0169-328X(94)90181-3; WOOD PL, 1984, ANALGESICS NEUROCHEM, P175; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736	26	1693	1778	1	47	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 3	1995	270	5237					792	794		10.1126/science.270.5237.792	http://dx.doi.org/10.1126/science.270.5237.792			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC712	7481766				2022-12-28	WOS:A1995TC71200038
J	REES, DC; COX, M; CLEGG, JB				REES, DC; COX, M; CLEGG, JB			WORLD DISTRIBUTION OF FACTOR-V LEIDEN	LANCET			English	Note							POOR ANTICOAGULANT RESPONSE; ACTIVATED PROTEIN-C; THROMBOPHILIA; EPIDEMIOLOGY; THROMBOSIS	We have analysed 3380 chromosomes (1690 unrelated individuals) from twenty-four populations for the presence of factor V Leiden, an important risk factor in venous thromboembolism, The allele frequency in 618 Europeans was 4.4%, with the highest prevalence among Greeks (7%). It was 0.6% in Asia Minor. Factor V Leiden was not found in any of 1600 chromosomes from Africa, Southeast Asia, Australasia, and the Americas. This distribution may partly explain the rarity of thromboembolic disease in these populations, The high prevalence in Europeans suggests that screening for this mutation should be considered in some circumstances.			REES, DC (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,MRC,MOLEC HAEMATOL UNIT,OXFORD OX3 9DU,ENGLAND.		Rees, David/B-6789-2011	Rees, David/0000-0003-3647-1050				BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BURKITT DP, 1972, BMJ-BRIT MED J, V2, P556, DOI 10.1136/bmj.2.5813.556; COOPER DN, 1994, BAILLIERE CLIN HAEM, V7, P637, DOI 10.1016/S0950-3536(05)80102-7; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; FLINT J, 1993, HUM GENET, V91, P91; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; NATHWANI AC, 1992, BAILLIERE CLIN HAEM, V5, P383, DOI 10.1016/S0950-3536(11)80025-9; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504	10	1065	1089	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 28	1995	346	8983					1133	1134		10.1016/S0140-6736(95)91803-5	http://dx.doi.org/10.1016/S0140-6736(95)91803-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB549	7475606				2022-12-28	WOS:A1995TB54900013
J	AGASHE, VR; SHASTRY, MCR; UDGAONKAR, JB				AGASHE, VR; SHASTRY, MCR; UDGAONKAR, JB			INITIAL HYDROPHOBIC COLLAPSE IN THE FOLDING OF BARSTAR	NATURE			English	Article							FLOW CIRCULAR-DICHROISM; GLOBULAR-PROTEINS; SECONDARY STRUCTURE; INTERMEDIATE; MECHANISM; STABILITY; FRAMEWORK; PATHWAYS; STATE	Two models are commonly used to describe the poorly understood earliest steps of protein folding. The framework model(1-3) stresses very early formation of nascent secondary structures, which coalesce into a compact, molten, globule-like form(4,5) from which structure slowly develops(6,7). The hydrophobic collapse model(8-10) gives overriding precedence to a nonspecific collapse of the polypeptide chain which facilitates subsequent formation of specific secondary and tertiary structure(11,12). Here we report our analysis of the earliest observable events of the major folding pathway of barstar, a small protein. We compare the kinetics of folding using circular dichroism at 222 nm and 270 nm, intrinsic tryptophan fluorescence, fluorescence of the hydrophobic dye 8-anilino-1-naphthalene-sulphonic acid on binding, and restoration of tryptophan-dansyl fluorescence energy transfer as structure-monitoring probes. We show that the polypeptide chain rapidly collapses (within 4 ms) to a compact globule with a solvent-accessible hydrophobic core(6), but with no optically active secondary or tertiary structure. Thus the earliest event of the major folding pathway of barstar is a nonspecific hydrophobic collapse that does not involve concomitant secondary structure formation.	NATL CTR BIOL SCI,CTR TIFR,BANGALORE 560012,KARNATAKA,INDIA	Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS)								CHAN HS, 1989, J CHEM PHYS, V90, P492, DOI 10.1063/1.456500; DILL KA, 1985, BIOCHEMISTRY-US, V24, P1501, DOI 10.1021/bi00327a032; ELOVE GA, 1992, BIOCHEMISTRY-US, V31, P6876, DOI 10.1021/bi00145a003; FENG HP, 1994, BIOCHEMISTRY-US, V33, P13382, DOI 10.1021/bi00249a026; FINKELSTEIN AV, 1987, PROG BIOPHYS MOL BIO, V50, P171, DOI 10.1016/0079-6107(87)90013-7; GUIJARRO JI, 1995, BIOCHEMISTRY-US, V34, P2998, DOI 10.1021/bi00009a031; GUTIN AM, 1995, BIOCHEMISTRY-US, V34, P3066, DOI 10.1021/bi00009a038; ITZHAKI LS, 1994, BIOCHEMISTRY-US, V33, P5212, DOI 10.1021/bi00183a026; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; KAWATA Y, 1991, BIOCHEMISTRY-US, V30, P4367, DOI 10.1021/bi00232a001; KHORASANIZADEH S, 1993, BIOCHEMISTRY-US, V32, P7054, DOI 10.1021/bi00078a034; KHURANA R, 1994, BIOCHEMISTRY-US, V33, P106, DOI 10.1021/bi00167a014; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KUWAJIMA K, 1993, FEBS LETT, V334, P265, DOI 10.1016/0014-5793(93)80691-M; KUWAJIMA K, 1987, FEBS LETT, V221, P115, DOI 10.1016/0014-5793(87)80363-0; MANN CJ, 1993, BIOCHEMISTRY-US, V32, P5282, DOI 10.1021/bi00071a002; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; PTITSYN OB, 1994, PROTEIN ENG, V7, P593, DOI 10.1093/protein/7.5.593; PTITSYN OB, 1973, DOKL AKAD NAUK SSSR+, V210, P1213; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; Ptitsyn Oleg B., 1992, P243; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; ROBSON B, 1971, J MOL BIOL, V58, P237, DOI 10.1016/0022-2836(71)90243-9; RODER H, 1994, MECHANISMS PROTEIN F, P26; SCHREIBER G, 1993, BIOCHEMISTRY-US, V32, P11195, DOI 10.1021/bi00092a032; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SHASTRY MCR, 1995, J MOL BIOL, V247, P1013, DOI 10.1006/jmbi.1994.0196; SHASTRY MCR, 1994, PROTEIN SCI, V3, P1409, DOI 10.1002/pro.5560030907; SUGAWARA T, 1991, BIOCHEMISTRY-US, V30, P2698, DOI 10.1021/bi00224a018; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; VARLEY P, 1993, SCIENCE, V260, P1110, DOI 10.1126/science.8493553	31	193	196	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 26	1995	377	6551					754	757		10.1038/377754a0	http://dx.doi.org/10.1038/377754a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB469	7477269				2022-12-28	WOS:A1995TB46900063
J	SHAW, RA; HOLT, PA; STEVENS, MB				SHAW, RA; HOLT, PA; STEVENS, MB			HEEL PAIN IN SARCOIDOSIS	ANNALS OF INTERNAL MEDICINE			English	Note									GOOD SAMARITAN HOSP, JOHNS HOPKINS MED INST, BALTIMORE, MD 21239 USA	Johns Hopkins University; Johns Hopkins Medicine								CAPLAN HI, 1970, ARTHRITIS RHEUM, V13, P101, DOI 10.1002/art.1780130201; GUMPEL JM, 1967, ANN RHEUM DIS, V26, P194, DOI 10.1136/ard.26.3.194; KAPLAN H, 1963, ARCH INTERN MED, V112, P924, DOI 10.1001/archinte.1963.03860060148016; MYERS GB, 1952, AM J MED, V12, P161, DOI 10.1016/0002-9343(52)90209-X; SPILBERG I, 1969, ARTHRITIS RHEUM-US, V12, P126, DOI 10.1002/art.1780120209; TRUELOVE LH, 1960, ANN RHEUM DIS, V19, P174, DOI 10.1136/ard.19.2.174	6	9	9	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1988	109	8					675	677		10.7326/0003-4819-109-8-675	http://dx.doi.org/10.7326/0003-4819-109-8-675			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q6974	3421578				2022-12-28	WOS:A1988Q697400016
